Physical O
mapping O
220 O
kb O
centromeric O
of O
the O
human B_GENE/B_LOCATION
MHC I_GENE/I_LOCATION
and O
DNA O
sequence O
analysis O
of O
the O
43 O
- O
kb O
segment O
including O
the O
RING1 B_GENE
, O
HKE6 B_GENE/B_BACTERIUM[BIO]
, O
and O
HKE4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
synthesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
endo B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adduct B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
[ O
4aS B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5S B_LOCATION/B_PROTEIN[GENE]
, O
8R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
8aR B_LOCATION/B_MEASURE
, O
SS B_MEASURE
] I_MEASURE
- O
9d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulting O
from O
cycloaddition B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
substituted O
C B_PROTEIN[GENE]/B_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
- O
C B_PROTEIN[GENE]/B_LOCATION
( O
3 B_NUMBER[MEASURE]
) O
double B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bond I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
achieved O
in O
a O
chemo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
and O
diastereoselective B_LOCATION
way I_LOCATION
from O
quinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ZnBr B_LOCATION
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

DNA O
elements O
recognizing O
NF B_GENE
- I_GENE
Y I_GENE
and O
Sp1 B_GENE
regulate O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Radioimmunoassay O
of O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gonadotropins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
problems O
of O
specificity O
. O

patients B_PERSON
randomized O
into O
the O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
A30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
n B_OTHER/B_MEASURE
= O
49 B_MEASURE
) O
and O
A60 B_PROTEIN[GENE]/B_MEASURE
( O
n B_OTHER/B_MEASURE
= O
48 B_MEASURE
) O
received O
topical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
3 B_MEASURE
. O
0 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diclofenac I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
2 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
hyaluronan I_MEASURE
gel I_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
g I_MEASURE
twice O
daily O
for O
30 B_MEASURE
or O
60 B_TIME[MEASURE]
days I_TIME[MEASURE]
, O
respectively O
. O

As O
tat B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O
dramatically O
increases O
HIV O
- O
1 O
gene O
expression O
, O
it O
too O
is O
presumably O
regulated O
in O
the O
latent O
state O
, O
and O
may O
also O
be O
activated O
by O
mitogenic O
stimulation O
. O

To O
clarify O
the O
difference O
, O
both O
the O
Crk B_GENE/B_BIO
II I_GENE/I_BIO
and O
Crk B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
proteins O
were O
expressed O
in O
E O
. O
coli O
and O
examined O
their O
binding O
capacity O
in O
vitro O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Systemic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
increase O
bone B_DISEASE/B_GENE
mineral I_DISEASE/I_GENE
density I_DISEASE/I_GENE
appear O
to O
be O
involved O
in O
the O
pathogenesis B_DISEASE
of O
ossification B_DISEASE
of O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
longitudinal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ligament I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
these O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
be O
activated O
after O
middle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
age I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Thus O
, O
in O
V O
. O
furnissii O
, O
the O
E B_GENE/B_BACTERIUM[BIO]
. I_GENE/I_BACTERIUM[BIO]
coli I_GENE/I_BACTERIUM[BIO]
manX I_GENE/I_BACTERIUM[BIO]
equivalent I_GENE/I_BACTERIUM[BIO]
comprises O
two O
genes O
, O
which O
are O
separated O
in O
the O
genome O
by O
two O
other O
genes O
of O
the O
ptsM B_PROTEIN[GENE]/B_BIO
complex I_PROTEIN[GENE]/I_BIO
. O

Id B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1H I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Id B_PROTEIN[GENE]
- I_PROTEIN[GENE]
2H I_PROTEIN[GENE]
seem O
to O
be O
human O
homologues O
of O
mouse B_GENE/B_DISEASE
Id I_GENE/I_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
and O
Id B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
2 I_PROTEIN[GENE]/I_MEASURE
, O
respectively O
, O
and O
have O
potential O
to O
encode O
154 O
and O
135 O
amino O
acid O
proteins O
. O

characterization O
of O
insertion O
mutations O
in O
the O
Saccharomyces B_GENE/B_DISEASE
cerevisiae I_GENE/I_DISEASE
MSH1 I_GENE/I_DISEASE
and O
MSH2 B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
: O
evidence O
for O
separate O
mitochondrial O
and O
nuclear O
functions O
. O

transcription O
of O
FN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
chloramphenicol B_GENE/B_DISEASE
acetyltransferase I_GENE/I_DISEASE
fusion O
genes O
carrying O
the O
base O
substitution O
in O
one O
or O
more O
of O
these O
G O
- O
rich O
sequences O
both O
in O
vivo O
and O
in O
vitro O
revealed O
that O
the O
base O
substitution O
in O
any O
G O
- O
rich O
sequence O
results O
in O
reduction O
of O
promoter O
activity O
, O
although O
the O
downstream O
GC O
box O
( O
GCd O
) O
plays O
a O
primary O
role O
. O

Morphologically O
, O
corrugation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
internal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
elastic I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
lamina I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
vessels B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
often O
observed O
in O
the O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
group B_ORGANIZATION/B_PERSON
, O
but O
was O
not O
prominent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
GLNVA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
treated O
groups B_ORGANIZATION/B_PERSON
or O
healthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
GT O
- O
rich O
sequence O
binding O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
Sp1 I_GENE/I_LOCATION
is O
crucial O
for O
high O
expression O
of O
the O
human B_GENE
type I_GENE
VII I_GENE
collagen I_GENE
gene I_GENE
( O
COL7A1 B_GENE/B_LOCATION
) O
in O
fibroblasts O
and O
keratinocytes O
. O

Each O
received O
20 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mL I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
three B_PERSON/B_NUMBER[MEASURE]
test B_PERSON/I_NUMBER[MEASURE]
solutions B_PERSON/I_NUMBER[MEASURE]
: O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
, O
or O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
. O

The O
XPR2 B_GENE
gene I_GENE
from O
Yarrowia O
lipolytica O
encodes O
an O
inducible O
alkaline B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
extracellular I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
that O
the O
annual B_MEASURE
rate I_MEASURE
of O
de B_DISEASE
novo I_DISEASE
aneurysm I_DISEASE
formation I_DISEASE
is O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
0 B_MEASURE
. O
89 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
that O
the O
cumulative B_MEASURE/B_DISEASE
risk B_MEASURE/I_DISEASE
becomes O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
9 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
years I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

It O
was O
found O
that O
Nopp140 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O
primarily O
to O
the O
CK2 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regulatory B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunit B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
beta B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

juvenile B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
idiopathic B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myopathies B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
the O
value B_MEASURE/B_PERSON
of O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
muscle B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
. O

Previous O
analysis O
of O
this O
motif O
in O
the O
lactose B_SPECIES[BIO]/B_TIME[MEASURE]
permease I_SPECIES[BIO]/I_TIME[MEASURE]
( O
A O
. O

Combined O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
VM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
26 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gliomas B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Like O
other O
IAPs B_BIO/B_GENE
, O
ch B_GENE/B_DISEASE
- I_GENE/I_DISEASE
IAP1 I_GENE/I_DISEASE
contains O
the O
N B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
terminal B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
baculovirus B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
IAP B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
repeats B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and O
C O
- O
terminal O
Ring O
finger O
motifs O
. O

Effects O
of O
long O
- O
term O
use O
of O
raloxifene O
, O
a O
selective O
estrogen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulator O
, O
on O
thyroid O
function O
test O
profiles O
. O

The O
donors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
10 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
were O
ABO B_DISEASE/B_MEASURE
- O
incompatible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
for O
five B_NUMBER[MEASURE]/B_PERSON
pairs I_NUMBER[MEASURE]/I_PERSON
the O
ABO B_DISEASE_ADJECTIVE[DISEASE]
incompatibility I_DISEASE_ADJECTIVE[DISEASE]
was O
major B_DISEASE_ADJECTIVE[DISEASE]
. O

Alternative O
splicing O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serotonin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interestingly O
, O
basal O
MAPK B_GENE
, O
but O
not O
Raf B_GENE
- I_GENE
1 I_GENE
, O
activity O
was O
constitutively O
enhanced O
in O
Jak1 B_GENE
- O
deficient O
HeLa O
cells O
. O

This O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
describes O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
patient B_PERSON/B_BIO
with O
periodontosis B_DISEASE/B_LOCATION
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
to O
organize O
chemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O
a O
client B_PERSON/B_LOCATION
- O
server B_ORGANIZATION/B_LOCATION
environment B_ORGANIZATION/I_LOCATION
using O
Database B_ORGANIZATION/B_ENT
Management I_ORGANIZATION/I_ENT
System I_ORGANIZATION/I_ENT
and O
Web B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fashion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
client B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interface B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cerumen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
hearing B_LOCATION/B_PERSON
conservation I_LOCATION/I_PERSON
: O
the O
Dallas B_LOCATION/B_PERSON
( O
Texas B_LOCATION/B_PERSON
) O
Independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
School I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
District I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
actual B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
venous B_BODY_PART_OR_ORGAN_COMPONENT
blood I_BODY_PART_OR_ORGAN_COMPONENT
of O
newborn B_PERSON/B_BIO
calves I_PERSON/I_BIO
. O

This O
article B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focuses O
on O
a O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
ARV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

platelets B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
RBCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
each O
animal B_BIO/B_PERSON
were O
labeled O
with O
51Cr B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
99mTc B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
and O
were O
rapidly O
injected O
into O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT
atrium I_BODY_PART_OR_ORGAN_COMPONENT
while O
blood B_BODY_PART_OR_ORGAN_COMPONENT
was O
sampled O
from O
the O
ascending O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

The O
comparisons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
swimming B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
before O
and O
after O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
deltamethrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O
shown O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
locomotory B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
ability B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
rainbow B_BIO/B_PERSON
trout I_BIO/I_PERSON
which O
at O
the O
end B_MEASURE/B_LOCATION
of O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
e B_DISEASE/B_LOCATION
. O
g B_PROTEIN[GENE]/B_MEASURE
. O

Protection B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
33 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
36 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
37 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
were O
achieved O
in O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
had O
received O
, O
respectively O
, O
1000 B_TIME[MEASURE]
20 I_TIME[MEASURE]
- O
krad B_PERSON/B_MEASURE
cercariae I_PERSON/I_MEASURE
, O
1000 B_MEASURE
10 I_MEASURE
- O
krad B_MEASURE/B_PERSON
cercariae I_MEASURE/I_PERSON
, O
2000 B_TIME[MEASURE]
40 I_TIME[MEASURE]
- O
krad B_MEASURE/B_PERSON
cercariae I_MEASURE/I_PERSON
and O
2000 B_TIME[MEASURE]
60 I_TIME[MEASURE]
- O
krad B_PERSON/B_MEASURE
cercariae I_PERSON/I_MEASURE
. O

In O
types B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
and O
II B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
capillary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
walls I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
became O
thinner B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
more O
capillary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lumens I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
visiable B_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
primate O
vs O
. O
rodent O
promoter O
selectivity O
mediated O
by O
the O
TBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
TAFI B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O
is O
likely O
to O
be O
the O
result O
of O
cumulative O
subtle O
differences O
between O
individual O
subunits O
that O
lead O
to O
species O
- O
specific O
properties O
of O
RNA B_GENE/B_BIO
polymerase I_GENE/I_BIO
I I_GENE/I_BIO
transcription O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
the O
non O
- O
competitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NMDA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
801 B_NUMBER[MEASURE]
on O
the O
behavioral B_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
repeated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
restraint I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
investigated O
. O

When O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
conversion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
initiated O
by O
a O
double B_NUMBER[MEASURE]/B_LOCATION
- O
strand B_DISEASE/B_GENE
break B_DISEASE/I_GENE
( O
DSB B_DISEASE/B_PROTEIN[GENE]
) O
, O
any O
nonhomologous B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
may O
be O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
the O
ends B_LOCATION/B_GENE
must O
be O
removed O
before O
new B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
initiated O
. O

In O
this O
reconstituted O
system O
, O
RNAP B_GENE
IIA I_GENE
, O
but O
not O
RNAP B_PROTEIN[GENE]/B_LOCATION
IIB I_PROTEIN[GENE]/I_LOCATION
, O
can O
transcribe O
from O
the O
DHFR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
cDNA O
clones O
encode O
a O
polypeptide O
of O
657 O
amino O
acids O
with O
a O
bHLH O
( O
basic O
- O
helix O
- O
loop O
- O
helix O
) O
domain O
, O
characteristic O
of O
a O
large O
family O
of O
transcription O
factors O
, O
and O
a O
PAS B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Per B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Arnt B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
Sim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
domain O
in O
the O
amino O
- O
terminal O
half O
region O
. O

FTF B_ORGANIZATION/B_LOCATION
( O
Joint B_ORGANIZATION/B_PERSON
Council I_ORGANIZATION/I_PERSON
of O
civil B_PERSON/B_ORGANIZATION
servants I_PERSON/I_ORGANIZATION
and O
Functionaries B_PERSON
) O
: O
clarification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
about O
membership B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
main B_ORGANIZATION/B_LOCATION
organizations I_ORGANIZATION/I_LOCATION
. O

Lumbar B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spine B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mineral B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
density B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BMD B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
by O
dual B_MEASURE/B_LOCATION
- O
energy B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ray B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorptiometry I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DXA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
increased O
by O
0 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
3 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
8 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
after O
48 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
L B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
M B_LOCATION
and O
H B_OTHER/B_PROTEIN[GENE]
respectively O
, O
responses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
groups B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
and O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
L B_OTHER/B_PROTEIN[GENE]
( O
p B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
05 B_MEASURE
, O
Mann B_PERSON
- O
Whitney B_PERSON
U I_PERSON
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

Synergy O
between O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
transcriptional O
activation O
is O
mediated O
by O
cooperation O
between O
signal B_GENE
transducer I_GENE
and I_GENE
activator I_GENE
of I_GENE
transcription I_GENE
1 I_GENE
and O
nuclear B_GENE
factor I_GENE
kappaB I_GENE
. O

1H O
and O
15N O
magnetic O
resonance O
assignments O
, O
secondary O
structure O
, O
and O
tertiary O
fold O
of O
Escherichia B_GENE/B_BACTERIUM[BIO]
coli I_GENE/I_BACTERIUM[BIO]
DnaJ I_GENE/I_BACTERIUM[BIO]
( I_GENE/I_BACTERIUM[BIO]
1 I_GENE/I_BACTERIUM[BIO]
- I_GENE/I_BACTERIUM[BIO]
78 I_GENE/I_BACTERIUM[BIO]
) I_GENE/I_BACTERIUM[BIO]
. O

A O
cDNA O
for O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
microfibril I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAGP B_GENE
- I_GENE
2 I_GENE
) O
was O
used O
to O
screen O
a O
human O
leukocyte O
genomic O
DNA O
library O
in O
EMBL O
- O
3 O
vector O
. O

Furthermore O
, O
ERK B_GENE
phosphorylation O
was O
substantially O
prolonged O
in O
LC O
/ O
BRY O
- O
treated O
cells O
compared O
to O
those O
exposed O
to O
BRY O
alone O
, O
and O
pretreatment O
with O
the O
highly O
specific O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O
, O
PD98059 O
, O
U0126 O
, O
and O
SL327 O
, O
opposed O
ERK B_GENE
activation O
while O
protecting O
cells O
from O
LC O
/ O
BRY O
- O
induced O
lethality O
. O

The O
cholesterol B_GENE
7alpha I_GENE
- I_GENE
hydroxylase I_GENE
gene I_GENE
( O
CYP7A B_GENE/B_LOCATION
) O
is O
transcriptionally O
regulated O
by O
a O
number O
of O
factors O
, O
including O
hormones O
, O
bile O
acids O
, O
and O
diurnal O
rhythm O
. O

CNS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
preventive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
without O
cranial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
all O
the O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
All O
patients B_PERSON/B_LOCATION
. O

Additionally O
, O
the O
members B_PERSON/B_BIO
of O
this O
family B_PERSON/B_LOCATION
display O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
homologies I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
their O
larger B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
effector I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
binding I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
/ O
oligomerization B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
domains I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

Aspartame B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
a O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sweetener I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
commonly O
used O
in O
soft B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
drinks I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
many B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
foods B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

The O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anococcygeus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
in O
postsynaptic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
purpose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
presentation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
to O
review O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
5 B_NUMBER[MEASURE]
, O
8 B_NUMBER[MEASURE]
, O
11 B_NUMBER[MEASURE]
, O
14 B_MEASURE
- O
eicosatetraynoic B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ETYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Ro O
3 B_NUMBER[MEASURE]
- O
1428 B_MEASURE/B_LOCATION
) O
and O
its O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
lipid B_DISEASE
metabolism I_DISEASE
. O

A O
Meis1 B_GENE/B_DISEASE
cDNA I_GENE/I_DISEASE
clone O
that O
encoded O
a O
novel O
member O
of O
the O
homeobox B_GENE/B_BIO
gene I_GENE/I_BIO
family I_GENE/I_BIO
was O
identified O
. O

The O
S B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
typhimurium I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
asparaginyl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hydroxylase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologue I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
designated O
lpxO B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
cloned O
into O
pBluescriptSK O
and O
expressed O
in O
Escherichia O
coli O
K O
- O
12 O
, O
which O
does O
not O
contain O
lpxO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
levels O
of O
soluble O
L B_GENE
- I_GENE
selectin I_GENE
and O
ICAM B_GENE
- I_GENE
1 I_GENE
in O
the O
serum O
were O
determined O
by O
the O
ELISA O
method O
. O

The O
highest O
TTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
content O
is O
10 O
. O
0 O
microg O
/ O
g O
in O
N O
. O
livescens O
. O

On O
the O
other B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hand I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hypokalemia I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
induced O
by O
diuretics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
may O
also O
be O
accompanied O
by O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depletion I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
bringing O
about O
more B_DISEASE
general I_DISEASE
consequences I_DISEASE
. O

Glutathione B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O
in O
liver O
, O
kidney O
, O
lung O
, O
and O
brain O
were O
not O
affected O
by O
diet O
. O

Here O
, O
we O
describe O
the O
nucleotide O
( O
nt O
) O
sequence O
and O
genomic O
organization O
of O
ipiB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
ipiO B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eliminated O
toxin B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
stools B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
delayed O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

soluble O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer O
complexes O
in O
thromboembolism O
. O

comparison O
to O
the O
murine O
homologues O
of O
these O
molecules O
reveals O
a O
high O
degree O
of O
conservation O
between O
the O
products O
of O
one O
of O
these O
genes O
, O
Fc B_GENE
gamma I_GENE
RIIb I_GENE
, O
and O
the O
murine B_GENE/B_MEASURE
beta I_GENE/I_MEASURE
gene I_GENE/I_MEASURE
in O
primary O
sequence O
, O
splicing O
pattern O
, O
and O
tissue O
distribution O
. O

acidosis B_DISEASE
provoked O
by O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
irreversibly O
increased O
the O
BDRT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
however O
the O
TRT B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
not O
changed O
. O

Others B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
for O
example B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
11 B_MEASURE/B_LOCATION
labeled O
short B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
chain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
are O
on O
the O
horizon B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

The O
average B_MEASURE/B_LOCATION
progression I_MEASURE/I_LOCATION
was O
11 B_MEASURE
. O
6 B_MEASURE
( O
SD B_MEASURE
9 I_MEASURE
. O
0 B_MEASURE
) O
. O

80 B_TIME[MEASURE]/B_GENE
BP I_TIME[MEASURE]/I_GENE
) O
surrounding O
the O
site B_LOCATION
of O
transcription B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
initiation I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

ultrastructure B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
toxin B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
Cor B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
diphtheriae B_MEASURE/B_BACTERIUM[BIO]
PW I_MEASURE/I_BACTERIUM[BIO]
- O
8 B_NUMBER[MEASURE]/B_LOCATION
cultured O
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

EMT B_GENE/B_DISEASE
was O
localized O
to O
chromosome O
5q31 O
- O
32 O
, O
a O
region O
that O
contains O
the O
genes O
for O
several O
growth O
factors O
and O
receptors O
as O
well O
as O
early O
activation O
genes O
, O
particularly O
those O
involved O
in O
the O
hematopoietic O
system O
. O

Tbx6 B_GENE/B_DISEASE
maps O
to O
chromosome O
7 O
and O
does O
not O
appear O
to O
be O
linked O
to O
any O
known O
mutation O
. O

Kaposi B_PERSON/B_LOCATION
' O
s O
eruptive B_DISEASE
disease I_DISEASE
. O

It O
is O
not O
tested O
yet O
, O
whether O
the O
extent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
glaucoma B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O
be O
better O
quantified O
using O
reference B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
plane B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
1 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
or O
2 B_MEASURE/B_LOCATION
. O

Importin B_GENE/B_LOCATION
beta I_GENE/I_LOCATION
mediates O
nuclear O
translocation O
of O
Smad B_GENE
3 I_GENE
. O

The O
encoded O
protein O
contains O
an O
amino O
terminal O
PDZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O
, O
followed O
by O
a O
predicted O
coiled O
- O
coil O
region O
, O
a O
PEST O
domain O
, O
and O
a O
carboxy O
- O
terminal O
Sam O
domain O
. O

Using O
lasers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
PRK B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
involves O
reshaping O
the O
cornea B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
so O
that O
its O
refractive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
power B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
is O
increased O
. O

However O
, O
sphincter B_MEASURE/B_PERSON
length I_MEASURE/I_PERSON
decreased O
with O
age B_MEASURE/B_DISEASE
from O
24 B_MEASURE
. O
3 B_MEASURE
to O
14 B_MEASURE
. O
8 B_MEASURE
mm I_MEASURE
. O
, O
maximal B_MEASURE
urethral I_MEASURE
pressure I_MEASURE
from O
88 B_MEASURE
. O
7 B_MEASURE
to O
55 B_MEASURE
cm I_MEASURE
. O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
maximal B_MEASURE
urethral I_MEASURE
pressure I_MEASURE
during O
voluntary B_TIME[MEASURE]/B_DISEASE
contraction I_TIME[MEASURE]/I_DISEASE
from O
221 B_MEASURE
. O
4 B_MEASURE
to O
166 B_MEASURE
. O
3 B_MEASURE
cm I_MEASURE
. O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Several O
studies O
have O
demonstrated O
that O
the O
corticotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
releasing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
test O
( O
CRF B_LOCATION/B_GENE
) O
is O
useful O
for O
the O
aetiological O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
: O
in O
Cushing O
' O
s O
disease O
, O
as O
opposed O
to O
ectopic O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O
syndrome O
, O
the O
hypothalamus O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
can O
still O
be O
stimulated O
by O
CRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Transcription B_GENE
initiation I_GENE
from O
this O
region B_LOCATION/B_BIO
was O
also O
detected O
in O
vivo B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
when O
the O
cloned O
rRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
multi B_NUMBER[MEASURE]/B_ENT
- O
copy B_GENE/B_LOCATION
plasmid I_GENE/I_LOCATION
. O

The O
results O
of O
the O
transient O
- O
transfection O
assay O
showed O
that O
the O
Sp1 B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
element I_GENE/I_LOCATION
located O
in O
the O
core O
region O
( O
positions O
- O
- O
64 O
to O
+ O
1 O
) O
of O
the O
alpha2 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
integrin I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
plays O
an O
essential O
role O
in O
the O
alpha2 B_GENE
- I_GENE
integrin I_GENE
promoter I_GENE
activity O
and O
its O
downregulation O
by O
Erb B_GENE/B_DISEASE
- O
B2 B_PROTEIN[GENE]
. O

Principal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O
psychosocial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
women B_PERSON/B_MEASURE
showed O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
psychosocial B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
structures B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
i O
. O
e O
. O
the O
second B_SEQUENCE[MEASURE]/B_PERSON
principal I_SEQUENCE[MEASURE]/I_PERSON
( O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
SOC I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
high B_DISEASE_ADJECTIVE[DISEASE]
lifestyle I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
4th B_SEQUENCE[MEASURE]/B_PERSON
principal I_SEQUENCE[MEASURE]/I_PERSON
components I_SEQUENCE[MEASURE]/I_PERSON
( O
high B_DISEASE_ADJECTIVE[DISEASE]
supernatural I_DISEASE_ADJECTIVE[DISEASE]
HLC I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
PHLC I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
. O

expression O
of O
FNCAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
on O
serum O
treatment O
indicating O
that O
the O
region O
of O
the O
FN B_GENE
gene I_GENE
between O
positions O
+ O
69 O
and O
- O
510 O
BP O
mediated O
serum O
responsiveness O
. O

interaction O
of O
the O
v B_GENE
- I_GENE
rel I_GENE
protein I_GENE
with O
an O
NF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
kappa I_GENE/I_LOCATION
B I_GENE/I_LOCATION
DNA I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
. O

This O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alterations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
deposition B_MEASURE/B_DISEASE
of O
inhaled B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
particles I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
capsaicin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
brought O
about O
by O
volume B_DISEASE
restriction I_DISEASE
. O

providing O
appropriate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O
both O
sexes B_PERSON/B_LOCATION
. O

To O
test O
this O
hypothesis O
, O
we O
developed O
a O
system O
of O
transient O
transfection O
of O
rat O
adipocytes O
with O
constructs O
containing O
glyceraldehyde B_ENZYME[GENE]
- I_ENZYME[GENE]
3 I_ENZYME[GENE]
- I_ENZYME[GENE]
phosphate I_ENZYME[GENE]
dehydrogenase I_ENZYME[GENE]
( O
GAPDH B_GENE/B_LOCATION
) O
and O
fatty B_ENZYME[GENE]
acid I_ENZYME[GENE]
synthetase I_ENZYME[GENE]
( O
FAS B_DISEASE/B_LOCATION
) O
promoters O
fused O
to O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
green B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
unicellular I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
alga I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Chlamydomonas I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
eugametos I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
, O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
division B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
readily O
synchronized O
by O
light B_COLOR
/ O
dark B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycles I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

SHBG B_GENE
concentrations O
in O
women O
were O
also O
significantly O
higher O
at O
T O
- O
2 O
and O
T O
- O
3 O
when O
compared O
to O
T O
- O
1 O
values O
. O

Simvastatin O
decreased O
levels O
of O
total O
cholesterol O
by O
20 O
. O
8 O
% O
, O
LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
29 O
. O
7 O
% O
, O
triglycerides O
by O
13 O
. O
6 O
% O
, O
apolipoprotein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
by O
22 O
. O
4 O
% O
, O
alpha O
- O
tocopherol O
by O
16 O
. O
2 O
% O
, O
beta O
- O
carotene O
by O
19 O
. O
5 O
% O
, O
and O
ubiquinol O
- O
10 O
by O
22 O
. O
0 O
% O
( O
P O
< O
. O
001 O
for O
all O
) O
and O
increased O
levels O
of O
HDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
7 O
. O
0 O
% O
( O
P O
< O
. O
001 O
) O
and O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
13 O
. O
2 O
% O
( O
P O
= O
. O
005 O
) O
. O

The O
more O
severe O
the O
CRF O
, O
the O
more O
likely O
that O
total O
HDL B_GENE
and O
HDL2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
low O
. O

They O
are O
growth O
- O
inhibited O
by O
TGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

To O
investigate O
the O
in O
vivo O
role O
of O
this O
chimeric B_GENE/B_MEASURE
bZIP I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
in O
oncogenic O
transformation O
, O
its O
expression O
was O
directed O
to O
the O
lymphoid O
compartments O
of O
transgenic O
mice O
. O

This O
is O
consistent O
with O
the O
need O
for O
a O
nuclear O
retinoid B_GENE
receptor I_GENE
function O
in O
RA O
- O
induced O
ERK2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
. O

In O
the O
virus O
- O
infected O
cells O
, O
translation O
of O
the O
M1 B_GENE
protein I_GENE
was O
reduced O
to O
10 O
to O
20 O
% O
of O
that O
of O
the O
wild O
- O
type O
virus O
; O
however O
, O
the O
translation O
of O
neither O
the O
nucleoprotein O
nor O
NS1 B_GENE/B_BIO
was O
significantly O
interfered O
with O
, O
indicating O
the O
important O
role O
of O
NS1 B_GENE/B_BIO
in O
translational O
stimulation O
of O
the O
M1 B_GENE/B_BIO
protein I_GENE/I_BIO
. O

Some O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
were O
excited O
, O
others B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
inhibited O
by O
, O
and O
only O
some O
were O
directionally O
sensitive B_DISEASE
to O
the O
optomotor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimulus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

LT B_GENE/B_DISEASE
- I_GENE/I_DISEASE
beta I_GENE/I_DISEASE
transcription O
is O
maximal O
in O
the O
thymic O
medulla O
and O
in O
splenic O
white O
pulp O
. O

A O
novel O
Cdc42Hs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induces O
cellular O
transformation O
. O

interactions O
were O
also O
detected O
between O
full O
- O
length O
HSF1 B_GENE
and O
the O
small O
subunit O
( O
gamma O
) O
of O
TFIIA B_GENE
. O

We O
report O
that O
Nim1 B_GENE
possesses O
intrinsic O
serine B_ENZYME[GENE]
- I_ENZYME[GENE]
kinase I_ENZYME[GENE]
, O
threonine B_ENZYME[GENE]
- I_ENZYME[GENE]
kinase I_ENZYME[GENE]
and O
tyrosine B_ENZYME[GENE]
- I_ENZYME[GENE]
kinase I_ENZYME[GENE]
activities O
. O

A O
short O
conserved O
motif O
is O
required O
for O
repressor O
domain O
function O
in O
the O
myeloid O
- O
specific O
transcription O
factor O
CCAAT B_GENE/B_LOCATION
/ I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
- I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
epsilon I_GENE/I_LOCATION
. O

Androgen B_MEASURE
ablation I_MEASURE
- O
- O
50 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
later O
. O

In O
conclusion O
, O
ORCA3 B_GENE
regulates O
jasmonate O
- O
responsive O
expression O
of O
the O
Str B_GENE/B_BIO
gene I_GENE/I_BIO
via O
direct O
interaction O
with O
the O
JERE O
. O

Also O
, O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PdNi B_LOCATION/B_BIO
between O
the O
segments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reduces O
the O
heat B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
production I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
seed B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Theoretical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hyperuricemia B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ORF3 O
encodes O
a O
putative O
periplasmic B_ENZYME[GENE]
c I_ENZYME[GENE]
- I_ENZYME[GENE]
type I_ENZYME[GENE]
cytochrome I_ENZYME[GENE]
with O
a O
molecular O
mass O
of O
94 O
, O
000 O
Da O
and O
contains O
seven O
c O
- O
heme O
- O
binding O
motifs O
but O
shows O
no O
sequence O
homology O
to O
occ B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
ORF1 O
. O

Doxazosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
produced O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
mean B_MEASURE
and O
maximum B_MEASURE/B_LOCATION
urinary I_MEASURE/I_LOCATION
flow I_MEASURE/I_LOCATION
rates I_MEASURE/I_LOCATION
of O
1 B_MEASURE
. O
01 B_MEASURE/B_PERSON
ml I_MEASURE/I_PERSON
/ O
s B_OTHER/B_MEASURE
and O
3 B_MEASURE
. O
2 B_MEASURE
ml I_MEASURE
/ O
s B_OTHER/B_MEASURE
respectively O
, O
compared O
with O
0 B_MEASURE
. O
21 B_MEASURE
ml I_MEASURE
/ O
s B_OTHER/B_MEASURE
and O
2 B_MEASURE
. O
2 B_MEASURE
ml I_MEASURE
/ O
s B_TIME[MEASURE]/B_DISEASE
on O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Hypoxia B_DISEASE/B_PROTEIN[GENE]
decreased O
the O
rate B_MEASURE
of O
spontaneous B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
impulse I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
initiation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
SA B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nodal B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fibers B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
by O
decreasing O
the O
slope B_MEASURE
of O
diastolic B_DISEASE
depolarization I_DISEASE
. O

Background O
- O
- O
Platelet B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activating B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PAF B_LOCATION/B_GENE
) O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
airway O
hyperresponsiveness O
in O
asthma O
. O

TFEC B_GENE/B_BIO
RNA I_GENE/I_BIO
is O
found O
in O
many O
tissues O
of O
adult O
rats O
, O
but O
the O
relative O
concentrations O
of O
TFEC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TFE3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vary O
considerably O
in O
these O
different O
tissues O
. O

Our O
results O
show O
that O
unlike O
the O
case O
for O
sos1 B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sos2 B_GENE/B_PERSON
gene I_GENE/I_PERSON
function O
is O
dispensable O
for O
normal O
mouse O
development O
, O
growth O
, O
and O
fertility O
. O

Studies O
of O
HS2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gamma B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reporter B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
constructs B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O
CACCC O
box O
deletions O
revealed O
that O
the O
CACCC O
box O
sequence O
of O
the O
gamma O
gene O
promoter O
mediates O
the O
activation O
of O
the O
gamma O
gene O
by O
FKLF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Advisory B_PERSON/B_LOCATION
Committee I_PERSON/I_LOCATION
report I_PERSON/I_LOCATION
recommends O
that O
US O
make O
amends B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
human B_LOCATION
radiation I_LOCATION
experiments I_LOCATION
. O

Animals B_BIO/B_PERSON
were O
divided O
into O
six B_LOCATION/B_ORGANIZATION
equal I_LOCATION/I_ORGANIZATION
groups I_LOCATION/I_ORGANIZATION
as O
follows O
: O
( O
1 B_SEQUENCE[MEASURE]/B_LOCATION
) O
no O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
no O
hemodilution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
no O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
saline O
) O
; O
( O
2 B_SEQUENCE[MEASURE]/B_PERSON
) O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
hemodilution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
( O
3 B_SEQUENCE[MEASURE]/B_LOCATION
) O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
no O
hemodilution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
( O
4 B_NUMBER[MEASURE]/B_LOCATION
) O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
hemodilution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
( O
5 B_NUMBER[MEASURE]/B_LOCATION
) O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
hemodilution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
and O
( O
6 B_NUMBER[MEASURE]
) O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
hemodilution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

First O
, O
a O
GATA B_GENE
- I_GENE
1 I_GENE
motif I_GENE
was O
found O
to O
bind O
nuclear O
factor O
( O
s O
) O
, O
presumably O
the O
GATA B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
, O
present O
in O
K O
- O
562 O
cell O
extracts O
and O
in O
living O
K O
- O
562 O
cells O
. O

BPN B_DISEASE
can O
be O
experimentally O
produced O
by O
intratracheal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inoculation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
microorganisms B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
high B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
ventilator B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPECIES[BIO]
- O
associated O
BPN B_DISEASE/B_BIO
by O
ventilating O
baboons B_PERSON/B_BIO
with O
oleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lung I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
injury I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
mouth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
asymmetry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Additionally O
, O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
HIV B_DISEASE/B_VIRUS[BIO]
- O
1 B_MEASURE/B_DISEASE
latency B_MEASURE/I_DISEASE
and O
reactivation B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

This O
inhibition O
was O
due O
to O
competition O
from O
the O
EMC O
virus O
IRES O
present O
in O
pEP B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2A B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcripts B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
as O
well O
as O
the O
expression O
of O
proteolytically O
active O
2Apro B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Some O
may O
affect O
the O
folding O
pathway O
or O
the O
affinity O
for O
chaperonins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Diet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imbalances B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
aflatoxicosis B_DISEASE
. O

48 O
. O
35 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
07 B_MEASURE/B_PERSON
mg I_MEASURE/I_PERSON
/ O
l B_OTHER/B_MEASURE
in O
R3 B_LOCATION/B_PERSON
; O
p O
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
and O
in O
the O
AUC B_MEASURE
( O
0 B_MEASURE
. O
50 B_MEASURE
h O
) O
( O
1429 B_MEASURE
. O
92 B_MEASURE
+ I_MEASURE
/ O
- O
284 B_MEASURE
. O
23 B_MEASURE
in O
PR B_MEASURE/B_PROTEIN[GENE]
vs I_MEASURE/I_PROTEIN[GENE]
. O

The O
effect O
on O
FIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
of O
progressively O
deleting O
these O
nuclear O
factor O
binding O
sites O
was O
examined O
by O
linking O
LTR O
deletion O
mutants O
to O
the O
chloramphenicol B_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
gene O
. O

A O
series O
of O
sequence O
fragments O
were O
placed O
5 O
' O
to O
the O
chloramphenicol B_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
reporter O
gene O
and O
ability O
to O
mediate O
transcription O
of O
CAT B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
response O
to O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
LPS O
treatment O
was O
studied O
following O
transient O
transfection O
in O
the O
macrophage O
- O
like O
cell O
line O
Raw O
264 O
. O
7 O
. O

As O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Dutch I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
multicenter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Netherlands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Cooperative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
the O
adequacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Dialysis B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
2 B_NUMBER[MEASURE]
) O
, O
we O
consecutively O
included O
all O
new B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE/B_LOCATION
renal I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
for O
whom O
residual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
obtained O
0 B_NUMBER[MEASURE]/B_LOCATION
to O
4 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
before O
the O
start B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

module O
2 O
of O
RifA B_SPECIES[BIO]/B_LOCATION
lacks O
a O
beta B_GENE/B_MEASURE
- I_GENE/I_MEASURE
ketoacyl I_GENE/I_MEASURE
: I_GENE/I_MEASURE
acyl I_GENE/I_MEASURE
carrier I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
reductase I_GENE/I_MEASURE
( O
KR B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
domain O
and O
the O
one O
in O
module O
3 O
has O
an O
apparently O
inactive O
NADPH B_LOCATION/B_MEASURE
binding I_LOCATION/I_MEASURE
motif I_LOCATION/I_MEASURE
, O
similar O
to O
one O
found O
in O
the O
Er B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PKS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
while O
the O
other O
eight O
KR B_LOCATION/B_PERSON
domains I_LOCATION/I_PERSON
of O
the O
Rf B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
PKS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
should O
be O
functional O
. O

In O
murine O
cells O
, O
FPGS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
is O
controlled O
by O
two O
promoters O
that O
, O
as O
we O
show O
here O
, O
vary O
substantially O
in O
their O
efficiency O
, O
at O
least O
in O
the O
context O
of O
a O
reporter O
gene O
assay O
. O

Should O
we O
use O
thiazide O
diuretics O
in O
hypertensive O
patients O
with O
non O
- O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
diabetes O
mellitus O
. O

reduced O
glutathione B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
whole B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
decreases I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
within O
a O
blood B_MEASURE/B_LOCATION
Se I_MEASURE/I_LOCATION
range I_MEASURE/I_LOCATION
of O
1 B_MEASURE
. O
01 B_MEASURE
to O
2 B_MEASURE
. O
28 B_MEASURE
micrograms I_MEASURE
in O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Se B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
area B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

sucrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
in O
source B_BIO
leaves I_BIO
is O
the O
predominant B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
carbon I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
source I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
developing O
sink B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tissues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
most B_BIO
higher I_BIO
plants I_BIO
. O

A O
personal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
view I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trends I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
immunoassay B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
concludes O
this O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

In O
accordance B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Ann B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Arbor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
classification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
observed O
12 B_MEASURE
CS I_MEASURE
IA I_MEASURE
( O
21 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
, O
2 B_PROTEIN[GENE]/B_LOCATION
CS I_PROTEIN[GENE]/I_LOCATION
IB I_PROTEIN[GENE]/I_LOCATION
( O
3 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
, O
14 B_PROTEIN[GENE]/B_LOCATION
CS I_PROTEIN[GENE]/I_LOCATION
IIA I_PROTEIN[GENE]/I_LOCATION
( O
25 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
27 B_LOCATION/B_PERSON
CS I_LOCATION/I_PERSON
IIB I_LOCATION/I_PERSON
( O
49 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Numerous B_MEASURE/B_PERSON
genes B_MEASURE/I_PERSON
of O
this O
family B_PERSON/B_BIO
have O
been O
identified O
in O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
the O
largest B_MEASURE
number I_MEASURE
found O
in O
vertebrates B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
GST B_GENE/B_BIO
- O
CBL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
LZIP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O
protein O
contains O
a O
binding O
site O
for O
the O
SH2 B_PROTEIN[GENE]
domain I_PROTEIN[GENE]
of O
the O
p85 B_ENZYME[GENE]/B_PERSON
subunit I_ENZYME[GENE]/I_PERSON
of O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
mapped O
to O
Tyr731 O
, O
which O
is O
present O
in O
the O
sequence O
YEAM O
. O

We O
have O
previously O
shown O
that O
UNC B_GENE
- I_GENE
4 I_GENE
expression O
in O
the O
VA O
motor O
neurons O
specifies O
the O
wild O
- O
type O
pattern O
of O
presynaptic O
input O
. O

significant O
differences O
were O
observed O
in O
the O
composition O
of O
nuclear O
transcription O
factors O
bound O
to O
cis O
- O
elements O
within O
the O
LDH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
somatic O
versus O
germ O
cells O
. O

Above O
this O
transition B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
temperature O
the O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
lowers O
FM B_LOCATION/B_DISEASE
more O
pronouncedly O
than O
below O
. O

( O
1986 O
) O
described O
optic B_DISEASE
nerve I_DISEASE
degenerations I_DISEASE
in O
patients B_PERSON/B_BIO
with O
Alzheimer B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
and O
Sadun B_PERSON/B_TIME[MEASURE]
published O
a O
dropout B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
retinal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglion B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
range O
from O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
to O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

It O
has O
become O
clear O
that O
there O
is O
not O
one O
mediator O
responsible O
for O
Ali O
, O
but O
rather O
a O
complex O
interplay O
exists O
between O
diverse O
proinflammatory O
( O
e O
. O
g O
. O
, O
lipopolysaccharide O
, O
complement O
products O
, O
cytocains O
, O
chemocains O
, O
reactive O
oxygen O
species O
and O
arachidonic O
acid O
products O
) O
and O
anti O
- O
inflammatory O
( O
IL B_GENE
- I_GENE
10 I_GENE
, O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
PGI2 O
) O
mediators O
. O

We O
then O
supplemented O
these O
spliceosomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
purified B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
proteins I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
or O
yeast B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
extract O
fractions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
a O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
second B_NUMBER[MEASURE]/B_LOCATION
- O
step B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Contrast B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
an O
especially O
inaccurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
document O
pud B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CF B_LOCATION/B_DISEASE
because O
the O
duodenal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
mucosa I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
typically O
appears O
nodular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
distorted O
with O
poor B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
definition I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
mucosal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
folds I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
now O
show O
that O
the O
FRAP B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ser2035 O
- O
- O
> O
Ala O
mutant O
displays O
similar O
binding O
affinity O
when O
compared O
with O
the O
wild O
- O
type O
protein O
, O
whereas O
all O
other O
mutations O
at O
this O
site O
, O
including O
mimics O
of O
phosphoserine O
, O
abolish O
binding O
, O
presumably O
due O
to O
either O
unfavorable O
steric O
interactions O
or O
induced O
conformational O
changes O
. O

A O
Brassica O
cDNA O
clone O
encoding O
a O
bifunctional O
hydroxymethylpyrimidine B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
thiamin B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrophosphorylase I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
thiamin O
biosynthesis O
. O

Titres O
of O
antistreptolysin B_VIRUS[BIO]/B_DISEASE
O B_VIRUS[BIO]/I_DISEASE
in O
mothers O
of O
children O
affected O
with O
Down O
' O
s O
syndrome O
. O

differential O
decay O
of O
a O
polycistronic O
Escherichia O
coli O
transcript O
is O
initiated O
by O
RNaseE B_GENE/B_BIO
- O
dependent O
endonucleolytic O
processing O
. O

defects O
in O
RT6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
coincide O
with O
increased O
susceptibility O
in O
animal O
models O
for O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent O
diabetes O
mellitus O
and O
other O
autoimmune O
diseases O
. O

By O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
possible B_DISEASE_ADJECTIVE[DISEASE]
causes I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
goal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O
increasing O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O
be O
achieved O
. O

We O
have O
previously O
described O
the O
partial O
purification O
of O
Ap4A B_GENE
hydrolase I_GENE
from O
S O
. O
pombe O
[ O
Robinson O
, O
de O
la O
Pena O
and O
Barnes O
( O
1993 O
) O
Biochim O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inotropic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
OPC B_LOCATION/B_PROTEIN[GENE]
- O
8212 B_NUMBER[MEASURE]/B_LOCATION
) O
on O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isolated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
canine I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ventricular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
papillary I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
unc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
101 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
sli B_MEASURE/B_GENE
- I_MEASURE/I_GENE
1 I_MEASURE/I_GENE
, O
and O
rok B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
genes I_GENE/I_MEASURE
encode O
a O
distinct O
set O
of O
negative O
regulators O
of O
vulval O
differentiation O
. O

Thirty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
severe B_DISEASE/B_LOCATION
temporal I_DISEASE/I_LOCATION
lobe I_DISEASE/I_LOCATION
epilepsy I_DISEASE/I_LOCATION
were O
studied O
interictally O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
18F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
fluorodeoxyglucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
each O
of O
three B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
resting O
, O
during O
emotional B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
speech B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
while O
performing O
a O
visual B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
task I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

SYC1 B_PROTEIN[GENE]/B_DISEASE
( O
suppressor B_PROTEIN[GENE]
of I_PROTEIN[GENE]
yeast I_PROTEIN[GENE]
cbf5 I_PROTEIN[GENE]
- I_PROTEIN[GENE]
1 I_PROTEIN[GENE]
) O
was O
identified O
as O
a O
multicopy O
suppressor O
of O
cbf5 B_GENE/B_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
1 B_GENE/I_SPECIES[BIO]
and O
subsequently O
was O
found O
to O
be O
identical O
to O
RRN3 B_GENE
, O
an O
RNA B_GENE/B_TIME[MEASURE]
polymerase I_GENE/I_TIME[MEASURE]
I I_GENE/I_TIME[MEASURE]
transcription I_GENE/I_TIME[MEASURE]
factor I_GENE/I_TIME[MEASURE]
. O

newly O
hatched O
F1 B_PERSON/B_ENT
nymphs I_PERSON/I_ENT
of O
Aiolopus B_BIO
thalassinus I_BIO
( O
Fabr B_PERSON/B_DISEASE
. O
) O
were O
fed O
on O
food B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treated O
with O
various B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
HgCl2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
CdCl2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
PbCl2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
until O
the O
end B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adult B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
life I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

neuronal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
58 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dopaminergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
and O
200 B_MEASURE/B_PROTEIN[GENE]
non B_MEASURE/I_PROTEIN[GENE]
- O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
non B_DISEASE/B_LOCATION
- O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O
the O
ventral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tegmental I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
area I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
VTA B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
female B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
monkeys I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O
recorded O
, O
and O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
bar B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
press I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feeding I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sensory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
change B_DISEASE_ADJECTIVE[DISEASE]
in O
motivation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
investigated O
. O

Both O
sequence O
analysis O
and O
restriction O
fragment O
length O
polymorphism O
analysis O
revealed O
a O
high O
degree O
of O
sequence O
( O
97 O
% O
homology O
) O
and O
structural O
similarity O
among O
members O
of O
the O
ART B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CH B_GENE/B_DISEASE
family O
, O
indicating O
their O
common O
origin O
and O
recent O
penetration O
into O
chicken O
DNA O
. O

Three B_NUMBER[MEASURE]/B_PERSON
of O
these O
positions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
that O
they O
had O
not O
been O
identified O
to O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
binding O
PC B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
previous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
crystallographic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

We O
demonstrate O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
2 B_MEASURE
- O
deoxyglucose B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
isolated B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
primary B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rat B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adipocytes B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
3T3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
- O
L1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
adipocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pretreated O
with O
U73122 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
elevated O
levels O
of O
inositol O
phosphates O
resulting O
from O
N B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epi I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
qQ209L I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
were O
similar O
to O
those O
obtained O
with O
carbachol O
activation O
of O
the O
M1 B_GENE/B_LOCATION
muscarinic I_GENE/I_LOCATION
acetylcholine I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
. O

In O
addition O
, O
wild O
- O
type O
and O
mutated O
DNA O
templates O
were O
used O
as O
probes O
in O
DNase B_GENE
I I_GENE
protection O
experiments O
to O
determine O
sites O
of O
protein O
- O
DNA O
interaction O
. O

We O
tested O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
PEH B_DISEASE
is O
associated O
with O
reductions B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
TPR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
sympathetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nerve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
SNA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Salt B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
wars I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
BMK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
other O
19 O
contents O
significantly O
decreased O
depolarization O
parameters O
Vmax O
, O
APA O
, O
OS O
, O
and O
MDP O
, O
which O
was O
similar O
to O
that O
of O
TTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
different O
from O
that O
of O
Nim O
and O
BaCl2 O
. O

In O
the O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
adjacent B_BODY_PART_OR_ORGAN_COMPONENT
matrix I_BODY_PART_OR_ORGAN_COMPONENT
had O
several B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
characteristics I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
fibrocartilage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
including O
chondrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Mannich B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
bases I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
of O
vanillin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxime I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

All O
exon B_GENE/B_DISEASE
/ O
intron B_GENE/B_LOCATION
splice I_GENE/I_LOCATION
junctions I_GENE/I_LOCATION
follow O
the O
GT B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
AG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rule B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

Previous O
work O
has O
shown O
that O
glucose O
repression O
of O
PRB1 B_GENE
transcription O
is O
not O
mediated O
by O
HXK2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
by O
the O
SNF1 B_GENE/B_DISEASE
, O
SNF4 B_GENE/B_DISEASE
, O
and O
SNF6 B_GENE
genes I_GENE
( O
C O
. O

comparison O
of O
the O
encoded O
ERCC3Dm B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
homologous O
proteins O
of O
mouse O
and O
man O
shows O
a O
strong O
amino O
acid O
conservation O
( O
71 O
% O
identity O
) O
, O
especially O
in O
the O
postulated O
DNA O
binding O
region O
and O
seven O
' B_GENE/B_LOCATION
helicase B_GENE/I_LOCATION
' B_GENE/I_LOCATION
domains B_GENE/I_LOCATION
. O

The O
pyridostigmine O
inhibited O
AChE B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recovered O
only O
in O
the O
100 O
mumol O
kg O
- O
1 O
kg O
oxime O
groups O
at O
the O
end O
of O
the O
experiment O
. O

In O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
buccal I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Class I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
II I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tendency I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
55 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
molars B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
in O
a O
Class B_MEASURE/B_PERSON
I O
relationship B_PERSON/B_MEASURE
when O
evaluated O
from O
the O
lingual B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
side I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
whereas O
45 B_PERSON/B_NUMBER[MEASURE]
% B_PERSON/I_NUMBER[MEASURE]
belonged O
to O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
1st B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
degrees B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
Class B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
molar B_DISEASE
rotations I_DISEASE
present O
in O
81 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mutation O
of O
this O
threonine O
to O
isoleucine O
had O
no O
observable O
effect O
on O
either O
nuclear O
localization O
of O
E1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
DNA O
replication O
of O
the O
intact O
viral O
genome O
. O

Serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
oestradiol O
levels O
at O
different O
stages O
of O
puberty O
. O

This O
suggests O
that O
the O
duration B_MEASURE
of O
varicocele B_DISEASE/B_BACTERIUM[BIO]
per O
se B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
affect O
DHT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seminal I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Left O
ventricular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
dopamine O
in O
dilated B_DISEASE/B_PERSON
cardiomyopathy I_DISEASE/I_PERSON
as O
assessed O
by O
two B_NUMBER[MEASURE]
- O
dimensional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
compared O
with O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
thallium B_MEASURE/B_DISEASE
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
urinary B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excretion B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
purines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
in O
a O
patient B_PERSON
with O
the O
Lesch B_PERSON
- O
Nyhan B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
and O
a O
control B_PERSON
subject I_PERSON
. O

This O
enzyme O
is O
distinct O
from O
other O
known O
E3s B_GENE/B_BIO
, O
including O
E3 B_GENE
alpha I_GENE
/ O
UBR1 B_PROTEIN[GENE]
, O
E3 B_GENE
beta I_GENE
, O
and O
E6 B_GENE
- I_GENE
AP I_GENE
. O

This O
evidence O
, O
together O
with O
the O
ability O
of O
a O
carboxyl O
- O
terminal O
coding O
sequence O
starting O
from O
the O
BamHI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
complement O
a O
shy1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
suggests O
that O
the O
Shy1p B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O
two O
domains O
that O
can O
be O
separately O
expressed O
to O
form O
a O
functional O
protein O
. O

The O
zinc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
finger I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A20 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
tumor B_DISEASE/B_GENE
necrosis B_DISEASE/I_GENE
factor B_DISEASE/I_GENE
( O
TNF B_GENE/B_LOCATION
) O
- O
and O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
) O
- O
inducible O
protein O
that O
negatively O
regulates O
nuclear B_GENE
factor I_GENE
- I_GENE
kappa I_GENE
B I_GENE
( O
NF B_GENE
- I_GENE
kappaB I_GENE
) O
- O
dependent O
gene O
expression O
. O

A O
visibly O
distinct B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscular I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
MH B_DISEASE/B_LOCATION
) O
, O
commonly O
known O
as O
double B_DISEASE/B_LOCATION
muscling I_DISEASE/I_LOCATION
, O
occurs O
with O
high B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
frequency B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
Belgian B_PERSON/B_LOCATION
Blue I_PERSON/I_LOCATION
and O
Piedmontese B_COLOR/B_PERSON
cattle I_COLOR/I_PERSON
breeds I_COLOR/I_PERSON
. O

For O
the O
population B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
with O
melanoma B_DISEASE/B_LOCATION
levels I_DISEASE/I_LOCATION
III I_DISEASE/I_LOCATION
and O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
significant I_NUMBER[MEASURE]/I_PROTEIN[GENE]
differences I_NUMBER[MEASURE]/I_PROTEIN[GENE]
in O
survival B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
were O
associated O
with O
thickness B_MEASURE/B_LOCATION
( O
less B_MEASURE
than O
2 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
or O
greater B_MEASURE
than O
or O
equal B_MEASURE
to O
2 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
; O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
, O
001 B_MEASURE
) O
, O
though O
not O
with O
level B_MEASURE/B_DISEASE
. O

At O
least O
one O
such O
complex O
is O
eliminated O
by O
preincubating O
the O
nuclear O
extract O
with O
an O
antibody O
with O
broad O
cross O
- O
reactivity O
with O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
thus O
confirming O
that O
an O
ETS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recognizes O
the O
- O
12 O
motif O
. O

mutant O
beta2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
adrenergic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O
a O
Tyr O
- O
to O
- O
Phe O
substitution O
at O
Tyr O
- O
350 O
do O
not O
display O
agonist O
- O
induced O
desensitization O
, O
Src B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
recruitment O
, O
or O
Src B_GENE
activation O
. O

Role O
of O
distinct O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
pathways O
and O
cooperation O
between O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
ATF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
, O
and O
Jun B_GENE
family I_GENE
members I_GENE
in O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
urokinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O
by O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
tetradecanoyl O
phorbol O
acetate O
. O

Immunoblot O
analysis O
of O
purified O
and O
protease O
- O
digested O
intracellular O
mature O
virus O
( O
IMV O
) O
and O
extracellular O
enveloped O
virus O
( O
EEV O
) O
showed O
that O
the O
A36R B_GENE
proteins I_GENE
were O
present O
on O
the O
surface O
of O
EEV O
with O
type O
II O
membrane O
topology O
, O
but O
were O
absent O
from O
IMV O
. O

Here O
we O
demonstrate O
that O
several B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
NHEJ B_GENE/B_DISEASE
perform O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
endonuclease B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
DSBs B_DISEASE/B_GENE
in O
vivo B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
failure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
suggests O
that O
these O
assembly B_DISEASE_ADJECTIVE[DISEASE]
competent I_DISEASE_ADJECTIVE[DISEASE]
but O
complementation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
alpha I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
lack O
an O
as O
yet O
unidentified B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
s O
) O
. O

Psychopathological B_DISEASE_ADJECTIVE[DISEASE]/B_EDU[ORGANIZATION]
, O
vegetative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
vital B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
assessed O
every O
hour B_TIME[MEASURE]/B_ENT
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Considering O
an O
inulin B_MEASURE
clearance I_MEASURE
of O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
80 B_MEASURE
ml I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
/ O
1 B_MEASURE
. O
73 B_MEASURE
m2 I_MEASURE
, O
the O
cut O
- O
off O
value B_MEASURE/B_LOCATION
for O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creatinine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
11 B_MEASURE
. O
5 B_MEASURE/B_PERSON
mumol I_MEASURE/I_PERSON
/ O
liter B_MEASURE/B_PERSON
for O
men B_PERSON
and O
90 B_MEASURE/B_PERSON
mumol I_MEASURE/I_PERSON
/ O
liter B_MEASURE/B_PERSON
for O
women B_PERSON/B_BIO
. O

These O
data O
may O
indicate O
redundancy O
between O
members O
of O
the O
NGFI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Nurr1 B_GENE
/ O
Nor1 B_GENE
subfamily O
and O
could O
explain O
why O
no O
phenotypic O
disturbances O
have O
yet O
been O
found O
in O
mice O
in O
which O
the O
NGFI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
inactivated O
. O

Manual B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clean O
- O
up O
procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
an O
internal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
needed O
. O

To O
directly O
address O
this O
issue O
, O
we O
used O
a O
tetracycline O
- O
regulated O
system O
in O
human O
U2OS O
osteosarcoma O
cells O
and O
thus O
found O
that O
BCL6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediates O
growth O
suppression O
associated O
with O
impaired O
S O
phase O
progression O
and O
apoptosis O
. O

TAAG B_GENE/B_LOCATION
sites I_GENE/I_LOCATION
that O
serve O
as O
functional B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
late I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
OpMNPV B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
were O
found O
to O
mediate O
transcription B_GENE_EXPRESSION_ADJECTIVE[GENE]
initiation I_GENE_EXPRESSION_ADJECTIVE[GENE]
at O
only O
basal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
context B_LOCATION/B_MEASURE
of O
the O
AcMNPV B_GENE/B_BIO
genome I_GENE/I_BIO
, O
suggesting O
that O
late B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
promoter B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
may O
be O
virus B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
the O
family B_BIO
Baculoviridae I_BIO
. O

stability O
of O
125 O
I O
- O
labeled O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O
in O
radioimmunoassay O
of O
insulin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
i O
. O
m B_DISEASE/B_PROTEIN[GENE]
. O
medication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
levels B_LOCATION/B_PERSON
over O
1 B_MEASURE
, O
000 B_MEASURE
U I_MEASURE
must O
be O
carefully O
screened O
in O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
rule O
out O
SNM B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
organic B_DISEASE/B_LOCATION
pathology B_DISEASE/I_LOCATION
associated O
. O

Paclitaxel O
caused O
a O
rapid O
and O
transient O
increase O
in O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
JNK B_GENE/B_LOCATION
) O
activity O
, O
a O
proposed O
mediator O
of O
stress O
activation O
pathways O
. O

These O
results O
indicate O
that O
H B_GENE
- I_GENE
2RIIBP I_GENE
( O
i O
) O
is O
a O
member O
of O
the O
superfamily O
of O
nuclear B_GENE/B_BIO
hormone I_GENE/I_BIO
receptors I_GENE/I_BIO
and O
( O
ii O
) O
may O
regulate O
not O
only O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O
also O
genes O
containing O
the O
ERE O
and O
related O
sequences O
. O

Two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
courses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CBCDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
VDS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
failed O
to O
gain O
any O
improvement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
the O
pain B_DISEASE
resulting O
from O
recurrent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bone I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
managed O
mainly O
by O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
the O
best B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
show O
here O
that O
Spb1p B_GENE/B_LOCATION
is O
able O
to O
bind O
[ O
( O
3 O
) O
H O
] O
AdoMet O
in O
vitro O
, O
suggesting O
that O
it O
is O
a O
novel O
methylase O
, O
whose O
possible O
substrates O
will O
be O
discussed O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Lateral B_DISEASE/B_LOCATION
PF B_DISEASE/I_LOCATION
OA B_DISEASE/I_LOCATION
was O
more O
common B_DISEASE_ADJECTIVE[DISEASE]
than O
medial B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
PF I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
OA I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Urbanisation B_DISEASE/B_PERSON
is O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
prevalence B_MEASURE
rates I_MEASURE
of O
some O
risk B_DISEASE
behaviours I_DISEASE
. O

However O
, O
additional O
studies O
on O
cell O
lines O
and O
whole O
animals O
are O
required O
to O
understand O
GnRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signaling O
in O
the O
context O
of O
other O
hormones O
during O
the O
reproductive O
cycle O
of O
mouse O
and O
human O
. O

Serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiogenin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O
in O
young O
patients O
with O
diabetes O
mellitus O
. O

This O
duplicated O
genomic O
region O
is O
also O
linked O
tightly O
to O
D1Z2 B_GENE/B_DISEASE
, O
a O
genetic O
marker O
containing O
a O
highly O
polymorphic O
VNTR O
( O
variable O
number O
tandem O
repeat O
) O
consisting O
of O
an O
unusual O
40 O
- O
BP O
reiterated O
sequence O
. O

ATF6 B_GENE
, O
a O
basic B_GENE
- I_GENE
leucine I_GENE
zipper I_GENE
protein I_GENE
, O
was O
isolated O
by O
binding O
to O
SRF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
in O
particular O
to O
its O
transcriptional O
activation O
domain O
. O

Cetn1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O
the O
sequence O
features O
of O
an O
expressed O
retroposon O
: O
the O
gene O
lacks O
introns O
, O
the O
open O
reading O
frame O
is O
not O
interrupted O
by O
stop O
codons O
, O
and O
the O
coding O
region O
is O
flanked O
by O
a O
pair O
of O
direct O
repeats O
. O

The O
largest O
one O
probably O
corresponds O
to O
the O
precursor O
form O
of O
PS2 B_GENE
in O
E O
. O
coli O
. O

The O
Aspergillus B_GENE/B_MEASURE
uvsH I_GENE/I_MEASURE
gene I_GENE/I_MEASURE
encodes O
a O
product O
homologous O
to O
yeast B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RAD18 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
Neurospora B_BIO/B_GENE
UVS B_BIO/I_GENE
- B_BIO/I_GENE
2 B_BIO/I_GENE
. O

On O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
these O
maximum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potency I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimates I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
within O
one B_MEASURE/B_LOCATION
order I_MEASURE/I_LOCATION
of O
magnitude B_NUMBER[MEASURE]
of O
the O
inverse B_MEASURE
maximum I_MEASURE
dose I_MEASURE
tested O
. O

VAV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
SOCS1 B_GENE/B_DISEASE
form O
a O
protein O
complex O
through O
interactions O
between O
the O
VAV B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NH I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
region I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
SH2 B_GENE/B_MEASURE
domain I_GENE/I_MEASURE
of O
SOCS1 B_GENE
in O
a O
phosphotyrosine O
- O
independent O
manner O
. O

The O
originally O
embryonic B_GENE/B_BIO
gamma I_GENE/I_BIO
- I_GENE/I_BIO
globin I_GENE/I_BIO
locus I_GENE/I_BIO
duplicated O
and O
acquired O
a O
novel O
( O
fetal O
) O
pattern O
of O
expression O
in O
a O
defined O
time O
period O
( O
55 O
- O
40 O
million O
years O
ago O
) O
during O
primate O
phylogeny O
. O

Clostridium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
botulinum I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O
marine B_LOCATION/B_PERSON
sediment I_LOCATION/I_PERSON
. O

Northern O
blot O
analysis O
with O
GPR37 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes O
revealed O
a O
main O
3 O
. O
8 O
- O
kb O
mRNA O
and O
a O
less O
abundant O
8 O
- O
kb O
mRNA O
, O
both O
expressed O
in O
human O
brain O
tissues O
, O
particularly O
in O
corpus O
callosum O
, O
medulla O
, O
putamen O
, O
and O
caudate O
nucleus O
. O

Our O
studies O
indicate O
no O
single O
trans O
- O
acting O
factor O
is O
absolutely O
essential O
for O
enhancer O
activity O
, O
and O
that O
the O
enhancer O
activity O
of O
MerI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
mediated O
via O
a O
combinatorial O
and O
additive O
mechanism O
. O

In O
human O
WI38 O
cells O
, O
the O
E1B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
19K I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
viruses O
had O
a O
substantial O
growth O
advantage O
over O
the O
wild O
- O
type O
virus O
, O
yielding O
500 O
- O
fold O
- O
higher O
titers O
. O

To O
elucidate O
the O
mechanism O
of O
these O
hormonal O
effects O
, O
we O
have O
studied O
the O
regulatory O
regions O
of O
the O
PFK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transfection O
experiments O
. O

Consequently O
, O
during O
the O
evolution O
of O
mammals O
, O
it O
is O
the O
CKbeta4GT B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
I B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
gene B_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
lineage O
that O
has O
been O
recruited O
for O
the O
biosynthesis O
of O
lactose O
. O

Furthermore O
, O
disruption O
of O
pcr1 B_GENE
reduced O
expression O
of O
fbp1 B_GENE
, O
a O
glucose O
- O
repressible O
gene O
negatively O
regulated O
by O
PKA B_GENE
. O

In O
solution O
, O
[ O
( O
125 O
) O
I O
] O
- O
labeled O
ankyrin B_GENE/B_BACTERIUM[BIO]
was O
found O
by O
ND O
- O
PAGE3 O
to O
enhance O
the O
affinity O
of O
spectrin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
self O
- O
association O
by O
10 O
- O
fold O
. O

transcription O
analysis O
of O
the O
EcoRI B_GENE
D I_GENE
region I_GENE
of O
the O
baculovirus O
Autographa O
californica O
nuclear O
polyhedrosis O
virus O
identifies O
an O
early O
4 O
- O
kilobase O
RNA O
encoding O
the O
essential O
p143 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
radical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surgery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
arteriosclerotic B_DISEASE
coronary I_DISEASE
disease I_DISEASE
. O

5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Intravenous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prizidilol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O
resting O
blood B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
pressure I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
area B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
increases O
pulse B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
and O
has O
virtually O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
this O
study O
, O
the O
subcellular O
location O
, O
domain O
structure O
, O
and O
biochemical O
function O
of O
metaxin B_GENE/B_BACTERIUM[BIO]
were O
investigated O
. O

The O
human B_GENE
cDNA I_GENE
was O
cloned O
and O
sequenced O
; O
it O
was O
shown O
to O
have O
an O
open B_GENE
reading I_GENE
frame I_GENE
encoding O
a O
296 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
acid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
could O
be O
identified O
four B_LOCATION/B_BIO
peptides I_LOCATION/I_BIO
previously O
identified O
by O
micro B_GENE
- O
sequencing O
purified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
to O
evaluate O
this O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
calibrating O
the O
DXA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
the O
carcass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
chemical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
a O
heterogeneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
nondiabetic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Wistar I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
diabetic B_PERSON
GK I_PERSON
rats I_PERSON
( O
21 B_MEASURE/B_ENT
animals I_MEASURE/I_ENT
were O
used O
for O
precision B_MEASURE
error I_MEASURE
and O
reproducibility B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinations I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
26 B_NUMBER[MEASURE]
were O
used O
for O
accuracy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

flux O
of O
the O
paramyxovirus O
hemagglutinin B_PROTEIN[GENE]/B_BIO
- O
neuraminidase B_PROTEIN[GENE]
glycoprotein O
through O
the O
endoplasmic O
reticulum O
activates O
transcription O
of O
the O
GRP78 B_PROTEIN[GENE]/B_DISEASE
- O
BiP B_GENE
gene O
. O

The O
preference O
for O
third O
base O
codon O
in O
Y O
position O
prolines O
is O
U O
for O
the O
alpha B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
2 I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
( I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
VI I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
) I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
collagen I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
it O
is O
for O
the O
human B_GENE/B_MEASURE
fibrillar I_GENE/I_MEASURE
collagen I_GENE/I_MEASURE
genes I_GENE/I_MEASURE
. O

Small B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumors B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
children B_PERSON/B_LOCATION
: O
contribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
solution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
problem B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
differential B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
immunohistochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Detonation B_DISEASE/B_LOCATION
- O
traumatic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
load B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
military B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
service I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
static B_MEASURE/B_LOCATION
conditions I_MEASURE/I_LOCATION
, O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
sway O
was O
assessed O
using O
a O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
force I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
platform I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
open I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O
with O
eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
closed O
. O

Soggy B_GENE/B_BIO
, O
a O
spermatocyte O
- O
specific O
gene O
, O
lies O
3 O
. O
8 O
kb O
upstream O
of O
and O
antipodal O
to O
TEAD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
a O
transcription O
factor O
expressed O
at O
the O
beginning O
of O
mouse O
development O
. O

Teratospermia B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
is O
therefore O
an O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
evaluating O
fertilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
capacity I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
Chinese B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
medicine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
among O
this O
population B_PERSON/B_LOCATION
depends O
on O
health B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
that O
having O
a O
regular B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
source I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
Chinese B_PERSON/B_ORGANIZATION
medicine I_PERSON/I_ORGANIZATION
as O
well O
as O
a O
preference B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Chinese B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicine I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
two B_DISEASE_ADJECTIVE[DISEASE]
predictors I_DISEASE_ADJECTIVE[DISEASE]
for O
its O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

The O
greatest B_DISEASE
risk I_DISEASE
of O
preterm B_DISEASE/B_ORGANISM_FUNCTION
prelabour I_DISEASE/I_ORGANISM_FUNCTION
rupture I_DISEASE/I_ORGANISM_FUNCTION
of O
membranes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PPROM B_DISEASE/B_GENE
) O
is O
preterm B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
higher B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
absolute I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knee I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
extension I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strength I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
measures I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leg B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
similar B_MEASURE/B_LOCATION
extension I_MEASURE/I_LOCATION
strength I_MEASURE/I_LOCATION
of O
the O
trunk B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
obese B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
sample I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
compared O
to O
the O
lean B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
might O
be O
explained O
by O
the O
training B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
weight B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
bearing I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
support B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
larger B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
body B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
mass B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

residues B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Stauffer B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3828 B_MEASURE
and O
its O
oxygen B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogue I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
cattle B_BIO/B_PERSON
fed O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3828 B_MEASURE
in O
the O
diet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
goals O
of O
these O
experiments O
were O
to O
determine O
whether O
lactational O
anestrus O
would O
be O
prolonged O
by O
a O
48 O
- O
h O
fast O
at O
days O
13 O
and O
14 O
postpartum O
( O
pp O
) O
and O
, O
if O
so O
, O
to O
determine O
whether O
this O
effect O
could O
be O
reversed O
by O
treatment O
with O
the O
Ob B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
leptin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
pituitary O
GH3 O
cells O
, O
vitamin O
D O
increases O
the O
levels O
of O
PRL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
stimulates O
the O
PRL B_GENE
promoter I_GENE
. O

However O
, O
electron O
microscopy O
revealed O
that O
while O
sec4 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cells O
accumulate O
secretory O
vesicles O
, O
ypt31 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
/ I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
32 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cells O
accumulate O
aberrant O
Golgi O
structures O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
retrospectively O
analyzed O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
20 B_PERSON
patients I_PERSON
who O
underwent O
both O
gated O
fluorine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
18 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
deoxyglucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
FDG B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
equilibrium B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
radionuclide I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
angiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
ERNA B_DISEASE/B_LOCATION
) O
. O

However O
, O
it O
is O
now O
suggested O
that O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
more O
slowly O
digested B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
starchy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
foods I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
have O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
benefits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Northern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
the O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
transcribed O
separately O
. O

Complete O
activation O
of O
signal B_GENE
transducer I_GENE
and I_GENE
activator I_GENE
of I_GENE
transcription I_GENE
1 I_GENE
( O
STAT1 B_GENE
) O
requires O
phosphorylation O
at O
both O
Y701 O
and O
a O
conserved O
PMS O
( O
727 O
) O
P O
sequence O
. O

Over O
half O
of O
the O
children B_PERSON/B_BIO
initially O
unresponsive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O
influenzae B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meningitis B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subsequently O
developed O
specific B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
understand O
the O
etiology B_DISEASE
of O
HITT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
of O
its O
devastating B_DISEASE_ADJECTIVE[DISEASE]
clinical I_DISEASE_ADJECTIVE[DISEASE]
consequences I_DISEASE_ADJECTIVE[DISEASE]
. O

Five B_NUMBER[MEASURE]/B_PERSON
sequence I_NUMBER[MEASURE]/I_PERSON
variants I_NUMBER[MEASURE]/I_PERSON
were O
identified O
. O

The O
Ras B_ENZYME[GENE]/B_LOCATION
GTPase I_ENZYME[GENE]/I_LOCATION
- I_ENZYME[GENE]/I_LOCATION
activating I_ENZYME[GENE]/I_LOCATION
- I_ENZYME[GENE]/I_LOCATION
protein I_ENZYME[GENE]/I_LOCATION
- I_ENZYME[GENE]/I_LOCATION
related I_ENZYME[GENE]/I_LOCATION
human I_ENZYME[GENE]/I_LOCATION
protein I_ENZYME[GENE]/I_LOCATION
IQGAP2 I_ENZYME[GENE]/I_LOCATION
harbors O
a O
potential O
actin B_GENE
binding I_GENE
domain I_GENE
and O
interacts O
with O
calmodulin B_GENE/B_DISEASE
and O
Rho B_GENE
family I_GENE
GTPases I_GENE
. O

We O
anticipated O
SNS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
CVA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
be O
asymmetric B_DISEASE_ADJECTIVE[DISEASE]
and O
selected O
null B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypotheses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
bilaterally O
symmetric B_MEASURE/B_LOCATION
SSR I_MEASURE/I_LOCATION
latencies I_MEASURE/I_LOCATION
and O
amplitudes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irrespective I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
side B_MEASURE/B_DISEASE
of O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
/ O
or O
recording B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O

Partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
metastatic B_TIME[MEASURE]/B_PERSON
Wilms I_TIME[MEASURE]/I_PERSON
' I_TIME[MEASURE]/I_PERSON
tumor I_TIME[MEASURE]/I_PERSON
. O

The O
adoption O
of O
a O
twisted O
structure O
of O
importin B_GENE
- I_GENE
beta I_GENE
is O
essential O
for O
the O
protein O
- O
protein O
interaction O
required O
for O
nuclear O
transport O
. O

The O
presence O
of O
a O
short O
( O
70 O
BP O
) O
intron O
near O
the O
N O
- O
terminus O
of O
the O
atX B_GENE
gene I_GENE
was O
predicted O
that O
contains O
the O
canonical O
GT O
and O
AG O
dinucleotides O
at O
its O
5 O
' O
- O
and O
3 O
' O
- O
splicing O
junctions O
. O

Moreover O
, O
a O
hybrid O
protein O
composed O
of O
a O
PvALF B_GENE
activation I_GENE
domain I_GENE
and O
the O
DNA O
binding O
and O
dimerization O
domain O
of O
ROM2 B_GENE
activated O
gene O
expression O
, O
indicating O
that O
ROM2 B_GENE/B_MEASURE
recognizes O
the O
DLEC2 B_GENE/B_LOCATION
enhancer I_GENE/I_LOCATION
in O
vivo O
; O
consequently O
, O
ROM2 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions O
as O
a O
DNA O
binding O
site O
- O
dependent O
repressor O
. O

Tc B_MEASURE/B_PROTEIN[GENE]
- O
99m B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HMPAO I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
brain I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SPECT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
compared O
to O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
EEG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
after O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
childhood B_PERSON/B_DISEASE
. O

We O
found O
that O
the O
central B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
nonconserved I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
region I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
large B_ENZYME[GENE]/B_LOCATION
subunit I_ENZYME[GENE]/I_LOCATION
is O
not O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
likely B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
spacer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
between O
the O
conserved O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
and O
C B_PROTEIN[GENE]/B_LOCATION
- O
terminal B_LOCATION/B_BIO
regions I_LOCATION/I_BIO
. O

On O
the O
other O
hand O
, O
NE O
transport O
and O
antagonist O
( O
[ O
125I O
] O
RTI O
- O
55 O
) O
binding O
assays O
on O
whole O
LLC O
- O
Net O
cells O
treated O
with O
tunicamycin O
reveal O
a O
pronounced O
reduction O
in O
NE O
transport O
activity O
and O
hNET B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
membrane O
density O
paralleled O
by O
an O
inability O
of O
NET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
replenish O
the O
higher O
M O
( O
r O
) O
hNET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pool O
. O

We O
show O
that O
the O
upstream O
region O
of O
the O
beta B_GENE/B_BIO
- I_GENE/I_BIO
MyHC I_GENE/I_BIO
gene I_GENE/I_BIO
( O
- O
5518 O
to O
- O
2490 O
relative O
to O
the O
transcriptional O
start O
site O
) O
directed O
high O
levels O
of O
transcriptional O
activity O
only O
when O
stably O
integrated O
, O
but O
not O
when O
expressed O
extrachromosomally O
in O
transient O
assays O
. O

DNase B_GENE
I I_GENE
protection O
analysis O
as O
well O
as O
oligonucleotide O
competition O
experiments O
indicate O
that O
this O
binding O
is O
sequence O
specific O
. O

Plasmid O
pSP64E6E7 O
which O
contains O
the O
reading O
frames O
of O
both O
E6 B_PROTEIN[GENE]
and O
E7 B_PROTEIN[GENE]
was O
constructed O
in O
order O
to O
study O
the O
expression O
of O
both O
proteins O
in O
a O
coupled O
transcription O
/ O
rabbit O
reticulocyte O
translation O
system O
. O

In O
transient O
transfections O
using O
luciferase B_GENE/B_LOCATION
reporter I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
driven O
by O
1 O
kb O
of O
the O
5 O
' O
flanking O
DNA O
of O
the O
three O
CALM B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
, O
the O
promoter O
activity O
correlated O
with O
the O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CALM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O
activity O
, O
but O
only O
when O
the O
5 O
' O
untranslated O
regions O
were O
included O
in O
the O
constructs O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
PGE1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
increasing O
PVF B_DISEASE
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplanted I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
however O
, O
the O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
circulatory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attributed O
to O
this O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
be O
limited O
to O
the O
first B_TIME[MEASURE]/B_ENT
few I_TIME[MEASURE]/I_ENT
days I_TIME[MEASURE]/I_ENT
following O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
derepressed O
expression O
of O
fixN B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
observed O
in O
a O
purH B_DISEASE/B_PERSON
mutant I_DISEASE/I_PERSON
. O

Nearly O
1 B_MEASURE
. O
5 B_TIME[MEASURE]
million I_TIME[MEASURE]
American I_TIME[MEASURE]
men I_TIME[MEASURE]
age I_TIME[MEASURE]
65 I_TIME[MEASURE]
and O
older B_MEASURE/B_PERSON
have O
osteoporosis O
, O
and O
another O
3 B_NUMBER[MEASURE]
. O
5 B_TIME[MEASURE]
million I_TIME[MEASURE]
are O
at O
risk B_DISEASE/B_MEASURE
. O

Both O
viruses O
express O
the O
mil B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
raf B_GENE/B_DISEASE
oncogene O
product O
as O
a O
gag B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polyprotein O
, O
while O
the O
myc B_GENE/B_SPECIES[BIO]
oncogene O
of O
MH2 O
is O
expressed O
via O
a O
subgenomic O
mRNA O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
DaunoXome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
an O
improved B_DISEASE_ADJECTIVE[DISEASE]
pharmacokinetic B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O
with O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daunorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
is O
well O
tolerated O
. O

This O
regimen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
considered O
front B_LOCATION/B_SEQUENCE[MEASURE]
- O
line B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
when O
autologous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stem O
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
feasible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
when O
a O
rapid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
response I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
particularly O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recombinant O
protein O
encoded O
by O
ESX B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
for O
epithelial B_GENE
- I_GENE
restricted I_GENE
with I_GENE
serine I_GENE
box I_GENE
) O
exhibits O
Ets B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O
binding O
specificity O
in O
electrophoretic O
mobility O
shift O
assays O
and O
, O
in O
transient O
transfection O
assays O
, O
transactivates O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O
that O
found O
in O
the O
HER2 B_GENE
/ O
neu B_GENE/B_LOCATION
oncogene O
. O

In O
area B_LOCATION/B_BIO
CA1 I_LOCATION/I_BIO
of O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
, O
numbers B_MEASURE/B_LOCATION
of O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
increased O
11 B_NUMBER[MEASURE]
- O
to O
14 B_MEASURE
- O
fold B_MEASURE/B_BIO
by O
Mk B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
801 B_MEASURE
treatment I_MEASURE
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

The O
temporal O
changes O
in O
the O
plasma O
concentration O
of O
immunoreactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
atrial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
natriuretic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
iANF B_GENE/B_LOCATION
) O
were O
studied O
in O
six O
conscious O
dogs O
with O
an O
arteriovenous O
( O
AV O
) O
fistula O
, O
a O
model O
of O
chronic O
high O
- O
output O
heart O
failure O
. O

The O
revaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
at O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
good B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
compliance I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
proposed O
diet B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
scheme I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
by O
children B_PERSON
, O
but O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
their O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
. O

The O
delta B_MEASURE/B_LOCATION
G I_MEASURE/I_LOCATION
values I_MEASURE/I_LOCATION
of O
these O
regions B_DISEASE/B_GENE
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
i O
. O
e O
. O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
secondary I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
structural I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
elements I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
fewer B_DISEASE_ADJECTIVE[DISEASE]
, O
than O
in O
TIR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_SPECIES[BIO]/B_MEASURE
. O

Two O
closely O
related O
groups O
of O
transcripts O
, O
Sagrp1 B_GENE
and O
Sagrp2 B_PROTEIN[GENE]
, O
controlled O
by O
a O
circadian O
rhythm O
have O
been O
isolated O
. O

Of O
921 O
specimens O
, O
95 O
yielded O
non O
- O
albicans O
species O
, O
mainly O
from O
patients O
with O
low O
CD4 B_GENE/B_MEASURE
lymphocyte O
counts O
and O
extensive O
previous O
azole O
exposure O
. O

These O
findings O
suggest O
that O
eIF5 B_GENE
- O
eIF2beta B_GENE
interaction O
plays O
an O
essential O
role O
in O
eIF5 B_GENE
function O
in O
eukaryotic O
cells O
. O

Three B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
simple I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
detecting O
malnutrition B_DISEASE
on O
medical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
wards I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Compared O
with O
controls B_PERSON/B_BIO
, O
patients B_PERSON/B_BIO
in O
the O
unmedicated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O
low B_DISEASE/B_MEASURE
smooth I_DISEASE/I_MEASURE
pursuit I_DISEASE/I_MEASURE
gain I_DISEASE/I_MEASURE
, O
had O
a O
higher B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
of O
corrective B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
catch O
- O
up O
saccades B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
tended O
to O
spend O
less B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
engaged O
in O
the O
tracking B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Cytokine O
- O
mediated O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reappearance O
was O
completely O
blocked O
by O
the O
protein O
synthesis O
inhibitor O
cycloheximide O
. O

Development O
of O
P O
carinii O
pneumonia O
was O
associated O
with O
the O
stage O
of O
Kaposi O
' O
s O
sarcoma O
, O
B O
subtype O
disease O
, O
and O
the O
presence O
of O
0 O
. O
20 O
X O
10 O
( O
9 O
) O
/ O
L O
( O
200 O
/ O
mm3 O
) O
or O
fewer O
CD4 B_GENE/B_DISEASE
cells O
at O
study O
entry O
. O

The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
tilmicosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
feed B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
at O
400 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
and O
an O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
clinically O
diseased B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pigs I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
long O
- O
acting O
oxytetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Terramycine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
at O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
bodyweight I_MEASURE
were O
compared O
. O

Those O
participating O
in O
this O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
65 B_MEASURE/B_ORGANIZATION
centers I_MEASURE/I_ORGANIZATION
= O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
received O
a O
series B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
50 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
99mTc I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DMSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

pathogenesis B_DISEASE/B_TIME[MEASURE]
of O
fever B_DISEASE/B_GENE
. O

Two B_MEASURE/B_PERSON
full I_MEASURE/I_PERSON
- O
length B_GENE
clones I_GENE
( O
pBCH1 B_GENE
and O
pBCH2 B_GENE
) O
were O
isolated O
. O

Childbirth B_DISEASE/B_ORGANIZATION
and O
authoritative B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
knowledge I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
ends B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
barrel B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
capped O
by O
short B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
helices B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Non O
- O
finger O
- O
coding O
modules O
conserved O
among O
members O
of O
subfamilies O
of O
zinc B_BIO/B_GENE
finger I_BIO/I_GENE
genes I_BIO/I_GENE
have O
been O
described O
in O
the O
murine O
genome O
( O
finger O
- O
associated O
boxes O
, O
or O
FAX O
domain O
) O
and O
the O
human O
genome O
( O
Kruppel B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
associated I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
boxes I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
KRAB B_GENE/B_DISEASE
domain I_GENE/I_DISEASE
) O
. O

This O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
considered O
pathognomonic B_DISEASE_ADJECTIVE[DISEASE]
for O
factitious B_DISEASE/B_LOCATION
hyperinsulinism I_DISEASE/I_LOCATION
. O

comparison O
of O
the O
5 O
' O
flanking O
regions O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
J I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
the O
conserved O
putative O
recombination O
target O
sequences O
, O
shows O
no O
obvious O
differences O
consistent O
with O
the O
variation O
in O
recombinational O
efficiency O
, O
so O
we O
conclude O
that O
, O
although O
the O
consensus O
heptamer O
and O
nonamer O
signals O
may O
be O
sufficient O
to O
identify O
a O
recombination O
site O
, O
the O
probability O
that O
that O
site O
will O
be O
used O
depends O
also O
on O
other O
determinants O
. O

The O
melanoma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CXCL1 B_GENE/B_LOCATION
, O
is O
constitutively O
expressed O
at O
high O
levels O
during O
inflammation O
and O
progression O
of O
melanocytes O
into O
malignant O
melanoma O
. O

genetic O
analysis O
places O
CWH43 B_LOCATION/B_GENE
upstream O
of O
the O
BCK2 B_GENE
branch O
of O
the O
PKC1 B_GENE
signalling O
pathway O
, O
since O
cwh43 B_NUMBER[MEASURE]/B_LOCATION
mutations O
were O
synthetic O
lethal O
with O
pkc1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deletion O
, O
whereas O
the O
cwh43 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B_GENE
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B_GENE/B_DISEASE
pathway O
However O
, O
unlike O
BCK2 B_GENE/B_BIO
, O
whose O
disruption O
in O
a O
cln3 B_LOCATION/B_GENE
mutant B_LOCATION/I_GENE
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B_DISEASE_ADJECTIVE[DISEASE]
cln3 I_DISEASE_ADJECTIVE[DISEASE]
mutants I_DISEASE_ADJECTIVE[DISEASE]
. O

Twelve B_NUMBER[MEASURE]/B_PERSON
( O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
showed O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
including O
impairments B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
memory B_PERSON/B_DISEASE
, O
attention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
affective B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
anxiety B_DISEASE
, O
depression B_DISEASE
, O
irritability B_DISEASE
, O
and O
poor B_DISEASE
frustration I_DISEASE
tolerance I_DISEASE
) O
. O

To O
clarify O
the O
mechanisms O
that O
regulate O
transcription O
of O
the O
GTP B_GENE
cyclohydrolase I_GENE
I I_GENE
gene I_GENE
and O
to O
generate O
multiple O
species O
of O
mRNA O
, O
we O
isolated O
genomic O
DNA O
clones O
for O
the O
human O
and O
mouse O
GTP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclohydrolase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
, O
a O
structural O
interaction O
between O
PsaL B_GENE/B_BACTERIUM[BIO]
and O
PsaI B_GENE/B_BACTERIUM[BIO]
may O
stabilize O
the O
association O
of O
PsaL B_PROTEIN[GENE]/B_BACTERIUM[BIO]
with O
the O
photosystem B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
core I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

reversal O
of O
' O
refractory O
septic O
shock O
' O
by O
infusion O
of O
amrinone O
and O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
an O
anthracycline O
- O
treated O
patient O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deals O
with O
the O
screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
11 B_NUMBER[MEASURE]/B_BIO
of O
these O
plants B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
against O
the O
opportunistic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogen I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fungus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Candida I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
albicans I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

negative O
modulation O
of O
alpha1 B_GENE
( I_GENE
I I_GENE
) I_GENE
procollagen I_GENE
gene I_GENE
expression O
in O
human O
skin O
fibroblasts O
: O
transcriptional O
inhibition O
by O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

On O
the O
basis O
of O
this O
homology O
, O
we O
examined O
the O
potential O
role O
of O
c B_GENE
- I_GENE
Rel I_GENE
in O
controlling O
IL B_GENE
- I_GENE
2R I_GENE
alpha I_GENE
transcription O
. O

expression O
of O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentiated O
HS2 O
- O
mediated O
transactivation O
. O

We O
next O
developed O
a O
rapid O
purification O
method O
for O
bacterial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MyoD I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
affinity O
chromatography O
using O
a O
calmodulin B_GENE
- O
Sepharose O
column O
and O
investigated O
the O
phosphorylation O
of O
that O
peptide O
by O
PKC B_GENE
and O
its O
interactions O
with O
calmodulin B_GENE
and O
S100a B_GENE
. O

According O
to O
the O
penetration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ca B_LOCATION/B_PROTEIN[GENE]
- O
45 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
microleakage B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
scored O
for O
each O
section B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

HL B_GENE/B_DISEASE
is O
hypothesized O
to O
directly O
couple O
HDL B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lipid O
metabolism O
to O
tissue O
/ O
cellular O
lipid O
metabolism O
. O

Epstein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Barr I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exerts O
its O
transactivating O
function O
through O
interaction O
with O
recombination B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
J I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
homologue O
of O
Drosophila B_GENE
Suppressor I_GENE
of I_GENE
Hairless I_GENE
. O

Maduromycosis B_BACTERIUM[BIO]/B_LOCATION
in O
Italy B_LOCATION/B_BIO
. O

Two B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
were O
studied O
: O
Type B_MEASURE/B_DISEASE
I O
- O
- O
with O
a O
new B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ePTFE I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
graft I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O
and O
Type B_TIME[MEASURE]/B_PROTEIN[GENE]
II I_TIME[MEASURE]/I_PROTEIN[GENE]
- O
- O
with O
thrombectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
/ O
or O
revision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
previously O
placed O
ePTFE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
graft I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
author B_PERSON
describes O
the O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
detail B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
presents O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
25 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
( O
10 B_NUMBER[MEASURE]/B_SPORT[ENT]
men I_NUMBER[MEASURE]/I_SPORT[ENT]
and O
15 B_PERSON/B_NUMBER[MEASURE]
women I_PERSON/I_NUMBER[MEASURE]
) O
examined O
for O
suspected O
ileostomy B_DISEASE
dysfunction I_DISEASE
, O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Crohn B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
' B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
s B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
ileal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
obstruction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remote I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
stoma B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

increased O
susceptibility B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aphasics B_PERSON
to O
a O
distractor B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
recall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
verbal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
commands I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

lasting B_DISEASE
paraplegia I_DISEASE
caused O
by O
loss B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spinal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
interneurons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
no O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
correlation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
motor B_DISEASE_ADJECTIVE[DISEASE]
neuron I_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
existence B_DISEASE/B_ORGANIZATION
of O
universal B_MEASURE/B_BIO
non B_MEASURE/I_BIO
- O
specific B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
external B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
upon O
the O
living O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
the O
Del B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
suggested O
. O

RV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
7 B_MEASURE
. O
7 B_MEASURE
+ O
/ O
- O
1 B_MEASURE
. O
4 B_MEASURE
mmHg I_MEASURE
. O
ml B_MEASURE/B_PERSON
- O
1 B_MEASURE/B_LOCATION
. O
min B_MEASURE/B_PERSON
. O
100 B_MEASURE/B_LOCATION
g B_MEASURE/I_LOCATION
- O
1 B_MEASURE/B_LOCATION
and O
cv B_PROTEIN[GENE]/B_BIO
was O
0 B_MEASURE
. O
59 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
25 B_MEASURE
ml I_MEASURE
/ O
mmHg B_MEASURE
, O
tau B_PROTEIN[GENE]
v O
calculated O
from O
the O
product B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
RV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cv B_PROTEIN[GENE]/B_BIO
was O
4 B_MEASURE
. O
20 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE/B_LOCATION
. O
58 B_MEASURE
s I_MEASURE
and O
from O
the O
ratio B_MEASURE
of O
delta B_PROTEIN[GENE]/B_MEASURE
V O
to O
delta B_MEASURE/B_PROTEIN[GENE]
Q B_MEASURE/I_PROTEIN[GENE]
was O
4 B_MEASURE
. O
95 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_NUMBER[MEASURE]
. O
53 B_MEASURE
s I_MEASURE
( O
P B_OTHER/B_MEASURE
= O
NS B_MEASURE
) O
at O
a O
mean B_MEASURE/B_PERSON
Pel I_MEASURE/I_PERSON
of O
17 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
. O
7 B_MEASURE
mmHg I_MEASURE
. O
delta B_PROTEIN[GENE]/B_DISEASE
V I_PROTEIN[GENE]/I_DISEASE
was O
also O
produced O
by O
changing O
PV B_DISEASE/B_MEASURE
; O
the O
average B_MEASURE/B_PROTEIN[GENE]
Tau B_MEASURE/I_PROTEIN[GENE]
v O
( O
1 B_MEASURE
. O
95 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
37 B_MEASURE
s I_MEASURE
) O
, O
was O
shorter B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
with O
changes B_MEASURE
in O
flow B_MEASURE/B_PROTEIN[GENE]
. O

We O
constructed O
a O
stable O
, O
doubly O
transfected O
cell O
line O
( O
TIS O
- O
10 O
) O
carrying O
a O
chromosomally O
integrated O
ptetO7 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CMV I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O
construct O
and O
expressing O
the O
TetR B_GENE/B_DISEASE
- O
KRAB B_GENE/B_MEASURE
protein O
. O

We O
suggest O
that O
electrical O
stimulation O
of O
the O
NTS O
in O
rats O
undergoing O
such O
surgical O
preparation O
to O
observe O
the O
pressor O
response O
and O
/ O
or O
increase O
in O
pVP O
, O
represents O
a O
rapid O
approach O
for O
screening O
the O
neurosecretory O
function O
of O
the O
central O
neural O
integration O
to O
release O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

To O
study O
adaptive B_DISEASE_ADJECTIVE[DISEASE]
processes I_DISEASE_ADJECTIVE[DISEASE]
following O
spinal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
unstructured B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audiotaped I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interviews I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
conducted O
on O
an O
almost O
daily B_TIME[MEASURE]/B_PERSON
basis B_TIME[MEASURE]/I_PERSON
with O
a O
30 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
divorced O
male B_PERSON
during O
the O
first B_TIME[MEASURE]/B_LOCATION
3 I_TIME[MEASURE]/I_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
his O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
comprehensive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
inpatient I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
rehabilitation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
. O

Melioidosis B_DISEASE_ADJECTIVE[DISEASE]
in O
Sika B_LOCATION
deer I_LOCATION
( O
Cervus B_LOCATION
Nippon I_LOCATION
Nippon I_LOCATION
) O
. O

Enterobius B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vermicularis B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eggs B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
demonstrated O
during O
microscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
smear B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
taken O
from O
the O
posterior B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
fornix I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
vagina B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Together O
with O
previous O
work O
our O
results O
suggest O
that O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
a O
general O
cooperation O
partner O
for O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
myelomonocytic O
cells O
. O

When O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
aid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
sought O
a O
false B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
given O
and O
the O
true B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
child B_PERSON
' O
s B_DISEASE
illness I_DISEASE
, O
heat B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stroke B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
, O
was O
not O
determined O
until O
after O
death B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
DMP2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
DMP3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
closely O
localized O
on O
mouse O
chromosome O
5q21 O
, O
corresponding O
to O
human O
chromosome O
4q21 O
. O

This O
article B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
expands O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
a O
numeric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
example I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
included O
in O
the O
SAS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GLM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cover O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
crucial I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
statistical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aspects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relevant I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
ANCOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
to O
highlight O
the O
meaning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
. O

A O
novel O
alternative O
spliced O
variant O
of O
the O
transcription O
factor O
AP2alpha B_GENE
is O
expressed O
in O
the O
murine O
ocular O
lens O
. O

Fig1p B_GENE/B_PERSON
and O
Fig2p B_PROTEIN[GENE]/B_LOCATION
are O
likely O
to O
act O
at O
the O
cell O
surface O
as O
Fig1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O
: O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gal I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Fig2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O
: O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localize O
to O
the O
periphery O
of O
mating O
cells O
. O

crystals O
of O
the O
triple O
mutant O
A42D B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
D47P B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
A63L B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
stable O
for O
days O
in O
its O
oxidized O
form O
, O
were O
grown O
from O
ammonium O
sulfate O
, O
with O
the O
cell O
constants O
a O
= O
b O
= O
34 O
. O
3 O
A O
and O
c O
= O
111 O
. O
8 O
A O
belonging O
to O
space O
group O
P3 O
( O
2 O
) O
21 O
. O

Nevertheless O
, O
PEG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
influenced O
in O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
availability I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
considerably O
, O
by O
increasing O
both O
drug B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
solubility I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
dissolution B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
. O

Normal O
replication O
of O
DNA B_BIO/B_GENE
A I_BIO/I_GENE
still O
carrying O
the O
AC3 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ORF I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O
was O
found O
in O
extracts O
from O
these O
plants O
. O

Such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
often O
occurs O
for O
several B_ENT/B_TIME[MEASURE]
recording B_ENT/I_TIME[MEASURE]
sweeps B_ENT/I_TIME[MEASURE]
after O
large B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
amplitude B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signals B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
such B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
eye B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blinks I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
rejected O
. O

muscle O
and O
liver O
biopsies O
demonstrated O
the O
same O
anomalies O
, O
again O
without O
branching B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
deficiency O
in O
the O
liver O
. O

possibility B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
using O
gynecologic B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nurses I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
independently O
administered O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
centers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Airborne B_MEASURE/B_DISEASE
rabies I_MEASURE/I_DISEASE
encephalitis I_MEASURE/I_DISEASE
: O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
rabies B_DISEASE/B_SPECIES[BIO]
virus I_DISEASE/I_SPECIES[BIO]
in O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
central I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

T1 B_PROTEIN[GENE]/B_LOCATION
and O
T2 B_MEASURE
values I_MEASURE
were O
calculated O
from O
guinea B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pig I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
brain I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
vivo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O
0 B_MEASURE
. O
5 B_MEASURE/B_LOCATION
T I_MEASURE/I_LOCATION
. O

Autophosphorylation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
major B_GENE
phosphorylation I_GENE
site I_GENE
Y1235 I_GENE
upregulates O
the O
kinase B_MEASURE
activity I_MEASURE
of O
the O
receptor B_GENE
, O
increasing O
the O
Vmax B_MEASURE
of O
the O
phosphotransfer B_ENZYME[GENE]
reaction I_ENZYME[GENE]
. O

Clinical O
development O
of O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

By O
cloning O
genes O
encoding O
benzene O
- O
degradative O
enzymes O
, O
we O
found O
that O
strain O
JS150 O
also O
carries O
genes O
for O
a O
toluene B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
benzene I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
monooxygenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
data O
suggest O
that O
association O
of O
TBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
TATA O
box O
may O
be O
regulated O
, O
directly O
or O
indirectly O
, O
by O
a O
substrate O
of O
Snf1 B_GENE
. O

Fusion B_NUMBER[MEASURE]/B_GENE
proteins I_NUMBER[MEASURE]/I_GENE
were O
isolated O
by O
affinity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
APTG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Sepharose B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
differed O
from O
cued B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recall I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
in O
the O
instructions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
, O
which O
directed O
subjects B_PERSON
away O
from O
the O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
aspects B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
asked O
them O
to O
complete O
each O
three B_NUMBER[MEASURE]
- O
letter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cue I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
first B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
word I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
came O
to O
mind B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O

Real B_PERSON/B_NUMBER[MEASURE]
- O
time B_NUMBER[MEASURE]/B_ENT
two I_NUMBER[MEASURE]/I_ENT
- O
dimensional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
mitral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valve I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
short B_MEASURE/B_PERSON
- O
axis B_TIME[MEASURE]/B_LOCATION
view I_TIME[MEASURE]/I_LOCATION
were O
obtained O
from O
10 B_PERSON/B_MEASURE
normal I_PERSON/I_MEASURE
subjects I_PERSON/I_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
sixty B_NUMBER[MEASURE]/B_LOCATION
- O
one B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_BIO
had O
damage B_DISEASE
within O
7 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
onset B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
mean B_MEASURE
3 I_MEASURE
. O
8 B_TIME[MEASURE]
yrs I_TIME[MEASURE]
) O
. O

It O
was O
previously O
shown O
that O
Vi B_GENE/B_DISEASE
antigen I_GENE/I_DISEASE
expression O
was O
regulated O
by O
a O
system O
similar O
to O
the O
rcs B_DISEASE_ADJECTIVE[DISEASE]
regulatory O
system O
involved O
in O
colanic O
acid O
synthesis O
in O
Escherichia O
coli O
. O

The O
map B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
based O
on O
the O
CEPH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pedigrees I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
includes O
over O
4000 B_MEASURE/B_ORGANIZATION
new I_MEASURE/I_ORGANIZATION
genotypes I_MEASURE/I_ORGANIZATION
, O
our O
previously O
reported O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
29 B_GENE/B_PERSON
allele I_GENE/I_PERSON
systems I_GENE/I_PERSON
from O
the O
published O
CEPH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
version I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
was O
constructed O
using O
the O
program B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
package B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Cri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
Map B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
identify O
the O
GRK6 B_GENE/B_LOCATION
homologue I_GENE/I_LOCATION
on O
chromsome O
13 O
, O
several O
sets O
of O
closely O
- O
spaced O
primers O
were O
designed O
based O
on O
the O
GRK6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
then O
used O
to O
amplify O
human O
genomic O
DNA O
by O
PCR O
. O

In O
the O
absence O
of O
Mg2 O
+ O
, O
the O
extent O
of O
destabilization O
of O
tRNAPhe B_GENE
is O
greater O
but O
appears O
to O
be O
confined O
to O
internal O
regions O
of O
the O
acceptor O
and O
T O
psi O
C O
helices O
, O
as O
evidenced O
by O
the O
selectively O
enhanced O
exchange O
rates O
for O
imino O
protons O
associated O
with O
these O
base O
pairs O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
26 B_EDU[ORGANIZATION]/B_LOCATION
patients I_EDU[ORGANIZATION]/I_LOCATION
. O

Serum B_MEASURE/B_GENE
alpha I_MEASURE/I_GENE
- I_MEASURE/I_GENE
amylase I_MEASURE/I_GENE
, O
trypsin B_ENZYME[GENE]
, O
trypsin B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lipase B_ENZYME[GENE]
and O
total O
protease O
activity O
in O
the O
pancreatic O
tissue O
was O
studied O
as O
indicator O
of O
the O
treatment O
efficacy O
with O
5 O
- O
fluorouracil O
electro O
- O
cumulation O
. O

1 B_MEASURE
The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
piretanide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diuretic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemically O
related O
to O
frusemide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
bumetanide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
evaluated O
in O
twelve B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
severe B_DISEASE/B_GENE
chronic I_DISEASE/I_GENE
renal I_DISEASE/I_GENE
insufficiency I_DISEASE/I_GENE
( O
creatinine B_MEASURE/B_DISEASE
clearance B_MEASURE/I_DISEASE
below O
25 B_MEASURE
ml I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
) O
. O

synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
22 B_MEASURE
- O
oxavitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analogues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
effect O
is O
independent O
of O
the O
Gal4 B_GENE
protein I_GENE
, O
as O
it O
operates O
in O
a O
gal4 B_DISEASE_ADJECTIVE[DISEASE]
mutant I_DISEASE_ADJECTIVE[DISEASE]
background O
as O
well O
. O

consistent O
with O
the O
large O
pocket O
of O
Rb B_GENE
binding O
to O
TAF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
large O
pocket O
domains O
of O
both O
p107 B_GENE/B_DISEASE
and O
p130 B_GENE
are O
able O
to O
bind O
to O
TAF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
. O

50 B_NUMBER[MEASURE]
- O
nucleotide B_MEASURE
) O
intron B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
AA B_GENE/B_DISEASE
. O

The O
educational B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
the O
significant B_MEASURE/B_ORGANIZATION
factor I_MEASURE/I_ORGANIZATION
that O
influenced O
the O
change B_MEASURE
of O
concern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trajectories I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
/ O
non B_DISEASE/B_LOCATION
- O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
influenced O
the O
change B_MEASURE/B_ORGANISM_FUNCTION
of O
concern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
in O
pamphlet B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
. O

Amplification O
of O
4q21 O
- O
q22 O
and O
the O
MXR B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
in O
independently O
derived O
mitoxantrone O
- O
resistant O
cell O
lines O
. O

activation O
of O
the O
receptor O
induces O
Ret B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O
that O
leads O
the O
survival O
- O
promoting O
effects O
. O

In O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
these O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
not O
met O
only O
the O
reproducibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
VO2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
in O
both O
the O
P B_PROTEIN[GENE]/B_LOCATION
- O
MET B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
C B_OTHER/B_PROTEIN[GENE]
- O
MET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
indicated O
that O
the O
maximal B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VO2 B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
4 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
had O
been O
reached O
. O

This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O
a O
course B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
an O
agoraphobic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
female I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
patient I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

A O
previously O
developed O
kinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
used O
to O
identify O
major B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
PAH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
afterburner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Henry B_PERSON
Quastler I_PERSON
brought O
experience B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
an O
actual B_MEASURE/B_LOCATION
x I_MEASURE/I_LOCATION
- O
ray B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
and O
Dr B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Critical O
review O
of O
tests O
for O
the O
HBs B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
detection O
of O
infectious O
blood O
. O

A O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
statistically O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
decrease B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
enzymes B_PROTEIN[GENE]/B_MEASURE
with O
the O
initial B_TIME[MEASURE]/B_LOCATION
state I_TIME[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON/B_DISEASE
has O
been O
established O
in O
an O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
25 B_PERSON/B_BIO
patients I_PERSON/I_BIO
aged O
from O
18 B_MEASURE
to O
60 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
in O
prosthesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
+ B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
mitral B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
valve I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_MEASURE
- O
9 B_MEASURE
) O
and O
closed B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
commissurotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
n O
- O
16 B_MEASURE
) O
. O

DSS4 B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
is O
a O
dominant O
suppressor O
of O
sec4 B_GENE/B_BACTERIUM[BIO]
- B_GENE/I_BACTERIUM[BIO]
8 B_GENE/I_BACTERIUM[BIO]
that O
encodes O
a O
nucleotide O
exchange O
protein O
that O
aids O
Sec4p B_GENE
function O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
KCTG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O
contribute O
to O
improved O
monitoring B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pregnancies I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
MI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
site B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
hemodynamic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
left O
ventricular B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
both O
at O
rest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
during O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O
anterior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MIs I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
more O
impaired B_DISEASE_ADJECTIVE[DISEASE]
than O
inferior B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
MIS I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

The O
vaccine O
was O
highly O
immunogenic O
, O
since O
111 O
of O
113 O
patients O
( O
98 O
% O
) O
produced O
anti B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HBs B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
mIU O
/ O
ml O
or O
more O
) O
. O

The O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
2R I_PROTEIN[GENE]/I_LOCATION
alpha I_PROTEIN[GENE]/I_LOCATION
) O
chain O
gene O
contains O
a O
sequence O
similar O
to O
the O
immunoglobulin B_GENE
( I_GENE
Ig I_GENE
) I_GENE
kappa I_GENE
( O
Kappa O
) O
enhancer O
NF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
kappa I_GENE/I_LOCATION
B I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
. O

comparison O
of O
the O
derived O
amino O
acid O
sequence O
with O
that O
of O
the O
HCMV B_GENE/B_PERSON
UL99 I_GENE/I_PERSON
gene I_GENE/I_PERSON
product I_GENE/I_PERSON
reveals O
34 O
. O
8 O
% O
identity O
in O
an O
overlap O
of O
66 O
amino O
acids O
. O

Although O
mutant B_SPECIES[BIO]/B_GENE
pex5delta I_SPECIES[BIO]/I_GENE
cells O
expressing O
a O
yeast B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tobacco I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pex5p I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimaera I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
import O
a O
GFP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Eci1p B_GENE
reporter O
protein O
, O
they O
were O
able O
to O
grow O
on O
oleic O
acid O
. O

consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O
a O
TGFbeta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
insensitive O
LEF1 B_GENE/B_LOCATION
/ O
TCF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O
gene O
confers O
cooperative O
TGFbeta B_GENE/B_DISEASE
and O
Wnt B_GENE
responsiveness O
to O
the O
promoter O
. O

In O
analogy O
to O
human B_GENE
CD70 I_GENE
, O
mCD70 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcript I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
are O
strongly O
but O
transiently O
up O
- O
regulated O
during O
lymphocyte O
activation O
, O
which O
is O
in O
line O
with O
a O
role O
for O
the O
CD27 B_GENE
- I_GENE
CD70 I_GENE
receptor I_GENE
pair O
early O
in O
the O
immune O
response O
. O

Serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgM I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
showed O
a O
highly O
significant O
increase O
in O
all O
types O
of O
brain O
tumour O
when O
compared O
to O
controls O
. O

Beyond O
the O
first B_DISEASE/B_MEASURE
year I_DISEASE/I_MEASURE
post I_DISEASE/I_MEASURE
- O
renal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O
was O
no O
difference B_MEASURE
in O
C B_DISEASE/B_GENE
( O
IO B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
between O
LRD B_DISEASE_ADJECTIVE[DISEASE]
and O
CAD B_LOCATION/B_DISEASE
allografts I_LOCATION/I_DISEASE
. O

Vk8 B_GENE
/ O
Jk2 B_MEASURE
and O
Vk1 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Jk5 B_GENE/B_MEASURE
rearrangements O
encoded O
the O
respective O
L B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
phenomena B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
nursing B_PERSON
are O
deeply O
rooted O
in O
the O
human B_PERSON/B_LOCATION
condition I_PERSON/I_LOCATION
. O

Clinical B_MEASURE/B_LOCATION
findings B_MEASURE/I_LOCATION
plaque B_MEASURE/I_LOCATION
index B_MEASURE/I_LOCATION
, O
Pi B_LOCATION/B_PROTEIN[GENE]
; O
gingival B_MEASURE/B_DISEASE
index B_MEASURE/I_DISEASE
, O
GI B_LOCATION/B_PROTEIN[GENE]
; O
bleeding O
on O
probing O
, O
BOP B_LOCATION/B_DISEASE
; O
pus B_DISEASE
discharge I_DISEASE
, O
pus B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
and O
probing O
depth B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
PD B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
both O
PT B_LOCATION/B_PROTEIN[GENE]
- O
01 B_MEASURE/B_LOCATION
and O
control B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
at O
every O
visit B_PERSON/B_LOCATION
for O
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
these O
elements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resembles O
the O
binding O
site B_LOCATION/B_MEASURE
of O
a O
previously O
identified O
cellular B_DISEASE/B_SPECIES[BIO]
' O
transcription B_GENE/B_DISEASE
' O
factor B_MEASURE/B_LOCATION
. O

NER O
was O
also O
measured O
by O
a O
plasmid O
host O
cell O
re O
- O
activation O
assay O
using O
a O
vector O
containing O
a O
luciferase B_GENE
reporter I_GENE
gene I_GENE
. O

plasma B_MEASURE/B_LOCATION
Pi I_MEASURE/I_LOCATION
, O
tibia B_MEASURE/B_LOCATION
breaking B_MEASURE/I_LOCATION
strength B_MEASURE/I_LOCATION
, O
and O
percentage B_MEASURE/B_DISEASE
of O
tibia B_MEASURE/B_DISEASE
ash B_MEASURE/I_DISEASE
were O
increased O
by O
raising O
dietary B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
Pav B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
in O
the O
presence B_LOCATION/B_MEASURE
of O
. O
392 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
either O
level B_MEASURE/B_LOCATION
of O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
total B_MEASURE
of O
114 B_MEASURE
animals I_MEASURE
were O
infected O
by O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_BACTERIUM[BIO]
O2 I_BACTERIUM[BIO]
: O
K1 B_PROTEIN[GENE]/B_MEASURE
: O
H4 B_MEASURE/B_LOCATION
by O
the O
hematogenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
route I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
fungus O
Neurospora O
crassa O
, O
nit B_GENE
- I_GENE
2 I_GENE
, O
the O
major O
nitrogen O
regulatory O
gene O
, O
activates O
the O
expression O
of O
unlinked O
structural O
genes O
that O
specify O
nitrogen O
- O
catabolic O
enzymes O
during O
conditions O
of O
nitrogen O
limitation O
. O

The O
matrix O
of O
the O
CBS O
contains O
the O
diagnostic O
protein O
p80 B_PROTEIN[GENE]/B_DISEASE
- O
coilin B_MEASURE/B_LOCATION
, O
which O
is O
colocalized O
with O
the O
U7 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
snRNP O
) O
, O
whereas O
the O
attached O
and O
embedded O
B O
- O
snurposomes O
contain O
splicing O
snRNPs O
. O

During O
an O
observation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
12 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
halving O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
from O
a O
mean B_MEASURE/B_LOCATION
dose I_MEASURE/I_LOCATION
of O
82 B_MEASURE
mg I_MEASURE
to O
41 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
systolic B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
diastolic B_MEASURE/B_DISEASE
blood B_MEASURE/I_DISEASE
pressure B_MEASURE/I_DISEASE
or O
in O
response B_DISEASE/B_GENE
rate I_DISEASE/I_GENE
( O
defined O
as O
a O
diastolic B_MEASURE/B_LOCATION
blood I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
of O
95 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
Hg I_NUMBER[MEASURE]
or O
less B_MEASURE
) O
were O
observed O
. O

Comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
volumetric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
defined O
as O
the O
difference B_MEASURE
between O
mean B_MEASURE
corpuscular I_MEASURE
erythrocyte I_MEASURE
volume I_MEASURE
in O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
MCVB B_LOCATION/B_DISEASE
) O
diluted O
in O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supernatant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O
centrifugation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
mean B_MEASURE/B_LOCATION
corpuscular I_MEASURE/I_LOCATION
volume I_MEASURE/I_LOCATION
of O
urinary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythrocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MCVU B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

patients O
: O
33 O
HIV O
- O
infected O
, O
zidovudine O
- O
experienced O
patients O
with O
serum O
HIV O
RNA O
levels O
of O
at O
least O
20 O
, O
000 O
copies O
/ O
mL O
and O
CD4 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
counts O
ranging O
from O
50 O
to O
400 O
cells O
/ O
mm3 O
. O

Within O
the O
last B_TIME[MEASURE]/B_ENT
few I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
, O
the O
www B_ORGANIZATION/B_LOCATION
has O
grown O
enormously O
. O

These O
data O
, O
taken O
together O
, O
suggest O
that O
CRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produces O
its O
behavioral O
activating O
and O
anxiogenic O
effects O
, O
at O
least O
in O
part O
, O
by O
increasing O
the O
activity O
of O
LC O
noradrenergic O
neurons O
. O

On O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
8 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O
different B_LOCATION/B_ENT
clinical I_LOCATION/I_ENT
pictures I_LOCATION/I_ENT
all O
caused O
by O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
5FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
sequence O
of O
Vac1p B_GENE/B_BIO
contains O
two O
putative O
zinc O
- O
binding O
Ring O
motifs O
, O
a O
zinc O
finger O
motif O
, O
and O
a O
coiled O
- O
coil O
motif O
. O

Although O
cardiac B_MEASURE/B_DISEASE
output B_MEASURE/I_DISEASE
decreased O
slightly O
with O
PCF B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
hemodynamic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O
to O
PCF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
unlikely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
account O
for O
the O
observed O
fall B_DISEASE_ADJECTIVE[DISEASE]
in O
PaO2 B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Anti B_PERSON/B_DISEASE
- I_PERSON/I_DISEASE
Jo I_PERSON/I_DISEASE
- I_PERSON/I_DISEASE
1 I_PERSON/I_DISEASE
antibody I_PERSON/I_DISEASE
was O
not O
present O
. O

The O
first O
operon O
, O
orf1 O
- O
tolQRA B_MEASURE
, O
is O
iron O
regulated O
throughout O
growth O
, O
but O
iron O
- O
regulated O
expression O
of O
tolB B_GENE/B_BACTERIUM[BIO]
and O
oprL B_DISEASE/B_GENE
fusions B_DISEASE/I_GENE
occurs O
only O
in O
late O
log O
phase O
. O

S B_LOCATION/B_DISEASE
. O
aureus B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
leakage B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
into O
the O
totally O
submerged B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
detected O
in O
1 B_NUMBER[MEASURE]/B_LOCATION
of O
5 B_MEASURE/B_PERSON
samples I_MEASURE/I_PERSON
incubated O
for O
4 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
while O
no O
leakage B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
detected O
in O
specimens B_BIO/B_PERSON
incubated O
for O
3 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
6 B_SEQUENCE[MEASURE]
, O
7 B_SEQUENCE[MEASURE]
, O
and O
8 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
. O

We O
examined O
the O
contribution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
cryptic B_GENE/B_BIO
plasmid I_GENE/I_BIO
, O
pRmeGR4b O
, O
to O
the O
nodulation B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
Medicago B_BIO/B_DISEASE
sativa I_BIO/I_DISEASE
by O
strain B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GR4 B_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Rhizobium B_BIO/B_LOCATION
meliloti I_BIO/I_LOCATION
. O

It O
also O
appears O
that O
in O
patients B_PERSON/B_LOCATION
with O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prerenal B_DISEASE
acute I_DISEASE
renal I_DISEASE
failure I_DISEASE
( O
i O
. O
e O
. O
, O
a O
RFT B_MEASURE
less I_MEASURE
than O
1 B_NUMBER[MEASURE]
. O
0 B_MEASURE
) O
, O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unpredictable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
in O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
have O
a O
worse B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
in O
those O
with O
a O
RFI B_MEASURE/B_ORGANIZATION
greater I_MEASURE/I_ORGANIZATION
than O
1 B_NUMBER[MEASURE]
. O
0 B_MEASURE
( O
5 B_MEASURE
/ O
7 B_MEASURE
deaths I_MEASURE
vs I_MEASURE
10 I_MEASURE
/ O
48 B_MEASURE
deaths I_MEASURE
) O
. O

Paraplegia B_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
intraaortic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balloon I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counterpulsation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
GDP B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
GTP B_GENE/B_LOCATION
, O
ITP B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
did O
not O
affect O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
green B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusions O
we O
demonstrate O
that O
the O
SYT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SSX B_LOCATION/B_GENE
and O
the O
SYT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
SSX B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O
are O
nuclear O
proteins O
. O

The O
anaesthetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
41 B_PERSON
patients I_PERSON
who O
underwent O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
during O
a O
40 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
month B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
at O
Clinica B_LOCATION/B_PERSON
Puerta I_LOCATION/I_PERSON
de I_LOCATION/I_PERSON
Hierro I_LOCATION/I_PERSON
is O
reviewed O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
respiratory I_DISEASE_ADJECTIVE[DISEASE]
distress I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
suggested O
that O
mutant B_DISEASE
PS1 I_DISEASE
may O
cause O
disease O
as O
a O
result O
of O
reduction O
in O
PS1 B_GENE
function O
. O

The O
analysis O
of O
the O
organization O
of O
the O
sequence O
of O
the O
human O
ABP B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
DAO B_LOCATION/B_PROTEIN[GENE]
gene O
reveals O
that O
the O
2 O
. O
4 O
- O
kilobase O
messenger O
RNA O
is O
transcribed O
from O
two O
close O
origins O
identifying O
the O
proximal O
promoter O
. O

Most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
all O
, O
is O
not O
the O
ionization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
the O
stage B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
47 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
five I_MEASURE
- O
year B_SEQUENCE[MEASURE]/B_LOCATION
survival I_SEQUENCE[MEASURE]/I_LOCATION
rate I_SEQUENCE[MEASURE]/I_LOCATION
in O
T1N0 B_PROTEIN[GENE]/B_MEASURE
as O
compared O
to O
T2N0 B_PROTEIN[GENE]/B_DISEASE
with O
28 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
T1N1 B_PROTEIN[GENE]/B_MEASURE
with O
19 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

To O
investigate O
the O
step O
of O
spliceosome O
assembly O
at O
which O
Snu17p B_GENE
acts O
, O
we O
have O
used O
nondenaturing O
gel O
electrophoresis O
. O

We O
also O
show O
that O
an O
internal O
fragment O
of O
U24 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
guide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
snoRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
encompassing O
the O
upstream O
antisense O
element O
and O
the O
D O
' O
and O
C O
' O
box O
motifs O
, O
can O
support O
the O
site O
- O
specific O
methylation O
of O
rRNA O
. O

Mammalian O
ribonucleotide B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
S O
- O
phase O
specific O
expression O
and O
consists O
of O
two O
non O
- O
identical O
subunits O
, O
proteins B_PROTEIN[GENE]/B_DISEASE
R1 I_PROTEIN[GENE]/I_DISEASE
( O
large O
subunit O
) O
and O
R2 B_PROTEIN[GENE]
( O
small O
subunit O
) O
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
radiation B_DISEASE
nephropathy I_DISEASE
in O
the O
rat B_BIO/B_PERSON
. O

Recombinant B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MsERK1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
rMsERK1 B_GENE
) O
, O
when O
overexpressed O
in O
Escherichia O
coli O
, O
is O
recognized O
by O
antibodies O
raised O
against O
MAP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rat I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Xenopus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
star I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
anti B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotyrosine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibodies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
identification O
of O
SRP54sc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SRP54sp B_GENE
provides O
the O
first O
evidence O
for O
SRP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
related O
proteins O
in O
yeast O
. O

We O
previously O
demonstrated O
that O
AKT2 B_GENE
, O
a O
member O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
activated O
by O
a O
number O
of O
growth O
factors O
via O
Ras B_GENE/B_DISEASE
and O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
signaling O
pathways O
. O

So O
it O
is O
sometimes O
more O
convenient B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
use O
the O
back B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
radon I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transform O
R B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_LOCATION
and O
then O
to O
correct O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Before O
flecainide B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
all O
patients B_PERSON/B_BIO
had O
easily O
inducible B_DISEASE
VT I_DISEASE
that O
was O
morphologically O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
their O
spontaneously O
occurring O
arrhythmia B_DISEASE/B_PERSON
. O

An O
additional B_MEASURE/B_LOCATION
dose I_MEASURE/I_LOCATION
of O
20 B_MEASURE/B_LOCATION
- O
25 B_MEASURE/B_PERSON
Gy I_MEASURE/I_PERSON
was O
delivered O
to O
the O
site B_LOCATION/B_PERSON
of O
original B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
involvement B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O
an O
implant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
when O
feasible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
prominent B_DISEASE/B_MEASURE
fracture I_DISEASE/I_MEASURE
of O
women B_PERSON/B_TIME[MEASURE]
older B_PERSON/I_TIME[MEASURE]
than O
75 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
is O
the O
hip B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fracture B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
osteoporosis I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
expected O
products O
of O
the O
cloned O
bph B_GENE
genes I_GENE
, O
except O
bphA3 B_GENE/B_BIO
, O
were O
observed O
in O
E O
. O
coli O
in O
an O
in O
vitro O
transcription O
- O
translation O
system O
. O

It O
is O
our O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
Sonoclot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coagulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
analysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
unlikely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
identify O
patients B_PERSON/B_BIO
with O
prolonged B_DISEASE
bleeding I_DISEASE
time I_DISEASE
in O
whom O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
count B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
other B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coagulation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
Pearson B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
the O
subjects B_PERSON
who O
had O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SSMS B_DISEASE
during O
the O
drum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rotation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generated O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
a O
) O
a O
higher B_MEASURE
rating I_MEASURE
of O
over O
- O
all O
sickness B_DISEASE/B_MEASURE
( O
r B_PROTEIN[GENE]/B_MEASURE
= O
0 B_NUMBER[MEASURE]
. O
76 B_MEASURE
) O
; O
b O
) O
a O
higher B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
of O
spectral B_MEASURE/B_LOCATION
power I_MEASURE/I_LOCATION
of O
egg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
4 B_NUMBER[MEASURE]
- O
9 B_NUMBER[MEASURE]/B_LOCATION
cycles I_NUMBER[MEASURE]/I_LOCATION
per O
minute B_TIME[MEASURE]
( O
cpm B_MEASURE/B_PROTEIN[GENE]
) O
between O
drum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O
baseline B_MEASURE/B_ENT
periods B_MEASURE/I_ENT
( O
r B_OTHER/B_PROTEIN[GENE]
= O
0 B_NUMBER[MEASURE]
. O
63 B_MEASURE
) O
; O
c O
) O
a O
higher B_MEASURE
net I_MEASURE
percent I_MEASURE
increase I_MEASURE
of O
spectral B_MEASURE/B_LOCATION
power I_MEASURE/I_LOCATION
in O
the O
EEG B_MEASURE
frequency I_MEASURE
band I_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
- O
4 B_MEASURE
Hz I_MEASURE
between O
drum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
rotation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O
baseline B_TIME[MEASURE]/B_LOCATION
periods I_TIME[MEASURE]/I_LOCATION
on O
C3 B_PROTEIN[GENE]
( O
r B_PROTEIN[GENE]
= O
0 B_NUMBER[MEASURE]
. O
29 B_MEASURE
) O
and O
C4 B_PROTEIN[GENE]
( O
r B_PROTEIN[GENE]/B_MEASURE
= O
0 B_NUMBER[MEASURE]
. O
31 B_MEASURE
) O
; O
d O
) O
a O
higher B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
of O
spectral B_MEASURE/B_LOCATION
power I_MEASURE/I_LOCATION
of O
EEG B_MEASURE
frequency I_MEASURE
band I_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
- O
4 B_MEASURE
Hz I_MEASURE
between O
drum B_MEASURE/B_ENT
rotation I_MEASURE/I_ENT
and O
baseline B_TIME[MEASURE]/B_ENT
periods I_TIME[MEASURE]/I_ENT
on O
C3 B_MEASURE/B_GENE
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE/B_LOCATION
. O
31 B_MEASURE
) O
; O
and O
e O
) O
a O
higher B_MEASURE
level I_MEASURE
of O
net B_MEASURE
increase I_MEASURE
in O
skin B_MEASURE/B_DISEASE
conductance I_MEASURE/I_DISEASE
from O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
drum B_MEASURE
rotation I_MEASURE
( O
r B_MEASURE/B_GENE
= O
0 B_NUMBER[MEASURE]
. O
30 B_MEASURE
) O
. O

salts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
these O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metal I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O
be O
added O
to O
the O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
medium I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
to O
facilitate O
selective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
isolation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
Acinetobacter B_BIO/B_GENE
. O

The O
consensus O
mammalian O
ER O
stress O
response O
element O
( O
ERSE O
) O
conserved O
among O
grp B_SPECIES[BIO]/B_GENE
promoters I_SPECIES[BIO]/I_GENE
consists O
of O
a O
tripartite O
structure O
CCAAT O
( O
N9 O
) O
CCACG O
, O
with O
N O
being O
a O
strikingly O
GC O
- O
rich O
region O
of O
9 O
BP O
. O

Acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
conducted O
to O
measure O
the O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
first B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instar I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Toxorhynchites I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splendens I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
commonly O
used O
mosquito B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adulticides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
malathion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
naled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resmethrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
positive O
correlation O
was O
also O
established O
between O
the O
level O
of O
FP9C B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
and O
the O
degree O
of O
cell O
differentiation O
in O
vitro O
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acute B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
cold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
pulmonary B_DISEASE
arterial I_DISEASE
blood I_DISEASE
pressure I_DISEASE
in O
awake B_PERSON/B_BIO
rats B_PERSON/I_BIO
. O

When O
labeled O
by O
the O
described O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
DTPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
coupled O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
instability B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
superior B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stability B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
the O
attached B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DTPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Unlike O
CSK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
SH3 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
HYL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
unique O
since O
the O
ALYDY O
motif O
was O
absent O
. O

As O
the O
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
intractability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
involved O
in O
the O
defense B_ORGANIZATION/B_DISEASE
against O
infection B_DISEASE
was O
evaluated O
. O

88 B_MEASURE
, O
3739 B_MEASURE
- O
3743 B_MEASURE
) O
) O
. O

objective B_MEASURE
: O
To O
report O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fulminant B_DISEASE/B_PERSON
neuropathy I_DISEASE/I_PERSON
with O
severe B_DISEASE
quadriparesis I_DISEASE
associated O
with O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
median B_TIME[MEASURE]/B_PERSON
survival I_TIME[MEASURE]/I_PERSON
time I_TIME[MEASURE]/I_PERSON
was O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

Hemorrheological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
proposed O
pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Its O
phosphorylation O
strongly O
potentiates O
its O
ability O
to O
activate O
transcription O
of O
the O
c B_GENE
- I_GENE
fos I_GENE
promoter I_GENE
through O
a O
ternary O
complex O
assembled O
on O
the O
c B_GENE
- I_GENE
fos I_GENE
serum I_GENE
response I_GENE
element I_GENE
. O

Fus3p B_GENE
and O
Kss1p B_GENE/B_LOCATION
together O
increase O
the O
expression O
of O
CLN3 B_GENE/B_DISEASE
and O
PCL2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
promote O
budding O
, O
and O
Kss1p B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
inhibits O
the O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cascade O
. O

consistent O
with O
our O
observation O
that O
AP B_GENE
- I_GENE
1 I_GENE
binding O
does O
not O
contribute O
to O
c B_GENE
- I_GENE
Jun I_GENE
coactivation O
is O
the O
observation O
that O
the O
activation O
of O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
c B_GENE
- I_GENE
Jun I_GENE
is O
blocked O
by O
overexpression O
of O
c B_GENE
- I_GENE
Fos I_GENE
. O

A O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
mandibular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
growth B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
retardation B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
palatal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clefting I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
discussed O
. O

Time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dependence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
frequency B_DISEASE
potentiation I_DISEASE
in O
the O
isolated B_BIO/B_NUMBER[MEASURE]
Guinea I_BIO/I_NUMBER[MEASURE]
- O
pig B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_BODY_PART_OR_ORGAN_COMPONENT
atrium I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
found O
4 O
highly O
conserved O
regions O
to O
vertebrate B_LOCATION/B_ENZYME[GENE]
Hsp90 I_LOCATION/I_ENZYME[GENE]
exclusively O
and O
27 O
amino O
acids O
conserved O
among O
but O
differing O
between O
Hsp90 B_SPECIES[BIO]/B_GENE
alpha I_SPECIES[BIO]/I_GENE
and O
Hsp90 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trinucleotide B_DISEASE/B_GENE
- O
and O
tandem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
containing O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
from O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spinal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
density B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
filter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
present O
here O
the O
complete O
primary O
structure O
of O
human B_GENE
gp330 I_GENE
, O
the O
human O
variant O
of O
the O
principal O
kidney O
autoantigen O
causing O
Heymann O
membranous O
glomerulonephritis O
in O
rats O
. O

The O
platelet B_GENE
membrane I_GENE
glycoprotein I_GENE
IIb I_GENE
/ I_GENE
IIIa I_GENE
receptor I_GENE
inhibitor O
abciximab O
is O
used O
for O
the O
treatment O
of O
patients O
undergoing O
high O
- O
risk O
percutaneous O
coronary O
interventions O
and O
is O
used O
in O
approximately O
one O
third O
of O
coronary O
interventions O
in O
the O
United O
States O
and O
a O
growing O
number O
of O
procedures O
in O
Europe O
. O

In O
the O
conscious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
animals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O
statistical B_MEASURE/B_LOCATION
significance I_MEASURE/I_LOCATION
when O
the O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
exposed O
to O
12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
nitrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
which O
produced O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
arterial B_MEASURE
PaO2 I_MEASURE
of O
44 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
. O

prenatal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genetic B_DISEASE/B_GENE
diseases I_DISEASE/I_GENE
. O

Human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
epidermal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
EGF B_GENE/B_DISEASE
) O
, O
a O
naturally O
occurring O
protein O
, O
has O
been O
implicated O
in O
the O
protection O
of O
gastrointestinal O
mucosal O
integrity O
. O

A O
ready O
- O
made O
prosthesis B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
placed O
on O
the O
external B_LOCATION
side I_LOCATION
of O
the O
ribs B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vertically O
bridging O
the O
flailed B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
chest I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segment I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
fixed O
to O
the O
first B_LOCATION/B_SEQUENCE[MEASURE]
upper I_LOCATION/I_SEQUENCE[MEASURE]
and O
first B_SEQUENCE[MEASURE]/B_LOCATION
lower I_SEQUENCE[MEASURE]/I_LOCATION
intact I_SEQUENCE[MEASURE]/I_LOCATION
rib I_SEQUENCE[MEASURE]/I_LOCATION
as O
well O
as O
to O
the O
mobile B_LOCATION
segments I_LOCATION
of O
the O
affected B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
ribs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Design B_PERSON/B_MEASURE
: O
prospective B_LOCATION
case I_LOCATION
study I_LOCATION
( O
Canadian B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Task I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Force I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
) O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
T4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonuclease I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
role O
of O
lysine O
- O
130 O
. O

A O
minimal O
pheromone O
induction O
domain O
, O
delineated O
as O
residues O
301 O
to O
335 O
of O
Ste12p B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
dependent O
on O
the O
pheromone O
mitogen B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activated I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
MAP I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pathway O
for O
induction O
activity O
. O

The O
library O
will O
thus O
be O
useful O
for O
the O
selection O
of O
cosmid O
clones O
which O
carry O
CDC B_GENE
genes I_GENE
from I_GENE
yeast I_GENE
by O
complementing O
first O
, O
with O
the O
vectorial O
yeast B_GENE/B_BIO
gene I_GENE/I_BIO
URA1 I_GENE/I_BIO
, O
the O
pyrimidine O
auxotrophy O
of O
most O
cdc B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
strains O
and O
then O
, O
with O
the O
respective O
CDC B_GENE/B_MEASURE
wild I_GENE/I_MEASURE
- I_GENE/I_MEASURE
type I_GENE/I_MEASURE
genes I_GENE/I_MEASURE
, O
of O
the O
temperature O
- O
sensitive O
mutant O
alleles O
. O

These O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rps7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leaders O
were O
ligated O
into O
an O
aadA O
expression O
cassette O
and O
transformed O
into O
the O
chloroplast O
of O
C O
. O
reinhardtii O
and O
into O
E O
. O
coli O
. O

In O
addition O
, O
both O
activated O
Ral B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GDS I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O
and O
Raf B_GENE/B_DISEASE
stimulate O
cyclin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription O
and O
E2F B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
and O
act O
in O
synergy O
with O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
. O

From O
the O
present O
results O
a O
concept O
of O
hormone O
- O
dependent O
AR B_GENE/B_DISEASE
activation O
is O
proposed O
, O
which O
requires O
a O
functional O
, O
direct O
or O
indirect O
intramolecular O
interaction O
between O
the O
Tad O
and O
the O
LBD O
. O

Like O
the O
DMA B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
unlike O
all O
other O
mammalian B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
zebrafish O
gene O
codes O
for O
two O
cysteine O
residues O
which O
might O
potentially O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
bond O
in O
the O
alpha O
1 O
domain O
. O

Down O
- O
regulation O
of O
Id1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
correlated O
with O
mitogenesis O
and O
occurred O
when O
quiescent O
cells O
were O
treated O
with O
growth O
factors O
that O
activate O
G B_GENE
protein I_GENE
- I_GENE
coupled I_GENE
receptors I_GENE
and O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O
not O
with O
a O
non O
- O
mitogenic O
Camp O
analog O
. O

Secretogranin B_GENE
II I_GENE
( O
SgII B_GENE/B_LOCATION
) O
is O
a O
secretory O
polypeptide O
stored O
in O
large O
dense O
core O
vesicles O
of O
neuroendocrine O
and O
neuronal O
cells O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SDB B_DISEASE
, O
even O
snoring B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
was O
independently O
associated O
with O
hypertension B_DISEASE/B_LOCATION
in O
both O
men B_PERSON/B_BIO
and O
women B_PERSON/B_BIO
. O

The O
electron O
spin O
resonance O
study O
also O
demonstrated O
that O
the O
formation O
of O
superoxide O
- O
DMPO O
spin O
adduct O
was O
strongly O
inhibited O
by O
a O
selective O
cyclooxygenase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
, O
etodolac O
, O
in O
a O
concentration O
- O
dependent O
manner O
. O

BK B_GENE/B_BIO
- O
induced O
translocation O
and O
overexpression O
of O
PKC B_GENE
isoforms I_GENE
as O
well O
as O
coexpression O
of O
inactive O
or O
constitutively O
active O
mutants O
of O
different O
PKC B_GENE
isozymes I_GENE
provided O
evidence O
for O
a O
role O
of O
the O
diacylglycerol O
- O
sensitive O
PKCs B_ENZYME[GENE]/B_LOCATION
alpha I_ENZYME[GENE]/I_LOCATION
and I_ENZYME[GENE]/I_LOCATION
epsilon I_ENZYME[GENE]/I_LOCATION
in O
BK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
signaling O
toward O
MAPK B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Embryonal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
lead O
phthalocyanin O
method O
for O
the O
demonstration O
of O
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
hydrolases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O
plant O
and O
animal O
tissues O
. O

Here O
we O
describe O
the O
characterization O
of O
cDNAs O
encoding O
two O
unusual O
E2Fs B_GENE/B_BIO
, O
E2F B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
E2F B_MEASURE
- I_MEASURE
5 I_MEASURE
, O
each O
identified O
by O
the O
ability O
of O
their O
gene O
product O
to O
interact O
with O
p130 B_GENE/B_BIO
in O
a O
yeast O
two O
- O
hybrid O
system O
. O

Interestingly O
, O
unlike O
PAK65 B_GENE
, O
HPK1 B_GENE/B_LOCATION
does O
not O
contain O
the O
small B_GENE
GTPase I_GENE
Rac1 I_GENE
/ O
Cdc42 B_GENE
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B_GENE
or O
Cdc42 B_GENE
, O
suggesting O
that O
HPK1 B_PROTEIN[GENE]/B_DISEASE
. O
activation O
is O
Rac1 B_GENE
/ O
Cdc42 B_GENE
- O
independent O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
compared O
with O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
pair O
- O
fed O
non B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Control B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
were O
measured O
by O
enzyme O
- O
linked O
immunoabsorbent O
assay O
in O
plasma O
samples O
obtained O
from O
the O
hyperthermic O
isolated O
limb O
perfusion O
circuit O
and O
systemic O
circulation O
. O

However O
, O
only O
plasma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrinogen B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O
showed O
statistically O
significant O
positive O
associations O
with O
IMT O
in O
both O
groups O
. O

Without O
a O
team B_ORGANIZATION/B_PERSON
, O
there O
is O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
hope I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
for O
fetal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
mortality B_DISEASE/B_MEASURE
will O
be O
80 B_MEASURE
- O
100 B_MEASURE
% I_MEASURE
. O

Analysis O
of O
deletion O
and O
substitution O
mutations O
in O
the O
MER2 B_GENE/B_BIO
5 I_GENE/I_BIO
' I_GENE/I_BIO
exon I_GENE/I_BIO
demonstrates O
that O
the O
unusually O
large O
size O
of O
this O
exon O
plays O
an O
important O
role O
in O
splicing O
regulation O
. O

To O
study O
the O
signaling O
pathways B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
regulate O
cytoskeletal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
rearrangements B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
set O
up O
a O
conjugate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
formation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O
Jurkat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
effectors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
- O
sized O
latex B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
beads I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
coated O
with O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O
artificial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
APCs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Reexamination O
of O
the O
cdc4 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O
that O
, O
in O
addition O
to O
being O
defective O
in O
the O
onset O
of O
S O
phase O
, O
it O
is O
also O
defective O
in O
G O
( O
2 O
) O
/ O
M O
transition O
when O
released O
from O
hydroxyurea O
- O
induced O
S O
- O
phase O
arrest O
. O

All O
such O
polypeptides O
containing O
263 O
or O
more O
residues O
derived O
from O
the O
C O
- O
terminus O
of O
P130gag B_MEASURE/B_GENE
- O
fps B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
e O
. O
residues O
920 O
- O
1182 O
) O
were O
enzymatically O
active O
as O
tyrosine B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinases I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O

A O
structural O
model O
for O
Vpu B_GENE/B_BACTERIUM[BIO]
is O
proposed O
in O
which O
the O
membrane O
anchor O
precedes O
a O
region O
comprising O
two O
amphipathic O
alpha O
- O
helices O
of O
opposed O
polarity O
, O
joined O
by O
a O
strongly O
acidic O
turn O
that O
protrudes O
into O
the O
cytoplasm O
and O
contains O
the O
CK B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
2 B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
phosphorylation B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
recombinant O
containing O
the O
full O
- O
length O
polyhedrin B_PROTEIN[GENE]/B_BIO
leader O
sequence O
gave O
levels O
of O
N B_GENE
mRNA I_GENE
comparable O
to O
those O
of O
AcNPV B_GENE/B_BIO
polyhedrin I_GENE/I_BIO
mRNA I_GENE/I_BIO
. O

Immune B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
impact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
Lactobacillus B_BACTERIUM[BIO]/B_DISEASE
acidophilus B_BACTERIUM[BIO]/I_DISEASE
on O
asthma B_DISEASE/B_PERSON
. O

Thus O
, O
CARP B_GENE/B_BIO
is O
a O
YB B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
1 I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
associated I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factor I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O
represents O
the O
first O
identified O
cardiac O
- O
restricted O
downstream O
regulatory O
gene O
in O
the O
homeobox O
gene O
Nkx2 B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
5 I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway O
and O
may O
serve O
as O
a O
negative O
regulator O
of O
HF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
dependent O
pathways O
for O
ventricular O
muscle O
gene O
expression O
. O

Each O
receptor O
must O
therefore O
engage O
a O
unique O
subset O
of O
the O
available O
signaling O
elements O
- O
- O
at O
least O
partly O
through O
the O
selection O
of O
proteins O
with O
src B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
homology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domains I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

A O
proposed O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
model O
for O
the O
SMase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
sphingomyelin O
complex O
structure O
was O
built O
to O
investigate O
how O
the O
SMase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
specifically O
recognizes O
its O
substrate O
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
fractal B_MEASURE
exponent I_MEASURE
are O
considered O
which O
do O
not O
suffer O
from O
this O
limit B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
one B_NUMBER[MEASURE]/B_PERSON
derived O
from O
the O
Allan B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
was O
developed O
by O
the O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
one B_NUMBER[MEASURE]/B_LOCATION
based O
on O
the O
periodogram B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

births B_PERSON
, O
marriages B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
divorces B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
deaths B_PERSON/B_DISEASE
for O
July B_PERSON
1997 I_PERSON
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
coronary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
artery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
disease I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
exercise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
redistribution B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
201Thallium I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cardiac I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
reinjection B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
rest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
identify O
severely O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
but O
still O
viable B_DISEASE_ADJECTIVE[DISEASE]
myocardium I_DISEASE_ADJECTIVE[DISEASE]
and O
may O
be O
particularly O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
prognosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
such B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
recovery B_MEASURE
curve I_MEASURE
of O
the O
R2 B_MEASURE/B_PERSON
component I_MEASURE/I_PERSON
of O
the O
blink B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflex B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diminished O
in O
patients B_PERSON
with O
tension B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
type B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
headache I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
with O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

When O
recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O
in O
HeLa O
cells O
was O
probed O
with O
the O
same O
antiphosphotyrosine O
antibody O
, O
a O
dimeric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
gE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
form O
at O
130 O
kDa O
was O
detected O
on O
the O
cell O
surface O
. O

Transforming B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TGF B_GENE
- I_GENE
beta I_GENE
) O
inhibits O
cell O
cycle O
progression O
, O
in O
part O
through O
up O
- O
regulation O
of O
gene O
expression O
of O
the O
p21 B_GENE
( O
WAF1 B_PROTEIN[GENE]/B_LOCATION
/ O
Cip1 B_PROTEIN[GENE]/B_MEASURE
) O
( O
p21 B_GENE/B_DISEASE
) O
cell O
cycle O
inhibitor O
. O

The O
results O
suggest O
that O
both O
superficial O
and O
deep O
cortical O
venous O
drainage O
of O
the O
cat O
kidney O
should O
be O
considered O
when O
measuring O
renal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
head B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
neck B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O
feasible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
FDG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
PET I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

There O
were O
no O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
incidence B_MEASURE
of O
fractured B_DISEASE
zonas I_DISEASE
. O

DSIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
found O
to O
significantly O
increase O
slow B_DISEASE/B_PROTEIN[GENE]
- O
waves B_DISEASE/B_MEASURE
( O
delta B_DISEASE/B_ENT
sleep I_DISEASE/I_ENT
) O
in O
the O
sleep B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
EEG I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

accuracy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
predictive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
ultrasound B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
acute B_DISEASE/B_PERSON
rejection B_DISEASE/I_PERSON
. O

7 O
- O
Nitroindazole O
( O
7NI O
) O
, O
a O
relatively O
selective O
neuronal O
nitric B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
nNOS B_GENE/B_LOCATION
) O
inhibitor O
. O
was O
intraperitoneally O
administered O
to O
the O
Guinea O
pigs O
30 O
minutes O
before O
the O
onset O
of O
local O
anoxia O
. O

mutations O
that O
extend O
the O
specificity O
of O
the O
endonuclease O
activity O
of O
lambda B_GENE
terminase I_GENE
. O

The O
gene B_GENE
set O
in O
this O
mitochondrial B_BIO/B_GENE
genome I_BIO/I_GENE
is O
a O
subset B_MEASURE/B_PERSON
of O
that O
of O
Reclinomonas B_SPECIES[BIO]
americana I_SPECIES[BIO]
, O
an O
amoeboid B_BIO/B_PERSON
protozoan I_BIO/I_PERSON
. O

An O
evaluation O
of O
a O
positive O
control O
for O
platelet O
neutralization O
procedure O
testing O
with O
seven O
commercial O
activated O
partial O
thromboplastin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O
reagents O
. O

The O
prosomal B_GENE/B_BIO
RNA I_GENE/I_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
protein I_GENE/I_BIO
p27K I_GENE/I_BIO
is O
a O
member O
of O
the O
alpha B_GENE/B_PERSON
- I_GENE/I_PERSON
type I_GENE/I_PERSON
human I_GENE/I_PERSON
prosomal I_GENE/I_PERSON
gene I_GENE/I_PERSON
family I_GENE/I_PERSON
. O

A O
single O
clone O
, O
which O
was O
conserved O
and O
had O
near O
- O
perfect O
homology O
to O
eight O
human O
/ O
rodent O
expressed O
sequence O
tags O
, O
was O
used O
as O
template O
for O
5 O
' O
and O
3 O
' O
rapid O
amplification O
of O
cDNA O
ends O
and O
SPICE O
( O
system O
for O
polymerase O
chain O
reaction O
amplification O
of O
cDNA O
ends O
) O
reactions O
to O
obtain O
the O
3 O
. O
6 O
- O
kb O
cDNA O
, O
LGL2 B_PROTEIN[GENE]/B_LOCATION
( O
Genbank B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
110195 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
encoding O
a O
deduced O
polypeptide O
( O
lgl2 B_GENE
) O
of O
963 O
amino O
acids O
. O

These O
tiny B_PERSON/B_BIO
premature I_PERSON/I_BIO
infants I_PERSON/I_BIO
also O
received O
PN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
significantly O
longer B_MEASURE/B_LOCATION
periods I_MEASURE/I_LOCATION
of O
time B_TIME[MEASURE]
, O
and O
the O
longer B_TIME[MEASURE]
the O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
administered O
the O
greater B_MEASURE
was O
the O
risk B_MEASURE/B_PERSON
of O
cholestasis B_DISEASE
developing O
. O

The O
SM B_DISEASE/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
selection B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
exon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
exon B_GENE
3 I_GENE
. O

It O
is O
always O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
has O
a O
discrete B_DISEASE/B_MEASURE
origin B_DISEASE/I_MEASURE
and O
insertion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
early B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
stage B_DISEASE
breast I_DISEASE
cancer I_DISEASE
. O

Five O
girls O
with O
Turner O
' O
s O
syndrome O
aged O
12 O
to O
17 O
years O
showed O
LH B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O
( O
5 O
. O
0 O
- O
14 O
. O
5 O
IU O
/ O
12 O
h O
) O
at O
the O
upper O
end O
of O
or O
slightly O
above O
the O
normal O
range O
and O
pathologically O
high O
values O
( O
22 O
. O
2 O
- O
43 O
. O
5 O
IU O
/ O
12 O
h O
) O
for O
FSH B_PERSON/B_GENE
. O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
2 O
) O
the O
LRR B_DISEASE/B_PROTEIN[GENE]
/ O
CARD B_LOCATION/B_GENE
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B_DISEASE/B_GENE
/ O
CARD B_LOCATION/B_GENE
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O
Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
and O
to O
a O
lesser O
extent O
by O
Asp O
- O
Glu O
- O
Val O
- O
Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
; O
and O
4 O
) O
the O
CARD B_PROTEIN[GENE]
is O
critical O
for O
killing O
activity O
of O
DEFCAP B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
6 B_MEASURE/B_BIO
patients I_MEASURE/I_BIO
( O
9 B_MEASURE/B_ENT
kidneys I_MEASURE/I_ENT
) O
irrigation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pelvis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
performed O
for O
the O
dissolution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
their O
infectious B_DISEASE
stones I_DISEASE
. O

The O
use O
of O
sigma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
54 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
known O
to O
require O
cognate O
binding O
proteins O
, O
could O
allow O
the O
fine O
- O
tuning O
that O
provides O
the O
temporal O
ordering O
of O
flagellar O
gene O
transcription O
. O

The O
association O
of O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
92 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
p92 B_GENE
, O
p84 B_GENE/B_MEASURE
, O
p75 B_GENE/B_MEASURE
, O
p73 B_GENE/B_MEASURE
, O
p69 B_GENE/B_MEASURE
, O
and O
p57 B_GENE
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
Doc O
) O
. O

To O
our O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O
transcription B_GENE
factors I_GENE
have O
previously O
been O
identified O
that O
exhibit B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
androgen O
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
epididymis B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

focal B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
or O
regional B_NUMBER[MEASURE]
8 I_NUMBER[MEASURE]
- O
to O
20 B_MEASURE
- O
Hz B_MEASURE/B_LOCATION
low I_MEASURE/I_LOCATION
- O
voltage B_MEASURE/B_LOCATION
epileptiform I_MEASURE/I_LOCATION
paroxysms O
in O
either O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
10 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
) O
, O
amygdala B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
1 B_MEASURE/B_PERSON
patient I_MEASURE/I_PERSON
) O
, O
or O
both O
( O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
) O
preceded O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
motionless I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staring O
. O

The O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
heterozygous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
positions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
essentially O
facilitates O
on O
the O
one B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
on O
the O
other B_PERSON/B_SEQUENCE[MEASURE]
hand B_PERSON/I_SEQUENCE[MEASURE]
the O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
new B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
cell B_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
activation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
is O
achieved O
by O
the O
cooperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
interaction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
apparently O
ubiquitous B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvovirus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B19 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
from O
the O
viral B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
p6 I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
promoter I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
B19p6 B_GENE
) O
is O
restricted O
to O
primary O
human O
hematopoietic O
cells O
undergoing O
erythroid O
differentiation O
. O

The O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expediency I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
correcting O
disorders B_DISEASE_ADJECTIVE[DISEASE]
of O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O
atherosclerosis B_DISEASE/B_PERSON
with O
enterosorbents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O
substantiated O
. O

To O
prevent O
section B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wrinkles I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O
encountered O
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
coated B_NUMBER[MEASURE]/B_LOCATION
single I_NUMBER[MEASURE]/I_LOCATION
- O
hole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
grids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
developed O
. O

The O
Cryotherapy B_ORGANIZATION/B_LOCATION
for O
retinopathy B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prematurity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O
shown O
that O
this O
number B_MEASURE
can O
be O
halved O
with O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Ultrasound B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
guided O
fine B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
needle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aspiration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
US B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
FNAB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
) O
revealed O
normal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O
looking O
squamous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

bleeding B_DISEASE
was O
successfully O
prevented O
in O
28 B_TIME[MEASURE]
patients I_TIME[MEASURE]
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
a O
combined O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
incorporating O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
desmopressin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
an O
antifibrinolytic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
, O
and O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
methods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
glue I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
compression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
techniques I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
. O

Hetero O
- O
oligomerization O
of O
Smad4 B_GENE
with O
the O
pathway O
- O
restricted O
SMAD B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
is O
essential O
for O
Smad4 B_GENE
- O
mediated O
transcription O
. O

This O
fragment O
contains O
two O
complete O
endo B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucanase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
designated O
celCCC B_DISEASE/B_GENE
and O
celCCG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
them O
is O
its O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
weak B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
are O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
mammalian B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
cerebral I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
cortex I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Analysis O
of O
the O
5 O
' O
and O
3 O
' O
termini O
of O
the O
transcripts O
produced O
in O
vivo O
from O
the O
puf B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
operon B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
R B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
sphaeroides B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
PUF B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
delta B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
348 B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
420 B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
three O
transcripts O
; O
0 O
. O
59 O
, O
0 O
. O
64 O
, O
and O
2 O
. O
63 O
kilobases O
) O
lacking O
the O
puf O
- O
intercistronic O
terminator O
structure O
were O
identical O
to O
those O
of O
the O
corresponding O
puf B_GENE/B_BIO
transcripts I_GENE/I_BIO
derived O
from O
wild O
- O
type O
R O
. O
sphaeroides O
2 O
. O
4 O
. O
1 O
( O
four O
transcripts O
; O
0 O
. O
50 O
, O
0 O
. O
66 O
, O
0 O
. O
71 O
, O
and O
2 O
. O
7 O
kilobases O
) O
showing O
that O
the O
transcripts O
begin O
and O
end O
at O
the O
same O
sites O
. O

The O
optimum B_MEASURE/B_DISEASE
cooling I_MEASURE/I_DISEASE
rate I_MEASURE/I_DISEASE
from O
RT B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
5 B_LOCATION/B_PROTEIN[GENE]
degrees I_LOCATION/I_PROTEIN[GENE]
C I_LOCATION/I_PROTEIN[GENE]
resulting O
in O
maximum B_TIME[MEASURE]/B_DISEASE
survival I_TIME[MEASURE]/I_DISEASE
of O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
to O
be O
0 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
to O
1 B_MEASURE
degree I_MEASURE
per O
minute B_TIME[MEASURE]
when O
cooled O
from O
RT B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
5 B_LOCATION/B_PROTEIN[GENE]
degrees I_LOCATION/I_PROTEIN[GENE]
C I_LOCATION/I_PROTEIN[GENE]
and O
subsequently O
frozen O
- O
thawed O
in O
liquid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LN2 B_PROTEIN[GENE]/B_LOCATION
) O
. O

The O
cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortical B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vessels B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
they O
are O
compared O
to O
the O
cerebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessels I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

transesophageal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
echocardiography I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
risk I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
factors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O
stroke B_DISEASE
in O
nonvalvular B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
atrial I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
fibrillation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

22 B_TIME[MEASURE]/B_LOCATION
- O
Veneto B_MEASURE/B_LOCATION
Region I_MEASURE/I_LOCATION
) O
. O

preventive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
counseling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tailored O
to O
the O
needs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
group B_ORGANIZATION/B_PERSON
may O
be O
most O
beneficial B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

strains O
lacking O
a O
functional B_GENE
RPL16A I_GENE
gene I_GENE
grow O
as O
rapidly O
as O
wild O
type O
, O
whereas O
those O
containing O
a O
null O
allele O
of O
RPL16B B_GENE/B_DISEASE
grow O
more O
slowly O
than O
wild O
type O
. O

Neonatal B_DISEASE_ADJECTIVE[DISEASE]
hyperthyroidism I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
Northern O
blot O
hybridization O
, O
two O
Cx31 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
in O
total O
RNA O
of O
the O
human O
keratinocyte O
cell O
line O
HaCaT O
and O
two O
transcripts O
of O
2 O
. O
2 O
and O
1 O
. O
9 O
kb O
in O
total O
RNA O
of O
E6 B_PROTEIN[GENE]
/ O
E7 B_MEASURE/B_PROTEIN[GENE]
transfected O
human O
keratinocytes O
( O
HEK O
cells O
) O
. O

In O
summary O
, O
FGFR3 B_GENE
signaling O
pathway O
utilizes O
two O
GRB2 B_LOCATION/B_BIO
- I_LOCATION/I_BIO
containing I_LOCATION/I_BIO
complexes I_LOCATION/I_BIO
; O
Shc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
GRB2 B_MEASURE/B_GENE
. O
Sos B_LOCATION/B_DISEASE
and O
80K B_GENE/B_LOCATION
- I_GENE/I_LOCATION
H I_GENE/I_LOCATION
. O
pp66 B_PROTEIN[GENE]/B_LOCATION
. O
GRB2 B_MEASURE/B_PERSON
. O
Sos B_LOCATION/B_DISEASE
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B_GENE
to O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
. O

In O
an O
effort O
to O
identify O
factors O
involved O
in O
the O
expression O
of O
this O
important O
erythroid O
- O
specific O
regulatory O
protein O
, O
we O
have O
isolated O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EKLF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
systematically O
analyzed O
the O
promoter O
region O
. O

Their O
main B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
representatives I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
the O
American B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manual I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mental B_DISEASE
disorders I_DISEASE
, O
DSM B_LOCATION/B_DISEASE
- O
III B_TIME[MEASURE]
, O
its O
revised O
version B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
DSM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
III B_TIME[MEASURE]
- O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
international I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
mental B_DISEASE/B_LOCATION
disorders I_DISEASE/I_LOCATION
ICD I_DISEASE/I_LOCATION
- O
10 B_SEQUENCE[MEASURE]
. O

Any O
opacity B_DISEASE
on O
a O
chest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
radiograph I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
has O
a O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
the O
same B_TIME[MEASURE]/B_LOCATION
acoustic I_TIME[MEASURE]/I_LOCATION
power I_TIME[MEASURE]/I_LOCATION
, O
the O
rate B_MEASURE
of O
chloride B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
formation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
20 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kHz B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ultrasound B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
greater B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
when O
a O
probe B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
with O
a O
larger B_MEASURE/B_PERSON
tip B_MEASURE/I_PERSON
area B_MEASURE/I_PERSON
was O
used O
, O
but O
significantly O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
rate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
900 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kHz I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
Torpedo B_SPECIES[BIO]
, O
where O
only O
a O
single B_GENE/B_MEASURE
transcript I_GENE/I_MEASURE
is O
seen O
, O
the O
mouse B_SPECIES[BIO]/B_DISEASE
expresses O
several B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
different B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Four O
families O
of O
homing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonucleases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
identified O
, O
including O
the O
LAGLIDADG B_GENE/B_LOCATION
, O
the O
His B_GENE/B_DISEASE
- I_GENE/I_DISEASE
Cys I_GENE/I_DISEASE
box I_GENE/I_DISEASE
, O
the O
GIY B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
YIG I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
H B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
endonucleases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

convergence B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trigeminal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
input I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
with O
visceral B_BODY_PART_OR_ORGAN_COMPONENT
and O
phrenic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inputs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
primate B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
C2 B_MEASURE/B_PROTEIN[GENE]
spinothalamic I_MEASURE/I_PROTEIN[GENE]
tract I_MEASURE/I_PROTEIN[GENE]
neurons I_MEASURE/I_PROTEIN[GENE]
. O

The O
GvpE B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
involved O
in O
the O
regulation O
of O
gas O
vesicles O
synthesis O
in O
halophilic O
archaea O
has O
been O
identified O
as O
the O
transcriptional O
activator O
for O
the O
promoter O
located O
upstream O
of O
the O
gvpA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
the O
major O
gas O
vesicle O
structural O
protein O
GvpA B_GENE/B_MEASURE
. O

Nosographic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
early B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
midgestation I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
embryos I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
it O
is O
expressed O
in O
telencephalic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
diencephalic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
mesencephalic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
but O
from O
day B_TIME[MEASURE]/B_LOCATION
11 I_TIME[MEASURE]/I_LOCATION
. O
75 B_TIME[MEASURE]/B_LOCATION
of O
gestation B_ORGANISM_FUNCTION
its O
expression B_GENE
disappears O
from O
dorsal B_ORGANISM_FUNCTION/B_MEASURE
telencephalon I_ORGANISM_FUNCTION/I_MEASURE
and O
is O
confined O
to O
diencephalic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
mesencephalic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
training B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O
a O
duration B_MEASURE/B_LOCATION
of O
30 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
/ O
week B_TIME[MEASURE]
, O
and O
was O
performed O
on O
a O
motor B_PRODUCT[OBJECT]/B_DISEASE
- O
driven O
treadmill B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

phylogenetic O
analysis O
using O
a O
neighbor O
- O
joining O
algorithm O
showed O
closest O
similarity O
of O
the O
horse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mu I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chain I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
region I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
human O
and O
dog O
sequences O
. O

Using O
probes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
these O
regions B_LOCATION/B_DISEASE
, O
rearrangements B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
identified O
in O
each O
of O
nine B_NUMBER[MEASURE]/B_LOCATION
cases I_NUMBER[MEASURE]/I_LOCATION
of O
t B_DISEASE/B_GENE
( O
8 B_MEASURE
; O
21 B_MEASURE
) O
AML B_DISEASE/B_LOCATION
examined O
. O

Cloning O
and O
nucleotide O
sequence O
analysis O
reveals O
that O
BUR6 B_PERSON/B_GENE
encodes O
a O
homolog O
of O
DRAP1 B_GENE/B_DISEASE
( O
also O
called O
NC2alpha B_GENE
) O
, O
a O
mammalian O
repressor O
of O
basal O
transcription O
. O

BRAP2 B_GENE/B_PERSON
also O
shares O
significant O
homology O
with O
a O
hypothetical O
protein O
from O
yeast O
Saccharomyces O
cerevisiae O
, O
especially O
in O
the O
zinc O
finger O
region O
. O

Earlier O
published O
data O
, O
indicating O
Sp1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O
to O
the O
R1 B_PROTEIN[GENE]/B_LOCATION
alpha I_PROTEIN[GENE]/I_LOCATION
/ I_PROTEIN[GENE]/I_LOCATION
beta I_PROTEIN[GENE]/I_LOCATION
regions I_PROTEIN[GENE]/I_LOCATION
, O
could O
not O
be O
confirmed O
, O
suggesting O
that O
the O
R1 O
initiator O
element O
may O
function O
independent O
of O
Sp1 B_GENE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
reduced O
metabolism B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cotinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
proliposomes B_LOCATION/B_PROTEIN[GENE]
and O
MP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
apparently O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
sustained O
plasma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nicotine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HIV B_DISEASE/B_GENE
- O
1 B_NUMBER[MEASURE]/B_DISEASE
requires O
the O
binding B_TIME[MEASURE]/B_GENE
of O
host B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
cis O
elements B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
proviral B_GENE
long I_GENE
terminal I_GENE
repeat I_GENE
( O
LTR B_GENE/B_DISEASE
) O
. O

The O
yeast B_GENE/B_PERSON
mitochondrial I_GENE/I_PERSON
Hsp70 I_GENE/I_PERSON
, O
Ssc1p B_GENE/B_LOCATION
, O
functions O
as O
a O
molecular O
chaperone O
with O
its O
partner O
proteins O
, O
Mdj1p B_GENE
( O
DnaJ B_GENE
homologue I_GENE
) O
and O
Yge1p B_GENE
( O
GrpE B_GENE/B_PERSON
homologue I_GENE/I_PERSON
) O
. O

increased O
TRE O
DNA O
binding O
failed O
to O
lead O
to O
increased O
transactivation O
correlating O
with O
the O
inability O
of O
SB O
203580 O
to O
increase O
phosphorylation O
of O
these O
AP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
rice B_GENE
gene I_GENE
consists O
of O
four B_GENE/B_NUMBER[MEASURE]
exons B_GENE/I_NUMBER[MEASURE]
. O

However O
, O
and O
in O
contrast O
to O
other O
MMP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
genes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
no O
significative O
synergistic O
effect O
on O
CAT B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O
between O
the O
AP B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
1 I_LOCATION/I_ORGANIZATION
and O
PEA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O
in O
the O
collagenase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
. O

The O
equation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
mean B_MEASURE
trabecular I_MEASURE
number I_MEASURE
passed O
the O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
whereas O
the O
validity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
equations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
mean B_MEASURE/B_LOCATION
trabecular I_MEASURE/I_LOCATION
separation I_MEASURE/I_LOCATION
and O
Tb B_PROTEIN[GENE]/B_LOCATION
. O
WI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
appeared O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

methodological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considerations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limiting O
causal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assertions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permissible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
nonexperimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
discussed O
. O

In O
contrast O
, O
postmitotic O
neurons O
possessed O
extremely O
low O
levels O
of O
E2F1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
assessed O
by O
the O
electrophoretic O
mobility O
shift O
assay O
and O
Western O
blotting O
. O

Recurrence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
hepatic B_DISEASE
cyst I_DISEASE
after O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
excision I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
drainage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
complicated O
by O
fistula B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
the O
cyst B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
duodenum B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

reversal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
mefloquine B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
in O
rodent B_SPECIES[BIO]/B_DISEASE
Plasmodium B_SPECIES[BIO]/I_DISEASE
. O

Possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consequences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binder B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
distribution B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
through O
powder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aggregates I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvalbumin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
the O
putative O
polyadenylation O
signal O
AATAAA O
13 O
nucleotides O
upstream O
from O
the O
polyadenylation O
site O
. O

The O
delta O
Mo O
+ O
SV O
tumor O
DNAs O
from O
B O
- O
lineage O
tumors O
were O
typically O
rearranged O
at O
the O
immunoglobulin B_GENE
gene I_GENE
loci I_GENE
and O
contained O
germ O
line O
configurations O
of O
the O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O
equilibrium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
formation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
OTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
PVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
being O
mainly O
the O
complex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O
is O
i O
. O
v O
. O
injected O
when O
both O
products B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
combined O
in O
an O
injection B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
formulation I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

We O
conclude O
that O
the O
MMF B_DISEASE
lesion I_DISEASE
is O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
intramuscular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aluminium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
vaccines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
shows O
both O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
persistence I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
aluminium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hydroxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
an O
ongoing B_DISEASE
local I_DISEASE
immune I_DISEASE
reaction I_DISEASE
, O
and O
is O
detected O
in O
patients B_PERSON/B_BIO
with O
systemic B_DISEASE
symptoms I_DISEASE
which O
appeared O
subsequently O
to O
vaccination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

To O
examine O
the O
effect O
of O
the O
Camp O
signal O
transduction O
pathway O
on O
transcription O
of O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
glucose B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
G6Pase B_GENE/B_LOCATION
) O
, O
G6Pase B_GENE
- O
chloramphenicol B_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
fusion O
genes O
were O
transiently O
transfected O
into O
either O
the O
liver O
- O
derived O
HepG2 O
or O
kidney O
- O
derived O
LLC O
- O
PK O
cell O
line O
. O

Whereas O
the O
sequence O
of O
alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
actinin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Noegel O
, O
A O
. O
, O
W O
. O

By O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
) O
elicited O
an O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
prolonged B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
and O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
when O
given O
into O
the O
vertebral B_BODY_PART_OR_ORGAN_COMPONENT
artery I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
not O
intravenously O
. O

The O
shift O
from O
complex O
I O
to O
complex O
II O
seen O
only O
in O
SCM B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
- O
producer O
T O
cell O
lines O
upon O
activation O
was O
completely O
suppressed O
by O
cyclosporin O
A O
. O

( O
We O
observed O
a O
ferritin B_GENE/B_MEASURE
value O
as O
high O
as O
47 O
mg O
/ O
L O
in O
one O
patient O
. O
) O
Results O
with O
all O
these O
kits O
did O
not O
inter O
- O
compare O
well O
for O
ferritin B_PROTEIN[GENE]
concentrations O
greater O
than O
300 O
micrograms O
/ O
L O
, O
a O
finding O
that O
casts O
further O
doubt O
on O
the O
controversial O
use O
of O
serum B_MEASURE/B_PROTEIN[GENE]
ferritin I_MEASURE/I_PROTEIN[GENE]
measurement O
in O
cases O
of O
iron O
overload O
. O

Post B_DISEASE/B_MEASURE
- O
CPB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
cardiac I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
index I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
3 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
3 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O

ER B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
less O
potent O
than O
ER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
activating O
E2 O
- O
stimulated O
ERELuc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
( O
4 O
- O
vs O
. O

The O
expression O
pattern O
of O
LjEmx B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O
dramatically O
during O
embryogenesis O
; O
expression O
was O
seen O
initially O
in O
the O
entire O
neural O
tube O
and O
mesoderm O
, O
which O
were O
secondarily O
downregulated O
, O
and O
secondarily O
in O
cranial O
nerve O
ganglia O
and O
in O
the O
craniofacial O
mesenchyme O
. O

disruption O
of O
PML B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subnuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
acidic B_GENE
IE1 I_GENE
protein I_GENE
of O
human O
cytomegalovirus O
is O
mediated O
through O
interaction O
with O
PML B_GENE/B_DISEASE
and O
may O
modulate O
a O
Ring O
finger O
- O
dependent O
cryptic O
transactivator O
function O
of O
PML B_GENE/B_DISEASE
. O

Furthermore O
, O
the O
GC O
- O
rich O
sequences O
could O
confer O
Sp1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent O
transactivation O
to O
a O
heterologous O
prolactin B_GENE/B_LOCATION
minimal I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
. O

Twelve O
patients O
of O
leprosy O
with O
arthritis O
and O
161 O
patients O
without O
arthritis O
were O
studied O
for O
immunological O
parameters O
like O
immunoglobulins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
IgG B_GENE/B_LOCATION
, O
IgM B_PROTEIN[GENE]/B_LOCATION
, O
IgA B_GENE/B_LOCATION
) O
, O
C B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reactive B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
rheumatoid B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
. O

Several O
reports O
assert O
that O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affects O
the O
delta O
5 O
and O
delta O
4 O
pathways O
through O
its O
effect O
on O
the O
activity O
of O
3beta B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxysteroid B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3beta B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
OHSD I_DISEASE/I_LOCATION
) O
. O

The O
NrfC B_GENE/B_LOCATION
polypeptide I_GENE/I_LOCATION
, O
M B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
r I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
567 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
contains O
16 O
cysteine O
residues O
arranged O
in O
four O
clusters O
typical O
of O
the O
CooF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
super I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
non O
- O
haem O
iron O
- O
sulphur O
proteins O
. O

Zonography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
urology B_LOCATION/B_PERSON
( O
author B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transl I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

( O
i O
) O
p60 B_MEASURE/B_GENE
bound O
fast O
- O
migrating O
, O
underprocessed O
wild B_GENE
- I_GENE
type I_GENE
ICP22 I_GENE
and O
ICP22 B_GENE/B_MEASURE
lacking O
the O
carboxyl O
- O
terminal O
24 O
amino O
acids O
but O
not O
ICP22 B_TIME[MEASURE]/B_GENE
lacking O
the O
carboxyl O
- O
terminal O
40 O
amino O
acids O
, O
whereas O
the O
previously O
identified O
cellular B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p78 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
R O
. O

stress B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thallium I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
myocardial I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
in O
two B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
angina B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free B_PERSON
patients I_PERSON
with O
severe B_DISEASE/B_LOCATION
congestive I_DISEASE/I_LOCATION
heart I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
to O
identify O
clinically O
silent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
myocardium I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
distinguish O
between O
scar B_DISEASE_ADJECTIVE[DISEASE]
and O
reversibly O
ischemic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
as O
a O
cause B_DISEASE/B_MEASURE
for O
akinesia B_DISEASE_ADJECTIVE[DISEASE]
of O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segments I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
community B_ORGANIZATION/B_LOCATION
- O
acquired O
bacteremia B_DISEASE
was O
mainly O
due B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_BACTERIUM[BIO]/B_PERSON
. O

Y1 B_PROTEIN[GENE]
, O
Y2 B_PROTEIN[GENE]/B_BIO
, O
and O
Y4 B_PROTEIN[GENE]/B_DISEASE
/ O
PP1 B_MEASURE
. O

Low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
plasma I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
glucose I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
or O
may O
not O
be O
sufficiently O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
result O
in O
symptoms B_DISEASE
can O
be O
observed O
as O
a O
concomitant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
several B_DISEASE
diverse I_DISEASE
diseases I_DISEASE
. O

Developmentally O
- O
regulated O
interaction O
of O
a O
transcription O
factor O
complex O
containing O
CDP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
cut B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
early B_GENE
histone I_GENE
H3 I_GENE
gene I_GENE
promoter I_GENE
of I_GENE
the I_GENE
sea I_GENE
urchin I_GENE
Tetrapygus I_GENE
niger I_GENE
is O
associated O
with O
changes O
in O
chromatin O
structure O
and O
gene O
expression O
. O

procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
perfected B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
method I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

After O
a O
shift O
to O
37 O
degrees O
C O
, O
the O
mutant O
Rat7 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1p I_GENE/I_LOCATION
/ O
Nup159 B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1p I_GENE/I_MEASURE
is O
lost O
from O
the O
nuclear O
rim O
of O
rat7 O
- O
1 O
cells O
and O
NPCs O
, O
which O
are O
clustered O
together O
in O
these O
cells O
grown O
under O
permissive O
conditions O
become O
substantially O
less O
clustered O
. O

The O
mRNA O
for O
this O
protein O
is O
expressed O
in O
the O
T O
- O
All O
cell O
line O
Jurkat O
and O
has O
been O
designated O
HUG1 B_GENE/B_SPECIES[BIO]
, O
for O
HOX11 B_TIME[MEASURE]/B_GENE
Upstream I_TIME[MEASURE]/I_GENE
Gene I_TIME[MEASURE]/I_GENE
. O

The O
STS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WI I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14920 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
in O
fact O
derived O
from O
the O
3 O
' O
- O
untranslated O
region O
of O
the O
human B_GENE
PUNC I_GENE
gene I_GENE
. O

Its O
activity O
was O
twice O
that O
of O
a O
construct O
where O
the O
CAT B_GENE
gene I_GENE
was O
driven O
by O
the O
H B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2Kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
H2TF1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
KBF1 B_PROTEIN[GENE]/B_LOCATION
site O
) O
and O
comparable O
to O
that O
of O
pRSVCAT O
construct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
carrying I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
the I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strong I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Rous I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

ORF3 O
appears O
to O
encode O
the O
homologue O
of O
the O
well O
- O
conserved O
proteasomal B_GENE/B_LOCATION
26S I_GENE/I_LOCATION
regulatory I_GENE/I_LOCATION
subunit I_GENE/I_LOCATION
. O

The O
tam B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Aspergillus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nidulans I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
a O
739 O
- O
amino O
acid O
protein O
with O
similarity O
to O
Uga35p B_LOCATION/B_GENE
/ O
Dal81p B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
DurLp B_MEASURE/B_GENE
of O
Saccharomyces O
cerevisiae O
. O

Little O
honoured O
in O
his O
own B_PERSON/B_LOCATION
country I_PERSON/I_LOCATION
: O
statues B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
recognition B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Edward B_PERSON/B_DISEASE
Jenner I_PERSON/I_DISEASE
MD I_PERSON/I_DISEASE
FRS I_PERSON/I_DISEASE
. O

A O
pharmacokinetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
LY354740 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
to O
the O
lowering B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
plasma B_MEASURE/B_DISEASE
level I_MEASURE/I_DISEASE
of O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diazepam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
also O
demonstrated O
. O

The O
promoter B_GENE/B_LOCATION
of O
this O
methyltransferase B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
lacks O
an O
identifiable B_GENE
TATA I_GENE
box I_GENE
but O
is O
characterized O
by O
a O
CpG B_LOCATION/B_MEASURE
island I_LOCATION/I_MEASURE
which O
begins O
approximately O
723 B_MEASURE/B_LOCATION
nucleotides I_MEASURE/I_LOCATION
upstream O
of O
the O
major B_GENE/B_MEASURE
transcriptional I_GENE/I_MEASURE
start I_GENE/I_MEASURE
site I_GENE/I_MEASURE
and O
extends O
through O
exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
into O
the O
first B_GENE/B_LOCATION
intron I_GENE/I_LOCATION
. O

No O
promoter O
activity O
could O
be O
detected O
with O
various O
mouse B_GENE
Fli I_GENE
- I_GENE
1 I_GENE
promoter I_GENE
- O
CAT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O
containing O
600 O
BP O
of O
the O
5 O
' O
flanking O
region O
, O
the O
complete O
exon O
1 O
, O
the O
5 O
' O
end O
of O
intron O
1 O
and O
/ O
or O
retroviral O
LTR O
sequence O
. O

The O
D O
. O
discoideum O
proteins O
were O
entirely O
conserved O
over O
the O
four O
regions O
known O
to O
be O
important O
for O
GTP O
binding O
and O
all O
contained O
the O
C O
- O
terminal O
CAAX O
AA O
motifs O
shared O
by O
other O
Rho B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
81 O
- O
nt O
tandem O
duplication O
of O
the O
C O
- O
terminal O
coding O
region O
is O
located O
adjacent O
to O
the O
termination O
codon O
of O
the O
CyIIIb B_GENE
gene I_GENE
, O
a O
potential O
relic O
of O
a O
slipped O
mispairing O
and O
replication O
event O
. O

Only O
53 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
all O
injuries B_DISEASE
and O
12 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
of O
serious B_DISEASE/B_PERSON
injuries I_DISEASE/I_PERSON
involved O
children B_PERSON
, O
and O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
1950s B_TIME[MEASURE]
and O
early B_TIME[MEASURE]/B_LOCATION
1960s I_TIME[MEASURE]/I_LOCATION
, O
young B_PERSON/B_LOCATION
adults I_PERSON/I_LOCATION
appear O
at O
greatest B_MEASURE
risk I_MEASURE
in O
the O
1980s B_TIME[MEASURE]/B_LOCATION
. O

The O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
tested O
on O
7 B_PERSON/B_BIO
rats I_PERSON/I_BIO
with O
48 B_MEASURE
- O
hr B_TIME[MEASURE]/B_PERSON
- O
old B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sham I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
operated O
controls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Here O
we O
examine O
the O
population O
of O
gammaS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
adult O
human O
lens O
and O
the O
structure O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CRYGS I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
slope B_MEASURE
of O
QD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
QEMF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tubes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
near O
unity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
extent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
odontoblast B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
dentin I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

Mouse B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD11b B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
CR3 B_GENE/B_DISEASE
complement I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
/ O
Mac B_GENE
- I_GENE
1 I_GENE
antigen I_GENE
. O

Enoxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
been O
shown O
to O
be O
an O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerated I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
convenient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
gonorrhoea B_DISEASE/B_BIO
. O

We O
assessed O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
variables I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
O2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
contents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
order B_SPECIES[BIO]/B_DISEASE
to O
characterize O
O2 B_DISEASE
transport I_DISEASE
in O
ponies B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
during O
treadmill B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
exercise I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
discussed O
with O
reference B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
by O
which O
parasite B_DISEASE/B_PERSON
development I_DISEASE/I_PERSON
might O
be O
controlled O
. O

The O
80 O
kb O
preceding O
the O
expression O
site O
has O
few O
, O
if O
any O
, O
functional O
ORFs O
, O
but O
contains O
50 O
BP O
repeats O
, O
INGI B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
retrotransposon B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
and O
novel O
4 O
- O
12 O
kb O
repeats O
found O
near O
other O
telomeres O
. O

The O
predicted O
proteins O
show O
strong O
homology O
to O
an O
ABA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rich I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
maize O
embryos O
and O
to O
the O
mammalian B_GENE/B_PERSON
RNA I_GENE/I_PERSON
- I_GENE/I_PERSON
binding I_GENE/I_PERSON
protein I_GENE/I_PERSON
A1 I_GENE/I_PERSON
of O
the O
heterogeneous O
nuclear O
ribonucleoprotein O
complex O
involved O
in O
pre O
- O
mRNA O
splicing O
. O

increase O
in O
[ B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ca O
+ O
+ B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
counteracted O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
RAD B_DISEASE/B_GENE
. O

We O
compared O
the O
quantities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
collected O
with O
both O
pollen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
traps I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
during O
February B_TIME[MEASURE]/B_LOCATION
, O
March B_TIME[MEASURE]/B_LOCATION
and O
April B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1988 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1989 B_TIME[MEASURE]/B_LOCATION
. O

Cbl B_GENE
is O
a O
signaling O
molecule O
with O
multiple O
functional O
domains O
: O
an O
SH2 B_GENE
domain I_GENE
which O
binds O
phosphotyrosine O
residues O
, O
a O
Ring O
finger O
domain O
which O
acts O
as O
a O
ubiquitin B_LOCATION/B_ENZYME[GENE]
ligase I_LOCATION/I_ENZYME[GENE]
, O
a O
proline O
- O
rich O
region O
which O
serves O
as O
a O
docking O
site O
for O
SH3 B_GENE/B_BIO
- I_GENE/I_BIO
containing I_GENE/I_BIO
proteins I_GENE/I_BIO
, O
phosphotyrosine O
residues O
which O
serve O
as O
docking O
sites O
for O
SH2 B_BIO/B_GENE
- I_BIO/I_GENE
containing I_BIO/I_GENE
proteins I_BIO/I_GENE
such O
a O
CrkL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
p85 B_ENZYME[GENE]/B_LOCATION
subunit I_ENZYME[GENE]/I_LOCATION
of O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
, O
and O
a O
nuclear O
localization O
signal O
. O

surprisingly O
, O
apo B_GENE
- I_GENE
iso I_GENE
- I_GENE
1 I_GENE
- I_GENE
cytochrome I_GENE
c I_GENE
is O
absent O
in O
cyc3 B_GENE/B_PERSON
- I_GENE/I_PERSON
strains O
, O
although O
apo B_GENE/B_LOCATION
- I_GENE/I_LOCATION
iso I_GENE/I_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
- I_GENE/I_LOCATION
cytochrome I_GENE/I_LOCATION
c I_GENE/I_LOCATION
is O
present O
at O
approximately O
the O
same O
level O
at O
which O
holo B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iso I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytochrome I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
found O
in O
CYC3 B_GENE/B_NUMBER[MEASURE]
+ I_GENE/I_NUMBER[MEASURE]
strains O
. O

Here O
, O
we O
identify O
the O
analytical B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
form I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
PDF B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
order B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameter B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
temperature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
2D B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
XY I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
ventricular B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
demand I_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
pacemaker I_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
VVI B_DISEASE/B_LOCATION
) O
was O
implanted O
three B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
ago O
and O
because O
of O
further B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
of O
cardiac B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
an O
av B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
sequential B_DISEASE/B_MEDICAL_DEVICE[OBJECT]
pacemaker B_DISEASE/I_MEDICAL_DEVICE[OBJECT]
( O
DDD B_DISEASE/B_LOCATION
) O
was O
used O
to O
restore O
atrio B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
synchronisation I_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
was O
predicted O
that O
the O
Stroop B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
task I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
would O
trigger O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cream I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
than O
a O
fearful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
film I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
be O
more O
pronounced O
for O
binge B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
eaters B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
than O
non B_DISEASE
- O
binge B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
eaters B_PERSON/B_ORGANIZATION
. O

Our O
data O
are O
in O
line O
with O
the O
hypothesis O
that O
E2F B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O
as O
a O
growth O
- O
and O
cell O
cycle O
regulated O
tethering O
factor O
between O
Sp1 B_GENE
and O
the O
basic O
transcription O
machinery O
. O

There O
was O
a O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
parietal B_COLOR/B_PERSON
lobe I_COLOR/I_PERSON
gray I_COLOR/I_PERSON
- O
matter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytosolic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
choline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
expressed O
in O
terms B_MEASURE/B_DISEASE
of O
choline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cognitive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
measured O
with O
the O
Alzheimer B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
s I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Disease I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Assessment I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Scale I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Cognitive I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
subscale I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

colonization B_TIME[MEASURE]/B_DISEASE
increased O
with O
level B_MEASURE/B_PERSON
of O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
from O
9 B_MEASURE
per O
cent B_SEQUENCE[MEASURE]
in O
independent B_PERSON/B_LOCATION
residents I_PERSON/I_LOCATION
of O
apartments B_LOCATION
to O
60 B_MEASURE
per O
cent B_SEQUENCE[MEASURE]
in O
patients B_PERSON/B_LOCATION
on O
an O
acute B_LOCATION
hospital I_LOCATION
ward I_LOCATION
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE/B_LOCATION
. O
0001 B_MEASURE
) O
. O

IRA2 B_GENE/B_MEASURE
, O
a O
second O
gene O
of O
Saccharomyces O
cerevisiae O
that O
encodes O
a O
protein O
with O
a O
domain O
homologous O
to O
mammalian O
ras B_GENE/B_LOCATION
GTPase I_GENE/I_LOCATION
- I_GENE/I_LOCATION
activating I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
. O

exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A1a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
most B_DISEASE/B_LOCATION
of O
the O
5 B_TIME[MEASURE]/B_LOCATION
' I_TIME[MEASURE]/I_LOCATION
- O
untranslated B_GENE/B_LOCATION
region I_GENE/I_LOCATION
. O

Co O
- O
operativity O
of O
functional O
domains O
in O
the O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
specific I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
factor I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Myf I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
5 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Creatinine O
and O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CPK B_MEASURE/B_DISEASE
) O
. O

In O
our O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
we O
treated O
MCF B_PROTEIN[GENE]/B_BIO
- O
7 B_MEASURE
cells I_MEASURE
with O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
results O
in O
the O
arrest B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
G1 B_MEASURE
with O
4n B_MEASURE/B_DISEASE
DNA B_MEASURE/I_DISEASE
content B_MEASURE/I_DISEASE
( O
pseudo B_PROTEIN[GENE]/B_MEASURE
G1 I_PROTEIN[GENE]/I_MEASURE
) O
. O

These O
alterations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
at O
both O
the O
mRNA B_GENE
and O
protein B_GENE
levels I_GENE
but O
did O
not O
significantly O
affect O
the O
subcellular B_MEASURE
distribution I_MEASURE
of O
any O
of O
the O
four B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
glyoxysomal O
and O
plastid O
molecular O
chaperones O
( O
70 B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
kDa I_DISEASE/I_LOCATION
heat I_DISEASE/I_LOCATION
shock I_DISEASE/I_LOCATION
protein I_DISEASE/I_LOCATION
) O
of O
watermelon O
cotyledons O
are O
encoded O
by O
a O
single O
gene O
. O

suspected O
pelvic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
endometriosis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
prospectively O
evaluated O
in O
31 B_PERSON/B_ORGANIZATION
women B_PERSON/I_ORGANIZATION
with O
T1 B_MEASURE/B_PROTEIN[GENE]
- O
and O
T2 B_MEASURE/B_LOCATION
- O
weighted O
conventional B_LOCATION/B_MEASURE
spin B_LOCATION/I_MEASURE
- O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CSE B_LOCATION/B_DISEASE
) O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alone O
and O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
T1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
weighted O
fat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
suppressed O
( O
T1FS B_LOCATION/B_PROTEIN[GENE]
) O
and O
gadolinium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
enhanced O
T1FS B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Gd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
T1FS B_LOCATION/B_DISEASE
) O
spin B_MEASURE/B_ORGANIZATION
- O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
techniques I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

seroconversion B_DISEASE/B_TIME[MEASURE]
after O
hepatitis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
B I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vaccination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bilateral B_DISEASE
testicular I_DISEASE
germ I_DISEASE
cell I_DISEASE
tumors I_DISEASE
in O
a O
23 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
male I_PERSON
is O
reported O
. O

Total B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BMD I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
r O
= O
0 B_MEASURE
. O
30 B_MEASURE
; O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
02 B_MEASURE
) O
and O
femoral B_MEASURE/B_PROTEIN[GENE]
neck B_MEASURE/I_PROTEIN[GENE]
BMD B_MEASURE/I_PROTEIN[GENE]
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
. O
39 B_MEASURE
; O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
002 B_MEASURE
) O
were O
positively O
correlated O
with O
weight B_MEASURE/B_BIO
- O
bearing O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
but O
not O
with O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
weight B_MEASURE/B_DISEASE
- O
bearing O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
castor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
alone O
, O
as O
well O
as O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
PGI2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
gastrointestinal B_DISEASE
functions I_DISEASE
have O
been O
examined O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

checking O
for O
patient B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
n B_OTHER/B_MEASURE
= O
10 B_MEASURE
) O
with O
a O
FK B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
concentration B_MEASURE
of O
0 B_MEASURE
ng I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
were O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
analyzed O
. O

K B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
hematopoietic O
form O
of O
PTPN6 B_GENE
transcript I_GENE
is O
initiated O
at O
a O
downstream O
promoter O
separated O
by O
7 O
kb O
from O
the O
first O
. O

The O
residual B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
poky B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
] B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
appear O
to O
be O
synthesized O
via O
the O
upstream B_GENE
promoter I_GENE
( O
s B_PROTEIN[GENE]/B_DISEASE
) O
, O
but O
are O
missing O
37 B_MEASURE
- O
44 B_TIME[MEASURE]/B_LOCATION
nucleotides I_TIME[MEASURE]/I_LOCATION
from O
their O
5 B_GENE/B_MEASURE
' I_GENE/I_MEASURE
ends I_GENE/I_MEASURE
, O
indicating O
either O
that O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
rRNAs B_GENE
are O
processed O
abnormally O
or O
that O
abnormal B_NUMBER[MEASURE]
5 I_NUMBER[MEASURE]
' O
RNA B_GENE/B_LOCATION
ends B_GENE/I_LOCATION
are O
unstable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
. O

Extra B_MEASURE/B_LOCATION
dose B_MEASURE/I_LOCATION
due O
to O
extravehicular B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
the O
NASA4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mission I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measured O
by O
an O
on O
- O
board B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TLD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

unconventional O
mRNA O
processing O
in O
the O
expression O
of O
two O
calcineurin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Dictyostelium O
. O

The O
deduced O
amino O
acid O
sequence O
of O
this O
open O
reading O
frame O
is O
significantly O
homologous O
to O
the O
HSV B_GENE/B_BIO
1 I_GENE/I_BIO
UL49 I_GENE/I_BIO
. I_GENE/I_BIO
5 I_GENE/I_BIO
gene I_GENE/I_BIO
product I_GENE/I_BIO
, O
and O
as O
with O
UL49 B_GENE/B_BIO
. I_GENE/I_BIO
5 I_GENE/I_BIO
, O
it O
contains O
a O
potential O
signal O
sequence O
and O
transmembrane O
domain O
characteristic O
of O
membrane O
- O
associated O
proteins O
. O

It O
has O
been O
demonstrated O
that O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pontomesencephalic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
parabrachial B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
region B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
PBR B_DISEASE/B_PROTEIN[GENE]
) O
by O
microinjection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cholinergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
electricity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cat B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
produces O
potent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
is O
not O
antagonized O
by O
the O
opiate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

GAGA B_GENE
factor I_GENE
is O
known O
to O
remodel O
the O
chromatin O
structure O
in O
concert O
with O
nucleosome B_GENE
- I_GENE
remodeling I_GENE
factor I_GENE
NURF I_GENE
in O
a O
Drosophila O
embryonic O
S150 O
extract O
. O

Also O
, O
like O
TUB B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
has O
a O
wider O
pattern O
of O
tissue O
expression O
than O
either O
TULP1 B_GENE
or O
TULP2 B_GENE
. O

After O
nine B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
GFR I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improved O
spontaneously O
to O
32 B_MEASURE
ml I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
/ O
1 B_MEASURE
. O
73 B_MEASURE
m2 I_MEASURE
despite O
no O
improvement B_DISEASE_ADJECTIVE[DISEASE]
in O
his O
hypertension B_DISEASE
. O

First O
, O
ste12Delta B_PERSON/B_GENE
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ste20Delta B_GENE/B_DISEASE
, O
ste5Delta B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ste11Delta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ste7Delta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
or O
fus3Delta B_PERSON/B_GENE
kss1Delta I_PERSON/I_GENE
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O
. O

Herein O
, O
we O
report O
that O
CRE O
- O
decoy O
oligonucleotide O
treatment O
results O
in O
an O
increase O
in O
the O
p53 B_GENE
protein I_GENE
level O
in O
MCF O
- O
7 O
human O
breast O
cancer O
cells O
that O
express O
wild O
- O
type O
p53 B_GENE
. O

The O
selective O
5 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT2 B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O
ketanserin O
was O
found O
to O
reduce O
maximal O
urethral O
pressures O
in O
healthy O
females O
by O
about O
40 O
% O
without O
reducing O
blood O
pressure O
. O

It O
thus O
seems O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O
genistein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affects O
a O
common B_MEASURE/B_LOCATION
pathway I_MEASURE/I_LOCATION
downstream I_MEASURE/I_LOCATION
of O
these O
signals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
B B_LOCATION/B_DISEASE
. O
glabrata B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
B B_LOCATION/B_DISEASE
. O
straminea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O
B B_PROTEIN[GENE]/B_LOCATION
. O
tenagophila B_SPECIES[BIO]/B_DISEASE
under O
outdoor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
electrocardiogram B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
tachycardia B_BIO/B_DISEASE
. O

identification O
of O
a O
putative O
chromosomal O
replication O
origin O
from O
Helicobacter O
pylori O
and O
its O
interaction O
with O
the O
initiator B_GENE
protein I_GENE
DnaA I_GENE
. O

The O
primary O
structure O
of O
cholesterol B_GENE
esterase I_GENE
displayed O
no O
significant O
homology O
with O
other O
lipases B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
although O
the O
putative O
lipid O
interfacial O
recognition O
site O
of O
G O
- O
X O
- O
S O
- O
X O
- O
G O
is O
present O
in O
the O
cholesterol B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
esterase I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
questions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
about O
hepatitis B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
C B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
transcriptional O
initiation O
site O
of O
RAG1 B_GENE
was O
localized O
at O
A O
, O
26 O
BP O
upstream O
of O
the O
putative O
translational O
initiation O
codon O
, O
ATG O
, O
by O
the O
primer O
extension O
assay O
. O

Coronary B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arteriographies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
ventriculographies B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corresponding O
to O
274 B_TIME[MEASURE]/B_PERSON
consecutive I_TIME[MEASURE]/I_PERSON
patients I_TIME[MEASURE]/I_PERSON
( O
January B_TIME[MEASURE]/B_LOCATION
, O
1975 B_MEASURE
- O
October B_TIME[MEASURE]/B_LOCATION
, O
1978 B_MEASURE
) O
with O
significant B_DISEASE/B_LOCATION
coronary I_DISEASE/I_LOCATION
lesions I_DISEASE/I_LOCATION
are O
reviewed O
. O

Visualization O
of O
the O
cells O
by O
phase O
contrast O
microscopy O
indicated O
that O
murine B_GENE
PKCepsilon I_GENE
expression O
in O
the O
presence O
of O
glycerol O
resulted O
in O
a O
significant O
increase O
in O
the O
number O
of O
yeast O
cells O
exhibiting O
very O
small O
buds O
. O

Sonography B_PERSON
depicted O
the O
true B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
morphology I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
these O
cystic B_DISEASE/B_LOCATION
lesions I_DISEASE/I_LOCATION
more O
clearly O
than O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
the O
sonographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
virtually O
excluded O
uncomplicated B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatic B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyst B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Protein B_NUMBER[MEASURE]/B_PERSON
kinase I_NUMBER[MEASURE]/I_PERSON
C I_NUMBER[MEASURE]/I_PERSON
transiently O
activated O
heteromeric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
N I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
channels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
independent O
of O
the O
phosphorylatable O
C O
- O
terminal O
splice O
domain O
and O
of O
consensus O
phosphorylation O
sites O
. O

A O
24 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
pregnant I_PERSON
woman I_PERSON
started O
to O
have O
hyperemesis B_DISEASE
gravidarum I_DISEASE
6 I_DISEASE
weeks I_DISEASE
before O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B_GENE/B_LOCATION
and O
those O
of O
GENA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B_GENE/B_LOCATION
) O
located O
upstream O
of O
the O
aceEF B_DISEASE/B_GENE
- O
lpd B_PROTEIN[GENE]/B_MEASURE
operon O
] O
, O
and O
GNTR B_GENE/B_LOCATION
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B_GENE/B_BACTERIUM[BIO]
operon I_GENE/I_BACTERIUM[BIO]
of O
Bacillus O
subtilis O
) O
. O

In O
vitro O
DNA O
binding O
assays O
indicate O
that O
the O
elements O
identified O
can O
specifically O
interact O
with O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ets I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

They O
are O
found O
to O
have O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantages B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
skewness B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
kurtosis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
square B_MEASURE
root I_MEASURE
of O
B1 B_PROTEIN[GENE]
and O
B2 B_PROTEIN[GENE]
) O
and O
no O
serious B_DISEASE_ADJECTIVE[DISEASE]
drawbacks I_DISEASE_ADJECTIVE[DISEASE]
. O

They O
elicit O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regional B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cerebral B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
rCBF B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
patterns B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
even O
though O
sign B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
language I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Siglec B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
predicted O
to O
contain O
three O
extracellular O
immunoglobulin B_GENE/B_LOCATION
- B_GENE/I_LOCATION
like B_GENE/I_LOCATION
domains B_GENE/I_LOCATION
that O
comprise O
an O
N B_GENE
- I_GENE
terminal I_GENE
V I_GENE
- I_GENE
set I_GENE
domain I_GENE
and O
two O
C2 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
set I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
domains I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
a O
transmembrane O
region O
and O
a O
cytoplasmic O
tail O
containing O
two O
putative O
tyrosine O
- O
based O
signaling O
motifs O
. O

Determination B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
LD B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_MEASURE/B_LOCATION
) O
during O
infant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O
growth B_TIME[MEASURE]/B_PERSON
period B_TIME[MEASURE]/I_PERSON
. O

The O
availability B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
commercial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PCNONLIN B_ORGANIZATION/B_LOCATION
) O
is O
needed O
to O
carry O
out O
matrix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
handling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gives O
also O
the O
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
Research B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Programme I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MZ I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
XVII B_MEASURE
and O
its O
implementation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
several B_LOCATION/B_ORGANIZATION
regions I_LOCATION/I_ORGANIZATION
of O
Poland B_LOCATION
. O

The O
fecal B_MEASURE
excretion I_MEASURE
is O
found O
to O
be O
only O
one B_MEASURE/B_LOCATION
third I_MEASURE/I_LOCATION
of O
that O
measured O
in O
urine B_BIO/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
COR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biosynthetic O
gene O
cluster O
in O
P O
. O
syringae O
pv O
. O
glycinea O
PG4180 O
is O
encoded O
by O
a O
32 O
- O
kb O
region O
which O
contains O
both O
the O
structural O
and O
regulatory O
genes O
needed O
for O
COR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O
. O

Model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pheasants B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
using O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
the O
insecticide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Lindane B_PERSON/B_PROTEIN[GENE]
) O
the O
herbicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Terbutryn B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
a O
mineral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fertilizer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
calcium B_LOCATION/B_ORGANIZATION
ammonium I_LOCATION/I_ORGANIZATION
nitrate I_LOCATION/I_ORGANIZATION
) O
and O
the O
fungicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
HCB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

In O
this O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
neopharynx B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consists O
only O
of O
the O
prevertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
flap B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
forms O
the O
anterior B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
lateral B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
walls I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
hosts I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
were O
equines B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
31 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
bovines B_SPECIES[BIO]
( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
and O
raccoons B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
( O
19 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
. O

A O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
session I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
cellulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triacetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
polysulfone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
increased O
water B_MEASURE/B_DISEASE
content B_MEASURE/I_DISEASE
both O
at O
forearm B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
leg I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Both O
claR B_PROTEIN[GENE]/B_DISEASE
and O
car B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
expressed O
as O
monocistronic O
transcripts O
; O
the O
level O
of O
transcript O
declined O
rapidly O
after O
48h O
in O
complex O
media O
, O
but O
low O
sustained O
levels O
of O
both O
transcripts O
were O
observed O
in O
defined O
GSPG O
medium O
until O
96h O
. O

claR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
car B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
significantly O
expressed O
in O
mutants O
disrupted O
in O
the O
ccaR B_GENE
gene I_GENE
, O
a O
regulatory O
gene O
that O
controls O
positively O
clavulanic O
acid O
and O
cephamycin O
biosynthesis O
. O

Whereas O
mutant B_PERSON/B_LOCATION
6C4 I_PERSON/I_LOCATION
specified O
a O
wild B_GENE
- I_GENE
type I_GENE
- I_GENE
size I_GENE
Pol I_GENE
protein I_GENE
, O
we O
detected O
no O
full B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
length I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pol I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
7E4 O
- O
infected O
cell O
extracts O
. O

The O
hepatic O
isoform O
of O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
phosphofructo I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
/ O
fructose B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
bisphosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PF2K B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Fru B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BPase I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blocks O
this O
stimulatory O
effect O
. O

Being O
implicated O
in O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
GK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulations O
as O
a O
common O
transcription O
factor O
, O
IPF1 B_GENE/B_DISEASE
/ O
STF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
/ O
PDX B_MEASURE/B_GENE
- I_MEASURE/I_GENE
1 I_MEASURE/I_GENE
is O
likely O
to O
play O
an O
essential O
role O
in O
maintaining O
normal O
beta O
- O
cell O
functions O
. O

The O
Caenorhabditis B_GENE/B_LOCATION
elegans I_GENE/I_LOCATION
NK I_GENE/I_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
class I_GENE/I_LOCATION
homeoprotein I_GENE/I_LOCATION
CEH I_GENE/I_LOCATION
- I_GENE/I_LOCATION
22 I_GENE/I_LOCATION
is O
involved O
in O
combinatorial O
activation O
of O
gene O
expression O
in O
pharyngeal O
muscle O
. O

Mouse O
embryo O
cells O
( O
C57BL O
/ O
6 O
, O
H O
- O
2b O
) O
transformed O
by O
the O
E1A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
E1B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O
of O
adenovirus O
type O
5 O
( O
Ad5E1 O
MEC O
) O
are O
highly O
immunogenic O
. O

The O
largest B_MEASURE
age I_MEASURE
adjusted O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
men B_PERSON/B_BIO
with O
low B_DISEASE/B_LOCATION
and O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mood I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
for O
the O
AH4 B_DISEASE/B_ORGANIZATION
( O
3 B_MEASURE/B_LOCATION
points I_MEASURE/I_LOCATION
, O
t O
= O
5 B_MEASURE
. O
6 B_MEASURE
, O
p O
< B_NUMBER[MEASURE]/B_LOCATION
0 I_NUMBER[MEASURE]/I_LOCATION
. O
0001 B_MEASURE
) O
and O
the O
CAMCOG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
2 B_MEASURE/B_LOCATION
points I_MEASURE/I_LOCATION
, O
t O
= O
5 B_MEASURE
. O
8 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
resting O
Tl B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
201 B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
limited O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
in O
patients B_PERSON
with O
Hurler B_DISEASE
syndrome I_DISEASE
. O

We O
demonstrate O
that O
the O
WRM B_GENE
- I_GENE
1 I_GENE
protein I_GENE
binds O
to O
LIT B_GENE
- I_GENE
1 I_GENE
in O
vivo O
and O
that O
WRM B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
can O
activate O
the O
LIT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O
coexpressed O
in O
vertebrate O
tissue O
culture O
cells O
. O

Results O
: O
All O
primary O
tumors O
were O
positive O
for O
CAM5 B_GENE
. I_GENE
2 I_GENE
. O

Nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
extracts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
Sertoli B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
to O
cause O
an O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
box B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
gel I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
shift I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
when O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
stimulated O
to O
differentiate O
in O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
under O
basal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

On O
the O
sixth B_TIME[MEASURE]/B_LOCATION
postirradiation B_TIME[MEASURE]/I_LOCATION
day B_TIME[MEASURE]/I_LOCATION
the O
absorption B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phenobarbitone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
sulphafurazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mecamylamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
returned O
to O
the O
control B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
level B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
the O
absorption B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
quinidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
still O
retarded B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
determine O
the O
transactivation O
potential O
of O
each O
of O
the O
four O
Ahr B_GENE/B_LOCATION
Sp1 I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
, O
we O
fused O
the O
Ahr B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
to O
a O
luciferase B_GENE
( O
LUC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
reporter O
gene O
and O
transfected O
the O
construct O
into O
the O
Drosophila O
cell O
line O
Schneider O
- O
2 O
, O
which O
contains O
no O
Sp1 B_GENE/B_DISEASE
or O
Sp1 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
like I_GENE/I_LOCATION
factors I_GENE/I_LOCATION
. O

We O
determined O
that O
Hop B_GENE/B_MEASURE
( I_GENE/I_MEASURE
T42 I_GENE/I_MEASURE
) I_GENE/I_MEASURE
contains O
a O
glutamic O
acid O
- O
to O
- O
lysine O
substitution O
at O
amino O
acid O
residue O
695 O
( O
E695K O
) O
. O

The O
organotins B_LOCATION/B_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
binding O
of O
biotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
protection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
regions B_LOCATION/B_PERSON
of O
the O
central B_ENZYME[GENE]/B_LOCATION
domain I_ENZYME[GENE]/I_LOCATION
in O
the O
vicinity B_LOCATION/B_MEASURE
of O
the O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_MEASURE
domain I_LOCATION/I_MEASURE
from O
chemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cleavage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
psh3 B_GENE/B_MEASURE
( I_GENE/I_MEASURE
+ I_GENE/I_MEASURE
) I_GENE/I_MEASURE
gene I_GENE/I_MEASURE
encodes O
a O
protein O
of O
215 O
amino O
acids O
, O
which O
shares O
a O
high O
degree O
of O
structural O
and O
functional O
similarity O
with O
Shr3p B_GENE/B_BIO
. O

The O
impairment O
of O
the O
nocturnal O
secretion O
was O
related O
to O
the O
subjects O
' O
age O
and O
, O
for O
the O
GH B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory O
pattern O
only O
, O
also O
to O
the O
MMSE O
score O
. O

Thus O
, O
the O
antibody O
class O
switch O
appears O
to O
be O
directed O
by O
induction O
of O
accessibility O
, O
as O
assayed O
by O
transcription O
of O
germ O
line O
CH B_DISEASE/B_GENE
genes O
. O

This O
growth O
- O
inhibitory O
effect O
was O
suppressed O
by O
the O
mpk1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
delta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation O
, O
suggesting O
that O
hyperactivation O
of O
the O
Mpk1 B_GENE
pathway O
is O
toxic O
to O
cells O
. O

The O
chicken O
genome O
contains O
two O
functional O
nonallelic O
beta1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosyltransferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Erythropoietin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Platinum O
- O
Based O
Chemotherapy O
In O
Advanced O
Ovarian O
Cancer O
. O

Homodimers O
of O
RIP60 B_GENE/B_DISEASE
( O
replication B_PROTEIN[GENE]
initiation I_PROTEIN[GENE]
- I_PROTEIN[GENE]
region I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
60 I_PROTEIN[GENE]
kDA I_PROTEIN[GENE]
) O
purified O
from O
nuclear O
extract O
bind O
two O
ATT O
- O
rich O
sites O
in O
oribeta O
and O
foster O
the O
formation O
of O
a O
twisted O
720 O
BP O
DNA O
loop O
in O
vitro O
. O

endodontic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
deciduous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
teeth I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
using O
the O
formocresol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amputation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Some O
of O
these O
physiological O
responses O
are O
regulated O
via O
activation O
of O
transcription O
factors O
such O
as O
activator B_GENE
protein I_GENE
1 I_GENE
( O
AP B_GENE
- I_GENE
1 I_GENE
) O
. O

To O
test O
the O
role O
of O
myb B_GENE
family I_GENE
members I_GENE
in O
progression O
through O
the O
cell O
cycle O
, O
we O
comicroinjected O
c B_GENE
- I_GENE
myc I_GENE
and O
myb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
vectors O
into O
serum O
- O
deprived O
quiescent O
SMCs O
. O

Overall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
graft I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
patient B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
hat B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
33 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
and O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
respectively O
. O

LAC9 B_GENE
is O
a O
DNA O
- O
binding O
protein O
that O
regulates O
transcription O
of O
the O
lactose B_GENE/B_BIO
- I_GENE/I_BIO
galactose I_GENE/I_BIO
regulon I_GENE/I_BIO
in O
Kluyveromyces O
lactis O
. O

We O
determined O
the O
complete O
nucleotide O
sequence O
of O
the O
gypsy B_GENE/B_BACTERIUM[BIO]
element I_GENE/I_BACTERIUM[BIO]
present O
at O
the O
forked B_GENE
locus I_GENE
of O
Drosophila O
melanogaster O
in O
the O
F1 O
allele O
. O

The O
same O
high O
degree O
of O
sequence O
homology O
between O
the O
two O
F O
. O
diplosiphon O
PC B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PC B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
85 O
and O
77 O
% O
, O
respectively O
) O
was O
found O
at O
both O
the O
nucleotide O
and O
amino O
acid O
levels O
, O
and O
similar O
results O
were O
obtained O
for O
interspecies O
comparisons O
. O

A O
wound O
model O
for O
decubitus O
and O
leg O
ulcers O
consisting O
of O
human O
dermal O
fibroblasts O
in O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
dermal O
' O
equivalent O
' O
matrix O
( O
dem O
) O
was O
exposed O
in O
vitro O
to O
electric O
fields O
similar O
to O
postulated O
endogenous O
fields O
in O
wounds O
. O

A O
group O
of O
factors O
known O
as O
activating B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
have O
been O
found O
to O
bind O
to O
the O
latter O
and O
related O
sequences O
found O
upstream O
of O
early O
adenovirus O
promoters O
induced O
by O
E1A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
these O
factors O
are O
highly O
homologous O
to O
the O
CREB B_GENE/B_TIME[MEASURE]
protein I_GENE/I_TIME[MEASURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
these O
cases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
patients B_PERSON/B_BIO
w I_PERSON/I_BIO
with O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Loa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
microfilaremia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
developed O
milder B_DISEASE
neurologic I_DISEASE
manifestations I_DISEASE
causing O
functional B_DISEASE
impairment I_DISEASE
lasting O
for O
at O
least O
one B_TIME[MEASURE]
week I_TIME[MEASURE]
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
vertebrate B_GENE
transcription I_GENE
factors I_GENE
TCF I_GENE
( O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
LEF B_LOCATION/B_GENE
( O
lymphocyte B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
enhancer B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
binding B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
interact O
with O
beta B_GENE
- I_GENE
catenin I_GENE
and O
are O
hypothesized O
to O
mediate O
Wingless B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
Wnt B_GENE/B_LOCATION
signaling O
. O

Some O
of O
these O
DNA O
: O
protein O
complexes O
were O
also O
present O
, O
but O
at O
lower O
levels O
, O
in O
nuclear O
extracts O
from O
untransformed O
rat O
cells O
suggesting O
the O
possible O
involvement O
of O
cellular O
factors O
in O
the O
mechanism O
of O
down O
- O
regulation O
mediated O
by O
Ad12 B_GENE/B_DISEASE
E1A I_GENE/I_DISEASE
. O

Hypocalcemia O
is O
usually O
due O
to O
either O
a O
disturbance O
in O
the O
parathyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
adenylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cyclase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
system O
or O
a O
disturbance O
in O
vitamin O
D O
metabolism O
. O

Activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
reconstituted O
, O
however O
, O
by O
combining O
fractions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
were O
enriched O
in O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

If O
failure B_DISEASE
to O
solve O
invisible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displacements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
due O
to O
increased O
memory B_DISEASE/B_MEASURE
requirements I_DISEASE/I_MEASURE
, O
then O
the O
primates B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
perform O
at O
chance B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
on O
all O
3 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
problems I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
seven O
patients O
( O
7 O
. O
8 O
% O
) O
with O
new O
Q O
- O
waves O
and O
a O
pathologic O
CK B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
MB I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
profile O
( O
group O
II O
) O
troponin B_PERSON/B_LOCATION
T I_PERSON/I_LOCATION
reached O
median O
levels O
of O
10 O
. O
47 O
micrograms O
/ O
l O
( O
quartile O
6 O
. O
34 O
- O
12 O
. O
50 O
micrograms O
/ O
l O
) O
( O
P O
< O
0 O
. O
001 O
I O
vs O
II O
) O
. O

Mineralized B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
bone B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
nodule B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
by O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
populations I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
young B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adult I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rabbit I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alveolar I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bone I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Mouse B_GENE/B_PERSON
GRK6 I_GENE/I_PERSON
- I_GENE/I_PERSON
C I_GENE/I_PERSON
displays O
none O
of O
these O
motifs O
. O

Comparisons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
benazepril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
and O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
have O
shown O
that O
benazepril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O
daily O
is O
as O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
or O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
lowering O
diastolic B_MEASURE/B_DISEASE
blood B_MEASURE/I_DISEASE
pressure B_MEASURE/I_DISEASE
than O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O
daily O
and O
that O
the O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
benazepril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
possibly O
synergistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
diastolic B_DISEASE
blood I_DISEASE
pressure I_DISEASE
. O

The O
132 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PHO8p I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
connected O
at O
position O
- O
281 O
of O
the O
5 O
' O
upstream O
region O
of O
a O
HIS5 B_MEASURE
' I_MEASURE
- O
' B_GENE/B_LOCATION
lacZ I_GENE/I_LOCATION
fused O
gene O
, O
could O
sense O
Pi O
signals O
in O
vivo O
, O
but O
a O
20 O
- O
BP O
synthetic O
oligonucleotide O
having O
the O
same O
sequence O
from O
- O
544 O
to O
- O
525 O
of O
the O
PHO8p B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O
not O
. O

1988 B_MEASURE
) O
. O

sequences O
within O
the O
UAS2 O
element O
of O
the O
ENO2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
bound O
a O
second O
protein O
which O
corresponded O
to O
the O
ABFI B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
autonomously B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
replicating I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
protein O
. O

Plasmid O
subclones O
of O
recombinant O
phage O
lambda O
Asm152 O
were O
able O
to O
complement O
both O
Escherichia B_BACTERIUM[BIO]/B_PERSON
coli I_BACTERIUM[BIO]/I_PERSON
gltB I_BACTERIUM[BIO]/I_PERSON
and O
A O
. O
sesbaniae O
Asm O
- O
VI O
mutants O
; O
NADPH B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
was O
detected O
in O
all O
such O
strains O
complemented O
to O
Asm O
+ O
. O

The O
sequence O
of O
LZ321 B_GENE/B_PERSON
matched O
that O
of O
RREB1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
transcription O
factor O
that O
bound O
to O
a O
Ras B_GENE
responsive I_GENE
element I_GENE
( O
RRE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
very O
different O
from O
the O
sequence O
with O
which O
we O
isolated O
LZ321 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

steady O
- O
state O
levels O
of O
murine B_GENE
MMR I_GENE
mRNA I_GENE
were O
measured O
in O
the O
macrophage O
cell O
line O
J774E O
, O
which O
is O
known O
to O
express O
the O
protein O
at O
the O
cell O
surface O
. O

Basal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
to O
20 B_MEASURE
and O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
when O
the O
UGA B_GENE
stop I_GENE
codon I_GENE
was O
replaced O
by O
UAG B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
UAA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
in O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
translation I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
terminates O
more O
efficiently O
at O
UAG B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
UAA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
at O
UGA B_PROTEIN[GENE]/B_LOCATION
. O

discriminant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
function I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggests O
that O
audit B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
successfully O
identify O
SAT B_GENE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SAT B_GENE/B_DISEASE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
; O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accounted O
for O
42 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
of O
the O
variance B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
correctly O
classified O
84 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Coronatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
COR B_LOCATION/B_ORGANIZATION
) O
is O
a O
plasmid O
- O
encoded O
phytotoxin O
synthesized O
by O
several O
pathovars O
of O
phytopathogenic O
Pseudomonas O
syringae O
. O

Both O
the O
5 B_MEASURE
' O
and O
3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
untranslated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
show O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
similarity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
murine B_GENE/B_BIO
gene I_GENE/I_BIO
, O
with O
79 B_MEASURE
and O
70 B_MEASURE
% I_MEASURE
sequence I_MEASURE
identity I_MEASURE
, O
respectively O
. O

One B_PERSON
patient I_PERSON
exhibited O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
sense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O
codon B_LOCATION/B_PROTEIN[GENE]
388 I_LOCATION/I_PROTEIN[GENE]
) O
, O
which O
changed O
a O
glutamine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codon B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CAG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
to O
a O
stop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
codon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Tag B_LOCATION/B_PROTEIN[GENE]
) O
. O

The O
transcriptional O
activity O
of O
P B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
450 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
11 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
studied O
with O
an O
in O
vitro O
transcription O
system O
using O
nuclear O
extracts O
prepared O
from O
bovine O
adrenal O
cortex O
. O

Renal B_PERSON
dysplasia I_PERSON
with O
multisystem B_DISEASE
malformation I_DISEASE
- O
- O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
9 B_DISEASE/B_PERSON
cases I_DISEASE/I_PERSON
. O

This O
Bud O
morphology O
results O
at O
least O
in O
part O
from O
a O
cell O
cycle O
delay O
imposed O
by O
the O
Cdc28p B_GENE/B_DISEASE
- O
inhibitory O
kinase O
Swe1p B_LOCATION/B_GENE
. O

Eleven O
of O
the O
12 O
exons O
have O
complete O
sequence O
homology O
with O
the O
RBM B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
sequence I_GENE/I_MEASURE
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Laparoscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
revealed O
an O
enlarged O
, O
thin B_MEASURE/B_COLOR
- O
walled B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
and O
fluid B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
filled O
uterine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
segment I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
cranial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
to O
the O
midcornus B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
occlusion B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sites B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
all O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
three O
proteins O
copurified O
through O
several O
biochemical O
fractionation O
steps O
and O
could O
be O
coimmunoprecipitated O
by O
using O
antibodies O
against O
GCD1 B_GENE
or O
GCD2 B_GENE/B_DISEASE
. O

cellular O
fractionation O
and O
Percoll O
gradient O
centrifugation O
combined O
with O
immunoblotting O
show O
that O
p67 B_GENE/B_LOCATION
cofractionates O
with O
nuclei O
and O
is O
enriched O
in O
resistant O
structure O
that O
is O
insoluble O
in O
2 O
M O
NaCl O
, O
25 O
mm O
lithium O
3 O
, O
5 O
' O
- O
diiodosalicylate O
, O
and O
1 O
% O
Triton O
but O
is O
soluble O
in O
8 O
M O
urea O
. O

For O
the O
first O
time O
also O
a O
genomic O
sequence O
for O
a O
red B_SPECIES[BIO]/B_PERSON
algal I_SPECIES[BIO]/I_PERSON
lhc I_SPECIES[BIO]/I_PERSON
gene I_SPECIES[BIO]/I_PERSON
is O
presented O
. O

elimination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
brush B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
border I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
well O
as O
of O
glomerular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
marker I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
proteins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
was O
significantly O
lower B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
after O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
low B_DISEASE/B_MEASURE
- O
osmolar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
iopamidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
370 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
832 B_MEASURE/B_LOCATION
mOsm I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
) O
than O
after O
meglumine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diatrizoate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
76 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2100 B_MEASURE
mOsm I_MEASURE
/ O
kg B_MEASURE
) O
. O

Raman B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scattering I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
VO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
single I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
crystals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
A O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
surface B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oxidation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
advanced B_DISEASE/B_LOCATION
ovarian I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Making O
sense B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
out O
of O
oxygen B_PERSON/B_LOCATION
sensor I_PERSON/I_LOCATION
. O

In O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
a O
silent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
baseline I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O
CBF B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
auditory B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
bilaterally O
and O
in O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
superior I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
parietal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
right B_BODY_PART_OR_ORGAN_COMPONENT
dorsolateral I_BODY_PART_OR_ORGAN_COMPONENT
frontal I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
right B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
premotor B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
regions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
with O
no O
modulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
a O
function B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
attentional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
condition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
vitro O
, O
c B_GENE
- I_GENE
Src I_GENE
phosphorylated O
FAK B_GENE
Tyr I_GENE
- I_GENE
925 I_GENE
in O
a O
glutathione B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
FAK B_GENE
C O
- O
terminal O
domain O
fusion O
protein O
, O
whereas O
FAK O
did O
not O
. O

methods O
AND O
Results O
: O
The O
effect O
of O
prolonged O
nitrate O
therapy O
between O
2 O
days O
and O
6 O
weeks O
during O
healing O
after O
infarction O
on O
serial O
parameters O
of O
ventricular O
remodeling O
( O
scar O
expansion O
, O
scar O
thinning O
, O
ventricular O
dilation O
, O
and O
hypertrophy O
) O
and O
function O
( O
asynergy O
or O
akinesis O
plus O
dyskinesis O
and O
ejection O
fraction O
) O
by O
serial O
two O
- O
dimensional O
echocardiography O
, O
hemodynamics O
, O
postmortem O
topography O
( O
computerized O
planimetry O
, O
geometric O
maps O
, O
and O
radiographs O
) O
, O
and O
collagen B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
content O
( O
hydroxyproline O
) O
was O
studied O
in O
64 O
instrumented O
dogs O
randomized O
2 O
days O
after O
left O
anterior O
descending O
coronary O
artery O
ligation O
to O
various O
nitrate O
regimens O
( O
n O
= O
32 O
) O
over O
the O
first O
2 O
weeks O
( O
subgroup O
1 O
: O
2 O
% O
transdermal O
nitroglycerin O
at O
8 O
AM O
and O
4 O
PM O
, O
n O
= O
6 O
; O
subgroup O
2 O
: O
2 O
% O
transdermal O
nitroglycerin O
plus O
2 O
. O
6 O
mg O
of O
sustained O
- O
release O
oral O
nitroglycerin O
at O
8 O
AM O
, O
3 O
PM O
, O
and O
10 O
PM O
, O
n O
= O
5 O
; O
subgroup O
3 O
: O
oral O
isosorbide O
dinitrate O
, O
30 O
mg O
at O
8 O
AM O
and O
4 O
PM O
, O
n O
= O
11 O
) O
or O
6 O
weeks O
( O
subgroup O
4 O
: O
isosorbide O
dinitrate O
, O
n O
= O
10 O
) O
and O
in O
matching O
controls O
( O
n O
= O
32 O
) O
. O

The O
essential B_BIO
oil I_BIO
composition I_BIO
of O
three B_BIO/B_NUMBER[MEASURE]
Zingiberaceae B_BIO/I_NUMBER[MEASURE]
widely O
used O
as O
medicinal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aromatic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
S B_LOCATION/B_OTHER
. O

gel O
shift O
analysis O
of O
protein O
binding O
from O
nuclear O
extracts O
to O
these O
caveolin B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
together O
with O
DNase B_GENE
I I_GENE
footprinting O
, O
confirmed O
nucleoprotein O
binding O
to O
the O
SRE O
- O
like O
elements O
as O
part O
of O
the O
transcriptional O
response O
to O
LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cervical B_DISEASE/B_ORGANISM_FUNCTION
ripening I_DISEASE/I_ORGANISM_FUNCTION
: O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
prelabor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contractility I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
MC B_LOCATION/B_PROTEIN[GENE]
/ O
UA B_LOCATION/B_MEASURE
ratio I_LOCATION/I_MEASURE
improves O
the O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
prediction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
poor B_DISEASE/B_LOCATION
perinatal I_DISEASE/I_LOCATION
outcome I_DISEASE/I_LOCATION
when O
it O
is O
combined O
with O
the O
NST B_DISEASE/B_PROTEIN[GENE]
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
technics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vascular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
using O
111 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Indium B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
claustrocortical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
connection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
investigated O
in O
13 B_SPECIES[BIO]/B_TIME[MEASURE]
cats I_SPECIES[BIO]/I_TIME[MEASURE]
with O
selective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HRP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
three B_LOCATION/B_BIO
subdivisions I_LOCATION/I_BIO
of O
the O
auditory B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O
( O
abstract B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED I_TIME[MEASURE]/I_ORGANIZATION
AT O
400 B_LOCATION/B_MEASURE
Words I_LOCATION/I_MEASURE
) O
. O

applying O
the O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mentioned O
above O
, O
4 B_MEASURE/B_LOCATION
- O
Meta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
to O
bond O
a O
proprietary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
photocuring B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
microfilled O
composite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
material I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O
Class B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
V B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cavities B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
freshly O
extracted O
human B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
teeth I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
phP1 B_GENE/B_MEASURE
mutation O
was O
induced O
by O
insertion O
of O
a O
1 O
. O
2 O
- O
kb O
P B_GENE/B_LOCATION
element I_GENE/I_LOCATION
into O
the O
5 O
' O
transcribed O
nontranslated O
region O
of O
the O
proximal O
polyhomeotic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Six B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instruments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
reviewed O
: O
the O
Berg B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Berg B_PERSON/B_DISEASE
) O
, O
the O
Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sensory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
balance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
CTSIB B_DISEASE/B_PERSON
) O
, O
the O
Functional B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reach I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Test I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
Tinetti B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
balance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
Performance B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
oriented O
Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
mobility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
problems I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
Tinetti B_PERSON/B_DISEASE
) O
, O
the O
timed O
' O
Up O
and O
Go O
' O
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
Tu B_LOCATION/B_PROTEIN[GENE]
& O
GT B_ORGANIZATION/B_PROTEIN[GENE]
) O
, O
and O
the O
Physical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Performance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Test B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PPT B_DISEASE/B_ORGANIZATION
) O
. O

Genome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
timeline I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Initial O
computer O
based O
similarity O
searches O
identified O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoblastoma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
RBP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
, O
Drosophila B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
melanogaster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
male I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lethal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Msl B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
S B_GENE/B_SPECIES[BIO]
. B_GENE/I_SPECIES[BIO]
pombe B_GENE/I_SPECIES[BIO]
altered B_GENE/I_SPECIES[BIO]
polarity B_GENE/I_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
13 B_GENE/I_SPECIES[BIO]
( O
Alp13 B_GENE/B_MEASURE
) O
and O
S B_GENE/B_SPECIES[BIO]
. I_GENE/I_SPECIES[BIO]
cerevisiae I_GENE/I_SPECIES[BIO]
Eaf3p I_GENE/I_SPECIES[BIO]
, O
a O
component O
of O
the O
yeast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NuA4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HAT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex O
( O
Galarneau O
et O
al O
. O
, O
2000 O
. O

The O
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
steady B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flow I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
conditions I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
showed O
that O
the O
hemodynamic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
including O
pressure B_MEASURE/B_LOCATION
gradient I_MEASURE/I_LOCATION
and O
effective B_MEASURE/B_DISEASE
orifice I_MEASURE/I_DISEASE
area I_MEASURE/I_DISEASE
) O
of O
SPAB B_DISEASE
is O
superior B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
its O
stented B_PERSON
counterpart I_PERSON
, O
especially O
in O
the O
smaller B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
sizes I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

serum O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rapidly O
decreased O
after O
institution O
of O
treatment O
, O
with O
actual O
normalization O
( O
less O
than O
20 O
ng O
/ O
ml O
) O
by O
the O
3rd O
month O
. O

We O
report O
five O
of O
13 O
evaluable O
patients O
undergoing O
allogeneic O
sibling O
BM O
or O
PBSC O
transplantation O
for O
mm O
between O
1990 O
and O
1997 O
who O
met O
the O
criteria O
for O
adjuvant O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

moist B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
healing I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
versus I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wet I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
to B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dry B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
report O
, O
we O
identify O
Tyr319 O
as O
a O
functionally O
important O
phosphorylation O
site O
in O
the O
ZAP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
70 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interdomain B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
power B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
laser B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
can O
be O
used O
for O
promotion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vascularization B_DISEASE/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
and O
take O
of O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transplants I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Research B_ORGANIZATION/B_TIME[MEASURE]
Design B_ORGANIZATION/I_TIME[MEASURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
26 B_PERSON
IDDM I_PERSON
patients I_PERSON
with O
normoalbuminuria B_DISEASE/B_LOCATION
were O
randomized O
into O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
one B_NUMBER[MEASURE]/B_ORGANIZATION
group I_NUMBER[MEASURE]/I_ORGANIZATION
receiving O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_MEASURE/B_LOCATION
= O
13 B_MEASURE
, O
age B_MEASURE/B_PERSON
36 I_MEASURE/I_PERSON
+ I_MEASURE/I_PERSON
/ O
- O
3 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
, O
BMI B_MEASURE
24 I_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
1 B_MEASURE
kg I_MEASURE
/ O
m2 B_MEASURE/B_PERSON
) O
and O
the O
other B_SEQUENCE[MEASURE]/B_PERSON
group I_SEQUENCE[MEASURE]/I_PERSON
receiving O
an O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O
15 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
lisinopril I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
daily O
( O
n B_MEASURE/B_LOCATION
= O
13 B_MEASURE
, O
age B_MEASURE/B_PERSON
34 I_MEASURE/I_PERSON
+ I_MEASURE/I_PERSON
/ O
- O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
, O
BMI B_MEASURE
24 I_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
9 B_MEASURE
kg I_MEASURE
/ O
m2 B_MEASURE/B_PERSON
) O
. O

Previously O
, O
a O
cDNA O
( O
GT2 B_GENE/B_LOCATION
) O
encoding O
this O
protein O
was O
isolated O
from O
a O
mouse O
3T3 O
- O
L1 O
adipocyte O
library O
and O
was O
sequenced O
. O

expression O
of O
human B_GENE
complement I_GENE
receptor I_GENE
type I_GENE
2 I_GENE
( O
CR2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
CD21 B_PROTEIN[GENE]/B_MEASURE
) O
is O
primarily O
restricted O
to O
mature O
B O
cells O
and O
follicular O
dendritic O
cells O
. O

The O
6 O
. O
5 O
- O
kb O
genomic O
fragment O
contains O
the O
complete O
coding O
region O
of O
MyoD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
distributed O
over O
three O
exons O
, O
plus O
2 O
. O
3 O
kb O
of O
5 O
' O
- O
noncoding O
sequence O
and O
1 O
. O
4 O
kb O
of O
3 O
' O
- O
noncoding O
sequence O
. O

synthetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
furan B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
wittig B_ORGANIZATION
reaction I_ORGANIZATION
. O

The O
apparent O
binding O
constant O
of O
6 O
to O
calf O
thymus O
DNA O
is O
1 O
. O
68 O
X O
10 O
( O
5 O
) O
M O
- O
1 O
whereas O
netropsin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
under O
similar O
conditions O
gives O
a O
value O
of O
1 O
. O
85 O
X O
10 O
( O
7 O
) O
M O
- O
1 O
. O

Phenotypic O
screening O
of O
mutations O
in O
Pmr1 B_GENE
, O
the O
yeast B_ENZYME[GENE]/B_PERSON
secretory I_ENZYME[GENE]/I_PERSON
pathway I_ENZYME[GENE]/I_PERSON
Ca2 I_ENZYME[GENE]/I_PERSON
+ I_ENZYME[GENE]/I_PERSON
/ I_ENZYME[GENE]/I_PERSON
Mn2 I_ENZYME[GENE]/I_PERSON
+ I_ENZYME[GENE]/I_PERSON
- I_ENZYME[GENE]/I_PERSON
ATPase I_ENZYME[GENE]/I_PERSON
, O
reveals O
residues O
critical O
for O
ion O
selectivity O
and O
transport O
. O

Molecular O
cloning O
of O
cDNAs O
encoding O
alpha O
- O
subunits O
of O
guanine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
G B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
has O
revealed O
the O
existence O
of O
nine O
species O
of O
alpha O
- O
subunits O
. O

No O
transactivation O
of O
the O
ovalbumin B_GENE
promoter I_GENE
( O
pLovTATA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
template O
control O
was O
observed O
. O

Pros O
and O
cons O
of O
selective O
inhibition O
of O
cyclooxygenase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
versus O
dual O
lipoxygenase B_GENE
/ O
cyclooxygenase B_ENZYME[GENE]
inhibition O
: O
is O
two O
better O
than O
one O
. O

At O
11 B_MEASURE
. O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
521 B_MEASURE
major I_MEASURE
coronary I_MEASURE
disease I_MEASURE
events I_MEASURE
had O
occurred O
, O
261 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fatal B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
260 B_MEASURE/B_LOCATION
non I_MEASURE/I_LOCATION
- O
fatal B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
etiology B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
established O
in O
73 B_MEASURE
( O
76 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
out O
of O
95 B_MEASURE
cases I_MEASURE
. O

morphometry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
intestine B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
pig B_BIO/B_PERSON
. O

Serum B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
zinc I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
copper B_BODY_PART_OR_ORGAN_COMPONENT
levels I_BODY_PART_OR_ORGAN_COMPONENT
and O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
copper I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
men B_PERSON/B_BIO
were O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
women B_PERSON/B_BIO
, O
while O
there O
were O
no O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
serum B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
urinary B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zinc I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
age B_TIME[MEASURE]/B_PERSON
. O

HDE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
to O
be O
exclusively O
targeted O
to O
and O
imported O
into O
peroxisomes O
in O
both O
heterologous O
expression O
systems O
. O

GeneCalling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
detecting O
members B_PERSON/B_LOCATION
of O
complex B_BIO/B_LOCATION
metabolic I_BIO/I_LOCATION
pathways I_BIO/I_LOCATION
and O
uncovering O
novel B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
were O
either O
coincidentally O
regulated O
or O
directly O
involved O
in O
such B_DISEASE/B_ORGANISM_FUNCTION
pathways I_DISEASE/I_ORGANISM_FUNCTION
. O

transformations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
circular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasmids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
yielded O
slowly O
and O
irregularly O
growing O
geneticin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
resistant B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mycelia B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
1 B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
of O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
contained O
plasmid B_GENE
sequences I_GENE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
these O
patients B_PERSON/B_LOCATION
control O
of O
ventricular B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
either O
HbA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
VVIR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pacemaker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
or O
atrioventricular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modifying B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
+ B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
VVI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
pacemaker B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
will O
lead O
to O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
exercise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
duration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
quality B_MEASURE/B_LOCATION
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
other O
regions O
include O
potential O
binding O
sites O
for O
transcription O
factors O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
NF1 B_GENE/B_DISEASE
, O
and O
a O
CCAAT B_GENE/B_MEASURE
- I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
. O

Both O
purH B_GENE/B_DISEASE
and O
purD B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
constitute O
a O
single O
operon O
and O
are O
coregulated O
in O
expression O
by O
purines O
as O
other O
purine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
. O

The O
patient B_PERSON
demographics O
( O
means B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
standard B_MEASURE
deviations I_MEASURE
) O
were O
as O
follows O
: O
age B_TIME[MEASURE]/B_PERSON
, O
57 B_MEASURE
+ I_MEASURE
/ O
- O
12 B_TIME[MEASURE]
years I_TIME[MEASURE]
; O
sex B_PERSON
, O
nine B_NUMBER[MEASURE]/B_PERSON
males I_NUMBER[MEASURE]/I_PERSON
and O
three B_PERSON/B_NUMBER[MEASURE]
females I_PERSON/I_NUMBER[MEASURE]
; O
APACHE B_DISEASE/B_MEASURE
II I_DISEASE/I_MEASURE
score I_DISEASE/I_MEASURE
, O
15 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_TIME[MEASURE]
; O
diagnosis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
9 B_MEASURE
of O
12 B_PERSON
patients I_PERSON
with O
pneumonia B_DISEASE
. O

In O
situ O
hybridization O
reveals O
strong O
signals O
for O
Zep B_GENE
mRNA I_GENE
in O
the O
cerebellum O
and O
olfactory O
bulb O
with O
moderate O
signals O
detected O
in O
the O
hippocampus O
and O
cortex O
. O

TNF B_PERSON
- I_PERSON
alpha I_PERSON
effect O
was O
eliminated O
by O
a O
2 O
- O
BP O
substitution O
mutation O
in O
the O
NF B_GENE/B_LOCATION
- B_GENE/I_LOCATION
kappa B_GENE/I_LOCATION
B1 B_GENE/I_LOCATION
binding B_GENE/I_LOCATION
half B_GENE/I_LOCATION
site B_GENE/I_LOCATION
of O
the O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
cis I_GENE
element I_GENE
. O

UV O
- O
cross O
- O
linking O
studies O
suggested O
that O
these O
two O
complexes O
represent O
one O
and O
two O
molecules O
of O
ADR1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bound O
to O
DNA O
. O

As O
already O
available O
for O
the O
other O
known O
mammalian O
members O
of O
this O
enzyme O
family O
, O
we O
here O
define O
structural O
and O
functional O
features O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphoma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
convertase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
LPC B_DISEASE/B_LOCATION
) O
. O

The O
M O
- O
phase O
induction O
activity O
of O
Cdc2 B_PROTEIN[GENE]/B_LOCATION
- O
Cdc13 B_MEASURE/B_GENE
is O
inhibited O
by O
Wee1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
which O
phosphorylates O
Cdc2 B_GENE
on O
tyrosine O
- O
15 O
. O

nucleotide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
a O
2076 B_NUMBER[MEASURE]
- O
base B_GENE
pair I_GENE
open I_GENE
reading I_GENE
frame I_GENE
encoding O
a O
692 B_MEASURE
- O
amino B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

But O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
two B_PERSON/B_ORGANIZATION
hemispheres I_PERSON/I_ORGANIZATION
differ O
in O
the O
manner B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
they O
make O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
semantic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
selective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
appropriate B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
solution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
and O
the O
right B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
in O
a O
more O
diffuse B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
global B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
manner I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

supportive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
xenogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON/B_BIO
with O
metastatic B_DISEASE
breast I_DISEASE
cancer I_DISEASE
undergoing O
aggressive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
modified O
AC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
protocol B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
: O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
randomized O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
pregnancies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
terminated O
at O
19 B_NUMBER[MEASURE]
and O
12 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
of O
gestation B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
respectively O
. O

Single O
substitutions O
of O
three O
highly O
conserved O
phenylalanine O
residues O
( O
Phe O
- O
15 O
, O
Phe O
- O
17 O
, O
Phe O
- O
27 O
) O
by O
alanine O
and O
substitution O
of O
one O
histidine O
( O
His O
- O
29 O
) O
by O
glutamine O
, O
all O
located O
within O
the O
putative O
RNA O
- O
binding O
sites O
RNP B_PROTEIN[GENE]/B_DISEASE
- I_PROTEIN[GENE]/I_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
and O
RNP B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
abolished O
the O
nucleic O
acid O
- O
binding O
activity O
of O
CspB B_GENE/B_BACTERIUM[BIO]
. O

The O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
terminal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
forces B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
left B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
direction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
the O
delta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wave I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
superiorly O
and O
to O
the O
left O
at O
- O
60 B_MEASURE
degrees I_MEASURE
or O
inferiorly O
and O
to O
the O
right B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
at O
+ O
120 B_MEASURE
degrees I_MEASURE
, O
forming O
a O
single B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deflection I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
over O
0 B_NUMBER[MEASURE]
, O
12 B_MEASURE
seconds I_MEASURE
' I_MEASURE
duration I_MEASURE
, O
are O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
delayed B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
anterior B_BODY_PART_OR_ORGAN_COMPONENT
or O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
fascicle I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
bundle I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
after O
a O
long B_DISEASE/B_MEASURE
delay I_DISEASE/I_MEASURE
. O

The O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O
these O
carotenoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
E B_OTHER/B_LOCATION
. O
herbicola B_SPECIES[BIO]/B_DISEASE
Eho13 I_SPECIES[BIO]/I_DISEASE
are O
clustered O
in O
a O
7 B_GENE/B_LOCATION
kb I_GENE/I_LOCATION
DNA I_GENE/I_LOCATION
fragment I_GENE/I_LOCATION
. O

The O
results O
show O
that O
while O
a O
larger O
polypeptide O
substrate O
carrying O
the O
HD1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3C I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
processed O
more O
efficiently O
than O
a O
polypeptide O
substrate O
carrying O
the O
POL B_LOCATION/B_PROTEIN[GENE]
/ B_LOCATION/I_PROTEIN[GENE]
Zn B_LOCATION/I_PROTEIN[GENE]
site B_LOCATION/I_PROTEIN[GENE]
, O
cleavage O
of O
the O
synthetic O
peptide O
substrates O
containing O
these O
two O
cleavage O
sites O
occurred O
at O
similar O
efficiencies O
. O

Using O
transgenic O
lines O
a O
detailed O
analysis O
of O
the O
Hoxa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer O
- O
directed O
expression O
during O
embryogenesis O
was O
performed O
. O

lacZ B_GENE/B_PERSON
expression O
was O
first O
detected O
in O
the O
allantois O
at O
day O
7 O
. O
5 O
p O
. O
c O
. O
and O
in O
mesoderm O
and O
ectoderm O
at O
day O
8 O
. O
5 O
of O
gestation O
. O

An O
ERp60 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
filarial O
parasite O
Dirofilaria O
immitis O
has O
both O
transglutaminase O
and O
protein O
disulfide O
isomerase O
activity O
. O

At O
promoters O
that O
initiate O
with O
+ O
1 O
GGG O
, O
T7 B_GENE/B_SPECIES[BIO]
RNAP I_GENE/I_SPECIES[BIO]
synthesizes O
a O
ladder O
of O
poly O
( O
G O
) O
products O
as O
a O
result O
of O
slippage O
of O
the O
transcript O
on O
the O
three O
C O
residues O
in O
the O
template O
strand O
from O
+ O
1 O
to O
+ O
3 O
. O

serum O
levels O
of O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
converting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
well O
maintained O
. O

The O
UL3 B_GENE
ORF I_GENE
of O
204 O
amino O
acids O
shows O
significant O
homology O
to O
UL3 B_PROTEIN[GENE]/B_LOCATION
( O
nuclear O
phosphoprotein O
) O
of O
HSV O
- O
1 O
( O
62 O
% O
) O
and O
PRV O
( O
53 O
% O
) O
. O

On O
Western O
blots O
, O
the O
same O
antibodies O
recognized O
the O
recombinant O
protein O
migrating O
slightly O
slower O
on O
SDS O
/ O
Page O
than O
chicken B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
axonin I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
1 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

For O
routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
medical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
no O
sophisticated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjustment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
CHESS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pulse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
needed O
, O
as O
reported O
in O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
10 B_BODY_PART_OR_ORGAN_COMPONENT
eyes I_BODY_PART_OR_ORGAN_COMPONENT
injected O
with O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RPE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
Stage B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
2 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
or O
less B_NUMBER[MEASURE]
in O
4 B_TIME[MEASURE]/B_DISEASE
weeks B_TIME[MEASURE]/I_DISEASE
. O

This O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
establishes O
that O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
homozygous B_DISEASE/B_ORGANISM_FUNCTION
sickle I_DISEASE/I_ORGANISM_FUNCTION
cell I_DISEASE/I_ORGANISM_FUNCTION
disease I_DISEASE/I_ORGANISM_FUNCTION
on O
growth B_DISEASE/B_ORGANISM_FUNCTION
patterns I_DISEASE/I_ORGANISM_FUNCTION
in O
childhood B_PERSON/B_BIO
is O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
the O
age B_TIME[MEASURE]/B_LOCATION
of O
6 B_NUMBER[MEASURE]/B_PERSON
years I_NUMBER[MEASURE]/I_PERSON
. O

The O
remaining O
77 O
nucleotides O
at O
the O
3 O
' O
end O
of O
domain O
II O
and O
all O
of O
domains O
III O
( O
655 O
nucleotides O
) O
and O
IV O
( O
770 O
nucleotides O
) O
are O
not O
present O
in O
DIssE B_BIO/B_GENE
RNA B_BIO/I_GENE
. O

The O
biological O
actions O
of O
VHR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
oocytes O
clearly O
distinguish O
it O
from O
other O
dual O
specificity O
phosphatases O
, O
which O
have O
shown O
inhibitory O
effects O
when O
tested O
in O
oocytes O
. O

The O
presence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
saliva B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O
seven B_PERSON/B_BIO
healthy I_PERSON/I_BIO
volunteers I_PERSON/I_BIO
for O
21 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
600 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
established O
by O
chromatographic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
spectroscopic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
gp41 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glu I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Leu I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Asp I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lys I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trp I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ala I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fused O
to O
the O
C O
- O
terminus O
of O
Sj B_GENE/B_DISEASE
GST I_GENE/I_DISEASE
forms O
a O
loop O
stabilized O
by O
symmetry O
- O
related O
GSTs B_GENE/B_LOCATION
. O

comparison O
of O
bioreactive O
and O
immunoreactive O
gastrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Also O
, O
PTx B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
no O
effect O
on O
shear O
- O
dependent O
activation O
of O
JNK B_GENE
. O

A O
score B_MEASURE
( O
APACHE B_MEASURE/B_LOCATION
II I_MEASURE/I_LOCATION
) O
was O
calculated O
to O
assess O
the O
severity B_MEASURE
of O
disease B_DISEASE
. O

We O
tested O
several O
growth O
regulatory O
genes O
that O
are O
repressed O
in O
senescent O
cells O
for O
ability O
to O
restore O
activity O
to O
T B_GENE/B_PERSON
[ I_GENE/I_PERSON
K1 I_GENE/I_PERSON
] I_GENE/I_PERSON
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ERK B_GENE
, O
JNK B_GENE/B_LOCATION
/ O
SAPK B_MEASURE/B_GENE
, O
and O
p38 B_GENE/B_LOCATION
) O
to O
the O
activation O
of O
the O
murine O
uPA B_GENE
promoter O
by O
UV O
. O

The O
high O
degree O
of O
sequence O
conservation O
together O
with O
the O
ability O
to O
direct O
nucleolar O
protein O
transport O
supports O
the O
hypothesis O
that O
MAK16 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O
a O
key O
role O
in O
the O
biogenesis O
of O
60S B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunits B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

characterization O
of O
a O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deformed I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epidermal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoregulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DEAF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
related O
( O
NUDR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
transcriptional O
regulator O
protein O
. O

Here O
we O
show O
that O
the O
sck1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
cloned O
as O
a O
high O
copy O
number O
suppressor O
of O
a O
mutation O
in O
git3 B_SPECIES[BIO]/B_GENE
, O
is O
able O
to O
suppress O
the O
defects O
conferred O
by O
a O
mutation O
in O
any O
of O
these O
git B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hamdija B_PERSON/B_MEASURE
Karamehmedovic I_PERSON/I_MEASURE
; O
Ibn O
al B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Nefis B_PERSON/B_LOCATION
, O
' O
Mudzez B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Kanum B_PERSON/B_LOCATION
' O
, O
Republicki B_LOCATION
zavod I_LOCATION
za I_LOCATION
zdravstvenu I_LOCATION
zastitu I_LOCATION
Sarajevo I_LOCATION
, O
1961 B_MEASURE
, O
1 B_MEASURE
- O
219 B_MEASURE
; O
Mr B_PERSON/B_MEASURE
pH I_PERSON/I_MEASURE
Samuel I_PERSON/I_MEASURE
Elazar I_PERSON/I_MEASURE
, O
Ajnija B_PERSON/B_LOCATION
Omanic I_PERSON/I_LOCATION
: O
' O
Bibliografija B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicinskih I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
djela I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
u I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BiH I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
1895 B_NUMBER[MEASURE]/B_LOCATION
. O
' O
Medicinska B_LOCATION
knjiga I_LOCATION
Beograd I_LOCATION
- O
Zagreb B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1984 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Besides B_TIME[MEASURE]/B_LOCATION
, O
the O
great B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contribution I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bibliography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
given O
by O
DR B_PERSON/B_LOCATION
Lujo I_PERSON/I_LOCATION
Taler I_PERSON/I_LOCATION
, O
Prof B_PERSON/B_GENE
. O

DR B_LOCATION/B_PERSON
. O

The O
longest O
cDNA O
insert O
identified O
was O
2 O
. O
2 O
kb O
and O
encoded O
the O
entire O
462 O
- O
amino O
acid O
open O
reading O
frame O
of O
rat B_GENE/B_BACTERIUM[BIO]
CgA I_GENE/I_BACTERIUM[BIO]
including O
an O
18 O
- O
amino O
acid O
hydrophobic O
signal O
peptide O
. O

We O
have O
used O
systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
ototoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
amikacin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
to O
induce O
total B_DISEASE
cochlear I_DISEASE
haircell I_DISEASE
loss I_DISEASE
in O
the O
chinchilla B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
in O
order B_SPECIES[BIO]/B_DISEASE
to O
create O
an O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
profound B_DISEASE/B_LOCATION
deafness I_DISEASE/I_LOCATION
. O

Cotransfection O
with O
C B_GENE/B_LOCATION
/ I_GENE/I_LOCATION
EBPbeta I_GENE/I_LOCATION
and O
GATA B_GENE
- I_GENE
1 I_GENE
expression O
vectors O
produced O
a O
5 O
- O
fold O
increase O
compared O
with O
cotransfection O
with O
the O
C B_GENE/B_LOCATION
/ I_GENE/I_LOCATION
EBPbeta I_GENE/I_LOCATION
or O
GATA B_GENE
- I_GENE
1 I_GENE
expression O
vectors O
individually O
. O

Among O
the O
different B_DISEASE/B_BIO
epithelial I_DISEASE/I_BIO
cell I_DISEASE/I_BIO
lines I_DISEASE/I_BIO
tested O
, O
only O
RTS3b B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O
an O
expression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similar I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
that O
observed O
in O
naturally O
infected B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
benign B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
condylomas B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
contrast O
to O
the O
p16 B_GENE
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B_GENE/B_DISEASE
inhibitors O
p21Cip1 B_GENE
or O
p27Kip1 B_GENE
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B_GENE
or O
overexpression O
of O
E2F B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
, O
the O
authors O
found O
one O
an3 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
allele B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
an3 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
W138A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
which O
a O
dTph1 B_GENE
element I_GENE
had O
inserted O
30 O
BP O
upstream O
the O
translation O
start O
, O
without O
inactivating O
the O
gene O
. O

Case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nephrotic B_DISEASE
syndrome I_DISEASE
caused O
by O
gold B_DISEASE
preparations I_DISEASE
. O

To O
investigate O
the O
role O
of O
bHLH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
MC3T3 O
- O
E1 O
osteoblasts O
, O
which O
undergo O
a O
developmental O
sequence O
in O
vitro O
, O
we O
analyzed O
the O
transcriptional O
control O
of O
osteocalcin B_GENE
gene I_GENE
expression O
by O
stable O
transfection O
of O
an O
osteocalcin B_GENE
promoter I_GENE
- O
luciferase B_GENE
chimeric O
gene O
( O
p637OC B_PROTEIN[GENE]/B_BIO
- I_PROTEIN[GENE]/I_BIO
luc I_PROTEIN[GENE]/I_BIO
) O
and O
assessed O
the O
role O
of O
E O
- O
box O
cis O
- O
acting O
elements O
in O
osteocalcin B_GENE
promoter I_GENE
by O
DNA O
binding O
assays O
. O

In O
summary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
only B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
related O
effect B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
noted O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
hydrocarbon B_DISEASE
nephropathy I_DISEASE
in O
male B_SPECIES[BIO]/B_PERSON
rats I_SPECIES[BIO]/I_PERSON
, O
which O
is O
not O
considered O
relevant B_DISEASE_ADJECTIVE[DISEASE]
for O
human B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study O
, O
we O
show O
that O
HNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
member O
of O
the O
steroid B_GENE/B_PERSON
hormone I_GENE/I_PERSON
receptor I_GENE/I_PERSON
superfamily I_GENE/I_PERSON
, O
binds O
the O
AF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
site I_GENE/I_LOCATION
on O
the O
apoB B_GENE
promoter I_GENE
and O
through O
it O
activates O
transcription O
in O
transient O
transfection O
assays O
in O
both O
liver O
and O
non O
- O
liver O
cell O
lines O
, O
HepG2 O
and O
HeLa O
, O
respectively O
. O

Gastrointestinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
indium B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
111 B_TIME[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O
granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
reactive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
arthritis I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intoxication B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
cypermethrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
NRDC B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
149 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

We O
have O
previously O
shown O
that O
the O
transcriptional O
activator O
CREM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
highly O
expressed O
in O
postmeiotic O
cells O
. O

No O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
epidural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
. O

In O
late B_TIME[MEASURE]/B_LOCATION
October I_TIME[MEASURE]/I_LOCATION
, O
1974 B_MEASURE
, O
Staphylococcus B_DISEASE
aureus I_DISEASE
postoperative I_DISEASE
wound I_DISEASE
infection I_DISEASE
was O
recorded O
in O
a O
nonhuman B_SPECIES[BIO]
primate I_SPECIES[BIO]
( O
Macaca B_SPECIES[BIO]
mulatta I_SPECIES[BIO]
) O
which O
had O
recently O
undergone O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
operation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Twenty B_NUMBER[MEASURE]
- O
six B_NUMBER[MEASURE]/B_ENT
calves I_NUMBER[MEASURE]/I_ENT
were O
subjected O
to O
a O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cryoablation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
order B_SPECIES[BIO]/B_DISEASE
to O
establish O
an O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
complete B_DISEASE
cardiac I_DISEASE
denervation I_DISEASE
. O

Our O
current O
study O
aims O
at O
clarifying O
the O
role O
of O
myristoylation O
in O
caveolar O
targeting O
using O
well O
- O
characterized O
acylation O
mutants O
of O
two O
model O
proteins O
, O
namely O
Gi1 B_GENE
alpha I_GENE
and O
c B_GENE
- I_GENE
Src I_GENE
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
deferoxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sugar I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
intravenous B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
glucose I_PERSON/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
loading I_PERSON/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
in O
healthy B_SPECIES[BIO]/B_PERSON
persons I_SPECIES[BIO]/I_PERSON
. O

We O
infer O
that O
RecA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
mediated O
cleavage O
of O
UmuD B_GENE/B_BIO
is O
another O
role O
for O
RecA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
SOS O
mutagenesis O
, O
probably O
activating O
UmuD B_GENE/B_BIO
for O
its O
mutagenic O
function O
. O

setting B_MEASURE/B_LOCATION
: O
participants B_PERSON
in O
the O
Physicians B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
a O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
carotene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
U B_OTHER/B_MEASURE
. O
S B_LOCATION/B_DISEASE
. O
male B_PERSON/B_LOCATION
physicians I_PERSON/I_LOCATION
. O

The O
prevalence B_MEASURE
of O
microalbuminuria B_DISEASE/B_LOCATION
, O
defined O
as O
an O
UAER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
range B_MEASURE
of O
15 B_MEASURE
- O
150 B_MEASURE
micrograms I_MEASURE
min I_MEASURE
- O
1 B_TIME[MEASURE]
in O
an O
overnight B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
3 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
C I_LOCATION/I_MEASURE
. O
I O
. O
interval B_MEASURE
: O
1 B_MEASURE
. O
9 B_MEASURE
- O
4 B_MEASURE
. O
0 B_MEASURE
) O
. O

The O
Rep B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
adeno O
- O
associated O
virus O
type O
2 O
( O
AAV O
) O
are O
known O
to O
bind O
to O
Rep B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
RRSs B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
the O
AAV O
inverted O
terminal O
repeats O
( O
ITRs O
) O
, O
the O
AAV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
preferred O
AAV O
integration O
site O
in O
human O
chromosome O
19 O
, O
called O
AAVS1 O
. O

Lip B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
Dip B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
less O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
IIPs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
both O
characterized O
by O
ground B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
glass B_MEASURE/B_LOCATION
attenuation B_MEASURE/I_LOCATION
. O

The O
levels O
of O
TPAR1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
dramatically O
down O
- O
regulated O
in O
regenerating O
rat O
liver O
when O
compared O
to O
normal O
adult O
liver O
. O

Copyright B_LOCATION/B_PERSON
1999 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

The O
authors O
suggest O
that O
alprazolam O
may O
have O
enhanced O
specificity O
for O
a O
subpopulation O
of O
benzodiazepine B_PERSON/B_BIO
receptors I_PERSON/I_BIO
. O

Southern O
hybridization O
analysis O
of O
BenR B_DISEASE/B_PROTEIN[GENE]
and O
BenS B_LOCATION/B_GENE
transformants I_LOCATION/I_GENE
suggested O
that O
plasmid O
integration O
occurred O
most O
frequently O
at O
the O
chromosomal O
bens B_LOCATION/B_GENE
locus I_LOCATION/I_GENE
, O
however O
evidence O
for O
gene O
conversion O
and O
heterologous O
recombination O
was O
also O
observed O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B_GENE/B_LOCATION
, O
FGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Hh B_GENE/B_LOCATION
, O
Wnt B_GENE/B_LOCATION
, O
and O
EGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
families I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
induced O
by O
activinbetaA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
Wnt6 B_GENE
induced O
ectodysplasin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
. O

In O
mouse O
, O
two O
high O
- O
affinity O
binding O
sites O
with O
an O
apparent O
dissociation O
constant O
( O
Kd O
) O
of O
50 O
to O
100 O
nm O
have O
been O
mapped O
in O
the O
5 O
' O
ETS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
upstream O
from O
the O
early O
pre O
- O
rRNA O
processing O
site O
. O

Single B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
oblique I_NUMBER[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mammography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
periodic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
breast B_DISEASE
cancer I_DISEASE
in O
women B_PERSON/B_BIO
. O

Radiative B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
corrections I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
to O
pi B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
L2 I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decays I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
deletion O
disrupts O
the O
PU B_GENE
. I_GENE
1 I_GENE
Ets I_GENE
domain I_GENE
. O

In O
turn O
, O
production O
of O
sufficient O
amounts O
of O
TraR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O
is O
sensitive O
to O
a O
cellular O
function O
requiring O
RNase B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
predicted O
product O
exhibits O
91 O
% O
amino O
acid O
identity O
to O
the O
murine B_GENE/B_PERSON
voltage I_GENE/I_PERSON
- I_GENE/I_PERSON
gated I_GENE/I_PERSON
potassium I_GENE/I_PERSON
channel I_GENE/I_PERSON
protein I_GENE/I_PERSON
Kv1 I_GENE/I_PERSON
. I_GENE/I_PERSON
7 I_GENE/I_PERSON
( O
Kcna7 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
which O
plays O
an O
important O
role O
in O
the O
repolarization O
of O
cell O
membranes O
. O

Phytohemagglutinin B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PHA B_PROTEIN[GENE]/B_DISEASE
) O
, O
the O
seed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lectin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
common O
bean O
, O
accumulates O
in O
protein O
storage O
vacuoles O
of O
storage O
parenchyma O
cells O
in O
cotyledons O
. O

This O
dynamic O
nature O
may O
be O
relevant O
to O
the O
ability O
of O
E47 B_GENE
both O
to O
homodimerize O
and O
to O
heterodimerize O
with O
MyoD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
Id B_GENE/B_DISEASE
, O
and O
Tal1 B_GENE
. O

Blood B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
( O
30 B_TIME[MEASURE]/B_LOCATION
ml B_TIME[MEASURE]/I_LOCATION
) O
were O
collected O
via O
an O
indwelling O
arm B_PRODUCT[OBJECT]/B_LOCATION
catheter B_PRODUCT[OBJECT]/I_LOCATION
at O
rest B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
at O
minutes B_MEASURE/B_ENT
13 I_MEASURE/I_ENT
and O
28 B_NUMBER[MEASURE]
of O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
determinations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
EPI I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
serum O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
FFA B_LOCATION/B_PROTEIN[GENE]
) O
, O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycerol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Gly B_PROTEIN[GENE]/B_LOCATION
) O
, O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GLU B_LOCATION/B_PROTEIN[GENE]
) O
, O
and O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Among O
these O
, O
four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
had O
the O
AIDS B_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
42 B_NUMBER[MEASURE]/B_PERSON
individuals I_NUMBER[MEASURE]/I_PERSON
were O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
carriers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

subjects B_PERSON/B_LOCATION
were O
73 B_PERSON/B_COLOR
male I_PERSON/I_COLOR
and O
female B_PERSON/B_MEASURE
employees I_PERSON/I_MEASURE
of O
the O
Xerox B_LOCATION/B_ORGANIZATION
Corporation I_LOCATION/I_ORGANIZATION
joining O
a O
newly O
developed O
health B_ORGANIZATION/B_PERSON
fitness I_ORGANIZATION/I_PERSON
program I_ORGANIZATION/I_PERSON
. O

Overexpression O
of O
p50 B_GENE
in O
transient O
cotransfection O
studies O
using O
the O
proximal O
CRP B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
( O
- O
125 O
/ O
+ O
9 O
) O
linked O
to O
a O
luciferase B_GENE
reporter I_GENE
caused O
a O
3 O
- O
fold O
increase O
of O
luciferase B_GENE/B_LOCATION
activity O
, O
while O
C B_GENE
/ I_GENE
EBPbeta I_GENE
overexpression O
caused O
an O
18 O
- O
fold O
increase O
; O
simultaneous O
overexpression O
of O
both O
transcription O
factors O
increased O
luciferase B_GENE/B_MEASURE
activity O
approximately O
600 O
- O
fold O
. O

Our O
results O
suggest O
that O
it O
might O
be O
possible O
to O
augment O
IN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O
in O
vivo O
through O
a O
heterologous O
domain O
. O

While O
differential O
expression O
of O
the O
two O
transcripts O
was O
not O
found O
, O
the O
promoter O
controlling O
LT1 B_GENE
/ O
LT2 B_PROTEIN[GENE]/B_MEASURE
transcription O
is O
regulated O
in O
a O
cell O
cycle O
- O
dependent O
manner O
. O

Schottky B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
barrier B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
heights I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Ti B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TiSi2 B_LOCATION/B_PERSON
on O
n B_PROTEIN[GENE]
- O
type B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p B_MEASURE/B_PROTEIN[GENE]
- O
type B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Si B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
100 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

A O
survey O
of O
children O
with O
HBsAg B_DISEASE
markers I_DISEASE
related O
to O
their O
parents O
HBV O
markers O
. O

Immunological O
studies O
also O
failed O
to O
demonstrate O
any O
significant O
change O
except O
for O
a O
significant O
increase O
of O
natural O
killer O
( O
NK O
) O
cell O
activity O
after O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
. O

Fetal B_MEASURE/B_PERSON
PaO2 I_MEASURE/I_PERSON
fell O
somewhat O
during O
the O
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
stages I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O
both O
Nit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
control B_LOCATION/B_ORGANIZATION
groups I_LOCATION/I_ORGANIZATION
. O

genetic O
analyses O
indicate O
that O
most O
of O
the O
dominant O
mutants O
are O
cis O
- O
acting O
and O
that O
the O
recessive O
mutants O
define O
a O
minimum O
of O
three O
complementation O
groups O
, O
indicating O
that O
defects O
in O
several O
different O
genes O
can O
restore O
higher O
levels O
of O
HIS4C B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
. O

Rat B_ENZYME[GENE]
cholesterol I_ENZYME[GENE]
side I_ENZYME[GENE]
- I_ENZYME[GENE]
chain I_ENZYME[GENE]
cleavage I_ENZYME[GENE]
cytochrome I_ENZYME[GENE]
P I_ENZYME[GENE]
- I_ENZYME[GENE]
450 I_ENZYME[GENE]
( O
P B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
450scc I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
gene O
. O

histopathologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
displaying O
spongiform B_DISEASE
changes I_DISEASE
in O
the O
gray B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
neuronal B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
atrogliosis B_DISEASE
confirmed O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Creutzfeldt B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Jakob B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

Pig O
uPA B_SPECIES[BIO]/B_GENE
promoter O
- O
CAT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O
were O
more O
active O
than O
mouse O
constructs O
in O
this O
assay O
. O

Cloning O
the O
cDNA O
for O
a O
new O
human B_PROTEIN[GENE]/B_BIO
zinc I_PROTEIN[GENE]/I_BIO
finger I_PROTEIN[GENE]/I_BIO
protein I_PROTEIN[GENE]/I_BIO
defines O
a O
group O
of O
closely O
related O
Kruppel B_GENE/B_BIO
- I_GENE/I_BIO
like I_GENE/I_BIO
transcription I_GENE/I_BIO
factors I_GENE/I_BIO
. O

By O
computed O
homology O
search O
, O
we O
noticed O
significant O
similarities O
between O
US3 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p21 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
activated I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
( O
PAK B_GENE/B_PERSON
) O
, O
which O
is O
activated O
by O
the O
Cdc42 B_GENE
or O
Rac B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mean B_MEASURE
amount I_MEASURE
of O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
loss I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prior I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
time B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
4 B_MEASURE
. O
5 B_MEASURE
units I_MEASURE
( O
a O
range B_MEASURE/B_LOCATION
of O
3 B_NUMBER[MEASURE]/B_LOCATION
to O
10 B_MEASURE
units I_MEASURE
) O
. O

In O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
acoustical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
the O
properties B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
response B_MEASURE
latency I_MEASURE
, O
discharge B_MEASURE
pattern I_MEASURE
, O
frequency B_MEASURE/B_LOCATION
tuning I_MEASURE/I_LOCATION
, O
binaural B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
and O
habituation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O
examined O
to O
allow O
an O
appraisal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
differentiation B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
MGB B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O
electrophysiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
means I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

These O
8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxoguanine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
hOgg1 B_GENE/B_DISEASE
( O
human O
) O
and O
mOgg1 B_GENE
( O
murine O
) O
, O
are O
homologous O
to O
each O
other O
and O
to O
yeast B_SPECIES[BIO]/B_GENE
Ogg1 I_SPECIES[BIO]/I_GENE
. O

The O
CHED B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I_ENZYME[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
includes O
the O
consensus O
ATP O
binding O
and O
phosphorylation O
domains O
characteristic O
of O
kinases O
, O
displays O
34 O
- O
42 O
% O
identically O
aligned O
amino O
acid O
residues O
with O
other O
cdc2 B_GENE/B_BIO
- I_GENE/I_BIO
related I_GENE/I_BIO
kinases I_GENE/I_BIO
, O
and O
is O
considerably O
longer O
at O
its O
amino O
and O
carboxyl O
termini O
. O

conclusions O
: O
These O
results O
suggest O
that O
, O
by O
interacting O
with O
cellular O
transcription O
factors O
and O
cofactors O
, O
vIRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O
modulate O
the O
expression O
of O
the O
early O
inflammatory O
genes O
and O
potentially O
deregulate O
the O
immune O
system O
. O

However O
, O
in O
7 B_PERSON/B_MEASURE
patients I_PERSON/I_MEASURE
with O
normal B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
latter B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
method I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
cerebral B_DISEASE
activity I_DISEASE
anatomically O
correlated O
with O
neurological B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
signs I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
vascular B_DISEASE_ADJECTIVE[DISEASE]
lesions I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
that O
Gcn5 B_GENE
, O
a O
histone B_GENE
H3 I_GENE
acetylase I_GENE
, O
plays O
a O
central O
role O
in O
initiation O
of O
meiosis O
via O
effects O
on O
IME2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
. O

The O
carboxy O
- O
proximal O
regions O
of O
the O
VP1 B_GENE/B_SPECIES[BIO]
, O
which O
contain O
very O
low O
amino O
acid O
homology O
, O
displayed O
evidence O
of O
conservation O
in O
structural O
features O
such O
as O
a O
hydrophilic O
, O
highly O
basic O
domain O
. O

Interferon B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducibility O
of O
IFI16 B_GENE
may O
be O
regulated O
by O
an O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
/ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
stimulated O
response O
consensus O
element O
in O
the O
5 O
' O
UT O
exon O
, O
as O
a O
similar O
motif O
is O
conserved O
in O
the O
corresponding O
position O
in O
the O
related O
myeloid B_GENE
cell I_GENE
nuclear I_GENE
differentiation I_GENE
antigen I_GENE
gene O
. O
( O
abstract O
TRUNCATED O
AT O
400 O
Words O
) O
. O

Design B_PERSON/B_MEASURE
- O
- O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_OTHER
randomised O
double B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blind I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controlled O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Genealogical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggested O
mainly O
a O
mother B_PERSON
- O
to O
- O
offspring O
transmission B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
STLV B_GENE/B_DISEASE
- O
1 B_MEASURE/B_BIO
. O

These O
back B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
a O
modest B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
kinase B_DISEASE/B_GENE
activity I_DISEASE/I_GENE
, O
decreased O
tumorigenic B_PERSON/B_DISEASE
potential B_PERSON/I_DISEASE
in O
chickens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
and O
an O
unexpected B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
transforming O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
rat B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
quantification B_MEASURE
limit I_MEASURE
was O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
for O
each O
of O
PHT B_NUMBER[MEASURE]/B_PERSON
, O
m B_PROTEIN[GENE]/B_DISEASE
- O
HPPH B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p O
- O
HPPH B_DISEASE/B_LOCATION
. O

Individual B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intolerance I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
betaxolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
continue O
to O
occur O
and O
care O
is O
always O
required O
when O
patients B_PERSON
with O
cardiac B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O
respiratory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysfunction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O
exposed O
to O
any O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
antagonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pretoria B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Pasteurisation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
feasible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
reliable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
under O
a O
range B_MEASURE
of O
conditions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
the O
present O
study O
we O
use O
a O
tnaC B_GENE/B_BACTERIUM[BIO]
- O
UGA O
- O
' B_GENE
lacZ I_GENE
construct O
lacking O
the O
tnaC B_GENE/B_BACTERIUM[BIO]
- O
tnaA B_GENE/B_BACTERIUM[BIO]
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B_GENE/B_BACTERIUM[BIO]
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B_GENE/B_BACTERIUM[BIO]
. O

The O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
KP B_LOCATION/B_DISEASE
- O
103 B_MEASURE
, O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
against O
pathogenic B_BIO/B_DISEASE
fungi I_BIO/I_DISEASE
that O
cause B_DISEASE/B_SPECIES[BIO]
dermatomycoses B_DISEASE/I_SPECIES[BIO]
and O
its O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficacy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
plantar B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tinea I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pedis I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cutaneous B_DISEASE
candidiasis I_DISEASE
in O
guinea B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pigs I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O
investigated O
. O

restriction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
isolated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
that O
the O
endogenous B_GENE/B_LOCATION
sequences I_GENE/I_LOCATION
abutting O
the O
3 B_LOCATION/B_GENE
' I_LOCATION/I_GENE
ends I_LOCATION/I_GENE
of O
the O
94 B_MEASURE
- O
A B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
94 B_MEASURE
- O
K B_PROTEIN[GENE]/B_LOCATION
transgenes I_PROTEIN[GENE]/I_LOCATION
are O
separated O
by O
less B_MEASURE
than O
20 B_MEASURE/B_LOCATION
kb I_MEASURE/I_LOCATION
, O
providing O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

serum B_PERSON/B_MEASURE
triglycerides I_PERSON/I_MEASURE
also O
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
birth B_NUMBER[MEASURE]
to O
6 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
age B_TIME[MEASURE]/B_PERSON
, O
but O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
6 B_TIME[MEASURE]/B_PERSON
months I_TIME[MEASURE]/I_PERSON
to O
1 B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
of O
age B_TIME[MEASURE]/B_PERSON
. O

Female B_PERSON
Wistar I_PERSON
rats I_PERSON
receiving O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
in O
drinking B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
during O
lactation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
( O
N B_OTHER/B_LOCATION
= O
7 B_MEASURE
) O
were O
compared O
to O
normal B_PERSON/B_BIO
controls I_PERSON/I_BIO
fed O
ad B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
libitum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
N B_OTHER/B_LOCATION
= O
6 B_MEASURE
) O
. O

Antisense O
oligonucleotides O
complementary O
to O
the O
5 O
' O
end O
of O
PKC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
significantly O
reduced O
the O
collagen B_GENE/B_DISEASE
lattice O
- O
stimulated O
alpha2 O
and O
MMP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
. O

Overexpression O
of O
a O
HIF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1alpha I_GENE/I_DISEASE
construct O
with O
deletions O
of O
the O
basic O
domain O
and O
carboxy O
terminus O
blocked O
reporter O
gene O
activation O
by O
endogenous O
HIF B_GENE
- I_GENE
1 I_GENE
in O
hypoxic O
cells O
. O

We O
hypothesized O
that O
conjugated O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
contain O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasoactive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
estrogenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
may O
favorably O
influence O
the O
vasomotor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
acetylcholine O
in O
men B_PERSON/B_SPECIES[BIO]
. O

In O
Experiment B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
levels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
: O
amprolium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
ethopabate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
. O
02 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
; O
salinomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
55 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
; O
monensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
99 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
; O
and O
lasalocid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
110 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
. O

residues O
crucial O
for O
Ras B_GENE/B_DISEASE
interaction O
with O
GDP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GTP I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

4 B_NUMBER[MEASURE]
. O

In O
serum O
- O
starved O
NIH O
3T3 O
cells O
, O
v B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
raf I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O
mdr1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
approximately O
10 O
- O
fold O
compared O
to O
a O
v B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
raf I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
frame O
- O
shift O
control O
. O

searching O
the O
human O
DNA O
data O
base O
of O
expressed O
sequence O
tags O
( O
est O
) O
revealed O
novel O
partial O
sequences O
similar O
to O
, O
but O
distinct O
from O
, O
the O
sequences O
of O
the O
previously O
known O
PEF B_GENE/B_BIO
proteins I_GENE/I_BIO
. O

Under O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
3 B_MEASURE
micromol I_MEASURE
/ O
kg B_MEASURE
MIB I_MEASURE
and O
Ver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
maximal B_MEASURE/B_LOCATION
effect I_MEASURE/I_LOCATION
of O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reached O
at O
0 B_MEASURE
. O
1 B_MEASURE
micromol I_MEASURE
/ O
kg B_MEASURE/B_PERSON
whereas O
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
10 B_MEASURE
micromol I_MEASURE
/ O
kg B_MEASURE/B_PERSON
MIB I_MEASURE/I_PERSON
and O
Ver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
it O
was O
reached O
at O
a O
dose B_MEASURE
of O
1 B_MEASURE
micromol I_MEASURE
/ O
kg B_MEASURE
. O

It O
is O
also O
affected O
by O
the O
HAP2 B_GENE/B_DISEASE
/ I_GENE/I_DISEASE
3 I_GENE/I_DISEASE
/ I_GENE/I_DISEASE
4 I_GENE/I_DISEASE
transcription I_GENE/I_DISEASE
factor I_GENE/I_DISEASE
complex I_GENE/I_DISEASE
and O
by O
SNF1 B_GENE/B_DISEASE
and O
SSN6 B_GENE
. O

The O
effective O
use O
of O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
human O
erythrocytes O
in O
the O
late O
stages O
of O
experimental O
influenza O
infection O
. O

Two O
different O
genes O
( O
polA B_GENE/B_BIO
and O
polB B_PROTEIN[GENE]/B_BIO
) O
encoding O
family B_ENZYME[GENE]
B I_ENZYME[GENE]
DNA I_ENZYME[GENE]
polymerases I_ENZYME[GENE]
were O
cloned O
from O
the O
organism O
by O
PCR O
using O
degenerated O
primers O
based O
on O
the O
two O
conserved O
motifs O
( O
motif O
A O
and O
B O
) O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
on O
survival B_DISEASE
of O
adjuvant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
including O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
or O
postoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
systemic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
or O
postoperative B_DISEASE
intra I_DISEASE
- O
arterial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
are O
currently O
under O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Structure O
and O
regulation O
of O
the O
luteinizing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
disease B_DISEASE_ADJECTIVE[DISEASE]
processes O
that O
affect O
transplant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
both O
before O
and O
after O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O
not O
seen O
frequently O
in O
the O
general B_LOCATION
practice I_LOCATION
of O
gastroenterology B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Single B_DISEASE/B_MEASURE
white B_DISEASE/I_MEASURE
flash B_DISEASE/I_MEASURE
ERG B_DISEASE/I_MEASURE
, O
photopic B_DISEASE
ERG I_DISEASE
, O
scotopic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ERG B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
flicker B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ERG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
were O
recorded O
in O
30 B_PERSON/B_TIME[MEASURE]
cases I_PERSON/I_TIME[MEASURE]
of O
unilateral B_DISEASE
CRVO I_DISEASE
. O

However O
, O
to O
encourage O
good B_ORGANIZATION/B_PERSON
contact I_ORGANIZATION/I_PERSON
between O
the O
farmers B_PERSON/B_BIO
and O
the O
inseminating B_PERSON/B_BIO
personnel I_PERSON/I_BIO
, O
it O
is O
beneficial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
herdsmen B_PERSON/B_BIO
are O
present B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
cows B_BIO/B_PERSON
are O
inseminated O
. O

Soft B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
independent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modelling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
class B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analogy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
SIMCA B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
applied O
to O
identify O
near O
- O
infrared O
( O
NIR B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
spectra B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ten B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
excipients I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
used O
in O
the O
pharmaceutical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
industry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Multiple B_DISEASE_ADJECTIVE[DISEASE]
organ I_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
( O
MOF B_LOCATION/B_DISEASE
) O
following O
major B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
trauma I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
perfusion B_DISEASE
deficits I_DISEASE
, O
a O
persistent B_DISEASE
inflammatory I_DISEASE
focus I_DISEASE
, O
or O
a O
persistent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
focus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dead B_DISEASE
and O
/ O
or O
injured O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Western O
immunoblot O
analysis O
detected O
p55gag B_GENE
and O
its O
cleavage O
products O
p39 B_GENE
and O
p27 B_GENE/B_MEASURE
in O
purified O
particles O
derived O
by O
expression O
of O
gag B_GENE
and O
gag B_PROTEIN[GENE]/B_DISEASE
- O
pol B_GENE/B_DISEASE
, O
respectively O
. O

Cefminox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
shows O
greater B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O
that O
expected O
for O
the O
MICs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
excellent B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
high B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
ERG B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
more O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
than O
low B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MF I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
ERG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

3 O
- O
5 O
- O
fold O
increases O
in O
EGF B_GENE
receptor I_GENE
but O
not O
p185 B_GENE
( O
neu B_GENE/B_DISEASE
) O
tyrosine O
phosphorylation O
occur O
following O
Gi B_GENE
- I_GENE
coupled I_GENE
receptor I_GENE
stimulation O
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B_GENE
/ O
ERM B_LOCATION/B_GENE
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B_GENE/B_LOCATION
/ O
ERM B_LOCATION/B_GENE
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GDP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dissociation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GDI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
regulator O
of O
Rho B_GENE
GTPase I_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
a O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
on O
the O
active B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
days B_TIME[MEASURE]
7 I_TIME[MEASURE]
, O
21 B_MEASURE
, O
and O
35 B_MEASURE
postinoculation I_MEASURE
( O
PI B_PROTEIN[GENE]/B_LOCATION
) O
, O
all O
birds B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
sheep B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
erythrocytes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intravenously O
. O

To O
determine O
cis O
- O
acting O
elements O
controlling O
the O
rat O
B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
GAP B_GENE/B_MEASURE
- I_GENE/I_MEASURE
43 I_GENE/I_MEASURE
gene O
expression O
, O
the O
genomic O
DNA O
encoding O
exon O
1 O
and O
the O
5 O
' O
flanking O
sequence O
was O
isolated O
. O

In O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
measured B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
1 B_MEASURE
, O
259 B_MEASURE/B_PERSON
white I_MEASURE/I_PERSON
women I_MEASURE/I_PERSON
aged O
65 B_MEASURE
- O
74 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
from O
the O
Epidemiologic B_SEQUENCE[MEASURE]
Follow O
- O
up O
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
First B_ORGANIZATION/B_LOCATION
National I_ORGANIZATION/I_LOCATION
Health I_ORGANIZATION/I_LOCATION
and O
Nutrition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
examine O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
overweight B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
coronary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mean B_TIME[MEASURE]/B_LOCATION
length I_TIME[MEASURE]/I_LOCATION
of O
follow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_LOCATION/B_TIME[MEASURE]
, O
14 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
) O
. O

Through O
genomic O
library O
screening O
and O
PCR O
- O
based O
genomic O
walking O
we O
have O
now O
cloned O
the O
mouse B_GENE
E I_GENE
- I_GENE
Tmod I_GENE
gene I_GENE
, O
whose O
coding O
region O
spans O
approximately O
60kb O
containing O
nine O
exons O
and O
eight O
introns O
. O

TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulated O
these O
changes O
in O
part O
by O
increasing O
transcription O
and O
stabilization O
of O
RNA O
for O
amphiregulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
EGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand O
, O
and O
amphiregulin B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
directly O
increased O
HPV O
- O
16 O
E6 B_PROTEIN[GENE]/B_DISEASE
/ O
E7 B_MEASURE/B_PROTEIN[GENE]
and O
cyclin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
included O
1 B_NUMBER[MEASURE]/B_PERSON
) O
the O
mean B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
of O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
teased O
myelinated B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers B_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
its O
upper B_MEASURE
limit I_MEASURE
value I_MEASURE
of O
95 B_MEASURE/B_PERSON
% B_MEASURE/I_PERSON
confidence B_MEASURE/I_PERSON
interval O
, O
and O
2 B_NUMBER[MEASURE]
) O
the O
mean B_MEASURE
densities I_MEASURE
of O
total B_MEASURE/B_PERSON
, O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
myelinated I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fibers I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
of O
unmyelinated B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibers B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
their O
lower B_MEASURE
limit I_MEASURE
value I_MEASURE
of O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
for O
each O
decade B_MEASURE/B_PERSON
. O

Fusions O
between O
the O
GAL B_GENE
DNA I_GENE
binding I_GENE
domain I_GENE
and O
full B_GENE
- I_GENE
length I_GENE
mSin3 I_GENE
were O
also O
capable O
of O
repression O
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
the O
19 B_PERSON/B_MEASURE
women I_PERSON/I_MEASURE
with O
probable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
RA I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
100 B_NUMBER[MEASURE]
of O
the O
116 B_MEASURE/B_PERSON
women I_MEASURE/I_PERSON
with O
definite B_DISEASE/B_LOCATION
RA I_DISEASE/I_LOCATION
met O
the O
1987 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
oral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
the O
1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
doses I_MEASURE
of O
enoximone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improved O
central B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hemodynamic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
preferential I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
limb B_DISEASE
vascular I_DISEASE
resistance I_DISEASE
and O
augmentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
the O
limb B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O
peripheral B_DISEASE/B_PROTEIN[GENE]
musculoskeletal B_DISEASE/I_PROTEIN[GENE]
system B_DISEASE/I_PROTEIN[GENE]
) O
. O

antibodies O
against O
REAP B_GENE
- I_GENE
1 I_GENE
inhibit O
in O
vitro O
RNA O
editing O
reactions O
confirming O
its O
role O
in O
RNA O
editing O
. O

The O
full O
- O
length O
cDNA O
was O
cloned O
and O
sequenced O
, O
and O
the O
inferred O
amino O
acid O
sequence O
was O
found O
to O
encode O
a O
novel O
protein O
, O
which O
we O
named O
cystatin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
M I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
40 O
% O
homology O
to O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cystatins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
similar O
overall O
structure O
. O

42nd B_PERSON
annual I_PERSON
meeting I_PERSON
of O
the O
American B_ORGANIZATION/B_LOCATION
Academy I_ORGANIZATION/I_LOCATION
of O
Oral B_PERSON
Pathology I_PERSON
. O

BAG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
prevented O
growth O
arrest O
following O
UV O
- O
irradiation O
- O
induced O
genotoxic O
injury O
without O
interfering O
with O
accumulation O
of O
p53 B_GENE
protein I_GENE
or O
p21 B_GENE/B_DISEASE
( O
waf B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
expression O
. O

The O
side B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pulmonary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fibrosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurs O
in O
20 B_NUMBER[MEASURE]/B_LOCATION
to O
30 B_MEASURE
percent I_MEASURE
of O
patients B_PERSON
receiving O
this O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

These O
larger O
sizes O
, O
however O
, O
are O
consistent O
with O
predictions O
from O
the O
DNA O
sequence O
of O
the O
pol B_BIO/B_GENE
gene I_BIO/I_GENE
. O

Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
indigent B_PERSON/B_LOCATION
. O

N0 B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
more O
favorable B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
N1 B_PROTEIN[GENE]
or O
N2 B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O

In O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recall I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
short B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
repeated O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
are O
recalled O
well O
when O
close O
together O
( O
repetition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
facilitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
, O
but O
not O
when O
far O
apart O
( O
repetition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O
the O
Ranschburg B_MEASURE/B_PERSON
effect I_MEASURE/I_PERSON
) O
. O

In O
addition O
, O
two O
cis O
- O
acting O
elements O
direct O
the O
first O
zygotic O
expression O
of O
Kr B_GENE
in O
a O
striped O
subpattern O
within O
the O
central O
region O
of O
the O
blastoderm O
embryo O
. O

Two B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
and O
eighty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
, O
217 B_PERSON/B_MEASURE
females B_PERSON/I_MEASURE
( O
median B_TIME[MEASURE]/B_PERSON
age B_TIME[MEASURE]/I_PERSON
24 B_TIME[MEASURE]/I_PERSON
years B_TIME[MEASURE]/I_PERSON
, O
range B_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
- O
73 B_MEASURE
) O
and O
66 B_MEASURE/B_PERSON
males I_MEASURE/I_PERSON
( O
median B_TIME[MEASURE]/B_PERSON
age B_TIME[MEASURE]/I_PERSON
20 B_TIME[MEASURE]/I_PERSON
years B_TIME[MEASURE]/I_PERSON
, O
range B_MEASURE
0 I_MEASURE
. O
75 B_MEASURE
- O
72 B_MEASURE
) O
, O
were O
examined O
. O

The O
Robert B_LOCATION/B_PERSON
Wood I_LOCATION/I_PERSON
Johnson I_LOCATION/I_PERSON
Foundation I_LOCATION/I_PERSON
: O
billion B_PERSON/B_ORGANIZATION
dollar I_PERSON/I_ORGANIZATION
force I_PERSON/I_ORGANIZATION
for O
health B_PERSON/B_DISEASE
- O
care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
change I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

We O
have O
isolated O
a O
unique O
murine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
FLT3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
codes O
for O
a O
variant O
isoform O
of O
FLT3 B_GENE
, O
devoid O
of O
the O
fifth O
Ig B_GENE
- I_GENE
like I_GENE
domain I_GENE
, O
by O
comparison O
with O
the O
prototypic O
form O
. O

P53 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
also O
offer O
new O
approaches O
to O
the O
study O
of O
the O
origins O
of O
mutations O
in O
human O
cancer O
. O

( O
1993 B_MEASURE
) O
8 B_MEASURE
, O
94 B_MEASURE
- O
99 B_MEASURE
) O
. O

Desarrollo B_MEASURE/B_ENT
de I_MEASURE/I_ENT
un I_MEASURE/I_ENT
modelo I_MEASURE/I_ENT
matematico I_MEASURE/I_ENT
general I_MEASURE/I_ENT
para I_MEASURE/I_ENT
los I_MEASURE/I_ENT
procesos I_MEASURE/I_ENT
fermentativos I_MEASURE/I_ENT
, O
Cinetica B_MEASURE/B_ENT
de I_MEASURE/I_ENT
la I_MEASURE/I_ENT
degradacion I_MEASURE/I_ENT
anaerobia I_MEASURE/I_ENT
, O
Ph B_PROTEIN[GENE]/B_LOCATION
. O
D B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

particle O
bombardment O
of O
barley O
aleurone O
with O
a O
B22EL8 B_GENE
promoter I_GENE
- O
GUS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
beta B_PROTEIN[GENE]/B_BIO
- I_PROTEIN[GENE]/I_BIO
glucuronidase I_PROTEIN[GENE]/I_BIO
) O
construct O
demonstrates O
that O
the O
promoter O
( O
3 O
kb O
) O
is O
active O
in O
developing O
barley O
grains O
. O

Changes B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BHR B_DISEASE
were O
found O
to O
correlate O
significantly O
with O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
levels B_MEASURE/B_GENE
of O
24 B_MEASURE
h O
mean O
SO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
NO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
smoke O
; O
48 B_MEASURE
h O
mean O
NO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
smoke O
; O
24 B_MEASURE
h O
lag B_MEASURE/B_LOCATION
NO2 I_MEASURE/I_LOCATION
; O
although O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
only O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
accounting O
for O
approximately O
10 B_MEASURE
% I_MEASURE
of O
the O
variability B_MEASURE
in O
within O
- O
subject B_PERSON/B_MEASURE
BHR I_PERSON/I_MEASURE
between O
visits B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_GENE/B_LOCATION
sequences B_GENE/I_LOCATION
of O
isoforms B_PROTEIN[GENE]
beta I_PROTEIN[GENE]
to O
epsilon O
contain O
a O
PEST B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
which O
could O
induce O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
intracellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
degradation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
isoforms B_PROTEIN[GENE]
beta I_PROTEIN[GENE]
and O
delta B_PROTEIN[GENE]
. O

characterization O
of O
regions O
of O
fibronectin B_GENE/B_BIO
besides O
the O
arginine O
- O
glycine O
- O
aspartic O
acid O
sequence O
required O
for O
adhesive O
function O
of O
the O
cell O
- O
binding O
domain O
using O
site O
- O
directed O
mutagenesis O
. O

The O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ethosuximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
related O
to O
this O
differential B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
thalamocortical B_DISEASE
excitability I_DISEASE
. O

Elements O
regulating O
cell O
- O
and O
stage O
- O
specific O
expression O
of O
the O
C O
. O
elegans O
MyoD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family O
homolog O
hlh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
analysis O
of O
the O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
the O
bacterial B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloramphenicol B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetyltransferase B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O
) O
in O
human O
erythroleukemia O
HEL O
cells O
, O
which O
express O
the O
endogenous O
c B_GENE
- I_GENE
kit I_GENE
mRNA I_GENE
at O
high O
levels O
, O
showed O
that O
a O
region O
from O
- O
180 O
to O
- O
22 O
is O
important O
for O
the O
expression O
of O
the O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
5 O
days O
stimulation O
with O
G B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
micrograms O
/ O
kg O
) O
1l O
of O
blood O
was O
drawn O
, O
kept O
unprocessed O
for O
3 O
days O
and O
reinfused O
24 O
h O
after O
completion O
of O
chemotherapy O
. O

OAT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O
become O
safer B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
recent B_LOCATION/B_PERSON
years I_LOCATION/I_PERSON
, O
particularly O
if O
monitored O
in O
special B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
anticoagulation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
clinics I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

However O
, O
the O
relative O
substrate O
specificity O
of O
RSK3 B_GENE/B_BIO
differed O
from O
that O
reported O
for O
other O
isoforms O
. O

Our O
data O
indicate O
that O
the O
various O
subunits O
of O
the O
human O
P B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TEFb I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O
may O
play O
distinct O
roles O
at O
multiple O
stages O
to O
mediate O
Tat B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O
of O
HIV O
- O
1 O
transcription O
elongation O
. O

corresponding O
oligonucleotides B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
used O
to O
screen O
a O
rat B_GENE
liver I_GENE
cDNA I_GENE
library I_GENE
constructed O
in O
the O
plasmid B_GENE/B_SPECIES[BIO]
cloning O
vector B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pcDV O
. O

In O
fifty B_NUMBER[MEASURE]/B_PERSON
non I_NUMBER[MEASURE]/I_PERSON
selected O
ductal B_DISEASE/B_PERSON
carcinomas I_DISEASE/I_PERSON
of O
the O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
we O
found O
that O
a O
marked O
tumoral B_DISEASE
inflammatory I_DISEASE
infiltrate I_DISEASE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
025 B_MEASURE
) O
, O
perinodal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumoral B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrate O
( O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
, O
sinus B_DISEASE
catarrh I_DISEASE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
, O
follicular B_DISEASE
hyperplasia I_DISEASE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
025 B_MEASURE
) O
, O
mixed B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
lymph B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nodes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
and O
with O
54 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
or O
younger B_TIME[MEASURE]/B_PERSON
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
correlated O
significantly O
with O
lymph B_DISEASE/B_MEASURE
node I_DISEASE/I_MEASURE
metastases I_DISEASE/I_MEASURE
and O
/ O
or O
high B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
histologic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grade I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

capillary B_MEASURE/B_DISEASE
tortuosity I_MEASURE/I_DISEASE
was O
a O
function B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sarcomere B_MEASURE/B_DISEASE
length I_MEASURE/I_DISEASE
in O
all O
animals B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O
this O
relationship B_PERSON/B_MEASURE
was O
not O
changed O
by O
hypoxia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sox8 B_GENE/B_PERSON
maps O
to O
the O
t B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
mouse O
chromosome O
17 O
and O
to O
human O
chromosome O
16p13 O
. O
3 O
, O
a O
region O
associated O
with O
the O
microphthalmia O
- O
cataract O
syndrome O
CATM O
and O
the O
alpha O
- O
thalassemia O
/ O
mental O
retardation O
syndrome O
ATR O
- O
16 O
. O

directional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
a O
smectic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
smectic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
interface I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lying O
along O
a O
forbidden B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
orientation I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
TCR B_GENE
beta I_GENE
enhancer I_GENE
was O
active O
on O
both O
the O
minimal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simian I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
40 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
TCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
both O
TCR B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
/ I_GENE/I_LOCATION
beta I_GENE/I_LOCATION
+ O
and O
TCR B_GENE/B_LOCATION
gamma I_GENE/I_LOCATION
/ I_GENE/I_LOCATION
delta I_GENE/I_LOCATION
+ O
T O
cells O
. O

U B_OTHER/B_MEASURE
. O

Recently O
, O
we O
demonstrated O
that O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
derived I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PDGF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O
, O
but O
not O
various O
other O
growth O
factors O
, O
inhibits O
transcription O
of O
alpha1D B_PROTEIN[GENE]/B_LOCATION
- O
, O
but O
not O
alpha1A B_PROTEIN[GENE]/B_LOCATION
- O
or O
alpha1B B_GENE
- I_GENE
ARs I_GENE
, O
resulting O
in O
reduced O
norepinephrine O
- O
mediated O
SMC O
growth O
. O

Southern O
blot O
analysis O
following O
reverse O
transcription O
and O
PCR O
showed O
that O
B2R B_GENE
is O
expressed O
in O
most O
mouse O
tissues O
, O
except O
the O
liver O
and O
spleen O
, O
which O
is O
consistent O
with O
the O
wide O
distribution O
of O
B2R B_GENE
activity O
as O
deduced O
from O
pharmacological O
studies O
. O

Long B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_MEASURE/B_LOCATION
renal B_MEASURE/I_LOCATION
function B_MEASURE/I_LOCATION
in O
on O
- O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
beating O
donor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
kidney I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
: O
a O
single B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
center B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
intensity B_MEASURE
of O
pain B_DISEASE
evoked O
by O
heat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
relatively O
exhaustive B_DISEASE_ADJECTIVE[DISEASE]
: O
the O
influence B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
local I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
stimulus B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
upon O
threshold B_MEASURE/B_DISEASE
values I_MEASURE/I_DISEASE
has O
been O
well O
studied O
, O
as O
has O
the O
relation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
pain B_DISEASE/B_MEASURE
and O
stimulus B_MEASURE/B_DISEASE
intensities B_MEASURE/I_DISEASE
. O

The O
vaccine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
at O
least O
80 B_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
efficacious I_DISEASE_ADJECTIVE[DISEASE]
against O
Chlamydia B_BACTERIUM[BIO]/B_DISEASE
and O
Campylobacter B_VIRUS[BIO]/B_DISEASE
spp I_VIRUS[BIO]/I_DISEASE
and O
appeared O
to O
be O
protective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
centromeric B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dodeca I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
satellite B_LOCATION/B_GENE
of O
Drosophila B_SPECIES[BIO]/B_GENE
forms I_SPECIES[BIO]/I_GENE
altered O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
which O
its O
purine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_GENE/B_BACTERIUM[BIO]
strand I_GENE/I_BACTERIUM[BIO]
( O
G B_PROTEIN[GENE]/B_LOCATION
- O
strand B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
forms O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fold O
- O
back B_LOCATION/B_MEASURE
structures I_LOCATION/I_MEASURE
, O
while O
the O
complementary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
strand B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
remains O
unstructured B_DISEASE_ADJECTIVE[DISEASE]
. O

Pneumatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dilation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
esophageal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sphincter I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
accomplished O
by O
endoscopic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
visualization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
positioning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
modified O
polyurethane B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dilator I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
90 B_MEASURE/B_LOCATION
F B_MEASURE/I_LOCATION
diameter B_MEASURE/I_LOCATION
) O
without O
fluoroscopy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
17 B_PERSON/B_ORGANIZATION
consecutive I_PERSON/I_ORGANIZATION
patients I_PERSON/I_ORGANIZATION
with O
advanced B_DISEASE
symptomatic I_DISEASE
achalasia I_DISEASE
. O

Mean O
CD4 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
percentages O
were O
lower O
postpartum O
( O
21 O
. O
9 O
+ O
/ O
- O
3 O
. O
4 O
) O
than O
prepartum O
( O
45 O
. O
1 O
+ O
/ O
- O
6 O
. O
7 O
) O
in O
all O
five O
patients O
studied O
, O
although O
proliferative O
responses O
to O
the O
mitogens B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phytohemagglutinin B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pokeweed B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
unchanged O
during O
the O
study O
period O
. O

The O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VacFix B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
uses O
a O
0 B_MEASURE/B_LOCATION
. O
15 B_MEASURE
mm I_MEASURE
thick I_MEASURE
plastic I_MEASURE
bag I_MEASURE
loosely O
filled O
with O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polysterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spheres I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mean O
24 B_MEASURE/B_LOCATION
h B_MEASURE/I_LOCATION
urinary B_MEASURE/I_LOCATION
excretion B_MEASURE/I_LOCATION
values B_MEASURE/I_LOCATION
confirmed O
this O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

However O
, O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
design B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
assured O
as O
long O
as O
all O
patients B_PERSON
received O
three B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
courses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
unusual B_DISEASE_ADJECTIVE[DISEASE]
in O
phase B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
studies O
in O
Japan B_LOCATION/B_PERSON
. O

The O
results O
indicate O
that O
the O
RNA O
in O
T7 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
free O
of O
steric O
interactions O
in O
the O
ternary O
complex O
and O
not O
available O
for O
structure O
formation O
until O
it O
is O
at O
least O
10 O
bases O
away O
from O
the O
site O
of O
polymerization O
. O

The O
STP1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
located O
on O
chromosome O
IV O
close O
to O
at O
least O
two O
other O
genes O
involved O
in O
RNA O
splicing O
: O
PRP3 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
SPP41 B_GENE/B_DISEASE
. O

An O
ICU B_MEASURE
length I_MEASURE
of O
stay O
shorter B_TIME[MEASURE]
than O
24 B_NUMBER[MEASURE]
h I_NUMBER[MEASURE]
was O
not O
related O
to O
the O
frequency B_MEASURE
of O
group B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
vitro O
, O
SHIP B_GENE
catalyzes O
the O
conversion O
of O
the O
phosphoinositide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI3K B_GENE
) O
product O
phosphatidylinositol O
3 O
, O
4 O
, O
5 O
- O
trisphosphate O
( O
PIP3 O
) O
into O
phosphatidylinositol O
3 O
, O
4 O
- O
bisphosphate O
. O

Like O
pimethixene O
and O
cyproheptadine O
, O
WA O
335 O
has O
no O
distinct O
antagonistic O
qualities O
against O
bradykinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

To O
confirm O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
obtained O
using O
the O
HPLC B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ESI B_LOCATION
- O
MS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
fractions B_NUMBER[MEASURE]/B_LOCATION
of O
the O
glycosides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
berries B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
separated O
, O
hydrolyzed O
, O
silylated O
and O
the O
sugars B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
analyzed O
using O
gas B_DISEASE/B_PROTEIN[GENE]
chromatography B_DISEASE/I_PROTEIN[GENE]
- O
mass B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectrometry B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
clone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
will O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
identifying O
the O
genetic B_LOCATION/B_PERSON
determinants I_LOCATION/I_PERSON
of O
FIV B_GENE/B_DISEASE
- O
Oma B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
WEB2 B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
encodes O
a O
1 O
, O
522 O
- O
amino O
- O
acid O
protein O
with O
homology O
to O
nucleic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Evidence O
that O
the O
AT1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O
transcription B_GENE
factor I_GENE
- I_GENE
Stat91 I_GENE
and O
/ O
or O
a O
related O
protein O
. O

There O
was O
91 B_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
concordance I_DISEASE_ADJECTIVE[DISEASE]
between O
ST B_PROTEIN[GENE]/B_DISEASE
- O
Rd B_LOCATION/B_DISEASE
/ O
RI B_LOCATION/B_PROTEIN[GENE]
/ O
LRD B_LOCATION/B_PROTEIN[GENE]
201Tl I_LOCATION/I_PROTEIN[GENE]
and O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
ST B_PROTEIN[GENE]/B_DISEASE
/ O
N B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Inf B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
99Tcm B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
tetrofosmin B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
regarding O
reversibility B_DISEASE
. O

The O
two O
complexes O
were O
detected O
with O
a O
similar O
activation O
kinetics O
upon O
IL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
dauricine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
a O
salutary B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
extracorporeal B_DISEASE/B_BIO
circulation I_DISEASE/I_BIO
. O

These O
results O
demonstrate O
the O
preferential O
endometrial O
cell O
- O
type O
expression O
of O
BTEB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
suggest O
its O
regulatory O
role O
in O
pregnancy O
- O
associated O
endometrial O
epithelial O
gene O
expression O
. O

Spen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
the O
only O
known O
homeotic B_GENE/B_BIO
protein I_GENE/I_BIO
with O
RNP O
binding O
motifs O
, O
which O
indicates O
that O
splicing O
, O
transport O
, O
or O
other O
RNA O
regulatory O
steps O
are O
involved O
in O
the O
diversification O
of O
segmental O
morphology O
. O

Long B_MEASURE/B_DISEASE
- O
term B_TIME[MEASURE]
follow I_TIME[MEASURE]
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
kidney B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
donors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
a O
longitudinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
research I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
lipolysis B_DISEASE/B_SPECIES[BIO]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
use O
a O
modified O
Stroop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
a O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
implicit B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
alcohol B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Six B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
24 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
developed O
sepsis B_DISEASE
and O
only O
one B_NUMBER[MEASURE]
survived O
. O

None O
of O
the O
10 O
sequences O
has O
hitherto O
been O
recognized O
as O
part O
of O
the O
p53 B_GENE
signaling O
pathway O
. O

The O
prompt B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
Praise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
condition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
other B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
two I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
encouraging O
participation B_PERSON/B_ORGANIZATION
in O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
interest B_MEASURE/B_PERSON
recreational I_MEASURE/I_PERSON
activities I_MEASURE/I_PERSON
. O

The O
majority O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ig I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IgH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
cloned O
and O
mapped O
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
analyzed O
right B_MEASURE/B_ORGANISM_FUNCTION
ventricular I_MEASURE/I_ORGANISM_FUNCTION
size I_MEASURE/I_ORGANISM_FUNCTION
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
201Tl B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
uptake I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
determine O
if O
there O
was O
a O
relationship B_PERSON/B_MEASURE
between O
201Tl B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
uptake B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
systolic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
19 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
pulmonary B_DISEASE
artery I_DISEASE
hypertension I_DISEASE
who O
were O
being O
evaluated O
for O
heart B_DISEASE/B_MEASURE
- O
lung B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
transcriptional O
start O
site O
( O
s O
) O
of O
the O
IA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
mapped O
by O
5 O
' O
rapid O
amplification O
of O
cDNA O
ends O
to O
97 O
BP O
upstream O
of O
the O
translational O
start O
site O
. O

The O
RAG B_GENE
- I_GENE
2 I_GENE
gene I_GENE
encodes O
a O
component O
of O
the O
V B_GENE
( I_GENE
D I_GENE
) I_GENE
J I_GENE
recombinase I_GENE
which O
is O
essential O
for O
the O
assembly O
of O
antigen O
receptor O
genes O
in O
B O
and O
T O
lymphocytes O
. O

The O
lamina B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
densa I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
always O
interrupted O
by O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
small B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gaps B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
in O
some O
areas B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
basement B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
could O
not O
be O
identified O
over O
a O
long B_TIME[MEASURE]/B_LOCATION
distance I_TIME[MEASURE]/I_LOCATION
. O

We O
have O
characterized O
21 O
mutations O
in O
the O
type B_GENE
VII I_GENE
collagen I_GENE
gene I_GENE
( O
COL7A1 B_GENE/B_DISEASE
) O
encoding O
the O
anchoring O
fibrils O
, O
18 O
of O
which O
were O
not O
previously O
reported O
, O
in O
patients O
from O
15 O
unrelated O
families O
with O
recessive O
dystrophic O
epidermolysis O
bullosa O
( O
RDEB O
) O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
when O
used O
to O
stimulate O
the O
collection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
antenatal B_ORGANISM_FUNCTION/B_PERSON
or O
postnatal B_PERSON/B_LOCATION
visits I_PERSON/I_LOCATION
, O
nonetheless O
provide O
an O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
under O
- O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
mortality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
trends I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
two B_TIME[MEASURE]/B_PERSON
periods B_TIME[MEASURE]/I_PERSON
examined O
- O
- O
before O
1984 B_MEASURE
and O
before O
1989 B_MEASURE
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B_GENE/B_NUMBER[MEASURE]
: O
YetI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
YezB B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
domain O
. O

There O
is O
a O
good B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
correlation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
the O
occurrence B_DISEASE/B_MEASURE
in O
any O
particular B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
vascular I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
segment I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
transient B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
contractile I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
intrinsic B_DISEASE/B_MEASURE
tone I_DISEASE/I_MEASURE
as O
assessed O
by O
relaxation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
papaverine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE/B_LOCATION
( O
- O
6 B_MEASURE
) O
M B_MEASURE/B_LOCATION
) O
. O

Both O
atracurium B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
100 B_MEASURE/B_LOCATION
mumol I_MEASURE/I_LOCATION
litre I_MEASURE/I_LOCATION
- O
1 B_NUMBER[MEASURE]
and O
laudanosine B_MEASURE
1 I_MEASURE
- O
50 B_MEASURE/B_LOCATION
mumol I_MEASURE/I_LOCATION
litre I_MEASURE/I_LOCATION
- O
1 B_NUMBER[MEASURE]
enhanced O
the O
release B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evoked O
by O
field B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
2 B_MEASURE
Hz I_MEASURE
, O
24 B_MEASURE/B_LOCATION
stimuli I_MEASURE/I_LOCATION
) O
, O
but O
did O
not O
affect O
resting O
release B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

S16 B_MEASURE/B_LOCATION
, O
16 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_MEASURE
= O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

The O
Zn B_GENE/B_BIO
- I_GENE/I_BIO
15 I_GENE/I_BIO
DNA I_GENE/I_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
domain I_GENE/I_BIO
comprises O
three O
zinc O
fingers O
separated O
by O
unusually O
long O
linker O
sequences O
that O
would O
be O
expected O
to O
interrupt O
specific O
DNA O
site O
recognition O
. O

replication B_GENE/B_MEASURE
regions I_GENE/I_MEASURE
from O
plant B_BIO/B_DISEASE
- O
pathogenic B_BIO/B_GENE
Pseudomonas I_BIO/I_GENE
syringae I_BIO/I_GENE
plasmids I_BIO/I_GENE
are O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
ColE2 B_BIO/B_DISEASE
- O
related O
replicons B_GENE/B_BIO
. O

There O
has O
been O
no O
significant B_DISEASE
toxicity I_DISEASE
associated O
with O
repeated O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instillation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
airway B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Twenty B_PERSON/B_ENT
male I_PERSON/I_ENT
volunteers I_PERSON/I_ENT
were O
studied O
during O
almokalant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aiming O
at O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Cpl B_LOCATION/B_PROTEIN[GENE]
) O
of O
20 B_MEASURE
, O
50 B_MEASURE
, O
100 B_MEASURE
, O
and O
150 B_MEASURE/B_LOCATION
nmol I_MEASURE/I_LOCATION
/ O
l B_MEASURE/B_OTHER
. O

consistently O
, O
we O
show O
that O
phosphorylation O
by O
protein B_GENE
kinase I_GENE
A I_GENE
inhibits O
Sfl1 B_GENE/B_PERSON
DNA O
binding O
in O
vitro O
, O
and O
that O
a O
tpk2Delta B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O
increases O
the O
levels O
of O
Sfl1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
specific O
promoter O
elements O
in O
vivo O
. O

The O
response O
sequences O
were O
localized O
between O
- O
67 O
and O
+ O
30 O
in O
the O
simian O
cytomegalovirus O
IE94 B_GENE
promoter I_GENE
and O
upstream O
of O
position O
+ O
9 O
in O
the O
HCMV B_GENE/B_BIO
IE68 I_GENE/I_BIO
promoter I_GENE/I_BIO
. O

Some O
CHOP B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers O
apparently O
bind O
to O
alternative O
DNA O
sequence O
and O
thereby O
regulate O
the O
transcription O
of O
other O
genes O
. O

To O
identify O
and O
determine O
the O
function O
of O
Ino2p B_GENE
in O
yeast O
cells O
, O
we O
raised O
antibodies O
to O
a O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
Ino2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O
protein O
. O

Northern O
blot O
analyses O
were O
used O
to O
examine O
the O
regulated O
expression O
of O
the O
cys B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Typicality B_MEASURE/B_PERSON
is O
probably O
a O
better B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
representation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Alexander B_PERSON
, O
Dunbar B_TIME[MEASURE]/B_PERSON
and O
others B_PERSON
' I_PERSON
conclusions I_PERSON
than O
specificity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
which O
was O
always O
too O
absolute B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
a O
term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Additions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
NH4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
up O
to O
200 B_MEASURE
micrograms I_MEASURE
1 I_MEASURE
( O
- O
1 B_NUMBER[MEASURE]
) O
were O
not O
stimulatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
at O
1 B_MEASURE
. O
0 B_MEASURE
mg I_MEASURE
1 I_MEASURE
( O
- O
1 B_NUMBER[MEASURE]
) O
levels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Ke B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
50 B_MEASURE
% I_MEASURE
greater I_MEASURE
than O
for O
NO3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
enriched O
medium B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
drug I_DISEASE_ADJECTIVE[DISEASE]
use I_DISEASE_ADJECTIVE[DISEASE]
and O
hospitalizations B_DISEASE_ADJECTIVE[DISEASE]
attributable I_DISEASE_ADJECTIVE[DISEASE]
to O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
. O

The O
arrangement O
of O
amino O
acids O
in O
the O
helix O
1 O
and O
helix O
2 O
regions O
is O
quite O
similar O
to O
those O
of O
Mxi B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Mad B_PROTEIN[GENE]/B_BIO
, O
but O
different O
from O
those O
of O
E2F B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
1 I_PROTEIN[GENE]/I_LOCATION
and O
DP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
. O

They O
contain O
a O
large B_MEASURE
( O
0 B_MEASURE
. O
9 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
3 B_NUMBER[MEASURE]
) O
to O
1 B_MEASURE
. O
88 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
3 B_MEASURE
) O
base B_LOCATION/B_MEASURE
- O
pairs B_PERSON/B_MEASURE
) O
intron B_GENE/B_LOCATION
in O
the O
middle B_MEASURE/B_LOCATION
of O
the O
gene B_GENE
and O
are O
further O
interrupted O
close O
to O
the O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
gene B_GENE
. O

The O
present O
study O
also O
emphasizes O
the O
need O
of O
establishing O
dose O
- O
response O
curves O
to O
correctly O
assess O
the O
relative O
contribution O
of O
the O
different O
regions O
of O
steroid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
activation O
of O
transcription O
. O

Routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
default B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
retrieval I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
home I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
visits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
given O
to O
ensure O
maximal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compliance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

D B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Long B_PERSON/B_COLOR
, O
C B_OTHER/B_PROTEIN[GENE]
. O

By O
contrast O
with O
ama B_GENE/B_BIO
- I_GENE/I_BIO
1 I_GENE/I_BIO
, O
rpc B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
was O
not O
deleted O
by O
mDf4 O
or O
larger O
deficiencies O
examined O
, O
indicating O
that O
these O
genes O
are O
no O
closer O
than O
150 O
kb O
. O

Accordingly O
, O
constitutive O
downregulation O
of O
expression O
of O
accessory O
molecules O
of O
the O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
reveal O
differences O
between O
H2 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
class I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
antigen O
presentation O
not O
encountered O
when O
the O
expression O
levels O
are O
augmented O
. O

Anovulatory O
cycles O
with O
an O
apparently O
normal O
level O
of O
blood O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Legionella B_DISEASE/B_ORGANISM_FUNCTION
antibodies I_DISEASE/I_ORGANISM_FUNCTION
in O
domestic O
animals O
. O

By O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
a O
Xenopus B_GENE
laevis I_GENE
egg I_GENE
cDNA I_GENE
library I_GENE
, O
we O
have O
isolated O
a O
2 B_MEASURE
, O
111 B_MEASURE/B_GENE
BP I_MEASURE/I_GENE
cDNA I_MEASURE/I_GENE
which O
corresponds O
to O
a O
maternal B_GENE
mRNA I_GENE
specifically O
deadenylated O
after O
fertilisation B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

Similar B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunological I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disturbances I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
observed O
in O
SCI B_DISEASE/B_PERSON
but O
not O
in O
the O
PC2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
subgroup I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
patients B_PERSON/B_LOCATION
examined O
later O
than O
6 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
after O
injury B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O
that O
Fluosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
significantly O
attenuates O
neutrophil B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adherence I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cytotoxicity B_DISEASE
, O
and O
enzyme B_DISEASE_ADJECTIVE[DISEASE]
release I_DISEASE_ADJECTIVE[DISEASE]
in O
an O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
microvascular B_DISEASE
injury I_DISEASE
. O

Using O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
electrical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analog I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
we O
present O
an O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
allows O
calculation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
parameters B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
as O
well O
as O
the O
corner B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
of O
the O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
F1 B_PROTEIN[GENE]/B_MEASURE
) O
, O
without O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O
similar B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assumptions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
further O
examined O
the O
interaction O
of O
JAK2 B_GENE
with O
the O
GHR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytoplasmic O
domain O
by O
two O
lines O
of O
investigation O
. O

These O
p21 B_PROTEIN[GENE]/B_LOCATION
- O
E2F B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O
, O
while O
present O
in O
young O
G1 O
cells O
at O
very O
low O
levels O
, O
were O
elevated O
in O
senescent O
cells O
. O

There O
is O
little O
similarity O
among O
the O
sequences O
upstream O
from O
the O
Cap O
site O
of O
the O
Spec2 B_GENE
genes I_GENE
except O
the O
TATA O
consensus O
sequence O
and O
a O
repeating O
trinucleotide O
, O
AAC O
. O

Thus O
, O
d B_PROTEIN[GENE]/B_LOCATION
- O
delta3 B_GENE
- O
carene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
about O
four B_SEQUENCE[MEASURE]/B_ENT
times I_SEQUENCE[MEASURE]/I_ENT
more O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
sensory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irritant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
I O
- O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
pinene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
the O
difference B_MEASURE
with O
I O
- O
alpha B_PROTEIN[GENE]
- O
pinene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
more O
marked O
; O
as O
a O
sensory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
irritant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
I O
- O
alpha B_PROTEIN[GENE]
- O
pinene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
almost O
inactive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
reconstituted O
RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O
the O
mutant O
alpha O
subunits O
were O
examined O
for O
their O
response O
to O
transcription O
activation O
by O
cAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CRP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
rrnBP1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
UP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
element I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

The O
study B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vinblastine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
single B_NUMBER[MEASURE]/B_DISEASE
- O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triazinate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
dactinomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
) O
failed O
to O
provide O
any O
meaningful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antitumor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
patients B_PERSON/B_BIO
with O
advanced B_DISEASE
renal I_DISEASE
cell I_DISEASE
cancer I_DISEASE
. O

Our O
results O
indicate O
that O
GCN4 B_GENE
contains O
two O
activation O
domains O
of O
similar O
potency O
that O
can O
function O
independently O
to O
promote O
high O
- O
level O
transcription O
of O
the O
target O
genes O
HIS3 B_GENE
and O
HIS4 B_GENE
. O

Those O
diagnosed O
as O
having O
affective B_DISEASE/B_LOCATION
disorder I_DISEASE/I_LOCATION
( O
n B_MEASURE/B_LOCATION
= O
96 B_MEASURE
) O
, O
according O
to O
DSM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
IIIR B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
compared O
with O
the O
other B_DISEASE/B_MEASURE
non I_DISEASE/I_MEASURE
- O
affective B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suicide I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attempters I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
161 B_MEASURE
) O
. O

Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
demonstrated O
to O
interact O
directly O
with O
CREB1 B_GENE
but O
not O
with O
other O
bZIP B_GENE/B_BIO
proteins I_GENE/I_BIO
, O
including O
CREB2 B_GENE/B_LOCATION
and O
Jun B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Anxiogenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pentagastrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
with O
social B_DISEASE/B_LOCATION
phobia I_DISEASE/I_LOCATION
and O
healthy B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ischaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
reperfusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
: O
current B_TIME[MEASURE]/B_LOCATION
status I_TIME[MEASURE]/I_LOCATION
and O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
direction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Non O
- O
dialyzable O
transfer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
demonstrate O
that O
a O
p110RB1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
which O
is O
refractory O
to O
cell O
cycle O
phosphorylation O
but O
intact O
in O
E1a B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
large B_GENE/B_LOCATION
T I_GENE/I_LOCATION
antigen I_GENE/I_LOCATION
- O
binding O
properties O
, O
represses O
EIIaE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
50 O
- O
to O
80 O
- O
fold O
greater O
efficiency O
than O
wild B_GENE/B_TIME[MEASURE]
- I_GENE/I_TIME[MEASURE]
type I_GENE/I_TIME[MEASURE]
p110RB1 I_GENE/I_TIME[MEASURE]
. O

Subgroup B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
failed O
to O
show O
any O
benefit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
patients B_PERSON/B_ORGANIZATION
with O
monocytic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
myelomonocytic B_DISEASE
disease I_DISEASE
, O
or O
in O
any O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
subgroup I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
IGFBP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
IRS I_GENE/I_DISEASE
and O
PEPCK B_LOCATION/B_GENE
IRS I_LOCATION/I_GENE
both O
bind O
the O
alpha O
and O
beta O
forms O
of O
hepatic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HNF B_GENE
- I_GENE
3 I_GENE
) O
, O
although O
the O
latter O
does O
so O
with O
a O
sixfold O
- O
lower O
relative O
affinity O
. O

Polyglutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
containing O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
shown O
to O
accumulate O
as O
aggregates B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
to O
induce O
cell B_DISEASE/B_GENE
death I_DISEASE/I_GENE
when O
expressed O
in O
cultured O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
leading O
to O
the O
proposal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
polyglutamine B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
aggregation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
pathogenesis B_DISEASE
. O

It O
is O
suggested O
that O
on O
presentation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
tail B_DISEASE
tip I_DISEASE
necrosis I_DISEASE
in O
kittens B_PERSON/B_BIO
a O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neonatal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoerythrolysis I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
isoagglutination B_DISEASE/B_BACTERIUM[BIO]
should O
be O
considered O
. O

Microscopically O
, O
cartilage B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
showed O
markedly O
stunted B_DISEASE_ADJECTIVE[DISEASE]
and O
disorganized B_DISEASE_ADJECTIVE[DISEASE]
endochondral I_DISEASE_ADJECTIVE[DISEASE]
ossification I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
differential B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
splicing I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
receptor B_GENE
gene I_GENE
generates O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
variants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
different B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
binding O
specificities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Sucrose O
- O
specific O
signalling O
represses O
translation O
of O
the O
Arabidopsis B_GENE
ATB2 I_GENE
bZIP I_GENE
transcription I_GENE
factor I_GENE
gene I_GENE
. O

Wolf B_BIO/B_PERSON
- O
Hirschhorn B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
WHS B_LOCATION/B_DISEASE
) O
is O
a O
malformation B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
associated O
with O
a O
hemizygous B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deletion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
distal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
arm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
chromosome B_GENE/B_MEASURE
4 I_GENE/I_MEASURE
( O
4p16 B_MEASURE/B_GENE
. O
3 B_MEASURE
) O
. O

Our O
aim O
was O
to O
check O
whether O
, O
during O
PG O
- O
DS O
administration O
, O
serum O
lipase B_ENZYME[GENE]
activity O
changes O
simultaneously O
with O
serum O
amylase B_GENE
activity O
, O
and O
, O
if O
so O
, O
what O
the O
reason O
is O
for O
the O
detected O
change O
. O

A O
long B_NUMBER[MEASURE]/B_LOCATION
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O
- O
up O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
children B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
psychiatric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
day I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
center I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Sequencing B_GENE
and O
restriction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O
that O
this O
single B_NUMBER[MEASURE]/B_LOCATION
- O
copy B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
contains O
11 B_GENE
exons I_GENE
and O
spans O
9596 B_NUMBER[MEASURE]/B_GENE
base I_NUMBER[MEASURE]/I_GENE
pairs I_NUMBER[MEASURE]/I_GENE
. O

In O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
MDL B_MEASURE/B_PROTEIN[GENE]
72 I_MEASURE/I_PROTEIN[GENE]
, O
974A B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
proving O
to O
be O
a O
useful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjunct I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
no O
consensus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
indications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exists O
and O
, O
according O
to O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
contradictory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effect O
of O
the O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O
( O
+ O
/ O
- O
) O
- O
CPP O
on O
the O
conditioned O
- O
reflex O
activation O
of O
an O
operant O
reaction O
in O
the O
brain O
electrical O
self O
- O
stimulation O
test O
in O
rats O
. O

Within O
any O
cell O
line O
, O
several O
Tcfs B_GENE/B_BACTERIUM[BIO]
and O
TLEs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O
co O
- O
expressed O
. O

Constructs O
containing O
fragments O
of O
the O
upstream O
region O
of O
the O
cytotactin B_GENE
gene I_GENE
fused O
to O
a O
promoterless O
gene O
for O
chloramphenicol B_GENE/B_TIME[MEASURE]
acetyltransferase I_GENE/I_TIME[MEASURE]
were O
transiently O
transfected O
into O
chicken O
embryo O
fibroblasts O
to O
define O
functional O
promoter O
sequences O
. O

We O
investigated O
the O
pattern O
of O
evolution O
of O
bronchial O
albumin B_GENE/B_DISEASE
, O
IgA B_GENE
, O
and O
IgG B_GENE
levels O
in O
ventilated O
ICU O
patients O
in O
relation O
to O
nosocomial O
pneumonia O
. O

Mortality B_DISEASE
among O
patients B_PERSON
with O
CAVB B_DISEASE/B_GENE
is O
still O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
has O
not O
declined O
within O
the O
last B_TIME[MEASURE]/B_LOCATION
decade I_TIME[MEASURE]/I_LOCATION
. O

mutations O
away O
from O
splice O
site O
recognition O
sequences O
might O
cis O
- O
modulate O
alternative O
splicing O
of O
goat O
alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
s1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
casein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

setting B_LOCATION/B_PERSON
: O
A O
private B_PERSON/B_LOCATION
office I_PERSON/I_LOCATION
- O
based O
fertility B_LOCATION/B_ORGANIZATION
program I_LOCATION/I_ORGANIZATION
. O

promoter O
, O
spliced O
leader O
, O
and O
coding O
sequence O
for O
BICP4 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
largest O
of O
the O
immediate B_GENE/B_NUMBER[MEASURE]
- I_GENE/I_NUMBER[MEASURE]
early I_GENE/I_NUMBER[MEASURE]
proteins I_GENE/I_NUMBER[MEASURE]
of I_GENE/I_NUMBER[MEASURE]
bovine I_GENE/I_NUMBER[MEASURE]
herpesvirus I_GENE/I_NUMBER[MEASURE]
1 I_GENE/I_NUMBER[MEASURE]
. O

The O
limb B_DISEASE
defects I_DISEASE
, O
oligodactyly O
and O
syndactyly O
, O
have O
been O
traced O
to O
improper B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
differentiation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ectodermal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ridge I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
Aer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
and O
shortening B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
anteroposterior B_BODY_PART_OR_ORGAN_COMPONENT
limb I_BODY_PART_OR_ORGAN_COMPONENT
axis I_BODY_PART_OR_ORGAN_COMPONENT
. O

Our O
data O
suggest O
that O
the O
ZF B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
HD I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
class O
of O
homeodomain B_GENE/B_BIO
proteins I_GENE/I_BIO
may O
be O
involved O
in O
the O
establishment O
of O
the O
characteristic O
expression O
pattern O
of O
the O
C4 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
PEPCase I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

There O
was O
no O
correlation O
between O
starting O
platelet O
- O
associated O
IgG B_GENE
levels O
or O
changes O
in O
platelet O
- O
associated O
IgG B_GENE
levels O
with O
therapy O
and O
the O
increment O
in O
the O
patient O
' O
s O
platelet O
count O
. O

We O
investigated O
whether O
two O
WT1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splice B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking O
or O
including O
a O
three O
- O
amino O
- O
acid O
( O
KTS O
) O
insertion O
between O
the O
third O
and O
fourth O
zinc O
finger O
in O
the O
DNA O
- O
binding O
domain O
could O
repress O
the O
IR B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
in O
vitro O
. O

An O
oligomer B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesized O
to O
this O
region B_LOCATION/B_MEASURE
of O
homology B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O
two B_GENE
DNA I_GENE
- O
protein B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
oviduct B_GENE
nuclear I_GENE
proteins I_GENE
. O

The O
deduced O
amino O
acid O
sequence O
exhibits O
95 O
. O
3 O
and O
76 O
. O
1 O
% O
identity O
with O
the O
CAD B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hamster I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Squalus I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acanthias I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast O
translocation O
of O
G1 B_PROTEIN[GENE]
to O
the O
Golgi O
was O
not O
observed O
when O
G1 B_PROTEIN[GENE]
was O
coexpressed O
with O
NSm B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
NSm B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O
was O
still O
detected O
in O
the O
Golgi O
. O

Since O
simian B_GENE/B_DISEASE
virus I_GENE/I_DISEASE
40 I_GENE/I_DISEASE
( I_GENE/I_DISEASE
SV40 I_GENE/I_DISEASE
) I_GENE/I_DISEASE
large I_GENE/I_DISEASE
T I_GENE/I_DISEASE
antigen I_GENE/I_DISEASE
and O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
16 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPV16 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
bind O
host O
regulatory O
factors O
, O
we O
investigated O
whether O
these O
viral O
proteins O
can O
complement O
E1A B_DISEASE/B_GENE
mutants I_DISEASE/I_GENE
which O
are O
defective O
in O
early O
gene O
activation O
. O

We O
further O
showed O
a O
significant O
repression O
of O
promoter O
activity O
( O
> O
40 O
fold O
) O
by O
E2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
lacking O
the O
amino O
acid O
sequence O
RSRS O
) O
when O
the O
E47 B_GENE
reporter I_GENE
construct I_GENE
, O
containing O
a O
hexameric O
E O
- O
box O
site O
, O
was O
used O
. O

Similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
when O
these O
mutated O
versions B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
site B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
evaluated O
by O
transient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cotransfection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
CV1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
shear B_MEASURE/B_LOCATION
bond I_MEASURE/I_LOCATION
strength I_MEASURE/I_LOCATION
recorded O
for O
the O
Novabond B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
17 B_MEASURE
MPa I_MEASURE
) O
. O

A O
400 O
- O
BP O
fragment O
( O
BP O
- O
339 O
through O
+ O
71 O
) O
of O
the O
CD22 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
subcloned O
into O
a O
pGEM O
- O
chloramphenicol B_PROTEIN[GENE]/B_MEASURE
acetyltransferase I_PROTEIN[GENE]/I_MEASURE
vector O
and O
after O
transfection O
into O
B O
and O
T O
cells O
was O
found O
to O
be O
active O
in O
both O
B O
and O
T O
cells O
. O

Results O
: O
There O
were O
no O
significant O
differences O
in O
the O
mean O
serum O
vitamin O
A O
, O
E O
concentrations O
and O
vitamin O
E O
/ O
cholesterol O
ratio O
between O
pregnant O
women O
with O
normal O
hemoglobin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
hemoglobinopathies O
, O
while O
confounding O
variables O
that O
might O
affect O
serum O
vitamin O
levels O
i O
. O
e O
. O
maternal O
age O
, O
gravida O
, O
BMI O
, O
gestational O
age O
, O
hematocrit O
, O
hemoglobin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mean O
corpuscular O
hemoglobin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
concentration O
and O
blood O
group O
were O
not O
different O
. O

Fourteen B_TIME[MEASURE]/B_LOCATION
samples I_TIME[MEASURE]/I_LOCATION
, O
seven B_NUMBER[MEASURE]/B_LOCATION
each O
of O
IR64 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IR66 B_MEASURE/B_PROTEIN[GENE]
were O
studied O
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
moisture B_MEASURE/B_COLOR
content I_MEASURE/I_COLOR
, O
germination B_MEASURE/B_LOCATION
test I_MEASURE/I_LOCATION
, O
abnormal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
seedlings I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
speed B_MEASURE/B_SPORT[ENT]
of O
germination B_DISEASE/B_BIO
, O
conductance B_MEASURE/B_LOCATION
of O
leachates B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
total B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
free I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
soluble I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sugar I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
fat B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
acidity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
gelatinization B_MEASURE/B_PERSON
temperature I_MEASURE/I_PERSON
, O
gel B_MEASURE/B_DISEASE
consistency I_MEASURE/I_DISEASE
, O
amylose B_MEASURE/B_ORGANIZATION
content I_MEASURE/I_ORGANIZATION
, O
translucency B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
per O
cent B_MEASURE
whiteness I_MEASURE
. O

Electrophoretic O
mobility O
- O
shift O
assays O
between O
viral O
RNA O
and O
BMV B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CP I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
either O
proline O
or O
alanine O
substitutions O
revealed O
that O
the O
interaction O
is O
nonspecific O
. O

Thus O
, O
over O
a O
wide B_MEASURE
range I_MEASURE
of O
arterial B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimensions B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
with O
caliper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
luminal B_MEASURE/B_LOCATION
area I_MEASURE/I_LOCATION
and O
diameter B_MEASURE
are O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
obtained O
with O
videodensitometry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
XR B_LOCATION/B_PROTEIN[GENE]
- O
70 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
system I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
neurodevelopmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
at O
1 B_TIME[MEASURE]/B_LOCATION
year B_TIME[MEASURE]/I_LOCATION
is O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
school B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
outcome B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
adolescent B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
reviewed O
the O
different B_NUMBER[MEASURE]
published O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acute B_DISEASE
high I_DISEASE
dose I_DISEASE
methotrexate I_DISEASE
neurotoxicity I_DISEASE
and O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underlying B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AAPMC B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
directed O
at O
reducing O
the O
amount B_MEASURE
of O
Cl B_LOCATION
. O
difficile B_BACTERIUM[BIO]/B_DISEASE
in O
the O
colon B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
promoting O
normalization B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intestinal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flora B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
yield B_MEASURE/B_LOCATION
of O
endocervical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
incidence B_MEASURE/B_LOCATION
of O
dysplasia B_DISEASE/B_GENE
was O
determined O
for O
both O
the O
prenatal B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
postpartum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
Pap I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
smears I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
performed O
for O
this O
group B_ORGANIZATION/B_MEASURE
of O
patients B_PERSON/B_BIO
. O

No O
significant O
difference O
in O
plasma O
ET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
was O
found O
between O
cardiac O
and O
peripheral O
sampling O
sites O
( O
pulmonary O
artery O
; O
1 O
. O
07 O
+ O
/ O
- O
0 O
. O
28 O
, O
right O
atrium O
; O
1 O
. O
02 O
+ O
/ O
- O
0 O
. O
28 O
, O
peripheral O
artery O
; O
1 O
. O
12 O
+ O
/ O
- O
0 O
. O
23 O
, O
peripheral O
vein O
; O
1 O
. O
14 O
+ O
/ O
- O
0 O
. O
38 O
fmol O
/ O
ml O
: O
N O
. O
S O
. O
) O
, O
or O
among O
patients O
with O
uncomplicated O
MI O
, O
unstable O
angina O
( O
1 O
. O
00 O
+ O
/ O
- O
0 O
. O
32 O
fmol O
/ O
ml O
) O
, O
and O
healthy O
subjects O
( O
1 O
. O
01 O
+ O
/ O
- O
0 O
. O
29 O
fmol O
/ O
ml O
) O
. O

dose B_TIME[MEASURE]/B_ORGANIZATION
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pharmacokinetics I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
emphasis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O
metabolism O
. O

Inhibition O
of O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
topoisomerase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
by O
the O
p53 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
UV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
must O
therefore O
involve O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
those O
triggered O
by O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
damage B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
for O
generation B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
full B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

4 B_NUMBER[MEASURE]
. O

Microsporum B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
persicolor I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
an O
easily O
misinterpreted O
dermatophyt B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

We O
propose O
that O
, O
while O
Y B_OTHER/B_PROTEIN[GENE]
. O
lipolytica B_SPECIES[BIO]/B_PROTEIN[GENE]
CEN B_SPECIES[BIO]/I_PROTEIN[GENE]
DNA B_SPECIES[BIO]/I_PROTEIN[GENE]
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
plasmid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
maintenance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
this O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
be O
supplied O
by O
several B_DISEASE/B_GENE
sub B_DISEASE/I_GENE
- O
fragments B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
which O
, O
together O
, O
form O
the O
active B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromosomal I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centromere I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
case B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
microphthalmia B_DISEASE/B_LOCATION
in O
sheep B_BIO/B_LOCATION
reported O
by O
Wagenaar B_PERSON
is O
discussed O
in O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detail I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
a O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
adhesion B_GENE
receptor I_GENE
- O
mediated O
signaling B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
which O
is O
potentially O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
T B_DISEASE/B_GENE
cell I_DISEASE/I_GENE
activation I_DISEASE/I_GENE
, O
including O
production B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
expression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
proto B_DISEASE
- O
oncogenes B_GENE/B_DISEASE
, O
many O
of O
which O
are O
controlled O
through O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
rich B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
gap B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O
knirps B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mediates O
both O
quenching O
and O
direct O
repression O
in O
the O
Drosophila O
embryo O
. O

The O
family B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
histories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
obtained O
from O
the O
parents B_PERSON/B_LOCATION
. O

The O
DW B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uniformly O
sampled O
the O
diffusion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ellipsoid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
surface I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Here O
we O
demonstrate O
that O
CD40 B_GENE
or O
IgM B_GENE
receptor I_GENE
stimulation O
of O
primary O
B O
cells O
results O
in O
transactivation O
of O
this O
enhancer O
. O

This O
cell O
line O
expresses O
productively O
rearranged O
immunoglobulin B_GENE
genes I_GENE
as O
well O
as O
the O
Oct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O
high O
levels O
which O
are O
comparable O
to O
those O
observed O
in O
activated O
murine O
splenic O
B O
cells O
. O

The O
relationship O
between O
CSF B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
somatostatin I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
peripheral O
thyroid O
hormones O
was O
assessed O
in O
11 O
affectively O
ill O
patients O
before O
and O
during O
carbamazepine O
treatment O
. O

Both O
RNA14 B_GENE/B_BIO
and O
RNA15 B_PROTEIN[GENE]
wild I_PROTEIN[GENE]
- I_PROTEIN[GENE]
type I_PROTEIN[GENE]
genes I_PROTEIN[GENE]
, O
when O
cloned O
on O
a O
multicopy O
plasmid O
, O
are O
able O
to O
suppress O
the O
temperature O
- O
sensitive O
phenotype O
of O
strains O
bearing O
either O
the O
rna14 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
rna15 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
suggesting O
that O
the O
encoded O
proteins O
could O
interact O
with O
each O
other O
. O

treatments O
were O
two O
adrenocorticotrophin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
preparations O
given O
intramuscularly O
at O
2 O
. O
2 O
U O
/ O
kg O
, O
one O
of O
the O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O
given O
intramuscularly O
at O
1 O
U O
/ O
kg O
and O
a O
synthetic O
polypeptide O
with O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
like I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O
( O
tetracosactrin O
, O
cosyntropin O
) O
given O
intravenously O
at O
5 O
micrograms O
/ O
kg O
. O

It O
is O
very O
probable B_DISEASE_ADJECTIVE[DISEASE]
that O
this O
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
due O
to O
mechanical B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
injecting O
a O
hypertonic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
solution I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
Mt B_LOCATION/B_PROTEIN[GENE]
- O
141 B_NUMBER[MEASURE]
at O
a O
rate B_MEASURE/B_LOCATION
of O
70 B_MEASURE/B_LOCATION
- O
- O
130 B_MEASURE/B_PERSON
ml I_MEASURE/I_PERSON
/ O
dog B_TIME[MEASURE]/B_BIO
. O

It O
is O
not O
well O
known O
that O
giant B_DISEASE
cell I_DISEASE
arteritis I_DISEASE
can O
cause O
fatal B_DISEASE
complications I_DISEASE
due O
to O
rupture B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aortic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aneurysms B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
cerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
myocardial B_DISEASE
infarctions I_DISEASE
. O

PRIP B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O
two O
LXXLL O
signature O
motifs O
. O

basal B_NUMBER[MEASURE]
urinary I_NUMBER[MEASURE]
17 I_NUMBER[MEASURE]
- O
hydroxycorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
17 B_MEASURE/B_LOCATION
- O
OHCS B_DISEASE/B_PROTEIN[GENE]
) O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
elevated O
in O
9 B_NUMBER[MEASURE]
/ O
12 B_TIME[MEASURE]
patients I_TIME[MEASURE]
and O
low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
dose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dexamethasone I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suppression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
favoured O
Cushing B_PERSON
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
8 B_NUMBER[MEASURE]
/ O
9 B_TIME[MEASURE]
patients I_TIME[MEASURE]
. O

Like O
the O
human O
gene O
, O
the O
Drosophila O
gene O
encodes O
at O
least O
three O
isoforms O
of O
full B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
length I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
dmDLP1 B_PROTEIN[GENE]/B_DISEASE
, O
dmDLP2 B_GENE
and O
dmDLP3 B_GENE
, O
) O
, O
regulated O
by O
different O
promoters O
located O
at O
the O
5 O
' O
end O
of O
the O
gene O
, O
and O
a O
smaller O
product O
regulated O
by O
an O
internal O
promoter O
( O
dmDp186 B_PROTEIN[GENE]/B_LOCATION
) O
. O

Accordingly O
, O
infection O
of O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
pretreated O
HeLa O
S3 O
cells O
with O
an O
E3L O
- O
deficient O
VV O
( O
VVDeltaE3L O
) O
resulted O
in O
increased O
phosphorylation O
levels O
of O
both O
PKR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
eIF2alpha B_GENE
. O

The O
goal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O
our O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
hearing O
thresholds B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
patients B_PERSON/B_BIO
with O
hearing B_DISEASE
impairment I_DISEASE
due O
to O
hereditary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
motor B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
sensory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
HMSN B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dietary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
supplementation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
Streptococcus B_LOCATION/B_BACTERIUM[BIO]
faecium I_LOCATION/I_BACTERIUM[BIO]
M I_LOCATION/I_BACTERIUM[BIO]
- O
74 B_NUMBER[MEASURE]
on O
broiler B_MEASURE/B_BIO
body B_MEASURE/I_BIO
weight B_MEASURE/I_BIO
, O
feed B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
conversion B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
carcass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
and O
intestinal B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
microbial B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
colonization B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reveal O
preferences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initiating O
nucleotides B_LOCATION/B_BIO
( O
ATP B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
= O
GTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
> O
UTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O
> B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
and O
for O
starting O
positions B_LOCATION
downstream I_LOCATION
of O
the O
Pribnow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
box B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
7 B_MEASURE
> I_MEASURE
> I_MEASURE
6 I_MEASURE
and O
8 B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
9 I_MEASURE/I_LOCATION
> I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
) O
. O

Trimethylcolchicinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ether I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
d I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
tartrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
TMCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O
NSC B_LOCATION/B_PROTEIN[GENE]
- O
36351 B_MEASURE
) O
was O
administered O
daily O
by O
mouth B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
71 B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
malignant B_DISEASE/B_LOCATION
lymphomas I_DISEASE/I_LOCATION
. O

Gene B_PERSON
transcripts I_PERSON
are O
detected O
on O
tissues B_DISEASE/B_LOCATION
such B_DISEASE/I_LOCATION
as O
bovine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
liver I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ammonia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
metabolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
base B_DISEASE/B_ORGANISM_FUNCTION
disorders I_DISEASE/I_ORGANISM_FUNCTION
in O
white B_BIO/B_PERSON
rats I_BIO/I_PERSON
. O

The O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
remote B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
renal B_DISEASE
adenocarcinomas I_DISEASE
. O

Vibrio O
cholerae O
iron O
transport O
: O
haem O
transport O
genes O
are O
linked O
to O
one O
of O
two O
sets O
of O
tonB B_GENE/B_BACTERIUM[BIO]
, O
exbB B_PROTEIN[GENE]/B_LOCATION
, O
exbD B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
predicted O
amino O
- O
acid O
sequence O
includes O
an O
N O
- O
terminal O
signal O
sequence O
of O
27 O
amino O
acids O
, O
a O
27 O
amino O
- O
acid O
pro O
- O
region O
, O
a O
251 O
amino O
- O
acid O
catalytic O
domain O
typical O
of O
a O
serine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protease I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
trypsin B_ENZYME[GENE]
- O
like O
specificity O
, O
and O
a O
C O
- O
terminal O
hydrophobic O
extension O
which O
is O
predicted O
to O
function O
as O
a O
membrane O
anchor O
. O

To O
examine O
the O
biochemical O
mechanism O
of O
Tax1 B_GENE/B_ORGANIZATION
transactivation O
, O
we O
have O
developed O
an O
in O
vitro O
transactivation O
assay O
in O
which O
wild O
- O
type O
Tax1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
able O
to O
specifically O
transactivate O
a O
polymerase B_GENE/B_SPECIES[BIO]
II B_GENE/I_SPECIES[BIO]
promoter O
through O
upstream O
Tax1 B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
responsive B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
elements B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O

Interestingly O
, O
PMA O
- O
, O
PDGF B_GENE
- O
, O
and O
serum O
- O
induced O
GHR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteolysis O
was O
associated O
with O
substantial O
decreases O
in O
GH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
activation O
of O
Janus B_GENE
kinase I_GENE
- I_GENE
2 I_GENE
, O
which O
were O
also O
prevented O
by O
IC3 O
. O

Thus O
, O
IF O
- O
laser O
therapy O
has O
a O
certain O
antioxidative O
effect O
by O
increasing O
SOD B_GENE
activity O
in O
RA O
patients O
' O
blood O
cells O
and O
reducing O
the O
production O
of O
highly O
reactive O
oxygen O
and O
nitrogen O
forms O
. O

reactive O
mesothelial O
cells O
, O
usually O
seen O
as O
exfoliated O
cells O
, O
were O
consistently O
strongly O
positive O
for O
alpha B_GENE
1 I_GENE
- I_GENE
antichymotrypsin I_GENE
and O
more O
variably O
for O
alpha B_GENE
1 I_GENE
- I_GENE
antitrypsin I_GENE
and O
lysozyme B_GENE
. O

Recombinant O
propeptides O
containing O
mutations O
of O
one O
of O
the O
three O
tryptophan O
residues O
were O
three O
orders O
of O
magnitude O
less O
effective O
as O
inhibitors O
of O
mature B_ENZYME[GENE]
cathepsin I_ENZYME[GENE]
S I_ENZYME[GENE]
than O
the O
wild O
- O
type O
propeptide O
. O

The O
highest B_MEASURE/B_DISEASE
incidence I_MEASURE/I_DISEASE
was O
observed O
for O
V B_OTHER/B_PROTEIN[GENE]
. O
alginolyticus B_BACTERIUM[BIO]/B_DISEASE
( O
92 B_MEASURE
- O
100 B_MEASURE
% I_MEASURE
) O
, O
followed O
by O
V B_OTHER/B_MEASURE
. O
parahaemolyticus B_BACTERIUM[BIO]/B_DISEASE
( O
67 B_MEASURE
- O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
V B_OTHER/B_LOCATION
. O
fluvialis B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O
34 B_MEASURE
- O
67 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
V B_OTHER/B_DISEASE
. O
vulnificus B_BACTERIUM[BIO]/B_DISEASE
( O
8 B_MEASURE
- O
17 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
V B_OTHER/B_LOCATION
. O
furnissii B_BACTERIUM[BIO]/B_DISEASE
( O
0 B_MEASURE
- O
17 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
V B_OTHER/B_MEASURE
. O
mimicus B_BACTERIUM[BIO]/B_DISEASE
( O
0 B_MEASURE
- O
17 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
V B_OTHER/B_MEASURE
. O
cholerae B_BACTERIUM[BIO]/B_DISEASE
non I_BACTERIUM[BIO]/I_DISEASE
- O
O1 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
( O
0 B_MEASURE
- O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Acute B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
did O
not O
increase O
the O
locomotor B_MEASURE
activity I_MEASURE
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
withdrawn O
for O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
day I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
withdrawal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
that O
in O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
after O
5 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
the O
increase B_DISEASE_ADJECTIVE[DISEASE]
was O
clearly O
larger B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
in O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
patients O
with O
active O
TB O
, O
cytokines O
that O
were O
elevated O
in O
serum O
were O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IL B_GENE
- I_GENE
10 I_GENE
. O

isolation O
and O
properties O
of O
Drosophila B_GENE
melanogaster I_GENE
ferritin I_GENE
- O
- O
molecular O
cloning O
of O
a O
cDNA O
that O
encodes O
one O
subunit O
, O
and O
localization O
of O
the O
gene O
on O
the O
third O
chromosome O
. O

We O
show O
that O
Fos B_GENE
down O
regulates O
several O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
early B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
c B_GENE
- I_GENE
fos I_GENE
, O
Egr B_GENE
- I_GENE
1 I_GENE
, O
and O
Egr B_GENE
- I_GENE
2 I_GENE
) O
after O
mitogenic O
stimulation O
. O

This O
study O
demonstrates O
a O
novel O
link O
between O
alterations O
in O
platelet B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PDGF B_GENE/B_LOCATION
) O
regulation O
of O
ornithine B_ENZYME[GENE]
decarboxylase I_ENZYME[GENE]
( O
ODC B_GENE/B_DISEASE
) O
expression O
during O
malignant O
conversion O
. O

circulating O
immune B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
determined O
by O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phagocytosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
immunofluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFI16 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
member O
of O
an O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
inducible O
family O
of O
mouse O
and O
human O
genes O
closely O
linked O
on O
syntenic O
regions O
of O
chromosome O
1 O
. O

In O
agreement O
with O
this O
model O
, O
elimination O
of O
the O
ADAM13 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O
developmental O
alterations O
attributable O
to O
ADAM13 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteolytic O
activity O
. O

Diabetic B_DISEASE_ADJECTIVE[DISEASE]
osteopathy I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
third O
GEF B_GENE/B_LOCATION
, O
GRP3 B_GENE
( O
KIAA0846 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
activated O
both O
Ras B_GENE/B_DISEASE
and O
Rap1 B_GENE
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B_GENE/B_ORGANIZATION
, O
GRP1 B_GENE
and O
GRP2 B_GENE
. O

A O
new O
simple O
identification O
of O
rheumatoid B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
nitrocellulose O
was O
developed O
that O
allows O
quantitative O
detection O
. O

Comparisons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
defective B_DISEASE/B_GENE
HTLV B_DISEASE/I_GENE
- O
I O
proviruses B_BIO/B_GENE
predict O
the O
mode B_LOCATION
of O
origin B_TIME[MEASURE]/B_DISEASE
and O
coding B_MEASURE/B_PERSON
potential I_MEASURE/I_PERSON
of O
internally O
deleted O
genomes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

reversal O
of O
biliary O
sphincter O
spasm O
with O
low O
dose O
glucagon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
operative O
cholangiography O
. O

Previous O
studies O
have O
shown O
that O
the O
IME1 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
required O
for O
sporulation O
and O
the O
expression O
of O
meiosis O
specific O
genes O
in O
Saccharomyces O
cerevisiae O
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
acquired O
immune B_DISEASE
deficiency I_DISEASE
syndrome I_DISEASE
( O
AIDS B_DISEASE
) O
in O
homosexual B_PERSON/B_BIO
males I_PERSON/I_BIO
with O
spindle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
endothelial B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
and O
with O
recrudescent B_DISEASE/B_PERSON
melioidosis I_DISEASE/I_PERSON
. O

Intrathecal O
injections O
of O
small O
volumes O
of O
the O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adrenoceptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O
, O
xylazine O
and O
clonidine O
, O
into O
the O
cervical O
region O
of O
the O
spinal O
cord O
of O
conscious O
unrestrained O
sheep O
produced O
a O
dose O
- O
dependent O
analgesia O
of O
the O
forelimbs O
as O
measured O
using O
a O
mechanical O
pressure O
device O
. O

Second O
, O
CGGA O
- O
containing O
sequences O
placed O
at O
- O
88 O
in O
the O
delta B_GENE/B_PERSON
MTV I_GENE/I_PERSON
- I_GENE/I_PERSON
CAT I_GENE/I_PERSON
reporter I_GENE/I_PERSON
plasmid O
conferred O
insulin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsiveness O
to O
the O
mammary B_GENE/B_DISEASE
tumor I_GENE/I_DISEASE
virus I_GENE/I_DISEASE
promoter I_GENE/I_DISEASE
. O

In O
the O
absence O
of O
c B_GENE
- I_GENE
fos I_GENE
gene I_GENE
expression O
, O
c B_GENE
- I_GENE
Fos I_GENE
protein I_GENE
appears O
to O
be O
replaced O
by O
proteins O
of O
Fos B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fra B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
1 I_PROTEIN[GENE]/I_LOCATION
) O
and O
ATF B_PERSON/B_GENE
family I_PERSON/I_GENE
( O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ATFa B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
dopamine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D1 B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopamine B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O
SCH O
23390 O
dose O
dependently O
( O
7 O
. O
5 O
- O
30 O
micrograms O
/ O
kg O
s O
. O
c O
. O
) O
antagonized O
the O
stimulant O
locomotor O
effect O
on O
both O
drugs O
but O
did O
not O
prevent O
their O
antiimmobility O
effect O
on O
the O
behavioral O
despair O
test O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
show B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
expression B_GENE
of O
the O
gene B_GENE
is O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O
23 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
and O
is O
induced O
rapidly O
at O
37 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
. O

characterization O
of O
Chlamydomonas O
reinhardtii O
zygote O
- O
specific O
cDNAs O
that O
encode O
novel O
proteins O
containing O
ankyrin B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
repeats O
and O
WW O
domains O
. O

adenomas B_DISEASE
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
gastrointestinal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
in O
all O
of O
the O
patients B_PERSON/B_BIO
: O
Vater B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' O
s B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
papilla I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
12 B_NUMBER[MEASURE]
, O
duodenum B_BODY_PART_OR_ORGAN_COMPONENT
- O
- O
nine B_NUMBER[MEASURE]
, O
and O
gastric B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
antrum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
seven B_NUMBER[MEASURE]
. O

Microenvironments B_LOCATION/B_ORGANIZATION
dominated O
by O
cyanobacteria B_BIO
( O
BPC B_PROTEIN[GENE]/B_LOCATION
) O
had O
a O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pH O
( O
pH O
7 B_MEASURE
- O
8 B_MEASURE
) O
than O
those O
dominated O
by O
lichen B_SPECIES[BIO]/B_DISEASE
( O
LTL B_LOCATION/B_PROTEIN[GENE]
) O
( O
pH B_MEASURE
4 I_MEASURE
. O
5 B_MEASURE
- O
5 B_MEASURE
. O
5 B_MEASURE
) O
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
64 B_MEASURE
uncomplicated I_MEASURE
Type I_MEASURE
- O
2 B_PERSON/B_MEASURE
diabetic I_PERSON/I_MEASURE
individuals I_PERSON/I_MEASURE
of O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
middle I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
class I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
rich B_DISEASE/B_MEASURE
socio I_DISEASE/I_MEASURE
- O
economic B_MEASURE/B_LOCATION
status B_MEASURE/I_LOCATION
were O
studied O
. O

A O
drop B_DISEASE/B_LOCATION
of O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
placed O
on O
the O
dissected O
plantar B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
proximal I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
to O
the O
stimulating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
electrodes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
after O
recording O
control B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
fibre B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
volley B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
sciatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
C B_PROTEIN[GENE]/B_MEASURE
- O
fibre B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
evoked B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflex B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
discharge B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
flexor B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
motoneurons I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
) O
. O

Basic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helix I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loop I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
helix I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
act O
at O
the O
E O
- O
box O
within O
the O
serum O
response O
element O
of O
the O
c B_GENE
- I_GENE
fos I_GENE
promoter I_GENE
to O
influence O
hormone O
- O
induced O
promoter O
activation O
in O
Sertoli O
cells O
. O

Using O
yeast O
two O
- O
hybrid O
screening O
, O
we O
isolated O
histone B_GENE
H3 I_GENE
as O
an O
interacting O
factor O
of O
CIA B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Co B_LOCATION
, O
Cu B_LOCATION/B_TIME[MEASURE]
, O
Fe B_LOCATION/B_MEASURE
, O
Hg B_LOCATION
, O
Mn B_LOCATION/B_PERSON
, O
Sb B_LOCATION/B_PERSON
, O
Se B_LOCATION/B_PERSON
and O
Zn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
IAEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
milk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
dry B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O
standard B_MEASURE/B_LOCATION
A I_MEASURE/I_LOCATION
- O
11 B_MEASURE/B_LOCATION
were O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
evaluated O
with O
the O
help B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
instrumental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
radiochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
neutron I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
activation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
NAA B_LOCATION/B_DISEASE
) O
. O

Gallstone B_DISEASE
- O
formation B_DISEASE
has O
traditionally O
been O
attributed O
to O
supersaturation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Sixteen B_TIME[MEASURE]/B_LOCATION
patients I_TIME[MEASURE]/I_LOCATION
on O
maintenance B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hemodialysis B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
either O
cuprophane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
8 B_MEASURE
) O
or O
polymethylmethacrylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PMMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
n O
= O
8 B_MEASURE
) O
membranes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
then O
switched O
to O
the O
opposite B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
during O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Gene O
expression O
is O
in O
part O
controlled O
by O
chromatin O
remodeling O
factors O
and O
the O
acetylation O
state O
of O
nucleosomal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Each O
patient B_PERSON/B_ORGANIZATION
was O
seen O
for O
5 B_NUMBER[MEASURE]/B_LOCATION
to O
13 B_MEASURE
postsurgical I_MEASURE
maintenance I_MEASURE
visits I_MEASURE
. O

Furthermore O
, O
Grap B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
associated O
with O
a O
Ras B_GENE
guanine I_GENE
nucleotide I_GENE
exchange I_GENE
factor I_GENE
mSos1 I_GENE
, O
primarily O
through O
its O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
terminal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SH3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
domain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Recurrent B_DISEASE/B_MEASURE
infections I_DISEASE/I_MEASURE
, O
episodic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphopenia I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
impaired B_DISEASE
cellular I_DISEASE
immunity I_DISEASE
. O

After O
3 O
months O
of O
intervention O
, O
sustained O
physical O
training O
was O
associated O
with O
the O
decrease O
of O
FVII B_GENE/B_DISEASE
and O
PAI B_GENE
- I_GENE
1 I_GENE
levels O
. O

Thirty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
had O
elevated O
titers B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
above O
1 B_MEASURE
: O
20 B_MEASURE
dilution I_MEASURE
) O
. O

Xa4 B_GENE/B_DISEASE
is O
a O
dominantly O
inherited O
rice O
gene O
that O
confers O
resistance O
to O
Philippine O
race O
1 O
of O
the O
bacterial O
blight O
pathogen O
Xanthomonas O
oryzae O
pv O
. O
oryzae O
in O
rice O
. O

In O
uraemic B_MEASURE/B_LOCATION
patients I_MEASURE/I_LOCATION
, O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maximum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentrations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
after O
a O
single B_MEASURE
7 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
IV I_MEASURE
dose I_MEASURE
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
buthionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoximine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BSO B_LOCATION/B_DISEASE
) O
and O
disulfiram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
DSF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
on O
the O
urotoxicity B_DISEASE
induced O
by O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CPA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
examined O
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
the O
previously O
mapped O
structural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
encoding O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phage B_PROTEIN[GENE]/B_BACTERIUM[BIO]
LL I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O
H B_MEASURE/B_OTHER
were O
included O
in O
the O
sequence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
a O
longer O
- O
714 O
to O
+ O
78 O
fragment O
of O
the O
PBGD B_GENE
promoter I_GENE
is O
used O
, O
the O
- O
70 O
GATA O
mutant O
still O
displays O
erythroid O
- O
specific O
activity O
and O
is O
cis O
- O
activated O
by O
the O
5 B_GENE
' I_GENE
HS I_GENE
- I_GENE
2 I_GENE
enhancer I_GENE
, O
while O
the O
- O
100 O
CCACC O
mutant O
is O
completely O
inactive O
in O
the O
absence O
or O
in O
the O
presence O
of O
the O
5 B_GENE
' I_GENE
HS I_GENE
- I_GENE
2 I_GENE
enhancer I_GENE
. O

surprisingly O
, O
in O
adult O
animals O
, O
the O
suprabasal O
expression O
of O
dnRXR B_GENE
alpha I_GENE
significantly O
reduced O
the O
ability O
of O
topically O
applied O
tRA O
to O
stimulate O
proliferation O
of O
undifferentiated O
keratinocytes O
in O
the O
basal O
layer O
of O
epidermis O
. O

In O
many B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
other B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
contractile B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
protein B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
gene B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
families B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O
cardiac B_GENE/B_PERSON
isoforms I_GENE/I_PERSON
are O
expressed O
early O
in O
skeletal B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
are O
later O
repressed B_DISEASE_ADJECTIVE[DISEASE]
. O

1995 B_NUMBER[MEASURE]
. O

For O
il8ra B_GENE
, O
it O
is O
formed O
from O
two O
exons O
, O
whereas O
for O
il8rb B_GENE
, O
seven O
distinct O
neutrophil O
mRNAs O
are O
formed O
by O
alternative O
splicing O
of O
11 O
exons O
. O

endocarditis B_DISEASE/B_GENE
remains O
a O
life B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
threatening O
disease B_DISEASE
with O
substantial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
morbidity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
mortality B_DISEASE/B_MEASURE
. O

The O
gene O
encoding O
the O
cellulase B_ENZYME[GENE]/B_BACTERIUM[BIO]
( O
Avicelase B_LOCATION/B_BIO
) O
Cel1 B_ENZYME[GENE]/B_LOCATION
from O
Streptomyces O
reticuli O
and O
analysis O
of O
protein O
domains O
. O

From O
this O
comparison O
of O
AA O
sequences O
, O
the O
ATPK7 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
considered O
to O
be O
a O
member O
of O
a O
novel O
subfamily O
of O
Ser B_GENE/B_BIO
/ I_GENE/I_BIO
Thr I_GENE/I_BIO
PKs I_GENE/I_BIO
in O
plants O
. O

Of O
these O
, O
23 B_MEASURE
( O
13 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
due B_DISEASE_ADJECTIVE[DISEASE]
to O
GIB B_DISEASE/B_PERSON
( O
Upper B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
GIB I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
= O
19 B_MEASURE
, O
Lower B_MEASURE/B_LOCATION
GIB I_MEASURE/I_LOCATION
= O
4 B_MEASURE
) O
. O

The O
E B_OTHER/B_GENE
. O
multilocularis B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
Mongolian B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gerbil I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
replace O
the O
natural B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
canid B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
hosts B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
as O
a O
new B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
way I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
obtain O
infective B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
eggs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
analyze O
host B_SPECIES[BIO]
- O
parasite B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

E1 B_GENE/B_NUMBER[MEASURE]
recognition O
sequences O
in O
the O
bovine O
papillomavirus O
type O
1 O
origin O
of O
DNA O
replication O
: O
interaction O
between O
half O
sites O
of O
the O
inverted O
repeats O
. O

We O
found O
that O
secretion O
of O
chitinolytic O
enzymes O
by O
cultured O
L O
. O
major O
parasites O
is O
inhibited O
by O
blood O
or O
hemoglobin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
hence O
these O
enzymes O
are O
apparently O
absent O
from O
the O
blood O
- O
fed O
infected O
flies O
, O
where O
the O
cardiac O
valve O
appears O
undamaged O
. O

patients O
in O
the O
mucinous O
cyst O
group O
had O
significantly O
lower O
CA B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
125 I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
cystic O
fluid O
levels O
compared O
with O
women O
with O
endometriomas O
and O
dermoids O
( O
P O
& O
Lt O
; O
0 O
. O
05 O
) O
. O

SATB1 B_GENE
interacted O
with O
CDP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
through O
its O
DNA O
- O
binding O
domain O
, O
as O
demonstrated O
by O
glutathione B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GST B_LOCATION/B_GENE
) O
pull O
- O
down O
assays O
. O

Plasma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O
in O
pinealectomized O
ewes O
receiving O
melatonin O
treatment O
and O
in O
pineal O
intact O
ewes O
maintained O
under O
a O
non O
- O
24 O
- O
hour O
photoperiod O
. O

It O
is O
targeted O
to O
peroxisomes B_BIO/B_GENE
when O
expressed O
in O
mammalian B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
yeast B_BIO
. O

The O
transcriptional O
start O
site O
, O
identified O
by O
primer O
extension O
and O
S1 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O
, O
is O
34 O
nt O
upstream O
of O
the O
translation O
initiation O
codon O
. O

Nonlinearities B_DISEASE_ADJECTIVE[DISEASE]
in O
cochlear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
hydrodynamics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Electronic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
structure I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
and O
optical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
B12O2 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
crystal I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Spongiosa B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
regeneration B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
millipore B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chamber I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
predicted O
5 O
' O
and O
3 O
' O
ends O
of O
the O
transcript O
are O
in O
very O
good O
agreement O
with O
the O
previously O
determined O
size O
of O
the O
LEU3 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
message O
. O

This O
cDNA O
corresponded O
to O
FGF B_GENE
- I_GENE
binding I_GENE
protein I_GENE
( O
FGF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
a O
secreted O
protein O
previously O
shown O
to O
bind O
acidic O
and O
basic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
FGF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
modulate O
their O
activities O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
replicative B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
intermediates B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
shows O
that O
plasmid B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
YRp7 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
contains O
the O
chromosomal B_GENE/B_LOCATION
replicator I_GENE/I_LOCATION
ARS1 I_GENE/I_LOCATION
, O
initiates O
bidirectional B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
replication I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
a O
100 B_LOCATION
BP I_LOCATION
region I_LOCATION
within O
the O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
for O
autonomous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replication B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

Such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O
that O
there O
are O
no O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
BMR B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
age B_MEASURE/B_PERSON
- O
and O
weight B_MEASURE/B_PERSON
- O
matched O
Asian B_PERSON/B_LOCATION
Indian I_PERSON/I_LOCATION
males I_PERSON/I_LOCATION
, O
other B_PERSON/B_LOCATION
tropical I_PERSON/I_LOCATION
populations I_PERSON/I_LOCATION
and O
Americans B_PERSON/B_SPORT[ENT]
. O

Rewarding O
properties O
of O
methylphenidate O
: O
sensitization O
by O
prior O
exposure O
to O
the O
drug O
and O
effects O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O
. O

Similar O
to O
what O
was O
observed O
for O
P O
. O
putida O
, O
a O
psrA B_BACTERIUM[BIO]/B_GENE
null O
mutant O
of O
P O
. O
aeruginosa O
also O
showed O
a O
90 O
% O
reduction O
in O
rpoS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
; O
both O
mutants O
could O
be O
complemented O
for O
rpoS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O
when O
the O
psrA B_GENE/B_BACTERIUM[BIO]
gene I_GENE/I_BACTERIUM[BIO]
was O
provided O
in O
trans O
. O

psrA B_PERSON/B_BIO
mutants I_PERSON/I_BIO
of O
both O
Pseudomonas O
species O
lost O
the O
ability O
to O
induce O
rpoS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
at O
stationary O
phase O
, O
but O
they O
retained O
the O
ability O
to O
produce O
quorum O
- O
sensing O
autoinducer O
molecules O
. O

The O
role O
of O
the O
putative O
C2 B_MEASURE/B_PROTEIN[GENE]
domain O
of O
Nedd4 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
elucidated O
. O

ZF87 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
binds O
the O
ME1a1 O
element O
with O
higher O
affinity O
than O
the O
ME1a2 O
element O
. O

We O
found O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
evidenced O
by O
the O
major B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
urinary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
metabolite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
3 B_MEASURE
- O
dinorthromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
B2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
the O
oestrogen B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
group I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
as O
compared O
to O
the O
orchidectomy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Multivariable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
that O
mean B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
blood I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
glucose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
level I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
the O
first B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
days I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
002 B_MEASURE
) O
, O
obesity B_TIME[MEASURE]/B_DISEASE
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
002 B_MEASURE
) O
, O
and O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
internal B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
mammary B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
artery B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
02 B_MEASURE
) O
were O
all O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictors B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
deep B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wound I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
the O
precise O
function O
of O
DNA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
DNA O
double O
- O
strand O
break O
repair O
is O
not O
known O
. O

This O
new O
receptor O
, O
TOR B_GENE/B_DISEASE
( O
thymus B_PROTEIN[GENE]/B_MEASURE
orphan I_PROTEIN[GENE]/I_MEASURE
receptor I_PROTEIN[GENE]/I_MEASURE
) O
, O
is O
most O
closely O
related O
in O
both O
its O
DNA O
- O
binding O
domain O
and O
ligand O
- O
binding O
domain O
, O
90 O
% O
and O
53 O
% O
, O
respectively O
, O
to O
ROR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
RZR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
clusters O
with O
these O
two O
receptors O
and O
RZR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
beta I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
a O
phylogenetic O
tree O
, O
when O
both O
the O
DNA O
- O
binding O
domain O
and O
the O
ligand O
- O
binding O
domain O
sequences O
of O
nuclear O
receptors O
are O
compared O
. O

In O
this O
report O
, O
we O
have O
examined O
whether O
PTP1B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects O
transformation O
induced O
by O
p210 B_GENE/B_LOCATION
bcr I_GENE/I_LOCATION
- O
abl B_GENE/B_DISEASE
. O

S1 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O
of O
the O
RNA O
from O
a O
number O
of O
QT6 O
- O
LD O
clones O
gave O
similar O
results O
, O
indicating O
that O
the O
LD O
population O
was O
composed O
of O
viruses O
with O
similar O
but O
not O
identical O
deletion O
endpoints O
. O

Association O
of O
Smads B_GENE
with O
lymphoid B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhancer B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
T B_MEASURE/B_GENE
cell I_MEASURE/I_GENE
- I_MEASURE/I_GENE
specific I_MEASURE/I_GENE
factor I_MEASURE/I_GENE
mediates O
cooperative O
signaling O
by O
the O
transforming B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
wnt B_GENE
pathways O
. O

The O
three O
OAS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
flanked O
by O
markers B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WI I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10614 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
D12S2293 B_GENE/B_MEASURE
( O
tel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
are O
contained O
within O
three O
sets O
of O
overlapping O
cosmid O
clones O
. O

22 O
. O
6 O
% O
of O
patients O
were O
found O
to O
be O
positive O
at O
histology O
in O
the O
corpus O
mucosa O
; O
all O
but O
one O
of O
these O
patients O
had O
elevated O
circulating O
IgG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
H O
. O
pylori O
( O
Group O
C O
) O
. O

Rottlerin O
also O
inhibited O
the O
activation O
of O
MAP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MEK B_GENE/B_LOCATION
) O
in O
response O
to O
activated O
Raf B_GENE/B_DISEASE
, O
but O
had O
no O
effect O
upon O
c B_GENE
- I_GENE
Raf I_GENE
activity O
or O
ERK B_GENE/B_DISEASE
activation O
by O
activated O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Quasidiatomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Ly B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
alpha B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
producing O
H2 B_LOCATION
+ O
- O
Ne B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
collisions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
keV B_LOCATION/B_MEASURE
energies I_LOCATION/I_MEASURE
. O

The O
NH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_MEASURE/B_LOCATION
) O
- O
terminus B_LOCATION/B_MEASURE
of O
all O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
a O
POZ B_MEASURE/B_PROTEIN[GENE]
domain I_MEASURE/I_PROTEIN[GENE]
, O
a O
conserved B_LOCATION
120 I_LOCATION
amino I_LOCATION
acid I_LOCATION
motif I_LOCATION
involved O
in O
transcriptional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
repression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
dimerization B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

The O
isolation O
of O
crt5 B_GENE/B_MEASURE
- I_GENE/I_MEASURE
262 I_GENE/I_MEASURE
, O
an O
additional O
cdc B_GENE/B_PERSON
allele I_GENE/I_PERSON
of O
POL1 B_GENE/B_DISEASE
/ O
CDC17 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggests O
for O
the O
first O
time O
that O
directly O
blocking O
DNA O
replication O
can O
provide O
a O
signal O
to O
induce O
the O
DNA O
damage O
response O
. O

crt2 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
show O
a O
defect O
in O
basal O
level O
expression O
of O
RNR1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lacZ B_GENE
reporter O
constructs O
. O

Greer B_PERSON/B_COLOR
, O
and O
L B_OTHER/B_PROTEIN[GENE]
. O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
prospectively O
studied O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PRL B_PROTEIN[GENE]/B_LOCATION
) O
elevation O
after O
different O
types O
of O
documented O
seizures O
in O
17 O
patients O
. O

However O
, O
both O
peptides O
1 O
- O
49 O
and O
63 O
- O
87 O
bound O
to O
PDE B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
solid O
- O
phase O
binding O
assay O
. O

values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
K1 B_PROTEIN[GENE]/B_LOCATION
and O
VD B_DISEASE/B_PROTEIN[GENE]
were O
significantly O
increased O
in O
the O
tumour B_TIME[MEASURE]/B_DISEASE
tissue I_TIME[MEASURE]/I_DISEASE
. O

The O
mutation O
also O
preferentially O
limits O
( O
compared O
with O
total O
protein O
synthesis O
) O
translation O
of O
an O
induced O
gene O
that O
depends O
on O
five O
AGA O
codons O
, O
i O
. O
e O
. O
, O
the O
lambda B_GENE/B_PERSON
cI I_GENE/I_PERSON
repressor I_GENE/I_PERSON
gene I_GENE/I_PERSON
. O

Five O
RNA O
transcripts O
of O
about O
1 O
. O
2 O
to O
1 O
. O
7 O
kilobases O
were O
mapped O
to O
a O
part O
of O
the O
genome O
of O
insect O
iridescent O
virus O
type O
6 O
( O
Chilo O
iridescent O
virus O
; O
CIV O
) O
between O
genome O
coordinates O
0 O
. O
832 O
and O
0 O
. O
856 O
within O
the O
EcoRI B_GENE/B_SPECIES[BIO]
DNA B_GENE/I_SPECIES[BIO]
fragment B_GENE/I_SPECIES[BIO]
F B_GENE/I_SPECIES[BIO]
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
similar I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
must O
be O
found O
before O
it O
is O
established O
that O
the O
colloid B_DISEASE/B_BIO
cyst I_DISEASE/I_BIO
is O
part B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
nevoid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
basal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

portions O
of O
the O
3 O
' O
- O
coding O
and O
3 O
' O
- O
untranslated O
regions O
were O
found O
to O
be O
missing O
from O
the O
7 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
topo I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
Northern O
blot O
analysis O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
a O
double B_DISEASE_ADJECTIVE[DISEASE]
mutant I_DISEASE_ADJECTIVE[DISEASE]
( O
E482A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
D489A B_MEASURE/B_PROTEIN[GENE]
) O
which O
removed O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charges B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O
one B_LOCATION/B_ENT
side I_LOCATION/I_ENT
of O
the O
helix B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
negligible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
fusion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

A O
GTP O
/ O
GDP O
exchange O
assay O
was O
used O
to O
assess O
the O
potential O
role O
of O
Ras B_GENE/B_DISEASE
in O
the O
pathway O
leading O
to O
ERK B_GENE
phosphorylation O
; O
DADLE O
failed O
to O
stimulate O
GTP O
/ O
GDP O
exchange O
in O
comparison O
to O
PMA O
. O

Phenotypic O
analysis O
demonstrates O
that O
trio B_GENE/B_ENT
and O
Abl B_GENE/B_PERSON
cooperate O
in O
regulating O
axon O
outgrowth O
in O
the O
embryonic O
central O
nervous O
system O
( O
CNS O
) O
. O

Recombinant B_PERSON/B_GENE
caspases I_PERSON/I_GENE
are O
typically O
produced O
in O
Escherichia O
coli O
expression O
systems O
with O
the O
attendant O
problems O
of O
solubilization O
, O
re O
- O
folding O
and O
activation O
of O
the O
protease O
. O

The O
gene O
encoding O
rat O
peptidylglycine B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amidating I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monooxygenase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PAM B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
contains O
26 O
protein O
- O
coding O
exons O
. O

This O
bound O
[ O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O
iloprost B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
high B_GENE
affinity I_GENE
and O
stimulated B_DISEASE_ADJECTIVE[DISEASE]
cAMP I_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
when O
exposed O
to O
agonist O
. O

Structure B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
connective B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stroma I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
epididymis B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
zebu B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Free O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
deficiency O
in O
acute O
ischemic O
stroke O
. O

In O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
papers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
staging B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
melanoma B_DISEASE
was O
critically O
analyzed O
, O
and O
many B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shortcomings I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
identified O
. O

reproduction B_TIME[MEASURE]/B_PERSON
and O
maternal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
the O
rat B_BIO/B_PERSON
when O
thiamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
intake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
is O
limited O
. O

Total B_MEASURE/B_LOCATION
meso B_MEASURE/I_LOCATION
- O
pore B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
and O
surface B_MEASURE/B_LOCATION
area I_MEASURE/I_LOCATION
ranged O
from O
0 B_MEASURE/B_LOCATION
. O
004 B_MEASURE
- O
0 B_MEASURE
. O
08 B_MEASURE
cm3 I_MEASURE
g I_MEASURE
( O
- O
1 B_MEASURE
) O
and O
from O
0 B_MEASURE
. O
33 B_MEASURE
- O
6 B_MEASURE
. O
9 B_MEASURE
m2 I_MEASURE
g I_MEASURE
( O
- O
1 B_MEASURE
) O
respectively O
, O
accounting O
for O
up O
33 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
Bet B_MEASURE/B_LOCATION
surface I_MEASURE/I_LOCATION
area I_MEASURE/I_LOCATION
. O

The O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
precursor O
p100 B_GENE
( O
lyt B_GENE/B_DISEASE
- I_GENE/I_DISEASE
10 I_GENE/I_DISEASE
, O
p97 B_MEASURE/B_GENE
, O
p98 B_MEASURE/B_GENE
) O
generates O
after O
proteolytic O
processing O
a O
52 O
kDa O
subunit O
, O
which O
can O
bind O
to O
kappa B_GENE
B I_GENE
- I_GENE
motifs I_GENE
. O

conclusion O
: O
The O
biodistribution O
of O
111In O
IgG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
similar O
to O
that O
of O
99mTc O
- O
HMPAO O
- O
labeled O
leukocytes O
. O

Based O
on O
29 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
determinations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O
sinigrin B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
analyzed O
under O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
accuracy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
total B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucosinolate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
94 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
. O

Receptor B_GENE/B_PERSON
- I_GENE/I_PERSON
type I_GENE/I_PERSON
serine I_GENE/I_PERSON
/ I_GENE/I_PERSON
threonine I_GENE/I_PERSON
kinases I_GENE/I_PERSON
( O
RSKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
have O
been O
organized O
into O
two O
distinct O
classes O
known O
as O
types O
I O
and O
II O
on O
the O
basis O
of O
sequence O
similarity O
. O

In O
a O
previous O
study O
of O
transforming B_GENE
growth I_GENE
factor I_GENE
- I_GENE
beta1 I_GENE
- O
mediated O
inhibition O
of O
the O
cyclin B_GENE
A I_GENE
promoter I_GENE
, O
we O
mapped O
the O
inhibitory O
effect O
to O
the O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
in O
the O
present O
study O
of O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O
, O
functional O
analysis O
by O
transient O
transfection O
showed O
that O
inhibition O
of O
the O
cyclin B_GENE
A I_GENE
promoter I_GENE
persisted O
despite O
mutation O
of O
the O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
NF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
Y I_GENE/I_LOCATION
, O
or O
CDE O
elements O
. O

The O
RsmA B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
like O
its O
parent O
, O
produces O
N O
- O
( O
3 O
- O
oxohexanoyl O
) O
- O
L O
- O
homoserine O
lactone O
( O
HSL O
) O
, O
a O
starvation O
/ O
cell O
density O
- O
sensing O
signal O
required O
for O
extracellular O
enzyme O
production O
. O

The O
inactive B_GENE
X I_GENE
allele I_GENE
, O
however O
, O
is O
hypermethylated O
in O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
presumably O
reflecting O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inactivation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
become O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
gene B_MEASURE/B_ORGANISM_FUNCTION
dosage B_MEASURE/I_ORGANISM_FUNCTION
in O
expressing O
lineages B_BIO/B_DISEASE
. O

Intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
viral B_DISEASE
hepatitis I_DISEASE
. O

Also O
, O
the O
RVW B_DISEASE/B_PROTEIN[GENE]
hypertrophy B_DISEASE/I_PROTEIN[GENE]
, O
the O
IVS B_DISEASE/B_LOCATION
hypertrophy I_DISEASE/I_LOCATION
, O
and O
the O
RV B_DISEASE/B_MEASURE
high I_DISEASE/I_MEASURE
pressure I_DISEASE/I_MEASURE
load I_DISEASE/I_MEASURE
to O
the O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
through O
the O
IVS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O
be O
related O
to O
the O
small B_DISEASE/B_PROTEIN[GENE]
LV B_DISEASE/I_PROTEIN[GENE]
, O
high B_DISEASE/B_PROTEIN[GENE]
EF B_DISEASE/I_PROTEIN[GENE]
, O
and O
abnormal B_DISEASE/B_PROTEIN[GENE]
two B_DISEASE/I_PROTEIN[GENE]
chamber B_DISEASE/I_PROTEIN[GENE]
inflow B_DISEASE/I_PROTEIN[GENE]
in O
the O
PS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
before O
BV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Analysis O
of O
the O
DNA O
- O
binding O
and O
transcriptional O
activation O
functions O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
pattern O
of O
expression O
and O
differential O
processing O
suggests O
a O
role O
for O
inrpk1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
some O
aspect O
of O
SD O
photoperiodic O
- O
induced O
flowering O
in O
morning O
glory O
. O

Progressive O
immunodeficiency O
in O
a O
patient O
with O
IgA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O
. O

RMR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
positively O
correlated O
with O
TEF B_PROTEIN[GENE]/B_LOCATION
( O
r O
= O
0 B_MEASURE
. O
613 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
and O
net B_PROTEIN[GENE]/B_DISEASE
TEF I_PROTEIN[GENE]/I_DISEASE
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
. O
648 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
005 B_MEASURE
) O
in O
the O
luteal B_BODY_PART_OR_ORGAN_COMPONENT
but O
not O
the O
follicular B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
phase I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
. O

ESR B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Er3 B_LOCATION/B_MEASURE
+ O
in O
SmB6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
single I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
crystals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
dynamic B_PERSON/B_LOCATION
Jahn I_PERSON/I_LOCATION
- O
Teller B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
a O
mixed B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
valence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compound I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
N O
- O
terminal O
exon1 O
had O
no O
homology O
at O
the O
amino O
acid O
level O
with O
NGFI B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
mammalian O
homologue O
. O

This O
paper O
describes O
a O
longitudinal O
study O
in O
which O
clinical O
parameters O
and O
aspartate B_ENZYME[GENE]
aminotransferase I_ENZYME[GENE]
( O
AST B_GENE/B_ORGANIZATION
) O
in O
gingival O
crevicular O
fluid O
( O
GCF O
) O
were O
monitored O
bimonthly O
over O
a O
6 O
- O
12 O
months O
period O
in O
970 O
sites O
from O
7 O
treated O
periodontitis O
patients O
. O

We O
conclude O
from O
these O
observations O
that O
the O
cTnC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ile I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
composite O
enhancer O
that O
functions O
through O
the O
combined O
interactions O
of O
at O
least O
five O
regulatory O
elements O
and O
their O
cognate O
binding O
factors O
: O
three O
or O
four O
E O
- O
boxes O
, O
a O
MEF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
MEF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
1 B_NUMBER[MEASURE]/B_PERSON
) O
fitting O
first B_SEQUENCE[MEASURE]
- O
and O
second B_SEQUENCE[MEASURE]/B_LOCATION
- O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
autoregressive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
AR1 B_PROTEIN[GENE]/B_DISEASE
and O
AR2 B_PROTEIN[GENE]/B_DISEASE
) O
and O
2 B_SEQUENCE[MEASURE]
) O
obtaining O
the O
power B_MEASURE/B_PERSON
spectra I_MEASURE/I_PERSON
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
fast B_DISEASE/B_MEASURE
- O
Fourier B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transform B_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
identified O
Tyr O
( O
112 O
) O
and O
Leu O
( O
175 O
) O
within O
the O
RNA O
- O
binding O
domain O
of O
the O
U1 B_GENE
70K I_GENE
protein I_GENE
to O
be O
cross O
- O
linked O
to O
G O
( O
28 O
) O
and O
U O
( O
30 O
) O
in O
stem O
- O
loop O
I O
, O
respectively O
. O

Kudzu B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
extract I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
shows I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
potential I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
for O
moderating O
alcohol B_DISEASE_ADJECTIVE[DISEASE]
abuse I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
the O
data O
suggest O
an O
immunological O
non O
- O
responsiveness O
to O
enterotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
in O
a O
considerable O
portion O
of O
the O
patients O
. O

BCV B_PERSON/B_GENE
mRNAs I_PERSON/I_GENE
5 I_PERSON/I_GENE
and I_PERSON/I_GENE
5 I_PERSON/I_GENE
- I_PERSON/I_GENE
1 I_PERSON/I_GENE
appear O
to O
be O
used O
for O
the O
synthesis O
of O
the O
12 O
. O
7 O
- O
and O
9 O
. O
5 O
- O
kDa O
proteins O
, O
respectively O
, O
which O
demonstrates O
a O
pattern O
of O
expression O
strikingly O
different O
from O
that O
utilized O
by O
MHV O
. O

disaster B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
medicine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O

The O
longest B_PROTEIN[GENE]/B_DISEASE
S1 I_PROTEIN[GENE]/I_DISEASE
- O
S2 B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
at O
which O
S2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
failed O
to O
capture O
( O
effective B_MEASURE/B_DISEASE
refractory B_MEASURE/I_DISEASE
period B_MEASURE/I_DISEASE
) O
was O
longer B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O
5 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_NUMBER[MEASURE]
. O
2 B_MEASURE/B_PERSON
msec I_MEASURE/I_PERSON
at O
twice B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
threshold I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
0 B_MEASURE/B_LOCATION
. O
05 B_TIME[MEASURE]
less I_TIME[MEASURE]
than O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
10 B_MEASURE
) O
and O
5 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
. O
5 B_MEASURE/B_PERSON
msec I_MEASURE/I_PERSON
at O
5 B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
threshold I_MEASURE/I_LOCATION
stimulation I_MEASURE/I_LOCATION
( O
p B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
when O
the O
basic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
extrastimuli B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
delivered O
to O
separate B_PERSON/B_PROTEIN[GENE]
sites I_PERSON/I_PROTEIN[GENE]
. O

The O
use O
of O
specific O
somatic O
cell O
hybrids O
have O
allowed O
us O
to O
locate O
the O
YAC O
contig O
telomeric O
to O
the O
D3F15S2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
a O
region O
which O
is O
frequently O
deleted O
in O
lung O
carcinomas O
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
without O
polarization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
with O
cathodic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anodic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polarization I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
adsorbent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Chronic B_DISEASE
active I_DISEASE
hepatitis I_DISEASE
and O
cirrhosis B_DISEASE
of O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

This O
regulation O
is O
mediated O
by O
several O
kinases O
that O
phosphorylate O
specific O
residues O
in O
the O
different O
functional O
domains O
of O
the O
p53 B_GENE
molecule I_GENE
. O

These O
data O
show O
that O
the O
processing O
of O
specific O
target O
transcripts O
, O
such O
as O
the O
P B_GENE/B_BIO
- I_GENE/I_BIO
element I_GENE/I_BIO
mRNA I_GENE/I_BIO
, O
is O
regulated O
by O
a O
functional O
PSI B_GENE/B_DISEASE
- O
U1 B_GENE
snRNP O
interaction O
in O
Drosophila O
. O

Effect B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cooling O
rates B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
unrestrained B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
four O
calves O
given O
Haemonchus O
contortus O
larvae O
, O
the O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pepsinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O
rose O
quickly O
to O
reach O
a O
mean O
of O
3 O
. O
5 O
iu O
tyrosine O
on O
day O
14 O
after O
infection O
. O

These O
results O
strongly O
suggest O
that O
HSV O
- O
1 O
infection O
inhibits O
host O
cell O
splicing O
through O
the O
action O
of O
ICP27 B_GENE
. O

The O
T B_PROTEIN[GENE]/B_MEASURE
( O
CCO2 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
related O
to O
the O
PCO2 B_MEASURE
by O
a O
Pearson B_MEASURE
product I_MEASURE
coefficient I_MEASURE
of O
0 B_MEASURE
. O
79 B_MEASURE
( O
p B_MEASURE
< I_MEASURE
. O
0005 B_MEASURE
) O
, O
with O
a O
mean B_MEASURE/B_LOCATION
difference I_MEASURE/I_LOCATION
of O
1 B_MEASURE
. O
94 B_MEASURE
( O
T B_PROTEIN[GENE]/B_OTHER
( O
CCO2 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
> O
P B_OTHER/B_PROTEIN[GENE]
( O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
and O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
of O
- O
0 B_MEASURE
. O
12 B_MEASURE
to O
4 B_NUMBER[MEASURE]
. O
07 B_MEASURE
. O

transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B_GENE/B_LOCATION
- O
Crk B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B_GENE/B_MEASURE
, O
p110 B_GENE/B_MEASURE
, O
and O
p70 B_GENE/B_MEASURE
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Urease B_BACTERIUM[BIO]/B_ENZYME[GENE]
activity O
, O
judged O
as O
the O
amount O
of O
ammonia O
production O
from O
urea O
, O
could O
be O
measured O
at O
25 O
ng O
per O
tube O
( O
S O
/ O
N O
= O
1 O
. O
5 O
) O
with O
Jack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
bean I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
meal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
urease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O

Here O
, O
we O
provide O
direct O
evidence O
that O
the O
meiotic O
defect O
caused O
by O
either O
unregulated O
cAPK B_GENE
activity O
or O
unregulated O
ran1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
is O
due O
to O
inability O
to O
induce O
transcription O
of O
the O
mei2 B_GENE
+ I_GENE
gene I_GENE
, O
which O
is O
required O
for O
meiotic O
initiation O
. O

optical O
rotation O
of O
the O
second O
harmonic O
radiation O
from O
retinal O
in O
bacteriorhodopsin B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monomers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
Langmuir O
- O
Blodgett O
film O
: O
evidence O
for O
nonplanar O
retinal O
structure O
. O

ultrasonography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
a O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
may O
replace O
arthrography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
K562 O
cells O
, O
using O
the O
bicistronic O
vector O
, O
selection O
with O
colchicine O
led O
to O
at O
least O
20 O
- O
fold O
higher O
expression O
of O
the O
MDR1 B_GENE
gene I_GENE
product I_GENE
than O
did O
selection O
with O
G418 O
, O
suggesting O
that O
the O
stringent O
MDR1 B_GENE
selection O
system O
is O
very O
efficient O
for O
obtaining O
overexpression O
of O
foreign O
genes O
. O

In O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behaviors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
investigated O
in O
relation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
maintaining O
mobility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
during O
4 B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
up B_LOCATION/B_LANGUAGE
among O
6 B_MEASURE
, O
981 B_MEASURE/B_PERSON
men I_MEASURE/I_PERSON
and O
women B_PERSON
aged O
65 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
and O
older B_TIME[MEASURE]/B_PERSON
with O
intact B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobility I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
1981 B_MEASURE
and O
1983 B_MEASURE
who O
lived O
in O
one B_NUMBER[MEASURE]/B_LOCATION
of O
three B_NUMBER[MEASURE]/B_LOCATION
communities I_NUMBER[MEASURE]/I_LOCATION
: O
East B_LOCATION/B_PERSON
Boston I_LOCATION/I_PERSON
, O
Massachusetts B_LOCATION
; O
Iowa B_LOCATION/B_PERSON
and O
Washington B_LOCATION/B_PERSON
counties I_LOCATION/I_PERSON
, O
Iowa B_LOCATION
; O
and O
New B_LOCATION/B_PERSON
Haven I_LOCATION/I_PERSON
, O
Connecticut B_LOCATION
. O

Our O
analysis O
indicates O
that O
a O
gene O
correction O
mechanism O
has O
been O
operating O
on O
the O
Hbbs B_PROTEIN[GENE]/B_DISEASE
chromosome O
to O
keep O
beta B_PROTEIN[GENE]
s I_PROTEIN[GENE]
and O
beta B_PROTEIN[GENE]
t I_PROTEIN[GENE]
evolving O
in O
concert O
, O
whereas O
on O
the O
Hbbd B_GENE/B_PERSON
chromosome O
, O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dmin I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
diverged O
considerably O
from O
beta B_PERSON/B_GENE
dmaj I_PERSON/I_GENE
. O

Structure O
and O
regulation O
of O
KGD2 B_GENE
, O
the O
structural O
gene O
for O
yeast B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydrolipoyl I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transsuccinylase I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
dehydrated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
Ta B_MEASURE/B_LOCATION
38 I_MEASURE/I_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
Tb B_PROTEIN[GENE]/B_LOCATION
and O
EWL B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
were O
both O
significantly O
altered O
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
from O
the O
normally O
hydrated O
state B_LOCATION/B_PERSON
and O
were O
measured O
at O
39 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
degree I_MEASURE
C I_MEASURE
and O
0 B_MEASURE
. O
84 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
09 B_MEASURE/B_LOCATION
W I_MEASURE/I_LOCATION
. O

kg B_MEASURE
- O
1 B_MEASURE
respectively O
. O

We O
identify O
YY1 B_GENE
recognition O
sequences O
within O
the O
vitamin O
D O
response O
element O
( O
VDRE O
) O
of O
the O
osteocalcin B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
that O
are O
critical O
for O
YY1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent O
repression O
of O
vitamin O
D O
- O
enhanced O
promoter O
activity O
. O

Back B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ground B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
affect O
the O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
steroid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
withdrawal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
patients B_PERSON/B_LOCATION
with O
chronic B_DISEASE/B_LOCATION
type I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
hepatitis I_DISEASE/I_LOCATION
- O
- O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
mode B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
HBV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transmission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Point O
mutations O
of O
Stat3 B_GENE/B_LOCATION
within O
the O
interacting O
domains O
blocked O
both O
physical O
interaction O
of O
Stat3 B_GENE
with O
c B_GENE
- I_GENE
Jun I_GENE
and O
their O
cooperation O
in O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
transcription O
directed O
by O
the O
alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macroglobulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Three B_PERSON
patients I_PERSON
with O
Mirizzi B_DISEASE
type I_DISEASE
II I_DISEASE
syndrome I_DISEASE
and O
two B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
Mirizzi B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
type B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
I O
syndrome B_DISEASE/B_PERSON
were O
treated O
laparoscopically O
. O

synchronous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multicentric I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
giant I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumour I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
the O
comparison O
of O
the O
nod B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
box I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
( O
Brady O
) O
rhizobia O
with O
a O
more O
divergent O
nod B_GENE/B_LOCATION
box I_GENE/I_LOCATION
from O
Azorhizobium O
caulinodans O
, O
we O
now O
propose O
a O
modular O
build O
- O
up O
of O
the O
nod B_GENE/B_LOCATION
box I_GENE/I_LOCATION
with O
the O
sequence O
A O
- O
T O
- O
C O
- O
N9 O
- O
G O
- O
A O
- O
T O
as O
the O
binding O
target O
of O
the O
NodD B_PROTEIN[GENE]/B_BIO
protein I_PROTEIN[GENE]/I_BIO
( O
the O
NodD B_GENE/B_MEASURE
box I_GENE/I_MEASURE
) O
. O

The O
prgX B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
is O
adjacent O
to O
prgQ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
provides O
the O
promoter O
for O
prgB B_GENE/B_BACTERIUM[BIO]
expression O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
discriminant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predicting O
surgery B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
seizure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vs I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O
non B_DISEASE/B_LOCATION
- O
seizure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
computed O
separately O
for O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
patients B_PERSON/B_BIO
with O
left B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
79 B_MEASURE
) O
and O
right B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
62 B_MEASURE
) O
temporal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
lobectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
LATL B_LOCATION/B_PROTEIN[GENE]
, O
RATL B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

It O
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
these O
recordings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
incomplete B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
; O
the O
actual B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
activated O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O
estimated O
to O
be O
about O
300 B_MEASURE
in O
the O
acutely O
sensitized O
preparation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

The O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
use O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
problems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
indicated O
. O

genetic O
analysis O
of O
the O
role O
of O
herpes B_GENE
simplex I_GENE
virus I_GENE
type I_GENE
1 I_GENE
glycoprotein I_GENE
K I_GENE
in O
infectious O
virus O
production O
and O
egress O
. O

A O
conventional O
N O
- O
terminal O
signal O
sequence O
was O
not O
detected O
in O
the O
NodO B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

dynamic O
expression O
of O
broad B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O
temporal O
control O
of O
an O
ecdysteroid O
target O
gene O
at O
the O
onset O
of O
Drosophila O
metamorphosis O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
according O
to O
the O
BSI B_SEQUENCE[MEASURE]/B_LOCATION
( O
1980 B_MEASURE
) O
recommendations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
testing O
restorative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
materials I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
vivo B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cellular O
lysates O
were O
analyzed O
for O
luciferase B_ENZYME[GENE]
and O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O
. O

cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
use O
different B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sets B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
seem O
to O
be O
unrelated B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
suggest O
that O
the O
proteolipids O
of O
the O
vacuolar B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
H I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
+ I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O
evolved O
in O
parallel O
with O
the O
eubacterial O
proteolipid O
, O
from O
a O
common O
ancestral O
gene O
that O
underwent O
gene O
duplication O
. O

This O
mutant O
also O
functions O
in O
vivo O
as O
a O
trans O
- O
acting O
dominant O
negative O
regulator O
: O
the O
transcriptional O
inducibility O
of O
the O
HIV B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
which O
contains O
two O
potential O
NF B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
by O
phorbol O
ester O
( O
PMA O
) O
is O
inhibited O
when O
it O
is O
co O
- O
transfected O
into O
CD4 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
+ I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T O
cells O
with O
the O
delta O
SP O
mutant O
. O

In O
addition B_MEASURE/B_LOCATION
, O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
shielded B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
unshielded B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
syringes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
containing O
99mTc B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
labelled O
radiopharmaceuticals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tests O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
critical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
component I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
myocardial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
afforded O
by O
BCP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

biomass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
pressure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drop I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
cocurrent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biofilter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
alternative B_LOCATION
splice I_LOCATION
acceptor I_LOCATION
site I_LOCATION
is O
also O
used O
by O
a O
biologically O
active B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provirus I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
efficiency B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
approximately O
5 B_MEASURE
% I_MEASURE
compared O
with O
the O
upstream B_LOCATION/B_TIME[MEASURE]
site B_LOCATION/I_TIME[MEASURE]
. O

Homology O
is O
much O
higher O
( O
64 O
% O
) O
between O
the O
28 O
- O
kDa O
protein O
and O
regions O
that O
are O
strongly O
conserved O
among O
the O
members O
of O
the O
serine B_PERSON/B_BIO
protease I_PERSON/I_BIO
family I_PERSON/I_BIO
. O

We O
have O
isolated O
and O
structurally O
characterized O
genomic O
DNA O
and O
cDNA O
sequences O
encoding O
ribulose B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bisphosphate I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygenase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rbu I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P2 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
barley O
( O
Hordeum O
vulgare O
L O
. O
) O
. O

expression O
of O
putative O
constitutively O
active O
forms O
of O
DdMEK1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
ddmek1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
null O
background O
is O
capable O
, O
at O
least O
partially O
, O
of O
complementing O
the O
small O
aggregate O
size O
defect O
and O
the O
ability O
to O
activate O
guanylyl B_GENE
cyclase I_GENE
. O

constant B_DISEASE_ADJECTIVE[DISEASE]
slowing I_DISEASE_ADJECTIVE[DISEASE]
of O
median B_MEASURE/B_LOCATION
MNCV B_MEASURE/I_LOCATION
and O
SNCV B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
ulnar B_MEASURE/B_PROTEIN[GENE]
SNCV B_MEASURE/I_PROTEIN[GENE]
without O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
morphology B_MEASURE/B_LOCATION
, O
amplitude B_MEASURE
and O
duration B_MEASURE
of O
Map B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SAP B_DISEASE/B_PROTEIN[GENE]
have O
been O
observed O
in O
92 B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
with O
persistent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
64 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
six B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
months I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Moreover O
, O
such O
mutations O
lead O
to O
a O
dramatic O
transition O
in O
chromatin O
structure O
: O
the O
DNase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hypersensitive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
replaced O
by O
two O
stable O
, O
sequence O
- O
positioned O
nucleosomes O
. O

During O
chronic O
treatment O
with O
salmon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcitonin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
alkaline B_GENE/B_DISEASE
phosphatase I_GENE/I_DISEASE
activity O
and O
urinary O
hydroxyproline O
excretion O
decrease O
on O
an O
average O
of O
50 O
% O
in O
patients O
with O
Paget O
' O
s O
disease O
. O

187 O
- O
200 B_MEASURE
. O

Because O
of O
the O
structural O
similarities O
the O
new O
gene O
will O
be O
termed O
scERV2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
now O
on O
. O

Experience B_TIME[MEASURE]/B_LOCATION
in O
a O
Kenya B_LOCATION/B_PERSON
district I_LOCATION/I_PERSON
hospital I_LOCATION/I_PERSON
. O

The O
2 B_GENE
. I_GENE
3 I_GENE
x I_GENE
10 I_GENE
( I_GENE
3 I_GENE
) I_GENE
base I_GENE
SUF12 I_GENE
+ I_GENE
transcript I_GENE
contains O
an O
open O
reading O
frame O
sufficient O
to O
encode O
a O
88 O
x O
10 O
( O
3 O
) O
Mr O
protein O
. O

cortical B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
somatosensory I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
evoked O
potentials B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
median B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
nerve B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
revealed O
significantly O
delayed O
peak B_MEASURE
latencies I_MEASURE
of O
N20 B_PROTEIN[GENE]/B_MEASURE
, O
P20 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P25 B_PROTEIN[GENE]/B_MEASURE
, O
and O
N26 B_MEASURE/B_PROTEIN[GENE]
, O
although O
N16 B_MEASURE/B_PERSON
latency B_MEASURE/I_PERSON
was O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
new B_PERSON/B_ENT
family I_PERSON/I_ENT
of O
rate B_TIME[MEASURE]/B_PERSON
- O
adaptive O
pacemakers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
accomplishes O
this O
circadian B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
modeling O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s O
sleep B_DISEASE
- O
wake B_TIME[MEASURE]/B_ENT
cycle I_TIME[MEASURE]/I_ENT
using O
a O
time B_SEQUENCE[MEASURE]/B_LOCATION
- O
of O
- O
day B_TIME[MEASURE]/B_LOCATION
clock I_TIME[MEASURE]/I_LOCATION
inside O
the O
device B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Progestins B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
present B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
red B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
relation B_PERSON/B_DISEASE
to O
neonatal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
jaundice I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Each O
of O
these O
materials B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
placed O
by O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
placement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
bulk B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
pack B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
horizontal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layering I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
vertical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
layering I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
) O
into O
class B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
II B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cavities B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
extracted O
human B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
molars B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
ligand O
- O
independent O
pathway O
can O
function O
through O
another O
androgen O
- O
regulated O
promoter O
as O
shown O
by O
the O
use O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mammary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tumor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMTV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

stress O
- O
induced O
suppression O
of O
the O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
afternoon O
surge O
in O
ovariectomized O
, O
estrogen O
- O
treated O
rats O
and O
the O
nocturnal O
surge O
in O
pseudopregnant O
rats O
are O
accompanied O
by O
an O
increase O
in O
median O
eminence O
dihydroxyphenylacetic O
acid O
concentrations O
. O

The O
sensitivity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
ergometry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
treadmill B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
75 B_MEASURE
and O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
respectively O
. O

morphologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O
rhe B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
calyx I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
pelvis B_BODY_PART_OR_ORGAN_COMPONENT
control O
ureteric B_DISEASE/B_GENE
activity I_DISEASE/I_GENE
in O
the O
rabbit B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Children B_PERSON/B_BIO
with O
repeated O
proteinuria B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tend O
to O
have O
a O
higher B_MEASURE/B_LOCATION
incidence I_MEASURE/I_LOCATION
of O
pathologic B_DISEASE
findings I_DISEASE
on O
the O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
- O
pyelogram B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Parelaphostrongylus B_VIRUS[BIO]/B_DISEASE
odocoilei I_VIRUS[BIO]/I_DISEASE
is O
redescribed O
from O
worms B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
collected O
from O
the O
type B_SPECIES[BIO]
host I_SPECIES[BIO]
( O
Odocoileus B_SPECIES[BIO]/B_LOCATION
hemionus I_SPECIES[BIO]/I_LOCATION
columbianus I_SPECIES[BIO]/I_LOCATION
) O
in O
California B_LOCATION
, O
as O
well O
as O
material B_LOCATION/B_BIO
from O
experimentally O
infected O
mule B_SPECIES[BIO]/B_PERSON
deer I_SPECIES[BIO]/I_PERSON
( O
O B_OTHER/B_PROTEIN[GENE]
. O
h O
. O
heminus B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
Alberta B_LOCATION/B_PERSON
. O

The O
carboxyl B_PROTEIN[GENE]
globular I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
was O
found O
to O
be O
encoded O
by O
six B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exons I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
appear O
to O
delineate O
its O
structural B_LOCATION/B_MEASURE
subdomains I_LOCATION/I_MEASURE
. O

expression O
of O
the O
Asp O
but O
not O
the O
Ala O
gB B_DISEASE/B_MEASURE
mutation O
resulted O
in O
an O
increase O
in O
the O
steady O
- O
state O
expression O
of O
gB B_GENE/B_DISEASE
at O
the O
plasma O
membrane O
( O
PM O
) O
in O
U373 O
cells O
. O

Thus O
integration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
host B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
required O
for O
normal O
type B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
1 I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
fimbriae I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
phase O
variation O
in O
E O
. O
coli O
. O

Insulin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
has O
been O
expanded O
by O
development O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
new O
modes O
of O
injection O
, O
including O
insulin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
pumps O
. O

Because O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
Vo2DIR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Vo2INDIR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
pooled O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
septic B_DISEASE
and O
control B_DISEASE/B_ORGANIZATION
animals I_DISEASE/I_ORGANIZATION
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
interventions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
: O
nephrectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
2x B_NUMBER[MEASURE]/B_LOCATION
) O
, O
resection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
ligation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
inferior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
vena I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
cava I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O
1x B_NUMBER[MEASURE]/B_LOCATION
) O
, O
resection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
renal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
1x B_SEQUENCE[MEASURE]/B_LOCATION
) O
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tested O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
stimulating O
the O
central B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
noradrenergic B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
using O
the O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
noradrenaline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
re I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
uptake B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reboxetine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
result O
in O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enhancement I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
memory B_PERSON/B_DISEASE
for O
emotional B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_PERSON/B_BIO
. O

We O
examined O
the O
mechanisms O
by O
which O
two O
different O
types O
of O
photonic O
radiation O
, O
short O
wavelength O
UV O
( O
UV O
- O
C O
) O
and O
gamma O
radiation O
, O
activate O
transcription O
factor O
NF B_GENE
- I_GENE
kappaB I_GENE
. O

However O
, O
coligation O
of O
Fc B_GENE
gamma I_GENE
RIIB1 I_GENE
with O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
BCR B_GENE/B_LOCATION
) O
inhibits O
BCR B_GENE/B_LOCATION
- O
mediated O
signaling O
by O
a O
mechanism O
that O
may O
involve O
recruitment O
of O
phosphatases B_GENE
SHP I_GENE
- I_GENE
1 I_GENE
, O
SHP B_GENE
- I_GENE
2 I_GENE
, O
and O
the O
SH2 B_ENZYME[GENE]/B_LOCATION
containing I_ENZYME[GENE]/I_LOCATION
inositol I_ENZYME[GENE]/I_LOCATION
5 I_ENZYME[GENE]/I_LOCATION
' I_ENZYME[GENE]/I_LOCATION
phosphatase I_ENZYME[GENE]/I_LOCATION
( O
SHIP B_LOCATION/B_GENE
) O
to O
the O
phosphorylated O
Fc B_GENE/B_LOCATION
gamma B_GENE/I_LOCATION
RIIB1 B_GENE/I_LOCATION
immunoreceptor B_GENE/I_LOCATION
tyrosine B_GENE/I_LOCATION
- B_GENE/I_LOCATION
based B_GENE/I_LOCATION
inhibitory B_GENE/I_LOCATION
motif B_GENE/I_LOCATION
. O

Using O
the O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
children B_PERSON
with O
full B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
IQ I_MEASURE/I_LOCATION
< I_MEASURE/I_LOCATION
or O
= O
84 B_MEASURE
on O
the O
Wechsler B_PERSON/B_LOCATION
Preschool I_PERSON/I_LOCATION
and O
Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Intelligence B_EDU[ORGANIZATION]/B_DISEASE
at O
age B_NUMBER[MEASURE]/B_PERSON
4 I_NUMBER[MEASURE]/I_PERSON
- O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
were O
poorly O
identified O
( O
sensitivity B_DISEASE_ADJECTIVE[DISEASE]
54 I_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
) O
from O
the O
composite B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_MEASURE/B_LOCATION
IV I_MEASURE/I_LOCATION
score I_MEASURE/I_LOCATION
at O
age B_PERSON/B_TIME[MEASURE]
3 B_PERSON/I_TIME[MEASURE]
. O

11 O
: O
5801 O
- O
5812 O
, O
1991 O
) O
present O
evidence O
that O
the O
Vps18 B_GENE
/ O
Pep3 B_MEASURE/B_PERSON
protein O
colocalizes O
with O
the O
Vps11 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Pep5 B_MEASURE/B_PERSON
protein O
to O
the O
cytosolic O
face O
of O
the O
vacuolar O
membrane O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
includes O
200 B_PERSON
patients I_PERSON
treated O
from O
1964 B_MEASURE
to O
1978 B_MEASURE
, O
with O
an O
age B_TIME[MEASURE]/B_LOCATION
range I_TIME[MEASURE]/I_LOCATION
from O
15 B_MEASURE
to O
102 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
who O
required O
329 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
generators I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
conclude O
that O
the O
BR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
early I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directly O
activates O
late B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
gene I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
transcription O
by O
interacting O
with O
late B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
gene I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
cis O
- O
acting O
regulatory O
elements O
and O
that O
this O
interaction O
is O
responsible O
for O
the O
temporal O
linkage O
of O
early O
and O
late O
ecdysone O
- O
induced O
gene O
expression O
. O

The O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
sensitivity B_MEASURE
of O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
limit B_MEASURE
of O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
plasma B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
025 B_MEASURE
micrograms I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
and O
< B_MEASURE
or O
= O
0 B_MEASURE
. O
0125 B_MEASURE
micrograms I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
for O
febantel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
its O
metabolites B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
) O
were O
sufficiently O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O
enable O
us O
to O
characterize O
the O
time B_TIME[MEASURE]/B_LOCATION
course B_TIME[MEASURE]/I_LOCATION
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
after O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
sheep O
. O

We O
have O
identified O
the O
gene O
encoding O
sigma B_GENE/B_LOCATION
E I_GENE/I_LOCATION
using O
a O
genetic O
screen O
designed O
to O
isolate O
trans O
- O
acting O
mutations O
that O
abolish O
expression O
from O
either O
htrA B_GENE/B_BACTERIUM[BIO]
or O
rpoHP3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two O
promoters O
recognized O
uniquely O
by O
sigma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
RNA B_GENE/B_BIO
polymerase I_GENE/I_BIO
. O

Cytokinetics B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O
the O
Krebs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
2 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
carcinoma I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Through O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
it O
will O
be O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
shift O
away O
our O
vague B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
pre B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
analytic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
quality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
so O
far O
to O
its O
established B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
based O
on O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

These O
patients O
developed O
severe O
diabetic O
symptoms O
including O
glucose O
intolerance O
, O
weight O
loss O
, O
impaired O
energy O
utilization O
, O
and O
nerve O
and O
brain O
disorders O
that O
were O
refractory O
to O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
promoter O
, O
p53P1 B_GENE
, O
is O
located O
100 O
- O
250 O
BP O
upstream O
of O
the O
218 O
- O
BP O
noncoding O
first O
exon O
; O
a O
second O
, O
stronger O
promoter O
, O
p53P2 B_GENE
, O
maps O
within O
the O
first O
intron O
. O

Both O
PMP20 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O
the O
carboxyl O
- O
terminal O
sequence O
AKL O
, O
similar O
to O
the O
putative O
SKL O
peroxisomal O
sorting O
sequence O
( O
Gould O
, O
S O
. O

The O
likelihood B_MEASURE/B_PERSON
of O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
more B_MEASURE
than O
3 B_MEASURE
times I_MEASURE
higher I_MEASURE
among O
patients B_PERSON
in O
the O
ERA B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
II B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mortality B_MEASURE
risk I_MEASURE
ratio I_MEASURE
3 I_MEASURE
. O
82 B_MEASURE
[ O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
1 I_MEASURE
. O
48 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
to O
9 B_MEASURE
. O
84 B_MEASURE
] I_MEASURE
, O
p O
= O
0 B_MEASURE
. O
006 B_MEASURE
) O
. O

barium B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucosal B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coating B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
judged O
to O
be O
better B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
members B_PERSON/B_BIO
to O
whom O
magnesium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
0007 B_MEASURE
) O
. O

In O
both O
immortalized B_DISEASE/B_GENE
and O
normal B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diploid I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
human I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
wt O
AAV B_DISEASE
targeted O
integration B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
ch B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
19 B_MEASURE/B_BIO
. O

The O
corresponding O
tetrapeptide O
sequences O
SSPD O
and O
SATD O
for O
human B_GENE
and I_GENE
mouse I_GENE
PKC I_GENE
- I_GENE
epsilon I_GENE
, O
respectively O
, O
are O
unusual O
for O
caspase B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
lipopolysaccharide O
- O
binding O
protein O
is O
a O
secretory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acute I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O
gene O
is O
transcriptionally O
activated O
by O
APRF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
STAT B_GENE
/ I_GENE
3 I_GENE
and O
other O
cytokine O
- O
inducible O
nuclear O
proteins O
. O

Tritium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
environmental B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
to O
be O
determined O
within O
an O
accuracy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
10 B_MEASURE
% I_MEASURE
by O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
VI B_MEASURE/B_PROTEIN[GENE]
/ O
Vf B_MEASURE/B_DISEASE
was O
14 B_MEASURE/B_LOCATION
- O
25 B_MEASURE
. O

This O
region O
does O
not O
contain O
a O
consensus O
estrogen O
response O
element O
, O
and O
ER B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O
to O
this O
DNA O
sequence O
was O
not O
observed O
. O

These O
proteins O
, O
called O
variant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
VSGs B_LOCATION/B_ORGANIZATION
) O
, O
are O
expressed O
from O
a O
specific O
locus O
, O
the O
VSG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ES I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
strangulated O
intestinal O
pathologies O
of O
horses O
are O
accompanied O
by O
a O
local O
activation O
of O
the O
neutrophils O
, O
that O
can O
be O
revealed O
by O
measuring O
the O
tissular O
enzymatic O
activity O
of O
the O
granulocytic O
enzyme O
myeloperoxidase B_ENZYME[GENE]/B_MEASURE
( O
MPO B_PROTEIN[GENE]/B_LOCATION
) O
. O

A O
deletion O
analysis O
of O
the O
FAS1 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
lacking O
the O
previously O
characterized O
inositol O
/ O
choline O
- O
responsive O
- O
element O
motif O
defined O
a O
region O
( O
nucleotides O
- O
760 O
to O
- O
850 O
) O
responsible O
for O
most O
of O
the O
remaining O
activation O
potency O
. O

Here O
we O
report O
the O
fabrication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
single B_NUMBER[MEASURE]
- O
molecule B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transistors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
individual B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C60 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
connected O
to O
gold B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrodes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
homeodomain B_PROTEIN[GENE]/B_LOCATION
transcription I_PROTEIN[GENE]/I_LOCATION
factor I_PROTEIN[GENE]/I_LOCATION
CDP I_PROTEIN[GENE]/I_LOCATION
/ O
cut B_PROTEIN[GENE]/B_LOCATION
interacts O
with O
the O
cell O
cycle O
regulatory O
element O
of O
histone B_GENE
H4 I_GENE
genes I_GENE
packaged O
into O
nucleosomes O
. O

They O
encode O
proteins O
whose O
core O
regions O
display O
great O
similarity O
to O
Aspergillus B_SPECIES[BIO]/B_GENE
HAPB B_SPECIES[BIO]/I_GENE
, O
HAPC B_DISEASE/B_LOCATION
and O
HAPE B_DISEASE/B_PROTEIN[GENE]
and O
to O
known O
HAP B_GENE/B_BIO
homologs I_GENE/I_BIO
from O
other O
organisms O
. O

Furthermore O
, O
the O
cognate B_GENE
binding I_GENE
protein I_GENE
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
rat B_SPECIES[BIO]/B_GENE
and O
human B_SPECIES[BIO]
( O
HeLa B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
) O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transient O
cotransfection O
analyses O
indicate O
that O
the O
cooperative O
association O
of O
NF B_GENE
- I_GENE
IL I_GENE
- I_GENE
6 I_GENE
and O
RelA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
8 I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
results O
in O
synergistic O
transcriptional O
activation O
. O

Heart B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rate I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
shown O
to O
be O
as O
susceptible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
experimental B_DISEASE
demand I_DISEASE
as O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
approach B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behaviors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
be O
influenced O
. O

Function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
retained O
when O
one B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
copy I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
the O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
suggesting O
that O
this O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O
an O
essential B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

decreased O
plasma O
level O
of O
antithrombin B_GENE
III I_GENE
was O
assumed O
to O
be O
one O
of O
the O
major O
factors O
underlying O
hypercoagulable O
state O
in O
nephrotic O
syndrome O
. O

NO2 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pollution I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O
major B_LOCATION
trunk I_LOCATION
roads I_LOCATION
frequently O
exceeded O
British B_LOCATION/B_ORGANIZATION
and O
European B_LOCATION/B_PERSON
Union I_LOCATION/I_PERSON
air I_LOCATION/I_PERSON
quality I_LOCATION/I_PERSON
standards I_LOCATION/I_PERSON
, O
while O
particle B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
upstream I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O
to O
luciferase B_GENE
, O
with O
POU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeodomain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Oct1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Oct2 B_GENE/B_DISEASE
, O
Brn4 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SCIP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Skn1a B_GENE/B_DISEASE
or O
Skn1i B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

87 B_MEASURE
, O
7270 B_MEASURE
- O
7274 B_MEASURE
) O
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

transcripts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
initiating O
at O
the O
CAGT B_GENE/B_LOCATION
motif I_GENE/I_LOCATION
( O
proximal B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
abolished O
by O
deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
proximal B_GENE/B_LOCATION
TATA I_GENE/I_LOCATION
box I_GENE/I_LOCATION
located O
at O
- O
29 B_TIME[MEASURE]/B_LOCATION
relative I_TIME[MEASURE]/I_LOCATION
to O
CAGT B_MEASURE/B_GENE
. O

Genomic O
DNA O
blot O
analysis O
indicates O
that O
the O
trout B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
L2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
a O
cluster O
- O
like O
organization O
similar O
to O
the O
trout B_GENE
L1 I_GENE
locus I_GENE
and O
the O
IgL B_GENE/B_MEASURE
locus I_GENE/I_MEASURE
of O
several O
teleost O
fish O
. O

Although O
the O
energy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
based O
DFT B_MEASURE
was O
not O
affected O
by O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
from O
6 B_NUMBER[MEASURE]
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
1 B_NUMBER[MEASURE]
. O
5 B_MEASURE
to O
6 B_MEASURE
. O
0 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_NUMBER[MEASURE]
. O
7 B_MEASURE
J I_MEASURE
) O
, O
it O
was O
decreased O
to O
3 B_NUMBER[MEASURE]
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_NUMBER[MEASURE]
. O
6 B_MEASURE
J I_MEASURE
in O
the O
third B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
E4031 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE/B_PERSON
vs I_MEASURE/I_PERSON
. O
baseline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
vs B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

Gore B_PERSON
& O
Associates B_PERSON
, O
Inc B_ORGANIZATION/B_MEASURE
. O
) O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
wall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
graft B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
segments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
varying O
in O
length B_MEASURE/B_LOCATION
from O
4 B_NUMBER[MEASURE]
to O
12 B_MEASURE
cm I_MEASURE
. O

The O
dynamics B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
interaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
retention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hr I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
CPB I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
quantified O
with O
autologous B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O
- O
111 B_TIME[MEASURE]/B_BIO
labeled O
neutrophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Inn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
in O
4 B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
20 B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Yorkshire I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
28 B_MEASURE
- O
35 B_MEASURE
kg I_MEASURE
, O
5 B_PERSON/B_LOCATION
sham I_PERSON/I_LOCATION
; O
5 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
CPB I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
5 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
CPB I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
3 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
5 B_MEASURE
CPB I_MEASURE
with O
heparinized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
circuit I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
3 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
anesthetized B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
injected O
with O
Inn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
500 B_MEASURE
- O
650 B_MEASURE
microCi I_MEASURE
) O
, O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
before O
CPB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
heparinized O
, O
and O
underwent O
CPB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
a O
roller B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
pump I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
, O
a O
hollow B_LOCATION/B_PROTEIN[GENE]
fiber I_LOCATION/I_PROTEIN[GENE]
OX I_LOCATION/I_PROTEIN[GENE]
( O
Bentley B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CM I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
. O
0 B_MEASURE
m2 I_MEASURE
) O
and O
AF B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Bentley B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AF I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
025 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
25 B_MEASURE
m2 I_MEASURE
) O
at O
2 B_NUMBER[MEASURE]/B_LOCATION
. O
5 B_MEASURE
- O
3 B_MEASURE
. O
6 B_MEASURE/B_LOCATION
l I_MEASURE/I_LOCATION
/ O
min B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
region B_LOCATION/B_MEASURE
immediately O
following O
the O
promoter B_GENE
and O
5 B_MEASURE
' O
to O
ORF1 B_GENE/B_SPECIES[BIO]
has O
a O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcription B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
terminator B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
recurrences B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
gingival B_DISEASE/B_PERSON
hyperplasia B_DISEASE/I_PERSON
. O

Preface B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
acknowledgements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

We O
conclude O
that O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
produces O
sedation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
comparable I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
and O
also O
attenuates O
the O
intubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
response I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
without O
increasing O
the O
incidence B_MEASURE
of O
complications B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Pancreatic O
expression O
of O
the O
glucagon B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
depends O
on O
multiple O
transcription O
factors O
interacting O
with O
at O
least O
three O
DNA O
control O
elements O
: O
G1 O
, O
the O
upstream O
promoter O
element O
, O
and O
G2 O
and O
G3 O
, O
two O
enhancer O
- O
like O
sequences O
. O

We O
have O
compared O
the O
ability O
of O
GST B_GENE/B_BIO
- O
Bem3 B_MEASURE/B_GENE
to O
serve O
as O
a O
GAP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
Cdc42Hs B_GENE
relative O
to O
other O
members O
of O
the O
rho B_GENE
- O
GAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B_GENE
platelet I_GENE
Cdc42Hs I_GENE
GAP I_GENE
> O
p190 B_GENE
> O
Bem3 B_GENE
> O
break B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
point I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
p85 B_GENE
, O
like O
Bem2 B_GENE
, O
shows O
no O
GAP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B_GENE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Men B_PERSON
presenting O
with O
urethritis B_DISEASE
and O
women B_PERSON/B_BIO
presenting O
with O
PID B_DISEASE
both O
have O
significantly O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
peripheral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mononuclear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
proliferative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
the O
DK20 B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
C B_VIRUS[BIO]/B_DISEASE
trachomatis I_VIRUS[BIO]/I_DISEASE
than O
controls B_PERSON/B_BIO
. O

The O
PDSS B_DISEASE/B_GENE
identified O
17 B_MEASURE
( O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
the O
women B_PERSON
diagnosed O
with O
major B_DISEASE/B_LOCATION
postpartum I_DISEASE/I_LOCATION
depression I_DISEASE/I_LOCATION
, O
the O
EPDS B_DISEASE/B_ORGANIZATION
identified O
14 B_MEASURE
of O
these O
women B_PERSON
( O
78 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
and O
the O
BDI B_LOCATION/B_DISEASE
- O
II B_MEASURE/B_LOCATION
identified O
10 B_NUMBER[MEASURE]
of O
the O
18 B_PERSON/B_MEASURE
women I_PERSON/I_MEASURE
( O
56 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Men B_PERSON
and O
women B_PERSON/B_BIO
entering O
psychotherapy B_LOCATION/B_ORGANIZATION
more O
often O
had O
negative B_DISEASE
wish I_DISEASE
elements I_DISEASE
than O
others B_PERSON
. O

Single O
amino O
acid O
substitutions O
were O
shown O
to O
result O
from O
the O
mutations O
pdr1 B_GENE
- I_GENE
2 I_GENE
( O
M308I O
) O
, O
pdr1 B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
( O
F815S O
) O
, O
pdr1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
K302Q O
) O
, O
pdr1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P298A O
) O
and O
pdr1 B_MEASURE
- I_MEASURE
8 I_MEASURE
( O
L1036 O
W O
) O
, O
whereas O
the O
intragenic O
suppressor O
mutant O
pdr1 B_GENE/B_BIO
- I_GENE/I_BIO
100 I_GENE/I_BIO
is O
deleted O
for O
the O
two O
amino O
acids O
L537 O
and O
A538 O
. O

Both O
merR B_GENE
genes I_GENE
consist O
of O
a O
408 O
BP O
ORF O
coding O
for O
135 O
amino O
acids O
. O

Amniotic O
fluid O
ionic O
concentration O
in O
response O
to O
chronic O
fetal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasopressin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O
. O

The O
same B_BODY_PART_OR_ORGAN_COMPONENT/B_ENT
slice I_BODY_PART_OR_ORGAN_COMPONENT/I_ENT
was O
imaged O
three B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
each O
with O
sequences B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
using O
spatial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presaturation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
not O
. O

Molecular O
cloning O
of O
the O
alpha B_GENE
- I_GENE
globin I_GENE
transcription I_GENE
factor I_GENE
CP2 I_GENE
. O

The O
most O
distal O
active O
site O
in O
TIGA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
created O
by O
excision O
of O
a O
66 O
- O
BP O
intron O
. O

Denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
with O
sequence O
analysis O
showed O
that O
PGCL4 B_GENE
is O
a O
major O
member O
in O
the O
female O
mammary O
gland O
, O
and O
in O
the O
submaxillary O
and O
lachrymal O
glands O
of O
both O
sexes O
, O
while O
the O
counterpart O
in O
male O
liver O
and O
the O
coagulate O
glands O
was O
found O
to O
be O
PGCL1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

All O
possessed O
cutaneous B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptive I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fields I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
distal B_LOCATION/B_BIO
segments I_LOCATION/I_BIO
of O
digits B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
2 I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
3 B_NUMBER[MEASURE]
, O
or O
4 B_NUMBER[MEASURE]/B_LOCATION
. O

Sesame B_PERSON/B_DISEASE
seed I_PERSON/I_DISEASE
should O
also O
be O
considered O
a O
cause B_PERSON/B_DISEASE
of O
allergic B_DISEASE
reactions I_DISEASE
to O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
cosmetics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Ligand O
binding O
of O
multi O
- O
chain O
antigen O
receptors O
and O
hematopoietin B_GENE
/ O
cytokine O
receptors O
results O
in O
rapid O
activation O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
- O
dependent O
signalling O
molecules O
such O
as O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI B_GENE/B_LOCATION
3 I_GENE/I_LOCATION
- I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
) O
. O

The O
UASB B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
reactors I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
treated O
a O
VFA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
with O
an O
acetate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
propionate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
butyrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ratio I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
5 B_NUMBER[MEASURE]
: O
3 B_MEASURE
: O
2 B_MEASURE
on O
COD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
acetate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
sole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
substrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
different B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
COD I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
sulfate B_MEASURE/B_LOCATION
ratios I_MEASURE/I_LOCATION
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emphasize O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vagal B_DISEASE
involvement I_DISEASE
, O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
surgical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
extirpation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
mildness B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
post B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
operative I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
course I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Now O
: O
pleasure B_PERSON/B_LOCATION
in O
work B_LOCATION/B_PERSON
. O

This O
article B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concepts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pathophysiology B_DISEASE/B_LOCATION
and O
summarises O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Previous O
data O
suggested O
a O
subtle O
increase O
in O
serum O
P O
at O
the O
time O
of O
hCG B_GENE
injection O
without O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surge O
reduces O
the O
PR O
of O
women O
having O
oocyte O
retrievals O
for O
IVF O
; O
this O
study O
compared O
PRs O
of O
recipients O
in O
a O
shared O
oocyte O
program O
according O
to O
the O
donors O
' O
pre B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hCG B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P O
level O
. O

adequacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
Haldane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
transformation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
the O
computation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
exercise B_MEASURE
V I_MEASURE
O2 I_MEASURE
in O
man B_PERSON/B_MEASURE
. O

M B_OTHER/B_MEASURE
. O
, O
Adrich B_PERSON
, O
Z B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Fournet B_PERSON/B_LOCATION
, O
B B_PROTEIN[GENE]/B_DISEASE
. O
, O
Capon B_PERSON
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
, O
Bonicel B_PERSON
, O
J B_OTHER/B_PROTEIN[GENE]
. O

Association B_ORGANIZATION/B_LOCATION
between O
hyperhomocysteinemia B_DISEASE/B_ORGANISM_FUNCTION
and O
ischemic B_DISEASE
heart I_DISEASE
disease I_DISEASE
in O
Sri B_PERSON/B_BIO
Lankans I_PERSON/I_BIO
. O

radiological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
UGI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
series I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
arrive O
at O
an O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
architecture O
of O
the O
hRap1 B_GENE/B_LOCATION
Myb I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
is O
very O
close O
to O
that O
of O
each O
of O
the O
Myb B_GENE/B_BIO
domains I_GENE/I_BIO
from O
TRF1 B_SPECIES[BIO]/B_GENE
, O
scRap1p B_GENE
and O
c B_GENE
- I_GENE
Myb I_GENE
. O

80 O
v B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
encoded O
amino O
- O
acids O
located O
immediately O
after O
the O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myb I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
v B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ets I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
junction O
are O
not O
found O
in O
P54 B_GENE
/ O
56c B_MEASURE
- I_MEASURE
ets I_MEASURE
, O
the O
translation O
product O
of O
the O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ets I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proto I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
nor O
in O
a O
set O
of O
cellular O
proteins O
of O
64 O
, O
62 O
, O
and O
60 O
kDa O
related O
to O
but O
distinct O
from O
P54 B_GENE
/ O
56c B_MEASURE
- I_MEASURE
ets I_MEASURE
. O

We O
have O
raised O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
a O
peptide B_GENE/B_MEASURE
specific I_GENE/I_MEASURE
to O
the O
predicted O
protein B_GENE/B_LOCATION
product B_GENE/I_LOCATION
of O
this O
second B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
controlled O
- O
release B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
niacin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
to O
be O
more O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
crystalline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
niacin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
product B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
substitution I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
without O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
adjustment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O
be O
avoided O
. O

interobserver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agreement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Nottingham B_ORGANIZATION/B_LOCATION
histologic I_ORGANIZATION/I_LOCATION
grading I_ORGANIZATION/I_LOCATION
scheme I_ORGANIZATION/I_LOCATION
for O
infiltrating O
duct B_DISEASE
carcinoma I_DISEASE
breast I_DISEASE
. O

This O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
Na3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
no O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypocalcaemia B_DISEASE
in O
these O
subjects B_PERSON/B_BIO
, O
even O
though O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
NIH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formula I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
ACD B_DISEASE/B_LOCATION
- O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
under O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
been O
reported O
to O
reduce O
significantly O
the O
level B_MEASURE/B_LOCATION
of O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
serum B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
concomitantly O
increase O
the O
number B_DISEASE
or O
reactions B_DISEASE
occurring O
in O
donors B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Latex O
products O
( O
gloves O
, O
balloons O
, O
and O
condoms O
) O
directly O
bound O
IgE B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O
all O
four O
patients O
. O

The O
phosphoprotein B_GENE
pUL69 I_GENE
of O
human O
cytomegalovirus O
( O
HCMV O
) O
, O
which O
is O
a O
herpesvirus O
of O
considerable O
medical O
importance O
in O
immunosuppressed O
patients O
and O
newborns O
, O
has O
previously O
been O
identified O
as O
an O
early B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
late I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
viral I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
can O
stimulate O
several O
viral O
and O
cellular O
promoters O
and O
thus O
exerts O
a O
rather O
broad O
activation O
pattern O
. O

Southern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
performed O
on O
genomic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
altered B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
CpG I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
methylation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
within O
intron B_GENE/B_LOCATION
1 I_GENE/I_LOCATION
in O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
all O
BCC B_DISEASE/B_PERSON
compared O
to O
normal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mortal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
human I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mammary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
HMEC B_DISEASE/B_BACTERIUM[BIO]
) O
. O

Previous O
studies O
have O
shown O
that O
TGFbeta1 B_GENE
expression O
is O
upregulated O
in O
mouse O
keratinocytes O
infected O
with O
a O
v B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rasHa I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retrovirus O
, O
although O
the O
functional O
significance O
of O
this O
has O
not O
been O
clear O
. O

An O
increased O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ATN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
since O
the O
introduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
a O
GTP O
- O
dependent O
, O
brefeldin O
A O
- O
sensitive O
in O
vitro O
AP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
assay O
, O
we O
have O
determined O
here O
the O
parameters O
of O
the O
AP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
reaction O
. O

The O
overall B_MEASURE
rate I_MEASURE
of O
biohydrogenation B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
of O
C18 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
2 B_NUMBER[MEASURE]
was O
14 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
/ O
h O
, O
but O
declined O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
/ O
h B_OTHER/B_TIME[MEASURE]
for O
each O
percentage B_TIME[MEASURE]/B_LOCATION
unit I_TIME[MEASURE]/I_LOCATION
increase I_TIME[MEASURE]/I_LOCATION
in O
C18 B_MEASURE/B_PROTEIN[GENE]
: O
2 B_NUMBER[MEASURE]
added O
to O
the O
substrate B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Plasma B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enteroglucagon I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
measured O
before O
and O
during O
three O
hours O
after O
a O
standard O
meal O
in O
21 O
untreated O
adult O
patients O
with O
suspected O
coeliac O
disease O
who O
all O
had O
villous O
atrophy O
of O
the O
small O
intestinal O
mucosa O
and O
malabsorption O
, O
and O
in O
nine O
control O
subjects O
. O

After O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
body B_MEASURE/B_DISEASE
mass B_MEASURE/I_DISEASE
index B_MEASURE/I_DISEASE
, O
trait B_DISEASE/B_PERSON
anxiety I_DISEASE/I_PERSON
and O
anger B_LOCATION/B_DISEASE
- O
in B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O
independent B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diastolic B_DISEASE/B_LOCATION
blood I_DISEASE/I_LOCATION
pressure I_DISEASE/I_LOCATION
among O
the O
women B_PERSON/B_BIO
. O

Regulation O
of O
the O
human B_GENE
stress I_GENE
response I_GENE
gene I_GENE
GADD153 I_GENE
expression O
: O
role O
of O
ETS1 B_GENE
and O
FLI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
PRP4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Saccharomyces I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
an O
essential O
part O
of O
the O
U4 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
U6 B_MEASURE
snRNP O
, O
a O
component O
of O
the O
mRNA O
splicing O
apparatus O
. O

132 B_MEASURE/B_ENT
varix B_MEASURE/I_ENT
ligations B_MEASURE/I_ENT
were O
performed O
during O
44 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
separate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
EVL I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
sessions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

Here O
RFX B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
X2BP B_PROTEIN[GENE]/B_LOCATION
/ O
DNA O
complexes O
were O
formed O
on O
all O
class O
II O
isotypes O
regardless O
of O
the O
ability O
of O
the O
X O
box O
region O
to O
bind O
either O
factor O
individually O
. O

The O
psi B_GENE/B_DISEASE
zeta I_GENE/I_DISEASE
gene I_GENE/I_DISEASE
has O
a O
nonsense O
mutation O
in O
exon O
1 O
but O
has O
identical O
promoter O
sequence O
and O
RNA O
processing O
sites O
to O
the O
zeta B_GENE/B_BIO
gene I_GENE/I_BIO
, O
raising O
the O
possibility O
that O
both O
psi B_PROTEIN[GENE]
zeta I_PROTEIN[GENE]
and O
zeta B_GENE
are O
transcriptionally O
active O
. O

prospects B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chemosterilant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
genetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
rodents B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

serum O
PRL B_GENE
concentrations O
significantly O
increased O
after O
MCP O
administration O
in O
normal O
women O
, O
hyperprolactinemic O
patients O
with O
normal O
sella O
and O
patients O
with O
microadenoma O
, O
but O
not O
in O
macroadenoma O
patients O
with O
and O
without O
suprasellar O
expansion O
( O
SSE O
) O
. O

The O
Id4 B_GENE/B_BIO
protein I_GENE/I_BIO
contains O
a O
HLH O
domain O
highly O
conserved O
among O
the O
dnHLH B_GENE/B_BIO
proteins I_GENE/I_BIO
from O
mouse O
and O
drosophila O
. O

The O
coding O
region O
of O
nifA B_GENE/B_BACTERIUM[BIO]
was O
determined O
using O
a O
translational O
lacZ B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
by O
site O
- O
directed O
mutagenesis O
to O
identify O
which O
of O
four O
in O
frame O
Aug O
codons O
was O
used O
. O

Peptide O
competition O
studies O
have O
localized O
a O
cyclin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
site I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
a O
Lys381Lys382Leu383Met384Phe385 O
sequence O
within O
C O
- O
terminal O
negative O
regulatory O
domain O
of O
human B_GENE
p53 I_GENE
. O

Heterodimerization B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RXR I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
alter O
GFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
VDR B_PROTEIN[GENE]/B_LOCATION
and O
nlsGFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
VDR B_PROTEIN[GENE]/B_LOCATION
distribution O
or O
activity O
. O

Like O
troponin B_GENE
Cs I_GENE
and O
calmodulins B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
PfCPK B_GENE
also O
contains O
four O
EF O
hand O
calcium O
- O
binding O
motifs O
. O

A O
third B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
( O
n B_OTHER/B_MEASURE
= O
10 B_MEASURE
) O
was O
assigned O
to O
receive O
the O
canalith B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
repositioning O
maneuver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
without O
mastoid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vibration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

upstream O
of O
the O
afa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
1 O
. O
2 O
- O
kb O
region O
was O
found O
to O
be O
96 O
% O
identical O
to O
the O
RepFIB B_LOCATION/B_GENE
sequence I_LOCATION/I_GENE
of O
one O
of O
the O
enterotoxigenic O
E O
. O
coli O
plasmids O
( O
P307 O
) O
, O
suggesting O
a O
common O
ancestor O
plasmid O
. O

The O
cats B_BIO/B_PERSON
with O
stage B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
2 B_DISEASE
lymphomas I_DISEASE
that O
were O
FeLV B_BIO/B_GENE
- O
test B_DISEASE_ADJECTIVE[DISEASE]
negative I_DISEASE_ADJECTIVE[DISEASE]
had O
the O
best B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
hypothesize O
that O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
acidic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activators B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
specifically O
interact O
with O
multiple B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
components I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
transcription B_GENE/B_LOCATION
initiation B_GENE/I_LOCATION
complex B_GENE/I_LOCATION
likely O
underlies O
the O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functional I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synergy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
exhibited O
by O
this O
class B_PERSON/B_MEASURE
of O
activation B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Where O
the O
resonator B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
has O
two B_MEASURE/B_LOCATION
holes I_MEASURE/I_LOCATION
, O
these O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O
be O
somewhat O
modified O
: O
A B_OTHER/B_PROTEIN[GENE]
is O
the O
combined B_MEASURE/B_LOCATION
area I_MEASURE/I_LOCATION
of O
the O
two B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
holes I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O
L B_PROTEIN[GENE]/B_LOCATION
is O
16 B_MEASURE
/ O
3pi B_MEASURE
r I_MEASURE
( O
~ O
1 B_MEASURE
. O
7r B_MEASURE
) O
for O
a O
simple B_LOCATION/B_MEASURE
hole I_LOCATION/I_MEASURE
in O
a O
thin B_MEASURE/B_DISEASE
- O
walled B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
vessel I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O
r B_OTHER/B_PROTEIN[GENE]
is O
the O
radius B_MEASURE/B_LOCATION
of O
one B_LOCATION/B_MEASURE
hole B_LOCATION/I_MEASURE
( O
Seto B_PERSON/B_LOCATION
, O
1971 B_MEASURE
) O
. O

Histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immunophenotypic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
12 B_NUMBER[MEASURE]
large I_NUMBER[MEASURE]
cell I_NUMBER[MEASURE]
lymphomas I_NUMBER[MEASURE]
( O
11 B_DISEASE/B_NUMBER[MEASURE]
B B_DISEASE/I_NUMBER[MEASURE]
cell B_DISEASE/I_NUMBER[MEASURE]
and O
one B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
two B_NUMBER[MEASURE]
small I_NUMBER[MEASURE]
noncleaved I_NUMBER[MEASURE]
cell I_NUMBER[MEASURE]
lymphomas I_NUMBER[MEASURE]
( O
B B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
- O
cell B_DISEASE/B_PROTEIN[GENE]
phenotype B_DISEASE/I_PROTEIN[GENE]
) O
, O
and O
five B_MEASURE
low I_MEASURE
grade I_MEASURE
B I_MEASURE
- O
cell B_DISEASE
lymphomas I_DISEASE
( O
two B_DISEASE/B_NUMBER[MEASURE]
small B_DISEASE/I_NUMBER[MEASURE]
lymphocytic B_DISEASE/I_NUMBER[MEASURE]
and O
three B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
follicular B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mixed B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
deviation B_LOCATION/B_GENE
site B_LOCATION/I_GENE
is O
equivalent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
exon B_MEASURE
2 I_MEASURE
splice I_MEASURE
site I_MEASURE
of O
the O
mouse B_PROTEIN[GENE]/B_SPECIES[BIO]
C I_PROTEIN[GENE]/I_SPECIES[BIO]
- O
subunit B_GENE/B_LOCATION
. O

The O
determination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diacetyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
2 B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_NUMBER[MEASURE]
- O
pentanedione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
acetoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
in O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steps I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
also O
may O
be O
osmotic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
challenges I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
mucosal O
cell B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
function B_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
as O
evidenced O
by O
the O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
hyper B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
hypotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
F9 O
, O
which O
is O
a O
prototype O
of O
embryonal O
carcinoma O
cells O
expressing O
hst B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
expression O
of O
hst B_GENE
gene I_GENE
is O
positively O
regulated O
by O
a O
downstream O
octamer O
motif O
that O
functions O
as O
an O
enhancer O
. O

The O
reading B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
achievement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
students B_PERSON
with O
learning O
disabilities B_DISEASE
who O
received O
reading B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
instruction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
through O
the O
DISTAR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
compared O
to O
that O
of O
similar B_PERSON
students I_PERSON
using O
basal B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reader I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
materials I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
putative O
ATP O
- O
binding O
domains O
were O
identified O
, O
one O
in O
the O
amino O
- O
terminal O
half O
of O
the O
argA B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
encoded I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
other O
in O
the O
carboxy O
- O
terminal O
half O
. O

Chronic B_DISEASE
granulocytic I_DISEASE
leukemia I_DISEASE
in O
children B_PERSON/B_LOCATION
. O

Purified O
phosphorylated O
PhoP B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O
PhoPP B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
had O
a O
half O
- O
life O
of O
approximately O
2 O
. O
5 O
h O
, O
which O
was O
reduced O
to O
about O
15 O
min O
by O
addition O
of O
the O
same O
molar O
amount O
of O
* B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PhoR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
the O
cytoplasmic O
region O
of O
PhoR B_GENE/B_DISEASE
) O
. O

This O
transformation O
suppression O
by O
Rb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
further O
shown O
to O
be O
due O
to O
transcriptional O
repression O
of O
neu B_GENE
using O
Rb B_GENE
expressing O
effector O
plasmid O
and O
neu B_GENE
promoter O
- O
chloramphenicol B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
acetyltransferase I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
reporter O
gene O
. O

Before O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
started O
, O
trabecular B_DISEASE_ADJECTIVE[DISEASE]
bone I_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
observed O
which O
were O
typical B_DISEASE_ADJECTIVE[DISEASE]
for O
Paget B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
of O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
as O
there O
were O
bulky B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
trabeculare I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
increased O
remodelling O
surfaces B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
giant B_DISEASE
osteoclasts I_DISEASE
. O

T B_PROTEIN[GENE]/B_LOCATION
. O
infestans B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
delpontei B_SPECIES[BIO]/B_PERSON
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
rubrovaria B_SPECIES[BIO]/B_LOCATION
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
sordida B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
guasayana B_SPECIES[BIO]/B_LOCATION
and O
T B_PROTEIN[GENE]/B_LOCATION
. O
vitticeps B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
from O
infestans B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroup I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
T B_PROTEIN[GENE]/B_LOCATION
. O
pallidipennis B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
from O
rubrofasciata B_LOCATION
, O
were O
studied O
. O

Overexpression O
of O
N O
- O
terminal O
mutations O
disturbs O
mitosis O
and O
produces O
elongated O
cells O
, O
Using O
a O
PCR O
approach O
, O
we O
isolated O
a O
putative O
homologue O
of O
Prp4 B_GENE
from O
human O
and O
mouse O
cells O
. O

1 B_NUMBER[MEASURE]
. O

Biochemical O
studies O
and O
studies O
of O
cells O
expressing O
mutant O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O
that O
IL B_GENE
- I_GENE
2 I_GENE
- O
induced O
tyrosine B_GENE
kinase I_GENE
activation O
initiates O
a O
complex O
signaling O
Cascade O
. O

Background O
: O
peripheral O
kappa B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonists O
may O
provide O
a O
new O
therapeutic O
approach O
for O
the O
treatment O
of O
functional O
dyspepsia O
. O

Fourteen B_PERSON/B_ENT
eyes I_PERSON/I_ENT
( O
38 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
developed O
DLK B_DISEASE
after O
an O
epithelial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
defect B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
representing O
an O
odds B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
ratio B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
13 B_NUMBER[MEASURE]/B_ENT
times I_NUMBER[MEASURE]/I_ENT
. O

The O
yeast O
genome O
contains O
a O
single O
ORD1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
resides O
on O
chromosome O
XI O
. O

The O
system B_ORGANIZATION/B_LOCATION
consists O
of O
a O
TV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
compatible I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
to O
IBM B_LOCATION/B_DISEASE
PC I_LOCATION/I_DISEASE
/ O
AT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
software B_ORGANIZATION/B_LOCATION
. O

The O
N O
- O
terminal O
sequence O
of O
the O
extracellular B_GENE
MEP20 I_GENE
, O
TKVAS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
was O
found O
at O
AA O
194 O
- O
198 O
within O
the O
ORF O
. O

isolates B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
B B_GENE/B_DISEASE
. O
burgdorferi B_BACTERIUM[BIO]/B_DISEASE
from O
humans B_PERSON/B_SPECIES[BIO]
, O
rodents B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
I O
. O
dammini B_SPECIES[BIO]/B_DISEASE
are O
usually O
indistinguishable B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
strains B_BIO/B_PERSON
of O
B B_PROTEIN[GENE]/B_DISEASE
. O
burgdorferi B_BACTERIUM[BIO]/B_DISEASE
with O
different B_DISEASE_ADJECTIVE[DISEASE]
major I_DISEASE_ADJECTIVE[DISEASE]
proteins I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
identified O
. O

Cloning O
of O
the O
GATA B_GENE/B_LOCATION
- I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
that O
regulates O
endothelin B_GENE
- I_GENE
1 I_GENE
gene I_GENE
expression O
in O
endothelial O
cells O
. O

The O
Synechococcus B_GENE/B_BACTERIUM[BIO]
gene I_GENE/I_BACTERIUM[BIO]
rps1 I_GENE/I_BACTERIUM[BIO]
encoding O
S1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
located O
1 O
. O
1 O
kb O
downstream O
from O
psbB B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
which O
encodes O
the O
photosystem B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P680 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
chlorophyll I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
a I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two B_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
echocardiographic I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parasternal I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
short B_MEASURE
- O
axis B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
views B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
obtained O
during O
graded O
bleeding B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
rapid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
withdrawal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O
an O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cannula I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
increments B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
5 B_MEASURE/B_DISEASE
% I_MEASURE/I_DISEASE
each O
up O
to O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
calculated B_MEASURE/B_PERSON
blood B_MEASURE/I_PERSON
volume B_MEASURE/I_PERSON
. O

A O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
rate B_MEASURE
of O
recovery B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
time B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
mycobacteria B_BACTERIUM[BIO]/B_DISEASE
from O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
newly O
developed O
mycobacteria B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Growth I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicator I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tube I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MGIT B_LOCATION/B_GENE
) O
, O
the O
biphasic B_DISEASE/B_PERSON
Septi I_DISEASE/I_PERSON
- O
Chek B_MEASURE/B_BACTERIUM[BIO]
, O
and O
the O
egg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
Ogawa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
made O
. O

As O
in O
IncP O
alpha O
plasmids O
, O
these O
operons O
are O
transcribed O
from O
a O
bidirectional O
promoter O
region O
consisting O
of O
trfAp B_GENE/B_BACTERIUM[BIO]
for O
the O
trfA B_GENE
operon I_GENE
and O
trbAp B_GENE
and O
trbBp B_GENE
for O
the O
trb B_PERSON/B_GENE
operon I_PERSON/I_GENE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
These O
principally O
structural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
support O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
the O
thrombus B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
self B_PERSON/B_LOCATION
- O
sustaining O
entity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
may O
have O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
pathophysiologic B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
of O
abdominal B_DISEASE/B_LOCATION
aortic I_DISEASE/I_LOCATION
aneurysms I_DISEASE/I_LOCATION
. O

The O
BHV B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UL24 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
UL25 B_MEASURE
, O
UL26 B_MEASURE
and O
UL26 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
all O
terminated O
at O
a O
common O
3 O
' O
- O
polyadenylation O
site O
and O
varied O
significantly O
in O
their O
relative O
abundance O
. O

Electrophoretic O
mobility O
shift O
analysis O
of O
protein O
- O
DNA O
complexes O
formed O
with O
nuclear O
proteins O
isolated O
from O
I3C O
- O
treated O
and O
- O
untreated O
cells O
, O
in O
combination O
with O
supershift O
assays O
using O
Sp1 B_GENE
antibodies I_GENE
, O
demonstrated O
that O
the O
Sp1 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
in O
the O
CDK6 B_GENE
promoter I_GENE
forms O
a O
specific O
I3C O
- O
responsive O
DNA O
- O
protein O
complex O
that O
contains O
the O
Sp1 B_GENE/B_LOCATION
transcription I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
. O

These O
results O
suggest O
that O
both O
the O
distinct O
DNA O
binding O
properties O
of O
PMLRAR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
sequestration O
of O
RXR B_GENE
by O
PMLRARs B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
may O
contribute O
to O
the O
molecular O
mechanisms O
which O
underlie O
the O
pathogenesis O
of O
APL O
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
showed O
that O
the O
morning B_TIME[MEASURE]
active I_TIME[MEASURE]
( O
MA B_LOCATION
) O
individuals B_PERSON/B_ORGANIZATION
rose O
earlier O
and O
went O
to O
bed B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
earlier O
than O
the O
evening B_TIME[MEASURE]/B_LOCATION
active I_TIME[MEASURE]/I_LOCATION
( O
EA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
individuals B_PERSON/B_ORGANIZATION
, O
and O
the O
former B_PERSON/B_TIME[MEASURE]
had O
a O
longer B_MEASURE
sleep I_MEASURE
length I_MEASURE
than O
the O
latter B_TIME[MEASURE]/B_PERSON
during O
days B_TIME[MEASURE]/B_PERSON
with O
a O
morning B_TIME[MEASURE]/B_DISEASE
shift B_TIME[MEASURE]/I_DISEASE
, O
while O
the O
opposite B_LOCATION/B_MEASURE
was O
true B_DISEASE_ADJECTIVE[DISEASE]
for O
afternoon B_TIME[MEASURE]
and O
night B_TIME[MEASURE]
shifts I_TIME[MEASURE]
. O

This O
ERD B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
is O
recorded O
over O
the O
contralateral B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
central I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
region I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
. O

Deletion B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O
constructed O
, O
removing O
residues B_MEASURE
2 I_MEASURE
- O
30 B_MEASURE
, O
31 B_MEASURE
- O
60 B_MEASURE
, O
61 B_MEASURE
- O
90 B_MEASURE
, O
and O
49 B_MEASURE
- O
78 B_MEASURE
of O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]/B_LOCATION
cytoplasmic I_PROTEIN[GENE]/I_LOCATION
domain I_PROTEIN[GENE]/I_LOCATION
, O
as O
well O
as O
a O
missense B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
a O
dileucine B_GENE
motif I_GENE
. O

Kluyveromyces B_SPECIES[BIO]
lactis I_SPECIES[BIO]
, O
a O
budding O
yeast B_SPECIES[BIO]
related O
to O
Saccharomyces B_SPECIES[BIO]
cerevisiae I_SPECIES[BIO]
, O
can O
grow O
on O
a O
wider B_MEASURE/B_LOCATION
variety I_MEASURE/I_LOCATION
of O
substrates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
shows O
less B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sensitivity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
repression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
than O
does O
Saccharomyces B_SPECIES[BIO]
cerevisiae I_SPECIES[BIO]
. O

Low O
- O
affinity O
E2 B_GENE
- I_GENE
binding I_GENE
site I_GENE
mediates O
downmodulation O
of O
E2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Untransformed O
3T3 O
cells O
carry O
abundant O
1 O
. O
9 O
kb O
Hox B_GENE/B_DISEASE
1 I_GENE/I_DISEASE
. I_GENE/I_DISEASE
3 I_GENE/I_DISEASE
RNA O
, O
whereas O
the O
methylcholanthrene O
- O
transformed O
MB66 O
and O
LTK O
- O
cells O
or O
3T3 O
cells O
transformed O
by O
the O
oncogenes O
src B_GENE
, O
fos B_GENE
or O
SV40 B_GENE
T I_GENE
antigen I_GENE
express O
only O
low O
levels O
. O

Although O
analysis O
of O
the O
similarity O
between O
the O
44 O
- O
kDa O
protein O
and O
the O
E B_PROTEIN[GENE]/B_BIO
. I_PROTEIN[GENE]/I_BIO
coli I_PROTEIN[GENE]/I_BIO
RecA I_PROTEIN[GENE]/I_BIO
protein I_PROTEIN[GENE]/I_BIO
did O
not O
show O
any O
significant O
homology O
between O
them O
, O
it O
revealed O
their O
identity O
by O
five O
amino O
- O
acid O
residues O
involved O
in O
the O
formation O
of O
the O
epitope O
that O
recognized O
the O
paratope O
of O
the O
RecA B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
subsequent O
epitope O
- O
paratope O
binding O
of O
these O
proteins O
. O

Ureases B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O
purified O
from O
the O
recombinant O
cells O
and O
shown O
to O
be O
identical O
to O
control O
enzyme O
when O
analyzed O
by O
gel O
filtration O
chromatography O
and O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
; O
however O
, O
in O
every O
case O
the O
activity O
levels O
correlated O
to O
nickel O
contents O
as O
analyzed O
by O
atomic O
absorption O
analysis O
. O

Deoxyuridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
suppression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
bone B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
culture I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
macrocytic B_DISEASE/B_GENE
refractory I_DISEASE/I_GENE
anaemias I_DISEASE/I_GENE
. O

Finally O
, O
synthetic O
peptides O
corresponding O
to O
the O
mutant O
proteins O
were O
assessed O
for O
the O
ability O
to O
act O
as O
substrates O
for O
PR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
psoralens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O
being O
used O
in O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sponsored O
by O
the O
National B_ORGANIZATION/B_LOCATION
Toxicology I_ORGANIZATION/I_LOCATION
Program I_ORGANIZATION/I_LOCATION
. O

Root B_LOCATION/B_PERSON
surface B_LOCATION/I_PERSON
caries O
incidence B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inoculated O
with O
A O
. O
viscosus B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
and O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
viscosus B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
plus O
S B_DISEASE/B_LOCATION
. O
sobrinus B_BACTERIUM[BIO]/B_DISEASE
did O
not O
differ O
. O

These O
results O
demonstrate O
that O
the O
entire O
E3L B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
is O
required O
for O
pathogenesis O
in O
the O
mouse O
model O
. O

The O
development B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE
pathological I_DISEASE
lesions I_DISEASE
in O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
, O
spleen B_BODY_PART_OR_ORGAN_COMPONENT
, O
lymph B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nodes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
marrow B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O
frequently O
observed O
. O

Recently O
, O
we O
have O
demonstrated O
that O
mouse O
microglial O
cells O
, O
the O
brain O
macrophages O
, O
express O
both O
IL B_GENE
- I_GENE
15 I_GENE
and O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
15 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
analyzed O
the O
role O
of O
the O
HU B_GENE
protein I_GENE
in O
invertasome O
assembly O
when O
the O
enhancer O
is O
located O
at O
variable O
positions O
close O
to O
one O
of O
the O
recombination O
sites O
. O

The O
mode B_DISEASE/B_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
often O
suggested O
as O
an O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
slopes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
concentration B_MEASURE/B_LOCATION
- O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
may O
be O
another O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
principle B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
less B_NUMBER[MEASURE]/B_PERSON
is O
more B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

A O
wide O
conservation O
of O
iscSUA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
nature O
and O
evidence O
that O
NifU B_BACTERIUM[BIO]/B_GENE
and O
NifS B_LOCATION/B_GENE
participate O
in O
the O
mobilization O
of O
iron O
and O
sulfur O
for O
nitrogenase B_BIO/B_LOCATION
- O
specific O
iron O
- O
sulfur O
cluster O
formation O
suggest O
that O
the O
products O
of O
the O
iscSUA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O
play O
a O
general O
role O
in O
the O
formation O
or O
repair O
of O
iron O
- O
sulfur O
clusters O
. O

On O
transfer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
succinate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
malate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
glycerol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
citrate O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
Cit B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
+ I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
coli I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
showed O
a O
delay B_DISEASE/B_TIME[MEASURE]
of O
36 B_MEASURE
to O
48 B_MEASURE
h O
before O
growth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

These O
results O
suggest O
that O
camptothecin O
resistance O
in O
CEM O
/ O
DOX O
cells O
is O
due O
to O
different O
mechanism O
( O
s O
) O
than O
topoisomerase B_GENE/B_LOCATION
- O
or O
P B_GENE
- I_GENE
glycoprotein I_GENE
- O
associated O
multidrug O
resistance O
. O

Jornvall B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B B_OTHER/B_PERSON
. O

The O
pattern O
of O
expression O
of O
this O
and O
other O
Chi26 B_PROTEIN[GENE]/B_SPECIES[BIO]
/ O
Chi33 B_MEASURE
chimeric O
promoters O
suggest O
that O
the O
E B_GENE/B_LOCATION
- I_GENE/I_LOCATION
region I_GENE/I_LOCATION
contains O
cis O
- O
acting O
sequences O
which O
activate O
transcription O
in O
aleurone O
and O
silence O
transcription O
in O
leaves O
. O

Spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
spasm O
during O
coronary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
angiography I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
patient B_PERSON/B_LOCATION
with O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ST B_DISEASE/B_LOCATION
segment I_DISEASE/I_LOCATION
elevation I_DISEASE/I_LOCATION
. O

Four O
newborns O
in O
this O
group O
became O
HBsAg B_DISEASE/B_PERSON
carriers O
. O

effectively O
, O
the O
upstream O
, O
housekeeping O
- O
type O
promoter O
responds O
to O
FIXK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
positively O
regulates O
the O
downstream O
, O
sigma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
54 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

K B_OTHER/B_PERSON
. O
, O
Weiss B_PERSON/B_LANGUAGE
, O
M B_OTHER/B_PERSON
. O

New B_PERSON
TB I_PERSON
respirator I_PERSON
standards I_PERSON
mean O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
choices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O
less B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cost I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

electrophoretic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mobility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
shift B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O
oligonucleotides B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O
from O
these O
sites B_LOCATION/B_BIO
demonstrated O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

A O
5789 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EcoRI I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
genome O
of O
Thermotoga O
maritima O
, O
identified O
by O
cross O
- O
hybridization O
to O
L11 B_PROTEIN[GENE]
, O
L1 B_PROTEIN[GENE]/B_MEASURE
, O
L10 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
L12 B_PROTEIN[GENE]/B_MEASURE
ribosomal I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
gene I_PROTEIN[GENE]/I_MEASURE
sequences I_PROTEIN[GENE]/I_MEASURE
from I_PROTEIN[GENE]/I_MEASURE
Escherichia I_PROTEIN[GENE]/I_MEASURE
coli I_PROTEIN[GENE]/I_MEASURE
, O
was O
cloned O
and O
sequenced O
. O

Background B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O
a O
prominent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
DTIn1 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
well O
as O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DTPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biodistribution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

These O
data O
suggest O
that O
reduction O
in O
PRA O
may O
have O
contributed O
to O
the O
hemodynamic O
effects O
of O
this O
peak B_GENE
III I_GENE
PDE I_GENE
inhibitor O
. O

The O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
measured O
: O
onset B_PROTEIN[GENE]/B_LOCATION
time I_PROTEIN[GENE]/I_LOCATION
( O
time B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
from O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
maximal B_MEASURE
or O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
T125 B_MEASURE/B_PROTEIN[GENE]
/ O
75 B_MEASURE
( O
time B_TIME[MEASURE]/B_LOCATION
for O
T1 B_MEASURE
to O
reach O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
or O
75 B_MEASURE
% I_MEASURE
of O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
TOF70 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
time B_TIME[MEASURE]/B_LOCATION
for O
TOF B_PROTEIN[GENE]
ratio I_PROTEIN[GENE]
to O
reach O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
and O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Prematurely O
inactivating O
p42 B_GENE
MAPK I_GENE
in O
egg O
extracts O
resulted O
in O
a O
corresponding O
hastening O
of O
the O
first O
mitosis O
. O

The O
use O
of O
ALAD B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O
and O
EP O
as O
cumulative O
lead O
exposure O
indicators O
is O
suggested O
. O

binding O
of O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBPs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
all O
three O
spi B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
although O
rather O
weak O
, O
was O
confirmed O
by O
electrophoretic O
mobility O
shift O
assays O
that O
otherwise O
failed O
to O
reveal O
specific O
interactions O
with O
other O
liver O
nuclear O
proteins O
in O
vitro O
. O

Cell O
cycle O
regulatory O
components O
have O
been O
largely O
conserved O
in O
eukaryotes O
; O
however O
, O
orthologs O
of O
neither O
CAK1 B_GENE
nor O
csk1 B_GENE
have O
been O
identified O
in O
other O
species O
to O
date O
. O

In O
this O
study O
, O
we O
cloned O
the O
full O
- O
length O
cDNA O
of O
mouse O
PAX4 B_GENE/B_DISEASE
by O
Race O
( O
rapid O
amplification O
of O
cDNA O
ends O
) O
using O
RNA O
from O
MIN6 O
cells O
, O
a O
mouse O
insulinoma O
cell O
line O
. O

Kohtz B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Hence O
the O
GAP1 B_GENE
gene I_GENE
encodes O
a O
protein O
with O
characteristics O
typical O
of O
integral O
membrane O
proteins O
translocating O
ligants O
across O
cellular O
membranes O
. O

The O
results O
suggest O
that O
proenzyme O
processing O
is O
not O
essential O
for O
secretion O
of O
PC2 B_GENE
, O
but O
peptides O
containing O
mutations O
that O
affect O
the O
ability O
of O
the O
propeptide O
( O
and O
cleavage O
sites O
) O
to O
fold O
within O
the O
catalytic O
pocket O
are O
not O
transferred O
beyond O
the O
early O
stages O
of O
the O
secretory O
pathway O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
transcription B_GENE
influences O
aspects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
conversion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
after O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
strand B_DISEASE/B_GENE
invasion B_DISEASE/I_GENE
and O
/ O
or O
mismatch B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
MMR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

Important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
prognostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
physiotherapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercises I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
intermittent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
claudication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Finally O
, O
in O
samples O
obtained O
from O
two O
patients O
with O
drug O
refractory O
All O
, O
BAC O
- O
derived O
probes O
applied O
to O
Archived O
marrow O
cells O
demonstrated O
that O
a O
breakpoint O
occurred O
between O
MDR1 B_GENE/B_DISEASE
and O
sequences O
500 O
- O
1000 O
KB O
telomeric O
to O
MDR1 B_GENE
, O
consistent O
with O
a O
random O
chromosomal O
rearrangement O
. O

Application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O
an O
11 B_NUMBER[MEASURE]
- O
year B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
microseismicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
record B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O
systematic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spatial I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
temporal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
slip B_LOCATION/B_MEASURE
rate I_LOCATION/I_MEASURE
that O
were O
synchronous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O
earthquake B_MEASURE/B_LOCATION
activity B_MEASURE/I_LOCATION
and O
other B_MEASURE
independent I_MEASURE
measures I_MEASURE
of O
fault B_DISEASE/B_LOCATION
- O
zone B_DISEASE_ADJECTIVE[DISEASE]
slip I_DISEASE_ADJECTIVE[DISEASE]
. O

PC12 O
cultures O
that O
had O
been O
' O
primed O
' O
in O
this O
way O
showed O
an O
accelerated O
and O
augmented O
differentiation O
response O
to O
nerve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

One O
of O
these O
clones O
encodes O
Xenopus B_GENE
N I_GENE
- I_GENE
ras I_GENE
. O

The O
Molteno B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
implant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
an O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
complicated B_DISEASE_ADJECTIVE[DISEASE]
and O
refractory B_DISEASE_ADJECTIVE[DISEASE]
cases I_DISEASE_ADJECTIVE[DISEASE]
of O
glaucoma B_DISEASE
in O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
eyes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

The O
median O
levels O
of O
t B_GENE/B_LOCATION
- I_GENE/I_LOCATION
PA I_GENE/I_LOCATION
Ag I_GENE/I_LOCATION
and O
PAI B_LOCATION/B_GENE
in O
plasma O
were O
respectively O
10 O
. O
7 O
ng O
/ O
ml O
( O
interquartile O
range O
8 O
. O
6 O
ng O
/ O
ml O
) O
and O
15 O
. O
7 O
IU O
/ O
ml O
( O
interquartile O
range O
12 O
. O
2 O
IU O
/ O
ml O
) O
. O

In O
the O
remaining O
91 O
patients O
( O
group O
2 O
) O
, O
Pseudomonas O
( O
18 O
) O
, O
coagulase B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative O
Staphylococci O
( O
15 O
) O
, O
Staphylococcus O
epidermidis O
( O
23 O
) O
, O
Staphylococcus O
aureus O
( O
16 O
) O
, O
Corynebacterium O
species O
( O
12 O
) O
, O
and O
others O
( O
seven O
) O
were O
isolated O
. O

Stamps B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
cardiology B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
de B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Musset I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
factor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
present I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
wounded O
potato B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tubers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
found O
to O
bind O
specifically O
to O
nucleotides B_GENE/B_DISEASE
located O
between O
- O
135 B_MEASURE
to O
- O
105 B_MEASURE
, O
suggesting O
that O
this O
region B_LOCATION/B_BIO
contains O
important B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
regulatory B_GENE/B_ORGANIZATION
elements I_GENE/I_ORGANIZATION
. O

The O
leucine O
zipper O
region O
of O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
also O
similar O
to O
that O
of O
the O
AP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
/ O
c B_GENE/B_MEASURE
- I_GENE/I_MEASURE
jun I_GENE/I_MEASURE
family O
of O
transcription O
factors O
, O
whose O
DNA O
- O
binding O
site O
differs O
from O
the O
ATF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
binding O
site O
at O
a O
single O
position O
. O

The O
R260A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
expected O
, O
was O
unable B_DISEASE_ADJECTIVE[DISEASE]
to O
support O
mRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
a O
transcription B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reconstitution B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reaction B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
as O
well O
as O
transcription B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
minigenome B_GENE
using O
a O
reverse B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

PEAP B_DISEASE/B_GENE
was O
significantly O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
IDC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O
to O
controls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
48 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
32 B_MEASURE
. O
6 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O

uterine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
contractions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
began O
with O
a O
mean B_MEASURE
latency I_MEASURE
of O
62 B_TIME[MEASURE]
min I_TIME[MEASURE]
in O
the O
PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infused O
women B_PERSON/B_SPECIES[BIO]
, O
in O
controls B_PERSON/B_MEASURE
uterine I_PERSON/I_MEASURE
activity I_PERSON/I_MEASURE
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Were O
this O
hypothesis O
correct O
, O
the O
requirement O
for O
elF4A B_GENE
should O
correlate O
with O
the O
degree O
of O
mRNA O
secondary O
structure O
. O

In O
spite B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
presence B_LOCATION/B_DISEASE
of O
a O
physician B_DISEASE
, O
the O
real B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pathology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
an O
Indian B_DISEASE/B_MEASURE
population I_DISEASE/I_MEASURE
of O
Colombie B_LOCATION/B_PERSON
is O
not O
very O
well O
known O
. O

taken O
together O
, O
these O
results O
demonstrate O
that O
the O
BSMV B_GENE/B_BIO
coat I_GENE/I_BIO
protein I_GENE/I_BIO
is O
the O
sole O
translation O
product O
of O
the O
genomic B_GENE
RNA I_GENE
beta I_GENE
, O
whereas O
sgRNA B_GENE/B_BIO
beta I_GENE/I_BIO
1 I_GENE/I_BIO
serves O
as O
a O
messenger O
for O
translation O
of O
the O
beta B_GENE
b I_GENE
protein I_GENE
, O
and O
sgRNA B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
beta I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
2 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions O
as O
a O
messenger O
for O
translation O
of O
beta B_GENE
c I_GENE
and O
beta B_GENE
d I_GENE
and O
the O
newly O
discovered O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
d I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
electroencephalographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
schizophrenic B_PERSON/B_BIO
patients B_PERSON/I_BIO
. O

The O
concepts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
developed O
by O
Mines B_LOCATION/B_PERSON
and O
Garrey B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
during O
the O
next B_TIME[MEASURE]/B_ENT
10 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
. O

When O
the O
measured O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
in O
the O
pWP O
- O
transfected O
cells O
was O
normalized O
to O
the O
pCH110 O
- O
transfected O
cells O
( O
an O
appropriate O
control O
if O
the O
SV40 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O
constitutively O
in O
various O
cell O
lines O
) O
, O
the O
results O
suggested O
that O
the O
promoter O
region O
of O
the O
PLP B_GENE
gene I_GENE
contains O
the O
information O
necessary O
for O
initiation O
of O
transcription O
in O
a O
C6 O
cell O
- O
specific O
manner O
. O

PKK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O
in O
three O
discernible O
forms O
at O
steady O
state O
: O
an O
underphosphorylated O
form O
of O
100 O
kDa O
; O
a O
soluble O
, O
cytosolic O
, O
phosphorylated O
form O
of O
110 O
kDa O
; O
and O
a O
phosphorylated O
, O
detergent O
- O
insoluble O
form O
of O
112 O
kDa O
. O

The O
P B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ITIM I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
compelled I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
multi I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binds O
to O
and O
activates O
SHP B_GENE
- I_GENE
2 I_GENE
, O
which O
in O
turn O
dephosphorylates O
SHIP B_GENE
and O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
probably O
other O
substrates O
. O

When O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
used O
to O
amplify O
agar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
which O
do O
not O
express O
the O
fimbriae B_BACTERIUM[BIO]/B_GENE
, O
the O
switch B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
region I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
Off O
only O
. O

mechanisms B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaesthetics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Student B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
health I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
now O
report O
that O
both O
HSCR B_GENE/B_MEASURE
mutations O
impair O
the O
fixation O
of O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
RET B_GENE
and O
consequently O
prevent O
its O
phosphorylation O
. O

The O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
quantities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O
were O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
appendicitis B_DISEASE/B_PERSON
and O
a O
normal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
appendix I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
sex B_PERSON/B_MEASURE
, O
duration B_MEASURE/B_DISEASE
of O
symptoms B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
anorexia B_DISEASE
and O
vomiting B_DISEASE/B_MEASURE
. O

We O
propose O
that O
U73 B_GENE
is O
involved O
in O
methylation O
of O
the O
G1739 O
residue O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
28S I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

At O
the O
start B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
performance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ride I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
averaged O
4 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
, O
5 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE/B_LOCATION
. O
1 B_MEASURE
, O
and O
5 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE/B_PERSON
mmol I_MEASURE/I_PERSON
. O
l B_TIME[MEASURE]/B_DISEASE
- O
1 B_MEASURE
in O
CON B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
Cho B_PERSON/B_PROTEIN[GENE]
- O
7 B_MEASURE
, O
and O
CHO B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
0 B_MEASURE
/ O
21 B_NUMBER[MEASURE]
, O
respectively O
( O
all O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Therefore O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
characterized O
in O
relation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
alpha B_PROTEIN[GENE]
not O
only O
by O
a O
stronger B_DISEASE_ADJECTIVE[DISEASE]
uterine I_DISEASE_ADJECTIVE[DISEASE]
effectiveness I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
also O
at O
the O
same B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
a O
pronounced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Copyright B_LOCATION/B_PERSON
1999 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Ganglia B_PERSON
are O
cysts B_DISEASE/B_BIO
which O
frequently O
occur O
in O
the O
proximity B_LOCATION/B_MEASURE
of O
joints B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Lysates O
of O
COS O
cells O
transfected O
with O
modified B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hGrzB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
able O
to O
hydrolyze O
tert O
- O
butyloxycarbonyl O
- O
Ala O
- O
Ala O
- O
Asp O
- O
thiobenzyl O
ester O
( O
Boc O
- O
Ala O
- O
Ala O
- O
Asp O
- O
SBzl O
) O
, O
whereas O
lysates O
transfected O
with O
unmodified B_GENE
hGrzB I_GENE
cDNA I_GENE
were O
inactive O
. O

proteins O
PBP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
and O
PBP B_GENE
- I_GENE
2 I_GENE
bind O
to O
two O
of O
the O
three O
promoter O
elements O
in O
the O
trypanosomatid O
Leptomonas O
seymouri O
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
medical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efficiency I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
integration B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicators I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
rational B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
utilization B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
budgeted O
funds B_PERSON/B_LOCATION
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tries O
to O
associate O
some O
of O
the O
causes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hot B_DISEASE
ischaemia I_DISEASE
during O
the O
agony B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
corpse B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
donor I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
evaluate O
those O
that O
may O
be O
caused O
by O
sympathetic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efference I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
removal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
enzyme O
encoded O
by O
the O
cloned O
fragment O
is O
equally O
active O
on O
pyruvate O
and O
hydroxypyruvate O
, O
indicating O
that O
the O
enzyme O
has O
both O
D B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
lactate B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
D B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
glycerate B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
dehydrogenase B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
activities O
. O

noise B_DISEASE_ADJECTIVE[DISEASE]
in O
STM B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
due O
to O
atoms B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moving O
in O
the O
tunneling B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

The O
human O
sequence O
contains O
the O
element O
TGACTCT O
that O
also O
is O
found O
in O
a O
murine B_GENE/B_SPECIES[BIO]
ras B_GENE/I_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
responsive B_GENE/I_SPECIES[BIO]
enhancer B_GENE/I_SPECIES[BIO]
. O

There O
is O
an O
overall O
functional O
similarity O
between O
IL B_GENE/B_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
6 B_GENE/I_SPECIES[BIO]
and O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fos I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
since O
transfection O
of O
excess O
amounts O
of O
either O
promoter O
DNA O
into O
intact O
HeLa O
cells O
modulates O
the O
function O
of O
the O
heterologous O
promoter O
construct O
. O

enhanced O
phospholipid B_DISEASE_ADJECTIVE[DISEASE]
hydrolysis I_DISEASE_ADJECTIVE[DISEASE]
with O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
increased O
release B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
excitatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
decreased O
tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
magnesium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
levels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
may O
each O
serve O
to O
worsen O
secondary B_DISEASE
tissue I_DISEASE
damage I_DISEASE
and O
diminish O
neurologic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
spinal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O
with O
acute B_DISEASE
alcohol I_DISEASE
intoxication I_DISEASE
. O

To O
determine O
whether O
the O
transcript O
encodes O
an O
active O
enzyme O
, O
we O
developed O
a O
novel O
transient O
embryonic O
excision O
assay O
in O
which O
zebrafish O
fertilized O
eggs O
were O
co O
- O
injected O
with O
RNA O
transcribed O
in O
vitro O
using O
the O
Tol2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
template O
and O
a O
plasmid O
DNA O
harboring O
a O
nonautonomous O
Tol2 B_LOCATION/B_GENE
element B_LOCATION/I_GENE
, O
which O
has O
a O
deletion O
in O
the O
transposase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
overall B_MEASURE
objective I_MEASURE
response I_MEASURE
rate I_MEASURE
( O
RR B_LOCATION/B_PROTEIN[GENE]
) O
was O
50 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
[ I_MEASURE/I_LOCATION
95 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
confidence I_MEASURE/I_LOCATION
interval I_MEASURE/I_LOCATION
( O
CI B_LOCATION/B_ORGANIZATION
) O
= O
29 B_MEASURE
- O
71 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
] I_MEASURE/I_PERSON
including O
four B_MEASURE
complete I_MEASURE
responses I_MEASURE
and O
eight B_NUMBER[MEASURE]/B_DISEASE
partial I_NUMBER[MEASURE]/I_DISEASE
responses I_NUMBER[MEASURE]/I_DISEASE
. O

We O
suggest O
that O
this O
relatively O
small O
deletion O
affects O
a O
segment O
containing O
3 B_GENE/B_LOCATION
' I_GENE/I_LOCATION
VH I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
with O
important O
regulatory O
functions O
, O
the O
loss O
of O
which O
leads O
to O
the O
Ali O
phenotype O
. O

Two O
SH2 B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
p120 B_GENE
Ras I_GENE
GTPase I_GENE
- I_GENE
activating I_GENE
protein I_GENE
bind O
synergistically O
to O
tyrosine O
phosphorylated O
p190 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Rho O
GTPase B_GENE
- I_GENE
activating I_GENE
protein I_GENE
. O

p120 B_GENE
GTPase I_GENE
- I_GENE
activating I_GENE
protein I_GENE
( O
GAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
negative O
regulator O
of O
Ras B_GENE/B_DISEASE
that O
functions O
at O
a O
key O
relay O
point O
in O
signal O
transduction O
pathways O
that O
control O
cell O
proliferation O
. O

A O
homologue O
of O
the O
MAP B_LOCATION/B_GENE
/ O
ERK B_GENE/B_DISEASE
family O
of O
protein O
kinase O
genes O
is O
expressed O
in O
vegetative O
and O
in O
female O
reproductive O
organs O
of O
Petunia O
hybrida O
. O

Its O
prognostic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
impact I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
T1 B_PROTEIN[GENE]/B_MEASURE
/ O
2 B_PROTEIN[GENE]
one I_PROTEIN[GENE]
( O
RR B_PROTEIN[GENE]/B_MEASURE
= O
2 B_MEASURE
. O
9 B_MEASURE
; O
p O
= O
0 B_MEASURE
. O
0010 B_MEASURE
) O
. O

It O
encodes O
a O
sequence O
- O
specific O
transcription O
factor O
that O
controls O
, O
in O
concert O
with O
other O
gene O
products O
, O
differentiative O
pathways O
of O
tissues O
in O
which O
Scr B_GENE/B_DISEASE
is O
expressed O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
DMIPP B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
detects I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
regionally O
hypoperfused O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
in O
which O
agreement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O
MBF B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
fatty B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uptake I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deteriorates O
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
guaiphenesin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
absorption B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
bioavailability B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
composite B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
analgesic I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
preparations I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

transcription B_TIME[MEASURE]/B_PERSON
of O
the O
inserted O
gene B_GENE/B_LOCATION
into O
the O
predicted B_MEASURE/B_PERSON
subgenomic B_MEASURE/I_PERSON
polyadenylated O
mRNA B_GENE/B_LOCATION
was O
demonstrated O
by O
Northern B_GENE/B_LOCATION
( O
RNA B_GENE/B_BIO
) O
blot B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
encoded B_GENE
protein I_GENE
was O
detected O
by O
enzyme B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
radioimmunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
panretinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
photocoagulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
offers O
a O
highly O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
means I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dealing O
with O
early B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
moderately O
advanced B_DISEASE_ADJECTIVE[DISEASE]
cases I_DISEASE_ADJECTIVE[DISEASE]
of O
angle B_DISEASE
neovascularization I_DISEASE
. O

NBSII B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
ribosome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
stimulated O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

Sixteen B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
25 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
encountered O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
while O
weaning O
at O
median B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
of O
9 B_MEASURE
. O
5 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
, O
1 B_MEASURE
- O
63 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
from O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
weaning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

ALT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O
and O
Hb B_PROTEIN[GENE]/B_DISEASE
( O
hemoglobin B_DISEASE/B_PROTEIN[GENE]
) O
appeared O
to O
be O
predictive O
for O
efficacy O
. O

theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
QID I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
TID B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
bid O
and O
now O
QD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

A O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
24 B_NUMBER[MEASURE]
- O
hour B_TIME[MEASURE]
dosing I_TIME[MEASURE]
with O
slow B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
release B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
theophylline I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
formulations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
emphasis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
used O
to O
obtain O
Food B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Administration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
approval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
Theo B_PERSON/B_PROTEIN[GENE]
- O
24 B_NUMBER[MEASURE]/B_LOCATION
. O

Signal O
transduction O
in O
fibroblasts O
stably O
transformed O
by O
[ O
Val12 O
] O
Ras O
- O
- O
the O
activities O
of O
extracellular B_GENE
- I_GENE
signal I_GENE
- I_GENE
regulated I_GENE
kinase I_GENE
and O
Jun B_GENE
N I_GENE
- I_GENE
terminal I_GENE
kinase I_GENE
are O
only O
moderately O
increased O
, O
and O
the O
activity O
of O
the O
delta O
- O
inhibitor O
of O
c B_GENE
- I_GENE
Jun I_GENE
is O
not O
alleviated O
. O

Time B_TIME[MEASURE]/B_PERSON
for O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
on O
hepatitis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immunisation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Escherichia O
coli O
cells O
expressing O
a O
mutant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glyV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
glycine B_PROTEIN[GENE]/B_LOCATION
tRNA I_PROTEIN[GENE]/I_LOCATION
) O
gene O
have O
a O
UVM O
- O
constitutive O
phenotype O
: O
implications O
for O
mechanisms O
underlying O
the O
mutA B_DISEASE/B_GENE
or O
mutC B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutator B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
effect O
. O

By O
24 B_MEASURE
h O
, O
there O
was O
no O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
difference B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
FFA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
from O
shams B_PERSON/B_TIME[MEASURE]
. O

This O
result O
suggests O
that O
the O
target O
protein O
specificity O
of O
E2s B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
altered O
by O
the O
addition O
of O
appropriate O
C O
- O
terminal O
extensions O
, O
thus O
providing O
a O
way O
to O
modify O
the O
selectivity O
of O
the O
ubiquitin B_PROTEIN[GENE]/B_BIO
system O
. O

Here O
we O
report O
the O
cloning O
of O
the O
hemF B_GENE
gene I_GENE
, O
encoding O
the O
aerobic O
coproporphyrinogen B_ENZYME[GENE]/B_MEASURE
III I_ENZYME[GENE]/I_MEASURE
oxidase I_ENZYME[GENE]/I_MEASURE
from I_ENZYME[GENE]/I_MEASURE
Escherichia I_ENZYME[GENE]/I_MEASURE
coli I_ENZYME[GENE]/I_MEASURE
, O
by O
functional O
complementation O
of O
a O
Saccharomyces B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cerevisiae B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HEM13 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
physical O
and O
biological O
characteristics O
of O
nebulized O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
liposomes O
. O

The O
atopic O
disposition O
, O
indicated O
by O
positive O
skin O
reactions O
and O
IgE B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
antibody O
titers O
etc O
. O
, O
and O
the O
bronchial O
reactivity O
to O
inhaled O
acetylcholine O
were O
examined O
on O
the O
following O
three O
groups O
: O
( O
1 O
) O
20 O
young O
adults O
with O
a O
history O
of O
childhood O
asthma O
who O
have O
been O
symptom O
- O
free O
for O
more O
than O
4 O
yr O
; O
( O
2 O
) O
20 O
current O
asthmatics O
, O
and O
( O
3 O
) O
20 O
healthy O
young O
adults O
. O

Previous O
studies O
showed O
that O
a O
palindromic O
sequence O
located O
at O
- O
159 O
base O
pairs O
is O
essential O
for O
induction O
of O
cutinase B_DISEASE/B_GENE
gene I_DISEASE/I_GENE
in O
Fusarium O
solani O
f O
. O

SP B_LOCATION/B_PROTEIN[GENE]
. O
pisi B_MEASURE/B_LOCATION
( O
Nectria B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
haematococca B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mating B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
type B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
VI B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
by O
the O
hydroxy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
acids I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
from O
plant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cutin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
that O
a O
50 B_MEASURE
- O
kDa B_MEASURE/B_LOCATION
nuclear B_MEASURE/I_LOCATION
protein B_MEASURE/I_LOCATION
binds O
to O
a O
promoter B_GENE
that O
contains O
this O
element B_PROTEIN[GENE]
. O

This O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports O
an O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HMPAO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
SPECT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
assessing O
regional B_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
in O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
function B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O
opiate B_DISEASE
dependence I_DISEASE
and O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
that O
these O
cDNAs O
belong O
to O
a O
novel O
GST B_GENE/B_BIO
class O
hereby O
designated O
Kappa O
, O
with O
the O
rat B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
GST I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
subunit I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
13 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
designated O
rGSTK1 B_PROTEIN[GENE]
and O
the O
human O
gene O
being O
called O
hGSTK1 B_GENE
. O

Based O
on O
PCR O
strategies O
and O
expression O
studies O
, O
we O
define O
the O
genomic O
organization O
of O
the O
FUT8b B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present O
study O
demonstrates O
that O
the O
proto B_GENE
- I_GENE
oncogene I_GENE
c I_GENE
- I_GENE
jun I_GENE
represses O
transcription O
of O
the O
human B_GENE
CG I_GENE
alpha I_GENE
and O
CG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

c B_GENE
- I_GENE
Jun I_GENE
repressed O
the O
CG B_GENE
alpha I_GENE
promoter I_GENE
through O
a O
canonical O
Camp O
response O
element O
( O
CRE O
) O
that O
is O
known O
to O
bind O
c B_GENE
- I_GENE
Jun I_GENE
and O
other O
members O
of O
the O
B B_GENE/B_PERSON
- I_GENE/I_PERSON
Zip I_GENE/I_PERSON
transcription I_GENE/I_PERSON
factor I_GENE/I_PERSON
family I_GENE/I_PERSON
. O

pulse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
monitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
outpatient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
dental I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
anaesthesia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

Previous O
studies O
using O
partial O
sequences O
have O
suggested O
the O
potential O
of O
26S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
large B_MEASURE/B_GENE
- I_MEASURE/I_GENE
subunit I_MEASURE/I_GENE
( O
LSU B_LOCATION/B_MEASURE
) O
rDNA O
for O
phylogeny O
retrieval O
at O
taxonomic O
levels O
comparable O
to O
those O
investigated O
with O
18S B_GENE/B_MEASURE
rDNA I_GENE/I_MEASURE
. O

The O
sensitivity O
of O
99mTc O
- O
IgG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy O
ranged O
between O
71 O
% O
and O
100 O
% O
. O

The O
index B_PERSON/B_BIO
patient I_PERSON/I_BIO
, O
a O
10 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
boy I_PERSON
, O
presents O
typical B_DISEASE
symptoms I_DISEASE
of O
OPD B_DISEASE/B_MEASURE
type I_DISEASE/I_MEASURE
I O
together O
with O
bowing O
of O
the O
long B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
abnormalities B_DISEASE
of O
the O
thorax B_BODY_PART_OR_ORGAN_COMPONENT
and O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
cause O
for O
the O
increase O
in O
plasma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ANP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
the O
active O
phase O
remains O
to O
be O
determined O
. O

A O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
representing O
the O
5 B_PERSON/B_LOCATION
' B_PERSON/I_LOCATION
part B_PERSON/I_LOCATION
of O
the O
message B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
isolated O
. O

antibiotics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
CDCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediation B_NUMBER[MEASURE]/B_LOCATION
are O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
symptomatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
main B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
myelosuppression B_DISEASE
, O
mucositis B_DISEASE
and O
peripheral B_DISEASE
neuropathy I_DISEASE
, O
which O
were O
all O
common B_DISEASE_ADJECTIVE[DISEASE]
and O
often O
severe B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
column B_MEASURE
densities I_MEASURE
of O
frozen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
inferred O
to O
be O
about O
2 B_MEASURE
. O
5 B_MEASURE
x O
10 B_MEASURE
( O
18 B_MEASURE
) O
and O
3 B_MEASURE
. O
0 B_MEASURE
x O
10 B_MEASURE
( O
19 B_MEASURE
) O
, O
respectively O
. O

Similarly O
, O
an O
increase O
in O
CAT B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression O
from O
the O
same O
construct O
( O
pBLCAT O
- O
ENDOA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
also O
observed O
in O
7AQS2 O
. O
1 O
cells O
. O

The O
prevalence O
of O
antibodies O
to O
HRES B_DISEASE
- I_DISEASE
1 I_DISEASE
peptides I_DISEASE
pep14 I_DISEASE
- I_DISEASE
24 I_DISEASE
and I_DISEASE
pep117 I_DISEASE
- I_DISEASE
127 I_DISEASE
was O
determined O
in O
65 O
normal O
blood O
donors O
and O
146 O
patients O
with O
immunological O
disorders O
. O

We O
recently O
reported O
the O
cloning O
and O
sequencing O
of O
the O
alpha B_GENE
7 I_GENE
integrin I_GENE
chain I_GENE
and O
its O
regulated O
expression O
during O
the O
development O
of O
skeletal O
muscle O
( O
Song O
et O
al O
. O

The O
contractile O
effects O
of O
oxytocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prostaglandin O
F2 O
alpha O
and O
their O
combined O
use O
on O
human O
pregnant O
myometrium O
were O
studied O
in O
vitro O
. O

These O
involve O
( O
1 O
) O
subcloning O
a O
promoterless O
sucCD B_LOCATION/B_GENE
fragment B_LOCATION/I_GENE
downstream O
of O
the O
lac B_GENE/B_BIO
promoter I_GENE/I_BIO
in O
M13mp10 O
, O
and O
( O
2 O
) O
precise O
splicing O
of O
the O
suc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
efficient O
atpE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
ribosome I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
- I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
binding I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
site I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O
expression O
from O
the O
thermoinducible O
lambda O
promoters O
in O
the O
pJLA503 O
vector O
. O

These O
mutations O
prevent O
FKBP12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
rapamycin O
binding O
to O
TOR2 B_GENE
, O
as O
assayed O
with O
the O
two O
- O
hybrid O
system O
. O

Transcription B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
eukaryotic B_GENE
tRNA I_GENE
genes I_GENE
is O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O
the O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
and O
B B_PROTEIN[GENE]/B_DISEASE
- O
Box B_LOCATION/B_BIO
internal I_LOCATION/I_BIO
control I_LOCATION/I_BIO
regions I_LOCATION/I_BIO
( O
ICRs B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
upstream B_GENE/B_LOCATION
transcription I_GENE/I_LOCATION
modulatory I_GENE/I_LOCATION
region I_GENE/I_LOCATION
. O

Failure B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
demonstrate O
a O
major B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anti I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
with O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tocopherol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
supplementation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
400 B_MEASURE
IU I_MEASURE
/ O
day B_MEASURE/B_LOCATION
) O
in O
normal B_PERSON/B_BIO
subjects I_PERSON/I_BIO
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
paroxysmal B_DISEASE
AF I_DISEASE
have O
been O
equivocal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
this O
may O
be O
attributed O
to O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
defining O
paroxysmal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AF I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

High O
- O
level O
expression O
of O
sccypB B_GENE/B_BACTERIUM[BIO]
as O
well O
as O
of O
sccypA B_BIO/B_GENE
cloned O
into O
the O
expression O
vector O
pIJ702 O
did O
not O
produce O
detectable O
changes O
in O
growth O
and O
morphology O
of O
S O
. O
chrysomallus O
and O
S O
. O
lividans O
. O

Fas B_GENE
( O
APO B_GENE
- I_GENE
1 I_GENE
/ O
CD95 B_GENE/B_MEASURE
) O
, O
which O
is O
a O
member O
of O
the O
tumor B_GENE/B_LOCATION
necrosis I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
superfamily I_GENE/I_LOCATION
, O
is O
a O
cell O
surface O
receptor O
that O
induces O
apoptosis O
. O

In O
the O
future B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
transoesophageal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
may O
be O
used O
to O
measure O
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
wall B_MEASURE/B_LOCATION
thickness I_MEASURE/I_LOCATION
which O
change O
the O
global B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loading B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
basal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
midwall B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
compartments B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
studied O
18 B_SPECIES[BIO]/B_PERSON
dogs I_SPECIES[BIO]/I_PERSON
, O
anaesthetised O
and O
spontaneously O
breathing O
both O
room B_LOCATION/B_MEASURE
air I_LOCATION/I_MEASURE
and O
after O
the O
inhalation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
a O
gas B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
20 B_MEASURE
. O
9 B_MEASURE
% I_MEASURE
O2 I_MEASURE
, O
and O
69 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
N2 I_MEASURE
, O
to O
determine O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
acidaemia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
pulmonary B_DISEASE
hypertension I_DISEASE
produced O
by O
hypercapnia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sequencing O
of O
this O
fragment O
showed O
that O
the O
MRP13 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding O
region O
specifies O
a O
324 O
- O
amino O
- O
acid O
basic O
protein O
with O
a O
calculated O
Mr O
of O
37 O
, O
366 O
. O

viral O
complementary O
15 B_GENE
S I_GENE
mRNA I_GENE
that O
directs O
the O
synthesis O
of O
N B_GENE
protein I_GENE
and O
hybridizes O
to O
the O
predicted O
N B_GENE/B_VIRUS[BIO]
gene B_GENE/I_VIRUS[BIO]
DNA O
has O
been O
identified O
in O
infected O
cell O
extracts O
. O

Electrophoretic O
mobility O
shift O
assays O
and O
DNase B_GENE
I I_GENE
protection O
analyses O
revealed O
that O
FP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
bound O
by O
the O
transcription O
factor O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
Spi B_MEASURE/B_GENE
- I_MEASURE/I_GENE
1 I_MEASURE/I_GENE
. O

Retroviral O
vector O
producer O
cell O
populations O
and O
cell O
clones O
were O
established O
for O
each O
chLTR B_PERSON/B_GENE
vector O
, O
and O
all O
were O
capable O
of O
yielding O
high O
vector O
titers O
( O
> O
10 O
( O
5 O
) O
G418R B_MEASURE
cfu O
/ O
ml O
on O
NIH O
- O
3T3 O
) O
. O

However O
, O
a O
few O
sites O
in O
the O
genomes O
of O
EC O
cells O
permit O
M B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
MuLVneo I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
delta I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Enh I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proviral O
expression O
. O

increasing O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitivity O
in O
type O
I O
diabetic O
patients O
should O
alert O
clinicians O
to O
the O
possibility O
of O
glucocorticoid O
deficiency O
. O

However O
, O
differential O
utilization O
of O
these O
determinants O
mediate O
RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
RXR B_PROTEIN[GENE]/B_LOCATION
heterodimer O
binding O
to O
DR O
- O
2 O
and O
DR O
- O
5 O
RAREs O
. O

Galactorrhoea B_DISEASE/B_LOCATION
is O
a O
rare B_DISEASE_ADJECTIVE[DISEASE]
presentation I_DISEASE_ADJECTIVE[DISEASE]
of O
an O
empty B_DISEASE
sella I_DISEASE
syndrome I_DISEASE
. O

The O
addition O
of O
novel O
techniques O
, O
such O
as O
histopathologic O
ultrastaging O
, O
immunohistochemistry O
staining O
, O
and O
reverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptase B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O
chain O
reaction O
assays O
, O
will O
help O
increase O
the O
accuracy O
and O
rate O
of O
detection O
of O
disease O
. O

Several O
of O
the O
drugs O
used O
in O
the O
management O
of O
MAC O
have O
been O
associated O
with O
significant O
drug O
interactions O
involving O
the O
cytochrome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
P450 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CYP B_GENE/B_BIO
) O
enzyme O
system O
. O

Arterial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
intraarterial B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pulse I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contour I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
a O
modified O
Windkessel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
carried O
out O
in O
19 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
isolated B_DISEASE/B_GENE
systolic I_DISEASE/I_GENE
hypertension I_DISEASE/I_GENE
( O
> B_OTHER/B_MEASURE
or O
= O
160 B_MEASURE
/ O
< B_MEASURE/B_OTHER
or O
= O
90 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
) O
and O
compared O
to O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
29 B_PERSON
patients I_PERSON
with O
essential B_DISEASE_ADJECTIVE[DISEASE]
hypertension I_DISEASE_ADJECTIVE[DISEASE]
( O
diastolic B_MEASURE/B_LOCATION
blood I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
[ O
BP B_TIME[MEASURE]/B_PROTEIN[GENE]
] O
> B_MEASURE/B_OTHER
or O
= O
95 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
) O
and O
47 B_DISEASE/B_MEASURE
normotensive I_DISEASE/I_MEASURE
control I_DISEASE/I_MEASURE
subjects I_DISEASE/I_MEASURE
. O

Rather O
than O
seeking O
a O
blanket B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
an O
essentially O
heterogeneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
it O
may O
be O
more O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
consider O
idiom B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
comprehension I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manifestation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
semantic B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
pragmatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
difficulties B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
U B_PROTEIN[GENE]/B_LOCATION
- O
74006F B_MEASURE/B_LOCATION
were O
equally O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
preventing O
neurological B_DISEASE
dysfunction I_DISEASE
compared O
to O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
; O
U B_PROTEIN[GENE]/B_LOCATION
- O
78517F B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
slightly O
less O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
U B_PROTEIN[GENE]/B_LOCATION
- O
74006F B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
was O
significantly O
better B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
preventing O
neurological B_DISEASE
dysfunction I_DISEASE
. O

The O
women B_PERSON/B_BIO
in O
the O
intermediate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
calcium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O
approximately O
the O
same B_MEASURE/B_LOCATION
mean I_MEASURE/I_LOCATION
BMD I_MEASURE/I_LOCATION
values I_MEASURE/I_LOCATION
as O
those O
in O
the O
low B_PERSON
calcium I_PERSON
group I_PERSON
. O

International B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
now O
being O
made O
to O
standardize O
haemolytic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
meant O
as O
a O
contribution B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
this O
. O

The O
transition B_DISEASE/B_LOCATION
from O
expression B_GENE
of O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
meiotic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
expression B_GENE
of O
middle B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sporulation I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
specific B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
occurs O
at O
about O
the O
time B_TIME[MEASURE]/B_LOCATION
that O
cells O
exit O
from O
pachytene B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O
form O
the O
meiosis B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I O
spindle O
. O

NF B_GENE/B_PERSON
- I_GENE/I_PERSON
kappaB I_GENE/I_PERSON
DNA O
- O
protein O
binding O
and O
ICAM B_GENE
- I_GENE
1 I_GENE
promoter I_GENE
activity O
were O
enhanced O
by O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
these O
effects O
were O
inhibited O
by O
tyrphostin O
23 O
, O
but O
not O
by O
PD O
98059 O
or O
SB O
203580 O
. O

Peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
cherry B_PERSON/B_COLOR
- O
red B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
spot I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
- O
myoclonus B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
sialidosis B_DISEASE/B_MEASURE
type I_DISEASE/I_MEASURE
I I_DISEASE/I_MEASURE
) O
. O

Using O
the O
two O
- O
hybrid O
screening O
method O
, O
we O
have O
identified O
an O
additional O
component O
of O
the O
CCAAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
myb B_GENE
proto I_GENE
oncogene I_GENE
product I_GENE
( O
c B_GENE/B_DISEASE
- I_GENE/I_DISEASE
Myb I_GENE/I_DISEASE
) O
is O
a O
transcriptional O
regulator O
and O
its O
expression O
and O
function O
are O
tightly O
linked O
to O
the O
cellular O
entry O
into O
S O
phase O
and O
DNA O
synthesis O
. O

Both O
the O
p38 B_GENE
kinase I_GENE
inhibitor O
SB205380 O
( O
SB O
) O
and O
cotransfection O
of O
a O
dominant O
- O
negative O
mutant O
of O
p38 B_GENE
kinase I_GENE
reduced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O
of O
the O
hBNP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Clinical B_MEASURE
Features I_MEASURE
: O
This O
30 B_MEASURE
- O
yr B_TIME[MEASURE]/B_PERSON
- O
old B_LOCATION/B_PERSON
gravida B_LOCATION/I_PERSON
V I_PERSON
para B_PERSON/B_LOCATION
0 I_PERSON
woman I_PERSON
presented O
to O
the O
anaesthesia B_PERSON/B_LOCATION
consultation I_PERSON/I_LOCATION
clinic I_PERSON/I_LOCATION
at O
37 B_MEASURE/B_LOCATION
- O
wk B_TIME[MEASURE]/B_PERSON
gestation I_TIME[MEASURE]/I_PERSON
to O
discuss O
pain B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relief I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
options I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
labour B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
delivery B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
TaqI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
HaeIII B_GENE/B_DISEASE
RFLPs O
will O
provide O
tools O
for O
the O
genetic O
analysis O
of O
CR2 B_DISEASE/B_BIO
. O

In O
addition O
, O
because O
SB203580 O
had O
no O
effect O
of O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
or O
ceramide O
- O
induced O
apoptosis O
, O
our O
results O
strongly O
argue O
against O
a O
role O
for O
p38 B_GENE
MAPK I_GENE
in O
the O
induction O
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
or O
ceramide O
- O
induced O
apoptosis O
. O

Cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
attention B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
the O
Stroop B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
Controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Oral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
word I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Association I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
the O
letters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
' O
' O
F B_OTHER/B_PROTEIN[GENE]
, O
' O
and O
' O
L B_OTHER/B_PROTEIN[GENE]
' O
( O
COWAT B_TIME[MEASURE]/B_LOCATION
, O
CFL B_MEASURE/B_LOCATION
version I_MEASURE/I_LOCATION
) O
. O

Ptx1 B_GENE/B_PERSON
belongs O
to O
an O
expanding O
family O
of O
bicoid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
related I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
vertebrate O
homeobox O
genes O
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dietary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lipids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
whole B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
retention I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
organ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
organic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
inorganic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mercury I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

differential O
transcription O
of O
plastome O
- O
encoded O
genes O
in O
the O
mesophyll O
and O
bundle O
- O
sheath O
chloroplasts O
of O
the O
monocotyledonous O
NADP O
- O
malic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
type O
C4 O
plants O
maize O
and O
Sorghum O
. O

Sequential O
immunoprecipitation O
showed O
all O
detectable O
p53 B_GENE
to O
be O
of O
the O
PAb246 B_GENE
+ I_GENE
class O
in O
each O
LPV O
- O
transformed O
cell O
line O
, O
suggesting O
that O
the O
stable O
p53 B_GENE/B_MEASURE
was O
indeed O
wild O
type O
. O

Tissue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gene I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
regulation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
eukaryotic B_BIO/B_GENE
organisms B_BIO/I_GENE
is O
to O
a O
large B_MEASURE
extent I_MEASURE
mediated O
by O
transcription B_GENE
factors I_GENE
that O
interact O
with O
genomic B_GENE/B_BIO
DNA I_GENE/I_BIO
sequences I_GENE/I_BIO
in O
a O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

enhanced O
quantum B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bound B_SEQUENCE[MEASURE]/B_LOCATION
higher I_SEQUENCE[MEASURE]/I_LOCATION
- O
order B_MEASURE
solitons I_MEASURE
quantum I_MEASURE
effects I_MEASURE
in O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
bound O
solitons B_LOCATION
can O
be O
drastically O
enhanced O
compared O
to O
the O
fundamental B_TIME[MEASURE]/B_LOCATION
soliton I_TIME[MEASURE]/I_LOCATION
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
compromised O
fibrinolytic B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
a O
contributing O
factor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
thrombosis B_DISEASE
in O
patients B_PERSON/B_BIO
with O
the O
lupus B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
MEE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O
significantly O
greater B_MEASURE
than O
the O
bee B_PROTEIN[GENE]/B_LOCATION
and O
significantly O
less B_MEASURE
than O
the O
calculated B_MEASURE/B_LOCATION
energy I_MEASURE/I_LOCATION
expenditure I_MEASURE/I_LOCATION
. O

These O
results O
suggest O
that O
E6010 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
of O
clinical O
value O
in O
the O
treatment O
of O
coronary O
occlusion O
. O

To O
better O
understand O
the O
relationship O
between O
expression O
of O
an O
oncogene O
and O
genetic O
instability O
, O
we O
have O
studied O
a O
cell O
line O
expressing O
an O
activated B_GENE
human I_GENE
Ha I_GENE
- I_GENE
ras I_GENE
under O
the O
control O
of O
bacterial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lactose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
operon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
elements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
changes O
in O
methotrexate O
resistance O
and O
dihydrofolate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
dhfr B_LOCATION/B_PROTEIN[GENE]
) O
gene O
amplification O
following O
mutant B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ha B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O
. O

On O
a O
variety B_ENT/B_MEASURE
of O
fronts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
chronic B_DISEASE/B_GENE
bacterial I_DISEASE/I_GENE
infection I_DISEASE/I_GENE
is O
being O
found O
to O
be O
significantly O
associated O
with O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
atherosclerosis B_DISEASE
and O
the O
clinical B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
of O
unstable B_DISEASE
angina I_DISEASE
, O
myocardial B_DISEASE
infarction I_DISEASE
, O
and O
stroke B_DISEASE
. O

Long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
curative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanisms I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
vesicoureteral B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflux B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
endoscopic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

inspection O
of O
X B_GENE/B_BIO
. I_GENE/I_BIO
tropicalis I_GENE/I_BIO
, I_GENE/I_BIO
mouse I_GENE/I_BIO
and I_GENE/I_BIO
human I_GENE/I_BIO
U6 I_GENE/I_BIO
DNA I_GENE/I_BIO
upstream I_GENE/I_BIO
sequences I_GENE/I_BIO
revealed O
the O
presence O
of O
a O
TATA O
box O
as O
well O
as O
of O
the O
proximal O
and O
enhancer O
( O
octamer O
motif O
) O
elements O
contained O
in O
snRNA O
genes O
transcribed O
by O
RNA B_GENE/B_VIRUS[BIO]
polymerase B_GENE/I_VIRUS[BIO]
II B_GENE/I_VIRUS[BIO]
. O

Characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
an O
unusual B_GENE
tRNA I_GENE
- O
like B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
found O
inserted O
in O
a O
Neurospora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retroplasmid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

repeated O
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
course I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
same B_PERSON/B_LOCATION
patient B_PERSON/I_LOCATION
were O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
although O
the O
absolute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
some O
variation B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
represents O
an O
attempt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
develop O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
measuring O
relative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blood I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
intestinal B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
capillaries I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
by O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
F B_PROTEIN[GENE]/B_DISEASE
) O
as O
an O
indicator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PAX8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generates O
at O
least O
five O
different O
alternatively O
spliced O
transcripts O
encoding O
different O
PAX8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
show O
that O
both O
Sp1 B_GENE/B_LOCATION
and O
Sp3 B_GENE
transcription I_GENE
factors I_GENE
upregulate O
HGF B_GENE
promoter I_GENE
activity O
by O
binding O
to O
the O
Sp1 B_GENE/B_TIME[MEASURE]
binding I_GENE/I_TIME[MEASURE]
site I_GENE/I_TIME[MEASURE]
at O
position O
- O
318 O
to O
- O
303 O
BP O
in O
the O
HGF B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
. O

After O
a O
1 B_MEASURE
- O
h B_TIME[MEASURE]/B_LOCATION
rest I_TIME[MEASURE]/I_LOCATION
( O
for O
T2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
return I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
subjects B_PERSON
repeated O
the O
5 B_NUMBER[MEASURE]
- O
min B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
followed O
by O
a O
final B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
/ O
MRS B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
arrest O
in O
the O
G1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cell B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
grow O
a O
projection B_LOCATION/B_MEASURE
towards O
one B_NUMBER[MEASURE]/B_PERSON
another O
forming O
a O
shmoo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
projection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Mammalian O
homologues O
of O
the O
Polycomb B_GENE
- I_GENE
group I_GENE
gene I_GENE
Enhancer I_GENE
of I_GENE
zeste I_GENE
mediate O
gene O
silencing O
in O
Drosophila O
heterochromatin O
and O
at O
S O
. O
cerevisiae O
telomeres O
. O

With O
six B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
show O
there O
is O
an O
order B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
melanoma O
nodal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
that O
the O
SLN B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
histology B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
reflective B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
histology B_DISEASE
of O
the O
remainder B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
nodal B_DISEASE/B_PERSON
basin I_DISEASE/I_PERSON
, O
the O
more O
conservative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
SLN I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
biopsy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
can O
be O
performed O
to O
adequately O
stage O
nodally O
the O
patient B_PERSON/B_DISEASE
with O
melanoma B_DISEASE/B_GENE
. O

The O
results O
obtained O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F304 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
R2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
indicate O
that O
structural O
changes O
in O
E B_LOCATION/B_PROTEIN[GENE]
. B_LOCATION/I_PROTEIN[GENE]
coli B_LOCATION/I_PROTEIN[GENE]
R2 B_LOCATION/I_PROTEIN[GENE]
in O
the O
vicinity O
of O
this O
helix O
distortion O
can O
influence O
the O
catalytic O
activity O
of O
the O
holoenzyme O
. O

Cloning O
and O
characterization O
of O
the O
5 O
' O
flanking O
region O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
citrate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lyase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cryoglobulinaemia B_DISEASE
among O
maintenance B_PERSON/B_BIO
haemodialysis I_PERSON/I_BIO
patients I_PERSON/I_BIO
and O
its O
relation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
hepatitis B_DISEASE
C I_DISEASE
infection I_DISEASE
. O

The O
S3 B_GENE
protein I_GENE
also O
contains O
a O
DNA O
repair O
activity O
, O
efficiently O
processing O
8 O
- O
oxoguanine O
residues O
in O
DNA O
via O
an O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycosylase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
/ O
apurinic B_ENZYME[GENE]
- I_ENZYME[GENE]
apyrimidinic I_ENZYME[GENE]
( I_ENZYME[GENE]
AP I_ENZYME[GENE]
) I_ENZYME[GENE]
lyase I_ENZYME[GENE]
activity O
. O

25 B_PERSON
patients I_PERSON
received O
20 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mgs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
hyoscine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
butyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
rest B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mgs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propinoxate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
plus O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
present O
here O
a O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
we O
developed O
to O
identify O
the O
sequence B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
elements B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
may O
be O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
this O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cycle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Computed B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tomographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pancreatic B_DISEASE
ductal I_DISEASE
adenocarcinoma I_DISEASE
were O
studied O
with O
the O
combined O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
early B_DISEASE_ADJECTIVE[DISEASE]
enhancement I_DISEASE_ADJECTIVE[DISEASE]
CT I_DISEASE_ADJECTIVE[DISEASE]
and O
high B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancement I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
72 B_MEASURE/B_DISEASE
carcinomas I_MEASURE/I_DISEASE
. O

No O
other B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcripts B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_GENE
length I_GENE
could O
be O
detected O
after O
prolonged B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
, O
therefore O
, O
that O
in O
the O
absence O
of O
E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
E4orf4 B_GENE
is O
sufficient O
by O
itself O
to O
trigger O
a O
p53 B_GENE
- O
independent O
apoptosis O
pathway O
that O
may O
operate O
independently O
of O
the O
known O
zVAD O
- O
inhibitable O
caspases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
may O
involve O
an O
as O
yet O
uncharacterized O
mechanism O
. O

The O
antiserum O
used O
for O
immunoblotting O
specifically O
supershifts O
uteroglobin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
gel O
shift O
experiments O
. O

The O
nucleotide O
sequence O
of O
the O
estrogen B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Oreochromis I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aureus I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OaER B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
indicates O
that O
the O
hormone O
- O
binding O
E O
domain O
is O
composed O
of O
4 O
exons O
interspersed O
by O
short O
introns O
of O
only O
0 O
. O
18 O
- O
1 O
. O
3 O
kb O
each O
. O

The O
expression O
of O
Scmh1 B_GENE
and O
rae28 B_LOCATION/B_GENE
/ O
mph1 B_MEASURE
is O
well O
correlated O
in O
most O
tissues O
of O
embryos O
. O

The O
nucleoporin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
98 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NUP98 B_GENE/B_DISEASE
) O
, O
which O
is O
rearranged O
in O
several O
acute O
myeloid O
leukemia O
translocations O
, O
is O
located O
within O
this O
region O
. O

We O
have O
isolated O
and O
sequenced O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O
to O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
novel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
map O
to O
Xq28 B_SPECIES[BIO]/B_GENE
. O

A O
new O
direct O
hemagglutination O
test O
( O
hi O
- O
GONAVIS O
) O
for O
urinary O
LH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
compared O
with O
the O
serum O
radioimmuno O
- O
assay O
of O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

diffusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
epidemic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
incubation B_LOCATION/B_GENE
and O
crisscross B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

CERIP B_ORGANIZATION/B_PERSON
interaction O
. O

The O
encoded O
Arabidopsis B_GENE/B_LOCATION
U3 I_GENE/I_LOCATION
snRNAs I_GENE/I_LOCATION
can O
be O
folded O
into O
a O
secondary O
structure O
which O
is O
more O
similar O
to O
that O
of O
U3 B_GENE/B_BIO
RNAs I_GENE/I_BIO
from O
lower O
eukaryotes O
rather O
than O
from O
metazoa O
. O

Therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
irreversible B_DISEASE
shock I_DISEASE
with O
pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
some O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
1 B_MEASURE
mL I_MEASURE
) O
and O
2H5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
internal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
05 B_MEASURE
mL I_MEASURE
, O
100 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_MEASURE
) O
were O
extracted O
with O
Toxi B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tubes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
Toxi B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Lab B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Irvine B_LOCATION/B_PERSON
, O
CA B_LOCATION/B_MEASURE
) O
and O
analyzed O
by O
gas B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
radioactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Guarapari B_DISEASE/B_LOCATION
. O

The O
LT B_GENE
- I_GENE
beta I_GENE
gene I_GENE
is O
expressed O
in O
lymphoid O
cells O
and O
organs O
, O
but O
little O
is O
known O
about O
its O
inducible O
regulation O
. O

ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
attained O
a O
peak B_MEASURE/B_DISEASE
serum I_MEASURE/I_DISEASE
concentration I_MEASURE/I_DISEASE
of O
1 B_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
l B_OTHER/B_MEASURE
and O
a O
serum B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
half I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
life B_TIME[MEASURE]/B_LOCATION
of O
34 B_NUMBER[MEASURE]/B_PERSON
min I_NUMBER[MEASURE]/I_PERSON
. O

Dmyd B_PERSON
clone O
encodes O
a O
polypeptide O
of O
332 O
amino O
acids O
with O
82 O
% O
identity O
to O
MyoD B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
the O
41 O
amino O
acids O
of O
the O
putative O
helix O
- O
loop O
- O
helix O
region O
and O
100 O
% O
identity O
in O
the O
13 O
amino O
acids O
of O
the O
basic O
domain O
proposed O
to O
contain O
the O
essential O
recognition O
code O
for O
muscle O
- O
specific O
gene O
activation O
. O

identification O
of O
an O
osteocalcin B_GENE
gene I_GENE
promoter I_GENE
sequence I_GENE
that O
binds O
AP1 B_GENE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
based O
on O
antifungal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
most O
frequently O
nystatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

mutations O
abolishing O
MalK B_GENE/B_BIO
function O
not O
only O
result O
in O
inability O
to O
transport O
maltose O
but O
also O
cause O
constitutive O
expression O
of O
the O
maltose B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
regulon I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Drosophila B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
melanogaster I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
casein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DmCKII B_GENE/B_TIME[MEASURE]
) O
is O
composed O
of O
catalytic O
( O
alpha O
) O
and O
regulatory O
( O
beta O
) O
subunits O
associated O
as O
an O
alpha2beta2 O
heterotetramer O
. O

The O
aims B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
to O
examine O
whether O
the O
EORTC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
European B_ORGANIZATION/B_PERSON
Organisation I_ORGANIZATION/I_PERSON
for O
Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Cancer B_DISEASE/B_LOCATION
) O
QLQ B_MEASURE/B_DISEASE
- O
C30 B_NUMBER[MEASURE]/B_LOCATION
core I_NUMBER[MEASURE]/I_LOCATION
questionnaire I_NUMBER[MEASURE]/I_LOCATION
alone O
could O
distinguish O
between O
two B_NUMBER[MEASURE]
clinically O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
patients B_PERSON/B_DISEASE
and O
to O
design O
a O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
which O
included O
relevant B_PERSON/B_LOCATION
patient B_PERSON/I_LOCATION
- O
defined O
gastric B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cancer I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
both O
indocyanine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
green I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
video I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
fluorescein B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
angiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
hypofluorescent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
almost O
the O
same B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
size I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
as O
the O
light B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
yellow I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
area I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
dark B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yellow I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
center I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
placoid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lesion I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
have O
measured O
percentage B_MEASURE/B_DISEASE
O3 B_MEASURE/I_DISEASE
uptake B_MEASURE/I_DISEASE
in O
30 B_PERSON
adult I_PERSON
Sprague I_PERSON
- O
Dawley B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O
, O
nose B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
, O
for O
1 B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hr B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
0 B_MEASURE/B_LOCATION
. O
3 B_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
6 B_MEASURE
, O
or O
1 B_MEASURE
. O
0 B_MEASURE
ppm I_MEASURE
O3 I_MEASURE
. O

The O
signal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
to O
- O
noise B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SNR B_LOCATION/B_DISEASE
) O
was O
calculated O
in O
the O
T2 B_MEASURE/B_LOCATION
- O
weighted O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Cell O
rounding O
was O
abrogated O
by O
expression O
of O
either O
kinase O
- O
dead O
forms O
of O
US3 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
a O
mutant O
protein O
lacking O
the O
acidic O
cluster O
in O
the O
kinase O
regulatory O
domain O
. O

Three O
distinct O
human B_GENE/B_BIO
HDACs I_GENE/I_BIO
are O
homologous O
to O
RPD3 B_GENE
, O
a O
yeast O
transcriptional O
regulator O
. O

The O
4 B_NUMBER[MEASURE]
- O
nt B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
of O
the O
rotavirus B_MEASURE/B_BIO
3 I_MEASURE/I_BIO
' O
TE B_GENE/B_DISEASE
represents O
by O
far O
the O
shortest B_SEQUENCE[MEASURE]
of O
any O
of O
the O
sequence B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O
to O
stimulate O
translation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
audiologic B_DISEASE_ADJECTIVE[DISEASE]
presentation I_DISEASE_ADJECTIVE[DISEASE]
of O
vestibular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
schwannoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
vs B_MEASURE/B_PROTEIN[GENE]
) O
associated O
with O
neurofibromatosis B_DISEASE/B_GENE
type I_DISEASE/I_GENE
2 I_DISEASE/I_GENE
( O
NF2 B_GENE/B_LOCATION
) O
has O
not O
been O
well O
characterized O
. O

expression O
of O
these O
chemokines O
is O
similar O
in O
that O
both O
require O
the O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
element I_GENE
and O
additional O
regions O
such O
as O
the O
CAAT B_GENE
/ I_GENE
enhancer I_GENE
binding I_GENE
protein I_GENE
( O
C B_GENE/B_LOCATION
/ I_GENE/I_LOCATION
EBP I_GENE/I_LOCATION
) O
element O
of O
the O
IL B_GENE
- I_GENE
8 I_GENE
promoter I_GENE
. O

The O
meaning B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
hope B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
health B_PERSON/B_DISEASE
and O
illness B_DISEASE/B_PERSON
. O

Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
two B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anion I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exchange B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resins I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
screening B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
urinary B_DISEASE
porphobilinogen I_DISEASE
. O

Aggravation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
blood B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cytopenia B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
during O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hypocellularity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
marrow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
aspirates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
suggest O
that O
low B_MEASURE/B_COLOR
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ara I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exerts O
its O
main B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leukaemic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
rather O
than O
by O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
malignant B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

All O
depressive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
error B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Triaxiality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
proton B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
neutron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boson I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Perturbed O
O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_NUMBER[MEASURE]
) O
symmetry B_MEASURE/B_LOCATION
with O
application B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
mass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
best B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
pelvic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
, O
in O
our O
experience B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IR B_MEASURE/B_PERSON
or O
short B_LOCATION/B_MEASURE
TR B_LOCATION/I_MEASURE
spin B_LOCATION/I_MEASURE
- O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
T1 B_MEASURE/B_LOCATION
- O
weighted O
images B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
spin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
1200 B_MEASURE/B_PROTEIN[GENE]
TR B_MEASURE/I_PROTEIN[GENE]
for O
T2 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cells O
were O
co O
- O
infected O
simultaneously O
with O
IBV O
, O
the O
recombinant O
FPV O
( O
rFPV O
) O
containing O
the O
D O
- O
RNA O
sequence O
and O
a O
second O
rFPV O
expressing O
T7 B_GENE
RNA I_GENE
polymerase I_GENE
for O
the O
initial O
expression O
of O
the O
D O
- O
RNA O
transcript O
, O
subsequently O
rescued O
by O
helper O
IBV O
. O

seasonal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cadmium B_MEASURE/B_DISEASE
content B_MEASURE/I_DISEASE
of O
Murex B_BIO/B_LOCATION
trunculus I_BIO/I_LOCATION
in O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
cadmium B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
polluted I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
environment I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
in O
relation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
predicted O
isoform B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
L I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diversity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
across O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Doctors B_PERSON/B_TIME[MEASURE]
given O
intrathecal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
methotrexate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O
headache B_DISEASE
when O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gauge I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
needle I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
. O

The O
AP B_GENE
- I_GENE
1 I_GENE
recruited O
by O
ARF1 B_GENE
. I_GENE
GTP I_GENE
is O
released O
from O
the O
Golgi O
membrane O
by O
treatment O
with O
1 O
M O
Tris O
- O
HCl O
( O
pH O
7 O
) O
or O
upon O
reincubation O
at O
37 O
degreesC O
, O
whereas O
AP B_GENE
- I_GENE
1 I_GENE
recruited O
with O
GTPgammaS O
or O
by O
a O
constitutively O
active O
point O
mutant O
, O
ARF1 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
Q71L I_GENE/I_LOCATION
) I_GENE/I_LOCATION
, O
remains O
membrane O
bound O
after O
either O
treatment O
. O

The O
formation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tumorlike B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cockroach B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
leucophaea I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
maderae O
after O
anal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blockage B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Fine B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tangled I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
pili I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
expressed O
by O
Haemophilus B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ducreyi B_BACTERIUM[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
class I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
pili B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
found O
remarkable O
differences O
in O
the O
expression O
patterns O
of O
MTB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Zf I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
two O
other O
hybridizable O
mRNAs O
of O
5kb O
and O
8 O
. O
5 O
kb O
when O
human O
brain O
and O
primary O
brain O
tumors O
were O
compared O
. O

The O
two B_LOCATION/B_BIO
redox B_LOCATION/I_BIO
centers B_LOCATION/I_BIO
in O
the O
protein B_ENZYME[GENE]/B_BACTERIUM[BIO]
, O
FAD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
a O
[ B_LOCATION/B_BIO
4Fe4S B_LOCATION/I_BIO
] O
+ B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
, O
+ O
1 B_MEASURE/B_LOCATION
cluster I_MEASURE/I_LOCATION
, O
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
64 B_MEASURE
- O
kDa B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
pra2 B_GENE/B_BIO
gene I_GENE/I_BIO
encodes O
a O
pea B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pisum I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sativum I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
small I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
GTPase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
belonging O
to O
the O
YPT B_GENE/B_DISEASE
/ O
rab B_PERSON/B_PROTEIN[GENE]
family O
, O
and O
its O
expression O
is O
down O
- O
regulated O
by O
light O
, O
mediated O
by O
phytochrome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

carotid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreceptor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
recorded O
from O
the O
petrosal B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglion I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cats B_BIO/B_PERSON
. O

Human B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxic I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocyte I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
subsite O
mapping O
with O
peptide O
thioester O
substrates O
and O
inhibition O
of O
enzyme O
activity O
and O
cytolysis O
by O
isocoumarins O
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B_PROTEIN[GENE]/B_DISEASE
E2s I_PROTEIN[GENE]/I_DISEASE
incorporating O
sequences O
from O
CDC34 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
related O
but O
functionally O
distinct O
E2 B_GENE/B_BIO
RAD6 I_GENE/I_BIO
( O
UBC2 B_GENE
) O
. O

MAPKK B_GENE
kinase I_GENE
/ O
MEKK B_GENE
phosphorylates O
and O
activates O
its O
downstream O
protein O
kinase O
, O
MAPK B_GENE
kinase I_GENE
/ O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
in O
turn O
activates O
MAPK B_GENE
. O

Kondo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
Cu B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
Fe B_MEASURE
) O
films B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

However O
, O
ADAR1 B_GENE
and O
the O
related O
deaminase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ADAR2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
significant O
expression O
in O
all O
regions O
of O
the O
brain O
examined O
, O
including O
cortex O
, O
hippocampus O
, O
olfactory O
bulb O
, O
and O
striatum O
, O
where O
the O
5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HT2CR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pre I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
extensively O
edited O
. O

To O
investigate O
its O
transcription O
, O
1 O
. O
1 O
kilobases O
of O
the O
5 O
' O
- O
flanking O
sequence O
were O
fused O
to O
a O
luciferase B_GENE
reporter I_GENE
gene I_GENE
. O

influence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
copper B_PERSON
addition I_PERSON
. O

The O
0 B_MEASURE
. O
018 B_MEASURE
- O
inch B_MEASURE/B_LOCATION
FloWire I_MEASURE/I_LOCATION
provides O
a O
high B_MEASURE/B_LOCATION
- O
fidelity B_MEASURE
continuous I_MEASURE
Doppler I_MEASURE
signal I_MEASURE
. O

Monosulfates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
16 B_MEASURE/B_LOCATION
- O
oxygenated O
ketonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C19 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
adult B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
urine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Under O
anaerobic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
a O
50 B_NUMBER[MEASURE]
- O
day B_MEASURE/B_ENT
experiment I_MEASURE/I_ENT
) O
these O
organisms B_BIO
degraded O
15 B_NUMBER[MEASURE]
- O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
TEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
20 B_MEASURE
- O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
some O
alkanes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
15 B_NUMBER[MEASURE]
- O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
selected B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polycyclic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aromatic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hydrocarbons I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_MEASURE/B_LOCATION
, O
WR B_PROTEIN[GENE]/B_DISEASE
- O
3689 B_MEASURE
, O
WR B_PROTEIN[GENE]/B_DISEASE
- O
109342 B_MEASURE
, O
and O
WR B_PROTEIN[GENE]/B_DISEASE
- O
168643 B_MEASURE
were O
used O
with O
per O
os B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
determine O
hematopoietic B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lethality B_DISEASE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Further O
, O
we O
will O
review O
our O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
survival B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prognostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
9 B_MEASURE
, O
262 B_MEASURE
patients I_MEASURE
from O
1981 B_MEASURE
to O
1996 B_MEASURE
. O

Measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
SF B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
36 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
questionnaires I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
completed O
by O
patients B_PERSON
at O
both O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
discharge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
examinations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
contrast O
, O
corticotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
releasing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CRF B_GENE/B_DISEASE
) O
, O
injected O
centrally O
produces O
a O
suppression O
of O
punished O
and O
non O
- O
punished O
responding O
in O
the O
conflict O
test O
consistent O
with O
its O
hypothesized O
role O
in O
mediating O
behavioral O
responses O
to O
stress O
. O

temporal O
recruitment O
of O
the O
mSin3A B_GENE
- O
histone B_GENE
deacetylase I_GENE
corepressor O
complex O
to O
the O
ETS B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
domain I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
transcription I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
factor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
Elk I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
1 I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

The O
cluster B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
mapped O
to O
nucleotides B_LOCATION/B_MEASURE
- O
464 B_MEASURE
to O
- O
434 B_MEASURE
( O
relative B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
nucleotide O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
initiation B_PERSON/B_GENE
codon I_PERSON/I_GENE
) O
in O
genomic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
, O
FOP B_DISEASE/B_PROTEIN[GENE]
- O
FGFR1 B_PROTEIN[GENE]/B_MEASURE
- O
expressing O
cells O
show O
constitutive O
phosphorylation O
of O
the O
positive O
regulator O
of O
translation O
p70S6 B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_ENZYME[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
this O
phosphorylation O
is O
inhibited O
by O
PI3 B_GENE
- I_GENE
kinase I_GENE
and O
mTOR B_GENE
( O
mammalian B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapamycin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
inhibitors O
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
orbital B_DISEASE
cavernous I_DISEASE
hemangioma I_DISEASE
diagnosed O
by O
Tc B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
99m B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
RBC I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
SPECT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

ciprofloxacin B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
blister B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
end B_LOCATION/B_MEASURE
of O
the O
dosing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
8 B_TIME[MEASURE]/B_LOCATION
h B_TIME[MEASURE]/I_LOCATION
) O
were O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
almost O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
MICs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
sensitive B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organisms I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
including O
Pseudomonas B_BACTERIUM[BIO]/B_DISEASE
aeruginosa I_BACTERIUM[BIO]/I_DISEASE
. O

Antibiotic B_PERSON/B_LOCATION
prophylaxis I_PERSON/I_LOCATION
in O
a O
surgical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
setting I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
identified O
clones O
of O
Chlamydomonas O
genomic O
DNA O
that O
rescued O
the O
ca O
( O
2 O
+ O
) O
- O
dependent O
axonemal O
microtubule O
severing O
defect O
of O
fa1 B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persisted O
during O
the O
first B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hyperlipemia B_DISEASE/B_GENE
has O
been O
recently O
described O
in O
children B_PERSON/B_ORGANIZATION
with O
migraine B_DISEASE/B_LOCATION
, O
being O
suggested O
that O
this O
alteration B_DISEASE_ADJECTIVE[DISEASE]
is O
in O
the O
base B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
disease B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hemopexin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
homeostasis O
during O
the O
acute O
phase O
response O
. O

The O
newly O
identified O
repressor O
element O
is O
a O
rare O
example O
of O
a O
naturally O
occurring O
perfect O
palindromic O
binding O
motif O
for O
the O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
/ O
Rel B_GENE/B_DISEASE
family O
of O
transcription O
factors O
. O

Tryptophan O
induction O
prevents O
Rho B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
transcription O
termination O
in O
the O
leader O
region O
of O
the O
operon O
. O

There O
remains O
the O
physiological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
problem I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
has O
always O
been O
foremost B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Moruzzi B_PERSON
' O
s O
thinking O
about O
the O
intrinsic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
brain B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
of O
how O
the O
separate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
actions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
different B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arousal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
systems I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
brought O
together O
into O
a O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
nramp2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
is O
comprised O
of O
17 O
exons O
and O
spans O
more O
than O
36 O
kb O
. O

The O
immune B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
seems O
to O
be O
partially O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
both O
protection B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
destructive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chlamydial B_DISEASE
infection I_DISEASE
. O

Results B_MEASURE
: O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydatidosis B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
177 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
. O

This O
is O
similar O
to O
previous O
reports O
of O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
creatine B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O
in O
psychiatric O
patients O
. O

The O
majority O
of O
putative O
TSC2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
found O
in O
sporadic O
rather O
than O
TSC2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
linked O
families O
. O

Murine B_GENE/B_LOCATION
ELAM I_GENE/I_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
is O
encoded O
by O
a O
single O
- O
copy O
gene O
, O
spanning O
about O
13 O
kb O
, O
which O
is O
structurally O
organized O
into O
14 O
exons O
and O
13 O
introns O
; O
very O
similar O
to O
that O
of O
its O
human O
counterpart O
. O

A O
biopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
specimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
taken O
from O
the O
frontal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
branch I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
right B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
superficial B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
revealed O
segmental B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
intimal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
thickening O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
intimal B_DISEASE
fibroplasia I_DISEASE
type I_DISEASE
FMD I_DISEASE
upon O
histological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Thus O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
used O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O
directly O
evaluate O
whether O
isolated O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
saphenous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
segments I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
respond O
to O
vasoconstrictor O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
arterial B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
levels I_MEASURE/I_LOCATION
. O

We O
found O
that O
the O
PRP20 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
is O
identical O
to O
the O
yeast B_GENE/B_BIO
SRM1 I_GENE/I_BIO
gene I_GENE/I_BIO
( O
Clark O
and O
Sprague O
1989 O
) O
. O

basal O
JNK B_GENE
MAPK I_GENE
kinase I_GENE
activity O
was O
also O
specifically O
induced O
by O
deltaEGFR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
correlated O
with O
increased O
phosphorylation O
of O
a O
54 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
JNK2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
observed O
in O
deltaEGFR B_GENE
- O
containing O
cells O
. O

Deletion O
analysis O
defines O
distinct O
functional O
domains O
for O
protein O
- O
protein O
and O
nucleic O
acid O
interactions O
in O
the O
ORF1 B_GENE/B_BIO
protein I_GENE/I_BIO
of O
mouse O
LINE B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_VIRUS[BIO]
- B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_VIRUS[BIO]
. O

PMA O
produced O
similar O
results O
, O
but O
the O
induction O
of O
the O
WT B_GENE
AP1 I_GENE
c I_GENE
- I_GENE
jun I_GENE
promoter O
- O
Cat O
plasmid O
was O
smaller O
. O

The O
determination O
of O
antithrombin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
its O
clinical O
significance O
. O

One B_GENE/B_BIO
ORF I_GENE/I_BIO
extends O
from O
nucleotides B_MEASURE
415 I_MEASURE
to O
1620 B_MEASURE
, O
encodes O
402 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
is O
preceded O
by O
a O
ribosome B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
binding O
site B_LOCATION/B_BIO
. O

glucose O
consumption O
of O
the O
human O
brain O
under O
the O
influence O
of O
intravenous O
infusions O
of O
glucose O
, O
glucagon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glucose O
- O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

D B_OTHER/B_LOCATION
. O
, O
Hughes B_PERSON/B_COLOR
, O
F B_OTHER/B_PERSON
. O

Deletion O
of O
CDC5 B_GENE
was O
lethal O
and O
resulted O
in O
a O
dumbbell O
- O
shaped O
terminal O
morphology O
, O
with O
the O
nuclei O
almost O
divided O
but O
still O
connected O
. O

These O
cDNAs O
were O
found O
to O
be O
derived O
from O
the O
3 O
' O
- O
untranslated O
region O
( O
3 O
' O
- O
UTR O
) O
of O
the O
methyl B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CpG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MeCP2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

A O
) O
During O
O2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
both O
extracellular B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
[ O
K B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
] B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
change B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pH B_MEASURE/B_LOCATION
in O
the O
subepicardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
are O
significantly O
less B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
in O
the O
midmyocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
generation O
of O
dorso O
- O
ventral O
polarity O
during O
Drosophila O
embryogenesis O
is O
regulated O
by O
the O
action O
of O
12 O
maternally O
expressed O
gene O
products O
, O
the O
dorsal B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
group I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Ultimobranchial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
body I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
parathyroid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
glands I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
of O
the O
freshwater B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
snake I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
Natrix I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
piscator I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
vitamin O
D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
administration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

These O
observations O
suggest O
that O
the O
AF O
- O
1 O
region O
of O
PPARalpha B_GENE
is O
partially O
silenced O
by O
corepressor O
proteins O
, O
which O
might O
interact O
in O
a O
phosphorylation O
- O
dependent O
manner O
. O

Two B_TIME[MEASURE]/B_LOCATION
authors I_TIME[MEASURE]/I_LOCATION
, O
two B_MEASURE/B_PERSON
journal B_MEASURE/I_PERSON
titles B_MEASURE/I_PERSON
, O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
names I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
topics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
a O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
medical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
nature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
retrieved O
under O
identical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
circumstances I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
the O
hosts B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Data I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
star B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DIALOG B_LOCATION/B_PERSON
, O
DIMDI B_LOCATION/B_ORGANIZATION
, O
and O
STN B_ORGANIZATION/B_MEASURE
. O

However O
, O
in O
a O
variation O
of O
this O
assay O
in O
which O
the O
protease O
is O
omitted O
, O
the O
mutant O
enzymes O
exhibited O
substantial O
levels O
of O
prolyl B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
( O
5 O
- O
20 O
% O
of O
wild O
- O
type O
) O
, O
revealing O
that O
these O
mutations O
confer O
sensitivity O
to O
protease O
digestion O
and O
that O
the O
classic O
in O
vitro O
assay O
for O
prolyl B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
may O
be O
misleading O
. O

As O
a O
test O
of O
this O
hypothesis O
, O
we O
predicted O
that O
mice O
which O
have O
altered O
expression O
of O
class O
I O
gene O
products O
, O
the O
beta2 B_GENE
- I_GENE
microglobulin I_GENE
knockout O
mice O
, O
[ B_TIME[MEASURE]/B_LOCATION
beta2m I_TIME[MEASURE]/I_LOCATION
( I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
/ I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
) I_TIME[MEASURE]/I_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
would O
develop O
Fe O
overload O
. O

Nucleotide O
sequence O
of O
the O
gag B_GENE
gene I_GENE
and O
gag B_GENE/B_DISEASE
- O
pol B_GENE/B_DISEASE
junction O
of O
feline O
leukemia O
virus O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
endpoints O
based O
on O
magnitude B_MEASURE
of O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
HIV B_DISEASE/B_GENE
- O
1 B_GENE/B_DISEASE
RNA I_GENE/I_DISEASE
levels I_GENE/I_DISEASE
provide O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
endpoints B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
based O
on O
percentage B_MEASURE
of O
patients B_PERSON/B_DISEASE
achieving O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virologic B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

It O
also O
describes O
the O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
Phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
going O
on O
at O
the O
Central B_LOCATION/B_ORGANIZATION
Institute I_LOCATION/I_ORGANIZATION
for O
Tumors B_DISEASE
in O
Zagreb B_LOCATION
, O
using O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DDP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
basis O
of O
the O
physical O
interactions O
between O
Sxl B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Snf B_GENE/B_BACTERIUM[BIO]
, O
we O
present O
a O
model O
for O
Sxl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
splicing O
regulation O
. O

Though O
it O
has O
been O
established O
that O
skinfold B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anthropometry I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
limitations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
deriving O
total B_MEASURE/B_PROTEIN[GENE]
body B_MEASURE/I_PROTEIN[GENE]
fat B_MEASURE/I_PROTEIN[GENE]
( O
TBF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
be O
related O
more B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
the O
assumptions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
implicit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
densitometry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
to O
be O
addressed O
. O

The O
average B_MEASURE
mean I_MEASURE
difference I_MEASURE
compared O
with O
the O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
intermediate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calcium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
11 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
for O
the O
femoral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
neck I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
8 B_NUMBER[MEASURE]
- O
11 B_SEQUENCE[MEASURE]/B_PERSON
% I_SEQUENCE[MEASURE]/I_PERSON
for O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT
spine I_BODY_PART_OR_ORGAN_COMPONENT
and O
5 B_NUMBER[MEASURE]
- O
6 B_SEQUENCE[MEASURE]/B_PERSON
% I_SEQUENCE[MEASURE]/I_PERSON
for O
total B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BMDs I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
cloned O
the O
BamHI B_GENE/B_LOCATION
- I_GENE/I_LOCATION
F I_GENE/I_LOCATION
fragment I_GENE/I_LOCATION
from O
the O
left O
end O
of O
Ad4 O
in O
pUC13 O
- O
1 O
between O
the O
SalI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
BamHI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
order O
to O
carry O
out O
the O
structural O
analysis O
of O
the O
E1A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
region B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Ad4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
reviewed O
81 B_PERSON
patients I_PERSON
with O
dementia B_DISEASE
and O
autopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Alzheimer B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
AD B_DISEASE
) O
to O
identify O
patients B_PERSON
with O
seizures B_DISEASE
or O
myoclonus B_DISEASE
after O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dementia B_DISEASE
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
lung B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
expiratory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
pressure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
( O
PEEP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
slightly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
Pflex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
the O
airway B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
corresponding I_MEASURE/I_LOCATION
to O
the O
lower B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflection I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
lip B_LOCATION/B_PROTEIN[GENE]
) O
on O
the O
inspiratory B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
- O
volume B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
- O
V B_OTHER/B_PROTEIN[GENE]
) O
curve B_MEASURE
measured O
with O
ZEEP B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
is O
generally O
recommended O
. O

3 B_NUMBER[MEASURE]
. O

In O
both O
Raw O
cells O
and O
the O
microglia O
cell O
line O
EOC20 O
, O
two O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
activated O
transcription O
factors O
, O
STAT B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1alpha I_GENE/I_DISEASE
and O
IRF B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
, O
bind O
the O
GAS B_GENE/B_BACTERIUM[BIO]
and O
IRF B_GENE
elements I_GENE
, O
respectively O
. O

thermal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
bovine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
uterus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
following O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
17beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O

The O
starting O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
8 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
m2 B_MEASURE
administered O
intravenously O
( O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
as O
a O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
infusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
daily O
for O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
repeated O
every O
3 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
with O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
adjustments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
depending O
on O
patient B_DISEASE
tolerance I_DISEASE
. O

In O
agreement B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
authors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
recommend O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
a O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
providing O
satisfactory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
inhibition O
of O
monoamine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
pargyline O
( O
10 O
mg O
/ O
kg O
. O
i O
. O
v O
. O
) O
, O
the O
effects O
of O
tyramine O
( O
1000 O
micrograms O
) O
injected O
into O
the O
hepatic O
artery O
were O
potentiated O
. O

Helenalin O
triggers O
a O
CD95 B_GENE
death I_GENE
receptor I_GENE
- O
independent O
apoptosis O
that O
is O
not O
affected O
by O
overexpression O
of O
Bcl B_GENE
- I_GENE
x I_GENE
( I_GENE
L I_GENE
) I_GENE
or O
Bcl B_GENE
- I_GENE
2 I_GENE
. O

Of O
the O
47 B_PERSON
women I_PERSON
with O
AGCUS B_DISEASE
, O
16 B_MEASURE
had O
intraepithelial B_DISEASE_ADJECTIVE[DISEASE]
or O
invasive B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neoplasms I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
34 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
confidence I_MEASURE/I_PERSON
interval I_MEASURE/I_PERSON
, O
21 B_MEASURE
- O
49 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
including O
9 B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
low I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
grade I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
squamous I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
intraepithelial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lesions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
1 B_DISEASE/B_MEASURE
adenocarcinoma I_DISEASE/I_MEASURE
in O
situ B_DISEASE/B_PERSON
of O
the O
cervix B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
3 B_DISEASE
adenocarcinomas I_DISEASE
of O
the O
cervix B_BODY_PART_OR_ORGAN_COMPONENT
, O
2 B_NUMBER[MEASURE]/B_DISEASE
adenocarcinomas I_NUMBER[MEASURE]/I_DISEASE
of O
the O
endometrium B_BODY_PART_OR_ORGAN_COMPONENT
and O
1 B_DISEASE/B_NUMBER[MEASURE]
adenoid B_DISEASE/I_NUMBER[MEASURE]
basal B_DISEASE/I_NUMBER[MEASURE]
cell B_DISEASE/I_NUMBER[MEASURE]
carcinoma B_DISEASE/I_NUMBER[MEASURE]
of O
the O
cervix B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
DF3 B_GENE/B_LOCATION
/ O
MUC1 B_GENE/B_MEASURE
gene O
encodes O
a O
high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mucin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
is O
overexpressed O
at O
the O
transcriptional O
level O
in O
the O
majority O
of O
human O
breast O
cancers O
. O

The O
organization O
of O
the O
MBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
very O
similar O
to O
the O
arrangement O
of O
the O
gene O
encoding O
the O
highly O
homologous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pulmonary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
surfactant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
although O
one O
of O
the O
intron O
positions O
is O
shifted O
by O
a O
single O
amino O
acid O
. O

Hip B_TIME[MEASURE]/B_PERSON
fracture I_TIME[MEASURE]/I_PERSON
mortality I_TIME[MEASURE]/I_PERSON
and O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
payment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

These O
results O
indicate O
that O
patients O
with O
SS O
and O
evidence O
of O
exercise O
- O
induced O
ST O
- O
segment O
depression O
may O
have O
decreased O
myocardial O
oxygen O
supply O
due O
to O
low O
hemoglobin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O
and O
increased O
myocardial O
oxygen O
demand O
( O
elevated O
double O
products O
) O
when O
compared O
to O
subjects O
with O
SS O
who O
do O
not O
have O
exercise O
- O
induced O
ST O
- O
segment O
depression O
. O

Although O
hSSTR5 B_GENE/B_PERSON
displays O
approximately O
75 O
% O
sequence O
identity O
with O
rat B_GENE
SSTR5 I_GENE
, O
the O
two O
receptors O
display O
significantly O
different O
pharmacological O
profiles O
, O
especially O
with O
respect O
to O
their O
binding O
affinities O
for O
the O
SST B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analogue O
SMS O
201 O
- O
995 O
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
binaural B_MEASURE
peak I_MEASURE
amplitude I_MEASURE
and O
area B_MEASURE/B_DISEASE
of O
the O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
evoked O
middle B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
latency B_MEASURE/B_LOCATION
component B_MEASURE/I_LOCATION
Pa B_MEASURE/I_LOCATION
was O
observed O
. O

EMBO B_NUMBER[MEASURE]/B_ORGANIZATION
( O
Eur B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
this O
oligonucleotide O
as O
a O
probe O
, O
an O
8 O
- O
kilobase O
HindIII B_MEASURE/B_LOCATION
fragment O
of O
genomic O
DNA O
was O
isolated O
and O
subjected O
to O
Sanger O
dideoxy O
DNA O
sequencing O
. O

Arg O
- O
130 O
, O
Gly O
- O
132 O
and O
Lys O
- O
167 O
are O
conserved O
in O
all O
members O
of O
the O
type B_GENE/B_BIO
IB I_GENE/I_BIO
topoisomerase I_GENE/I_BIO
family I_GENE/I_BIO
. O

Four O
cDNAs O
( O
Kox4 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Kox7 B_MEASURE/B_GENE
, O
Kox12 B_MEASURE/B_GENE
, O
and O
Kox15 B_MEASURE
) O
were O
identified O
that O
match O
one O
or O
more O
genomic O
clones O
; O
these O
matches O
were O
confirmed O
by O
nucleotide O
sequence O
analysis O
. O

2 B_NUMBER[MEASURE]
. O

prevalence O
of O
use O
, O
claims O
volume O
, O
and O
expenditures O
were O
compared O
for O
cisapride O
, O
proton O
pump O
inhibitors O
, O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O
, O
and O
the O
prokinetic O
agent O
metoclopramide O
during O
these O
periods O
. O

Relaxant B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PGE1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
and O
papaverine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PAP B_PROTEIN[GENE]/B_DISEASE
) O
were O
measured O
in O
strips B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
corpus B_BODY_PART_OR_ORGAN_COMPONENT
cavernosum I_BODY_PART_OR_ORGAN_COMPONENT
smooth I_BODY_PART_OR_ORGAN_COMPONENT
muscle I_BODY_PART_OR_ORGAN_COMPONENT
taken O
from O
a O
healthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
men B_PERSON/B_BIO
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
n B_MEASURE/B_PROTEIN[GENE]
= O
5 B_MEASURE
) O
, O
from O
arteriogenically O
impotent B_DISEASE_ADJECTIVE[DISEASE]
men I_DISEASE_ADJECTIVE[DISEASE]
( O
B B_LOCATION/B_DISEASE
; O
n O
= O
6 B_MEASURE
) O
and O
from O
additionally O
diabetic B_PERSON/B_BIO
impotent I_PERSON/I_BIO
men I_PERSON/I_BIO
( O
C B_PROTEIN[GENE]/B_LOCATION
; O
n B_MEASURE/B_PROTEIN[GENE]
= O
5 B_MEASURE
) O
with O
venous B_DISEASE
leakage I_DISEASE
. O

primer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
dbcAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
differentiated O
U937 B_BIO/B_GENE
RNA B_BIO/I_GENE
indicated O
a O
single B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initiation B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
group B_PERSON/B_ORGANIZATION
II I_PERSON/I_ORGANIZATION
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
peak B_MEASURE/B_EDU[ORGANIZATION]
VO2 B_MEASURE/I_EDU[ORGANIZATION]
with O
rate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adaptive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
AV I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
delay I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O
to O
fixed O
AV B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
delay B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
programming B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
family B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
visits I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
of O
patients B_PERSON
in O
the O
coronary B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- O
care B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
unit I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

sequence O
analysis O
and O
electrophoretic O
mobility O
shift O
experiments O
suggest O
that O
GnSE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
elements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
interact O
, O
in O
these O
two O
regions O
, O
with O
GATA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LIM I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

The O
transfer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
conjugation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
E B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_BACTERIUM[BIO]/B_PERSON
K12 I_BACTERIUM[BIO]/I_PERSON
of O
ampicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
carbenicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
obtained O
with O
14 B_BACTERIUM[BIO]/B_NUMBER[MEASURE]
strains B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
: O
( O
E B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_BACTERIUM[BIO]
: O
9 B_NUMBER[MEASURE]
, O
C B_OTHER/B_GENE
. O
freundii B_BACTERIUM[BIO]/B_DISEASE
: O
1 B_NUMBER[MEASURE]
, O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
pneumoniae B_BACTERIUM[BIO]/B_MEASURE
: O
1 B_NUMBER[MEASURE]
, O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
cloacae B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
: O
2 B_NUMBER[MEASURE]
, O
P B_OTHER/B_LOCATION
. O
stuartii B_BACTERIUM[BIO]/B_MEASURE
: O
1 B_MEASURE
) O
. O

Wild O
type O
MEKK1 B_GENE
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B_GENE
, O
MEK1 B_GENE
, O
MEK7 B_GENE
, O
MEK3 B_GENE
, O
p38 B_GENE/B_LOCATION
/ O
RK B_MEASURE/B_GENE
, O
and O
c B_GENE
- I_GENE
Jun I_GENE
. O

250 B_MEASURE
, O
302 B_MEASURE
- O
311 B_MEASURE
] I_MEASURE
. O

The O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
permit O
considering O
the O
detected B_DISEASE_ADJECTIVE[DISEASE]
shifts I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
immunity B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
system O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pathogenesis B_DISEASE
of O
chronic B_DISEASE
nontumorous I_DISEASE
diseases I_DISEASE
of O
the O
parotid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glands I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

coexistence B_DISEASE_ADJECTIVE[DISEASE]
of O
Turner B_DISEASE
' I_DISEASE
s I_DISEASE
syndrome I_DISEASE
and O
schizophrenia B_DISEASE
. O

An O
scrR B_GENE
promoter I_GENE
fragment I_GENE
, O
which O
dose O
not O
contain O
a O
sequence O
resembling O
OB B_GENE/B_DISEASE
, O
was O
not O
shifted O
by O
the O
fusion O
protein O
. O

Using O
the O
conflict O
drinking O
test O
as O
a O
model O
, O
we O
studied O
in O
rats O
the O
effect O
of O
the O
nonselective O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers O
pindolol O
and O
cyanopindolol O
which O
bind O
to O
5 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1A I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT1B I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
of O
the O
selective O
beta B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenoceptor B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O
betaxolol O
and O
ICI O
118 O
, O
551 O
, O
respectively O
, O
which O
have O
a O
negligible O
affinity O
for O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
several O
other O
signal O
transduction O
molecules O
also O
contain O
tandemly O
occurring O
SH3 B_LOCATION/B_GENE
and O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
function O
of O
these O
closely O
spaced O
domains O
is O
not O
well O
understood O
. O

Glycoprotein O
biosynthesis O
in O
Saccharomyces O
cerevisiae O
: O
ngd29 B_LOCATION/B_GENE
, O
an O
N O
- O
glycosylation O
mutant O
allelic O
to O
och1 B_SPECIES[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
a O
defect O
in O
the O
initiation O
of O
outer O
chain O
formation O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
the O
majority B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O
patients B_PERSON/B_BIO
with O
severe B_DISEASE/B_LOCATION
ulcerative I_DISEASE/I_LOCATION
colitis I_DISEASE/I_LOCATION
, O
circulating O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
nox B_GENE
are O
increased O
at O
presentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
fall O
promptly O
during O
parenteral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
steroid I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
irrespective B_MEASURE/B_LOCATION
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
duration B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
naloxone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
appears O
to O
be O
dose B_MEASURE
- O
related B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
up O
to O
approximately O
1 B_MEASURE
. O
5 B_MEASURE
hr I_MEASURE
. O

But O
if O
one O
equalizes O
the O
upper O
limits O
of O
normal O
for O
both O
markers O
to O
a O
common O
95 O
% O
specificity O
, O
the O
tumour O
- O
indicating O
sensitivity O
of O
CA B_GENE/B_MEASURE
19 I_GENE/I_MEASURE
- I_GENE/I_MEASURE
9 I_GENE/I_MEASURE
clearly O
surpasses O
that O
of O
CA B_GENE/B_LOCATION
50 I_GENE/I_LOCATION
. O

These O
motions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
were O
found O
in O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
and O
C B_PROTEIN[GENE]/B_LOCATION
- O
terminal B_LOCATION/B_MEASURE
tails I_LOCATION/I_MEASURE
, O
in O
segment B_MEASURE/B_LOCATION
33 I_MEASURE/I_LOCATION
- O
35 B_MEASURE
which O
forms O
the O
turn B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
strands B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
S2 B_MEASURE/B_PROTEIN[GENE]
, O
and O
residues B_MEASURE
47 I_MEASURE
- O
52 B_MEASURE
located O
in O
a O
long B_LOCATION/B_MEASURE
loop I_LOCATION/I_MEASURE
preceding O
strand B_PROTEIN[GENE]/B_NUMBER[MEASURE]
S3 I_PROTEIN[GENE]/I_NUMBER[MEASURE]
. O

Genomic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Southern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reveals O
10 B_NUMBER[MEASURE]
to O
15 B_MEASURE
hybridising I_MEASURE
fragments I_MEASURE
, O
suggesting O
that O
maize B_BIO/B_GENE
contains O
a O
small B_GENE
gene I_GENE
family I_GENE
. O

Custom O
- O
made O
orthoses B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
play O
an O
invaluable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
achieving O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
improving O
function B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinch B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
stabilizing O
individual B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joints B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
preventing O
positional B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractures I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
protecting O
joints B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O
trauma B_DISEASE
, O
stretching O
the O
intrinsic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
correcting O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
and O
soft B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
tissue B_DISEASE_ADJECTIVE[DISEASE]
contractures I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
controlling O
inflammation B_DISEASE/B_BACTERIUM[BIO]
. O

Is O
exposure B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
a O
patient B_PERSON/B_BIO
with O
Crohn B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
an O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
developing O
the O
disease B_DISEASE
. O

The O
ZAG1 B_GENE
protein I_GENE
from O
in O
vitro O
translations O
binds O
to O
a O
consensus O
target O
site O
that O
is O
recognized O
by O
the O
AG B_GENE
protein I_GENE
. O

The O
uap100 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cis O
- O
acting O
, O
up O
- O
promoter O
, O
constitutive O
mutation O
is O
a O
duplication O
that O
comprises O
two O
GATA O
sites O
and O
suppresses O
weakly O
the O
AREA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
zinc B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
finger B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but O
does O
not O
alleviate O
the O
need O
for O
functional O
UAY B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
AREA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

pituitary B_DISEASE
thyrotropic I_DISEASE
adenoma I_DISEASE
associated O
with O
congenital B_DISEASE/B_GENE
hypothyroidism I_DISEASE/I_GENE
. O

This O
region B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
unfavourable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O
due O
to O
malaria B_DISEASE
in O
the O
past B_TIME[MEASURE]/B_LOCATION
. O

Indeed O
, O
after O
a O
single O
oral O
dose O
, O
the O
role O
of O
the O
mu B_GENE
- I_GENE
receptor I_GENE
agonist O
component O
of O
the O
antinociceptive O
effect O
of O
tramadol O
appears O
to O
be O
minor O
, O
with O
most O
of O
the O
analgesic O
effect O
being O
attributable O
to O
nonopioid O
properties O
of O
the O
parent O
compound O
. O

chief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Endoluminal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
prostacyclin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
6 B_MEASURE
- O
keto B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PGF1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TxB2 B_PROTEIN[GENE]
) O
, O
patency B_DISEASE
, O
EC B_DISEASE_ADJECTIVE[DISEASE]
coverage I_DISEASE_ADJECTIVE[DISEASE]
and O
cell B_DISEASE_ADJECTIVE[DISEASE]
identity I_DISEASE_ADJECTIVE[DISEASE]
. O

somatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
visceral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
inputs B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
thoracic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spinal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cat B_BIO/B_DISEASE
: O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
noxious B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
biliary B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
have O
produced O
the O
Ure2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
high O
yield O
in O
Escherichia O
coli O
from O
a O
synthetic O
gene O
. O

Transfection O
of O
both O
Calu O
- O
6 O
and O
JEG O
- O
3 O
cells O
with O
a O
PKA B_GENE
expression O
vector O
resulted O
in O
a O
10 O
- O
fold O
induction O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O
activity O
in O
constructs O
containing O
the O
native O
or O
consensus O
CRE O
and O
5 O
- O
fold O
activation O
in O
a O
construct O
containing O
a O
nonfunctional O
CRE O
. O

We O
undertook O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
examine O
the O
relationship B_PERSON/B_MEASURE
between O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxygen B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
DO2 B_GENE/B_LOCATION
) O
and O
tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tension I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TPO2 B_GENE/B_LOCATION
) O
in O
hypovolemic B_DISEASE/B_SPECIES[BIO]
shock B_DISEASE/I_SPECIES[BIO]
. O

White B_PERSON
female I_PERSON
cases I_PERSON
were O
more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
have O
worked O
as O
registered O
nurses B_PERSON/B_BIO
than O
were O
the O
controls B_PERSON/B_MEASURE
( O
OR O
= O
1 B_MEASURE
. O
9 B_MEASURE
, O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
CI I_LOCATION/I_MEASURE
= O
1 B_MEASURE
. O
0 B_MEASURE
- O
3 B_MEASURE
. O
5 B_MEASURE
) O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Children B_PERSON
with O
attention B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
deficit B_DISEASE
/ O
hyperactivity B_DISEASE
disorder I_DISEASE
( O
ADHD B_DISEASE
; O
n O
= O
282 B_MEASURE
) O
, O
all O
subtypes B_PERSON
, O
ages B_NUMBER[MEASURE]/B_LOCATION
6 I_NUMBER[MEASURE]/I_LOCATION
to O
12 B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
were O
randomized O
to O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
n B_MEASURE/B_LOCATION
= O
90 B_MEASURE
) O
, O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
release B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
methylphenidate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
IR B_DISEASE/B_PROTEIN[GENE]
MPH B_DISEASE/I_PROTEIN[GENE]
) O
3 B_NUMBER[MEASURE]/B_LOCATION
times I_NUMBER[MEASURE]/I_LOCATION
a O
day B_TIME[MEASURE]
( O
tid B_PROTEIN[GENE]/B_LOCATION
; O
dosed O
every O
4 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
; O
n B_MEASURE/B_LOCATION
= O
97 B_MEASURE
) O
, O
or O
OROS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MPH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O
a O
day B_TIME[MEASURE]
( O
QD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
n B_OTHER/B_LOCATION
= O
95 B_MEASURE
) O
in O
a O
double B_MEASURE
- O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
28 B_NUMBER[MEASURE]
- O
day B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

immunologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tolerance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_BIO/B_PERSON
during O
13 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
of O
inhalation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
trimellitic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anhydride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

They O
cause O
temporary B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disability I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
invalidity B_DISEASE
and O
mortality B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
great B_MEASURE/B_PERSON
part I_MEASURE/I_PERSON
of O
the O
productive B_PERSON/B_LOCATION
population I_PERSON/I_LOCATION
, O
significantly O
damaging O
the O
economic B_MEASURE/B_ORGANIZATION
status B_MEASURE/I_ORGANIZATION
of O
the O
country B_LOCATION/B_PERSON
. O

Cloning O
and O
sequence O
analysis O
of O
a O
chymotrypsinlike B_DISEASE_ADJECTIVE[DISEASE]
protease I_DISEASE_ADJECTIVE[DISEASE]
from I_DISEASE_ADJECTIVE[DISEASE]
Treponema I_DISEASE_ADJECTIVE[DISEASE]
denticola O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
The O
QTd B_LOCATION/B_DISEASE
and O
JTd B_MEASURE/B_DISEASE
intervals B_MEASURE/I_DISEASE
in O
39 B_PERSON/B_ENT
children I_PERSON/I_ENT
with O
long B_DISEASE/B_GENE
QT I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
were O
compared O
to O
those O
of O
50 B_TIME[MEASURE]/B_PERSON
normal I_TIME[MEASURE]/I_PERSON
age I_TIME[MEASURE]/I_PERSON
- O
matched O
children B_PERSON
. O

V B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
ErbB I_DISEASE/I_LOCATION
- I_DISEASE/I_LOCATION
mediated I_DISEASE/I_LOCATION
complex I_DISEASE/I_LOCATION
formation O
and O
transformation O
have O
been O
shown O
to O
occur O
independently O
of O
Ras B_GENE/B_DISEASE
activation O
. O

Both O
parameters B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
determined O
in O
an O
individual B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
applying O
the O
dye B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first O
by O
iontophoresis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
then O
by O
intravitreal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
injection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
which O
allows O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fluorescein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucuronide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
fluorophotometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O
be O
excluded O
. O

Organization O
of O
exons O
suggests O
that O
, O
similar O
to O
the O
human B_GENE/B_TIME[MEASURE]
VEGF I_GENE/I_TIME[MEASURE]
gene I_GENE/I_TIME[MEASURE]
, O
alternative O
splicing O
generates O
the O
120 O
- O
, O
164 O
- O
, O
and O
188 O
- O
amino O
acid O
isoforms O
, O
but O
does O
not O
predict O
a O
fourth O
VEGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoform I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O
to O
human B_GENE/B_PERSON
VEGF206 I_GENE/I_PERSON
. O

electron O
microscopy O
of O
pH O
7 O
. O
5 O
- O
treated O
TMV O
particles O
incubated O
in O
SPN B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- O
treated O
wheatgerm O
extract O
or O
rabbit O
reticulocyte O
lysate O
, O
showed O
that O
approximately O
10 O
% O
of O
virions O
complexed O
with O
one O
ribosome O
and O
approximately O
10 O
% O
with O
two O
bound O
ribosomes O
, O
confirming O
that O
Omega O
at O
least O
had O
been O
uncoated O
. O

The O
sequence B_LOCATION/B_PROTEIN[GENE]
contained O
five B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
repeats I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hypothetical B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
leucine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zipper I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motif I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
one B_NUMBER[MEASURE]
is O
in O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
globular B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
four B_NUMBER[MEASURE]/B_PERSON
are O
in O
the O
central B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
helical B_LOCATION/B_GENE
stalk I_LOCATION/I_GENE
. O

Postheparin O
lipoprotein B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipase B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
measured O
using O
fat O
emulsion O
as O
substrate O
, O
also O
was O
significantly O
greater O
in O
female O
rats O
compared O
with O
males O
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
painful B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wrist I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
related O
to O
a O
' O
Manieux B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscle I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
' O
of O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspect I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hand B_BODY_PART_OR_ORGAN_COMPONENT
. O

Genomic O
organization O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MDR1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
origin O
of O
P B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
however O
, O
remained O
intact B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
regardless O
of O
initial B_MEASURE/B_DISEASE
reperfusion I_MEASURE/I_DISEASE
pressure I_MEASURE/I_DISEASE
. O

Deletion O
analysis O
revealed O
that O
only O
the O
TM O
domain O
of O
E2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
required O
for O
Golgi O
targeting O
. O

In O
addition O
, O
putative O
binding O
sites O
for O
SH3 B_LOCATION/B_GENE
and O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
present O
in O
the O
amino O
- O
terminal O
half O
of O
the O
molecule O
. O

Since O
nearly O
all O
transformants O
involving O
homeologous O
DNAs O
carried O
a O
single O
recombinant O
plasmid O
in O
both O
Pms B_LOCATION/B_DISEASE
+ I_LOCATION/I_DISEASE
and O
Pms B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
strains O
, O
stable O
heteroduplex O
DNA O
appears O
less O
likely O
than O
for O
homologous O
DNAs O
. O

All O
rights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reserved O
. O

One O
new O
ORF O
, O
YBR0224 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
detected O
, O
coding O
for O
a O
protein O
with O
918 O
amino O
acids O
. O

A O
sequence O
- O
ready O
3 O
- O
MB O
Pac O
contig O
covering O
16 O
breakpoints O
of O
the O
Wilms B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tumor B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
/ B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
anirida B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
human O
chromosome O
11p13 O
. O

The O
MAP B_ENZYME[GENE]/B_MEASURE
kinase I_ENZYME[GENE]/I_MEASURE
kinase I_ENZYME[GENE]/I_MEASURE
kinase I_ENZYME[GENE]/I_MEASURE
MLK2 I_ENZYME[GENE]/I_MEASURE
co O
- O
localizes O
with O
activated O
JNK B_GENE
along O
microtubules O
and O
associates O
with O
kinesin B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
motor O
KIF3 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Bone B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
an O
excellent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
bone B_DISEASE/B_LOCATION
lesions I_DISEASE/I_LOCATION
and O
GA B_LOCATION/B_ORGANIZATION
- O
67 B_TIME[MEASURE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy I_TIME[MEASURE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
detecting O
inflammatory B_DISEASE
lesions I_DISEASE
. O

Spontaneous B_DISEASE
fracture I_DISEASE
of O
the O
tarsal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bone I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
2 B_PERSON/B_MEASURE
cases I_PERSON/I_MEASURE
of O
leprosy B_DISEASE
. O

They O
are O
transduced O
through O
TM O
to O
the O
cytoplasmic O
portion O
( O
cytoloops O
and O
the O
C O
- O
terminal O
tail O
) O
of O
the O
receptor O
and O
then O
, O
transferred O
to O
cytoplasmic O
signaling O
molecules O
, O
such O
as O
G B_GENE
protein I_GENE
. O

Serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
creatine B_ENZYME[GENE]
kinase I_ENZYME[GENE]
activities O
were O
significantly O
increased O
in O
the O
A O
praelongus O
- O
fed O
pigs O
and O
significantly O
decreased O
in O
Na2SeO4 O
- O
fed O
pigs O
. O

This O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bacteria B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrated O
at O
the O
dentinal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tubules B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
coronally O
and O
into O
the O
root B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
canals I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Seven B_PERSON
Zebu I_PERSON
cattle I_PERSON
were O
also O
exposed O
to O
challenge O
at O
the O
same B_LOCATION
time I_LOCATION
. O

However O
, O
the O
quasiparticle B_PROTEIN[GENE]/B_MEASURE
scattering I_PROTEIN[GENE]/I_MEASURE
rate I_PROTEIN[GENE]/I_MEASURE
tau I_PROTEIN[GENE]/I_MEASURE
( O
- O
1 B_NUMBER[MEASURE]
) O
is O
such B_MEASURE/B_LOCATION
that O
Planck B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
s O
over O
2pi B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
tau B_PROTEIN[GENE]/B_DISEASE
approximately O
6t B_MEASURE/B_LOCATION
( O
perpendicular B_TIME[MEASURE]
) O
, O
implying O
that O
kappa B_PROTEIN[GENE]/B_LOCATION
- O
( O
BEDT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
TTF B_PROTEIN[GENE]/B_LOCATION
) O
2Cu B_LOCATION
( O
NCS B_DISEASE/B_LOCATION
) O
( O
2 B_TIME[MEASURE]/B_LOCATION
) O
meets O
the O
criterion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
used O
to O
identify O
interlayer B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
incoherence I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
kidney B_DISEASE
length I_DISEASE
was O
considerably O
prolonged O
compared O
with O
the O
vascular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Although O
polyubiquitin B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chains I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
linked O
through O
Lys O
( O
29 O
) O
of O
ubiquitin B_GENE
have O
been O
implicated O
in O
the O
targeting O
of O
certain O
substrates O
to O
proteasomes O
, O
the O
signaling O
properties O
of O
these O
chains O
are O
poorly O
understood O
. O

Diabetic B_DISEASE/B_GENE
osteopenia I_DISEASE/I_GENE
, O
a O
known B_DISEASE_ADJECTIVE[DISEASE]
chronic I_DISEASE_ADJECTIVE[DISEASE]
complication I_DISEASE_ADJECTIVE[DISEASE]
of O
diabetes B_DISEASE
, O
has O
been O
demonstrated O
with O
alterations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
endocrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
system I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

An O
in O
vitro O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
assay O
, O
however O
, O
failed O
to O
detect O
LPS O
- O
induced O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
in O
Raw O
264 O
. O
7 O
cells O
, O
suggesting O
that O
in O
Raw O
264 O
. O
7 O
cells O
, O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
an O
activating O
component O
of O
the O
LPS O
signaling O
pathway O
regulating O
MAPK B_GENE
activity O
or O
sIL B_GENE
- I_GENE
1Ra I_GENE
promoter I_GENE
activity O
. O

Phosphorylation O
of O
the O
ras B_GENE/B_BIO
GTPase I_GENE/I_BIO
- I_GENE/I_BIO
activating I_GENE/I_BIO
protein I_GENE/I_BIO
( O
GAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
by O
the O
p93c B_ENZYME[GENE]
- I_ENZYME[GENE]
fes I_ENZYME[GENE]
protein I_ENZYME[GENE]
- I_ENZYME[GENE]
tyrosine I_ENZYME[GENE]
kinase I_ENZYME[GENE]
in O
vitro O
and O
formation O
of O
GAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
fes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complexes O
via O
an O
SH2 B_GENE/B_DISEASE
domain O
- O
dependent O
mechanism O
. O

gingival B_DISEASE_ADJECTIVE[DISEASE]
retraction I_DISEASE_ADJECTIVE[DISEASE]
for O
class B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
V I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
restorations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Two O
methods O
for O
the O
routine O
determination O
of O
blood O
hemoglobin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O
affinity O
are O
described O
. O

Thirty B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
lung B_MEASURE/B_PROTEIN[GENE]
lymph B_MEASURE/I_PROTEIN[GENE]
flow B_MEASURE/I_PROTEIN[GENE]
( O
QL B_PROTEIN[GENE]/B_LOCATION
) O
increased O
from O
4 B_MEASURE
. O
3 B_MEASURE
to O
8 B_MEASURE
. O
3 B_MEASURE
ml I_MEASURE
/ O
30 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_NUMBER[MEASURE]
. O
05 B_MEASURE
) O
, O
lymph B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O
plasma B_MEASURE/B_BIO
protein B_MEASURE/I_BIO
ratio B_MEASURE/I_BIO
was O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
0 B_MEASURE
. O
6 B_MEASURE
, O
and O
the O
lymph B_MEASURE
protein I_MEASURE
clearance I_MEASURE
increased O
from O
2 B_MEASURE
. O
6 B_MEASURE
to O
4 B_MEASURE
. O
6 B_MEASURE
ml I_MEASURE
/ O
30 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_NUMBER[MEASURE]
. O
05 B_MEASURE
) O
, O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
increased O
microvascular B_DISEASE
permeability I_DISEASE
. O

U B_OTHER/B_MEASURE
. O
S B_OTHER/B_DISEASE
. O
A B_OTHER/B_ORGANIZATION
. O

RET B_GENE/B_LOCATION
/ O
PTC B_LOCATION/B_GENE
oncogenes O
, O
generated O
by O
chromosomal O
rearrangements O
in O
papillary O
thyroid O
carcinomas O
, O
are O
constitutively O
activated O
versions O
of O
proto B_GENE/B_LOCATION
- I_GENE/I_LOCATION
RET I_GENE/I_LOCATION
, O
a O
gene O
coding O
for O
a O
receptor B_GENE
- I_GENE
type I_GENE
tyrosine I_GENE
kinase I_GENE
( O
TK B_GENE/B_DISEASE
) O
whose O
ligand O
is O
still O
unknown O
. O

PCC O
6803 O
mutant O
impaired O
in O
cytochrome B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENZYME[GENE]
c I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
maturation O
. O

Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Objective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
to O
characterize O
gas B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
exchange I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
cardiopulmonary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
maximal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progressive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arm I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
crank I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exercise I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
show O
that O
the O
activating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
mutation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
not O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
creating O
an O
exonic B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ESE B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
disrupting O
a O
putative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
secondary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
kinase B_GENE
domains I_GENE
encoded O
in O
the O
COOH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
moiety B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
94 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
% I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
conserved O
; O
the O
NH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
moieties B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
are O
approximately O
65 B_TIME[MEASURE]/B_PERSON
% I_TIME[MEASURE]/I_PERSON
homologous I_TIME[MEASURE]/I_PERSON
, O
suggesting O
this O
region B_LOCATION/B_BIO
may O
encode O
sequences B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
conferring O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
two B_ENZYME[GENE]
kinases I_ENZYME[GENE]
. O

In O
rats O
exposed O
to O
CD O
for O
30 O
d O
, O
the O
levels O
of O
urinary O
excretion O
of O
Camp O
after O
treatment O
with O
parathyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PTH B_GENE/B_LOCATION
) O
, O
parathyroidectomy O
( O
PTX O
) O
, O
or O
1 O
alpha O
- O
hydroxycholecalciferol O
( O
1 O
alpha O
- O
OH O
- O
D3 O
) O
showed O
almost O
the O
same O
patterns O
as O
those O
of O
control O
rats O
: O
the O
response O
of O
urinary O
Camp O
to O
treatment O
with O
PTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
not O
influenced O
by O
continuous O
oral O
administration O
of O
CD O
. O

The O
goal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O
this O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
whether O
BMIPP B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
used O
to O
differentiate O
viable B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
from O
scar B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soon O
after O
coronary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
thrombolysis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
acute B_DISEASE/B_LOCATION
myocardial I_DISEASE/I_LOCATION
infarction I_DISEASE/I_LOCATION
. O

There O
are O
three B_MEASURE/B_LOCATION
types I_MEASURE/I_LOCATION
of O
problems B_DISEASE
: O
problems B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arising O
before O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enters O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT
( O
solubilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
stabilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
improved B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
acceptability B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
) O
; O
problems B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
the O
penetration B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT
( O
absorption B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
barrier B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
crossing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
duration B_MEASURE/B_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
; O
problems B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relating O
to O
the O
therapeutic B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
selective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
local I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
delivery I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
. O

In O
the O
absence O
of O
shock O
, O
sepsis O
, O
or O
other O
identifiable O
causes O
of O
lactic O
acidosis O
, O
the O
severe O
anemia O
( O
hemoglobin B_MEASURE/B_LOCATION
1 O
. O
2 O
g O
/ O
DL O
) O
appeared O
to O
be O
the O
primary O
etiologic O
factor O
. O

The O
cumulative B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
experience I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
since O
the O
introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
confirmed O
its O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
diverse B_DISEASE
liver I_DISEASE
diseases I_DISEASE
in O
children B_PERSON/B_BIO
and O
adults B_PERSON/B_BIO
. O

Northern O
blot O
analysis O
of O
liver O
, O
muscle O
, O
fat O
, O
and O
pituitary O
RNA O
from O
normal O
( O
DwDw O
) O
chickens O
shows O
a O
major O
transcript O
of O
4 O
. O
3 O
kilobases O
( O
kb O
) O
and O
three O
minor O
transcripts O
( O
0 O
. O
8 O
, O
1 O
. O
7 O
, O
and O
3 O
. O
2 O
kb O
) O
, O
which O
correspond O
to O
the O
cGHR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Copyright B_LOCATION/B_PERSON
1999 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Despite O
a O
lowering O
of O
her O
plasma O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
during O
therapy O
with O
valproic O
acid O
, O
the O
patient O
' O
s O
tumour O
showed O
no O
evidence O
of O
regression O
while O
she O
was O
taking O
the O
drug O
. O

The O
Htf9 B_GENE
- I_GENE
a I_GENE
gene I_GENE
encodes O
the O
RanBP1 B_GENE
protein I_GENE
, O
a O
major O
partner O
of O
the O
Ran B_ENZYME[GENE]/B_LOCATION
GTPase I_ENZYME[GENE]/I_LOCATION
. O

Study B_MEASURE/B_LOCATION
Design I_MEASURE/I_LOCATION
: O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Sequence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
divergence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
approximately O
16 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
reduced O
transformation B_MEASURE/B_PERSON
frequencies B_MEASURE/I_PERSON
by O
at O
least O
10 B_NUMBER[MEASURE]
- O
fold B_TIME[MEASURE]
. O

Our O
studies O
suggest O
that O
the O
helicase B_GENE/B_DISEASE
assembly O
protein O
is O
responsible O
for O
loading O
T4 B_GENE
gene I_GENE
41 I_GENE
helicase I_GENE
specifically O
at O
replication O
forks O
, O
and O
that O
its O
binding O
sites O
for O
each O
arm O
must O
hold O
more O
than O
six O
, O
but O
not O
more O
than O
12 O
nucleotides O
. O

During O
the O
1st B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
all O
subjects B_PERSON
received O
either O
mianserin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
clomipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
75 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
once O
daily O
. O

CBD B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
exploration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O
avoided O
in O
7 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
with O
normal B_DISEASE
POC I_DISEASE
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SHBG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
analyzed O
by O
DNase B_GENE
I I_GENE
footprinting O
, O
and O
the O
functional O
significance O
of O
6 O
footprinted O
regions O
( O
FP1 O
- O
FP6 O
) O
within O
the O
proximal O
promoter O
was O
studied O
in O
human O
HepG2 O
hepatoblastoma O
cells O
. O

We O
exposed O
Dorper B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
cross B_PERSON/B_SPECIES[BIO]
ewes I_PERSON/I_SPECIES[BIO]
at O
approximately O
120 B_MEASURE
- O
135 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
gestation B_ORGANISM_FUNCTION
to O
a O
hot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
40 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
relative I_MEASURE/I_LOCATION
humidity I_MEASURE/I_LOCATION
) O
and O
a O
cold B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O
4 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
90 B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
relative B_MEASURE/I_LOCATION
humidity B_MEASURE/I_LOCATION
) O
environment B_LOCATION
and O
to O
treadmill B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exercise I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
2 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
km I_MEASURE/I_LOCATION
/ O
h O
, O
5 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
gradient I_MEASURE/I_LOCATION
) O
and O
measured O
fetal B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lamb I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
ewe B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
body B_MEASURE/B_ORGANISM_FUNCTION
temperatures I_MEASURE
using O
previously O
implanted O
abdominal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
radiotelemeters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O

Previously O
identified O
mutations O
in O
this O
variant O
have O
been O
within O
or O
close O
to O
the O
coding O
region O
of O
exon O
1 O
of O
the O
HMBS B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
, O
the O
only O
exon O
that O
is O
expressed O
solely O
in O
the O
ubiquitous O
isoform O
. O

As O
an O
approach O
to O
the O
determination O
of O
structure O
- O
function O
relationships O
in O
the O
PRP4 B_GENE/B_BIO
protein I_GENE/I_BIO
, O
we O
have O
isolated O
more O
than O
fifty O
new O
alleles O
of O
the O
PRP4 B_GENE
gene I_GENE
through O
random O
and O
site O
- O
directed O
mutagenesis O
, O
and O
have O
analyzed O
the O
phenotypes O
of O
many O
of O
them O
. O

Over O
a O
period B_MEASURE/B_LOCATION
of O
five B_TIME[MEASURE]
training I_TIME[MEASURE]
sessions I_TIME[MEASURE]
( O
2 B_MEASURE
. O
5 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
) O
, O
the O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
learned O
not O
to O
breathe O
, O
and O
the O
number B_MEASURE
of O
stimuli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
received O
in O
the O
fifth B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
session B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
the O
first B_SEQUENCE[MEASURE]/B_PERSON
session I_SEQUENCE[MEASURE]/I_PERSON
. O

The O
5 B_LOCATION/B_GENE
' I_LOCATION/I_GENE
- O
flanking O
region B_LOCATION/B_MEASURE
of O
the O
gene B_GENE
, O
approximately O
1 B_MEASURE
. O
1 B_MEASURE
kbp I_MEASURE
long O
, O
had O
no O
known O
regulatory B_GENE/B_LOCATION
elements B_GENE/I_LOCATION
for O
transcription B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
TATA B_GENE/B_LOCATION
, O
GC B_LOCATION/B_DISEASE
, O
and O
CCAAT B_LOCATION/B_GENE
boxes I_LOCATION/I_GENE
. O

We O
find O
that O
Fus3p B_GENE
and O
Kss1p B_GENE/B_DISEASE
both O
control O
G1 O
arrest O
through O
multiple O
functions O
that O
operate O
in O
parallel O
with O
Far1p B_GENE
. O

Tag B_GENE
expression O
induced O
apoptosis O
in O
mammary O
epithelial O
cells O
during O
late O
pregnancy O
. O

The O
composition B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stones B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysed O
by O
infrared B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectroscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

14 O
. O
9 B_MEASURE
x O
109 B_MEASURE/B_LOCATION
L I_MEASURE/I_LOCATION
- O
1 B_MEASURE/B_LOCATION
) O
was O
equal B_MEASURE
for O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
but O
CCI B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
bedside B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
filtered O
PC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
14 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
9 B_MEASURE
. O
5 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
case B_PERSON/B_DISEASE
of O
a O
patient B_PERSON/B_BIO
presenting O
a O
second B_DISEASE
hepatocellular I_DISEASE
carcinoma I_DISEASE
13 I_DISEASE
years I_DISEASE
after O
resection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
a O
first B_DISEASE
tumor I_DISEASE
of O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT
type I_BODY_PART_OR_ORGAN_COMPONENT
is O
reported O
. O

The O
time O
- O
dependent O
changes O
in O
measured O
facility O
of O
outflow O
or O
' O
washout O
phenomenon O
' O
appeared O
to O
result O
from O
the O
gradual O
dissolution O
of O
the O
hyaluronidase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
sensitive O
component O
of O
the O
barriers O
to O
aqueous O
outflow O
in O
the O
canine O
eye O
. O

The O
factors O
defective O
in O
groups O
A O
( O
CIITA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
C O
( O
RFX5 B_LOCATION/B_GENE
) O
and O
D O
( O
RFXAP B_GENE/B_LOCATION
) O
have O
been O
identified O
. O

It O
differed O
significantly O
by O
country B_LOCATION/B_MEASURE
( O
from O
2 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
the O
United B_LOCATION
Kingdom I_LOCATION
to O
24 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
Portugal B_LOCATION
) O
and O
by O
transmission B_MEASURE/B_PERSON
category I_MEASURE/I_PERSON
( O
2 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
among O
homo B_PERSON
/ O
bisexuals B_PERSON/B_DISEASE
, O
5 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
among O
injecting O
drug B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
, O
13 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
among O
heterosexual B_PERSON/B_DISEASE
subgroup I_PERSON/I_DISEASE
1 I_PERSON/I_DISEASE
) O
. O

On O
a O
national B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
, O
undiscounted B_MEASURE/B_PERSON
costs B_MEASURE/I_PERSON
are O
expected O
to O
increase O
up O
to O
approximately O
DF1 O
42 B_TIME[MEASURE]
million I_TIME[MEASURE]
annually O
during O
the O
first B_TIME[MEASURE]/B_ENT
40 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
after O
introduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
the O
preventative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

By O
deletion O
analysis O
, O
we O
identified O
the O
regions O
of O
c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
Jun I_GENE/I_LOCATION
encoding O
transformation O
and O
transactivation O
functions O
. O

A O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
274 B_PERSON
late I_PERSON
detected I_PERSON
cases I_PERSON
of O
CDH B_DISEASE/B_PERSON
born O
in O
the O
years B_TIME[MEASURE]/B_LOCATION
1970 B_TIME[MEASURE]/I_LOCATION
- O
- O
74 B_MEASURE
is O
presented O
. O

To O
test O
for O
progesterone B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
- O
mediated O
activation O
of O
transcription O
in O
yeast O
, O
reporter O
plasmids O
were O
constructed O
to O
transform O
yeast O
cells O
expressing O
PRB B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
C1C2 B_GENE/B_LOCATION
receptors I_GENE/I_LOCATION
. O

Fli B_GENE
- I_GENE
1 I_GENE
is O
a O
Proto O
- O
oncogene O
which O
is O
rearranged O
in O
tumors O
induced O
by O
three O
different O
retroviruses O
, O
Cas O
- O
BR O
- O
E O
, O
F O
- O
MuLV O
, O
and O
10A1 O
. O

ionic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
composition I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Na B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
K B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
ca O
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_MEASURE/B_LOCATION
, O
and O
Mg2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
of O
cerebrospinal B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
feeding B_BODY_PART_OR_ORGAN_COMPONENT
behavior I_BODY_PART_OR_ORGAN_COMPONENT
in O
sheep B_SPECIES[BIO]/B_PERSON
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
presented O
of O
a O
comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
cultural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
virulence B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
liophylized B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O
Leishmania B_SPECIES[BIO]
tropica I_SPECIES[BIO]
major I_SPECIES[BIO]
after O
their O
rehydration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
or O
after O
a O
long B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
passage B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
NNN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imply O
that O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
a O
simple B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
command I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
carrying O
medium B_LOCATION
from O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
limbs B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
implies O
that O
some O
computational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
take O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
level I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
101st B_TIME[MEASURE]/B_LOCATION
annual B_TIME[MEASURE]/I_LOCATION
meeting B_TIME[MEASURE]/I_LOCATION
of O
the O
Japanese B_ORGANIZATION/B_PERSON
Ophthalmological I_ORGANIZATION/I_PERSON
Society I_ORGANIZATION/I_PERSON
. O

The O
results O
corroborate O
the O
proposed O
physiological O
function O
of O
CCoAOMT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
elicited O
plant O
cells O
and O
may O
shed O
new O
light O
on O
the O
sequential O
action O
of O
trans O
- O
active O
factors O
in O
the O
regulation O
of O
phenylpropanoid O
genes O
. O

In O
src B_GENE/B_VIRUS[BIO]
- O
transformed O
cells O
GAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O
heteromeric O
complexes O
, O
notably O
with O
a O
highly O
tyrosine O
phosphorylated O
62 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kDa I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p62 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
characteristics B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adult B_PERSON/B_BIO
asthmatics I_PERSON/I_BIO
who O
are O
sensitized O
by O
cats B_SPECIES[BIO]
and O
dogs B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
allergens I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

PrRP B_GENE/B_PERSON
rapidly O
and O
transiently O
activated O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ERK B_GENE/B_LOCATION
) O
in O
both O
types O
of O
cells O
. O

Cell O
- O
free O
extracts O
of O
E O
. O
coli O
( O
fpg B_PROTEIN[GENE]/B_LOCATION
mutY I_PROTEIN[GENE]/I_LOCATION
) O
harboring O
pYSB10 O
possess O
an O
enzymatic O
activity O
that O
cleaves O
a O
34 O
- O
mer O
oligonucleotide O
containing O
a O
single O
8 O
- O
oxoG O
opposite O
a O
cytosine O
( O
8 O
- O
OxoG O
/ O
C O
) O
. O

estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
pretreated O
castrated B_PERSON/B_BIO
males I_PERSON/I_BIO
also O
showed O
no O
change B_DISEASE_ADJECTIVE[DISEASE]
in O
myocardial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
coronary B_MEASURE
flow I_MEASURE
velocity I_MEASURE
decreased O
( O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
compared O
with O
baseline B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
h O
after O
the O
200 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
kg B_TIME[MEASURE]/B_LOCATION
dose I_TIME[MEASURE]/I_LOCATION
( O
from O
1 B_MEASURE
. O
69 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
61 B_MEASURE
to O
1 B_MEASURE
. O
41 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
42 B_MEASURE
kHz I_MEASURE
) O
and O
diastolic B_MEASURE/B_LOCATION
coronary I_MEASURE/I_LOCATION
resistance I_MEASURE/I_LOCATION
increased O
significantly O
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
01 B_MEASURE
) O
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
this O
time B_MEASURE/B_LOCATION
( O
51 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
15 B_MEASURE
compared O
with O
39 B_MEASURE
+ I_MEASURE
/ O
- O
14 B_MEASURE
mmHg I_MEASURE
/ O
mkHz B_MEASURE
) O
. O

Acute B_DISEASE/B_MEASURE
renal I_DISEASE/I_MEASURE
vein I_DISEASE/I_MEASURE
thrombosis I_DISEASE/I_MEASURE
in O
renal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
allografts I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
: O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
duplex B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Doppler I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
US I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Several B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
clones B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O
obtained O
by O
this O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
which O
, O
clone B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
18 B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
is O
reported O
and O
characterized O
here O
. O

Long O
- O
range O
mapping O
by O
pulse O
- O
field O
gel O
electrophoresis O
indicated O
that O
the O
three O
mdr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
closely O
linked O
on O
a O
genomic O
DNA O
segment O
of O
approximately O
625 O
kilobases O
. O

These O
sequences O
were O
further O
tested O
for O
the O
presence O
of O
an O
enhancer O
element O
, O
by O
their O
ability O
to O
activate O
a O
fusion O
reporter O
gene O
consisting O
of O
the O
CAT B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
linked O
to O
the O
gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
erythroid O
( O
K562 O
) O
and O
non O
- O
erythroid O
( O
HeLa O
) O
cells O
. O

Two B_PERSON/B_ENT
sibs I_PERSON/I_ENT
with O
identical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
short B_PERSON/B_MEASURE
- O
limbed B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dwarfism I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
normal B_BODY_PART_OR_ORGAN_COMPONENT
skull I_BODY_PART_OR_ORGAN_COMPONENT
and O
face B_BODY_PART_OR_ORGAN_COMPONENT
and O
normal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
intelligence B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O
described O
. O

This O
article B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
describes O
a O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
resulted O
in O
a O
75 B_NUMBER[MEASURE]
- O
percent B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
reduction I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
inventory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O
a O
five B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
. O

Further O
comparative O
analysis O
identified O
an O
ADNP B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
paralog O
( O
33 O
% O
identity O
and O
46 O
% O
similarity O
) O
, O
indicating O
that O
these O
genes O
belong O
to O
a O
novel O
protein O
family O
with O
a O
nine O
- O
zinc O
finger O
motif O
followed O
by O
a O
homeobox O
domain O
. O

All O
patients O
received O
marrow O
from O
HLA B_GENE
- O
identical O
sibling O
donors O
, O
underwent O
similar O
myeloablative O
regimens O
, O
and O
had O
similar O
pretreatment O
characteristics O
. O

In O
female B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
toads I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
Bufo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bufo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
feeding O
at O
different B_TIME[MEASURE]/B_LOCATION
rates I_TIME[MEASURE]/I_LOCATION
, O
the O
uncorrected B_MEASURE
value I_MEASURE
of O
n B_MEASURE/B_PROTEIN[GENE]
was O
0 B_MEASURE
. O
44 B_MEASURE
, O
when O
metabolism B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
were O
expressed O
as O
kJ B_MEASURE
kJ I_MEASURE
- O
1 B_MEASURE/B_BIO
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Two B_PERSON
patients I_PERSON
developed O
cervical B_DISEASE
myelopathy I_DISEASE
or O
radiculopathy B_DISEASE
after O
spinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
manipulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
and O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
showed O
herniated O
cervical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
discs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O
C4 B_PROTEIN[GENE]
- O
C5 B_MEASURE/B_PROTEIN[GENE]
and O
C6 B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
C7 B_MEASURE/B_PROTEIN[GENE]
, O
respectively O
. O

Subclones O
stably O
expressing O
alpha1A B_PROTEIN[GENE]/B_LOCATION
- O
, O
alpha1B B_PROTEIN[GENE]/B_LOCATION
- O
, O
and O
alpha1D B_GENE
- O
ARs O
under O
control O
of O
an O
inducible O
promoter O
, O
or O
at O
high O
and O
low O
receptor O
density O
, O
were O
isolated O
and O
characterized O
. O

Analysis O
of O
WT1 B_GENE
target I_GENE
gene I_GENE
expression O
in O
stably O
transfected O
cell O
lines O
. O

soluble O
recombinant O
RI B_GENE
and O
soluble O
recombinant O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
associate O
in O
vitro O
and O
be O
activated O
by O
cyclic O
AMP O
. O

IRIS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O
GAS B_VIRUS[BIO]/B_GENE
DNA O
also O
formed O
a O
number O
of O
specific O
complexes O
with O
constitutively O
expressed O
factors O
, O
none O
of O
which O
were O
affected O
by O
the O
above O
ABS O
. O

Simulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
the O
presented O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
compared O
with O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cMUTs B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reported O
in O
the O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Tre B_GENE/B_LOCATION
during O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
35 B_MEASURE/B_LOCATION
W I_MEASURE/I_LOCATION
at O
23 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
correlated O
r O
= O
- O
70 B_MEASURE
with O
Vo2max B_MEASURE/B_LOCATION
and O
r B_PROTEIN[GENE]/B_MEASURE
= O
0 B_MEASURE
. O
80 B_MEASURE
with O
Tre B_PROTEIN[GENE]/B_LOCATION
during O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
heat B_LOCATION
. O

Electrophoretic O
mobility O
- O
shift O
assays O
with O
nuclear O
extracts O
from O
COS O
- O
1 O
cells O
transfected O
with O
expression O
vectors O
for O
SMADs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O
that O
SMAD3 B_GENE/B_DISEASE
forms O
a O
complex O
with O
a O
migration O
similar O
to O
that O
of O
the O
endogenous B_GENE/B_MEASURE
TGF I_GENE/I_MEASURE
- I_GENE/I_MEASURE
beta I_GENE/I_MEASURE
- I_GENE/I_MEASURE
specific I_GENE/I_MEASURE
complex I_GENE/I_MEASURE
observed O
in O
fibroblast O
extracts O
. O

The O
newly O
identified O
NF B_GENE/B_PERSON
kappa I_GENE/I_PERSON
B I_GENE/I_PERSON
enhancer I_GENE/I_PERSON
( O
TGGAAATTCC O
) O
is O
bound O
by O
a O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
induced O
nuclear O
protein O
and O
appears O
to O
be O
the O
key O
element O
in O
rapid O
transcription O
induction O
by O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
and O
TPA O
) O
, O
while O
transactivation O
of O
this O
element O
is O
repressed O
by O
the O
ligand O
- O
bound O
glucocorticoid B_GENE
receptor I_GENE
. O

Our O
results O
showed O
that O
the O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
content O
in O
platelets O
was O
: O
( O
1 O
) O
increased O
in O
the O
subgroup O
of O
anti O
- O
social O
alcoholics O
; O
( O
2 O
) O
transiently O
and O
differently O
altered O
in O
alcoholics O
compared O
to O
opiate O
addicts O
; O
and O
( O
3 O
) O
lowered O
in O
drinking O
alcoholics O
and O
normal O
in O
alcoholics O
who O
were O
drinking O
as O
well O
as O
smoking O
( O
that O
may O
occur O
via O
MAO B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O
by O
smoke O
) O
. O

In O
the O
second O
group O
, O
which O
consisted O
of O
babies O
of O
33 O
to O
36 O
weeks O
of O
gestational O
age O
, O
haptoglobin B_DISEASE/B_GENE
was O
detected O
in O
6 O
infants O
, O
with O
levels O
less O
than O
25 O
mg O
/ O
DL O
in O
3 O
. O

The O
polypeptide O
encoded O
by O
the O
cDNA O
contained O
450 O
amino O
acids O
with O
a O
calculated O
M O
( O
r O
) O
of O
52 O
, O
057 O
, O
and O
showed O
significant O
homology O
with O
human O
and O
mouse B_SPECIES[BIO]/B_GENE
CAD I_SPECIES[BIO]/I_GENE
( O
22 O
% O
identity O
) O
. O

correlation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alpha B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
frontal B_BODY_PART_OR_ORGAN_COMPONENT
and O
occipital B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

In O
situ O
localization O
of O
PCP B_GENE/B_BIO
- I_GENE/I_BIO
A1 I_GENE/I_BIO
transcripts I_GENE/I_BIO
revealed O
that O
they O
accumulate O
specifically O
in O
pollen O
at O
the O
late O
binucleate O
/ O
trinucleate O
stage O
of O
development O
rather O
than O
in O
the O
tapetum O
, O
which O
previously O
was O
taken O
to O
be O
the O
principal O
source O
of O
the O
pollen O
coat O
. O

successful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
progressive B_DISEASE
multifocal I_DISEASE
leukoencephalopathy I_DISEASE
after O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
cidofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
species B_BACTERIUM[BIO]
composition O
and O
abundance O
upon O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
manure B_BIO/B_LOCATION
with O
polyethylene B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
polystyrene B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
glass B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
i O
. O
e O
. O
natural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
inert B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sand I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
H19 B_GENE
and O
IGF2 B_GENE
lie O
within O
a O
larger O
imprinted O
domain O
, O
and O
the O
gene O
specificity O
of O
H19 B_GENE/B_PERSON
epimutation O
has O
been O
a O
persistent O
question O
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B_PROTEIN[GENE]/B_LOCATION
, O
RFC2 B_PROTEIN[GENE]/B_DISEASE
, O
RFC3 B_PROTEIN[GENE]/B_DISEASE
, O
RFC4 B_PROTEIN[GENE]/B_LOCATION
, O
and O
RFC5 B_GENE/B_DISEASE
. O

It O
is O
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
, O
aside O
from O
starvation B_TIME[MEASURE]/B_DISEASE
, O
the O
nutrition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catastrophes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
past B_TIME[MEASURE]/B_LOCATION
, O
including O
scurvy B_DISEASE
( O
vitamin B_DISEASE
C I_DISEASE
deficiency I_DISEASE
) O
resulting O
from O
lack B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
fresh B_BIO/B_ORGANISM_FUNCTION
vegetables I_BIO/I_ORGANISM_FUNCTION
and O
fruit B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O
beriberi B_DISEASE/B_BIO
( O
vitamin B_DISEASE/B_BIO
B1 I_DISEASE/I_BIO
deficiency I_DISEASE/I_BIO
) O
from O
consumption B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
polished B_BIO
rice I_BIO
, O
are O
forgotten O
and O
only O
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
history B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
sequence O
can O
interact O
with O
at O
least O
two O
proteins O
in O
a O
fibroblast O
nuclear O
extract O
that O
have O
binding O
characteristics O
of O
an O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
serum B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
much O
thrombin B_GENE
was O
formed O
during O
cardiopulmonary O
bypass O
( O
measured O
by O
the O
prothrombin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
thrombin B_GENE
- O
antithrombin B_GENE
complexes O
) O
as O
in O
normal O
patients O
, O
showing O
that O
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
XII I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
necessary O
for O
thrombin B_PROTEIN[GENE]
generation O
. O

The O
molecular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
event I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
s O
) O
underlying O
the O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificities I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
receptors B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
in O
regulating O
the O
expression B_GENE
of O
their O
native B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
very O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
issue I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
remains O
poorly O
understood O
. O

MUS81 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encodes O
a O
novel O
helix B_ENZYME[GENE]/B_MEASURE
- I_ENZYME[GENE]/I_MEASURE
hairpin I_ENZYME[GENE]/I_MEASURE
- I_ENZYME[GENE]/I_MEASURE
helix I_ENZYME[GENE]/I_MEASURE
protein I_ENZYME[GENE]/I_MEASURE
involved O
in O
the O
response O
to O
UV O
- O
and O
methylation O
- O
induced O
DNA O
damage O
in O
Saccharomyces O
cerevisiae O
. O

Treatment O
of O
chronic O
hepatitis O
B O
with O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
experience O
in O
western O
countries O
. O

Several O
positive O
clones O
were O
isolated O
, O
one O
of O
which O
encoded O
the O
C O
- O
terminal O
253 O
amino O
acids O
of O
a O
putative O
RNA B_GENE/B_BIO
helicase I_GENE/I_BIO
, O
a O
DEAD B_GENE/B_PERSON
box I_GENE/I_PERSON
protein I_GENE/I_PERSON
designated O
DDX3 B_PROTEIN[GENE]
. O

Kerstin B_PERSON/B_LOCATION
takes O
the O
abbreviated B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
medical B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
education B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
vitro O
binding O
studies O
previously O
showed O
that O
NF B_GENE/B_PERSON
- I_GENE/I_PERSON
kappa I_GENE/I_PERSON
B I_GENE/I_PERSON
p50 I_GENE/I_PERSON
homodimer O
binds O
the O
switch B_LOCATION
nuclear I_LOCATION
B I_LOCATION
- I_LOCATION
site I_LOCATION
protein I_LOCATION
( O
SNIP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
of O
the O
S B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gamma B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tandem B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
repeat B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
this O
case O
myogenic O
factors O
are O
not O
initially O
expressed O
and O
these O
migratory O
cells O
are O
characterized O
by O
the O
expression O
of O
the O
paired B_MEASURE/B_PROTEIN[GENE]
- O
box O
gene O
Pax3 B_GENE/B_LOCATION
. O

It O
is O
concluded O
that O
the O
atherogenic O
process O
includes O
stimulation O
of O
collagen B_GENE/B_DISEASE
and O
elastin B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O
. O

These O
results O
indicate O
that O
( O
1 O
) O
RXR B_PROTEIN[GENE]/B_LOCATION
- O
TR B_PROTEIN[GENE]/B_DISEASE
heterodimers O
play O
a O
role O
in O
basal O
transactivation O
and O
T3 O
suppression O
of O
negatively O
regulated O
genes O
, O
and O
( O
2 O
) O
RXRs B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
increase O
the O
dominant O
negative O
effect O
of O
some O
mutant O
TRs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
on O
specific O
negative O
TREs O
. O

Phenotypic O
responses O
of O
additional O
mutants O
, O
including O
exo1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
srs2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rad5 B_GENE/B_LOCATION
, O
and O
rdh54 B_NUMBER[MEASURE]/B_GENE
strains O
, O
suggest O
roles O
in O
recombinational O
repair O
, O
but O
not O
in O
NHEJ O
. O

Furthermore O
, O
the O
induction O
of O
cytochrome B_GENE/B_DISEASE
P I_GENE/I_DISEASE
- I_GENE/I_DISEASE
450 I_GENE/I_DISEASE
1A1 I_GENE/I_DISEASE
observed O
in O
the O
cormorant O
indicates O
that O
the O
Ah B_GENE
receptor I_GENE
- O
mediated O
process O
, O
by O
which O
TCDD O
and O
related O
chemicals O
exert O
many O
of O
their O
toxicities O
, O
has O
been O
activated O
. O

RESULT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
S B_OTHER/B_MEASURE
) O
: O
A O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
with O
44 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
34 B_PERSON
couples I_PERSON
with O
nafarelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
group B_NUMBER[MEASURE]/B_LOCATION
1 I_NUMBER[MEASURE]/I_LOCATION
) O
and O
47 B_TIME[MEASURE]
cycles I_TIME[MEASURE]
for O
40 B_TIME[MEASURE]/B_PERSON
couples B_TIME[MEASURE]/I_PERSON
with O
buserelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
a O
long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
IVF I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O
68 B_MEASURE/B_LOCATION
cycles I_MEASURE/I_LOCATION
for O
46 B_PERSON
couples I_PERSON
with O
nafarelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
group B_NUMBER[MEASURE]/B_ORGANIZATION
3 I_NUMBER[MEASURE]/I_ORGANIZATION
) O
and O
56 B_MEASURE
cycles I_MEASURE
for O
39 B_NUMBER[MEASURE]/B_PERSON
couples B_NUMBER[MEASURE]/I_PERSON
with O
buserelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
a O
short B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IVF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
protocol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O
39 B_TIME[MEASURE]
cycles I_TIME[MEASURE]
for O
32 B_PERSON
couples I_PERSON
with O
nafarelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
50 B_MEASURE
cycles I_MEASURE
for O
30 B_TIME[MEASURE]/B_PERSON
couples B_TIME[MEASURE]/I_PERSON
with O
buserelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
a O
long B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ICSI I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
protocol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O
and O
87 B_MEASURE
cycles I_MEASURE
for O
60 B_TIME[MEASURE]/B_PERSON
couples B_TIME[MEASURE]/I_PERSON
with O
nafarelin B_DISEASE/B_MEASURE
acetate I_DISEASE/I_MEASURE
( O
group B_NUMBER[MEASURE]/B_ORGANIZATION
7 I_NUMBER[MEASURE]/I_ORGANIZATION
) O
and O
81 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycles I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
61 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
couples I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
buserelin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
acetate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O
group B_NUMBER[MEASURE]/B_ORGANIZATION
8 I_NUMBER[MEASURE]/I_ORGANIZATION
) O
with O
a O
short B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ICSI B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrates O
the O
feasibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
syngeneic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
BM I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Txp I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
myeloma B_DISEASE/B_BIO
. O

5 O
. O
3 B_MEASURE
+ O
/ O
- O
6 B_MEASURE
. O
6 B_MEASURE
for O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
09 B_MEASURE
) O
. O

In O
this O
work O
, O
we O
determined O
the O
sequences O
of O
eight O
VirF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
four O
different O
genes O
, O
by O
DNase B_GENE
I I_GENE
or O
hydroxyl O
radical O
footprinting O
. O

Although O
they O
are O
similar O
to O
the O
IL9R B_GENE/B_TIME[MEASURE]
gene I_GENE/I_TIME[MEASURE]
( O
approximately O
90 O
% O
identity O
) O
, O
none O
of O
these O
copies O
encodes O
a O
functional O
receptor O
: O
none O
of O
them O
contains O
sequences O
homologous O
to O
the O
5 O
' O
flanking O
region O
or O
exon O
1 O
of O
the O
IL9R B_GENE
gene I_GENE
, O
and O
the O
remaining O
ORFs O
have O
been O
inactivated O
by O
various O
point O
mutations O
and O
deletions O
. O

Type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
neuroleptanalgesia I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
odonto B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
stomatology B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

273 B_MEASURE/B_LOCATION
, O
27420 B_TIME[MEASURE]/B_LOCATION
- O
27429 B_NUMBER[MEASURE]/B_LOCATION
) O
a O
putative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxisome I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proliferator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
activated O
receptor B_PROTEIN[GENE]/B_LOCATION
response I_PROTEIN[GENE]/I_LOCATION
element I_PROTEIN[GENE]/I_LOCATION
( O
PPRE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
- O
458 B_MEASURE
to O
- O
474 B_MEASURE
. O

While O
reviewing O
gastric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
215 B_LOCATION
baboons I_LOCATION
, O
we O
found O
diffuse B_DISEASE
giant I_DISEASE
mucosal I_DISEASE
folds I_DISEASE
in O
2 B_NUMBER[MEASURE]
specimens I_NUMBER[MEASURE]
and O
multiple B_DISEASE
giant I_DISEASE
mucosal I_DISEASE
nodules I_DISEASE
in O
another O
3 B_NUMBER[MEASURE]/B_BIO
. O

To O
investigate O
whether O
the O
two O
RPG B_GENE/B_LOCATION
- I_GENE/I_LOCATION
boxes I_GENE/I_LOCATION
mediate O
transcription O
activation O
of O
both O
the O
L46 B_PROTEIN[GENE]
and O
S24 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
two O
experimental O
strategies O
were O
followed O
: O
cloning O
of O
the O
respective O
genes O
on O
multicopy O
vectors O
and O
construction O
of O
fusion O
genes O
. O

When O
the O
opioid O
antagonist O
was O
administered O
to O
animals O
24 O
hr O
after O
termination O
of O
single O
or O
multiple O
exposures O
to O
restraint O
, O
NALT O
- O
induced O
increases O
in O
basal O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
significantly O
attenuated O
in O
the O
chronically O
stressed O
rats O
compared O
to O
animals O
subjected O
to O
stress O
only O
once O
or O
not O
at O
all O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

The O
psychosocial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
features I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
people B_PERSON
using O
self B_PERSON/B_DISEASE
- O
ignition B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
suicide B_PERSON/B_DISEASE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
those O
of O
suicide B_PERSON/B_ORGANIZATION
in O
general B_PERSON/B_ORGANIZATION
. O

This O
was O
further O
suggested O
by O
transactivation O
assays O
in O
which O
mouse O
fibroblasts O
were O
transiently O
transfected O
with O
a O
human B_GENE
beta I_GENE
- I_GENE
globin I_GENE
reporter I_GENE
gene I_GENE
in O
the O
absence O
and O
presence O
of O
an O
LKLF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulating I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
analysis O
and O
the O
clinical O
significance O
. O

Thus O
, O
in O
addition O
to O
the O
previously O
characterized O
FAS B_GENE/B_LOCATION
- I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
interacting O
with O
the O
inositol O
/ O
choline O
- O
responsive O
- O
element O
motif O
, O
a O
second O
motif O
common O
to O
the O
promoter O
regions O
of O
both O
FAS B_GENE/B_BIO
genes I_GENE/I_BIO
could O
be O
identified O
. O

Reconstruction B_MEASURE/B_PERSON
time I_MEASURE/I_PERSON
for O
a O
64 B_MEASURE
x O
64 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
approximately O
45 B_MEASURE/B_ORGANIZATION
s I_MEASURE/I_ORGANIZATION
/ O
transaxial B_MEASURE/B_LOCATION
slice I_MEASURE/I_LOCATION
. O

sequence O
analysis O
identifies O
a O
ras B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
associating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
RA B_DISEASE/B_PROTEIN[GENE]
) O
- O
like O
domain O
in O
the O
N O
- O
termini O
of O
band B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
JEF I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
the O
Grb7 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
10 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
14 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
adapter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

patients O
received O
BPB O
using O
bupivacaine O
2 O
mg O
kg O
- O
1 O
with O
adrenaline O
1 O
in O
200 O
, O
000 O
, O
either O
with O
or O
without O
hyaluronidase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3000 O
iu O
, O
in O
a O
volume O
of O
0 O
. O
5 O
ml O
per O
2 O
. O
54 O
cm O
of O
the O
patient O
' O
s O
height O
. O

Rhinovirus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protease I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
foot B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mouth I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
used O
to O
analyze O
the O
association O
of O
eIF4G B_GENE/B_DISEASE
with O
eIF4A B_GENE
, O
eIF4E B_GENE
, O
and O
eIF3 B_GENE
. O

One O
hundred O
cDNA O
clones O
were O
sequenced O
and O
8 O
RTKs B_GENE/B_PERSON
were O
identified O
, O
as O
well O
as O
12 O
non O
- O
RTKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
2 O
serine B_GENE/B_BIO
/ I_GENE/I_BIO
threonine I_GENE/I_BIO
kinases I_GENE/I_BIO
. O

Roller B_TIME[MEASURE]/B_LOCATION
pumps I_TIME[MEASURE]/I_LOCATION
, O
coronary B_PRODUCT[OBJECT]/B_LOCATION
suction I_PRODUCT[OBJECT]/I_LOCATION
and O
an O
open B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cardiotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
reservoir I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
were O
used O
. O

Furthermore O
, O
it O
was O
found O
that O
the O
Shb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
overexpressing O
cells O
extended O
neurites O
in O
response O
to O
epidermal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

levels O
of O
p53 B_GENE
were O
substantially O
increased O
by O
E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
during O
adenovirus O
infection O
. O

In O
cases O
of O
intracapsular O
prostatic O
cancer O
the O
level O
of O
prostatic B_GENE
acid I_GENE
phosphatase I_GENE
( O
PAP B_LOCATION/B_GENE
) O
measured O
by O
radioimmunoassay O
was O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
8 O
micrograms O
/ O
l O
. O

healthy B_PERSON
subjects I_PERSON
received O
the O
following B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regimens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
dosed O
to O
steady B_NUMBER[MEASURE]
state I_NUMBER[MEASURE]
: O
trovafloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
24 B_TIME[MEASURE]
h I_TIME[MEASURE]
; O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
400 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
12 B_MEASURE
h O
; O
trovafloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
24 B_MEASURE
h O
plus O
cefepime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
12 B_MEASURE
h O
, O
and O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
400 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
12 B_MEASURE
h O
plus O
cefepime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
12 B_MEASURE
h O
. O

In O
EGF B_GENE
receptor I_GENE
- O
mediated O
signaling O
, O
the O
protein B_GENE
kinase I_GENE
PKB I_GENE
/ O
Akt B_GENE
and O
the O
mitogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
function O
downstream O
of O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI B_GENE/B_LOCATION
3 I_GENE/I_LOCATION
- I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
) O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphotyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
MAPK B_GENE
in O
addition O
to O
p185 B_GENE
( O
neu B_GENE/B_DISEASE
) O
, O
suggesting O
that O
the O
Ras B_GENE/B_DISEASE
to O
MAPK B_GENE/B_PERSON
mitogenic O
pathway O
is O
activated O
. O

Acad B_LOCATION
. O

We O
suggest O
that O
this O
effect O
of O
Myc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B_GENE
E I_GENE
- O
CDK2 B_GENE/B_DISEASE
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B_GENE
( O
Kip1 B_PROTEIN[GENE]/B_LOCATION
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B_GENE
. O

bile B_DISEASE/B_LOCATION
reflux I_DISEASE/I_LOCATION
demonstrated O
by O
99m B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tc I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disofenin I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B_GENE/B_LOCATION
and O
Ran B_GENE/B_LOCATION
/ O
TC4 B_PROTEIN[GENE]/B_DISEASE
are O
closely O
linked O
and O
that O
NTF2 B_GENE/B_PERSON
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B_GENE/B_LOCATION
/ O
TC4 B_PROTEIN[GENE]/B_LOCATION
. O

Almost O
every O
image B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
appears O
during O
a O
therapy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
session I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
reveals O
a O
symbolic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
the O
very B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concept I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
symbol B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
free B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O
ambiguity B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
some O
positions B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
originated O
in O
different B_LOCATION
areas I_LOCATION
of O
investigation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
are O
mentioned O
, O
ending O
with O
a O
description B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
traits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O
, O
according O
to O
the O
writer B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
bestow O
a O
symbolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
character I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
images B_ENT/B_PERSON
. O

The O
severity B_MEASURE
of O
the O
psychomotor B_DISEASE
retardation I_DISEASE
varied O
from O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Both O
oligonucleotide O
cross O
- O
competition O
and O
antibody O
supershift O
experiments O
established O
that O
the O
double O
- O
strand O
binding O
protein O
is O
equivalent O
to O
Sp1 B_GENE
. O

The O
wet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
dry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
HA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
considered O
. O

All O
these O
abnormalities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
returned O
to O
normal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
removal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
tumor B_DISEASE
. O

Although O
FKH2 B_GENE
is O
redundant O
with O
FKH1 B_GENE
in O
controlling O
pseudohyphal O
growth O
, O
the O
two O
genes O
have O
different O
functions O
in O
silencing O
HMRa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Molecular O
analysis O
indicated O
that O
inactivation O
of O
H B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2L I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
nearly O
every O
null O
clone O
resulted O
from O
an O
apparent O
deletion O
or O
rearrangement O
of O
5 B_GENE
' I_GENE
- I_GENE
flanking I_GENE
and I_GENE
5 I_GENE
' I_GENE
- I_GENE
coding I_GENE
H I_GENE
- I_GENE
2L I_GENE
sequences I_GENE
, O
with O
breakpoints O
consistently O
mapping O
to O
within O
a O
550 O
BP O
GC O
- O
rich O
region O
between O
exon O
1 O
and O
the O
middle O
of O
intron O
2 O
. O

However O
, O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
EBP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulated O
transcription O
primarily O
through O
the O
Camp O
- O
responsive O
element O
( O
CRE O
) O
, O
which O
maps O
between O
positions O
- O
77 O
to O
- O
94 O
, O
but O
not O
at O
the O
more O
5 O
' O
- O
binding O
sites O
. O

Heliox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
improves O
pulsus B_DISEASE/B_BIO
paradoxus I_DISEASE/I_BIO
and O
peak B_DISEASE
expiratory I_DISEASE
flow I_DISEASE
in O
nonintubated B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
severe B_DISEASE/B_GENE
asthma I_DISEASE/I_GENE
. O

50 B_NUMBER[MEASURE]
- O
fold B_MEASURE
increase I_MEASURE
in O
foreign B_MEASURE/B_DISEASE
protein I_MEASURE/I_DISEASE
production I_MEASURE/I_DISEASE
. O

Ion B_PERSON/B_LANGUAGE
- O
Bernstein B_PERSON/B_MEASURE
- O
wave B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heating I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
improved B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
confinement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
Alcator B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
C I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tokamak I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
the O
molecular O
mechanisms O
by O
which O
specific O
cis O
- O
and O
trans O
- O
acting O
factors O
control O
activity O
of O
the O
prodynorphin B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
are O
not O
as O
clearly O
defined O
. O

Finally O
, O
antisense O
mediated O
reduction O
of O
Elk B_GENE
- I_GENE
1 I_GENE
in O
GH4 O
cells O
decreased O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
increased O
prolactin B_GENE
gene I_GENE
expression O
and O
confirmed O
the O
requirement O
for O
Elk B_GENE
- I_GENE
1 I_GENE
for O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
increased O
prolactin B_GENE
gene I_GENE
expression O
. O

substitutions B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Asp11 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
led O
to O
dominant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lethality I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Three B_PERSON/B_ORGANIZATION
modern B_PERSON/I_ORGANIZATION
hematology B_PERSON/I_ORGANIZATION
analyzers B_PERSON/I_ORGANIZATION
( O
Abbott B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
dyn B_MEASURE/B_LOCATION
3000 I_MEASURE/I_LOCATION
, O
Coulter B_MEASURE/B_PERSON
STKS I_MEASURE/I_PERSON
, O
and O
Sysmex B_LOCATION/B_DISEASE
NE I_LOCATION/I_DISEASE
- O
8000 B_MEASURE/B_LOCATION
) O
with O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughput B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
5 B_NUMBER[MEASURE]
- O
part B_MEASURE/B_LOCATION
differential I_MEASURE/I_LOCATION
capability I_MEASURE/I_LOCATION
were O
evaluated O
using O
a O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
designed O
by O
a O
quality B_PERSON/B_ORGANIZATION
team I_PERSON/I_ORGANIZATION
. O

Each O
subject B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O
injected O
in O
the O
antecubital B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vein I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O
7 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
25 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
and O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
were O
taken O
1 B_TIME[MEASURE]/B_LOCATION
hr I_TIME[MEASURE]/I_LOCATION
postinjection I_TIME[MEASURE]/I_LOCATION
at O
4 B_MEASURE
. O
5 B_MEASURE
mm I_MEASURE
and O
7 B_MEASURE
. O
5 B_MEASURE
mm I_MEASURE
from O
the O
retina B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
cleft B_DISEASE/B_LOCATION
walls B_DISEASE/I_LOCATION
are O
lined O
with O
highly O
conserved B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
residues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
NADP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
is O
bound O
along O
one B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wall I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cDNA O
cloning O
, O
sequencing O
and O
chromosome O
mapping O
of O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
erythroid B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
spectrin B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fodrin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
aromatic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AHR B_GENE/B_LOCATION
) O
is O
a O
ligand O
- O
activated O
transcription O
factor O
that O
regulates O
the O
expression O
of O
several O
drug O
- O
metabolizing O
enzymes O
and O
has O
been O
implicated O
in O
immunosuppression O
, O
teratogenesis O
, O
cell O
- O
specific O
hyperplasia O
, O
and O
certain O
types O
of O
malignancies O
and O
toxicities O
. O

( O
1996 B_MEASURE
) O
J B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
define O
the O
molecular O
mechanism O
regulating O
FGFR B_GENE
- I_GENE
1 I_GENE
gene I_GENE
expression O
in O
proliferating O
myoblasts O
and O
post O
- O
mitotic O
muscle O
fibers O
, O
we O
have O
isolated O
and O
partially O
characterized O
the O
avian O
FGFR B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter O
. O

Moreover O
, O
FACT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
interacts O
with O
nucleosomes O
and O
histone O
H2A B_PROTEIN[GENE]
/ O
H2B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dimers O
, O
indicating O
that O
it O
may O
work O
by O
promoting O
nucleosome O
disassembly O
upon O
transcription O
. O

Measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sedation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
BIS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
deltaBIS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
absolute B_MEASURE
change I_MEASURE
of O
BIS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
after O
a O
painful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
stimulus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O
, O
memory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
drug B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
obtained O
at O
each O
target B_MEASURE/B_LOCATION
drug B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
. O

ER O
and O
DR O
were O
significantly O
correlated O
with O
MIB B_GENE
- I_GENE
1 I_GENE
Li O
( O
P O
< O
0 O
. O
01 O
and O
P O
< O
0 O
. O
05 O
, O
respectively O
) O
, O
but O
RI O
and O
TD O
/ O
Te O
were O
not O
. O

Positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
linear I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
found O
when O
the O
AUC B_MEASURE
( O
0 B_MEASURE
- O
12 B_MEASURE
) O
( O
r B_OTHER/B_GENE
= O
0 B_NUMBER[MEASURE]
. O
68 B_MEASURE
; O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
, O
the O
maximum B_MEASURE
plasma I_MEASURE
concentration I_MEASURE
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
. O
34 B_MEASURE
; O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
, O
the O
minimum B_MEASURE/B_DISEASE
plasma I_MEASURE/I_DISEASE
concentration I_MEASURE/I_DISEASE
( O
r B_OTHER/B_GENE
= O
0 B_NUMBER[MEASURE]
. O
55 B_MEASURE
; O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
, O
and O
the O
elimination B_PROTEIN[GENE]/B_LOCATION
t1 I_PROTEIN[GENE]/I_LOCATION
/ O
2 B_MEASURE
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
. O
46 B_MEASURE
; O
P B_MEASURE
less I_MEASURE
than O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
were O
regressed O
with O
age B_MEASURE
. O

Psychophysical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
given O
for O
the O
existence B_DISEASE/B_LOCATION
of O
two B_LOCATION/B_MEASURE
distinct I_LOCATION/I_MEASURE
systems I_LOCATION/I_MEASURE
in O
human B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
vision I_EDU[ORGANIZATION]/I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
fast B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
sign B_LOCATION/B_MEASURE
- O
invariant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concerned O
with O
extracting O
contours B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
a O
slower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
sign B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concerned O
with O
assigning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
surface I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
color I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
. O

peripheral B_TIME[MEASURE]/B_PERSON
visual I_TIME[MEASURE]/I_PERSON
acuity I_TIME[MEASURE]/I_PERSON
with O
monovision B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
contact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lens I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
corrections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
presbyopia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Fourteen B_PERSON/B_ORGANIZATION
Centers I_PERSON/I_ORGANIZATION
participated O
in O
this O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
program O
for O
myogenic O
differentiation O
is O
subject O
to O
negative O
control O
by O
several O
peptide O
growth O
factors O
and O
by O
the O
products O
of O
mutationally O
activated O
ras B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogenes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
persistently O
activate O
intracellular O
cascades O
normally O
triggered O
by O
specific O
growth O
factors O
. O

Tetrazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O
dissociates O
sedation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
benzodiazepine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
difference B_MEASURE/B_PERSON
between O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
two B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Z B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mutation O
of O
the O
distal O
E2F B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
in O
the O
cdc25A B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
abolished O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
repression O
, O
whereas O
mutation O
of O
the O
proximal O
E2F B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
the O
E2 B_MEASURE/B_LOCATION
site I_MEASURE/I_LOCATION
had O
no O
effect O
. O

Plasmid O
pNK21 O
, O
in O
which O
2 O
. O
05 O
- O
kb O
sequence O
covering O
the O
region O
encoding O
the O
nitrilase B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O
was O
placed O
under O
the O
control O
of O
the O
lac B_GENE/B_BIO
promoter I_GENE/I_BIO
, O
directed O
overproduction O
of O
enzymatically B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
active I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
nitrilase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
response O
to O
addition O
of O
isopropyl O
beta O
- O
D O
- O
thiogalactopyranoside O
in O
Escherichia O
coli O
. O

A O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
determining O
the O
toxicity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neutralizers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
antimicrobial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
agents I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
A O
. O
castellanii B_BACTERIUM[BIO]/B_DISEASE
was O
also O
evaluated O
. O

Expression B_GENE
in O
all O
lines B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
decreased O
by O
the O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
regions B_LOCATION/B_GENE
further O
upstream O
, O
and O
extinguished O
by O
the O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
first B_LOCATION/B_PERSON
intron I_LOCATION/I_PERSON
. O

static B_MEASURE/B_DISEASE
and O
dynamic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
MRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathological B_DISEASE/B_MEASURE
female I_DISEASE/I_MEASURE
pelvic I_DISEASE/I_MEASURE
floor I_DISEASE/I_MEASURE
. O

IENF B_GENE/B_DISEASE
density B_GENE/I_DISEASE
at O
the O
calf B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
obtained O
from O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
at O
more O
proximal B_MEASURE/B_LOCATION
sites I_MEASURE/I_LOCATION
, O
indicating O
the O
length B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependency I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
small B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
fiber B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
these O
neuropathies B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
results O
demonstrate O
a O
specific O
association O
of O
SIV O
and O
HIV B_GENE/B_DISEASE
- I_GENE/I_DISEASE
2 I_GENE/I_DISEASE
nef I_GENE/I_DISEASE
, O
but O
not O
HIV B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
nef I_GENE/I_DISEASE
, O
with O
TCRzeta B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

insertion O
of O
alternatively O
spliced O
exon O
W O
into O
CREB B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
mRNA I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O
spermatogenesis O
results O
in O
a O
polycistronic O
RNA O
that O
encodes O
two O
novel O
internally O
translated O
CREB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repressor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
called O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CREBs I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
consisting O
of O
the O
carboxy O
- O
terminal O
DNA O
- O
binding O
domain O
devoid O
of O
the O
transactivation O
domains O
. O

A O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
BIPAP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
consists O
of O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
flow B_MEASURE/B_LOCATION
CPAP I_MEASURE/I_LOCATION
system I_MEASURE/I_LOCATION
, O
a O
reservoir B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bag I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
a O
pneumatically O
controlled O
membrane B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valve I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
expiratory B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Older B_PERSON
females I_PERSON
had O
lumbar O
( O
0 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_NUMBER[MEASURE]
. O
3 B_MEASURE
) O
and O
TB B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
1 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
1 B_NUMBER[MEASURE]
. O
1 B_MEASURE
) O
BMD B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Z I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O
greater B_LOCATION/B_MEASURE
than O
0 B_MEASURE/B_PERSON
( O
both O
, O
p O
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

smooth B_DISEASE/B_MEASURE
pursuit I_DISEASE/I_MEASURE
gain I_DISEASE/I_MEASURE
and O
the O
percentage B_MEASURE
of O
total B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
eye I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
movement I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
due O
to O
various B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
saccadic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
subtypes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
computed O
using O
infrared B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
oculography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
and O
computerized B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
software I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Upon O
incubation O
of O
the O
most O
highly O
purified O
fractions O
with O
Mn O
- O
ATP O
or O
MG O
- O
ATP O
, O
p40 B_GENE
was O
the O
only O
protein O
phosphorylated O
on O
tyrosine O
. O

consistent O
with O
this O
hypothesis O
, O
alpha1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDX B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevents O
cleavage O
of O
BMP B_GENE
- I_GENE
4 I_GENE
in O
an O
oocyte O
translation O
assay O
. O

A O
p53 B_GENE
cDNA I_GENE
deletion O
mutant O
( O
delta O
pro O
AE O
) O
, O
which O
lacks O
this O
entire O
proline O
- O
rich O
domain O
( O
deleted O
for O
amino O
acids O
62 O
- O
91 O
) O
, O
was O
created O
and O
characterized O
for O
a O
variety O
of O
p53 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions O
. O

Multiple O
aortic O
thrombi O
associated O
with O
protein B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficiency O
. O

Our O
results O
suggest O
that O
Bry1 B_GENE/B_LOCATION
/ O
Skn7 B_MEASURE/B_GENE
can O
influence O
the O
expression O
of O
MCB O
- O
and O
SCB O
- O
driven O
gene O
expression O
in O
budding O
yeast O
, O
perhaps O
including O
genes O
involved O
in O
cell O
wall O
metabolism O
, O
via O
a O
two O
- O
component O
signal O
transduction O
pathway O
which O
activates O
Bry1 B_GENE
/ O
Skn7 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response O
to O
an O
unidentified O
signal O
. O

( O
1992 B_MEASURE
) O
J B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
constructed O
phylogenetic O
tree O
suggests O
that O
the O
UbcP1 B_BIO/B_GENE
protein I_BIO/I_GENE
may O
represent O
a O
member O
of O
a O
distinct O
subfamily O
of O
E2s B_GENE/B_BIO
. O

Platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
patients O
with O
coronary O
artery O
disease O
. O

We O
functionally O
characterised O
AtXPO1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
its O
interaction O
with O
NESs O
of O
animal O
and O
plant O
proteins O
, O
which O
is O
inhibited O
by O
the O
cytotoxin O
leptomycin O
B O
( O
LMB O
) O
, O
and O
also O
by O
its O
interaction O
with O
the O
small B_GENE
GTPase I_GENE
Ran1 I_GENE
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

A O
backward B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
look I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
urinary B_PERSON
tract I_PERSON
infections I_PERSON
. O

The O
expression O
of O
cor14b B_GENE
was O
strongly O
impaired O
in O
the O
barley O
albino O
mutant O
an O
, O
suggesting O
the O
involvement O
of O
a O
plastidial O
factor O
in O
the O
control O
of O
gene O
expression O
. O

Mrs B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O
the O
differentiation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
following B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
metabolites I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
5 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
patients I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
: O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
acetyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NAA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phosphocreatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phosphorylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glycerophosphorylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
GLU B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Overall B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
free B_DISEASE/B_MEASURE
- O
chlorine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
0 B_MEASURE/B_LOCATION
. O
3 B_MEASURE
or O
1 B_MEASURE
. O
0 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
L B_OTHER/B_MEASURE
) O
showed O
significantly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterotrophic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
plate I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
numbers I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
those O
without O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chlorine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

S1 B_GENE
nuclease I_GENE
protection O
mapping O
and O
primer O
extension O
analysis O
allowed O
us O
to O
propose O
that O
the O
A O
residue O
located O
19 O
BP O
upstream O
from O
the O
translation O
initiation O
codon O
is O
the O
site O
of O
transcription O
initiation O
. O

Various O
stimuli O
inactivate O
IkappaB B_GENE
alpha I_GENE
by O
triggering O
phosphorylation O
of O
the O
N O
- O
terminal O
residues O
Ser32 O
and O
Ser36 O
. O

There O
was O
no O
difference B_MEASURE
in O
the O
day B_MEASURE/B_LOCATION
- O
42 B_MEASURE
cure I_MEASURE
rates I_MEASURE
between O
the O
QC7 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
65 B_MEASURE
) O
and O
A7 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_LOCATION
= O
64 B_MEASURE
) O
regimens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
an O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
100 B_MEASURE
% I_MEASURE
in O
both O
, O
confirmed O
by O
parasite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
genotyping I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B_OTHER/B_NUMBER[MEASURE]
( O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
J B_OTHER/B_PERSON
junctions O
within O
rearranged O
immunoglobulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
( O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
J B_OTHER/B_GENE
recombination O
reaction O
. O

We O
conclude O
that O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
HL91 B_MEASURE/B_GENE
is O
a O
potent B_MEASURE/B_GENE
marker I_MEASURE/I_GENE
of O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
viability I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O
used O
during O
the O
early B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phase I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Three B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
treated O
with O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
single B_NUMBER[MEASURE]/B_LOCATION
course I_NUMBER[MEASURE]/I_LOCATION
as O
well O
as O
multiple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
courses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antifungal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
hydroxystilbamidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
miconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
have O
all O
relapsed O
. O

An O
infant B_PERSON
of O
8 B_NUMBER[MEASURE]/B_PERSON
months I_NUMBER[MEASURE]/I_PERSON
with O
congenital B_DISEASE/B_GENE
glaucoma I_DISEASE/I_GENE
and O
hemophilia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
A I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lost O
one B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
due O
to O
haemorrhages B_DISEASE
after O
trabeculotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
an O
eye B_LOCATION/B_PERSON
hospital I_LOCATION/I_PERSON
. O

Anderson B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
Hospital B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O
tumor B_LOCATION/B_PERSON
Institute I_LOCATION/I_PERSON
at O
Houston B_LOCATION
during O
a O
30 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
( O
1944 B_MEASURE
to O
1974 B_MEASURE
) O
, O
with O
a O
minimum B_MEASURE/B_LOCATION
of O
ten B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
determined O
that O
the O
major B_MEASURE/B_PERSON
prognostic I_MEASURE/I_PERSON
factor I_MEASURE/I_PERSON
of O
survival B_DISEASE
was O
the O
number B_MEASURE/B_LOCATION
of O
positive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nodes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
have O
now O
isolated O
cDNA O
for O
an O
invertebrate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Pax I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
urchin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
embryos I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
study O
structural O
diversity O
of O
the O
three O
homologous O
loci O
encoding O
a O
KN1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
hexaploid O
wheat O
genome O
, O
we O
isolated O
clones O
from O
a O
cDNA O
library O
of O
young O
spikes O
of O
Japanese O
common O
wheat O
cultivar O
' O
Norin O
26 O
' O
. O

Whether O
or O
not O
these O
novel O
repeated O
sequences O
throughout O
the O
SMA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
involved O
in O
the O
disease O
remains O
to O
be O
determined O
. O

Thus O
, O
Shp2 B_GENE
regulates O
phosphotyrosine O
- O
signalling O
events O
during O
the O
complex O
ectodermal O
- O
mesenchymal O
interactions O
that O
regulate O
mammalian O
budding O
morphogenesis O
. O

Moyamoya B_DISEASE/B_LOCATION
is O
an O
intriguing B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
elimination O
of O
the O
kinase O
activity O
of O
DCAMKL1 B_GENE
has O
no O
detectable O
effect O
on O
its O
microtubule O
polymerization O
activity O
. O

We O
have O
thus O
cloned O
two O
yeast O
homologs O
of O
mammalian B_GENE
p220 I_GENE
. O

The O
glucose O
effect O
on O
the O
pyruvate B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinase B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gene B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
reversibly O
antagonized O
by O
agents O
increasing O
intracellular O
Camp O
. O

An O
identical B_GENE
polypeptide I_GENE
was O
detected O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
K1F B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
virions I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

patients B_PERSON/B_BIO
with O
PLM B_DISEASE/B_LOCATION
show O
excessive B_DISEASE
daytime I_DISEASE
sleepiness I_DISEASE
or O
insomnia B_DISEASE
. O

Coexpression O
of O
CREB B_GENE
- I_GENE
binding I_GENE
protein I_GENE
( O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
/ O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
TReP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
132 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
an O
additive O
effect O
on O
promoter O
activity O
, O
and O
the O
proteins O
were O
demonstrated O
to O
interact O
physically O
. O

It O
is O
believed O
that O
the O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O
it O
cuts O
the O
spinothalamic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tract B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
STT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
a O
primary B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
pathway I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
carrying O
nociceptive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
humans B_PERSON/B_SPECIES[BIO]
. O

Catalase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
plays O
a O
key O
role O
as O
an O
antioxidant O
, O
protecting O
aerobic O
organisms O
from O
the O
toxic O
effects O
of O
hydrogen O
peroxide O
, O
and O
in O
some O
cases O
has O
been O
postulated O
to O
be O
a O
virulence O
factor O
. O

Recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
energy B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
level I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
and O
intracellular B_MEASURE/B_DISEASE
pH I_MEASURE/I_DISEASE
during O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
at O
100Hz B_TIME[MEASURE]/B_LOCATION
were O
greater B_MEASURE
than O
those O
observed O
during O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
at O
30Hz B_MEASURE/B_LOCATION
. O

exhaled O
NO O
was O
assessed O
by O
controlled O
- O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemoluminescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
adjusting O
for O
trapped B_MEASURE/B_DISEASE
air I_MEASURE/I_DISEASE
and O
after O
generating O
pressure B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
oral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cavity I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
was O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
close O
the O
soft B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
palate I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
Eco B_PROTEIN[GENE]/B_LOCATION
physics I_PROTEIN[GENE]/I_LOCATION
CLD I_PROTEIN[GENE]/I_LOCATION
77 I_PROTEIN[GENE]/I_LOCATION
AM I_PROTEIN[GENE]/I_LOCATION
analyzer I_PROTEIN[GENE]/I_LOCATION
) O
. O

Recent O
developments O
in O
the O
study O
of O
growth O
factors O
: O
GRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
somatomedins B_GENE/B_BACTERIUM[BIO]
. O

New B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concepts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
condyloma B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acuminata I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
children B_PERSON/B_LOCATION
. O

This O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
NIHF B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
fetal B_PERSON
Kasabach I_PERSON
- O
Merritt B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O
was O
prenatally O
diagnosed O
by O
sonography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
computerized B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
percutaneous O
umbilical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blood I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sampling I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Acetoacetate B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ADC B_DISEASE/B_GENE
) O
( O
EC4 B_PROTEIN[GENE]/B_DISEASE
. I_PROTEIN[GENE]/I_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
. I_PROTEIN[GENE]/I_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
. I_PROTEIN[GENE]/I_DISEASE
4 I_PROTEIN[GENE]/I_DISEASE
) O
of O
Clostridium O
acetobutylicum O
DSM O
792 O
was O
purified O
to O
homogeneity O
, O
and O
its O
first O
25 O
N O
- O
terminal O
amino O
acids O
were O
determined O
. O

Transfer B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
natives B_PERSON/B_LOCATION
holds O
much B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
promise I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
lecturers B_PERSON
say O
. O

The O
sequence O
of O
the O
127 B_PROTEIN[GENE]/B_BIO
residue I_PROTEIN[GENE]/I_BIO
NrfF I_PROTEIN[GENE]/I_BIO
polypeptide I_PROTEIN[GENE]/I_BIO
, I_PROTEIN[GENE]/I_BIO
M I_PROTEIN[GENE]/I_BIO
( I_PROTEIN[GENE]/I_BIO
r I_PROTEIN[GENE]/I_BIO
) I_PROTEIN[GENE]/I_BIO
14 I_PROTEIN[GENE]/I_BIO
, I_PROTEIN[GENE]/I_BIO
522 I_PROTEIN[GENE]/I_BIO
, O
is O
strikingly O
similar O
to O
the O
CcI2 B_GENE/B_BIO
protein I_GENE/I_BIO
of O
R O
. O
capsulatus O
, O
especially O
in O
the O
putative O
haem O
- O
binding O
motif O
, O
RCPQCQNQN O
. O
( O
abstract O
TRUNCATED O
AT O
400 O
Words O
) O
. O

CAT B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O
demonstrated O
that O
overexpression O
of O
RXRalpha B_GENE/B_DISEASE
conferred O
the O
best O
RA O
response O
, O
consistent O
with O
our O
previous O
observation O
that O
9 O
- O
cis O
- O
RA O
is O
more O
potent O
than O
all O
- O
trans O
- O
RA O
for O
inducing O
the O
expression O
of O
the O
AFP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
rotating O
stimuli B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
presented O
to O
the O
dominant B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
this O
class B_PERSON/B_MEASURE
of O
neurons B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responded O
best O
to O
rotation B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
visual B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
world I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
about O
an O
axis B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
oriented O
near O
the O
horizontal B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O
approximately O
45 B_TIME[MEASURE]/B_LOCATION
degrees B_TIME[MEASURE]/I_LOCATION
azimuth B_TIME[MEASURE]/I_LOCATION
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
these O
patients B_PERSON/B_BIO
developed O
clinical B_DISEASE
events I_DISEASE
before O
disappearance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
phospholipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
coagulation B_GENE/B_DISEASE
. O

In O
spite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
variability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DD95 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
body B_MEASURE/B_DISEASE
weight B_MEASURE/I_DISEASE
, O
the O
recovery B_MEASURE
of O
neuromuscular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transmission I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
studied O
some O
of O
the O
parameters B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
governing O
the O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
foreign B_GENE
promoter I_GENE
- O
reporter B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
construct O
incorporated O
into O
herpes B_DISEASE/B_VIRUS[BIO]
simplex B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
HSV B_VIRUS[BIO]/B_DISEASE
) O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

relation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
clinical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
roentgenological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
scores I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lung B_DISEASE
function I_DISEASE
in O
cystic B_DISEASE/B_PERSON
fibrosis I_DISEASE/I_PERSON
, O
with O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
pulmonary B_DISEASE
Xenon133 I_DISEASE
elimination I_DISEASE
. O

Each O
fusion O
leads O
, O
in O
principle O
, O
to O
the O
same O
effect O
: O
The O
ret B_GENE/B_LOCATION
tyrosine I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
is O
uncoupled O
from O
its O
stringent O
physiological O
regulation O
by O
replacement O
of O
its O
5 O
' O
end O
and O
is O
aberrantly O
activated O
by O
the O
5 O
' O
parts O
of O
fused O
genes O
in O
thyrocytes O
that O
do O
not O
normally O
express O
ret B_GENE
tyrosine I_GENE
kinase I_GENE
. O

He O
had O
complained O
of O
fever B_DISEASE
and O
right B_DISEASE
hypochondralgia I_DISEASE
2 I_DISEASE
months I_DISEASE
after O
being O
operated O
for O
appendicitis B_DISEASE/B_LOCATION
. O

In O
the O
predicted O
amino O
acid O
sequence O
of O
NPS1 B_GENE
, O
sequences O
homologous O
to O
the O
catalytic O
domain O
of O
protein O
kinases O
were O
found O
. O

Carcinoma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O
may O
have O
played O
a O
role O
in O
the O
development O
of O
the O
observed O
renal O
lesions O
. O

These O
results O
provide O
strong O
evidence O
that O
conserved O
interhelical O
packing O
interactions O
in O
the O
gp41 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
important O
determinants O
of O
HIV O
- O
1 O
entry O
and O
its O
inhibition O
. O

Lag O
phases O
were O
14 O
. O
89 O
hours O
+ O
/ O
- O
0 O
. O
77 O
, O
13 O
. O
33 O
hours O
+ O
/ O
- O
0 O
. O
50 O
, O
20 O
. O
22 O
hours O
+ O
/ O
- O
0 O
. O
76 O
, O
and O
20 O
. O
00 O
hours O
+ O
/ O
- O
0 O
. O
79 O
, O
respectively O
, O
for O
endothelial O
cell O
- O
induced O
LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxidation O
. O

Forty B_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]/B_PERSON
pregnant I_NUMBER[MEASURE]/I_PERSON
adult I_NUMBER[MEASURE]/I_PERSON
and O
122 B_PERSON/B_SPECIES[BIO]
fetal I_PERSON/I_SPECIES[BIO]
Guinea I_PERSON/I_SPECIES[BIO]
pigs I_PERSON/I_SPECIES[BIO]
were O
sacrificed O
at O
intervals B_TIME[MEASURE]/B_LOCATION
throughout O
gestation B_TIME[MEASURE]/B_LOCATION
and O
the O
carcasses B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
analyzed O
for O
a O
variety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
growth B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parameters I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Here O
we O
demonstrate O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oligonucleotides B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
the O
C4T B_GENE/B_MEASURE
sequence I_GENE/I_MEASURE
to O
confer O
heat B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shock I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inducibility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
reporter B_GENE
gene I_GENE
and O
show O
that O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
two B_GENE
such I_GENE
elements I_GENE
produces O
more B_MEASURE
than O
additive B_MEASURE
effects I_MEASURE
on O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

The O
HPV O
E1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
E2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O
along O
with O
cellular O
factors O
, O
are O
required O
for O
replication O
of O
the O
viral O
genome O
. O

The O
observed B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lung B_DISEASE/B_GENE
functions B_DISEASE/I_GENE
in O
these O
subjects B_PERSON/B_BIO
indicate O
that O
individuals B_PERSON/B_BIO
performing O
heavy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
continuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exercise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
affected O
by O
lower B_DISEASE/B_LOCATION
O3 I_DISEASE/I_LOCATION
levels I_DISEASE/I_LOCATION
. O

In O
ten O
other O
endotoxin O
- O
albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
treated O
pigs O
PGE1 O
infusion O
( O
0 O
. O
25 O
micrograms O
X O
kg O
- O
1 O
X O
min O
- O
1 O
) O
was O
begun O
after O
established O
pulmonary O
and O
cardiovascular O
dysfunction O
, O
for O
closer O
mimicking O
of O
clinical O
use O
. O

The O
main B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
new I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
features I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
version B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
that O
end B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tidal B_TIME[MEASURE]/B_LOCATION
PO2 B_TIME[MEASURE]/I_LOCATION
instead O
of O
inspiratory B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PO2 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
kept O
constant B_MEASURE
, O
and O
that O
the O
correcting O
activity B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
both O
controllers B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
capnostat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
oxystat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
proportional B_MEASURE/B_PERSON
to O
the O
magnitude B_MEASURE
of O
the O
difference B_MEASURE
between O
the O
actual B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
adjusted O
end B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tidal B_MEASURE/B_LOCATION
PCO2 I_MEASURE/I_LOCATION
or O
PO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Like O
the O
human B_GENE/B_PERSON
erythrocyte I_GENE/I_PERSON
P4 I_GENE/I_PERSON
. I_GENE/I_PERSON
2 I_GENE/I_PERSON
, O
mouse B_PROTEIN[GENE]/B_LOCATION
erythrocyte I_PROTEIN[GENE]/I_LOCATION
P4 I_PROTEIN[GENE]/I_LOCATION
. I_PROTEIN[GENE]/I_LOCATION
2 I_PROTEIN[GENE]/I_LOCATION
contains O
regions O
strikingly O
homologous O
with O
the O
transglutaminase O
( O
TGase O
) O
proteins O
although O
it O
too O
most O
likely O
lacks O
TGase O
crosslinking O
activity O
. O

It O
spans O
20 B_MEASURE/B_BIO
kilobases I_MEASURE/I_BIO
, O
consists O
of O
7 B_NUMBER[MEASURE]
exons I_NUMBER[MEASURE]
and O
6 B_GENE/B_LOCATION
introns I_GENE/I_LOCATION
, O
and O
contains O
a O
TATA B_GENE/B_LOCATION
motif B_GENE/I_LOCATION
24 B_GENE/I_LOCATION
nucleotides B_GENE/I_LOCATION
upstream O
of O
the O
transcriptional B_GENE/B_BIO
start I_GENE/I_BIO
site I_GENE/I_BIO
. O

Nine O
months O
after O
the O
end O
of O
the O
vaccination O
anti B_DISEASE/B_GENE
- B_DISEASE/I_GENE
HBsAg B_DISEASE/I_GENE
levels O
had O
dropped O
to O
9 O
+ O
/ O
- O
4 O
IU O
/ O
1 O
( O
M O
+ O
/ O
- O
SE O
) O
, O
with O
a O
geometric O
mean O
of O
5 O
IU O
/ O
1 O
, O
in O
the O
nine O
remaining O
evaluable O
patients O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Ultrasound B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biomicroscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
a O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
APVR B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
is O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
ordinary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

It O
is O
postulated O
that O
the O
synthesis O
of O
the O
peptidoglycan O
layer O
was O
affected O
by O
the O
antimetabolites O
since O
the O
morphological O
effects O
were O
strikingly O
similar O
to O
those O
caused O
by O
treatment O
of O
E O
. O
cloacae O
with O
disodium O
edetate O
plus O
lysozyme B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

DRAP27 B_GENE/B_DISEASE
is O
recognized O
by O
CD9 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
we O
elucidate O
the O
subtle B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
highly O
anisotropic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interchain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reveal O
the O
detailed B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atomic I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
temperature B_MEASURE
( O
8x2 B_PROTEIN[GENE]/B_LOCATION
) O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Control O
oligomers O
of O
scrambled O
sequence O
but O
identical O
base O
composition O
were O
ineffective O
, O
and O
no O
TFO O
- O
induced O
recombination O
was O
seen O
in O
a O
control O
LTK O
( O
- O
) O
cell O
line O
carrying O
an O
otherwise O
identical O
dual O
TK B_GENE
gene I_GENE
construct I_GENE
lacking O
the O
30 O
- O
BP O
polypurine O
target O
site O
. O

To O
quantify O
the O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coupling B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
fresh B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cadaveric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
lumbar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
specimens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
L1 B_PROTEIN[GENE]
- O
S1 B_MEASURE/B_PROTEIN[GENE]
) O
were O
used O
. O

One O
cytoplasmic O
target O
which O
reflects O
the O
functional O
state O
of O
the O
plastids O
is O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
three O
chromosomes O
share O
the O
transferrin B_GENE
gene I_GENE
( O
TF B_PROTEIN[GENE]/B_LOCATION
) O
, O
the O
myosin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MYL3 B_GENE/B_LOCATION
) O
, O
and O
the O
acylpeptide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrolase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
APEH B_LOCATION/B_DISEASE
) O
. O

( O
i O
) O
Several B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribosomal I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
synthesized O
in O
substantial B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
excess I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
would O
recommend O
consideration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
home B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nutritional I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
support I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON/B_LOCATION
with O
systemic B_DISEASE
scleroderma I_DISEASE
when O
the O
disease B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
relatively O
stable B_DISEASE_ADJECTIVE[DISEASE]
and O
no O
major B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Based O
on O
our O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ORF2 B_GENE/B_BIO
from O
most B_BIO/B_PROTEIN[GENE]
isolates B_BIO/I_PROTEIN[GENE]
excluding O
G1 B_GENE/B_LOCATION
encode I_GENE/I_LOCATION
truncated O
49 B_GENE
aa I_GENE
( O
pORF2a B_PROTEIN[GENE]/B_LOCATION
) O
because O
of O
an O
in O
- O
frame B_GENE/B_LOCATION
stop B_GENE/I_LOCATION
codon B_GENE/I_LOCATION
, O
although O
ORF2s B_GENE/B_BIO
from O
most B_PROTEIN[GENE]/B_MEASURE
G1 I_PROTEIN[GENE]/I_MEASURE
isolates I_PROTEIN[GENE]/I_MEASURE
encode O
202 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
aa I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
pORF2ab B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
prospectively O
compared O
side B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O
in O
12 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
low B_NUMBER[MEASURE]/B_COLOR
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
OKT3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
twice O
daily B_TIME[MEASURE]/B_LOCATION
) O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
those O
in O
10 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
who O
were O
treated O
with O
a O
conventional B_MEASURE
dose I_MEASURE
of O
OKT3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
5 B_NUMBER[MEASURE]/B_LOCATION
mg I_NUMBER[MEASURE]/I_LOCATION
daily O
) O
for O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
data O
indicate O
that O
SB O
203580 O
sensitive O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
not O
involved O
in O
okadaic O
acid O
mediated O
increases O
in O
TRE O
DNA O
binding O
and O
transactivation O
. O

Together O
, O
these O
results O
indicate O
that O
YTS1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
bifunctional O
protein O
active O
in O
both O
splicing O
and O
protein O
synthesis O
. O

oscillatory B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
reestablished O
in O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O
the O
capillary B_BODY_PART_OR_ORGAN_COMPONENT
- O
cerebrospinal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
capillary B_BODY_PART_OR_ORGAN_COMPONENT
- O
venous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
interfaces I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Sgs B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
one O
of O
the O
eight O
known O
genes O
coding O
for O
larval O
secretion O
proteins O
in O
Drosophila O
melanogaster O
. O

We O
conclude O
that O
although O
the O
G3 B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
contains O
two B_GENE
protein I_GENE
- O
binding O
motifs B_PERSON/B_LOCATION
, O
the O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
G3 B_PROTEIN[GENE]
enhancer I_PROTEIN[GENE]
- O
like B_LOCATION/B_PERSON
element I_LOCATION/I_PERSON
is O
not O
bipartite B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. O

Human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myotonic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DMPK B_GENE/B_LOCATION
) O
is O
a O
member O
of O
a O
novel O
class O
of O
multidomain O
protein O
kinases O
that O
regulate O
cell O
size O
and O
shape O
in O
a O
variety O
of O
organisms O
. O

The O
human B_GENE/B_LOCATION
BRCA1 I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
also O
contains O
a O
conserved O
E2F B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
is O
similarly O
regulated O
by O
E2F1 B_GENE
and O
Rb B_GENE
. O

The O
translated O
sequence O
of O
the O
FLI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LRR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
FLAP B_DISEASE/B_GENE
) O
encodes O
a O
novel O
protein O
not O
represented O
in O
the O
data O
base O
. O

corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
before O
, O
during O
, O
or O
after O
fludarabine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
patients B_PERSON/B_LOCATION
with O
alkylator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
resistant B_DISEASE_ADJECTIVE[DISEASE]
, O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
grade B_DISEASE/B_MEASURE
lymphoid I_DISEASE/I_MEASURE
malignancies I_DISEASE/I_MEASURE
who O
have O
not O
received O
PCP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prophylaxis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
opportunistic B_DISEASE
pulmonary I_DISEASE
infections I_DISEASE
. O

In O
this O
respect O
, O
the O
promoter O
structure O
of O
COX B_BIO/B_GENE
genes I_BIO/I_GENE
resemble O
those O
of O
many O
house O
- O
keeping O
genes O
. O

In O
vitro O
, O
cytokine O
- O
or O
hypoxia O
- O
induced O
up O
- O
regulation O
of O
Fas B_GENE
expression O
is O
associated O
with O
RTC O
apoptosis O
. O

The O
site O
of O
acetylation O
of O
Tat B_GENE
was O
mapped O
to O
the O
double O
- O
lysine O
motif O
in O
a O
highly O
conserved O
region O
, O
( O
49 O
) O
RKKRRQ O
( O
54 O
) O
, O
of O
the O
basic O
RNA O
- O
binding O
motif O
of O
Tat B_GENE/B_DISEASE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
the O
PVB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
cure O
the O
cases B_PERSON/B_DISEASE
with O
choriocarcinoma B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
element I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O
bulky B_DISEASE
metastasis I_DISEASE
. O

The O
KEMAR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
give O
an O
improvement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
to O
- O
noise B_MEASURE
ratio I_MEASURE
of O
approximately O
7 B_MEASURE
. O
5 B_MEASURE/B_ORGANIZATION
DB I_MEASURE/I_ORGANIZATION
in O
a O
diffuse B_TIME[MEASURE]/B_LOCATION
sound B_TIME[MEASURE]/I_LOCATION
field B_TIME[MEASURE]/I_LOCATION
. O

indirect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
determination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
maximal B_GENE/B_MEASURE
O2 I_GENE/I_MEASURE
consumption I_GENE/I_MEASURE
in O
man B_PERSON/B_BIO
. O

Using O
unidirectional O
PCR O
we O
isolated O
a O
361 O
- O
BP O
5 O
' O
promoter O
region O
and O
delineated O
the O
intronic O
/ O
exonic O
boundaries O
which O
include O
a O
non O
- O
coding O
exon O
1 O
, O
a O
single O
intron O
, O
and O
a O
coding O
exon O
2 O
, O
a O
structure O
that O
is O
typical O
of O
genes O
of O
the O
RNase B_SPECIES[BIO]/B_GENE
A I_SPECIES[BIO]/I_GENE
superfamily I_SPECIES[BIO]/I_GENE
. O

When O
severe O
hypoxia O
was O
acutely O
produced O
by O
ventilation O
with O
low O
- O
oxygen O
mixtures O
in O
experimental O
( O
PaO2 O
, O
23 O
. O
7 O
+ O
/ O
- O
1 O
. O
7 O
torr O
) O
and O
control O
animals O
( O
PaO2 O
, O
26 O
. O
3 O
+ O
/ O
- O
1 O
. O
0 O
torr O
) O
, O
plasma B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O
were O
markedly O
inhibited O
in O
both O
. O

Uptake O
of O
colicins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
required O
different O
domains O
in O
TonB B_BACTERIUM[BIO]/B_PROTEIN[GENE]
, O
for O
colicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
M I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
around O
residue O
160 O
and O
for O
colicin B_PROTEIN[GENE]/B_BIO
Ia I_PROTEIN[GENE]/I_BIO
, O
a O
domain O
closer O
to O
the O
C O
- O
terminal O
end O
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
combined O
with O
ticarcillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
survival B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
both O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
prolonged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Central B_LOCATION/B_PERSON
treatment I_LOCATION/I_PERSON
unit I_LOCATION/I_PERSON
saves O
nurses B_PERSON/B_MEASURE
, O
adds O
income B_ORGANIZATION/B_PERSON
, O
improves O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Gold B_MEASURE/B_PERSON
flaxseed O
( O
whole B_TIME[MEASURE]/B_BIO
or O
ground B_BIO
) O
fed O
at O
levels B_MEASURE/B_GENE
of O
5 B_NUMBER[MEASURE]
or O
15 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
compared O
to O
a O
1 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
menhaden I_MEASURE
oil I_MEASURE
or O
a O
typical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
layer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

It O
is O
dangerous O
to O
label O
such O
conditions O
as O
' O
inappropriate O
' O
secretion O
of O
ADH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O
the O
maintenance O
of O
circulating O
volume O
is O
at O
least O
as O
important O
a O
physiological O
requirement O
as O
the O
defence O
of O
tonicity O
. O

The O
complete B_GENE/B_MEASURE
nucleotide I_GENE/I_MEASURE
sequence I_GENE/I_MEASURE
of O
odontoglossum B_SPECIES[BIO]
ringspot I_SPECIES[BIO]
virus I_SPECIES[BIO]
( O
Cy B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_VIRUS[BIO]/B_PROTEIN[GENE]
strain B_VIRUS[BIO]/I_PROTEIN[GENE]
) O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
enhancement B_DISEASE_ADJECTIVE[DISEASE]
of O
benign B_DISEASE/B_MEASURE
liver I_DISEASE/I_MEASURE
tumors I_DISEASE/I_MEASURE
( O
tumorigenic B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
observed O
only O
in O
CF1 B_MEASURE/B_PERSON
male I_MEASURE/I_PERSON
mice I_MEASURE/I_PERSON
( O
17 B_MEASURE
/ O
56 B_MEASURE
at O
the O
only B_MEASURE/B_ORGANIZATION
tested O
dose B_MEASURE/B_LOCATION
: O
400 B_MEASURE/B_LOCATION
ppm I_MEASURE/I_LOCATION
vs I_MEASURE/I_LOCATION
. O

cells O
were O
cotransfected O
with O
this O
plasmid O
, O
and O
the O
appropriate O
responder O
plasmids O
and O
clonies O
were O
selected O
on O
the O
basis O
of O
their O
resistance O
to O
Geneticin O
( O
via O
the O
neomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminoglycoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

This O
C O
- O
terminal O
domain O
contains O
several O
YxxI O
/ O
L O
motifs O
reminiscent O
of O
LMP2A B_GENE/B_DISEASE
and O
a O
putative O
TRAF B_GENE/B_LOCATION
binding B_GENE/I_LOCATION
site B_GENE/I_LOCATION
as O
in O
LMP1 B_SPECIES[BIO]/B_GENE
. O

Omitting O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
the O
experimental B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOE B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
derived O
distances B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
restraint B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
violations B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
lower B_DISEASE_ADJECTIVE[DISEASE]
R I_DISEASE_ADJECTIVE[DISEASE]
factors I_DISEASE_ADJECTIVE[DISEASE]
but O
impairs O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
convergence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rMD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
refinement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
exotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
shock I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
atherosclerosis B_DISEASE
related O
to O
nutrition B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
hypercholesterolemia B_DISEASE
, O
hyperglycemia B_DISEASE
- O
diabetes B_DISEASE
, O
and O
for O
hypertension B_DISEASE/B_PERSON
, O
obesity B_DISEASE
, O
high B_DISEASE
salt I_DISEASE
intake I_DISEASE
, O
and O
excessive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

This O
mutation O
was O
associated O
with O
reduced O
or O
absent O
expression O
of O
TGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RI I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
p53 B_GENE
protein I_GENE
in O
tumor O
tissues O
. O

SCAN B_DISEASE
boxes O
are O
found O
in O
eight O
other O
genes O
in O
the O
GenBank O
database O
, O
five O
of O
which O
are O
also O
in O
the O
Kruppel B_PERSON/B_LOCATION
family B_PERSON/I_LOCATION
of O
zinc B_PROTEIN[GENE]/B_BIO
finger I_PROTEIN[GENE]/I_BIO
proteins I_PROTEIN[GENE]/I_BIO
lacking O
KRAB B_GENE/B_MEASURE
A I_GENE/I_MEASURE
and I_GENE/I_MEASURE
B I_GENE/I_MEASURE
domains O
and O
thereby O
define O
a O
new O
subclass O
of O
zinc B_GENE/B_BIO
finger I_GENE/I_BIO
proteins I_GENE/I_BIO
. O

However O
, O
they O
had O
no O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
resistance B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
quinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
josamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
tylosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

seventy B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
the O
children B_PERSON
screened O
and O
91 B_MEASURE
. O
0 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
of O
the O
children B_PERSON
with O
PbB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
least O
10 B_MEASURE
micrograms I_MEASURE
/ O
dL B_MEASURE/B_PROTEIN[GENE]
were O
Hispanic B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Normal B_PERSON
dogs I_PERSON
were O
exposed O
to O
either O
10 B_NUMBER[MEASURE]
, O
15 B_MEASURE
, O
or O
30 B_MEASURE/B_PERSON
Gy I_MEASURE/I_PERSON
of O
X B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rays I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
a O
single B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
gross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
histopathologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
evaluated O
qualitatively O
. O

YACs O
selected O
from O
our O
contig O
will O
be O
the O
starting O
point O
for O
the O
cloning O
of O
the O
LGMD2B B_GENE/B_BIO
gene I_GENE/I_BIO
and O
thereby O
establish O
the O
biological O
basis O
for O
this O
form O
of O
muscular O
dystrophy O
and O
its O
relationship O
with O
the O
other O
limb O
- O
girdle O
muscular O
dystrophies O
. O

The O
amount O
of O
ERCC1 B_GENE
detectable O
by O
immunoblotting O
is O
reduced O
in O
group O
1 O
, O
group O
4 O
and O
XP O
- O
F O
extracts O
. O

In O
the O
plant B_BODY_PART_OR_ORGAN_COMPONENT
malate I_BODY_PART_OR_ORGAN_COMPONENT
synthases I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
extension O
is O
probably O
involved O
in O
routing O
to O
the O
microbodies O
, O
since O
it O
contains O
the O
potential O
peroxisomal O
targeting O
signal O
, O
Ser O
- O
Arg O
/ O
Lys O
- O
Leu O
, O
at O
the O
carboxy O
terminus O
. O

Optimized O
USF B_LOCATION/B_GENE
and O
MYC B_GENE/B_MEASURE
DNA O
- O
binding O
sites O
, O
which O
differ O
in O
the O
nucleotides O
bordering O
the O
hexanucleotide O
box O
displace O
the O
E B_GENE/B_MEASURE
- I_GENE/I_MEASURE
C4 I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
in O
competition O
assays O
but O
with O
lesser O
efficiency O
than O
the O
E B_GENE/B_MEASURE
- I_GENE/I_MEASURE
C4 I_GENE/I_MEASURE
site I_GENE/I_MEASURE
itself O
. O

screening O
of O
human O
cDNA O
libraries O
has O
identified O
two O
different O
5 O
' O
- O
termini O
and O
alternatively O
spliced O
forms O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fli B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1b I_GENE/I_LOCATION
) O
, O
suggesting O
the O
possible O
existence O
of O
two O
independent O
promoters O
. O

A O
surge O
in O
the O
rate O
of O
ascorbyl O
radical O
production O
, O
directly O
correlated O
with O
oxyradical O
stress O
and O
an O
abrupt O
fall O
in O
superoxide B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
in O
the O
granuloma O
, O
indicates O
' O
switching O
on O
' O
of O
a O
free O
radical O
- O
dependent O
machinery O
for O
the O
formation O
of O
granuloma O
after O
vasectomy O
. O

After O
5 O
- O
h O
thermal O
induction O
of O
cells O
carrying O
the O
runaway O
recombinant O
pBS1 O
, O
protein B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B2 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituted O
40 O
% O
of O
the O
soluble O
protein O
fraction O
of O
the O
cells O
. O

A O
regulatory O
element O
of O
the O
empty B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spiracles I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox O
gene O
is O
composed O
of O
three O
distinct O
conserved O
regions O
that O
bind O
regulatory O
proteins O
. O

Peak B_DISEASE/B_PROTEIN[GENE]
reactive B_DISEASE/I_PROTEIN[GENE]
hyperemia B_DISEASE/I_PROTEIN[GENE]
( O
mL B_MEASURE/B_LOCATION
. O
min B_MEASURE/B_PERSON
- O
1 B_MEASURE/B_LOCATION
. O
100 B_MEASURE
mL I_MEASURE
- O
1 B_MEASURE
) O
was O
determined O
in O
the O
calf B_BODY_PART_OR_ORGAN_COMPONENT
and O
forearm B_BODY_PART_OR_ORGAN_COMPONENT
immediately O
before O
and O
after O
12 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
characteristics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
add O
to O
the O
suitability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
NM441 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
an O
effective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodrug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NM394 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Vorozole O
( O
Rivizor O
) O
is O
a O
potent O
and O
stereospecific O
inhibitor O
of O
aromatase B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
shown O
promising O
endocrine O
effects O
in O
phase O
I O
studies O
. O

In O
5 B_MEASURE
cases I_MEASURE
, O
combined O
sensitization B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
mercury B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
other B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salts I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
particularly O
gold B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiosulfate I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GST B_LOCATION/B_DISEASE
) O
and O
palladium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PDC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
was O
observed O
. O

Gene B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
structure B_GENE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
precursor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
content B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
monoamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
5 B_NUMBER[MEASURE]
- O
hydroxyindoleacetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
- O
HIAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
homovanillic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
HVA B_DISEASE/B_PROTEIN[GENE]
) O
, O
and O
- O
- O
for O
17 B_PERSON/B_MEASURE
patients I_PERSON/I_MEASURE
- O
- O
tryptophan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
cerebrospinal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
determined O
. O

One B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
131I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
29 B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cats I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluated O
were O
clinically O
improved O
, O
and O
24 B_MEASURE
( O
83 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
the O
29 B_BIO/B_MEASURE
cats I_BIO/I_MEASURE
evaluated O
had O
normal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T4 I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_MEASURE/B_ENT
cats I_MEASURE/I_ENT
( O
10 B_MEASURE
% I_MEASURE
) O
remained O
hyperthyroxinemic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
2 B_NUMBER[MEASURE]/B_ENT
cats I_NUMBER[MEASURE]/I_ENT
( O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
hypothyroxinemic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
findings O
suggest O
that O
T3R B_GENE
can O
repress O
or O
activate O
transcription O
while O
tethered O
to O
the O
LBD O
of O
GAL4 B_PROTEIN[GENE]/B_SPECIES[BIO]
- O
RXR B_GENE
and O
that O
heterodimerization O
can O
occur O
in O
vivo O
without O
stabilization O
by O
hormone O
response O
elements O
. O

Most O
interestingly O
, O
although O
the O
effector O
plasmid O
containing O
the O
ICP27 B_GENE
gene I_GENE
had O
little O
effect O
on O
its O
own O
, O
two O
different O
and O
marked O
effects O
depending O
on O
the O
target O
were O
observed O
when O
ICP27 B_GENE
was O
combined O
with O
ICP4 B_GENE
or O
ICP0 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
both O
. O

In O
renal B_MEASURE
vein I_MEASURE
thrombosis I_MEASURE
, O
similar B_DISEASE_ADJECTIVE[DISEASE]
pattern I_DISEASE_ADJECTIVE[DISEASE]
to O
acute B_DISEASE
tubular I_DISEASE
necrosis I_DISEASE
was O
found O
but O
RI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
helpful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

TOM1 B_GENE/B_PERSON
encodes O
a O
member O
of O
the O
hect B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
domain O
- O
containing O
E3 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ubiquitin I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
family O
that O
is O
required O
for O
growth O
at O
elevated O
temperatures O
. O

Genomic O
clones O
containing O
the O
C O
. O
briggsae O
gene O
are O
able O
to O
completely O
rescue O
the O
unc B_DISEASE/B_GENE
- I_DISEASE/I_GENE
119 I_DISEASE/I_GENE
phenotype I_DISEASE/I_GENE
in O
transgenic O
C O
. O
elegans O
mutants O
. O

The O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potassium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
the O
first B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
two B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
HD I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
causes O
a O
membrane B_DISEASE
hyperpolarization I_DISEASE
. O

Region O
- O
specific O
enhancers O
near O
two O
mammalian B_GENE/B_LOCATION
homeo I_GENE/I_LOCATION
box I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
define O
adjacent O
rostrocaudal O
domains O
in O
the O
central O
nervous O
system O
. O

In O
this O
study O
, O
we O
report O
the O
cloning O
and O
sequencing O
of O
several O
overlapping O
cDNAs O
encoding O
approximately O
4 O
. O
1 O
kb O
of O
the O
human B_GENE
homologue I_GENE
of I_GENE
Wnt I_GENE
- I_GENE
5A I_GENE
. O

Subtype O
- O
and O
response O
element O
- O
dependent O
differences O
in O
transactivation O
by O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

MRI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
visualization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
proteoglycan B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depletion B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
articular B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
cartilage I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
via O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Gd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
DTPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
then O
developed O
a O
yeast B_GENE
artificial I_GENE
chromosome I_GENE
( O
YAC B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
contig B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
this O
region B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
suggest O
that O
the O
induction O
of O
IFNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O
cooperation O
between O
alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IRF B_GENE
- I_GENE
1 I_GENE
. O

Heterologous O
hybridization O
with O
a O
rps12 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
specific O
probe O
from O
Euglena O
has O
revealed O
the O
presence O
of O
rps12 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
homologous B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O
the O
inverted O
repeat O
of O
Spirodela O
chloroplast O
DNA O
on O
the O
fragment B_GENE
BamHI I_GENE
- I_GENE
V I_GENE
. O

To O
investigate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hyperthyroidism B_DISEASE
on O
the O
pattern B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
time B_MEASURE
course I_MEASURE
of O
O2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uptake I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
VO2 B_PROTEIN[GENE]
) O
following O
the O
transition B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
rest B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
six B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
and O
six B_PERSON
healthy I_PERSON
subjects I_PERSON
performed O
cycle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exercise I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O
an O
average B_MEASURE/B_LOCATION
work I_MEASURE/I_LOCATION
rate I_MEASURE/I_LOCATION
( O
WR B_PROTEIN[GENE]/B_DISEASE
) O
of O
18 B_MEASURE
and O
20 B_MEASURE/B_LOCATION
W I_MEASURE/I_LOCATION
respectively O
. O

However O
, O
to O
date B_TIME[MEASURE]/B_PERSON
, O
no O
viable B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
generated O
deletion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
PSTVd B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
. O

This O
raises O
the O
possibility O
that O
recombination O
occurred O
between O
corresponding O
LTR O
and O
vif B_PERSON/B_NUMBER[MEASURE]
loci B_PERSON/I_NUMBER[MEASURE]
of O
the O
quasi O
- O
species O
present O
in O
the O
isolates O
described O
here O
. O

In O
HMEC O
stably O
transfected O
with O
an O
ER B_GENE
mutant I_GENE
containing O
a O
deletion O
in O
the O
second O
zinc O
finger O
of O
the O
DNA O
- O
binding O
domain O
, O
E O
and O
HT O
had O
different O
effects O
on O
EBBP B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
expression O
; O
EBBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O
by O
E O
was O
dramatically O
reduced O
while O
the O
effects O
of O
HT O
were O
augmented O
. O

The O
gene B_GENE
atp6 I_GENE
, O
encoding O
subunit O
6 O
of O
the O
mitochondrial O
F0 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
ATPase B_PROTEIN[GENE]/B_MEASURE
complex O
, O
has O
been O
characterized O
from O
both O
the O
normal O
( O
fertile O
) O
and O
Ogura O
( O
male O
- O
sterile O
) O
radish O
cytoplasms O
in O
order O
to O
determine O
if O
previously O
identified O
atp6 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transcriptional O
differences O
could O
play O
a O
role O
in O
cytoplasmic O
male O
sterility O
. O

When O
the O
same B_MEASURE
single I_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
acid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
directly O
introduced O
into O
the O
parental B_PROTEIN[GENE]/B_DISEASE
PV I_PROTEIN[GENE]/I_DISEASE
/ O
CBV4 B_PROTEIN[GENE]/B_LOCATION
- O
2A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
chimeric B_BIO/B_DISEASE
viruses I_BIO/I_DISEASE
with O
a O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
plaque B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
a O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_VIRUS[BIO]
PV B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
- O
like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pattern I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
obtained O
upon O
transfection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
an O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O
that O
these O
point B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
alone O
had O
a O
drastic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
growth B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
PV B_DISEASE/B_PROTEIN[GENE]
/ O
CBV4 B_LOCATION/B_DISEASE
chimeric I_LOCATION/I_DISEASE
virus I_LOCATION/I_DISEASE
. O

The O
gag B_GENE/B_LOCATION
- O
myc B_BACTERIUM[BIO]/B_GENE
proteins O
encoded O
by O
these O
variants O
efficiently O
localized O
to O
the O
cell O
nucleus O
. O

Hpr1 B_PERSON/B_LOCATION
forms O
, O
together O
with O
Tho2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Mft1 B_GENE/B_LOCATION
, O
and O
Thp2 B_GENE/B_PERSON
, O
the O
THO B_LOCATION
complex I_LOCATION
, O
which O
controls O
transcription O
elongation O
and O
genome O
stability O
in O
Saccharomyces O
cerevisiae O
. O

UPR O
elements O
present O
in O
other O
ER O
chaperone O
genes O
, O
such O
as O
yeast B_GENE
KAR2 I_GENE
( O
BiP B_GENE/B_LOCATION
) O
, O
mammalian B_GENE/B_DISEASE
GRP78 I_GENE/I_DISEASE
( O
BiP B_GENE/B_DISEASE
) O
, O
and O
GRP94 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
function O
in O
an O
analogous O
manner O
to O
that O
in O
FKB2 B_GENE/B_BIO
. O

The O
objective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
if O
ergotamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
ergopeptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alkaloid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
isolated O
from O
Neotyphodium B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
infected O
grasses B_SPECIES[BIO]
and O
associated O
with O
toxicoses B_DISEASE/B_ORGANISM_FUNCTION
in O
livestock B_SPECIES[BIO]
, O
altered O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reproductive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
follicular B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
phase I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
heifers I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
cows B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
a O
progestin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
spontaneous I_DISEASE_ADJECTIVE[DISEASE]
subdural I_DISEASE_ADJECTIVE[DISEASE]
haematoma I_DISEASE_ADJECTIVE[DISEASE]
. O

strains O
carrying O
a O
snf1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
unable O
to O
grow O
on O
sucrose O
, O
galactose O
, O
maltose O
, O
melibiose O
, O
or O
nonfermentable O
carbon O
sources O
; O
utilization O
of O
these O
carbon O
sources O
is O
regulated O
by O
glucose O
repression O
. O

2 O
) O
Depending O
on O
the O
structure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
certain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O
sequestered O
in O
the O
cornea B_BODY_PART_OR_ORGAN_COMPONENT
( O
presumably O
the O
stroma B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
form O
a O
release B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
anterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aqueous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
neural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
compared O
with O
those O
of O
a O
density B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mask I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
thresholds B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
- O
750 B_MEASURE
/ O
- O
300 B_MEASURE
H I_MEASURE
) O
, O
with O
a O
radiologist B_PERSON/B_MEASURE
serving B_PERSON/I_MEASURE
as O
the O
gold B_PERSON
standard I_PERSON
. O

These O
data O
also O
suggest O
the O
existence O
of O
a O
mechanism O
by O
which O
regulatory O
subunits O
modulate O
the O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
- O
mediated O
signals O
, O
independent O
of O
the O
kinase O
activity O
, O
possibly O
through O
subcellular O
localization O
of O
the O
catalytic O
subunit O
or O
interaction O
with O
additional O
signaling O
molecules O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
the O
PVB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
cure O
the O
cases B_PERSON/B_DISEASE
with O
choriocarcinoma B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
element I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O
bulky B_DISEASE
metastasis I_DISEASE
. O

Right O
- O
sided O
hemiplegia B_DISEASE
of O
5 B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
years I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
duration I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
occurred O
in O
the O
remaining O
case B_PERSON
. O

Plasmid O
subclones O
of O
the O
hr1a B_GENE/B_SPECIES[BIO]
- O
containing O
AcMNPV O
HindIII B_MEASURE/B_PROTEIN[GENE]
- O
N O
fragment O
were O
examined O
for O
their O
ability O
to O
replicate O
in O
virus O
- O
infected O
( O
Spodoptera O
frugiperda O
) O
Sf9 O
cells O
, O
and O
to O
stimulate O
transcription O
when O
linked O
in O
cis O
with O
a O
39K B_GENE
gene I_GENE
promoter I_GENE
- I_GENE
beta I_GENE
- I_GENE
glucuronidase I_GENE
fusion I_GENE
and O
cotransfected O
into O
cells O
along O
with O
a O
plasmid O
( O
ple O
- O
1 O
) O
containing O
the O
gene O
encoding O
the O
trans O
- O
acting O
factor O
IE B_GENE
- I_GENE
1 I_GENE
. O

Transfection O
of O
H B_NUMBER[MEASURE]/B_PERSON
chain I_NUMBER[MEASURE]/I_PERSON
loss I_NUMBER[MEASURE]/I_PERSON
variant I_NUMBER[MEASURE]/I_PERSON
myeloma O
with O
the O
complete O
12 O
kb O
construct O
, O
termed O
238H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cmicro I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulted O
in O
secretion O
of O
intact O
Ig O
pairing O
238H B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Cmicro I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
with O
a O
lambda B_GENE
L I_GENE
chain I_GENE
; O
however O
, O
transfectant B_GENE/B_BIO
Ig I_GENE/I_BIO
lacked O
autoreactivity O
and O
pathogenicity O
. O

divergent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT
left O
hemisphere B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
used O
for O
decoding B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
storage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
information B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
emerged O
in O
each O
working O
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
versus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
normal O
B O
cells O
stimulated O
by O
LPS O
or O
IL B_LOCATION/B_GENE
- I_LOCATION/I_GENE
4 I_LOCATION/I_GENE
, O
new O
complexes O
appear O
that O
bind O
to O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
NF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
, O
located O
within O
the O
- O
125 O
/ O
- O
101 O
region O
. O

Here O
, O
we O
describe O
the O
crystal O
structure O
at O
2 O
. O
5 O
A O
resolution O
of O
a O
fragment O
of O
the O
integrase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rous I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
49 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
286 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
both O
the O
conserved O
catalytic O
domain O
and O
a O
modulatory O
DNA O
- O
binding O
domain O
( O
C O
domain O
) O
. O

Vectorcardiography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
coronary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
electrocardiographic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RS B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segment B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
V1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
lead B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aphidicola I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
argS I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rrn I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
endosymbionts O
from O
seven O
species O
of O
aphids O
had O
promoter O
activities O
in O
E O
. O
coli O
which O
ranged O
from O
6 O
to O
135 O
% O
of O
that O
observed O
with O
a O
comparable O
DNA O
fragment O
of O
E B_BIO/B_GENE
. I_BIO/I_GENE
coli I_BIO/I_GENE
rrnB I_BIO/I_GENE
. O

The O
adeno O
- O
associated O
virus O
type O
2 O
( O
AAV O
- O
2 O
) O
Rep78 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Rep68 B_MEASURE/B_GENE
regulatory O
proteins O
are O
pleiotropic O
effectors O
of O
viral O
and O
cellular O
DNA O
replication O
, O
of O
cellular O
transformation O
by O
viral O
and O
cellular O
oncogenes O
, O
and O
of O
homologous O
and O
heterologous O
gene O
expression O
. O

Role O
of O
the O
CCAAT B_GENE
/ I_GENE
enhancer I_GENE
binding I_GENE
protein I_GENE
- I_GENE
alpha I_GENE
transcription I_GENE
factor I_GENE
in O
the O
glucocorticoid O
stimulation O
of O
p21waf1 B_GENE
/ O
cip1 B_GENE/B_DISEASE
gene O
promoter O
activity O
in O
growth O
- O
arrested O
rat O
hepatoma O
cells O
. O

Long B_SEQUENCE[MEASURE]/B_PERSON
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ambulatory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
transcutaneous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
arterial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PCO2 B_DISEASE/B_LOCATION
) O
offers O
an O
opportunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
directly O
the O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
occurrence B_DISEASE/B_PROTEIN[GENE]
of O
panic B_DISEASE
and O
hyperventilation B_DISEASE
under O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
highly O
conserved O
region O
of O
U6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
a O
structural O
similarity O
with O
the O
catalytic O
domain O
of O
the O
negative O
strand O
of O
the O
satellite O
RNA O
of O
tobacco O
ring O
spot O
virus O
[ O
( O
- O
) O
sTRSV O
] O
, O
suggesting O
that O
the O
highly O
conserved O
region O
of O
U6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O
the O
catalytic O
center O
. O

Here O
we O
show O
that O
one O
nudF B_GENE
suppressor I_GENE
also O
suppresses O
hs O
- O
mutations O
in O
nudA B_GENE/B_DISEASE
, O
nudC B_DISEASE/B_PROTEIN[GENE]
, O
and O
nudG B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
deletions O
in O
nudA B_LOCATION/B_ORGANIZATION
and O
nudF B_PROTEIN[GENE]/B_LOCATION
. O

Treatment O
of O
cells O
for O
10 O
min O
with O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
activation O
of O
p44 B_GENE
/ I_GENE
42 I_GENE
MAPK O
, O
p38 B_GENE/B_LOCATION
, O
and O
JNK B_GENE
. O

This O
report O
describes O
the O
isolation O
and O
recombinant O
expression O
of O
a O
cDNA O
clone O
encoding O
HER4 B_GENE
, O
the O
fourth O
member O
of O
the O
human B_GENE
epidermal I_GENE
growth I_GENE
factor I_GENE
receptor I_GENE
( O
EGFR B_GENE/B_LOCATION
) O
family O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
when O
pulmonary B_DISEASE/B_LOCATION
abnormalities I_DISEASE/I_LOCATION
are O
found O
in O
HTLV B_DISEASE/B_VIRUS[BIO]
- O
1 B_MEASURE/B_PERSON
carriers I_MEASURE/I_PERSON
, O
we O
should O
be O
careful B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
determining O
whether O
such B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
involvements B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
etiologically O
related O
to O
HTLV B_DISEASE/B_VIRUS[BIO]
- O
1 B_DISEASE/B_PROTEIN[GENE]
infection B_DISEASE/I_PROTEIN[GENE]
. O

A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitomycin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
kW B_MEASURE/B_PROTEIN[GENE]
- O
2083 B_MEASURE
( O
7 B_MEASURE
- O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
( O
p B_OTHER/B_MEASURE
- O
hydroxyphenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
mitomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

excess O
recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
squelches O
the O
splicing O
switch O
and O
reestablishes O
exon O
skipping O
as O
the O
predominant O
splicing O
pathway O
. O

A O
child O
presumed O
to O
have O
the O
21 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxylase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O
form O
of O
congenital O
adrenal O
hyperplasia O
was O
studied O
extensively O
as O
an O
infant O
. O

Sixtieth O
anniversary O
of O
Angiotensin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Inability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
niacin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
protect O
from O
in O
vivo B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hyperoxia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
in O
vitro B_DISEASE
microsomal I_DISEASE
lipid I_DISEASE
peroxidation I_DISEASE
. O

MDA O
- O
MB O
- O
468 O
cells O
were O
stably O
transfected O
with O
either O
a O
plasmid O
having O
a O
CMV B_GENE
promoter I_GENE
- O
driven O
rabbit B_GENE
beta I_GENE
- I_GENE
globin I_GENE
gene I_GENE
or O
plasmids O
having O
a O
CMV B_GENE
promoter I_GENE
- O
driven O
chimeric O
gadd45 B_GENE/B_SPECIES[BIO]
5 O
' O
- O
UTR O
- O
rabbit B_GENE
beta I_GENE
- I_GENE
globin I_GENE
gene O
, O
where O
the O
entire B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gadd45 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
298 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
a O
45 O
BP O
subfragment O
of O
the O
gadd45 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
10 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
positioned O
at O
the O
5 O
' O
- O
end O
of O
the O
rabbit B_GENE
beta I_GENE
- I_GENE
globin I_GENE
gene I_GENE
. O

The O
University B_LOCATION/B_ORGANIZATION
of O
North B_LOCATION
Carolina I_LOCATION
caries I_LOCATION
risk I_LOCATION
assessment I_LOCATION
was O
conducted O
between O
1986 B_MEASURE
and O
1989 B_MEASURE
with O
5000 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
children B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initially O
in O
grades B_LOCATION/B_PERSON
1 I_LOCATION/I_PERSON
and O
5 B_NUMBER[MEASURE]
from O
low B_LOCATION/B_PERSON
fluoride I_LOCATION/I_PERSON
sites I_LOCATION/I_PERSON
in O
South B_LOCATION
Carolina I_LOCATION
and O
Maine B_LOCATION
. O

Following O
EGF B_GENE
or O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O
of O
the O
v O
- O
CrkPC12 O
cells O
, O
the O
v B_GENE
- I_GENE
Crk I_GENE
protein O
itself O
became O
tyrosine O
phosphorylated O
within O
1 O
min O
. O

BCR B_GENE/B_LOCATION
- O
ABL B_PROTEIN[GENE]/B_LOCATION
expression O
confers O
cross O
- O
resistance O
to O
multiple O
genotoxic O
anticancer O
drugs O
by O
inhibition O
of O
the O
apoptotic O
response O
to O
DNA O
damage O
in O
association O
with O
cell O
cycle O
arrest O
at O
the O
G2 O
- O
M O
restriction O
point O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
After O
lavage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
a O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
arterial B_DISEASE
pH I_DISEASE
and O
PaO2 B_MEASURE/B_LOCATION
, O
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
PaCO2 B_DISEASE/B_PROTEIN[GENE]
and O
PIP B_DISEASE/B_PROTEIN[GENE]
were O
observed O
in O
all O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
elevation B_DISEASE_ADJECTIVE[DISEASE]
of O
TBARS B_GENE
and O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
GSH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
show O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]
of O
oxidative B_DISEASE/B_GENE
stress I_DISEASE/I_GENE
during O
the O
PFD B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
hemodiafilter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
SG3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

ozone B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
assessed O
in O
awake B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
spontaneously O
breathing O
Fischer B_PERSON/B_LOCATION
- O
344 B_PERSON/B_MEASURE
Sprague I_PERSON/I_MEASURE
- O
Dawley B_PERSON
, O
and O
Long B_PERSON
- O
Evans B_PERSON/B_LOCATION
rats I_PERSON/I_LOCATION
and O
Hartley B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guinea B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigs B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
provide O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
dosimetry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
O3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
small B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laboratory I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

E O
. O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
C B_OTHER/B_PROTEIN[GENE]
. O
P B_OTHER/B_LOCATION
. O

is O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
diagnosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Deletion O
analysis O
of O
the O
3 O
. O
5kb O
DNA O
fragment O
revealed O
that O
the O
region O
between O
- O
125 O
to O
+ O
1 O
, O
containing O
a O
single O
Sp1 B_GENE
binding I_GENE
site I_GENE
, O
is O
essential O
for O
transcription O
of O
the O
embigin B_GENE
gene I_GENE
. O

Resistance B_PERSON/B_DISEASE
to O
Mup B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O
classified O
as O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
minimal B_LOCATION/B_MEASURE
inhibitory I_LOCATION/I_MEASURE
concentration I_LOCATION/I_MEASURE
[ I_LOCATION/I_MEASURE
MIC I_LOCATION/I_MEASURE
] O
> B_MEASURE/B_OTHER
or O
= O
8 B_MEASURE
microg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
) O
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
MIC B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
or O
= O
512 B_MEASURE
microg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
) O
degree B_DISEASE_ADJECTIVE[DISEASE]
. O

Extragonadal B_DISEASE/B_PERSON
endodermal I_DISEASE/I_PERSON
sinus I_DISEASE/I_PERSON
tumors I_DISEASE/I_PERSON
in O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT
and O
neck B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O
very O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

lesions B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
kind B_LOCATION
resemble O
those O
in O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
deficient B_DISEASE
chickens I_DISEASE
and O
are O
the O
first B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
induced O
by O
excess B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

essential B_DISEASE
fatty I_DISEASE
acid I_DISEASE
deficiency I_DISEASE
in O
childhood B_PERSON/B_DISEASE
. O

The O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
GF O
- O
109203X O
abolished O
the O
activation O
by O
phorbol O
ester O
and O
inhibited O
the O
effect O
of O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O
78 O
% O
but O
had O
no O
effect O
on O
EGF B_GENE
- O
activated O
MAPK B_GENE
activity O
. O

activated O
FGFR3 B_GENE/B_LOCATION
predominantly O
interacts O
with O
GRB2 B_GENE
. I_GENE
Sos I_GENE
in O
complex O
with O
a O
previously O
identified O
90 O
- O
kDa O
protein O
and O
designated O
protein B_GENE
80K I_GENE
- I_GENE
H I_GENE
. O

The O
rate O
of O
collagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
synthesis O
in O
normal O
scar O
was O
approximately O
constant O
between O
6 O
months O
and O
20 O
years O
after O
the O
initial O
wounding O
, O
but O
in O
both O
hypertrophic O
scar O
and O
keloid O
the O
rate O
was O
initially O
approximately O
twice O
that O
in O
normal O
scar O
, O
and O
2 O
- O
3 O
years O
after O
wounding O
it O
fell O
to O
approximately O
the O
same O
level O
as O
in O
normal O
scar O
. O

Evidence O
for O
a O
role O
of O
Smad6 B_GENE
in O
chick O
cardiac O
development O
. O

excellent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
recorded O
in O
390 B_MEASURE
( O
83 B_MEASURE
. O
69 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
the O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
improvement B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
46 B_MEASURE
( O
9 B_MEASURE
. O
87 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
where O
in O
the O
majority B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
varicose B_PERSON/B_DISEASE
complex I_PERSON/I_DISEASE
was O
involved O
. O

Mutational O
analysis O
of O
yeast B_GENE/B_BIO
CEG1 I_GENE/I_BIO
demonstrated O
that O
four O
of O
the O
five O
conserved O
motifs O
are O
essential O
for O
capping B_GENE/B_LOCATION
enzyme I_GENE/I_LOCATION
function O
in O
vivo O
. O

We O
report O
on O
a O
case B_PERSON/B_DISEASE
discovered O
in O
a O
13 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
- O
old B_PERSON
girl I_PERSON
presenting O
with O
anaemia B_DISEASE
. O

The O
LIF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
be O
released O
by O
the O
patient O
' O
s O
peripheral O
blood O
lymphocytes O
when O
cultured O
with O
optimal O
doses O
of O
propranolol O
. O

Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
selection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
Not O
applicable B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Co O
- O
expression O
of O
PLD1 B_GENE
in O
COS O
- O
7 O
cells O
with O
the O
two O
recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CK2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
alpha O
or O
beta O
, O
suggests O
that O
the O
association O
of O
PLD1 B_GENE
with O
the O
kinase O
is O
through O
the O
beta O
subunit O
. O

For O
capsules B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
only O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
value B_MEASURE
of O
T50 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O
as O
the O
particle B_MEASURE/B_DISEASE
size I_MEASURE/I_DISEASE
of O
the O
drug B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
decreased O
. O

The O
LAB B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
cecum B_LOCATION/B_BACTERIUM[BIO]
( O
mean B_MEASURE
9 I_MEASURE
. O
4 B_MEASURE
log I_MEASURE
CFU I_MEASURE
/ O
g B_OTHER/B_MEASURE
) O
increased O
slightly O
with O
increasing O
abattoir B_MEASURE/B_LOCATION
holding I_MEASURE/I_LOCATION
time I_MEASURE/I_LOCATION
. O

Our O
objective O
was O
to O
find O
possible O
predictors O
for O
the O
expression O
and O
progression O
of O
LJM O
and O
to O
evaluate O
the O
relationship O
between O
LJM O
and O
other O
long O
- O
term O
complications O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
diabetes O
mellitus O
. O

Human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recombinant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
erythropoietin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
r B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HuEPO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
EprexR B_MEASURE/B_PROTEIN[GENE]
) O
was O
administered O
to O
8 O
children O
with O
chronic O
renal O
failure O
and O
high O
transfusion O
requirement O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
LHB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
simple B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
easy B_DISEASE_ADJECTIVE[DISEASE]
and O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
implement O
, O
and O
is O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
capable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
maintaining O
independent B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upper I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
body I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
perfusion I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Northern O
analyses O
further O
confirm O
that O
the O
expression O
of O
endogenous O
alpha B_GENE
- I_GENE
ENaC I_GENE
gene I_GENE
in O
salivary O
Pa O
- O
4 O
cells O
is O
suppressed O
by O
an O
ectopic O
HMGI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overexpression O
. O

removal O
of O
cyclin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
cdks B_LOCATION/B_GENE
) O
or O
cdk2 B_GENE
from O
these O
extracts O
using O
affinity O
matrices O
severely O
inhibits O
initiation O
of O
S O
phase O
. O

gel O
mobility O
shift O
analyses O
reveal O
that O
FRTL O
- O
5 O
thyroid O
cell O
nuclear O
extracts O
form O
a O
specific O
protein O
/ O
DNA O
complex O
with O
this O
region O
, O
which O
is O
prevented O
by O
the O
TTF B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
element I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
TG B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
; O
FRT O
and O
BRL O
cell O
nuclear O
extracts O
do O
not O
have O
TTF B_GENE
- I_GENE
1 I_GENE
and O
do O
not O
form O
this O
complex O
. O

The O
Sty1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
stimulated O
by O
a O
variety O
of O
different O
stress O
conditions O
including O
osmotic O
and O
oxidative O
stress O
and O
heat O
shock O
. O

No O
viral B_DISEASE_ADJECTIVE[DISEASE]
RNA I_DISEASE_ADJECTIVE[DISEASE]
replication I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
detected O
in O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
transfected O
with O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Acad B_LOCATION
. O

comparison O
of O
the O
genes O
coding O
for O
mouse O
and O
human O
p36 B_GENE
( O
annexin B_GENE
II I_GENE
) O
and O
mouse O
, O
rat O
and O
human O
p35 B_GENE
( O
annexin B_GENE
I I_GENE
) O
and O
pigeon O
cp35 B_PROTEIN[GENE]
( O
an O
annexin B_ENZYME[GENE]/B_NUMBER[MEASURE]
I I_ENZYME[GENE]/I_NUMBER[MEASURE]
- I_ENZYME[GENE]/I_NUMBER[MEASURE]
related I_ENZYME[GENE]/I_NUMBER[MEASURE]
protein I_ENZYME[GENE]/I_NUMBER[MEASURE]
) O
shows O
strong O
genomic O
structural O
conservation O
supporting O
the O
hypothesis O
that O
these O
genes O
had O
a O
common O
ancestor O
. O

When O
incubated O
with O
infective B_BIO
larvae I_BIO
which O
had O
penetrated O
mouse B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
skin B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
both O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immune B_DISEASE
cells I_DISEASE
attached O
to O
larvae O
in O
the O
absence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
31 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
man I_PERSON
with O
primary B_DISEASE/B_GENE
myelofibrosis I_DISEASE/I_GENE
initially O
received O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Ara I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

collectively O
, O
these O
studies O
suggest O
that O
the O
major O
EGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
mitotic O
growth O
pathways O
may O
not O
be O
absolutely O
linked O
to O
the O
stat91 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
pathways O
and O
that O
such O
transcription O
complexes O
are O
more O
complex O
than O
previously O
reported O
. O

FEurea B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
measured O
during O
stable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
graft I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
function I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
7 B_NUMBER[MEASURE]
- O
14 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
prior I_TIME[MEASURE]/I_ENT
to O
allograft B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Nonsuicidal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mortality B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
late B_MEASURE/B_LOCATION
- O
life B_TIME[MEASURE]/B_PERSON
depression I_TIME[MEASURE]/I_PERSON
. O

Few B_PERSON/B_LOCATION
triers I_PERSON/I_LOCATION
or O
users B_PERSON
had O
received O
SLT B_PERSON
counseling I_PERSON
from O
their O
dentist B_PERSON
despite O
high B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dental I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
utilization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
UV B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
resistance B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
only O
minimally O
restored O
, O
and O
mutant B_DISEASE/B_BIO
cells B_DISEASE/I_BIO
remain O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
oxalate B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxidase B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O
results O
in O
a O
mean O
and O
reference O
interval O
for O
oxalate O
excretion O
that O
are O
comparable O
with O
those O
by O
isotope O
dilution O
, O
gas O
- O
chromatographic O
, O
colorimetric O
, O
and O
other O
enzymic O
procedures O
. O

In O
addition O
, O
we O
show O
that O
expression O
of O
antisense O
mRNA O
for O
p130CAS B_GENE
resulted O
in O
reversion O
of O
the O
transformed O
phenotype O
of O
all O
these O
cell O
lines O
. O

Starches B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Maximal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expiratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Flow I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
Peak B_MEASURE/B_LOCATION
Expiratory I_MEASURE/I_LOCATION
Flow I_MEASURE/I_LOCATION
Rate I_MEASURE/I_LOCATION
( O
PEFR B_LOCATION/B_DISEASE
) O
, O
rates B_DISEASE/B_MEASURE
at O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
forced O
vital B_TIME[MEASURE]/B_LOCATION
capacity I_TIME[MEASURE]/I_LOCATION
( O
V B_MEASURE/B_LOCATION
Max B_MEASURE/I_LOCATION
25 B_MEASURE/I_LOCATION
% B_MEASURE/I_LOCATION
, O
V B_TIME[MEASURE]/B_LOCATION
Max I_TIME[MEASURE]/I_LOCATION
50 I_TIME[MEASURE]/I_LOCATION
% I_TIME[MEASURE]/I_LOCATION
and O
V B_MEASURE/B_LOCATION
Max I_MEASURE/I_LOCATION
75 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
) O
and O
forced O
expiratory B_MEASURE
flow I_MEASURE
during O
the O
middle B_TIME[MEASURE]/B_LOCATION
half I_TIME[MEASURE]/I_LOCATION
of O
forced O
vital B_MEASURE/B_DISEASE
capacity B_MEASURE/I_DISEASE
( O
FEF B_MEASURE/B_PROTEIN[GENE]
25 I_MEASURE/I_PROTEIN[GENE]
- O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
were O
measured O
in O
273 B_MEASURE/B_PERSON
healthy I_MEASURE/I_PERSON
non O
- O
smoking O
adults B_PERSON
( O
144 B_MEASURE/B_PERSON
males I_MEASURE/I_PERSON
, O
129 B_PERSON/B_MEASURE
females I_PERSON/I_MEASURE
) O
aged O
15 B_MEASURE
- O
63 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
living O
in O
Madras B_LOCATION
. O

The O
amino O
acid O
sequence O
of O
the O
protein O
encoded O
by O
MSK1 B_GENE/B_LOCATION
is O
homologous O
to O
yeast B_GENE
cytoplasmic I_GENE
lysyl I_GENE
- I_GENE
tRNA I_GENE
synthetase I_GENE
and O
to O
the O
product O
of O
the O
herC B_GENE
gene I_GENE
, O
which O
has O
recently O
been O
suggested O
to O
code O
for O
the O
Escherichia O
coli O
enzyme O
. O

Similar O
to O
the O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B B_PROTEIN[GENE]/B_DISEASE
/ O
B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
E B_PROTEIN[GENE]/B_LOCATION
proteins I_PROTEIN[GENE]/I_LOCATION
, O
the O
F B_PROTEIN[GENE]/B_DISEASE
and O
G B_PROTEIN[GENE]/B_LOCATION
proteins I_PROTEIN[GENE]/I_LOCATION
do O
not O
possess O
any O
of O
the O
known O
RNA O
binding O
motifs O
, O
suggesting O
that O
other O
types O
of O
RNA O
- O
protein O
interactions O
occur O
in O
the O
snRNP O
core O
. O

These O
observations O
suggest O
that O
clr4 B_GENE
+ I_GENE
and O
rik1 B_GENE
+ I_GENE
must O
play O
a O
role O
in O
the O
assembly O
of O
Swi6p B_GENE/B_BACTERIUM[BIO]
into O
a O
transcriptionally O
silent O
, O
inaccessible O
chromatin O
structure O
at O
fission O
yeast O
centromeres O
which O
is O
required O
to O
facilitate O
interactions O
with O
spindle O
microtubules O
and O
to O
ensure O
normal O
chromosome O
segregation O
. O

characterization O
of O
a O
DEAD B_GENE
box I_GENE
ATPase I_GENE
/ O
RNA B_ENZYME[GENE]
helicase I_ENZYME[GENE]
protein O
of O
Arabidopsis O
thaliana O
. O

amplitude B_TIME[MEASURE]
of O
late B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
surface B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
P2 B_PROTEIN[GENE]
and O
N2 B_PROTEIN[GENE]
) O
and O
depth B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
B B_PROTEIN[GENE]/B_DISEASE
and O
C B_PROTEIN[GENE]
) O
components B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significantly O
decreased O
when O
patients B_PERSON/B_MEASURE
shifted O
from O
SWS B_LOCATION/B_PROTEIN[GENE]
IV I_LOCATION/I_PROTEIN[GENE]
to O
PS B_PROTEIN[GENE]/B_LOCATION
and O
increased O
from O
PS B_PROTEIN[GENE]/B_LOCATION
to O
W2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

oligo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
deoxynucleotides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
derived O
by O
stabilizing O
( O
intercalating O
) O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
reactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
cleaving O
reagents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
linkers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O
. O
) O
. O

This O
vector B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
applicable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
throughput B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
new B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
open B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reading B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
frames B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O
in O
genome B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
subjects B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
17 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
with O
android B_DISEASE
obesity I_DISEASE
( O
four B_NUMBER[MEASURE]/B_ENT
men I_NUMBER[MEASURE]/I_ENT
and O
13 B_PERSON/B_NUMBER[MEASURE]
women I_PERSON/I_NUMBER[MEASURE]
) O
aged O
21 B_MEASURE
to O
58 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
with O
a O
body B_MEASURE/B_BIO
mass I_MEASURE/I_BIO
index I_MEASURE/I_BIO
( O
BMI B_MEASURE/B_ORGANIZATION
) O
ranging O
from O
32 B_MEASURE
. O
0 B_MEASURE
to O
52 B_MEASURE
. O
2 B_MEASURE
kg I_MEASURE
/ O
m2 B_MEASURE/B_PERSON
and O
an O
abdominal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
gluteal B_MEASURE
ratio I_MEASURE
greater I_MEASURE
than O
1 B_MEASURE
. O
0 B_MEASURE
. O

No O
universally O
accepted O
standardized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
acne B_DISEASE/B_LOCATION
vulgaris I_DISEASE/I_LOCATION
exists O
, O
although O
there O
is O
a O
strong B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
need I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
it O
. O

Blood O
samples O
for O
determination O
of O
fibrinolytic O
activity O
and O
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma O
were O
obtained O
before O
and O
immediately O
after O
the O
end O
of O
compression O
and O
application O
of O
a O
stocking O
, O
respectively O
. O

Neither O
symptoms O
, O
virions O
, O
nor O
viral O
RNA O
was O
detectable O
in O
plants O
inoculated O
with O
this O
mutant O
or O
a O
mutant O
with O
a O
frameshift O
mutation O
in O
the O
coat B_GENE
gene I_GENE
. O

The O
cumulative B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
of O
the O
RGSV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
RNAs B_MEASURE/B_PROTEIN[GENE]
5 I_MEASURE/I_PROTEIN[GENE]
and O
6 B_MEASURE
, O
was O
25142 B_MEASURE/B_GENE
nt I_MEASURE/I_GENE
. O

Risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ratios I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
decreased O
with O
increasing O
age B_MEASURE/B_DISEASE
and O
increased O
with O
number B_MEASURE
of O
breast B_PERSON/B_DISEASE
biopsies I_PERSON/I_DISEASE
, O
family B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
breast B_DISEASE
cancer I_DISEASE
, O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
time B_MEASURE
between O
screenings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
previous B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mammograms I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
and O
the O
radiologist B_PERSON/B_ORGANIZATION
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
tendency I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
call O
mammograms B_TIME[MEASURE]/B_PERSON
abnormal I_TIME[MEASURE]/I_PERSON
. O

The O
AtNMT1 B_GENE
expression O
profile O
indicated O
ubiquity O
in O
roots O
, O
stem O
, O
leaves O
, O
flowers O
, O
and O
siliques O
( O
approximately O
1 O
. O
7 O
kb O
transcript O
and O
approximately O
50 O
kDa O
immunoreactive O
polypeptide O
) O
but O
a O
greater O
level O
in O
the O
younger O
tissue O
, O
which O
are O
developmentally O
very O
active O
. O

The O
ossification B_LOCATION
was O
located O
on O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
side I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
C3 B_PROTEIN[GENE]/B_LOCATION
- O
4 B_NUMBER[MEASURE]
. O

At O
a O
cutoff B_MEASURE/B_DISEASE
point I_MEASURE/I_DISEASE
for O
KISA B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
100 B_NUMBER[MEASURE]/B_PERSON
, O
280 B_MEASURE
of O
281 B_PERSON/B_LOCATION
participants I_PERSON/I_LOCATION
( O
99 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
correctly O
classified O
. O

Following O
replicate O
control O
measurements O
, O
test O
ramps O
were O
repeated O
in O
the O
presence O
of O
sodium O
nitroprusside O
( O
1 O
microM O
) O
and O
phentolamine O
( O
1 O
microM O
) O
to O
eliminate O
potential O
smooth O
muscle O
and O
alpha B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
1 I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
adrenoceptor I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
effects O
, O
respectively O
. O

Behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ligands I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
non O
- O
dependent B_PERSON/B_DISEASE
, O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
withdrawn O
baboons B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O
estimates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
prevalence B_MEASURE/B_DISEASE
of O
mental B_DISEASE
retardation I_DISEASE
and O
associated B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
a O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
to O
9 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON/B_ENT
children I_PERSON/I_ENT
in O
Greater B_LOCATION
Karachi I_LOCATION
, O
Pakistan B_LOCATION
. O

Thus O
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
lactate B_MEASURE
concentration I_MEASURE
of O
the O
magnitude B_BODY_PART_OR_ORGAN_COMPONENT
observed O
during O
alkali B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
need O
not O
indicate O
a O
worsening B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
metabolic B_DISEASE_ADJECTIVE[DISEASE]
picture I_DISEASE_ADJECTIVE[DISEASE]
in O
lactic B_DISEASE/B_BIO
acidosis I_DISEASE/I_BIO
. O

adjusting O
a O
steady B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
state B_MEASURE/B_LOCATION
warfarin B_MEASURE/I_LOCATION
dose B_MEASURE/I_LOCATION
depends O
on O
the O
measured B_MEASURE/B_EDU[ORGANIZATION]
INR B_MEASURE/I_EDU[ORGANIZATION]
values B_MEASURE/I_EDU[ORGANIZATION]
and O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
the O
dose B_MEASURE
does O
not O
need O
to O
be O
adjusted O
for O
a O
single B_MEASURE
INR I_MEASURE
that O
is O
slightly O
out O
of O
range B_MEASURE
, O
and O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O
alter O
the O
total B_MEASURE
weekly I_MEASURE
dose I_MEASURE
by O
5 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
to O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

All O
of O
this O
region B_LOCATION/B_BIO
is O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
prominent B_LOCATION/B_GENE
CpG I_LOCATION/I_GENE
island I_LOCATION/I_GENE
that O
may O
be O
acting O
as O
an O
extended O
, O
enhancer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_LOCATION/B_GENE
promoter I_LOCATION/I_GENE
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Healon B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Amvisc B_PERSON/B_LOCATION
. O

Large B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
volumes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
bone B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
required O
for O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
types B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
bone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
marrow B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplants B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Further O
analysis O
of O
the O
CAP59 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cryptococcus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
neoformans I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
structure O
defined O
by O
forced O
expression O
and O
description O
of O
a O
new O
ribosomal B_GENE
protein I_GENE
- I_GENE
encoding I_GENE
gene I_GENE
. O

We O
speculate O
that O
the O
enhancing O
effect O
of O
glucose O
and O
galactose O
on O
fructose O
absorption O
may O
be O
due O
to O
activation O
of O
the O
fructose B_ENZYME[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
carrier I_ENZYME[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Virol B_LOCATION/B_BACTERIUM[BIO]
. O

The O
DFGF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
R I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O
thus O
participate O
in O
receiving O
spatial O
cues O
that O
guide O
tracheal O
cell O
outgrowth O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
animal B_MEASURE
experiments I_MEASURE
indicate O
that O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
solid B_DISEASE
tumors I_DISEASE
in O
marrow B_PERSON/B_BIO
transplant I_PERSON/I_BIO
patients I_PERSON/I_BIO
may O
still O
rise O
in O
the O
coming B_TIME[MEASURE]/B_LOCATION
decades I_TIME[MEASURE]/I_LOCATION
. O

patients B_PERSON
adopt O
new B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sets I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
based O
partly O
on O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
topic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
partly O
on O
their O
own B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
personal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
idiosyncratic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
concerns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
NS B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
resolved O
at O
a O
Pi O
value O
close O
to O
5 O
. O
5 O
as O
three O
groups O
of O
unevenly O
phosphorylated O
polypeptides O
, O
each O
composed O
of O
at O
least O
two O
protein O
species O
. O

Prevalence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
rheumatic B_DISEASE
diseases I_DISEASE
in O
a O
rural B_LOCATION/B_PERSON
population I_LOCATION/I_PERSON
in O
western B_LOCATION
India I_LOCATION
: O
a O
WHO O
- O
ILAR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
COPCORD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
. O
nidulans O
transformants O
secreted O
high O
amounts O
of O
PGI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
PGII B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
comparison O
to O
the O
previously O
characterized O
A O
. O
Niger O
transformants O
and O
a O
novel O
polygalacturonase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
PGC B_LOCATION/B_GENE
) O
was O
produced O
at O
high O
levels O
by O
A O
. O
nidulans O
transformed O
with O
the O
subcloned O
pgaC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
interaction O
is O
functional O
as O
it O
leads O
to O
retargeting O
of O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
p50 I_GENE
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

The O
orf2 O
gene O
product O
is O
a O
protein O
of O
79 O
amino O
acids O
with O
characteristics O
similar O
to O
those O
of O
the O
Tat B_PROTEIN[GENE]/B_LOCATION
( O
transactivator B_PROTEIN[GENE]/B_LOCATION
) O
proteins O
of O
the O
ungulate O
lentiviruses O
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
of O
minor B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
flight B_DISEASE
phobia I_DISEASE
. O

Elevated B_DISEASE_ADJECTIVE[DISEASE]
total I_DISEASE_ADJECTIVE[DISEASE]
serum I_DISEASE_ADJECTIVE[DISEASE]
calcium I_DISEASE_ADJECTIVE[DISEASE]
to O
a O
level B_MEASURE/B_LOCATION
of O
11 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_PROTEIN[GENE]
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
001 B_MEASURE
compared O
to O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
developed O
in O
the O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
1 B_MEASURE
, O
25 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
vitamin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
D3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
on O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
4 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
days B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
pronounced O
structural B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
damage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
continued O
to O
be O
elevated O
through O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
7 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Rac2 B_GENE
, O
a O
member O
of O
the O
Rho B_GENE/B_PERSON
family I_GENE/I_PERSON
of O
GTPases B_GENE/B_BIO
, O
is O
highly O
expressed O
in O
myeloid O
cells O
and O
is O
a O
regulator O
of O
the O
NADPH B_GENE
- I_GENE
oxidase I_GENE
complex I_GENE
. O

In O
vitro O
kinase O
assays O
on O
isolated O
microvilli O
and O
microvillar O
fractions O
enriched O
in O
the O
putative O
signal O
transduction O
particle O
showed O
a O
high O
specific O
activity O
of O
tyrosine B_GENE/B_DISEASE
kinase I_GENE/I_DISEASE
activity O
compared O
to O
that O
of O
membranes O
from O
EGF B_GENE
receptor I_GENE
- O
overexpressing O
A431 O
cells O
maximally O
activated O
by O
EGF B_GENE
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
infantile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
undernutrition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
adult B_DISEASE/B_ORGANISM_FUNCTION
sucrose I_DISEASE/I_ORGANISM_FUNCTION
solution I_DISEASE/I_ORGANISM_FUNCTION
consumption I_DISEASE/I_ORGANISM_FUNCTION
in O
the O
rat B_BIO/B_PERSON
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding O
sites O
, O
EBS1 B_GENE/B_DISEASE
and O
EBS2 B_GENE
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
enhancers O
. O

KatA B_LOCATION/B_TIME[MEASURE]
, O
AhpCF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
heme O
biosynthesis O
enzymes O
, O
and O
MrgA B_ENZYME[GENE]/B_BACTERIUM[BIO]
are O
also O
induced O
upon O
entry O
into O
stationary O
phase O
under O
conditions O
of O
iron O
and O
manganese O
limitation O
. O

Although O
the O
Gly252Arg B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
observed O
in O
UM B_DISEASE/B_GENE
: O
JG5 B_MEASURE/B_GENE
is O
non O
- O
conservative B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
it O
was O
not O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
whether O
it O
is O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
or O
a O
polymorphism B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O

This O
region O
shows O
46 O
% O
identity O
with O
the O
calmodulin B_LOCATION/B_GENE
- I_LOCATION/I_GENE
binding I_LOCATION/I_GENE
region I_LOCATION/I_GENE
of O
rat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
brain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ca2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
32 O
% O
identity O
with O
the O
equivalent O
region O
of O
chicken B_GENE
smooth I_GENE
muscle I_GENE
myosin I_GENE
light I_GENE
chain I_GENE
kinase I_GENE
. O

The O
perforated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splint I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gives O
superior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
virtue B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
fact B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
it O
does O
not O
require O
to O
be O
removed O
for O
purposes B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
hygiene B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
can O
thus O
produce O
a O
satisfactory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
result I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
even O
in O
those O
patients B_PERSON
who O
fail O
to O
grasp O
the O
technique B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
removal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
splint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
contains O
31 O
exons O
and O
a O
high O
proportion O
of O
class O
0 O
introns O
, O
alternative O
splicing O
of O
which O
results O
in O
significant O
levels O
of O
variant O
transcripts O
that O
maintain O
the O
original O
open O
reading O
frame O
of O
MRP B_GENE
mRNA I_GENE
. O

issues B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
discussed O
include O
the O
validity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
MMPI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
MF I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scale I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
questions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
representativeness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
whether O
' O
straights B_PERSON/B_ORGANIZATION
' I_PERSON/I_ORGANIZATION
can O
do O
adequate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
homosexuality B_PERSON/B_ORGANIZATION
, O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
heterosexual B_PERSON
and O
homosexual B_PERSON
sexuality I_PERSON
, O
the O
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
subculture B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acculturation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
homosexual B_PERSON
psychological I_PERSON
adjustment I_PERSON
, O
and O
the O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
generate O
typologies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
homosexualities B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

A O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
discussion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
relationship B_PERSON/B_MEASURE
among O
these O
formulas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
given O
. O

lamivudine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
acute B_DISEASE/B_PERSON
hepatitis I_DISEASE/I_PERSON
B I_DISEASE/I_PERSON
infection I_DISEASE/I_PERSON
following O
peripheral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
stem O
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
findings O
suggest O
that O
NMDA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
blockade O
may O
ameliorate O
the O
dyskinetic O
complications O
of O
long O
- O
term O
levodopa O
therapy O
, O
without O
diminishing O
the O
beneficial O
effects O
on O
parkinsonian O
signs O
. O

Furthermore O
, O
the O
secondary B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
responses I_DISEASE_ADJECTIVE[DISEASE]
were O
more O
pronounced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
recover O
from O
them O
seemed O
to O
be O
impaired O
in O
exposed B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
fish I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O
compared O
to O
unexposed B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
distinct O
spatial O
pattern O
of O
expression O
, O
and O
unusual O
amino O
acid O
sequence O
in O
its O
DNA O
binding O
domain O
, O
may O
indicate O
a O
particular O
role O
for O
DTEF B_GENE
- I_GENE
1 I_GENE
in O
cell O
- O
specific O
gene O
regulation O
. O

As O
usual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O
' O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
of O
cephalin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O
slightly O
sensible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
LMW B_DISEASE/B_PROTEIN[GENE]
- O
Hep B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
only B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
Xa B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
. O

Usher B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
1c I_DISEASE/I_GENE
( O
USH1C B_DISEASE/B_LOCATION
) O
is O
a O
congenital B_DISEASE
condition I_DISEASE
manifesting O
profound B_DISEASE
hearing I_DISEASE
loss I_DISEASE
, O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]
of O
vestibular B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
eventual B_DISEASE
retinal I_DISEASE
degeneration I_DISEASE
. O

implantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
contraindicated O
for O
severe B_DISEASE_ADJECTIVE[DISEASE]
dysplasia I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cochlea B_BODY_PART_OR_ORGAN_COMPONENT
and O
for O
the O
recently O
described O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
x B_OTHER/B_MEASURE
- O
linked O
deafness B_DISEASE
with O
deficient B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bone I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
fundus B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
the O
internal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
auditory B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
meatus B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Over O
9 B_MEASURE
kb I_MEASURE
of O
DNA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
obtained O
for O
one B_DISEASE/B_GENE
clone B_DISEASE/I_GENE
( O
A1 B_PROTEIN[GENE]/B_MEASURE
) O
with O
a O
total B_MEASURE
IGS I_MEASURE
length I_MEASURE
of O
approximately O
12 B_MEASURE
. O
4 B_MEASURE
kb I_MEASURE
. O

Scleraxis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
overexpression O
enhanced O
expression O
of O
the O
aggrecan B_GENE
gene I_GENE
, O
which O
is O
not O
normally O
expressed O
at O
high O
levels O
in O
these O
osteoblastic O
cells O
. O

This O
study O
demonstrates O
that O
the O
exposure O
to O
sulphur O
mustard O
results O
in O
very O
low O
androgen O
levels O
and O
hypo O
- O
responsiveness O
to O
GnRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
first O
five O
weeks O
and O
normalization O
by O
the O
twelfth O
week O
after O
injury O
. O

New B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
importance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
optimization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
postoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
course I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
] O
Complications B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
major B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
may O
be O
related O
to O
factors B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
surgical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
endocrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Four B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multicannulated B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Holstein B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steers B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
initial B_MEASURE
BW I_MEASURE
424 I_MEASURE
+ I_MEASURE
/ O
- O
16 B_MEASURE
kg I_MEASURE
) O
were O
used O
in O
a O
4 B_MEASURE
x O
4 B_NUMBER[MEASURE]/B_LOCATION
Latin I_NUMBER[MEASURE]/I_LOCATION
square I_NUMBER[MEASURE]/I_LOCATION
to O
determine O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
supplementation B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
on O
forage B_MEASURE/B_BIO
intake I_MEASURE/I_BIO
, O
site B_LOCATION/B_MEASURE
and O
extent B_MEASURE
of O
digestion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
and O
nutrient B_MEASURE/B_DISEASE
flow I_MEASURE/I_DISEASE
in O
steers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consuming O
dormant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bluestem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
range B_BIO/B_LOCATION
forage I_BIO/I_LOCATION
( O
2 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
CP I_MEASURE
) O
. O

patients B_PERSON/B_LOCATION
with O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
with O
those O
without O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
dermatoglyphic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demostrates O
a O
distal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
triradius I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
small B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
whorl B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
term B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Kartagener I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applies O
to O
this O
syndrome B_DISEASE/B_PERSON
when O
accompanied O
by O
infertility B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
dextrocardia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O
situs B_DISEASE
inversus I_DISEASE
. O

Finally O
, O
we O
tested O
whether O
activation O
by O
either O
of O
these O
factors O
is O
dependent O
on O
components O
of O
the O
SAGA B_GENE/B_LOCATION
complex B_GENE/I_LOCATION
. O

Eight O
of O
the O
17 O
seropositive O
patients O
failed O
to O
develop O
detectable O
hepatitis B_DISEASE
B I_DISEASE
surface I_DISEASE
antibody I_DISEASE
within O
three O
months O
of O
the O
third O
injection O
compared O
with O
only O
one O
of O
the O
18 O
seronegative O
patients O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

The O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
choice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
prophylactic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
among O
asymptomatic B_PERSON/B_BIO
pregnant I_PERSON/I_BIO
women I_PERSON/I_BIO
exposed O
to O
Bacillus B_SPECIES[BIO]/B_DISEASE
anthracis B_SPECIES[BIO]/I_DISEASE
is O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
500 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
a O
day B_TIME[MEASURE]
for O
60 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

Overexpression O
of O
eIF4E B_GENE
transforms O
cells O
, O
and O
mutations O
in O
eIF4E B_GENE
arrest O
cells O
in O
G O
, O
in O
cdc33 B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O

benzyl B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alcohol I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
neonates B_BIO/B_PERSON
. O

repression O
of O
the O
herpes B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simplex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
its O
gene O
product O
( O
ICP4 B_GENE/B_DISEASE
) O
within O
the O
context O
of O
the O
viral O
genome O
is O
conditioned O
by O
the O
distance O
and O
stereoaxial O
alignment O
of O
the O
ICP4 B_GENE/B_LOCATION
DNA I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
relative O
to O
the O
TATA O
box O
. O

As O
anticipated O
, O
both O
intracellular O
p54 B_GENE
- O
SAPKbeta B_GENE
activation O
and O
Bcl B_GENE
- I_GENE
2 I_GENE
phosphorylation O
are O
blocked O
by O
co O
- O
transfection O
with O
the O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O
phosphatase O
MKP3 B_GENE
/ O
PYST1 B_GENE/B_MEASURE
. O

relation O
between O
circulating O
immune O
complexes O
and O
serum B_DISEASE
ferritin I_DISEASE
in O
hemosiderosis O
of O
different O
etiologies O
. O

patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
S B_OTHER/B_MEASURE
) O
: O
Two B_NUMBER[MEASURE]/B_ENT
hundred I_NUMBER[MEASURE]/I_ENT
thirty I_NUMBER[MEASURE]/I_ENT
- O
eight B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
RPLs B_DISEASE/B_ORGANISM_FUNCTION
, O
48 B_TIME[MEASURE]
patients I_TIME[MEASURE]
with O
recurrent B_DISEASE_ADJECTIVE[DISEASE]
IVF I_DISEASE_ADJECTIVE[DISEASE]
- O
ET B_DISEASE/B_ORGANISM_FUNCTION
failure B_DISEASE/I_ORGANISM_FUNCTION
and O
179 B_PERSON/B_DISEASE
nonpregnant I_PERSON/I_DISEASE
and O
120 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
pregnant B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
control B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
group B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
women B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
metabolic B_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
thiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diuretics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
however O
, O
can O
be O
limited O
by O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Teboroxime B_PERSON/B_LOCATION
is O
a O
new B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
boronic I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acid I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adduct I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
technetium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dioxime I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BATO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
compound B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
demonstrates O
favorable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
preliminary B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

The O
total B_MEASURE
area I_MEASURE
under O
the O
blood B_MEASURE
glucose I_MEASURE
curve I_MEASURE
over O
the O
initial B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
value B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
not O
altered O
2 B_MEASURE/B_LOCATION
h O
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
with O
SH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
209 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
Neogynon B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment O
of O
excessive O
bleeding O
after O
cardiopulmonary O
bypass O
was O
based O
on O
an O
algorithm O
using O
point O
- O
of O
- O
care O
testing O
with O
whole O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prothrombin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
time O
, O
activated O
partial O
thromboplastin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O
, O
heparinase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
activated O
clotting O
time O
, O
and O
platelet O
count O
. O

In O
all O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
large B_MEASURE
fraction I_MEASURE
of O
soluble B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Al I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
became O
insoluble B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
stomach B_BODY_PART_OR_ORGAN_COMPONENT
after O
ingestion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

To O
assess O
the O
safety O
of O
the O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
converting I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
enalapril O
a O
multicenter O
, O
open O
, O
randomized O
, O
prazosin O
- O
controlled O
trial O
was O
designed O
comparing O
the O
incidence O
and O
severity O
of O
symptomatic O
hypotension O
on O
the O
first O
day O
of O
treatment O
. O

glucose O
may O
reduce O
slightly O
the O
pool O
of O
amino O
nitrogen O
available O
for O
albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
urea O
synthesis O
by O
diverting O
some O
of O
the O
infused O
amino O
acids O
from O
protein O
synthesis O
by O
the O
liver O
to O
muscle O
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
previously O
reported O
the O
first O
isolation O
of O
a O
c B_DISEASE
- I_DISEASE
myc I_DISEASE
- I_DISEASE
null I_DISEASE
cell O
line O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrated O
that O
for O
both O
S B_LOCATION/B_DISEASE
. O
europaea B_SPECIES[BIO]/B_DISEASE
and O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
prostrata B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
total B_MEASURE
number I_MEASURE
of O
seeds B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
germinated O
decreased O
throughout O
the O
growing O
season B_TIME[MEASURE]
. O

A O
nationwide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
record I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
linkage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
Finnish B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
twin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
FTCS B_MEASURE/B_DISEASE
) O
with O
the O
Hospital B_ORGANIZATION/B_LOCATION
discharge I_ORGANIZATION/I_LOCATION
registry I_ORGANIZATION/I_LOCATION
and O
the O
registry B_TIME[MEASURE]/B_ORGANIZATION
of O
Rights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Free B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
medication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
presented O
. O

Considering O
these O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
facts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
together O
, O
we O
propose O
that O
vasectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O
lead O
to O
decrease O
in O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
prostatic B_DISEASE
tumors I_DISEASE
- O
a O
disease B_DISEASE
that O
claims O
nearly O
22 B_MEASURE
, O
000 B_MEASURE/B_ENT
lives I_MEASURE/I_ENT
each O
year B_TIME[MEASURE]
in O
the O
United B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
States I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
alone O
. O

antibodies O
specific O
to O
the O
different O
members O
of O
the O
Jun B_PERSON/B_GENE
and O
Fos B_GENE
family I_GENE
of I_GENE
transcription I_GENE
factors I_GENE
show O
that O
, O
in O
gel O
retardation O
assays O
, O
a O
Jun B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
like I_PROTEIN[GENE]/I_MEASURE
factor I_PROTEIN[GENE]/I_MEASURE
is O
a O
component O
of O
the O
H3 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
had O
been O
diagnosed O
with O
severe B_DISEASE/B_GENE
aplastic I_DISEASE/I_GENE
anemia I_DISEASE/I_GENE
1 I_DISEASE/I_GENE
year I_DISEASE/I_GENE
previously O
and O
, O
while O
hospitalized O
, O
had O
received O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prednisolone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pulse I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
which O
was O
not O
successful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
recombinant B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
L I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
F I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
as O
active O
as O
the O
previously O
purified O
wild O
type O
enzyme O
and O
contains O
no O
detectable O
RNA O
component O
. O

Cord B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
BACTEC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
7H12 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
medium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
presumptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Mycobacterium B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
tuberculosis I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
complex I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
site O
- O
specific O
integration O
of O
the O
ITR O
- O
flanked O
DNA O
was O
also O
detected O
by O
PCR O
amplification O
of O
the O
ITR B_GENE/B_LOCATION
- I_GENE/I_LOCATION
aavs1 I_GENE/I_LOCATION
junction I_GENE/I_LOCATION
in O
transduced O
human O
fibroblasts O
. O

Oct B_GENE
- I_GENE
1 I_GENE
is O
a O
ubiquitously O
expressed O
regulatory O
gene O
of O
the O
POU B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
domain I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
family I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O

In O
both O
study O
stages O
. O
post O
- O
exposure O
treatment O
consisted O
of O
five O
injections O
of O
vaccine O
[ O
( O
D O
) O
ays O
0 O
, O
3 O
, O
7 O
, O
14 O
, O
28 O
] O
, O
together O
with O
a O
dose O
of O
rabies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RIG B_LOCATION/B_MEASURE
) O
of O
equine O
or O
human O
origin O
on O
D0 O
. O

( O
3 O
) O
With O
the O
exception B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
anteroposterior B_LOCATION/B_MEASURE
direction I_LOCATION/I_MEASURE
of O
layers B_LOCATION/B_MEASURE
II I_LOCATION/I_MEASURE
- O
- O
III B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
and O
the O
mediolateral B_LOCATION/B_MEASURE
direction I_LOCATION/I_MEASURE
of O
layer B_BODY_PART_OR_ORGAN_COMPONENT
IV I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
vertical B_MEASURE/B_LOCATION
conductivity I_MEASURE/I_LOCATION
of O
the O
cortex B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
was O
always O
greater B_MEASURE
than O
either O
of O
the O
horizontal B_LOCATION
conductivities I_LOCATION
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigated O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
a O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NaCl I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diet I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
social B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isolation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O
increase O
systolic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
blood I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
SBP B_LOCATION/B_DISEASE
) O
and O
endogenous B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligands B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SPL B_LOCATION/B_ORGANIZATION
) O
, O
ouabainlike B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OLC B_LOCATION/B_DISEASE
) O
, O
and O
marinobufagenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MBG B_PROTEIN[GENE]/B_LOCATION
) O
. O

The O
relationship B_PERSON/B_MEASURE
between O
polymorphonuclear B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granulocytes I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
cartilage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
destruction I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
in O
rheumatoid B_DISEASE/B_SPECIES[BIO]
arthritis B_DISEASE/I_SPECIES[BIO]
. O

It O
is O
suggested O
that O
the O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
weight B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
food B_DISEASE/B_GENE
intake I_DISEASE/I_GENE
and O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
brain B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MOPEG I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
SO4 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
induced O
by O
cyanamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflect O
possible B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anorectic B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
properties B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Twenty B_NUMBER[MEASURE]
- O
two B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
showed O
ST B_LOCATION/B_NUMBER[MEASURE]
- O
segment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depression I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
AEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
34 B_NUMBER[MEASURE]
( O
49 B_MEASURE
% I_MEASURE
) O
on O
Ext B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
virus O
must O
progress O
past O
the O
immediate O
- O
early O
phase O
and O
express O
an O
early B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
activation O
of O
cyclin B_GENE/B_DISEASE
E I_GENE/I_DISEASE
expression O
. O

In O
CYP7A1 B_GENE/B_PERSON
transgenic O
mice O
, O
livers O
contained O
approximately O
3 O
- O
fold O
more O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

adenocarcinoma B_DISEASE/B_PERSON
and O
large B_DISEASE/B_LOCATION
cell I_DISEASE/I_LOCATION
carcinoma I_DISEASE/I_LOCATION
have O
a O
worse B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
squamous B_DISEASE/B_PERSON
cell I_DISEASE/I_PERSON
carcinoma I_DISEASE/I_PERSON
in O
the O
T1N1 B_PROTEIN[GENE]/B_DISEASE
and O
T2N1 B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
subsets B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O

In O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
during O
the O
pain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
free I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
26 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
81 B_PERSON
patients I_PERSON
had O
positive B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thallium I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
whereas O
20 B_TIME[MEASURE]
patients I_TIME[MEASURE]
had O
an O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
ECG I_DISEASE_ADJECTIVE[DISEASE]
at O
that O
time B_MEASURE/B_LOCATION
; O
during O
angina B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
transient B_DISEASE/B_LOCATION
ECG I_DISEASE/I_LOCATION
changes I_DISEASE/I_LOCATION
. O

The O
prototype B_PERSON/B_ORGANIZATION
now O
structures O
oncology B_DISEASE
- O
related O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
available I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O
the O
Internet B_ORGANIZATION/B_LOCATION
and O
also O
places O
resources B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintained O
locally O
at O
users B_MEASURE/B_LOCATION
' B_MEASURE/I_LOCATION
disposal B_MEASURE/I_LOCATION
. O

binding O
of O
the O
TorR B_GENE/B_BIO
regulator I_GENE/I_BIO
to O
cis O
- O
acting O
direct O
repeats O
activates O
tor B_GENE/B_BACTERIUM[BIO]
operon I_GENE/I_BACTERIUM[BIO]
expression O
. O

For O
the O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
only O
aerobic B_NUMBER[MEASURE]/B_ORGANIZATION
microbial I_NUMBER[MEASURE]/I_ORGANIZATION
degradation I_NUMBER[MEASURE]/I_ORGANIZATION
systems I_NUMBER[MEASURE]/I_ORGANIZATION
have O
been O
reported O
so O
far O
. O

asymptomatic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ischaemia B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
daily B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
life I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
coronary B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
artery B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
disease B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
redundant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
a O
consensus O
casein B_ENZYME[GENE]
kinase I_ENZYME[GENE]
II I_ENZYME[GENE]
( O
CKII B_GENE/B_MEASURE
) O
site O
and O
, O
using O
purified O
wild O
- O
type O
and O
mutant O
proteins O
, O
we O
show O
that O
it O
is O
the O
main O
CKII B_LOCATION/B_PERSON
site I_LOCATION/I_PERSON
in O
the O
body O
of O
the O
N O
- O
terminal O
complex O
- O
forming O
region O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Phase B_LOCATION/B_ORGANIZATION
III I_LOCATION/I_ORGANIZATION
, O
which O
has O
a O
single B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
design I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
- O
the O
controlled O
, O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
- O
Phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
requires O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
designs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
each O
of O
the O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
questions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Treatment O
with O
polyinosinic O
- O
polycytidylic O
acid O
to O
induce O
expression O
of O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
complete O
disruption O
of O
the O
Arnt B_GENE
gene I_GENE
and O
loss O
of O
ARNT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
messenger I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
mRNA O
) O
expression O
in O
liver O
. O

Physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
map I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
sonchus B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
yellow I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
net I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
plant B_SPECIES[BIO]/B_LOCATION
rhabdovirus O
with O
six B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
conserved B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
junction B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Tubular O
dysfunction O
in O
renal O
lithiasis O
: O
cause O
or O
consequence O
? O
] O
To O
investigate O
whether O
overall O
tubular O
dysfunction O
is O
encountered O
in O
a O
particular O
subgroup O
of O
patients O
with O
urolithiasis O
, O
the O
following O
parameters O
of O
renal O
tubular O
function O
have O
been O
measured O
in O
fasting O
morning O
urine O
in O
124 O
male O
stone O
formers O
: O
excretion O
of O
lysozyme B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
gamma B_LOCATION/B_PROTEIN[GENE]
- I_LOCATION/I_PROTEIN[GENE]
GT I_LOCATION/I_PROTEIN[GENE]
) O
, O
fractional O
excretion O
( O
Fe O
) O
or O
glucose O
, O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
bicarbonate O
after O
an O
alkali O
load O
, O
and O
theoretical O
phosphate O
threshold O
( O
TmP O
/ O
GFR O
) O
. O

interaction O
between O
the O
tobacco O
DNA O
- O
binding O
activity O
CBF B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
the O
cyt B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Agrobacterium O
tumefaciens O
T O
- O
DNA O
gene O
T B_LOCATION/B_PERSON
- I_LOCATION/I_PERSON
CYT I_LOCATION/I_PERSON
correlates O
with O
cyt B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
directed O
gene O
expression O
in O
multiple O
tobacco O
tissue O
types O
. O

As O
expected O
, O
the O
QOLS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
lower B_MEASURE
correlation I_MEASURE
with O
physical B_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
( O
r B_OTHER/B_PROTEIN[GENE]
= O
0 B_NUMBER[MEASURE]
. O
24 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
000 B_MEASURE
) O
and O
self B_PERSON/B_LOCATION
- O
reported O
symptoms B_DISEASE
( O
r B_OTHER/B_GENE
= O
- O
0 B_MEASURE
. O
20 B_MEASURE
, O
p O
< B_MEASURE
0 I_MEASURE
. O
001 B_MEASURE
) O
, O
and O
a O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
mental B_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
. O
52 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
000 B_MEASURE
) O
. O

The O
N1 B_PROTEIN[GENE]/B_DISEASE
- O
P2 B_MEASURE
amplitudes I_MEASURE
of O
the O
AEP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
decreased O
with O
increasing O
strength B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
muscular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
innervation B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

SN B_MEASURE/B_PROTEIN[GENE]
- O
38 B_MEASURE/B_BIO
rebound B_MEASURE/I_BIO
concentrations B_MEASURE/I_BIO
were O
observed O
in O
many B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
courses I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
at O
about O
0 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
to O
1 B_MEASURE/B_ENT
hour I_MEASURE/I_ENT
following O
the O
end B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
i O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
is O
suggestive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
enterohepatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recycling I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

sequence O
analysis O
of O
AEBP2 B_GENE
cDNA I_GENE
revealed O
that O
it O
encodes O
a O
protein O
containing O
three O
Gli B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
Kruppel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
Cys2 O
- O
His2 O
) O
- O
type O
zinc O
fingers O
. O

In O
the O
case O
of O
the O
pT181 O
plasmid O
, O
inactivation O
of O
the O
initiator B_ENZYME[GENE]
RepC I_ENZYME[GENE]
protein I_ENZYME[GENE]
occurs O
by O
the O
attachment O
of O
an O
oligonucleotide O
to O
its O
active O
tyrosine O
residue O
. O

Xanthoepocin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antibiotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
Penicillium B_LOCATION/B_BACTERIUM[BIO]
simplicissimum I_LOCATION/I_BACTERIUM[BIO]
IFO5762 I_LOCATION/I_BACTERIUM[BIO]
. O

Extracellular B_GENE
regulated I_GENE
kinases I_GENE
( I_GENE
ERK I_GENE
) I_GENE
1 I_GENE
and O
ERK2 B_GENE/B_MEASURE
are O
authentic O
substrates O
for O
the O
dual B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specificity I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
VHR I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Leukocytoclasic B_DISEASE_ADJECTIVE[DISEASE]
vasculitis I_DISEASE_ADJECTIVE[DISEASE]
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE
captopril I_MEASURE
. O

H B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Truncations O
from O
Hip B_GENE/B_DISEASE
' O
s O
N O
terminus O
resulted O
in O
an O
apparent O
loss O
of O
Hip B_GENE/B_DISEASE
homo O
- O
oligomerization O
, O
but O
these O
mutants O
retained O
association O
with O
hsp70 B_GENE
and O
were O
recovered O
in O
receptor O
complexes O
. O

The O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CNAPs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O
by O
CS2 B_DISEASE/B_GENE
is O
under O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
very O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
PC I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lan I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
the O
basis B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
hospital B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
was O
tragically O
highlighted O
by O
the O
death B_PERSON/B_DISEASE
of O
a O
17 B_PERSON
year I_PERSON
old I_PERSON
dental I_PERSON
nurse I_PERSON
after O
taking O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tablet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
encoded O
by O
a O
900 B_NUMBER[MEASURE]
- O
base B_MEASURE/B_LOCATION
pair I_MEASURE/I_LOCATION
- O
long B_GENE/B_LOCATION
mRNA I_GENE/I_LOCATION
that O
is O
expressed O
in O
the O
glandular B_BODY_PART_OR_ORGAN_COMPONENT
epithelial I_BODY_PART_OR_ORGAN_COMPONENT
cells I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
endometrium B_BODY_PART_OR_ORGAN_COMPONENT
in O
a O
cyclic B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
manner I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O
in O
addition B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
it O
is O
found O
in O
the O
mucosal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
fallopian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
report O
, O
we O
describe O
a O
patient O
with O
renal O
cell O
carcinoma O
who O
experienced O
ventricular O
tachycardia O
while O
undergoing O
treatment O
with O
high O
- O
dose O
bolus O
IL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Four B_NUMBER[MEASURE]/B_PERSON
antifungal I_NUMBER[MEASURE]/I_PERSON
agents I_NUMBER[MEASURE]/I_PERSON
were O
compared O
: O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
flucytosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
miconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
regulatory O
genes O
cnrYXH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
cloned O
, O
overexpressed O
, O
and O
purified O
in O
Escherichia O
coli O
. O

Examination O
of O
the O
Coomassie O
- O
stained O
gels O
revealed O
that O
the O
capsid O
- O
like O
particles O
composed O
of O
the O
N11 B_PERSON/B_VIRUS[BIO]
- I_PERSON/I_VIRUS[BIO]
VP1 I_PERSON/I_VIRUS[BIO]
protein O
did O
not O
contain O
any O
host O
- O
derived O
histones B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conversion O
of O
an O
NF B_GENE
- I_GENE
kappaB I_GENE
into O
a O
GABP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O
site O
is O
likely O
to O
have O
occurred O
also O
during O
the O
worldwide O
spread O
of O
HIV O
- O
1 O
, O
as O
we O
noticed O
the O
same O
LTR O
modification O
in O
subtype O
E O
isolates O
from O
Thailand O
. O

protein O
binding O
to O
UAS1MLS1 B_GENE
was O
observed O
with O
extracts O
from O
derepressed O
but O
not O
from O
repressed O
cells O
, O
and O
could O
be O
competed O
for O
by O
an O
excess O
of O
the O
unlabelled O
CSRE O
( O
ICL1 B_PROTEIN[GENE]/B_LOCATION
) O
sequence O
. O

We O
then O
isolated O
the O
full O
- O
length O
coding O
region O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BACH1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
expressed O
sequence O
tags O
, O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
rapid O
amplification O
of O
cDNA O
ends O
. O

authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O
the O
anatomical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
inferior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
mesenteric I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
its O
branches B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
62 B_PERSON/B_BIO
human B_PERSON/I_BIO
fetus B_PERSON/I_BIO
. O

The O
7 B_GENE
. I_GENE
2 I_GENE
kb I_GENE
EcoRI I_GENE
fragment I_GENE
of I_GENE
AfMNPV I_GENE
was O
cloned O
and O
the O
nucleotide O
sequences O
of O
the O
polyhedrin B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
coding O
region O
and O
its O
flanking O
regions O
were O
determined O
. O

1 B_NUMBER[MEASURE]
. O

The O
increments O
in O
median O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
secretin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O
were O
1 O
. O
6 O
, O
3 O
. O
0 O
, O
and O
6 O
. O
4 O
pmol O
x O
1 O
( O
- O
1 O
) O
after O
secretin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
125 O
, O
250 O
and O
500 O
fmol O
x O
kg O
- O
1 O
, O
and O
the O
corresponding O
15 O
- O
min O
bicarbonate O
output O
283 O
, O
442 O
, O
and O
1435 O
micromol O
, O
respectively O
. O

The O
resulting O
threshold B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
elevation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
curves I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
fell O
into O
a O
small B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
distinct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
suggesting O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
discrete B_DISEASE/B_MEASURE
spatial I_DISEASE/I_MEASURE
frequency I_DISEASE/I_MEASURE
mechanisms I_DISEASE/I_MEASURE
in O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
central B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
vision B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O

Because O
c B_GENE
- I_GENE
myb I_GENE
encodes O
a O
transcriptional O
activator O
that O
functions O
via O
DNA O
binding O
, O
it O
is O
likely O
that O
c B_GENE
- I_GENE
myb I_GENE
exerts O
its O
biological O
activity O
by O
regulating O
the O
transcription O
of O
genes O
required O
for O
DNA O
synthesis O
and O
cell O
cycle O
progression O
. O

The O
rest B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
3 B_GENE/B_LOCATION
' I_GENE/I_LOCATION
untranslated I_GENE/I_LOCATION
sequences I_GENE/I_LOCATION
were O
common B_DISEASE_ADJECTIVE[DISEASE]
to O
both O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Coexpression O
of O
c B_GENE
- I_GENE
Rel I_GENE
in O
combination O
with O
ATF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CREB2 B_GENE
, O
or O
ATF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
CREB2 B_GENE/B_MEASURE
leads O
to O
synergistic O
transactivation O
of O
a O
CD28RE B_GENE
- I_GENE
TRE I_GENE
reporter I_GENE
plasmid O
in O
quiescent O
Jurkat O
T O
- O
cells O
. O

Conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
toxicological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
considerations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O
that O
the O
adverse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
effects B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
any O
necessary B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increase I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
coal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combustion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effluents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O
be O
greatest B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
per O
unit B_ORGANIZATION/B_LOCATION
of O
coal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
those O
areas B_LOCATION
which O
are O
most O
heavily O
populated B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
have O
the O
highest B_MEASURE/B_LOCATION
preexisting B_MEASURE/I_LOCATION
levels B_MEASURE/I_LOCATION
of O
the O
gas B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
aerosol B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
genes O
on O
each O
chromosome O
involved O
in O
this O
translocation O
have O
been O
identified O
as O
the O
transcription O
factor O
- O
encoding O
genes O
PAX3 B_GENE/B_DISEASE
and O
FKHR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
search O
was O
conducted O
for O
suppressors O
of O
the O
inositol O
auxotrophic O
phenotype O
of O
the O
ino4 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
8 I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O
yeast O
. O

anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
induced O
by O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE
- O
1 B_NUMBER[MEASURE]
, O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
50 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
micrograms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
thiamylal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
150 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
250 B_MEASURE
mg I_MEASURE
, O
and O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
kg B_MEASURE
- O
1 B_NUMBER[MEASURE]
, O
and O
maintained O
with O
nitrous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
67 B_MEASURE
: O
33 B_MEASURE
) O
supplemented O
with O
repeated O
i O
. O
v B_GENE/B_LOCATION
. O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
within O
15 B_MEASURE/B_LOCATION
micrograms I_MEASURE/I_LOCATION
. O
kg B_MEASURE
- O
1 B_NUMBER[MEASURE]
) O
. O

Complexities B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
host B_PERSON/B_BIO
- O
pathogen B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
during O
actual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O
account O
for O
the O
difficulties B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
demonstrating O
this O
phenomena B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
novel O
TRPC7 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
could O
be O
a O
candidate O
gene O
for O
genetic O
disorders O
such O
as O
bipolar O
affective O
disorder O
, O
nonsyndromic O
hereditary O
deafness O
, O
Knobloch O
syndrome O
, O
and O
holoprosencephaly O
, O
which O
were O
mapped O
to O
this O
region O
. O

Paradoxically O
, O
loop O
3i O
from O
the O
M1Ach B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
muscarinic I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
maximally O
inhibited O
GnRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O
- O
stimulated O
Camp O
accumulation O
and O
PRL B_GENE
release O
by O
40 O
% O
( O
both O
effects O
mediated O
through O
activation O
of O
the O
Gs B_PROTEIN[GENE]/B_LOCATION
protein I_PROTEIN[GENE]/I_LOCATION
) O
. O

We O
present O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
patient B_PERSON/B_BIO
who O
presented O
an O
unusually O
large B_DISEASE/B_MEASURE
mucoid I_DISEASE/I_MEASURE
cyst I_DISEASE/I_MEASURE
measuring O
38 B_MEASURE
x O
25 B_MEASURE
mm I_MEASURE
in O
an O
uncommon B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
localization I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
, O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT
maxillary I_BODY_PART_OR_ORGAN_COMPONENT
. O

Acoustic B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
property B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
oxide B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
superconductor I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BaPb1 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
xBixO3 B_MEASURE
by O
the O
sphere B_LOCATION/B_MEASURE
- O
resonance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
7 B_MEASURE/B_SPORT[ENT]
men I_MEASURE/I_SPORT[ENT]
and O
1 B_PERSON
woman I_PERSON
who O
died O
suddenly O
the O
functionally O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
the O
sino B_DISEASE/B_GENE
- O
auricular B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
area I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
the O
subendocardial B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
layers B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
obtained O
by O
necropsy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O
more B_TIME[MEASURE]/B_LOCATION
than O
3 B_MEASURE
h O
after O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
then O
prepared O
for O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

IGF B_PERSON/B_GENE
- I_PERSON/I_GENE
I I_PERSON/I_GENE
levels O
were O
measured O
in O
the O
CSF O
of O
11 O
children O
with O
autism O
( O
4 O
females O
, O
7 O
males O
; O
mean O
age O
3 O
. O
8 O
years O
, O
SD O
1 O
. O
1 O
) O
using O
a O
sensitive O
radioimmunoassay O
method O
and O
compared O
with O
levels O
in O
11 O
control O
participants O
( O
6 O
females O
, O
5 O
males O
; O
mean O
age O
3 O
. O
8 O
years O
) O
. O

In O
a O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
safety I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transrectal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HIFU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
minimally O
invasive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modality I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
patients B_PERSON/B_BIO
with O
symptomatic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
benign I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
prostatic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hyperplasia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
BPH B_DISEASE
; O
n O
= O
102 B_MEASURE
) O
was O
determined O
. O

Three O
high O
- O
amylose O
rice O
varieties O
, O
IR42 O
, O
IR36 O
, O
and O
IR62 O
, O
with O
similar O
chemical O
composition O
including O
amylose O
content O
( O
26 O
. O
7 O
- O
27 O
. O
0 O
% O
) O
, O
were O
cooked O
under O
the O
same O
conditions O
and O
tested O
for O
in O
vitro O
digestibility O
as O
well O
as O
blood O
glucose O
and O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O
in O
healthy O
human O
volunteers O
. O

Slowly O
adapting O
type B_MEASURE/B_DISEASE
I O
mechanoreceptor O
discharge B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
a O
function B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
force B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
displacement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
glabrous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
skin I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
raccoon B_SPECIES[BIO]
and O
squirrel B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
monkey I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
hand I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Using O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
luciferase B_GENE
reporter O
recombinants O
, O
we O
have O
previously O
determined O
that O
important O
beta B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AR I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O
elements O
controlling O
expression O
within O
the O
C6 O
glioma O
cell O
line O
are O
contained O
within O
the O
region O
- O
396 O
to O
- O
299 O
, O
relative O
to O
the O
translational O
start O
site O
. O

FACS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
MCs B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O
reached O
middle O
to O
late B_MEASURE/B_LOCATION
G1 B_MEASURE/I_LOCATION
phase B_MEASURE/I_LOCATION
of O
cell B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progression B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
this O
timepoint B_TIME[MEASURE]/B_LOCATION
. O

Our O
case O
, O
however O
, O
had O
no O
histologic O
evidence O
of O
malignancy O
, O
no O
serum B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fetoprotein I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
7 O
months O
of O
age O
, O
and O
no O
recurrence O
at O
1 O
years O
. O

Analysis O
of O
tobacco O
mRNA O
using O
the O
ACBF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
probe O
showed O
that O
while O
ACBF B_GENE
mRNA I_GENE
was O
present O
in O
all O
tissues O
examined O
, O
the O
highest O
transcript O
accumulation O
occurred O
in O
stem O
tissues O
. O

Cotransfection O
experiments O
revealed O
that O
both O
hGATA B_GENE
- I_GENE
4 I_GENE
and O
PMA O
/ O
A23187 O
stimulation O
are O
necessary O
for O
the O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
5 I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
activation O
. O

Here O
we O
show O
that O
expression O
of O
KRAB B_GENE/B_DISEASE
domain I_GENE/I_DISEASE
suppresses O
in O
vivo O
the O
activating O
function O
of O
various O
defined O
activating B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
we O
demonstrate O
that O
the O
KRAB B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
specifically O
silences O
the O
activity O
of O
promoters O
whose O
initiation O
is O
dependent O
on O
the O
presence O
of O
a O
TATA O
box O
. O

Adult B_PERSON/B_TIME[MEASURE]
- O
onset B_DISEASE
parkinsonism I_DISEASE
has O
appeared O
in O
several B_NUMBER[MEASURE]/B_PERSON
previously O
unaffected B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O
DRD B_DISEASE/B_GENE
suggesting O
that O
this O
may O
be O
an O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phenotypical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
disease B_DISEASE/B_GENE
. O

We O
tested O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
antifungal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
adherence B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Candida B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
albicans B_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
enterocolitis B_DISEASE
, O
pathological B_DISEASE_ADJECTIVE[DISEASE]
microbial I_DISEASE_ADJECTIVE[DISEASE]
flora I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
stool B_BODY_PART_OR_ORGAN_COMPONENT
and O
changes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
colon B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucosa I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
absent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
results O
support O
an O
in O
vivo O
interaction O
between O
Nck B_GENE
and O
CKI B_GENE
- I_GENE
gamma2 I_GENE
and O
suggest O
that O
CKI B_GENE/B_PERSON
- I_GENE/I_PERSON
gamma2 I_GENE/I_PERSON
could O
be O
involved O
in O
signaling O
pathways O
downstream O
of O
RTKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nitrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
carbohydrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indices I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cooled O
under O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
an O
altered B_DISEASE/B_LOCATION
gaseous I_DISEASE/I_LOCATION
environment I_DISEASE/I_LOCATION
. O

reactivation B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hepatitis B_DISEASE
B I_DISEASE
virus I_DISEASE
replication I_DISEASE
is O
a O
rare B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
chronic B_DISEASE
hepatitis I_DISEASE
B I_DISEASE
. O

A O
minimal O
region O
which O
stimulates O
origin O
function O
mapped O
to O
50 O
amino O
acids O
within O
the O
C O
- O
terminus O
of O
Abf1p B_GENE
. O

cutaneous B_DISEASE/B_PERSON
melanoma I_DISEASE/I_PERSON
and O
bilateral B_DISEASE
retinoblastoma I_DISEASE
. O

Treatment O
of O
JEA2 O
cells O
with O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O
CBLB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphorylation O
as O
well O
. O

Phosphorylation O
by O
Cdc28 B_GENE
activates O
the O
Cdc20 B_GENE
- O
dependent O
activity O
of O
the O
anaphase O
- O
promoting O
complex O
. O

Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
After O
eligibility B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
patients B_PERSON
were O
randomly O
allocated O
in O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
M B_OTHER/B_LOCATION
= O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
30 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]/B_LOCATION
over O
1 B_NUMBER[MEASURE]/B_ENT
hour I_NUMBER[MEASURE]/I_ENT
, O
followed O
by O
5 B_MEASURE
. O
4 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
. O
h O
- O
1 B_NUMBER[MEASURE]
for O
23 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
N B_OTHER/B_LOCATION
= O
nimodipine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
015 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
. O
h O
- O
1 B_NUMBER[MEASURE]
over O
2 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
followed O
by O
0 B_MEASURE
. O
03 B_MEASURE/B_PERSON
mg I_MEASURE/I_PERSON
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
. O
h O
- O
1 B_NUMBER[MEASURE]
for O
7 B_ENT/B_LOCATION
days I_ENT/I_LOCATION
, O
MN B_LOCATION/B_DISEASE
or O
P B_PROTEIN[GENE]/B_LOCATION
. O

The O
amount B_MEASURE/B_LOCATION
of O
overlap B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
VFI B_LOCATION/B_DISEASE
, O
EF B_LOCATION/B_DISEASE
, O
and O
RVF B_LOCATION/B_MEASURE
values I_LOCATION/I_MEASURE
among O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O
considerable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

After O
5 B_MEASURE
, O
850 B_MEASURE
C14 I_MEASURE
BP I_MEASURE
, O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
Acer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
stands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
could O
be O
attributed O
to O
fire B_DISEASE
as O
suggested O
by O
the O
strong B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
Betula B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
by O
the O
delayed O
expansion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
Pinus B_BIO/B_LOCATION
cembra I_BIO/I_LOCATION
. O

Assays O
of O
APRE O
- O
luciferase B_GENE
reporter O
plasmids O
transfected O
into O
HepG2 O
cells O
show O
that O
a O
mutated O
APRE O
that O
binds O
only O
BPi B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O
as O
an O
IL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inducible O
enhancer O
, O
whereas O
a O
mutated O
APRE O
that O
binds O
only O
BPc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
. O

RNA O
unwinding O
in O
U4 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
U6 B_MEASURE
snRNPs O
requires O
ATP O
hydrolysis O
and O
the O
DEIH O
- O
box O
splicing O
factor O
Brr2 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Several B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
resembling O
binding B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sites I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
for O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
and O
fat B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
transcription B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
were O
identified O
within O
1 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kb I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upstream O
and O
downstream B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
gene B_GENE/B_LOCATION
. O

Northern O
blot O
analysis O
linked O
Plk B_GENE
expression O
to O
the O
proliferative O
activity O
of O
cells O
and O
tissues O
. O

It O
also O
showed O
which O
amino O
acid O
residues O
would O
contact O
an O
extended O
TATA O
box O
with O
a O
B B_GENE
recognition I_GENE
element I_GENE
, O
and O
evolutionary O
conservation O
of O
the O
TBP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
TFB B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DNA O
complex O
orientation O
between O
two O
archaeal O
organisms O
with O
widely O
different O
optimal O
temperature O
for O
growth O
( O
37 O
and O
100 O
degrees O
C O
) O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
and O
without O
attenuating O
media B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
performed O
, O
and O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
to O
- O
defect B_MEASURE/B_DISEASE
count B_MEASURE/I_DISEASE
ratios B_MEASURE/I_DISEASE
and O
defect B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sizes B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
dual B_NUMBER[MEASURE]/B_LOCATION
- O
isotope B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SPECT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
compared O
to O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
to O
- O
defect B_MEASURE/B_DISEASE
count B_MEASURE/I_DISEASE
ratios B_MEASURE/I_DISEASE
and O
defect B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sizes B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
single B_NUMBER[MEASURE]/B_PERSON
- O
isotope B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
201Tl B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
SPECT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

comparison O
of O
this O
gene O
with O
the O
available O
databases O
reveals O
very O
significant O
homology O
to O
the O
ETS B_MEASURE/B_GENE
factor I_MEASURE/I_GENE
PE I_MEASURE/I_GENE
- I_MEASURE/I_GENE
1 I_MEASURE/I_GENE
and O
probable O
near O
- O
identity O
with O
the O
recently O
cloned O
factor O
ERF B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients O
with O
Eales O
' O
disease O
, O
chorioretinitis O
, O
central O
serous O
retinopathy O
, O
or O
malignant O
choroidal O
melanoma O
were O
tested O
for O
HLA B_GENE/B_VIRUS[BIO]
antigen O
deviation O
. O

Copyright B_LOCATION/B_PERSON
1999 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

The O
1 B_MEASURE
. O
5 B_MEASURE
- O
MB B_MEASURE/B_LOCATION
region I_MEASURE/I_LOCATION
was O
covered O
by O
137 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmids I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
a O
minimum B_MEASURE/B_LOCATION
overlap I_MEASURE/I_LOCATION
set I_MEASURE/I_LOCATION
of O
52 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assigned O
to O
17 B_MEASURE
bins I_MEASURE
and O
9 B_LOCATION/B_PERSON
contigs I_LOCATION/I_PERSON
. O

Similarly O
, O
beta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptors I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blockade O
has O
been O
shown O
to O
be O
of O
value O
in O
achieving O
continence O
in O
a O
small O
group O
of O
patients O
. O

estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
mood B_DISEASE/B_ORGANISM_FUNCTION
, O
sexual B_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
, O
target B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
end I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
organs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
cognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
may O
play O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
etiology B_DISEASE
of O
Alzheimer B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
Disease I_DISEASE/I_LOCATION
by O
acting O
to O
prevent O
amyloid B_DISEASE
plaque I_DISEASE
formation I_DISEASE
, O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cholinergic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
neurotransmitter I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

These O
data O
also O
demonstrate O
that O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TPA O
activate O
MBP B_GENE
/ O
MAP2 B_GENE
kinase O
activity O
by O
de O
novo O
phosphorylation O
of O
threonine O
and O
tyrosine O
residues O
via O
a O
very O
similar O
pathway O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
hexobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
anesthetized B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
rats I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Triethylene B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
glycol I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Such O
tetranucleotides O
are O
common O
in O
promoter O
regions O
, O
particularly O
in O
activating B_GENE
transcription I_GENE
factor I_GENE
/ O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ATF B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
CREB B_GENE
) O
and O
E O
- O
box O
motifs O
, O
suggesting O
that O
PIF B_PERSON/B_GENE
may O
modulate O
the O
transcription O
of O
many O
genes O
. O

Red B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
EC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
131I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
OIH B_LOCATION/B_DISEASE
was O
6 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
and O
20 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

The O
dominant O
inhibitory O
biological O
activity O
of O
the O
N O
terminus O
correlated O
with O
its O
ability O
to O
impair O
EGF B_GENE
- O
dependent O
activation O
of O
GTP B_GENE
- I_GENE
Ras I_GENE
and O
of O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
with O
the O
ability O
of O
endogenous O
Sos B_GENE/B_DISEASE
to O
form O
a O
stable O
complex O
with O
activated O
EGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

brainstem B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
BAEPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
were O
recorded O
from O
CZ B_LOCATION/B_PROTEIN[GENE]
- O
A1 B_PROTEIN[GENE]
and O
CZ B_LOCATION/B_PROTEIN[GENE]
- O
A2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
scalp I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regions I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
23 B_NUMBER[MEASURE]
hypertensive I_NUMBER[MEASURE]
and O
14 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
normotensive I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
subjects I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

SM B_LOCATION/B_PERSON
binds O
RNA O
in O
vitro O
, O
suggesting O
that O
sequence O
- O
or O
structure O
- O
specific O
mRNA O
interactions O
might O
mediate O
SM B_PROTEIN[GENE]/B_DISEASE
specificity O
. O

The O
characterization O
of O
fly O
receptors O
with O
features O
similar O
to O
mammalian B_GENE/B_SPECIES[BIO]
glycoprotein B_GENE/I_SPECIES[BIO]
hormone B_GENE/I_SPECIES[BIO]
receptors B_GENE/I_SPECIES[BIO]
allows O
a O
better O
understanding O
of O
the O
evolution O
of O
this O
unique O
group O
of O
GPCRs B_GENE/B_BIO
and O
future O
elucidation O
of O
their O
ligand O
signaling O
mechanisms O
. O

Here O
we O
show O
that O
these O
sequences O
are O
essential O
for O
processing O
of O
U18 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
snR38 B_GENE
snoRNAs I_GENE
and O
that O
they O
compensate O
for O
the O
lack O
of O
a O
canonical O
terminal O
stem O
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
aluminum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydroxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
fecal B_MEASURE/B_DISEASE
fluoride I_MEASURE/I_DISEASE
excretion I_MEASURE/I_DISEASE
and O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
net B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fluoride B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regardless O
of O
the O
intake B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
fluoride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phosphorus B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
magnesium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
humans B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
was O
a O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
decrease I_DISEASE_ADJECTIVE[DISEASE]
of O
TEWL B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
both O
forearm B_BODY_PART_OR_ORGAN_COMPONENT
and O
thigh B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O
CS B_LOCATION
- O
treated O
patients B_PERSON/B_BIO
compared O
to O
non B_DISEASE
- O
CS B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients B_PERSON/B_BIO
and O
controls B_PERSON/B_BIO
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Kramer B_MEASURE/B_ENT
Hamburg I_MEASURE/I_ENT
1988 I_MEASURE/I_ENT
, O
ISBN B_ORGANIZATION/B_MEASURE
: O
3 B_MEASURE
926952 I_MEASURE
07 I_MEASURE
5 I_MEASURE
) O
, O
the O
syndromatic B_TIME[MEASURE]/B_PERSON
day I_TIME[MEASURE]/I_PERSON
- O
to O
- O
day B_TIME[MEASURE]
shifting I_TIME[MEASURE]
of O
the O
psychopathological B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
features I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
with O
manic B_DISEASE
, O
depressive B_DISEASE
and O
several B_DISEASE
mixed I_DISEASE
states I_DISEASE
has O
a O
well O
- O
defined O
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
in O
25 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
studied O
and O
reported O
on O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
. O

Ras B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
involvement O
in O
signal O
transduction O
by O
the O
serotonin B_GENE
5 I_GENE
- I_GENE
HT2B I_GENE
receptor I_GENE
. O

Analysis O
of O
exon O
2 O
of O
the O
factor B_GENE/B_BIO
IX I_GENE/I_BIO
gene I_GENE/I_BIO
revealed O
a O
C O
- O
- O
> O
T O
mutation O
in O
codon O
10 O
of O
the O
propeptide O
region O
, O
resulting O
in O
the O
substitution O
of O
alanine O
by O
valine O
. O

There O
was O
a O
direct B_MEASURE/B_LOCATION
proportional I_MEASURE/I_LOCATION
relationship I_MEASURE/I_LOCATION
between O
the O
spiral B_MEASURE/B_DISEASE
artery I_MEASURE/I_DISEASE
flow I_MEASURE/I_DISEASE
and O
the O
pressure B_MEASURE/B_DISEASE
difference I_MEASURE/I_DISEASE
between O
the O
spiral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
the O
amniotic B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
pressure B_MEASURE
difference I_MEASURE
per O
flow B_MEASURE/B_SPORT[ENT]
( O
the O
resistance B_MEASURE/B_PERSON
of O
the O
cotyledonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
unit B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
was O
found O
to O
be O
1 B_MEASURE/B_LOCATION
- O
- O
3 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
. O

ml B_TIME[MEASURE]/B_PERSON
- O
1 B_MEASURE
. O
min B_PERSON/B_MEASURE
( O
8 B_MEASURE
- O
- O
24kPa B_MEASURE
. O
ml B_MEASURE/B_PERSON
- O
1 B_MEASURE/B_LOCATION
. O
s O
) O
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
new O
member O
of O
the O
very O
large O
' B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seripauperins I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
new O
ABC B_GENE/B_LOCATION
transporter I_GENE/I_LOCATION
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
to O
the O
human B_GENE/B_BIO
multidrug I_GENE/I_BIO
resistance I_GENE/I_BIO
protein I_GENE/I_BIO
hMRP1 I_GENE/I_BIO
; O
the O
C O
- O
terminal O
part O
of O
L1325 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B_PERSON/B_PROTEIN[GENE]
. O

The O
cells B_BODY_PART_OR_ORGAN_COMPONENT
were O
densely O
ciliated O
, O
each O
cilium B_BIO/B_MEASURE
showing O
a O
typical B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
9 B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
+ B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
2 B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fibrilar B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Immunofluorescence O
obtained O
using O
antibodies O
against O
alphaI B_GENE
SigmaI I_GENE
/ I_GENE
+ I_GENE
+ I_GENE
betaI I_GENE
SigmaI I_GENE
spectrin I_GENE
and O
Abl B_GENE
tyrosine I_GENE
kinase I_GENE
but O
not O
against O
alphaII B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
betaII I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spectrin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colocalized O
with O
the O
overexpressed O
green B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
SH3 B_GENE
- I_GENE
binding I_GENE
protein I_GENE
. O

Extracellular B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
cancer O
biomarker O
: O
its O
expression O
by O
tumor O
cells O
and O
reversal O
by O
a O
myristate O
- O
lacking O
Calpha O
and O
RIIbeta O
subunit O
overexpression O
. O

Detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sinusoidal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gratings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O
pattern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
detectors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principle I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B_GENE/B_DISEASE
, O
ETS2 B_GENE/B_DISEASE
, O
PEA3 B_GENE/B_DISEASE
or O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
Egrl B_PROTEIN[GENE]/B_BIO
- O
SREs O
or O
c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
fos I_GENE/I_LOCATION
SRE O
. O

MADS B_GENE
- I_GENE
box I_GENE
genes I_GENE
in O
plants O
are O
a O
diverse O
class O
of O
transcription O
factors O
that O
are O
involved O
in O
regulating O
developmental O
processes O
, O
particularly O
meristem O
and O
organ O
identity O
during O
floral O
development O
. O

elevated O
systolic O
blood O
pressure O
and O
high O
postglucose O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
showed O
an O
independent O
, O
significant O
association O
with O
left O
ventricular O
mass O
in O
female O
diabetic O
subjects O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O
if O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
- O
averaged O
low B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplitude B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atrial B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predict O
atrial B_DISEASE
fibrillation I_DISEASE
or O
flutter B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Aff B_PROTEIN[GENE]/B_LOCATION
) O
. O

Thirty B_NUMBER[MEASURE]
- O
five B_NUMBER[MEASURE]
pts I_NUMBER[MEASURE]
were O
transplanted O
for O
constitutional B_DISEASE
disease I_DISEASE
: O
Fanconi B_DISEASE
anemia I_DISEASE
( O
FA B_LOCATION/B_PROTEIN[GENE]
) O
( O
26 B_MEASURE/B_LOCATION
pts I_MEASURE/I_LOCATION
) O
, O
Dyskeratosis B_DISEASE/B_GENE
congenita I_DISEASE/I_GENE
( O
2 B_LOCATION/B_PROTEIN[GENE]
pts I_LOCATION/I_PROTEIN[GENE]
) O
, O
Blackfan B_PERSON/B_DISEASE
- O
diamond B_DISEASE/B_GENE
erythroblastopenia I_DISEASE/I_GENE
( O
2 B_LOCATION/B_PERSON
pts I_LOCATION/I_PERSON
) O
, O
Glanzmann B_DISEASE
thrombasthenia I_DISEASE
( O
1 B_LOCATION
PT I_LOCATION
) O
, O
osteopetrosis B_DISEASE
( O
1 B_MEASURE/B_LOCATION
pt I_MEASURE/I_LOCATION
) O
and O
Gaucher B_PERSON/B_LOCATION
' O
s B_DISEASE/B_GENE
disease I_DISEASE
( O
1 B_LOCATION/B_PROTEIN[GENE]
PT I_LOCATION/I_PROTEIN[GENE]
) O
. O

Viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
U I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Vpu B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
is O
a O
protein O
encoded O
by O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
that O
promotes O
the O
degradation O
of O
the O
virus O
receptor O
, O
CD4 B_GENE
, O
and O
enhances O
the O
release O
of O
virus O
particles O
from O
cells O
. O

Because O
the O
variation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
carbohydrate B_MEASURE/B_ENT
content I_MEASURE/I_ENT
of O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
milk I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
very O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
a O
more O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O
be O
to O
include O
only O
an O
average B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbohydrate B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
an O
estimate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
energy B_MEASURE/B_BIO
content I_MEASURE/I_BIO
. O

Level B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mosaicism I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
in O
0 B_MEASURE
. O
9 B_MEASURE
per O
cent B_SEQUENCE[MEASURE]
of O
CVS B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
mesenchyme I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O
1 B_MEASURE
. O
5 B_MEASURE
per O
cent B_SEQUENCE[MEASURE]
of O
amniotic B_DISEASE/B_PERSON
fluid I_DISEASE/I_PERSON
cultures I_DISEASE/I_PERSON
and O
in O
general B_PERSON/B_MEASURE
was O
not O
perceived O
to O
be O
of O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concern I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
warrant O
cytogenetic B_DISEASE_ADJECTIVE[DISEASE]
follow O
- O
up O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Biol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IV B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sleeping O
position B_LOCATION/B_DISEASE
and O
sudden B_DISEASE_ADJECTIVE[DISEASE]
infant I_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
( O
SIDS B_DISEASE/B_LOCATION
) O
: O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
intervention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
programme I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
avoid O
prone B_DISEASE
sleeping I_DISEASE
. O

CSEn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O
transcription O
of O
a O
variety O
of O
promoters O
, O
including O
the O
hCS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
human B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thymidine B_GENE
kinase I_GENE
, O
and O
Rous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sarcoma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
human O
choriocarcinoma O
cell O
lines O
( O
BeWo O
and O
JEG O
- O
3 O
) O
but O
not O
HeLa O
cells O
or O
rat O
somatolactotrophes O
( O
GC O
) O
. O

Pretreatment O
of O
human O
skin O
with O
tRA O
inhibited O
UV O
induction O
of O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
, O
consequently O
, O
AP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
. O

c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O
occurred O
via O
a O
posttranscriptional O
mechanism O
, O
since O
tRA O
did O
not O
inhibit O
UV O
induction O
of O
c B_GENE
- I_GENE
Jun I_GENE
mRNA I_GENE
. O

Thus O
, O
apoptosis B_DISEASE
in O
hematopoietic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
is O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
a O
conflict B_MEASURE/B_DISEASE
between O
death B_DISEASE
and O
survival B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signals I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
rather O
than O
a O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
death B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
default B_TIME[MEASURE]/B_DISEASE
. O

Effect O
of O
age O
on O
glucose O
, O
reducing O
sugars O
and O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
blood O
of O
milk O
- O
fed O
calves O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
both O
male B_PERSON
and O
female B_PERSON/B_ENT
soldiers I_PERSON/I_ENT
who O
are O
diagnosed O
with O
Chlamydia B_DISEASE/B_LOCATION
infections I_DISEASE/I_LOCATION
have O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risks I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
reinfection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O
their O
20s B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

During O
seed O
maturation O
, O
the O
transcriptional O
activity O
of O
napin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
regulated O
by O
developmental O
signals O
involving O
the O
transcriptional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ABI3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
abscisic O
acid O
( O
ABA O
) O
. O

Design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Intradermally O
injected O
human B_DISEASE
squamous I_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
cells I_DISEASE
were O
grown O
to O
40 B_MEASURE/B_LOCATION
to O
80 B_MEASURE
mm3 I_MEASURE
in O
athymic B_MEASURE
nude I_MEASURE
mice I_MEASURE
and O
irradiated O
with O
675 B_MEASURE
- O
nm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
light I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
75 B_MEASURE/B_LOCATION
J I_MEASURE/I_LOCATION
/ O
cm2 B_MEASURE
, O
75 B_MEASURE/B_LOCATION
MW B_MEASURE/I_LOCATION
/ O
cm2 B_MEASURE
) O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
after O
the O
intraperitoneal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
SiPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
1 B_MEASURE
. O
0 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
. O

This O
results O
in O
a O
decreased O
secretion O
of O
immunoglobulin B_GENE
A I_GENE
, O
and O
, O
consequently O
, O
a O
decreased O
resistance O
against O
infections O
. O

The O
absolute O
CD4 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
count O
of O
patients O
with O
de O
novo O
IBD O
was O
210 O
- O
700 O
cells O
/ O
ml O
at O
the O
time O
of O
IBD O
. O

Categorisation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substructures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
sections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
allows O
them O
to O
be O
analysed O
and O
displayed O
separately O
. O

To O
study O
the O
mechanisms O
and O
the O
signaling O
pathways O
involved O
, O
IGF B_PERSON/B_GENE
- I_PERSON/I_GENE
1R I_PERSON/I_GENE
promoter I_PERSON/I_GENE
reporter I_PERSON/I_GENE
constructs I_PERSON/I_GENE
were O
transiently O
transfected O
in O
Cho O
- O
AT1 O
cells O
that O
overexpress O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AT1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

With O
this O
study O
, O
a O
total O
of O
13 O
operators O
for O
the O
glp B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regulon I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
characterized O
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Coexpression O
of O
a O
dominant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonized O
the O
ras B_GENE/B_DISEASE
- O
dependent O
stimulation O
of O
the O
92 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gelatinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter O
- O
driven O
CAT B_GENE
reporter I_GENE
. O

In O
two B_PERSON/B_MEASURE
patients I_PERSON/I_MEASURE
, O
a O
male B_PERSON/B_DISEASE
homosexual I_PERSON/I_DISEASE
and O
an O
hemophiliac B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
thrombocytopenia B_DISEASE
was O
associated O
with O
AIDS B_DISEASE
- O
related O
complex B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
LXRalpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O
binding O
of O
PPARalpha B_GENE
/ O
RXRalpha B_GENE
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B_GENE/B_PERSON
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B_GENE
/ O
RXRalpha B_GENE
in O
vivo O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O
be O
summarized O
as O
follows B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

A O
case B_PERSON/B_LOCATION
of O
heterotopic B_DISEASE
gastric I_DISEASE
mucosa I_DISEASE
( O
pyloric B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gland I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
the O
wall B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
the O
gallbladder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
reported O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
mechanism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
ribosomal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
frameshifting I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
at O
the O
PVM B_LOCATION/B_BIO
signal I_LOCATION/I_BIO
is O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O
the O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O
by O
the O
' B_PERSON
simultaneous I_PERSON
slippage I_PERSON
' O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
that O
only O
the O
string B_MEASURE
of O
four B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenosine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nucleotides I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
represents O
the O
slippery B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
a O
- O
1 B_NUMBER[MEASURE]/B_LOCATION
P I_NUMBER[MEASURE]/I_LOCATION
- O
site B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
slippage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

CTDK1 B_GENE/B_LOCATION
and O
CTDK2 B_GENE
also O
differ O
in O
their O
protein O
substrate O
specificity O
. O

This O
communication O
presents O
two O
patients O
with O
clinically O
massive O
PE O
of O
recent O
onset O
( O
confirmed O
by O
lung O
perfusion O
scans O
) O
who O
were O
successfully O
treated O
with O
a O
single O
i O
. O
v O
. O
dose O
of O
30 O
mg O
of O
anisoylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lys I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plasminogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
streptokinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
APSAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
comparable O
to O
1 O
, O
500 O
, O
000 O
U O
of O
streptokinase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
followed O
by O
systemic O
heparinization O
for O
7 O
days O
. O

A O
Laboratory B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Manual I_SEQUENCE[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2nd B_LOCATION/B_EDU[ORGANIZATION]
ed I_LOCATION/I_EDU[ORGANIZATION]
. O

Engineering O
temperature O
- O
sensitive O
SH3 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
domains B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
mean O
value O
for O
HbA1 B_PROTEIN[GENE]/B_DISEASE
greater O
than O
10 O
% O
was O
associated O
with O
an O
increased O
risk O
of O
progression O
of O
retinopathy O
and O
a O
mean O
value O
less O
than O
8 O
. O
7 O
% O
was O
associated O
with O
a O
diminished O
risk O
. O

allergic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
field I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
: O
how O
to O
detect O
it O
. O

At O
1 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
postalfentanil I_TIME[MEASURE]/I_PERSON
, O
N2O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caused O
significantly O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rigidity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
100 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

The O
preparative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
fractionated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TBI B_DISEASE/B_LOCATION
) O
and O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Cy B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

NGF B_PERSON/B_GENE
also O
induced O
a O
synthetic O
promoter O
with O
repeated O
Sp1 B_GENE/B_LOCATION
sites I_GENE/I_LOCATION
linked O
to O
a O
core O
promoter O
, O
and O
a O
plasmid O
regulated O
by O
a O
chimeric O
transactivator O
in O
which O
the O
Gal4 B_GENE/B_MEASURE
DNA I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
domain I_GENE/I_MEASURE
is O
fused O
to O
the O
Sp1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transactivation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
indicating O
that O
this O
transactivation O
domain O
is O
regulated O
by O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
collembolan B_BIO/B_LOCATION
Folsomia I_BIO/I_LOCATION
fimetaria I_BIO/I_LOCATION
L I_BIO/I_LOCATION
. O
was O
studied O
in O
soil B_BIO
incubated O
with O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
different B_TIME[MEASURE]
periods I_TIME[MEASURE]
before O
the O
introduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
collembolans B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
assess O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aging O
of O
contamination B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
frequency B_MEASURE
of O
severe B_DISEASE
congestive I_DISEASE
heart I_DISEASE
failure I_DISEASE
( O
Killip B_LOCATION/B_DISEASE
class I_LOCATION/I_DISEASE
III I_LOCATION/I_DISEASE
or O
IV B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O
at O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON
with O
early B_DISEASE_ADJECTIVE[DISEASE]
presentation I_DISEASE_ADJECTIVE[DISEASE]
, O
than O
with O
late B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
presentation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
30 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
7 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Comparative B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ultrafiltration B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
UF B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
BiGG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lactate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
La B_LOCATION/B_MEASURE
) O
solutions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
net B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
La B_LOCATION
solution I_LOCATION
peaked O
at O
2 B_MEASURE
h O
and O
decreased O
significantly O
at O
4 B_MEASURE
h O
and O
6 B_MEASURE
h O
. O

The O
Giessener B_DISEASE/B_LOCATION
Tumordokumentationssystem I_DISEASE/I_LOCATION
( O
GTDS B_DISEASE/B_LOCATION
) O
is O
such O
a O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Measurement B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
natural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
rubber I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
latex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
cotransfection O
assays O
, O
a O
small O
fragment O
of O
Sin B_GENE/B_DISEASE
retaining O
the O
Src B_GENE
- O
SH3 B_GENE/B_LOCATION
- O
binding O
site O
and O
one O
tyrosine O
- O
containing O
motif O
induced O
c B_GENE
- I_GENE
Src I_GENE
activation O
as O
measured O
by O
a O
transcriptional O
reporter O
. O

The O
related O
tumor O
suppressor O
, O
p130 B_GENE
, O
also O
effects O
this O
function O
. O

p107 B_GENE/B_MEASURE
levels O
increase O
substantially O
as O
cells O
progress O
through O
S O
phase O
. O

p107 B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
induction O
of O
E2F B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O
binding O
was O
observed O
primarily O
in O
S O
phase O
cells O
coincident O
with O
the O
increase O
in O
p107 B_GENE
protein I_GENE
levels O
. O

Both O
flavoproteins O
are O
active O
as O
AhpC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reductases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
mediate O
electron O
transfer O
, O
resulting O
in O
the O
NADH O
- O
dependent O
reduction O
of O
hydrogen O
peroxide O
and O
cumene O
hydroperoxide O
. O

Transcriptional O
regulation O
of O
the O
murine B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
k I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
fgf I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B_GENE
promoter I_GENE
- O
luciferase B_GENE/B_DISEASE
( O
- O
1935UF B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Luc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
reporter O
gene O
and O
the O
BTEB B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

Evasion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
host B_DISEASE/B_BIO
immunity I_DISEASE/I_BIO
by O
Toxocara B_SPECIES[BIO]/B_DISEASE
canis I_SPECIES[BIO]/I_DISEASE
infective I_SPECIES[BIO]/I_DISEASE
larvae I_SPECIES[BIO]/I_DISEASE
is O
mediated O
by O
the O
nematode B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
coat I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
shed O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
binding O
by O
host B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
molecules B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
effector B_GENE
cells I_GENE
. O

A O
frank B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
vectorcardiogram I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O
recorded O
before O
and O
every O
15 B_MEASURE
- O
30 B_NUMBER[MEASURE]/B_ENT
minutes I_NUMBER[MEASURE]/I_ENT
for O
10 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
after O
the O
occlusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
agreement O
with O
this O
, O
archaea O
appear O
to O
lack O
eIF5 B_GENE
, O
eIF2B B_GENE
and O
the O
lysine O
- O
rich O
binding O
domain O
for O
these O
factors O
in O
their O
eIF2beta B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
homolog B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Derepression O
of O
RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
by O
expressing O
a O
dominant O
- O
negative O
corepressor O
resulted O
in O
embryos O
that O
exhibited O
phenotypes O
similar O
to O
those O
treated O
by O
RA O
. O

chemiluminescence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
by O
opsonized B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
zymosan B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
significantly O
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
bacterial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
no O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
the O
fMLP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
PMNs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Lastly O
, O
several O
restriction O
length O
polymorphisms O
were O
identified O
and O
mapped O
within O
a O
1 O
kb O
region O
located O
immediately O
upstream O
from O
the O
JH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

radiographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spatial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
frequencies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
essential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
incipient B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interproximal I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

promoter O
region O
of O
the O
human B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
2A I_GENE/I_LOCATION
adrenergic I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
. O

( O
1982 B_MEASURE
) O
. O

( O
99m B_MEASURE
) O
Tc B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethyl I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cysteinate I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimer I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stable I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
6h B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O
contributed O
to O
develop O
ictal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
evaluate O
the O
location B_DISEASE_ADJECTIVE[DISEASE]
of O
partial B_DISEASE
seizure I_DISEASE
. O

Lif B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thermoluminescence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dosimeters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
TLD B_DISEASE/B_MEASURE
) O
in O
chip B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
placed O
onto O
1 B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
eyelid I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
the O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
over O
the O
thyroid B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
patient B_PERSON
' O
s B_BODY_PART_OR_ORGAN_COMPONENT
clothes I_BODY_PART_OR_ORGAN_COMPONENT
covering O
the O
region B_LOCATION/B_BIO
of O
breasts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ovaries B_BODY_PART_OR_ORGAN_COMPONENT
of O
female B_PERSON/B_BIO
patients I_PERSON/I_BIO
and O
the O
testicles B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
male B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Thus O
, O
the O
in O
vivo O
function O
of O
Gle2p B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
strictly O
coupled O
to O
the O
short O
GLEBS B_GENE/B_LOCATION
within O
Nup116p B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
links O
this O
putative O
mRNA O
transport O
factor O
to O
the O
nuclear O
pores O
. O

DNMT2 B_GENE
binds O
AdoHcy O
in O
the O
same O
conformation O
as O
confirmed O
m B_GENE
( I_GENE
5 I_GENE
) I_GENE
C I_GENE
MTases I_GENE
and O
, O
while O
DNMT2 B_TIME[MEASURE]/B_LOCATION
shares O
all O
sequence O
and O
structural O
features O
with O
m B_GENE/B_DISEASE
( I_GENE/I_DISEASE
5 I_GENE/I_DISEASE
) I_GENE/I_DISEASE
C I_GENE/I_DISEASE
MTases I_GENE/I_DISEASE
, O
it O
has O
failed O
to O
demonstrate O
detectable O
transmethylase O
activity O
. O

The O
structure O
of O
the O
murine B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dtk B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
determined O
. O

In O
previous O
studies O
, O
we O
showed O
that O
the O
nuclear O
import O
of O
SREBP B_GENE
- I_GENE
2 I_GENE
occurs O
via O
the O
direct O
interaction O
of O
importin B_GENE
beta I_GENE
with O
the O
HLH O
- O
ZIP O
domain O
. O

In O
the O
normal O
controls O
the O
plasma B_GENE
FPA I_GENE
level O
( O
mean O
+ O
/ O
- O
SD O
) O
was O
1 O
. O
43 O
+ O
/ O
- O
0 O
. O
46 O
ng O
/ O
ml O
. O

In O
this O
study O
we O
cloned O
the O
cDNA O
of O
AD1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
a O
rat O
basophilic O
leukemia O
2H3 O
cDNA O
library O
. O

Ten B_PERSON/B_BIO
patients I_PERSON/I_BIO
( O
aged B_MEASURE/B_PERSON
28 I_MEASURE/I_PERSON
- O
76 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
) O
with O
a O
terminal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
jejunostomy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
located O
within O
the O
first B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
meter B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
jejunum B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
treated O
by O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
elemental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O
the O
distal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
small I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
bowel I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O
IEDDSB B_PROTEIN[GENE]/B_LOCATION
) O
. O

The O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
technically O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
12 B_NUMBER[MEASURE]/B_PERSON
of O
14 B_NUMBER[MEASURE]
( O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
stenoses B_DISEASE/B_PERSON
in O
the O
fibromuscular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysplasia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
subgroup I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
but O
in O
only O
one B_NUMBER[MEASURE]
of O
five B_NUMBER[MEASURE]
( O
20 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
lesions B_DISEASE/B_PERSON
in O
the O
neurofibromatosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
subgroup I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Conventional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
digital B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
aorta B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vascularity I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Regulation O
of O
the O
p21 B_GENE
- I_GENE
activated I_GENE
kinase I_GENE
( O
PAK B_GENE/B_PERSON
) O
by O
a O
human B_SPECIES[BIO]/B_GENE
Gbeta I_SPECIES[BIO]/I_GENE
- I_SPECIES[BIO]/I_GENE
like I_SPECIES[BIO]/I_GENE
WD O
- O
repeat O
protein O
, O
hPIP1 B_GENE/B_LOCATION
. O

Other B_PERSON
clinicopathological I_PERSON
features I_PERSON
have O
no O
definite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
survival B_DISEASE
expectancy I_DISEASE
. O

These O
studies O
suggest O
that O
tandem O
alpha O
- O
helices O
located O
near O
the O
C O
- O
terminus O
of O
PC B_GENE
- I_GENE
TP I_GENE
facilitate O
membrane O
binding O
and O
extraction O
of O
phosphatidylcholines O
. O

The O
striking B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
preference B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
mismatched B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
weakly O
paired O
nucleotides B_LOCATION/B_BIO
for O
binding O
and O
for O
excision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suggests O
a O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relationship I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
binding B_TIME[MEASURE]/B_GENE
and O
cleavage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interestingly O
, O
these O
' O
activation O
- O
defective O
' O
mutants O
segregated O
into O
two O
classes O
: O
1 O
) O
those O
that O
were O
unable O
to O
form O
dimers O
but O
that O
could O
still O
form O
higher O
order O
oligomers O
and O
transform O
cells O
, O
and O
2 O
) O
those O
that O
were O
defective O
for O
PDGF B_GENE
- I_GENE
R I_GENE
binding O
and O
were O
transformation O
- O
incompetent O
. O

APL O
patients O
showed O
a O
low O
, O
yet O
variable O
, O
level O
of O
JEM B_GENE
- I_GENE
1 I_GENE
mRNA I_GENE
in O
bone O
marrow O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
intranasal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
challenge I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
Flu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
leukocyte B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
histamine I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
release I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
but O
not O
other B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
systemic B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
immune B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
inflammatory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
shown O
previously O
that O
EGF B_GENE
receptor I_GENE
activation O
stimulates O
gastrin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O
expression O
through O
a O
GC O
- O
rich O
element O
called O
gERE O
. O

We O
have O
earlier O
proposed O
that O
CG B_GENE/B_DISEASE
rich I_GENE/I_DISEASE
sequences I_GENE/I_DISEASE
resembling O
CpG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
islands I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
associated O
with O
many B_DISEASE/B_GENE
imprinted B_DISEASE/I_GENE
genes B_DISEASE/I_GENE
and O
often O
subject B_PERSON/B_TIME[MEASURE]
to O
parental B_PERSON/B_LOCATION
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
could O
act O
as O
a O
common B_GENE/B_PERSON
imprinting I_GENE/I_PERSON
element I_GENE/I_PERSON
. O

The O
secondary O
end O
points O
included O
creatine B_ENZYME[GENE]/B_DISEASE
kinase B_ENZYME[GENE]/I_DISEASE
peak O
, O
ventricular O
fibrillation O
/ O
tachycardia O
within O
the O
first O
24 O
hours O
, O
death O
and O
congestive O
heart O
failure O
within O
the O
30 O
- O
day O
follow O
- O
up O
, O
and O
30 O
- O
day O
left O
ventricular O
ejection O
fraction O
. O

Prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gravid B_DISEASE
rhesus I_DISEASE
isoimmunization I_DISEASE
. O

All O
relapses B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
within O
the O
first B_TIME[MEASURE]/B_LOCATION
year B_TIME[MEASURE]/I_LOCATION
and O
were O
confined O
to O
patients B_PERSON/B_LOCATION
with O
PS B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
four B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_ENT
sites I_NUMBER[MEASURE]/I_ENT
of O
involvement B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
demonstrates O
the O
presence O
of O
a O
PKC B_GENE
- O
dependent O
pathway O
which O
functions O
independently O
from O
Lck B_GENE/B_LOCATION
in O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O
. O

This O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exon B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
junction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
novel B_TIME[MEASURE]/B_ENT
deduced O
amino B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
open I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reading I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
frames I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
completely O
in O
- O
frame B_LOCATION/B_TIME[MEASURE]
with O
sequences B_LOCATION/B_DISEASE
located O
further O
downstream B_LOCATION
. O

Cell O
lines O
expressing O
single O
amino O
acid O
substitutions O
of O
the O
carboxyl O
- O
terminal O
asparagine O
of O
CD2 B_GENE
are O
incapable O
of O
avidity O
regulation O
by O
TCR B_GENE
signaling O
, O
PMA O
treatment O
, O
or O
elevation O
of O
intracellular O
Camp O
levels O
, O
demonstrating O
that O
each O
of O
these O
stimuli O
utilizes O
a O
common O
structural O
element O
for O
regulating O
CD2 B_GENE
avidity O
. O

12 B_NUMBER[MEASURE]
per O
cent B_MEASURE
was O
observed O
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
and O
4 B_MEASURE
- O
epianhydrotetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
doses B_MEASURE
of O
1000 B_MEASURE
and O
100gamma B_MEASURE/B_LOCATION
per O
embryo B_TIME[MEASURE]/B_PERSON
respectively O
. O

Present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
undertaken O
to O
elucidate O
what O
pharmacokinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
could O
be O
of O
more O
predictable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
beta B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blocking O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
atpA B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading O
frame O
ends O
with O
four O
tandem O
UGA O
codons O
which O
overlap O
four O
tandem O
Aug O
codons O
initiating O
an O
unidentified O
reading O
frame O
, O
orf214 O
. O

When O
transfected O
into O
HepG2 O
cells O
, O
which O
lack O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
mouse B_GENE
ob I_GENE
promoter I_GENE
was O
only O
weakly O
active O
. O

vasodilator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
hypotensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
optical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
isomers I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
nicardipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
YC B_LOCATION/B_PROTEIN[GENE]
- O
93 B_NUMBER[MEASURE]
) O
, O
a O
new B_PROTEIN[GENE]
Ca2 I_PROTEIN[GENE]
+ I_PROTEIN[GENE]
- O
antagonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Between O
1988 B_MEASURE
and O
1995 B_MEASURE
, O
341 B_PERSON/B_BIO
children I_PERSON/I_BIO
with O
acute B_DISEASE
myeloid I_DISEASE
leukaemia I_DISEASE
( O
AML B_DISEASE/B_LOCATION
) O
were O
treated O
on O
the O
Medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Council B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
myeloid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
leukaemia B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
MRC B_MEASURE/B_GENE
AML10 I_MEASURE/I_GENE
) O
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 B_GENE/B_LOCATION
site I_GENE/I_LOCATION
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CREB B_GENE/B_LOCATION
/ O
AP1 B_GENE/B_LOCATION
) O
element O
from O
the O
BZLF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O
to O
the O
beta B_GENE/B_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
globin B_GENE/I_SPECIES[BIO]
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

Nicotinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
antagonists O
mecamylamine O
( O
0 O
. O
5 O
and O
1 O
mg O
/ O
kg O
) O
and O
hexamethonium O
( O
5 O
and O
10 O
mg O
/ O
kg O
) O
reduced O
the O
response O
induced O
by O
nicotine O
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
. O

appl B_PERSON/B_MEASURE
. O

Thus O
, O
the O
predicted B_GENE
M3 I_GENE
ORF I_GENE
is O
a O
functional B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
that O
encodes O
an O
abundant B_GENE
secreted I_GENE
protein I_GENE
which O
is O
a O
candidate B_PERSON/B_LOCATION
for O
interacting O
with O
host B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Protein B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metabolism I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disorders I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
burns B_PERSON/B_DISEASE
. O

The O
cumulative B_MEASURE/B_DISEASE
dose I_MEASURE/I_DISEASE
to O
nursing B_DISEASE/B_MEASURE
staff I_DISEASE/I_MEASURE
for O
the O
week B_TIME[MEASURE]/B_DISEASE
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
dependent B_PERSON/B_MEASURE
on O
patient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mobility I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
was O
estimated O
at O
0 B_MEASURE
. O
08 B_MEASURE
mSv I_MEASURE
for O
a O
self B_PERSON/B_LOCATION
- O
caring O
patient B_PERSON
to O
6 B_MEASURE
. O
3 B_MEASURE
mSv I_MEASURE
for O
a O
totally O
helpless B_PERSON
patient I_PERSON
( O
1840 B_PERSON/B_LOCATION
MBq I_PERSON/I_LOCATION
/ O
group B_MEASURE/B_LOCATION
A I_MEASURE/I_LOCATION
) O
. O

JCAHO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
use O
ORYX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O
detect O
sentinel B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
also O
show O
that O
psbH B_GENE/B_LOCATION
and O
psbT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
transcribed O
from O
the O
upstream O
psbB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
the O
psbH B_GENE/B_MEASURE
mRNA I_GENE/I_MEASURE
has O
its O
own O
target O
sequence O
for O
Mbb1 B_GENE/B_PERSON
function O
. O

To O
test O
whether O
Cd B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O
increase O
ca O
release O
from O
bone B_BODY_PART_OR_ORGAN_COMPONENT
during O
pregnancy B_ORGANISM_FUNCTION/B_PERSON
and O
lactation B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
in O
relation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
the O
etiological B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
of O
Itai B_PERSON/B_LOCATION
- O
Itai B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
, O
virgin B_PERSON/B_BIO
female I_PERSON/I_BIO
mice I_PERSON/I_BIO
with O
45Ca B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
prelabeled O
skeletons B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
15 B_MEASURE/B_BIO
microCi I_MEASURE/I_BIO
/ O
mouse B_BIO/B_MEASURE
) O
were O
subjected O
to O
one B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
round B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pregnancy B_ORGANISM_FUNCTION/B_DISEASE
/ O
lactation B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
were O
exposed O
to O
a O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
deficient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
containing O
0 B_NUMBER[MEASURE]
, O
5 B_MEASURE
, O
or O
25 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
CD I_TIME[MEASURE]
or O
25 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ppm I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pb I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
32 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
from O
conception B_TIME[MEASURE]
until O
Lactation B_TIME[MEASURE]/B_ORGANISM_FUNCTION
Day I_TIME[MEASURE]/I_ORGANISM_FUNCTION
14 I_TIME[MEASURE]/I_ORGANISM_FUNCTION
. O

O5257 B_PERSON/B_GENE
shows O
homology O
with O
the O
SAS2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
another O
hypothetical O
protein O
from O
yeast O
. O

principles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
thyroid B_EDU[ORGANIZATION]
hormone I_EDU[ORGANIZATION]
treatment I_EDU[ORGANIZATION]
. O

significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
esophagocardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reflexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
inducing O
thoracic B_DISEASE
pain I_DISEASE
. O

The O
fate B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ochratoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
during O
malting B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
brewing B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
precision B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
accuracy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
measured O
using O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

Messenger O
RNA O
for O
the O
Ad2 B_GENE/B_BIO
DNA I_GENE/I_BIO
binding I_GENE/I_BIO
protein I_GENE/I_BIO
: O
DNA O
sequences O
encoding O
the O
first O
leader O
and O
heterogenity O
at O
the O
mRNA O
5 O
' O
end O
. O

consistent O
with O
this O
hypothesis O
, O
stimulation O
of O
A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
PKA B_GENE
enhanced O
nuclear B_GENE
aPKC I_GENE
activity O
. O

Atrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dissociation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predicts O
a O
150 B_MEASURE
, O
825 B_MEASURE/B_LOCATION
mol I_MEASURE/I_LOCATION
wt I_MEASURE/I_LOCATION
apoprotein I_MEASURE/I_LOCATION
of O
1363 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
an O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_PROTEIN[GENE]
hydrophobic I_LOCATION/I_PROTEIN[GENE]
signal I_LOCATION/I_PROTEIN[GENE]
sequence I_LOCATION/I_PROTEIN[GENE]
of O
17 B_MEASURE
amino I_MEASURE
acids I_MEASURE
, O
19 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
linked O
glycosylation B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
hydrophobic B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anchor I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
approximately O
17 B_MEASURE
amino I_MEASURE
acids I_MEASURE
near O
the O
C B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
terminus B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
a O
hydrophilic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_LOCATION
C I_LOCATION
terminus I_LOCATION
of O
35 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

However O
, O
depending O
upon O
the O
promoter B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
context I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
we O
observed O
cooperative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_NUMBER[MEASURE]/B_PROTEIN[GENE]
domains B_NUMBER[MEASURE]/I_PROTEIN[GENE]
to O
confer O
high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
affinity B_GENE/B_MEASURE
and O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

As O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
relative B_MEASURE
biological I_MEASURE
effects I_MEASURE
( O
RBE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
of O
2 B_NUMBER[MEASURE]
. O
3 B_MEASURE
- O
2 B_MEASURE
. O
7 B_MEASURE
was O
obtained O
from O
the O
straight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
line I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
that O
was O
given O
by O
modifying O
by O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
least B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
squares I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
curves B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
frequency B_MEASURE/B_LOCATION
of O
anomalous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fetuses I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
total B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
implants I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O
survived O
embryos B_LOCATION
irradiated O
from O
20 B_MEASURE
to O
120 B_MEASURE/B_LOCATION
rad I_MEASURE/I_LOCATION
by O
CF B_LOCATION
- O
252 B_MEASURE
and O
from O
80 B_MEASURE
to O
220 B_MEASURE/B_LOCATION
rad I_MEASURE/I_LOCATION
by O
Co B_LOCATION
- O
60 B_MEASURE/B_LOCATION
on O
day B_TIME[MEASURE]
8 I_TIME[MEASURE]
of O
pregnancy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

samples O
( O
1 O
g O
) O
were O
extracted O
with O
0 O
. O
5 O
% O
potassium O
chloride O
( O
KCl O
) O
in O
70 O
% O
methanol O
( O
5 O
ml O
) O
and O
diluted O
subsequently O
to O
give O
two O
- O
fold O
to O
ten O
- O
fold O
step O
- O
wise O
dilutions O
in O
phosphate O
- O
buffered O
saline O
containing O
0 O
. O
05 O
% O
Tween O
20 O
and O
0 O
. O
2 O
% O
bovine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PBS O
- O
T O
BSA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

To O
our O
knowledge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
108 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Eat O
treated O
by O
catheter B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ablation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
ectopic B_DISEASE/B_PROTEIN[GENE]
focus B_DISEASE/I_PROTEIN[GENE]
are O
reported O
in O
the O
literature B_PERSON/B_LOCATION
with O
a O
success B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
superior I_MEASURE/I_LOCATION
to O
90 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
% I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Following O
immunization O
of O
transgenic O
mice O
, O
hybrid O
molecules O
were O
isolated O
from O
B O
cell O
DNA O
which O
contained O
the O
transgene O
recombined O
with O
the O
endogenous B_GENE
IgH I_GENE
locus I_GENE
. O

It O
produced O
extrapyramidal B_DISEASE
disturbances I_DISEASE
in O
nearly O
every O
subject B_PERSON/B_LOCATION
, O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
being I_DISEASE_ADJECTIVE[DISEASE]
akathisia I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
most O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
in O
the O
case B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
one B_DISEASE
individual I_DISEASE
, O
being O
acute B_DISEASE
dystonia I_DISEASE
. O

Northern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
that O
both O
human B_SPECIES[BIO]
and O
murine B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encode O
approximately O
6 B_MEASURE
- O
kb B_MEASURE/B_BIO
transcripts I_MEASURE/I_BIO
. O

Transforming B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O
the O
promoter O
of O
cyclin B_GENE
- I_GENE
dependent I_GENE
kinase I_GENE
inhibitor O
p15INK4B B_GENE
through O
an O
Sp1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Cox B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
proportional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hazard I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
identified O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modality I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dialysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
UV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
1 B_MEASURE
, O
000 B_MEASURE
ml I_MEASURE
/ O
m2 B_MEASURE
per O
24 B_MEASURE
h O
as O
the O
only B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
significant I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
risk I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
UV B_DISEASE
survival I_DISEASE
. O

The O
hyperpigmentation O
is O
linked O
to O
the O
presence O
of O
numerous O
single O
melanosomes O
and O
polymelanosomes O
in O
keratinocytes O
at O
all O
levels O
of O
the O
epidermis O
, O
and O
in O
dermal O
Factor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
XIIIa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
positive O
dendrocytes O
. O

possible O
or O
definite O
neglect O
or O
abuse O
before O
36 O
months O
of O
age O
was O
correlated O
with O
low O
DBH B_PERSON/B_DISEASE
activity O
. O

Previously O
, O
we O
identified O
two O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SMC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
hCAP B_LOCATION/B_DISEASE
- I_LOCATION/I_DISEASE
C I_LOCATION/I_DISEASE
and O
hCAP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
E I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
form O
a O
heterodimeric O
complex O
( O
hCAP B_DISEASE/B_LOCATION
- B_DISEASE/I_LOCATION
C B_DISEASE/I_LOCATION
- O
hCAP B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
E I_PROTEIN[GENE]/I_LOCATION
) O
in O
the O
cell O
. O

The O
mouse B_GENE
alpha I_GENE
A I_GENE
- I_GENE
CRYBP1 I_GENE
gene I_GENE
specifies O
a O
2 O
, O
688 O
- O
amino O
acid O
protein O
with O
72 O
% O
amino O
acid O
identity O
to O
its O
human O
homologue O
, O
PRDII B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BF1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Methylation O
interference O
analysis O
established O
at O
single O
nucleotide O
resolution O
that O
purified O
recombinant O
Fos B_GENE/B_LOCATION
and O
Jun B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O
in O
a O
sequence O
- O
specific O
manner O
to O
the O
AP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
VDRE O
and O
OC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B_LOCATION/B_PROTEIN[GENE]
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B_PROTEIN[GENE]/B_LOCATION
, O
ALT B_PROTEIN[GENE]/B_PERSON
, O
ALP B_PROTEIN[GENE]/B_LOCATION
, O
gamma B_LOCATION/B_GENE
GTP I_LOCATION/I_GENE
, O
LDH B_PROTEIN[GENE]
, O
CPK B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B_PROTEIN[GENE]/B_LOCATION
, O
TG O
, O
BUN O
, O
CR O
, O
Glu O
, O
Na O
, O
K O
, O
ca O
, O
P O
and O
CRP B_LOCATION/B_GENE
) O
. O

Both O
the O
inactive O
domain B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
P68 I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
the O
deletion O
mutant O
lacking O
AA O
91 O
- O
243 O
were O
less O
inhibitory O
to O
growth O
in O
yeast O
due O
to O
the O
reduced O
ability O
to O
phosphorylate O
initiation B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
. O

All O
patients B_PERSON/B_LOCATION
studied O
were O
pregnant B_PERSON
women I_PERSON
and O
their O
delivered O
children B_PERSON/B_BIO
. O

Current B_MEASURE/B_LOCATION
body B_MEASURE/I_LOCATION
size B_MEASURE/I_LOCATION
( O
wt B_MEASURE/B_LOCATION
/ O
ht2 B_MEASURE/B_LOCATION
) O
was O
significantly O
associated O
with O
life B_TIME[MEASURE]/B_LOCATION
- O
time B_TIME[MEASURE]/B_LOCATION
weight I_TIME[MEASURE]/I_LOCATION
dissatisfaction I_TIME[MEASURE]/I_LOCATION
in O
both O
sexes B_BIO/B_PERSON
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE/B_LOCATION
. O
0005 B_MEASURE
) O
. O

Mad3 B_GENE
and O
Mad4 B_GENE/B_LOCATION
: O
novel O
Max B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
interacting O
transcriptional O
repressors O
that O
suppress O
c B_GENE
- I_GENE
myc I_GENE
dependent O
transformation O
and O
are O
expressed O
during O
neural O
and O
epidermal O
differentiation O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attainment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TGB B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monotherapy I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
their O
achievement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
positive B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
of O
varying O
degree B_MEASURE
on O
psychological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tests I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
pcaR B_GENE/B_LOCATION
regulatory I_GENE/I_LOCATION
locus I_GENE/I_LOCATION
has O
been O
found O
to O
be O
required O
for O
both O
induction O
of O
all O
of O
the O
genes O
within O
the O
pca B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulon I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
pcaBDC B_LOCATION/B_GENE
, O
pcaIJ B_LOCATION/B_GENE
, O
and O
pcaF B_GENE/B_LOCATION
) O
and O
the O
chemotactic O
response O
of O
the O
bacteria O
to O
aromatic O
compounds O
. O

Furthermore O
, O
we O
have O
identified O
the O
major O
open O
reading O
frame O
( O
RF4 O
; O
2 O
. O
3 O
kb O
) O
as O
being O
essential O
for O
activation O
, O
and O
we O
have O
shown O
that O
the O
NF B_GENE/B_LOCATION
kappa I_GENE/I_LOCATION
B I_GENE/I_LOCATION
, O
SP1 B_GENE/B_DISEASE
, O
and O
TATA O
box O
motifs O
in O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
all O
required O
for O
full O
induction O
of O
the O
promoter O
by O
the O
HHV B_GENE
- I_GENE
6 I_GENE
- I_GENE
encoded I_GENE
transactivator I_GENE
. O

However O
, O
mutations O
of O
the O
C O
- O
rich O
element O
that O
disrupted O
a O
GC O
box O
located O
on O
the O
inverse O
strand O
eliminated O
PMA O
responsiveness O
and O
, O
in O
gel O
mobility O
shift O
assays O
, O
eliminated O
binding O
of O
Sp1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

TFIIB B_GENE/B_LOCATION
and O
VDR B_GENE
can O
also O
interact O
directly O
, O
and O
these O
factors O
synergize O
to O
mediate O
transactivation O
. O

Both O
algorithms B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
have O
been O
implemented O
and O
applied O
to O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulated O
for O
a O
scanner B_PRODUCT[OBJECT]/B_ENT
with O
a O
large B_MEASURE/B_LOCATION
axial I_MEASURE/I_LOCATION
aperture I_MEASURE/I_LOCATION
( O
30 B_LOCATION/B_PROTEIN[GENE]
degrees I_LOCATION/I_PROTEIN[GENE]
) O
, O
and O
also O
to O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquired O
with O
the O
ECAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
HR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
and O
the O
ECAT B_ORGANIZATION
HR I_ORGANIZATION
+ I_ORGANIZATION
scanners I_ORGANIZATION
. O

The O
well O
- O
trained O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
measured O
once O
in O
the O
respiration B_LOCATION/B_TIME[MEASURE]
chamber B_LOCATION/I_TIME[MEASURE]
for O
36 B_NUMBER[MEASURE]
h O
according O
to O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Samarium B_MEASURE/B_PROTEIN[GENE]
- O
153 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
intravascular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
irradiation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O
liquid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
filled O
balloons B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
to O
prevent O
restenosis B_DISEASE
: O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
a O
hypercholesterolemic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rabbit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
restenosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Only O
viable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bacteria I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
high B_MEASURE/B_LOCATION
concentration B_MEASURE/I_LOCATION
induced O
purulent B_DISEASE
otitis I_DISEASE
media I_DISEASE
, O
which O
was O
culture B_DISEASE_ADJECTIVE[DISEASE]
positive I_DISEASE_ADJECTIVE[DISEASE]
in O
58 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
day B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Polyoma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
virus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
urine B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
during O
pregnancy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Transfer O
of O
F O
- O
like O
plasmids O
is O
regulated O
by O
the O
FinOP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O
, O
which O
controls O
the O
expression O
of O
traJ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
positive O
regulator O
of O
the O
transfer O
operon O
. O

PKCI B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
is O
a O
member O
of O
the O
HIT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
proteins O
, O
shown O
by O
sequence O
identity O
to O
be O
conserved O
in O
a O
broad O
range O
of O
organisms O
including O
mycoplasma O
, O
plants O
, O
and O
humans O
. O

conversion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
14C B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
14C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
passage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
through O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
obtaining O
ultra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
thin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sections I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
coccidian B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
oocysts I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
is O
reported O
. O

It O
was O
found O
that O
on O
the O
14th O
and O
21st O
day O
after O
cimetidine O
administration O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
were O
significantly O
elevated O
. O

Dual O
signal O
peptides O
mediate O
the O
signal B_GENE/B_LOCATION
recognition I_GENE/I_LOCATION
particle I_GENE/I_LOCATION
/ O
Sec B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
independent O
insertion O
of O
a O
thylakoid O
membrane O
polyprotein O
, O
PsbY B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
resulting O
score B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
allowed O
the O
disease B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
expressed O
as O
a O
continuous B_MEASURE
variable I_MEASURE
, O
was O
effectively O
utilized O
to O
see O
the O
correlations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
the O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
coronary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
arterial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CAD B_DISEASE/B_LOCATION
) O
and O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
risk B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
markers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

On O
guanidine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
botulism B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Electronic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
Si B_LOCATION/B_NUMBER[MEASURE]
( O
111 B_MEASURE
) O
- O
NiSi2 B_LOCATION/B_PERSON
( O
111 B_MEASURE
) O
A O
- O
type B_LOCATION/B_DISEASE
and O
B B_PROTEIN[GENE]/B_DISEASE
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
interfaces B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

In O
our O
case O
the O
development O
of O
the O
tumor O
at O
the O
posterior O
side O
of O
the O
prostate O
, O
the O
lack O
of O
PSA B_GENE
immunoreactivity O
and O
the O
presence O
of O
mucinous O
glands O
, O
sometimes O
' O
endocervical O
- O
like O
' O
, O
could O
suggest O
an O
origin O
from O
embryonic O
mullerian O
remnants O
in O
the O
prostatic O
utricle O
rather O
than O
urogenital O
sinus O
. O

Upon O
increasing O
the O
Marangoni B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
beyond O
this O
threshold B_LOCATION/B_MEASURE
, O
the O
initially O
stationary B_MEASURE
flow I_MEASURE
becomes O
quickly O
time B_DISEASE_ADJECTIVE[DISEASE]
dependent I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
each O
parahippocampal B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
during O
verbal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
memory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tasks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
which O
the O
side B_LOCATION
activated O
shifted O
depending O
on O
the O
nature B_LOCATION/B_MEASURE
of O
the O
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employed O
; O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
rCBF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
parahippocampal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
associated O
with O
retrieval B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
non B_DISEASE/B_PERSON
- O
matching B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
rCBF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
parahippocampal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
associated O
with O
retrieval B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
matching B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

evolution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
cytomegalovirus B_DISEASE
antibodies I_DISEASE
of O
maternal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
origin I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
acquired O
, O
throughout O
the O
first B_TIME[MEASURE]/B_LOCATION
year I_TIME[MEASURE]/I_LOCATION
of O
life B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
fetal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
liver B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
erythropoiesis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
using O
echo B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
planar B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
actual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
placement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
lesions B_DISEASE/B_PROTEIN[GENE]
was O
determined O
after O
mapping B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
GPI B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
by O
microrecording B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
stimulation B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
the O
sensorimotor B_LOCATION/B_DISEASE
region B_LOCATION/I_DISEASE
and O
its O
somatotopic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
organization B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
experimental B_DISEASE/B_ORGANISM_FUNCTION
atherosclerosis I_DISEASE/I_ORGANISM_FUNCTION
. O

Both O
the O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
venous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thrombi I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
clearly O
discernible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
2 B_NUMBER[MEASURE]/B_LOCATION
to O
8 B_MEASURE
h O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
99Tcm B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
SZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
51 B_NUMBER[MEASURE]
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lung B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
edema I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoactivity B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
furosemide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
malaria B_DISEASE/B_SPECIES[BIO]
vectors O
Anopheles B_SPECIES[BIO]/B_DISEASE
funestus I_SPECIES[BIO]/I_DISEASE
and O
An O
. O
gambiae B_SPECIES[BIO]/B_LOCATION
have O
both O
become O
more O
abundant B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
during O
the O
1970s B_TIME[MEASURE]
and O
1980s B_TIME[MEASURE]/B_BIO
and O
sporozoite B_SPECIES[BIO]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specimens I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
both O
have O
been O
found O
. O

soluble O
extracts O
from O
FGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
as O
compared O
with O
quiescent O
fibroblasts O
exhibited O
up O
to O
3 O
- O
fold O
higher O
kinase O
activity O
towards O
S6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
exogenously O
added O
rat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
liver I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ribosomes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
a O
synthetic O
peptide O
, O
RRLSSLRA O
. O

In O
bell O
pepper O
, O
a O
gene O
encoding O
a O
major O
plastid O
- O
lipid O
associated O
protein O
is O
expressed O
as O
both O
partially O
and O
totally O
spliced O
transcripts O
( O
respectively O
PAP2 B_GENE/B_DISEASE
and O
PAP1 B_GENE/B_DISEASE
) O
. O

Inhibitory B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
characterized O
by O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
a O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
known O
as O
an O
immunoreceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
based O
inhibitory B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ITIM B_ORGANIZATION/B_GENE
) O
in O
their O
cytoplasmic B_LOCATION/B_BIO
tail B_LOCATION/I_BIO
. O

We O
conclude O
that O
LGCS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
is O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
treating O
esophageal B_DISEASE
varices I_DISEASE
in O
the O
setting B_LOCATION
of O
hyperdynamic B_DISEASE/B_PERSON
portal I_DISEASE/I_PERSON
circulation I_DISEASE/I_PERSON
with O
acceptable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
function I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

candidate O
factors O
have O
been O
identified O
by O
the O
observation O
that O
changes O
in O
glucocorticoid O
induction O
parameters O
in O
CV O
- O
1 O
cells O
could O
be O
reproduced O
by O
varying O
the O
cellular O
levels O
of O
coactivators O
[ O
transcriptional B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intermediary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TIF2 B_GENE
) O
, O
steroid B_GENE/B_PERSON
receptor I_GENE/I_PERSON
coactivator I_GENE/I_PERSON
1 I_GENE/I_PERSON
( O
SRC B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
, O
and O
amplified B_PROTEIN[GENE]/B_DISEASE
in I_PROTEIN[GENE]/I_DISEASE
breast I_PROTEIN[GENE]/I_DISEASE
cancer I_PROTEIN[GENE]/I_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
( O
AIB1 B_GENE/B_SPECIES[BIO]
) O
] O
, O
comodulator O
[ O
CREB B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
] O
, O
or O
corepressor O
[ O
silencing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
retinoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thyroid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hormone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SMRT B_GENE/B_LOCATION
) O
] O
without O
concomitant O
increases O
in O
GR B_GENE/B_DISEASE
. O

Immunoblot O
analyses O
revealed O
that O
the O
loss O
of O
activator O
function O
coincides O
with O
selective O
removal O
of O
the O
C B_ENZYME[GENE]
- I_ENZYME[GENE]
terminal I_ENZYME[GENE]
domain I_ENZYME[GENE]
( I_ENZYME[GENE]
CTD I_ENZYME[GENE]
) I_ENZYME[GENE]
- I_ENZYME[GENE]
hyperphosphorylated I_ENZYME[GENE]
RNAP I_ENZYME[GENE]
IIO I_ENZYME[GENE]
along O
with O
NC2 B_GENE
. O

The O
nucleotide B_LOCATION
sequence I_LOCATION
of O
the O
gene B_GENE/B_LOCATION
encoding O
this O
product B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
determined O
and O
the O
amino B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deduced O
. O

At O
9 O
months O
postpartum O
, O
serum O
fT4 O
and O
fT3 O
levels O
were O
low O
normal O
( O
8 O
. O
0 O
and O
1 O
. O
7 O
pmol O
/ O
L O
, O
respectively O
) O
, O
but O
TSH B_GENE
was O
not O
raised O
( O
0 O
. O
4 O
Mu O
/ O
L O
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Three B_PERSON/B_BIO
patients I_PERSON/I_BIO
did O
not O
tolerate O
PPI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
managed O
by O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
type B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histamine B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
blockers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
considered O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
therefore O
, O
when O
treating O
diabetic B_PERSON
patients I_PERSON
with O
peripheral B_DISEASE
neuropathy I_DISEASE
not O
to O
assume O
that O
the O
diabetes B_DISEASE
itself O
is O
the O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
all O
cases B_PERSON/B_DISEASE
. O

TFIIIB B_GENE/B_DISEASE
assembles O
autonomously O
on O
the O
upstream O
promoter O
of O
the O
yeast B_GENE
U6 I_GENE
snRNA I_GENE
( O
SNR6 B_PROTEIN[GENE]/B_LOCATION
) O
gene O
in O
vitro O
, O
through O
the O
interaction O
of O
its O
TBP B_GENE/B_LOCATION
subunit I_GENE/I_LOCATION
with O
a O
consensus O
TATA O
box O
located O
at O
base O
pair O
- O
30 O
. O

Mutational O
analysis O
of O
the O
IME2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reveals O
two O
critical O
sequence O
elements O
: O
a O
G O
+ O
C O
- O
rich O
sequence O
( O
called O
URS1 O
) O
, O
previously O
identified O
at O
many O
meiotic O
genes O
, O
and O
a O
newly O
described O
element O
, O
the O
T4C O
site O
, O
that O
we O
found O
at O
a O
subset O
of O
meiotic O
genes O
. O

Molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
mannitol B_GENE/B_BIO
operon I_GENE/I_BIO
of O
Clostridium B_BIO/B_GENE
acetobutylicum I_BIO/I_GENE
encoding O
a O
phosphotransferase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
system I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
putative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
modulated O
regulator B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
results O
show O
that O
a O
combination O
of O
Pfu B_GENE/B_BACTERIUM[BIO]
exo I_GENE/I_BACTERIUM[BIO]
( I_GENE/I_BACTERIUM[BIO]
- I_GENE/I_BACTERIUM[BIO]
) I_GENE/I_BACTERIUM[BIO]
at O
the O
primer O
extension O
step O
and O
Taq B_LOCATION/B_GENE
at O
the O
PCR O
amplification O
step O
is O
ideal O
for O
in O
vivo O
DNA O
analysis O
and O
DNA O
damage O
mapping O
using O
LMPCR O
. O

Effect O
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL B_GENE
- I_GENE
1 I_GENE
, O
and O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
proliferation O
of O
human O
Tenon O
' O
s O
capsule O
fibroblasts O
in O
tissue O
culture O
. O

Estimating O
the O
health B_MEASURE/B_DISEASE
care I_MEASURE/I_DISEASE
costs I_MEASURE/I_DISEASE
of O
smokers B_DISEASE
. O

Using O
lacZ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
inducible O
T O
cells O
as O
a O
probe O
, O
we O
screened O
a O
splenic O
cDNA O
library O
in O
transiently O
transfected O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
and O
isolated O
a O
cDNA O
clone O
that O
allowed O
expression O
of O
the O
appropriate O
peptide B_GENE
/ I_GENE
Kb I_GENE
MHC I_GENE
complex I_GENE
in O
APC O
. O

Endotoxemia B_DISEASE
and O
bacteremia B_DISEASE
in O
patients B_PERSON
with O
sepsis B_DISEASE
syndrome I_DISEASE
in O
the O
intensive B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
care B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
unit B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attempts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
modifying O
growth B_MEASURE
functions I_MEASURE
to O
annual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dating O
back O
up O
to O
2 B_TIME[MEASURE]
decades I_TIME[MEASURE]
are O
recalled O
together O
with O
examples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
their O
application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
rather O
different B_MEASURE
degrees I_MEASURE
of O
approximation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

A O
significant O
reduction O
in O
total O
cellular O
p27 B_GENE
protein I_GENE
levels O
and O
a O
moderate O
reduction O
in O
p27 B_GENE
mRNA I_GENE
are O
observed O
, O
but O
no O
changes O
in O
Cdk B_GENE/B_PERSON
regulatory O
kinases O
and O
phosphatases O
occur O
. O

genetic O
linkage O
mapping O
of O
the O
CYP11A1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
the O
cholesterol O
side O
- O
chain O
cleavage O
P450scc B_GENE/B_LOCATION
close O
to O
the O
CYP1A1 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
D15S204 B_GENE/B_LOCATION
in O
the O
chromosome O
15q22 O
. O
33 O
- O
q23 O
region O
. O

genetic O
and O
physiological O
experiments O
suggest O
a O
close O
relationship O
between O
cdc27 B_GENE
+ I_GENE
and O
the O
cdc2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
key O
regulator O
of O
mitosis O
in O
yeast O
and O
also O
in O
higher O
eukaryotic O
cells O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
in O
a O
class B_LOCATION
100 I_LOCATION
laminar I_LOCATION
flow I_LOCATION
clean I_LOCATION
bench I_LOCATION
in O
order B_LOCATION/B_MEASURE
to O
minimize O
particulate B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contamination I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
extraneous B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sources B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cloned O
rRNA O
operon O
was O
transcribed O
in O
vitro O
by O
using O
purified B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Of O
the O
CSF B_MEASURE
tested O
, O
24 B_MEASURE
stimulated O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consumption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
above O
our O
cut B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
off O
, O
and O
8 B_NUMBER[MEASURE]
did O
not O
( O
0 B_MEASURE
. O
84 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
34 B_MEASURE
, O
n O
= O
24 B_MEASURE
compared O
with O
the O
rate B_MEASURE
of O
0 B_MEASURE
. O
27 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
1 B_MEASURE
mumol I_MEASURE
/ O
min B_PERSON/B_MEASURE
/ O
g B_MEASURE
dry I_MEASURE
wt I_MEASURE
, O
respectively O
; O
SD B_MEASURE/B_PROTEIN[GENE]
n B_MEASURE/I_PROTEIN[GENE]
= O
8 B_MEASURE
) O
at O
180 B_MEASURE
minutes I_MEASURE
. O

The O
sequence O
of O
the O
gene O
upstream O
to O
the O
cap O
site O
contains O
characteristic O
RNA B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
polymerase B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
II B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
promoter B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O
a O
putative O
TATA O
box O
at O
position O
- O
29 O
and O
a O
Sp B_GENE
1 I_GENE
binding I_GENE
site I_GENE
( O
GGGGCGGAGA O
) O
at O
position O
- O
48 O
. O

The O
kinetics B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
[ O
14C B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O
NG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
dosed O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
followed O
. O

These O
clones O
contain O
most O
of O
the O
exon O
of O
cyclin B_GENE/B_LOCATION
D2 I_GENE/I_LOCATION
except O
exon O
5 O
. O

One B_NUMBER[MEASURE]/B_PERSON
had O
a O
48 B_MEASURE
- O
hour B_TIME[MEASURE]
cycle I_TIME[MEASURE]
and O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
a O
24 B_MEASURE
- O
hour B_TIME[MEASURE]/B_LOCATION
cycle I_TIME[MEASURE]/I_LOCATION
. O

This O
action O
could O
be O
antagonized O
by O
aminophylline O
, O
a O
competitive O
antagonist O
on O
P1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
purinoceptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Evidence O
for O
Gcr1p B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
Gcr2p B_GENE
interaction O
has O
been O
presented O
earlier O
and O
is O
now O
supported O
by O
the O
isolation O
of O
mutations O
in O
Gcr1p B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
suppressing O
gcr2 B_GENE
, O
as O
assessed O
by O
growth O
and O
enzyme O
assay O
. O

Keys B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
for O
identifying O
species B_BIO/B_PERSON
from O
the O
European B_LOCATION
part I_LOCATION
of O
the O
USSR B_LOCATION/B_ORGANIZATION
and O
north O
- O
eastern B_LOCATION
Kazakhstan I_LOCATION
. O

promoter O
constructs O
containing O
mutations O
in O
the O
PTRE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
selectively O
abolished O
the O
binding O
of O
either O
one O
or O
both O
complexes O
exerted O
opposite O
effects O
on O
the O
transcriptional O
activity O
of O
trypsin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
A O
. O
gambiae O
and O
Aedes O
aegypti O
cell O
lines O
. O

The O
Rep78 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
adeno O
- O
associated O
virus O
( O
AAV O
) O
contains O
amino O
acid O
sequence O
motifs O
common O
to O
rolling B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
circle I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
replication I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RCR I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
initiator I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

plasma O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
patients O
with O
colorectal O
cancer O
. O

Reality O
and O
clinical O
application O
of O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
preparations O
. O

The O
extent B_DISEASE/B_MEASURE
of O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
coronary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sinus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
significantly O
correlated O
to O
the O
coronary B_MEASURE
diameters I_MEASURE
of O
the O
proximal B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
middle B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
segments I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Ramus B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventricularis I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anterior I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
middle B_MEASURE/B_LOCATION
segment I_MEASURE/I_LOCATION
of O
the O
Ramus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circumflexus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
r B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
87 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
02 B_MEASURE
) O
. O

The O
in O
- O
plane B_MEASURE/B_LOCATION
orientational I_MEASURE/I_LOCATION
anisotropy I_MEASURE/I_LOCATION
of O
the O
8CB B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grown O
on O
unidirectionally O
photopolymerized B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PVCN B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
considerably O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
intrinsic B_MEASURE
surface I_MEASURE
orientational I_MEASURE
anisotropy I_MEASURE
of O
these O
substrates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
which O
can O
explain O
the O
generally O
found O
weak B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surface I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anchoring I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
liquid B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
crystals I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
PVCN B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
alignment I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
layers I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Nuclear O
transcription O
assays O
confirmed O
that O
cys B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
under O
sulfur O
- O
regulated O
transcriptional O
control O
and O
that O
cys B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
3 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
+ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
transcription O
was O
constitutive O
in O
sulfur B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controller I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
scon B_LOCATION/B_DISEASE
) O
- O
negative O
regulator O
mutants O
. O

The O
rifampicin O
resistance O
of O
uvsW B_DISEASE/B_GENE
- O
repressed O
replication O
suggests O
that O
it O
involves O
either O
tertiary O
initiation O
or O
some O
novel O
mode O
of O
initiation O
. O

Pharmacokinetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
skin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
penetration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Furthermore O
, O
the O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conferred O
on O
a O
reporter B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
in O
Drosophila B_SPECIES[BIO]
by O
three B_NUMBER[MEASURE]/B_PERSON
closely O
related B_LOCATION/B_PERSON
sequences I_LOCATION/I_PERSON
demonstrates O
that O
even O
subtle B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
an O
E B_GENE/B_MEASURE
box I_GENE/I_MEASURE
or O
flanking B_GENE/B_LOCATION
bases I_GENE/I_LOCATION
have O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consequences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repertoire B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
proteins B_GENE/B_DISEASE
that O
can O
bind O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Buspirone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
Type B_DISEASE
A I_DISEASE
behavior I_DISEASE
, O
hostility B_DISEASE
, O
and O
perceived O
stress B_DISEASE
in O
cardiac B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Recently O
we O
have O
performed O
a O
detailed O
analysis O
of O
specific O
neuronal O
populations O
affected O
by O
the O
mutation O
which O
shed O
new O
light O
on O
the O
role O
of O
Krox B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
segmentation O
and O
on O
the O
physiological O
consequences O
of O
its O
inactivation O
. O

A O
species B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cDNA B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
genomic B_SPECIES[BIO]/B_GENE
clone B_SPECIES[BIO]/I_GENE
. O

The O
inhibition O
of O
monoamine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAO B_GENE/B_PERSON
) O
by O
tranylcypromine O
was O
studied O
in O
6 O
healthy O
volunteers O
given O
increasing O
doses O
of O
10 O
, O
15 O
, O
20 O
and O
25 O
mg O
/ O
day O
over O
a O
4 O
- O
week O
period O
. O

Deletion O
mutagenesis O
of O
the O
promoter O
indicated O
that O
a O
positive O
regulatory O
element O
( O
Pre O
) O
was O
likely O
to O
exist O
downstream O
of O
the O
UL94 B_GENE/B_PERSON
mRNA I_GENE/I_PERSON
start I_GENE/I_PERSON
site I_GENE/I_PERSON
, O
while O
a O
negative O
regulatory O
element O
( O
NRE O
) O
was O
present O
upstream O
of O
the O
TATA O
box O
. O

expression O
of O
Helios B_GENE/B_BIO
was O
detected O
in O
the O
earliest O
hematopoietic O
sites O
of O
the O
embryo O
, O
in O
hematopoietic O
stem O
cells O
in O
the O
adult O
and O
was O
subsequently O
restricted O
to O
a O
subset O
of O
cells O
in O
the O
T O
cell O
lineage O
. O

Metapsychiatry B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
is O
a O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
born O
of O
necessity B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
designate O
the O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
hitherto B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unclassified I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
interface I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
psychiatry B_DISEASE/B_EDU[ORGANIZATION]
and O
mysticism B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Effects B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
negative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pi I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mesons I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
mouse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
probes O
containing O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
iNOS B_GENE
gene I_GENE
revealed O
further O
binding O
of O
different O
complexes O
, O
all O
of O
which O
were O
strongly O
inducible O
by O
Camp O
and O
to O
a O
lower O
extent O
also O
by O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Pi O
signals O
are O
conveyed O
to O
PHO8 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
binding O
of O
PHO4 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
positive O
regulatory O
factor O
, O
to O
a O
promoter O
region O
of O
PHO8 B_GENE/B_BIO
( O
PHO8p B_PROTEIN[GENE]/B_LOCATION
) O
under O
the O
influence O
of O
the O
PHO B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
regulatory O
circuit O
. O

Thus O
, O
the O
end B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
a O
linearized B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
initiate O
new B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
bir B_LOCATION/B_DISEASE
in O
which O
the O
newly O
synthesized O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
displaced O
and O
subsequently O
forms B_DISEASE_ADJECTIVE[DISEASE]
circles I_DISEASE_ADJECTIVE[DISEASE]
by O
NHEJ B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
would O
seem O
that O
caution O
should O
be O
exercised O
in O
using O
HPL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
values O
as O
an O
index O
of O
placental O
function O
in O
anaemic O
women O
. O

A O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acquired O
immune B_DISEASE
deficiency I_DISEASE
syndrome I_DISEASE
before O
1980 B_TIME[MEASURE]/B_PERSON
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombination I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
bacteriophages B_BIO/B_GENE
with O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
took O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
to O
generate O
the O
prophage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
VT1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
Sakai B_MEASURE/B_BIO
. O

The O
adenovirus B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1B B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19 B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
000 B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19K B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
potent O
inhibitor O
of O
apoptosis O
and O
cooperates O
with O
E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
transform O
primary O
rodent O
cells O
. O

Desensitization O
of O
the O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
induced O
Janus B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
( O
Jak B_GENE
2 I_GENE
) O
/ O
signal B_GENE/B_MEASURE
transducer I_GENE/I_MEASURE
and I_GENE/I_MEASURE
activator I_GENE/I_MEASURE
of I_GENE/I_MEASURE
transcription I_GENE/I_MEASURE
5 I_GENE/I_MEASURE
( O
Stat5 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
signaling O
pathway O
requires O
protein O
synthesis O
and O
phospholipase B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
C B_GENE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

In O
two O
separate O
studies O
, O
specimens O
of O
saliva O
from O
57 O
individuals O
over O
the O
age O
of O
65 O
years O
( O
mean O
age O
, O
76 O
. O
7 O
years O
) O
and O
37 O
persons O
under O
the O
age O
of O
40 O
years O
( O
mean O
age O
, O
28 O
. O
8 O
years O
) O
were O
examined O
for O
concentrations O
of O
IgA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
functions O
of O
volume O
, O
total O
protein O
, O
and O
electrolyte O
conductivity O
; O
some O
were O
also O
tested O
for O
IgG B_GENE
and O
IgM B_GENE
content O
. O

E2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
HLF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
mediated O
cell O
transformation O
requires O
both O
the O
trans O
- O
activation O
domains O
of O
E2A B_GENE/B_LOCATION
and O
the O
leucine O
zipper O
dimerization O
domain O
of O
HLF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
adjacent O
, O
highly O
homologous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
endoglucanase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
celD B_LOCATION/B_GENE
and O
celE B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
Fibrobacter O
succinogenes O
S85 O
, O
which O
were O
separated O
by O
an O
AT O
- O
rich O
223 O
- O
nucleotide O
intergenic O
region O
were O
characterized O
. O

The O
Seldinger B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
technique I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
difficult B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transurethral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
catheterization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
gentle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
alternative I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
to O
suprapubic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
puncture I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
BR B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Surg I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2000 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
87 B_MEASURE
: O
1729 B_MEASURE
- O
30 B_MEASURE
) O
. O

We O
screened O
an O
A O
. O
thaliana O
cDNA O
library O
, O
whose O
inserts O
are O
under O
the O
control O
of O
the O
galactose O
- O
inducible O
GAL10 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
for O
cDNAs O
which O
enabled O
YDH8 O
cells O
to O
grow O
at O
the O
restrictive O
temperature O
. O

We O
generated O
' O
signature O
' O
oligonucleotides O
from O
these O
CDR3s B_GENE
and O
probed O
PCR O
amplified O
V B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
synovium O
and O
PBLs O
of O
the O
same O
patient O
, O
and O
from O
PBLs O
and O
spleen O
of O
individuals O
without O
rheumatic O
disease O
. O

One O
of O
the O
major O
transcripts O
encodes O
MEQ B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
339 O
- O
amino O
- O
acid O
bZIP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
is O
homologous O
to O
the O
Jun B_PERSON/B_GENE
/ O
Fos B_GENE/B_LOCATION
family O
of O
transcription O
factors O
. O

It O
is O
concluded O
that O
the O
new O
class O
of O
competitive O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O
, O
exemplified O
by O
CGP O
37849 O
, O
is O
the O
most O
promising O
candidate O
for O
clinical O
trials O
in O
anxiety O
disorders O
. O

An O
emended B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
Tylocephalum B_DISEASE
is O
proposed O
excluding O
this O
feature B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
along O
with O
distribution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
testes B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
preovarian B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
field I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
and O
circummedullary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vitelline B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
follicles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

induction O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IFNalpha B_PROTEIN[GENE]/B_LOCATION
) O
gene O
expression O
in O
virus O
- O
infected O
cells O
requires O
phosphorylation O
- O
induced O
activation O
of O
the O
transcription O
factors O
IRF3 B_GENE
and O
IRF7 B_GENE
. O

methods O
: O
The O
prevalence O
of O
haemagglutination B_DISEASE
inhibiting I_DISEASE
( I_DISEASE
HI I_DISEASE
) I_DISEASE
antibodies I_DISEASE
to O
Je O
virus O
( O
JEV O
) O
, O
West O
Nile O
virus O
( O
WNV O
) O
and O
dengue O
- O
2 O
virus O
( O
Den O
- O
2 O
) O
was O
detected O
by O
hi O
test O
and O
IgM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
capture O
ELISA O
( O
MAC O
ELISA O
) O
was O
performed O
to O
determine O
recent O
infections O
with O
Je O
virus O
. O

Moreover O
, O
since O
the O
integrated O
transforming O
DNA O
was O
not O
altered O
or O
lost O
expression O
of O
the O
RbcS2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
: O
aadA B_GENE/B_BACTERIUM[BIO]
: O
: O
RbcS2 B_GENE
gene I_GENE
( I_GENE
s I_GENE
) I_GENE
appears O
to O
be O
repressed O
. O

Donehower B_PERSON/B_LOCATION
and O
H B_OTHER/B_PERSON
. O

A O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feature B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
their O
tendency B_DISEASE
to O
form O
homo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
/ O
or O
heterodimeric B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Further O
, O
more O
recent O
communications O
suggest O
that O
liver O
disease O
led O
to O
a O
differential O
alteration O
of O
the O
cytochrome B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
P I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
450s I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
with O
regard O
to O
protein O
content O
and O
activity O
. O

apparent B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Buschke I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Loewenstein B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tumour B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
penis B_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
stronger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
multiple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
predoses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
sertraline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
when O
imipramine B_MEASURE
Cmax I_MEASURE
and O
AUC B_MEASURE/B_PROTEIN[GENE]
( O
0 B_MEASURE/B_LOCATION
- O
Infinity B_MEASURE
) O
were O
increased O
by O
39 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
68 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
. O

mutations O
in O
nifR1 B_GENE
( O
ntrC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
nifR4 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
rpoN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
encoding O
sigma54 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
had O
no O
influence O
on O
xdh B_GENE
gene I_GENE
expression O
. O

We O
therefore O
propose O
that O
PRR2 B_GENE/B_LOCATION
, O
and O
not O
PVR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
the O
true O
human O
homolog O
of O
MPH B_DISEASE/B_GENE
. O

Swarming O
of O
Moraxella B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Biochem B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

In O
contrast O
, O
vRel B_GENE/B_PERSON
lacks O
a O
strong O
C O
- O
terminal O
gene O
activation O
function O
, O
since O
a O
LexA B_GENE/B_LOCATION
fusion I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
containing O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vRel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alone O
only O
weakly O
activated O
transcription O
. O

The O
crystal O
structure O
of O
the O
yeast O
Phe B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tRNAPhe I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ternary I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Thermus O
aquaticus O
EF B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
Tu B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
GDPNP O
( O
Phe B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
TC B_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
has O
previously O
been O
determined O
as O
one O
representative O
of O
this O
general O
yet O
highly O
discriminating O
complex O
formation O
. O

Bovine B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
anaplasmosis I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
: O
susceptibility B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
seronegative B_SPECIES[BIO]/B_DISEASE
cows I_SPECIES[BIO]/I_DISEASE
from O
an O
infected B_DISEASE/B_LOCATION
herd I_DISEASE/I_LOCATION
to O
experimental B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
Anaplasma B_SPECIES[BIO]/B_DISEASE
marginale I_SPECIES[BIO]/I_DISEASE
. O

Because O
of O
gut B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
fermentation I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
substantial B_MEASURE/B_PERSON
portion I_MEASURE/I_PERSON
( O
16 B_MEASURE
- O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
of O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
absorbed O
as O
ammonia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
NH3N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

quantitative O
measurement O
of O
antigamma B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
globulin I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factors I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
rheumatoid B_DISEASE/B_LOCATION
factors I_DISEASE/I_LOCATION
) O
using O
laser O
- O
nephelometry O
in O
comparison O
with O
the O
latex O
agglutination O
test O
and O
the O
Waaler O
- O
Rose O
test O
. O

The O
densities B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
ranged O
between O
2 B_MEASURE
and O
3976 B_MEASURE
neurites I_MEASURE
/ O
mm2 B_MEASURE/B_BIO
skin I_MEASURE/I_BIO
surface I_MEASURE/I_BIO
, O
but O
the O
overlap B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
between O
subjects B_PERSON/B_LOCATION
and O
without O
PHN B_DISEASE/B_PERSON
was O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Zoonotic B_LOCATION/B_ORGANIZATION
areas I_LOCATION/I_ORGANIZATION
in O
which O
HIV B_DISEASE
co I_DISEASE
- O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
common B_DISEASE_ADJECTIVE[DISEASE]
could O
also O
be O
at O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
as O
sandflies B_PERSON/B_DISEASE
can O
become O
infected O
from O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
infected O
individuals B_PERSON/B_BIO
. O

The O
determination O
of O
antithrombin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
its O
clinical O
significance O
. O

The O
kinetics B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
erythromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
E B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
) O
was O
studied O
in O
16 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
different B_DISEASE_ADJECTIVE[DISEASE]
degrees I_DISEASE_ADJECTIVE[DISEASE]
of O
impairment B_DISEASE_ADJECTIVE[DISEASE]
of O
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
after O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Base O
substitutions O
within O
this O
NFIL B_LOCATION/B_BIO
- I_LOCATION/I_BIO
6 I_LOCATION/I_BIO
site I_LOCATION/I_BIO
resulted O
in O
virtual O
elimination O
of O
LPS O
- O
induced O
IL B_GENE
- I_GENE
1 I_GENE
beta I_GENE
gene I_GENE
transcription O
. O

mortality B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
chi2 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
0 B_MEASURE
. O
0298 B_MEASURE
, O
p O
> O
0 B_MEASURE
. O
5 B_MEASURE
) O
. O

The O
MALDI B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
TOF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
however O
, O
proved O
to O
be O
superior B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
GC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
particularly O
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
baseline B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resolution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
unsaturated B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Modern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
shock B_DISEASE/B_PERSON
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
extensive B_PERSON/B_DISEASE
burns I_PERSON/I_DISEASE
( O
author B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transl I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Of O
the O
private B_ORGANIZATION/B_LOCATION
practices B_ORGANIZATION/I_LOCATION
accredited O
in O
August B_PERSON/B_LOCATION
1995 I_PERSON/I_LOCATION
, O
40 B_MEASURE
. O
6 B_MEASURE
per O
cent B_MEASURE/B_PERSON
( O
122 B_MEASURE/B_PERSON
) O
participated O
. O

A O
Drosophila O
subobscura O
genomic O
fragment O
containing O
all O
the O
exons O
and O
the O
late O
and O
early O
promotors O
in O
the O
Sxl B_GENE
gene I_GENE
of I_GENE
D I_GENE
. I_GENE
melanogaster I_GENE
was O
isolated O
. O

collectively O
, O
a O
unique O
mechanism O
involving O
NF B_GENE
- I_GENE
ATp I_GENE
appears O
to O
regulate O
the O
cell O
type O
- O
specific O
and O
activation O
- O
dependent O
expression O
of O
the O
SCM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
sensitivity O
of O
central B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
with O
the O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O
to O
apomorphine O
application O
. O

Oral O
basal O
body O
temperature O
( O
BBT O
) O
recordings O
of O
46 O
women O
that O
conceived O
by O
donor O
insemination O
and O
who O
had O
midcycle O
monitoring O
of O
luteinising B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
analysed O
to O
establish O
features O
associated O
with O
an O
optimal O
cycle O
. O

Our O
results O
admit O
that O
a O
ribosome O
scanning O
mechanism O
of O
the O
MP B_GENE
gene I_GENE
expression O
from O
I O
( O
2 O
) O
sgRNA O
operates O
concurrently O
. O

The O
three B_NUMBER[MEASURE]
- O
dimensional B_LOCATION/B_MEASURE
structure I_LOCATION/I_MEASURE
of O
the O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
coli B_GENE
CR I_GENE
domain I_GENE
indicates O
that O
this O
sequence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conservation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
result O
in O
a O
conserved B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Otosclerosis B_DISEASE
in O
monozygotic B_PERSON/B_LOCATION
twins I_PERSON/I_LOCATION
: O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
genetical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
DNA O
fragment O
that O
complements O
the O
uvs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
mutation O
was O
subcloned O
by O
monitoring O
its O
ability O
to O
transform O
the O
uvs B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
2 I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
mutant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
MMS O
resistance O
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lbc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
guanine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
exchange I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
specifically O
activates O
the O
Rho B_GENE
small I_GENE
GTP I_GENE
binding I_GENE
protein I_GENE
, O
thus O
resulting O
in O
biologically O
active O
, O
GTP O
- O
bound O
Rho B_GENE
, O
which O
in O
turn O
mediates O
actin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal O
reorganization O
, O
gene O
transcription O
, O
and O
entry O
into O
the O
mitotic O
S O
phase O
. O

Insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
autophosphorylation O
at O
specific O
sites O
in O
the O
tyrosine B_LOCATION/B_PERSON
kinase I_LOCATION/I_PERSON
domain I_LOCATION/I_PERSON
of O
the O
receptor O
' O
s O
beta O
- O
subunit O
is O
correlated O
kinetically O
with O
activation O
of O
kinase O
- O
catalyzed O
phosphorylation O
of O
a O
model O
substrate O
( O
reduced O
and O
carboxyamidomethylated O
lysozyme B_GENE
; O
RCAM B_GENE
- I_GENE
lysozyme I_GENE
) O
. O

The O
critical B_DISEASE_ADJECTIVE[DISEASE]
obstacle I_DISEASE_ADJECTIVE[DISEASE]
in O
modeling O
psychiatric B_DISEASE/B_PERSON
disorders I_DISEASE/I_PERSON
has O
been O
limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
about O
their O
origin B_DISEASE
and O
underlying O
neural B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
allergic B_DISEASE/B_LOCATION
rhinoconjunctivitis I_DISEASE/I_LOCATION
is O
a O
common B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
, O
affecting O
> B_MEASURE/B_DISEASE
20 I_MEASURE/I_DISEASE
% I_MEASURE/I_DISEASE
of O
people B_PERSON
of O
all O
socioeconomic B_MEASURE/B_PERSON
strata I_MEASURE/I_PERSON
. O

The O
results O
of O
these O
studies O
indicate O
that O
EHV B_GENE
- I_GENE
1 I_GENE
gp13 I_GENE
is O
the O
structural O
homolog O
of O
herpes B_GENE/B_VIRUS[BIO]
simplex B_GENE/I_VIRUS[BIO]
virus B_GENE/I_VIRUS[BIO]
glycoprotein B_GENE/I_VIRUS[BIO]
C B_GENE/I_VIRUS[BIO]
and O
further O
suggest O
that O
the O
epitope O
- O
containing O
N O
- O
terminal O
amino O
acid O
sequences O
of O
the O
herpesvirus B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gC I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
undergone O
more O
extensive O
evolutionary O
divergence O
than O
the O
C O
- O
terminal O
sequences O
. O

Within O
the O
final B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
11 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
there O
are O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aromatic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
no O
acidic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
it O
has O
been O
proposed O
that O
these O
residues B_MEASURE/B_LOCATION
stack O
with O
and O
electrostatically O
interact B_MEASURE/B_LOCATION
with O
the O
kinked B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
DNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
at O
the O
site B_LOCATION/B_MEASURE
of O
a O
pyrimidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

By O
contrast O
, O
footprint O
II O
at O
position O
- O
125 O
is O
common O
to O
both O
HeLa O
and O
GH3 O
cell O
extracts O
and O
overlies O
a O
15 O
- O
base O
- O
pair O
sequence O
found O
in O
all O
members O
of O
the O
growth B_BIO/B_GENE
hormone I_BIO/I_GENE
gene I_BIO/I_GENE
family I_BIO/I_GENE
. O

significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
vascular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tonus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
the O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
rheumatic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
arteriosclerotic B_DISEASE_ADJECTIVE[DISEASE]
lesions I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
vessels B_BODY_PART_OR_ORGAN_COMPONENT
in O
middle B_TIME[MEASURE]/B_LOCATION
- O
aged B_PERSON/B_MEASURE
and O
elderly B_PERSON
persons I_PERSON
with O
fibrillation B_DISEASE
arrhythmia I_DISEASE
. O

The O
gene O
responsible O
for O
multiple O
endocrine O
neoplasia O
type O
1 O
( O
MEN1 B_GENE/B_DISEASE
) O
, O
a O
heritable O
predisposition O
to O
endocrine O
tumours O
in O
man O
, O
has O
recently O
been O
identified O
. O

toxicological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
dietary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maillard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rat B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

AST B_GENE
activity O
in O
PMNs O
was O
significantly O
low O
, O
approximately O
2 O
% O
of O
that O
observed O
in O
HPLFs O
. O

Specifically O
, O
we O
engineered O
two O
chimeras O
in O
which O
the O
N O
- O
terminal O
lobe O
of O
the O
SH1 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domain I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
c B_GENE
- I_GENE
Abl I_GENE
was O
swapped O
with O
that O
of O
v B_GENE
- I_GENE
Src I_GENE
. O

Biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
that O
the O
concentration B_MEASURE
of O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
significantly O
in O
cortex B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
and O
olfactory B_BODY_PART_OR_ORGAN_COMPONENT
bulb I_BODY_PART_OR_ORGAN_COMPONENT
but O
not O
in O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
altered O
in O
any O
brain B_LOCATION/B_BIO
region I_LOCATION/I_BIO
examined O
. O

The O
cDNA O
contains O
a O
reading O
frame O
for O
a O
145 O
- O
amino O
- O
acid O
protein O
and O
it O
lacks O
the O
UGA O
codons O
, O
which O
have O
been O
found O
in O
the O
reading O
frame O
of O
the O
mouse B_GENE
MCS I_GENE
cDNA I_GENE
and O
have O
been O
presumed O
to O
encode O
the O
selenocysteine O
in O
the O
amino O
terminal O
of O
the O
deduced O
mouse O
amino O
acid O
sequence O
. O

These O
results O
suggest O
that O
repetitive O
GAA O
sequences O
enhance O
splicing O
by O
binding O
a O
protein O
complex O
containing O
a O
sequence O
- O
specific O
RNA O
binding O
protein O
and O
a O
general O
splicing O
activator O
that O
, O
in O
turn O
, O
recruit O
additional O
SR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

letter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
Dehydrated O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strip I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
yeasts B_DISEASE/B_BACTERIUM[BIO]
. O

Cell B_BODY_PART_OR_ORGAN_COMPONENT
sloughing O
with O
proparacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

cytomegalovirus B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
- O
modern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

highly O
conserved O
regions O
called O
src B_PROTEIN[GENE]
homology I_PROTEIN[GENE]
2 I_PROTEIN[GENE]
and O
3 O
( O
SH2 B_GENE
and O
SH3 B_PROTEIN[GENE]
) O
, O
comprising O
amino O
acid O
residues O
88 O
to O
250 O
, O
are O
believed O
to O
modulate O
the O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
present O
in O
the O
carboxy O
- O
terminal O
halves O
of O
the O
src B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interestingly O
, O
the O
NES B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
appeared O
to O
have O
altered O
interactions O
with O
the O
splicing O
complex O
, O
binding O
more O
tightly O
to O
SC35 B_GENE/B_BIO
in O
co O
- O
immunoprecipitation O
assays O
. O

We O
propose O
2 O
separate O
PAI B_GENE
- I_GENE
1 I_GENE
inductory O
pathways O
for O
PMA O
and O
IL B_GENE/B_NUMBER[MEASURE]
- I_GENE/I_NUMBER[MEASURE]
1alpha I_GENE/I_NUMBER[MEASURE]
in O
HepG2 O
, O
both O
involving O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O
; O
the O
serum O
- O
induced O
signaling O
pathway O
may O
( O
partially O
) O
overlap O
with O
the O
PMA O
- O
activated O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
kinase I_GENE
pathway O
, O
leading O
to O
c B_GENE
- I_GENE
Jun I_GENE
homodimer I_GENE
binding O
to O
the O
PAI B_GENE
- I_GENE
1 I_GENE
TRE O
. O

We O
show O
that O
sae1 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
and O
sae3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutations I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
each O
confer O
a O
distinct O
defect O
in O
meiotic O
recombination O
. O

sae1 B_PERSON/B_GENE
- I_PERSON/I_GENE
1 I_PERSON/I_GENE
produces O
recombinants O
but O
very O
slowly O
and O
ultimately O
to O
less O
than O
half O
the O
wild O
- O
type O
level O
; O
sae3 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
1 B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
makes O
persistent O
hyper O
- O
resected O
meiotic O
double O
- O
strand O
breaks O
and O
has O
a O
severe O
defect O
in O
formation O
of O
recombinants O
. O

G6620 B_PROTEIN[GENE]
is O
the O
3 O
' O
end O
of O
the O
MOL1 B_GENE
gene I_GENE
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B_PROTEIN[GENE]
is O
the O
NAT2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
encodes O
a O
methionine B_ENZYME[GENE]
N I_ENZYME[GENE]
- I_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
; O
G6635 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
the O
RPL30B B_GENE
gene I_GENE
coding O
for O
the O
ribosomal B_GENE
protein I_GENE
L30 I_GENE
; O
G6658 B_PROTEIN[GENE]/B_LOCATION
is O
RSR1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O
a O
ras B_ENZYME[GENE]
- I_ENZYME[GENE]
related I_ENZYME[GENE]
protein I_ENZYME[GENE]
; O
G6667 B_PROTEIN[GENE]/B_LOCATION
is O
CYS4 B_GENE/B_LOCATION
, O
the O
gene O
for O
cystathionine B_GENE
beta I_GENE
- I_GENE
synthase I_GENE
; O
G6670 B_PROTEIN[GENE]/B_LOCATION
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B_GENE
; O
G6673 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
PEM1 B_PROTEIN[GENE]/B_LOCATION
/ O
CHO2 B_PROTEIN[GENE]/B_BACTERIUM[BIO]
encoding O
a O
phosphatidylethanolamine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
G7001 B_PROTEIN[GENE]/B_PERSON
is O
the O
NSR1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

Transcriptional O
analysis O
of O
this O
gene O
cluster O
was O
performed O
by O
detecting O
the O
presence O
of O
mRNAs O
spanning O
adjacent O
genes O
as O
well O
as O
by O
using O
a O
promoterless O
lacZ B_GENE
reporter I_GENE
gene I_GENE
fused O
to O
each O
of O
the O
seven O
genes O
contained O
in O
the O
tol B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
oprL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
locus O
. O

serum O
IgG B_GENE
and O
IgA B_GENE
level O
were O
decreased O
. O

Histopathologically O
, O
( O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killed O
with O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
GMC B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
given O
orally O
) O
there O
were O
diffuse B_DISEASE
hyperemia I_DISEASE
of O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
parenchymal B_DISEASE
degeneration I_DISEASE
of O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubuli I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
edema B_DISEASE
and O
emphysema B_DISEASE
of O
the O
lungs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
contribution B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reviewers B_PERSON
and O
editors B_PERSON
to O
the O
scientific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
work I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
authors B_PERSON/B_ORGANIZATION
. O

The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
space B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
partially O
known O
on O
astronauts B_BIO/B_PERSON
, O
but O
much O
remains O
to O
be O
discovered O
. O

Therefore O
the O
effect O
of O
GAL11 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
on O
PGK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription O
must O
be O
mediated O
at O
the O
PGK B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
presumably O
as O
part O
of O
the O
activation O
complex O
. O

Wingless B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
Wnt B_GENE/B_DISEASE
signaling O
directs O
cell O
- O
fate O
choices O
during O
embryonic O
development O
. O

RNase B_GENE
protection O
analysis O
reveals O
a O
10 O
- O
fold O
increase O
in O
the O
expression O
of O
SCD2 B_GENE
mRNA I_GENE
during O
3T3 O
- O
L1 O
preadipocyte O
differentiation O
. O

To O
determine O
whether O
transcription O
of O
orfX O
and O
vfr B_LOCATION/B_PROTEIN[GENE]
are O
controlled O
by O
the O
same O
mechanisms O
that O
control O
transcription O
of O
the O
region O
of O
the O
divergent O
ORF O
( O
dorf O
) O
and O
of O
crp B_GENE
, O
we O
compared O
the O
vfr B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
orfX O
and O
crp B_GENE/B_DISEASE
- O
dorf O
intergenic O
regions O
. O

As O
a O
member O
of O
the O
uncoupling B_GENE/B_PERSON
protein I_GENE/I_PERSON
family I_GENE/I_PERSON
, O
UCP2 B_GENE
is O
ubiquitously O
expressed O
in O
rodents O
and O
humans O
, O
implicating O
a O
major O
role O
in O
thermogenesis O
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

parental O
and O
vector O
- O
transfected O
MCF7 O
cells O
, O
which O
were O
sensitive O
to O
the O
growth O
- O
inhibitory O
effects O
of O
atRA O
, O
exhibited O
atRA O
- O
dependent O
retinoic B_GENE
acid I_GENE
receptor I_GENE
( O
RAR B_PROTEIN[GENE]/B_LOCATION
) O
transactivation O
and O
transrepression O
of O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
- O
induced O
AP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
activity O
. O

The O
majority B_PERSON/B_MEASURE
of O
the O
respondents B_PERSON/B_LOCATION
( O
83 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
considered O
that O
coitus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
should O
not O
be O
stopped O
during O
pregnancy B_DISEASE/B_PERSON
. O

Based O
on O
the O
ratios B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
areas B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
under O
the O
concentration B_TIME[MEASURE]/B_LOCATION
- O
time B_MEASURE/B_LOCATION
curves B_MEASURE/I_LOCATION
in O
CSF B_BODY_PART_OR_ORGAN_COMPONENT
and O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
penetration B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
CSF B_BODY_PART_OR_ORGAN_COMPONENT
was O
0 B_MEASURE
. O
13 B_MEASURE
- O
0 B_MEASURE
. O
42 B_MEASURE
( O
median B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
22 B_MEASURE
) O
. O

The O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mineral B_DISEASE
oil I_DISEASE
lipidosis I_DISEASE
in O
lymph B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nodes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
radiopaque B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oils I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
Whipple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
discussed O
. O

With O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fed O
on O
the O
Zn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
sufficient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
NaFe3 B_LOCATION/B_PERSON
+ O
EDTA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
Na2EDTA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
similarly O
increased O
the O
absorption B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
urinary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
excretion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
retention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
Zn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O
to O
a O
lesser B_DISEASE/B_MEASURE
extent B_DISEASE/I_MEASURE
. O

99Tcm O
- O
labelled O
albumin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
colloid O
, O
albures O
( O
radius O
250 O
nm O
) O
or O
nanocoll O
( O
radius O
25 O
nm O
) O
, O
or O
both O
were O
used O
as O
test O
substances O
to O
study O
the O
kinetics O
of O
vascular O
clearance O
after O
RES O
stimulation O
. O

Meq B_GENE/B_PERSON
/ O
c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
Jun I_GENE/I_LOCATION
heterodimers O
bind O
to O
an O
AP1 B_GENE/B_LOCATION
- I_GENE/I_LOCATION
like I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
in O
the O
meq B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
region I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
an O
affinity O
much O
greater O
than O
that O
of O
Meq B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Meq B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
Jun I_GENE/I_LOCATION
/ O
c B_GENE/B_PERSON
- I_GENE/I_PERSON
Jun I_GENE/I_PERSON
homodimers O
. O

Moreover O
, O
the O
noncoordinate O
effects O
of O
FSK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
PMA O
- O
stimulated O
MKK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
MAPK B_GENE
activities O
indicates O
the O
presence O
of O
a O
additional O
distal O
Camp O
- O
dependent O
inhibitory O
mechanisms O
. O

These O
findings O
indicated O
that O
p35 B_GENE
is O
a O
trans O
- O
dominant O
factor O
that O
facilitates O
AcMNPV O
growth O
in O
a O
cell O
line O
- O
specific O
manner O
. O

Pseudotumor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pulmonary B_DISEASE
nocardia I_DISEASE
infection I_DISEASE
( O
Nocardia B_LOCATION/B_DISEASE
Nova I_LOCATION/I_DISEASE
) O
in O
a O
renal B_PERSON/B_BIO
transplant I_PERSON/I_BIO
patient I_PERSON/I_BIO
. O

hematological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
leukocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
neutrophil B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
platelet B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
counts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O
and O
liver B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tests I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
determined O
by O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Karyo B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
cytometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cortical B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
layer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
V I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pyramidal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
albino B_PERSON/B_BIO
rat O
after O
three B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
fixations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experience I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
gained O
from O
a O
combined O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
252Cf B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
brachytherapy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O
the O
staff B_PERSON/B_ORGANIZATION
- O
members B_PERSON
of O
the O
Research B_LOCATION/B_ORGANIZATION
Institute B_LOCATION/I_ORGANIZATION
of O
Medical B_LOCATION/B_ORGANIZATION
radiology I_LOCATION/I_ORGANIZATION
, O
USSR B_LOCATION/B_PERSON
AMS I_LOCATION/I_PERSON
, O
was O
generalized O
. O

The O
team B_PERSON
physician I_PERSON
and O
conditioning B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
athletes B_PERSON/B_ORGANIZATION
for O
sports B_SPORT[ENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
a O
consensus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
statement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

To O
probe O
the O
inter O
- O
relationship O
between O
the O
virion O
- O
anchoring O
function O
and O
the O
oligomerization O
function O
, O
we O
constructed O
two O
serotype O
3 O
( O
T3 O
) O
sigma B_LOCATION/B_GENE
1 B_LOCATION/I_GENE
deletion O
mutants O
in O
SV40 O
expression O
vectors O
, O
one O
lacking O
the O
hydrophobic O
tail O
and O
the O
hinge O
, O
and O
the O
other O
lacking O
an O
adjacent O
region O
which O
constituted O
part O
of O
the O
coiled O
- O
coil O
. O

aims B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
assess O
static B_MEASURE/B_DISEASE
and O
dynamic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
suffering O
from O
rickets B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
law B_PERSON/B_ORGANIZATION
and O
the O
chiropractor B_ORGANIZATION/B_BIO
. O

In O
contrast O
, O
overexpression O
of O
the O
DREB2A B_GENE
cDNA I_GENE
induced O
weak O
expression O
of O
the O
target O
genes O
under O
unstressed O
conditions O
and O
caused O
growth O
retardation O
of O
the O
transgenic O
plants O
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
AIF B_DISEASE/B_GENE
may O
be O
a O
morphologic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlate B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
tumor B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
preoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cytotoxic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

Mean B_MEASURE/B_PERSON
total I_MEASURE/I_PERSON
homocysteine I_MEASURE/I_PERSON
( O
tHcy B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
21 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
9 B_MEASURE
. O
5 B_MEASURE
micromol I_MEASURE
/ O
L B_OTHER/B_MEASURE
and O
median B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
19 B_MEASURE/B_PERSON
micromol I_MEASURE/I_PERSON
/ O
L B_OTHER/B_MEASURE
. O

Efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
probiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feed I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
additives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
guidelines B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
efficiency B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
microorganisms B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cats B_SPECIES[BIO]
, O
and O
horses B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
] I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
probiotic I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
microorganisms I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O
frequently O
in O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
as O
feed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
additives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O
farm B_LOCATION/B_BIO
and O
pet B_LOCATION/B_PERSON
animals I_LOCATION/I_PERSON
. O

Lung B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
warranted O
for O
stable B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
ventilator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recipients I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Site O
- O
directed O
mutagenesis O
shows O
that O
sites O
throughout O
the O
IRE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alter O
negative O
control O
and O
IRE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
reflecting O
the O
fact O
that O
the O
footprint O
of O
the O
IRE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
over O
the O
entire O
IRE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

An O
alternative O
approach O
to O
random O
integration O
of O
large O
DNA O
fragments O
into O
plants O
is O
to O
utilize O
one O
of O
several O
site O
- O
specific O
recombination O
( O
SSR O
) O
systems O
, O
such O
as O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
lox B_GENE/B_BIO
. O

Neonatal B_PERSON/B_LOCATION
masculinization I_PERSON/I_LOCATION
affects O
maternal B_DISEASE/B_ORGANISM_FUNCTION
behavior B_DISEASE/I_ORGANISM_FUNCTION
sensitivity B_DISEASE/I_ORGANISM_FUNCTION
in O
female B_PERSON/B_BIO
rats I_PERSON/I_BIO
. O

Recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GSTT1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
catalytically O
active O
towards O
1 O
, O
2 O
- O
epoxy O
- O
3 O
- O
( O
p O
- O
nitrophenoxy O
) O
propane O
, O
4 O
- O
nitrobenzyl O
chloride O
and O
dichloromethane O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
six B_PERSON/B_LOCATION
other I_PERSON/I_LOCATION
landmarks I_PERSON/I_LOCATION
favored O
the O
xeroradiograph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O
not O
to O
the O
degree B_MEASURE/B_LOCATION
of O
statistical B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nonlethal O
sec71 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
sec72 B_DISEASE/B_LOCATION
- B_DISEASE/I_LOCATION
1 B_DISEASE/I_LOCATION
mutations B_DISEASE/I_LOCATION
eliminate O
proteins O
associated O
with O
the O
Sec63p B_GENE/B_LOCATION
- O
BiP B_GENE/B_MEASURE
complex O
from O
S O
. O
cerevisiae O
. O

sequence O
and O
deletion O
analysis O
of O
the O
recombination B_GENE/B_BIO
enhancement I_GENE/I_BIO
gene I_GENE/I_BIO
( O
ref B_PROTEIN[GENE]/B_DISEASE
) O
of O
bacteriophage O
P1 O
: O
evidence O
for O
promoter O
- O
operator O
and O
attenuator O
- O
antiterminator O
control O
. O

A O
high O
titer O
of O
anti B_DISEASE/B_GENE
- B_DISEASE/I_GENE
HBc B_DISEASE/I_GENE
, O
thus O
suggested O
to O
be O
an O
indicator O
of O
persistent O
hepatitis O
B O
virus O
infection O
, O
was O
found O
rarely O
in O
seronegative O
patients O
with O
chronic O
hepatitis O
, O
non O
- O
alcoholic O
cirrhosis O
, O
or O
alcoholic O
liver O
diseases O
. O

Adaptability B_DISEASE_ADJECTIVE[DISEASE]
of O
Nippostrongylus B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brasiliensis I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Travassos B_PERSON/B_LOCATION
, O
1914 B_MEASURE
) O
to O
lead O
contamination B_DISEASE/B_BIO
. O

Eph B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
their O
membrane O
- O
associated O
ephrin B_PERSON/B_GENE
ligands I_PERSON/I_GENE
regulate O
cell O
- O
cell O
interactions O
during O
development O
. O

We O
discuss O
the O
possibility O
that O
DNA O
- O
protein O
interactions O
at O
homologous O
nucleotide O
sequences O
like O
those O
identified O
in O
PII O
are O
part O
of O
a O
regulatory O
gene O
Cascade O
that O
participates O
in O
timing O
fla B_GENE
gene I_GENE
expression O
in O
the O
C O
. O
crescentus O
cell O
cycle O
. O

Postcontrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
also O
acquired O
in O
the O
sagittal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
six B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
) O
and O
coronal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
three B_NUMBER[MEASURE]/B_LOCATION
patients I_NUMBER[MEASURE]/I_LOCATION
) O
planes B_LOCATION/B_DISEASE
. O

nature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
thermopower B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
bipolar B_LOCATION/B_ORGANIZATION
semiconductors I_LOCATION/I_ORGANIZATION
. O

To O
increase O
the O
number O
of O
circulating O
polymorphonuclear O
neutrophils O
, O
the O
patient O
was O
treated O
with O
recombinant O
granulocyte B_GENE
- I_GENE
macrophage I_GENE
colony I_GENE
- I_GENE
stimulating I_GENE
factor I_GENE
( O
GM B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
at O
a O
dose O
of O
2 O
micrograms O
protein O
/ O
kg O
bodyweight O
s O
. O
c O
. O
/ O
12 O
h O
. O

By O
using O
methanol O
- O
0 O
. O
15 O
M O
borate O
buffer O
of O
pH O
8 O
. O
0 O
, O
cate B_ENZYME[GENE]
- I_ENZYME[GENE]
chol I_ENZYME[GENE]
- I_ENZYME[GENE]
O I_ENZYME[GENE]
- I_ENZYME[GENE]
methyltransferase I_ENZYME[GENE]
activity O
might O
be O
assayed O
. O

All O
patients B_PERSON
were O
peritonitis B_DISEASE
- O
free B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
least O
6 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
before O
each O
PET B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
amino O
acid O
residues O
and O
subdomains O
important O
for O
DNA O
binding O
, O
hormone O
binding O
, O
dimerization O
, O
and O
transactivation O
are O
mostly O
conserved O
among O
all O
VDR B_GENE/B_SPECIES[BIO]
species O
. O

Transcripts O
appear O
to O
be O
initiated O
from O
an O
upstream O
promoter O
, O
P1 O
, O
located O
in O
front O
of O
the O
tRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
from O
three O
internal O
promoters O
: O
P2 O
is O
located O
immediately O
in O
front O
of O
the O
tRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
PL10 O
is O
near O
the O
beginning O
of O
the O
L1 B_PROTEIN[GENE]
- O
L10 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intergenic O
space O
, O
and O
PL12 O
is O
at O
the O
end O
of O
the O
L10 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
the O
deduced O
amino O
acid O
sequence O
identity O
we O
designated O
GAPC1 B_GENE
and O
GAPC2 B_PROTEIN[GENE]
as O
group O
I O
( O
97 O
% O
identical O
) O
and O
GAPC3 B_GENE
and O
GAPC4 B_PROTEIN[GENE]
as O
group O
II O
( O
99 O
. O
4 O
% O
identical O
) O
. O

A O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
functioning O
parathyroid B_DISEASE/B_PERSON
carcinoma B_DISEASE/I_PERSON
with O
hypereninemic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertension I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Finally O
, O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shift I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
ORF2 B_GENE/B_BIO
was O
able B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
bind O
to O
promoter B_LOCATION/B_GENE
fragment I_LOCATION/I_GENE
566 I_LOCATION/I_GENE
- O
888 B_MEASURE
. O

Critical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
general B_TIME[MEASURE]/B_ENT
results B_TIME[MEASURE]/I_ENT
. O

saturated O
fatty O
acids O
induce O
a O
1 O
. O
6 O
- O
fold O
increase O
in O
transcription O
activity O
, O
whereas O
a O
large O
family O
of O
unsaturated O
fatty O
acids O
repress O
OLE1 B_GENE/B_BIO
transcription O
as O
much O
as O
60 O
- O
fold O
. O

This O
polypeptide O
includes O
the O
first O
three O
zinc O
fingers O
of O
the O
TFIIIA B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
DNA I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
binding I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

An O
exception O
is O
the O
Bcl B_GENE
- I_GENE
6 I_GENE
gene I_GENE
, O
encoding O
a O
transcription O
factor O
, O
which O
was O
found O
to O
be O
mutated O
in O
normal O
human O
memory O
B O
cells O
. O

3 B_NUMBER[MEASURE]
. O

A O
chest B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
X B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ray I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
film I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
infiltrative B_DISEASE
shadows I_DISEASE
in O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
middle I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fields B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
a O
chest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
an O
abnormal B_DISEASE/B_LOCATION
lung I_DISEASE/I_LOCATION
density I_DISEASE/I_LOCATION
in O
the O
right O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
both O
liver O
and O
pancreatic O
islet O
, O
glucokinase B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
subject O
to O
inhibition O
by O
a O
regulatory O
protein O
( O
GCKR B_GENE
) O
. O

MRI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Similarly O
, O
TAM B_PERSON/B_ORGANIZATION
- I_PERSON/I_ORGANIZATION
67 I_PERSON/I_ORGANIZATION
reverted O
the O
morphology O
of O
the O
AdoMetDC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antisense I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
concern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
unexplained B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prevalence I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
BV B_DISEASE
among O
African B_PERSON/B_LOCATION
- O
American B_PERSON/B_LOCATION
women I_PERSON/I_LOCATION
, O
who O
are O
also O
at O
extremely O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
preterm B_DISEASE
birth I_DISEASE
. O

The O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
bentonite B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
the O
compounding B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
of O
hydrogels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Cotransfection O
of O
expression O
plasmids O
encoding O
the O
protein B_GENE
kinase I_GENE
A I_GENE
inhibitor O
, O
or O
an O
inactive O
protein B_ENZYME[GENE]
kinase I_ENZYME[GENE]
A I_ENZYME[GENE]
( O
PKA B_GENE/B_LOCATION
) O
catalytic O
beta O
subunit O
, O
inhibited O
both O
forskolin O
and O
PACAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activation O
of O
chromogranin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O
, O
revealing O
that O
PACAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
trans O
- O
activation O
is O
highly O
dependent O
on O
PKA B_GENE
. O

GH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
rapid O
tyrosine O
phosphorylation O
of O
a O
protein O
at O
approximately O
93 O
kDa O
in O
normal O
fibroblasts O
, O
and O
Western O
blotting O
with O
STAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
STAT5 B_GENE
activation O
( O
phosphorylation O
) O
by O
GH O
. O

The O
most O
valid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
the O
AXB B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
bearing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
the O
cephalometric B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
90 B_MEASURE
. O
91 B_MEASURE
% I_MEASURE
concordance I_MEASURE
. O

The O
cdc42W97R B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
temperature I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
- I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
sensitive I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allele I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
S O
. O
cerevisiae O
displayed O
the O
same O
cell O
- O
division O
- O
cycle O
arrest O
phenotype O
( O
large O
, O
round O
unbudded O
cells O
) O
as O
the O
cdc42 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1ts I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
cyanobacterial B_BIO/B_PROTEIN[GENE]
phycobilisome B_BIO/I_PROTEIN[GENE]
is O
a O
large O
protein O
complex O
located O
on O
the O
photosynthetic O
membrane O
. O

One B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
48 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
% I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
injected O
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
in O
the O
skeleton B_BODY_PART_OR_ORGAN_COMPONENT
, O
9 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
3 B_MEASURE
% I_MEASURE
in O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
4 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
the O
rest B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
assess O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
practice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
blood B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
films I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
for O
malarial B_DISEASE
parasites I_DISEASE
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
thorough B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
malignant B_DISEASE
fibrous I_DISEASE
histiocytoma I_DISEASE
( O
MFH B_LOCATION/B_PROTEIN[GENE]
) O
, O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
subtype I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
soft B_DISEASE/B_LOCATION
tissue I_DISEASE/I_LOCATION
sarcoma I_DISEASE/I_LOCATION
, O
will O
lead O
to O
improved O
histologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocols I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
a O
partial B_GENE/B_LOCATION
941 I_GENE/I_LOCATION
bp I_GENE/I_LOCATION
cDNA I_GENE/I_LOCATION
that O
encoded O
a O
313 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
acid B_PROTEIN[GENE]
polypeptide I_PROTEIN[GENE]
. O

Furthermore O
, O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
both O
TGF B_GENE
- I_GENE
beta I_GENE
- O
and O
Smad B_GENE
- O
induced O
transcription O
in O
a O
Smad4 B_GENE
/ O
DPC4 B_MEASURE/B_PROTEIN[GENE]
- O
dependent O
fashion O
. O

sequences O
within O
and O
flanking O
hypersensitive O
sites O
3 O
and O
2 O
of O
the O
beta B_PROTEIN[GENE]/B_DISEASE
- I_PROTEIN[GENE]/I_DISEASE
globin I_PROTEIN[GENE]/I_DISEASE
locus O
control O
region O
required O
for O
synergistic O
versus O
additive O
interaction O
with O
the O
epsilon B_GENE/B_BIO
- I_GENE/I_BIO
globin I_GENE/I_BIO
gene I_GENE/I_BIO
promoter I_GENE/I_BIO
. O

sequence O
analysis O
revealed O
100 O
% O
homology O
of O
all O
RA O
- O
derived O
PTEN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
those O
from O
normal O
SF O
as O
well O
as O
to O
the O
published O
GenBank O
sequence O
( O
accession O
number O
U93051 B_MEASURE/B_PERSON
) O
. O

174 B_MEASURE
, O
233 B_MEASURE
- O
247 B_MEASURE
) O
and O
Serrate B_NUMBER[MEASURE]/B_LOCATION
( O
Serrate1 B_TIME[MEASURE]/B_PROTEIN[GENE]
and O
2 B_NUMBER[MEASURE]
; O
Myat B_PERSON/B_LOCATION
, O
A B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
, O
Henrique B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Ish B_PERSON/B_LOCATION
- O
Horowicz B_PERSON/B_LOCATION
, O
D B_OTHER/B_LOCATION
. O
and O
Lewis B_PERSON
, O
J B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
1996 B_MEASURE/B_PERSON
. O

Many B_SPECIES[BIO]/B_MEASURE
retroviruses I_SPECIES[BIO]/I_MEASURE
, O
including O
the O
human B_SPECIES[BIO]
and O
simian B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
viruses I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
contain O
a O
leucine B_GENE
zipper I_GENE
- O
like B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
highly O
conserved B_LOCATION/B_TIME[MEASURE]
region B_LOCATION/I_TIME[MEASURE]
of O
the O
external B_LOCATION/B_ORGANIZATION
domain I_LOCATION/I_ORGANIZATION
of O
the O
transmembrane B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O
TM B_LOCATION/B_DISEASE
) O
glycoprotein B_PROTEIN[GENE]/B_LOCATION
. O

functional B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
properly O
folded O
surface B_LOCATION
loop I_LOCATION
covering O
the O
catalytic B_LOCATION
center I_LOCATION
. O

The O
most O
frequent O
abnormality O
was O
GH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O
( O
six O
cases O
) O
, O
followed O
by O
gonadotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
four O
cases O
) O
, O
cortisol O
( O
four O
cases O
) O
, O
and O
TSH B_GENE
( O
one O
case O
) O
, O
whereas O
four O
patients O
showed O
high O
serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
values O
. O

Recombinant O
vaccinia O
viruses O
that O
express O
the O
bacteriophage B_GENE
T3 I_GENE
RNA I_GENE
polymerase I_GENE
( O
VV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3pol I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
the O
Escherichia B_ENZYME[GENE]
coli I_ENZYME[GENE]
lac I_ENZYME[GENE]
repressor I_ENZYME[GENE]
( O
VV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacI I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
under O
control O
of O
the O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vaccinia I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
constructed O
. O

Internal O
controls O
over O
the O
volume O
of O
milk O
suckled O
do O
not O
appear O
until O
infant O
rats O
are O
about O
2 O
weeks O
of O
age O
at O
which O
time O
gastric O
distension O
, O
milk O
, O
systemic O
dehydration O
, O
and O
intestinal B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholecystokinin I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppress O
milk O
intake O
derived O
through O
suckling O
. O

Shields B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
needed O
for O
pacemakers B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O

concerning O
the O
practical O
approach O
in O
a O
clinical O
setting O
, O
it O
has O
to O
be O
pointed O
out O
that O
with O
these O
diseases O
a O
hepatitis O
C O
infection O
has O
to O
be O
considered O
and O
testing O
for O
hepatitis B_DISEASE
C I_DISEASE
antibodies I_DISEASE
and O
, O
if O
positive O
, O
hepatitis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
indicated O
. O

confocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
fluorescent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
WT B_GENE/B_LOCATION
, O
VaI B_LOCATION/B_PROTEIN[GENE]
, O
and O
VaII B_LOCATION/B_PROTEIN[GENE]
all O
distribute O
equally O
to O
the O
cell B_BODY_PART_OR_ORGAN_COMPONENT
surface I_BODY_PART_OR_ORGAN_COMPONENT
while O
, O
as O
expected O
, O
a O
WT B_GENE
mutant I_GENE
lacking O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valine I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
residues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
does O
not O
. O

However O
, O
it O
is O
not O
easy B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
establish O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
thoracic B_DISEASE
MFH I_DISEASE
. O

In O
both O
cell O
types O
, O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
led O
to O
a O
dose O
- O
dependent O
increase O
in O
the O
association O
of O
tyrosine B_GENE
phosphorylated I_GENE
IRS I_GENE
- I_GENE
1 I_GENE
with O
the O
SH2 B_PROTEIN[GENE]
domain I_PROTEIN[GENE]
of O
the O
p85 B_ENZYME[GENE]/B_PERSON
regulatory I_ENZYME[GENE]/I_PERSON
subunit I_ENZYME[GENE]/I_PERSON
of O
PI B_GENE
- I_GENE
3 I_GENE
kinase I_GENE
, O
and O
also O
increased O
the O
amount O
of O
PI B_ENZYME[GENE]
kinase I_ENZYME[GENE]
activity O
detected O
in O
anti B_GENE/B_PERSON
- I_GENE/I_PERSON
IRS I_GENE/I_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
immunoprecipitates O
. O

The O
' O
Ulm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
Zucker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
Uhr B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
System B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
' O
comprises O
a O
microdialysis B_PERSON/B_MEDICAL_DEVICE[OBJECT]
probe I_PERSON/I_MEDICAL_DEVICE[OBJECT]
, O
a O
biosensor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
Glucosensor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Unitec B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Ulm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s O
. O
c B_OTHER/B_DISEASE
. O
) O
, O
a O
sender B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
transferring O
telemetrically O
the O
glucose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
concentrations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
, O
and O
a O
receiving B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicator I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
Xenopus B_GENE
annexin I_GENE
II I_GENE
heavy I_GENE
chain I_GENE
lacks O
the O
highly O
conserved O
tyrosine O
at O
position O
23 O
which O
is O
the O
site O
of O
src B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oncogene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphorylation O
in O
the O
murine O
protein O
. O

No O
bafilomycin O
- O
sensitive O
ATPase B_ENZYME[GENE]
is O
detected O
in O
a O
vacuolar O
fraction O
. O

Plasmids O
bearing O
the O
P B_PROTEIN[GENE]/B_DISEASE
. I_PROTEIN[GENE]/I_DISEASE
stipitis I_PROTEIN[GENE]/I_DISEASE
URA3 I_PROTEIN[GENE]/I_DISEASE
gene I_PROTEIN[GENE]/I_DISEASE
and O
ARS2 O
element O
produced O
more O
than O
30 O
, O
000 O
transformants O
per O
micrograms O
of O
plasmid O
DNA O
. O

Unfractionated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heparin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
UFH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
given O
at O
a O
dose B_MEASURE/B_LOCATION
of O
0 B_MEASURE
. O
3 B_MEASURE
mg I_MEASURE
x O
kg B_MEASURE/B_LOCATION
- O
1 B_MEASURE
bolus I_MEASURE
+ I_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
mg I_MEASURE
x O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
x O
h B_TIME[MEASURE]/B_OTHER
- O
1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
improve O
the O
incidence B_MEASURE
of O
reperfusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
lower O
the O
incidence B_MEASURE
of O
reocclusion B_DISEASE
. O

The O
scores B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
these O
three B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
which O
corresponded O
to O
recognizable B_MEASURE/B_LOCATION
dimensions I_MEASURE/I_LOCATION
of O
depressive B_DISEASE/B_GENE
illness I_DISEASE/I_GENE
, O
were O
then O
correlated O
with O
rCBF B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cloning O
, O
sequence O
analysis O
, O
and O
expression O
of O
the O
gene B_GENE
encoding I_GENE
formaldehyde I_GENE
dismutase I_GENE
from I_GENE
Pseudomonas I_GENE
putida I_GENE
F61 I_GENE
. O

However O
, O
at O
the O
time O
of O
salvage O
treatment O
, O
the O
mean O
serum B_GENE
PSA I_GENE
levels O
were O
9 O
. O
1 O
and O
1 O
. O
1 O
ng O
/ O
mL O
for O
the O
salvage O
RP O
and O
salvage O
RT O
groups O
, O
respectively O
( O
P O
= O
0 O
. O
0001 O
) O
. O

Protease O
digestion O
and O
alkaline O
extraction O
of O
microsomes O
containing O
labeled O
mutant O
proteins O
further O
showed O
that O
segment O
3 O
was O
sufficient O
for O
stable O
membrane O
anchoring O
of O
the O
glycoproteins O
, O
indicating O
that O
this O
segment O
may O
specify O
the O
transmembrane O
domain O
of O
the O
gB B_GENE
glycoprotein I_GENE
. O

The O
mean B_TIME[MEASURE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times B_TIME[MEASURE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
LNR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
in O
these O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
42 B_MEASURE
. O
0 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_LOCATION/B_MEASURE
, O
3 B_MEASURE
. O
0 B_MEASURE
- O
194 B_MEASURE
. O
5 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
and O
49 B_MEASURE
. O
0 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_LOCATION/B_MEASURE
, O
3 B_MEASURE
. O
6 B_MEASURE
- O
209 B_MEASURE
. O
0 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
respectively O
. O

A O
gene O
( O
FMR B_GENE
- I_GENE
1 I_GENE
) O
was O
identified O
within O
a O
four O
cosmid O
contig O
of O
YAC O
DNA O
that O
expresses O
a O
4 O
. O
8 O
kb O
message O
in O
human O
brain O
. O

detailed O
comparison O
of O
the O
sequences O
of O
cp35 B_SPECIES[BIO]
and O
human B_MEASURE/B_GENE
calpactin I_MEASURE/I_GENE
II I_MEASURE/I_GENE
shows O
that O
the O
only O
substantial O
sequence O
dissimilarity O
is O
a O
domain O
encoding O
amino O
acids O
between O
residues O
20 O
and O
40 O
which O
includes O
a O
tyrosine O
phosphorylation O
site O
in O
the O
human O
molecule O
, O
along O
with O
other O
residues O
of O
possible O
physiological O
significance O
. O

Exogenous B_PERSON
heart I_PERSON
stress I_PERSON
raised O
log B_MEASURE/B_LOCATION
circulating O
NE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
proportion B_MEASURE
to O
the O
rise B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
at O
a O
given O
work B_TIME[MEASURE]/B_LOCATION
load I_TIME[MEASURE]/I_LOCATION
so O
that O
the O
usual B_PERSON/B_MEASURE
relationship I_PERSON/I_MEASURE
between O
these O
variables B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
previously O
observed O
during O
other B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stresses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
was O
preserved O
. O

The O
implication O
of O
Rac B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Cdc42 B_GENE
was O
analyzed O
in O
transient O
transfection O
experiments O
using O
either O
constitutively O
active O
( O
V12 O
) O
or O
dominant O
- O
interfering O
( O
N17 O
) O
mutants O
. O

Alternative O
immune B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O
when O
standard O
immune B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
available O
. O

Plasma B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
insulin B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
responses O
to O
glucose O
in O
femoral O
, O
hepatic O
, O
and O
pancreatic O
veins O
in O
dogs O
. O

The O
bioconversion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
inexpensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
the O
valuable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intermediate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
semisynthetic B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cephalosporin B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
deacetoxycephalosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
G I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
DAOG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
had O
been O
recently O
shown O
to O
be O
increased O
by O
eliminating O
agitation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
adding O
decane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

elevated O
potassium O
stimulation O
of O
GAL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
completely O
blocked O
, O
but O
pituitary O
adenylyl B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
histamine O
stimulations O
were O
only O
partially O
blocked O
, O
by O
cycloheximide O
. O

In O
lyzozyme B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
activity O
there O
was O
periodicity O
in O
three O
groups O
but O
not O
in O
the O
youngest O
foals O
. O

GBF1 B_GENE/B_DISEASE
and O
GBF2 B_PROTEIN[GENE]
mRNA I_PROTEIN[GENE]
is O
present O
in O
light O
and O
dark O
grown O
leaves O
as O
well O
as O
in O
roots O
. O

We O
now O
report O
identification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transcriptional B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
by O
three B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cis I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
acting O
sites B_LOCATION/B_ENT
within O
a O
90 B_MEASURE/B_LOCATION
- O
BP B_MEASURE/B_LOCATION
portion I_MEASURE/I_LOCATION
of O
the O
rDNA B_GENE/B_LOCATION
enhancer I_GENE/I_LOCATION
designated O
the O
modulator B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
. O

A O
porcine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
diffuse B_DISEASE
axonal I_DISEASE
injury I_DISEASE
, O
developed O
with O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
these O
physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
earlier O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
tissue I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
modeling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
is O
used O
to O
correlate O
histologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
radiologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
axonal B_DISEASE
injury I_DISEASE
to O
predicted B_LOCATION
regions I_LOCATION
of O
injury B_DISEASE
from O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
size B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
repeated O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
continuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
transient O
induction O
of O
both O
c B_GENE
- I_GENE
fos I_GENE
and O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
TPA O
was O
observed O
in O
both O
cell O
populations O
, O
together O
with O
an O
associated O
suppression O
of O
BSP B_GENE
mRNA I_GENE
in O
the O
fetal O
rat O
calvarial O
cells O
. O

Videoanalysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirms O
the O
ballistic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
character B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
reaching O
movement B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
isomerization O
of O
the O
pre O
- O
existing O
closed O
complex O
to O
an O
open O
promoter O
form O
, O
as O
judged O
by O
the O
local O
denaturation O
of O
promoter O
DNA O
which O
rendered O
sequences O
from O
+ O
5 O
to O
- O
10 O
reactive O
towards O
KMnO4 O
, O
was O
shown O
to O
be O
fully O
dependent O
on O
NifA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

HPV B_VIRUS[BIO]/B_GENE
- O
16 B_MEASURE/B_GENE
mars B_MEASURE/I_GENE
are O
context B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
transcriptional I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
enhancers I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
and O
activated O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
HPV B_VIRUS[BIO]/B_GENE
- O
16 B_MEASURE
oncogenes I_MEASURE
dependent I_MEASURE
on O
chromosomal B_GENE/B_LOCATION
integration I_GENE/I_LOCATION
may O
positively O
select O
tumorigenic B_DISEASE/B_BIO
cells I_DISEASE/I_BIO
during O
the O
multistep B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
etiology I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
cervical B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Sociological B_PERSON/B_EDU[ORGANIZATION]
analysis I_PERSON/I_EDU[ORGANIZATION]
of O
the O
family B_PERSON/B_LOCATION
. O

This O
enhancer O
element O
functioned O
in O
a O
position O
- O
and O
orientation O
- O
independent O
manner O
both O
on O
the O
Pax B_SPECIES[BIO]/B_GENE
- I_SPECIES[BIO]/I_GENE
QNR I_SPECIES[BIO]/I_GENE
P0 I_SPECIES[BIO]/I_GENE
promoter I_SPECIES[BIO]/I_GENE
and O
the O
heterologous B_GENE/B_BIO
thymidine I_GENE/I_BIO
kinase I_GENE/I_BIO
promoter I_GENE/I_BIO
. O

These O
data O
suggest O
that O
overexpression O
of O
MT B_GENE/B_DISEASE
potentiates O
the O
growth O
of O
MCF7 O
cells O
, O
whereas O
downregulation O
of O
MT B_GENE/B_DISEASE
elicits O
antiproliferative O
effects O
. O

A O
multivariant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pituitary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adenoma B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
obtainment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
two B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
logistic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equations I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
an O
auxiliary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
tumors B_DISEASE/B_PERSON
. O

bile B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
salts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
the O
male B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disadvantage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Number B_MEASURE/B_LOCATION
of O
warm B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
units B_LOCATION
with O
higher B_MEASURE
rates I_MEASURE
of O
firing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O
greater B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thermal B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coefficients B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
comparable B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
of O
warm B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
units B_LOCATION
in O
the O
adult B_PERSON/B_LOCATION
, O
gradually O
increased O
with O
growth B_MEASURE/B_LOCATION
. O

Such O
unique O
recognition O
capabilities O
are O
generated O
with O
minimal O
alterations O
in O
the O
CDR3 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
loops O
of O
the O
TCR B_GENE
. O

To O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
puts O
in O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
maximum B_MEASURE/B_LOCATION
delay I_MEASURE/I_LOCATION
of O
stream B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
that O
guarantees O
the O
good B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dimensional I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stability I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
class B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
alginates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
of O
45 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
in O
the O
hot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
humid B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
climatic B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
tropical B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
country B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

Gene B_GENE/B_LOCATION
1 B_GENE/I_LOCATION
of B_GENE/I_LOCATION
the B_GENE/I_LOCATION
murine B_GENE/I_LOCATION
coronavirus B_GENE/I_LOCATION
, B_GENE/I_LOCATION
MHV B_GENE/I_LOCATION
- B_GENE/I_LOCATION
A59 B_GENE/I_LOCATION
, O
encodes O
approximately O
800 O
kDa O
of O
protein O
products O
within O
two O
overlapping O
open O
reading O
frames O
( O
ORFs O
1A O
and O
1b O
) O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B_GENE
and O
the O
N O
terminus O
of O
E2F1 B_GENE
, O
a O
domain O
also O
present O
in O
E2F2 B_GENE
and O
E2F3 B_GENE
but O
absent O
in O
E2F4 B_GENE
and O
E2F5 B_GENE
, O
were O
essential O
. O

Our O
results O
suggest O
a O
biological O
role O
for O
Elf B_GENE
- I_GENE
1 I_GENE
in O
the O
regulation O
of O
IgH B_GENE
gene I_GENE
expression O
, O
attribute O
a O
functional O
role O
for O
receptor O
- O
induced O
AP B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
B O
lymphocytes O
and O
provide O
evidence O
for O
a O
direct O
link O
between O
IgM B_GENE
receptor I_GENE
- O
mediated O
signalling O
and O
3 O
' O
enhancer O
activation O
. O

Oncogenic O
activation O
of O
RET B_GENE
is O
detected O
in O
human O
papillary O
thyroid O
tumours O
and O
in O
multiple O
endocrine O
neoplasia O
type O
2 O
syndromes O
. O

CD4 B_GENE
degradation O
mediated O
by O
Vpu B_GENE/B_BACTERIUM[BIO]
does O
not O
require O
the O
ER O
chaperone O
calnexin B_GENE/B_LOCATION
and O
is O
dependent O
on O
an O
intact O
ubiquitin B_GENE
- O
conjugating O
system O
. O

The O
maternal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
par I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
segregation O
of O
cell O
fate O
specification O
activities O
in O
early O
Caenorhabditis O
elegans O
embryos O
. O

These O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
antagonized O
by O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
1 B_MEASURE
- O
( O
2 B_MEASURE
- O
methoxyphenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
4 B_MEASURE
- O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
( O
2 B_MEASURE
- O
phthalimido B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O
butyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
piperazine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
To O
evaluate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adding O
a O
pulsating O
bristle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
established B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
oscillating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ O
rotating O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
the O
Braun B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ultra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
plaque I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Remover I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
D9 B_LOCATION/B_PROTEIN[GENE]
) O
on O
plaque B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

detailed O
analysis O
of O
the O
predicted O
amino O
acid O
sequence O
revealed O
sequence O
elements O
which O
are O
conserved O
in O
many O
DNA B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
and I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
polymerases I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

Sub B_DISEASE
- O
inhibitory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
post B_DISEASE/B_MEASURE
- O
antibiotic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
spiramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
erythromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
Staphylococcus B_BACTERIUM[BIO]/B_DISEASE
aureus I_BACTERIUM[BIO]/I_DISEASE
. O

The O
CydDC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
appears O
to O
be O
the O
first O
prokaryotic O
example O
of O
a O
heterodimeric B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ABC I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transport I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
each O
polypeptide O
contains O
both O
hydrophobic O
and O
ATP O
- O
binding O
domains O
. O

The O
single O
- O
copy O
U20 B_GENE
sequence I_GENE
is O
located O
on O
the O
same O
DNA O
strand O
as O
the O
nucleolin B_GENE/B_BIO
mRNA I_GENE/I_BIO
. O

gel O
shift O
and O
southwestern O
experiments O
revealed O
nuclear O
proteins O
of O
43 O
kDa O
and O
30 O
kDa O
in O
GC O
and O
fish O
cells O
, O
respectively O
, O
that O
bind O
specifically O
to O
the O
tGH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
CRE O
, O
suggesting O
the O
involvement O
of O
CRE B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
activating B_GENE
- I_GENE
transcription I_GENE
- I_GENE
factor I_GENE
- I_GENE
l I_GENE
- O
related O
peptides O
in O
Camp O
response O
. O

The O
coding O
sequence O
of O
rat B_GENE
MEK I_GENE
kinase I_GENE
1 I_GENE
( O
MEKK1 B_GENE/B_DISEASE
) O
has O
been O
determined O
from O
multiple O
, O
independent O
cDNA O
clones O
. O

In O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
quantitative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
estimates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
regional B_MEASURE/B_LOCATION
distribution I_MEASURE/I_LOCATION
of O
the O
active B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
bone B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
marrow B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
organ B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
infants B_PERSON/B_BIO
and O
children B_PERSON/B_BIO
, O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O
various B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anatomical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
data I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
developed O
. O

We O
compared O
these O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
six B_NUMBER[MEASURE]/B_PERSON
hatchling I_NUMBER[MEASURE]/I_PERSON
and O
eight B_NUMBER[MEASURE]/B_PERSON
adult I_NUMBER[MEASURE]/I_PERSON
Chrysemys I_NUMBER[MEASURE]/I_PERSON
picta I_NUMBER[MEASURE]/I_PERSON
from O
an O
Ohio B_MEASURE/B_LOCATION
population I_MEASURE/I_LOCATION
. O

On O
the O
basis O
of O
experiments O
with O
mutant O
virus O
and O
transfection O
with O
isolated O
genes O
, O
the O
herpes B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
simplex I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virus I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immediate I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
early I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product O
ICP4 B_GENE/B_MEASURE
is O
known O
to O
positively O
regulate O
the O
transcription O
of O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
negatively O
regulate O
expression O
from O
its O
own O
promoter O
. O

A O
female B_PERSON
infant I_PERSON
with O
isolated B_DISEASE
noncompaction I_DISEASE
of O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
myocardium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
who O
developed O
ventricular B_DISEASE
tachyarrhythmia I_DISEASE
is O
described O
. O

Recent B_TIME[MEASURE]/B_EDU[ORGANIZATION]
, O
highly O
visible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
subject B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
clearly O
pointed O
out O
that O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
the O
cellular B_LOCATION
mechanisms I_LOCATION
through O
which O
inhaled O
asbestos B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O
the O
well O
known O
, O
debilitating O
lung B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
- O
asbestosis B_DISEASE
( O
i O
. O
e O
. O
interstitial B_DISEASE
pulmonary I_DISEASE
fibrosis I_DISEASE
) O
. O

The O
POU B_GENE/B_DISEASE
- O
specific O
domain O
of O
Pit B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
is O
essential O
for O
sequence O
- O
specific O
, O
high O
affinity O
DNA O
binding O
and O
DNA O
- O
dependent O
Pit B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
- O
Pit B_GENE
- I_GENE
1 I_GENE
interactions O
. O

Also O
, O
the O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nondepressed O
patients B_PERSON
had O
significantly O
better B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
with O
the O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
depressed I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

obtaining O
kidney B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
a O
beagle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
puppy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
RPB B_LOCATION/B_DISEASE
- O
1 B_NUMBER[MEASURE]
) O
and O
the O
establishment B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
cryopreservation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bank I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

These O
results O
suggest O
an O
essential O
role O
of O
the O
binding O
of O
HNF B_GENE
- I_GENE
4 I_GENE
and O
/ O
or O
HNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
6 O
beta O
A O
- O
A O
site O
on O
the O
basal O
transcriptional O
activation O
of O
the O
CYP3A2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
liver O
cells O
. O

It O
is O
envisaged O
that O
the O
WHOQOL B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
BREF B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
will O
be O
most O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
require O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
for O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
in O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
epidemiological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

restriction O
mapping O
showed O
that O
the O
two O
recombinant O
plasmids O
shared O
an O
EcoRI B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fragment I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
8 O
. O
9 O
kb O
. O

usefulness B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
congestive B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
. O

The O
chromosomal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
YACs B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O
verified O
using O
FISH B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
which O
also O
demonstrated O
their O
nonchimeric B_DISEASE_ADJECTIVE[DISEASE]
nature I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
first O
strand B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
fetal B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
brain B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mRNAs B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
short B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
sF B_PROTEIN[GENE]/B_LOCATION
- O
cDNAs B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
synthesized O
with O
a O
two B_NUMBER[MEASURE]
- O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
our O
modified O
degenerate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oligonucleotide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primed I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shuttle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Dop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
Shuttle B_PERSON/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

For O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
simulations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
physiological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excitation B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
of O
pathologies B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Wolff B_PERSON/B_LOCATION
- O
Parkinson B_PERSON
- O
White B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
, O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
AV B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
block B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
inferior B_DISEASE
wall I_DISEASE
ischaemia I_DISEASE
) O
were O
examined O
. O

Profilins B_NUMBER[MEASURE]/B_PERSON
IIa I_NUMBER[MEASURE]/I_PERSON
and I_NUMBER[MEASURE]/I_PERSON
IIb I_NUMBER[MEASURE]/I_PERSON
are O
also O
present O
in O
humans O
, O
suggesting O
that O
all O
mammals O
have O
three O
profilin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
have O
isolated O
an O
835 O
amino O
acid O
Ring O
finger O
( O
C3HC4 O
zinc O
finger O
) O
protein O
, O
TIF1 B_GENE
beta I_GENE
( O
also O
named O
KAP B_GENE
- I_GENE
1 I_GENE
) O
, O
that O
specifically O
interacts O
with O
the O
KRAB B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
of O
the O
human O
zinc O
finger O
factor O
KOX1 B_PROTEIN[GENE]/B_MEASURE
/ O
ZNF10 B_MEASURE
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O
about O
the O
exeresis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
pyelonephrictic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
left O
small B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
kidney B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O
laparoscopic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

New B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
free B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
diet B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
in O
chronic B_LOCATION
renal I_LOCATION
insufficiency I_LOCATION
. O

Unestablished O
quail O
myoblasts O
were O
infected O
with O
a O
retroviral O
vector O
encoding O
the O
oncogenic O
form O
of O
H B_GENE
- I_GENE
Ras I_GENE
in O
order O
to O
investigate O
the O
mechanism O
by O
which O
this O
oncoprotein O
interferes O
with O
terminal O
differentiation O
. O

Early B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
signs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hepatoangiosarcoma B_DISEASE
among O
vinyl B_PERSON/B_BIO
chloride I_PERSON/I_BIO
workers I_PERSON/I_BIO
. O

The O
reduced O
expression O
caused O
by O
multimerization O
of O
UAS2 O
in O
the O
native O
promoter O
was O
observed O
only O
in O
the O
presence O
of O
ADR1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

VP4 B_GENE/B_SPECIES[BIO]
differentially O
regulates O
TRAF2 B_GENE
signaling O
, O
disengaging O
JNK B_GENE
activation O
while O
directing O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
to O
effect O
rotavirus O
- O
specific O
cellular O
responses O
. O

On O
the O
3rd B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
day I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
after O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
remained B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
kidney I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
for O
30 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
structural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
components I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
walls B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
glomerular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arterioles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
those O
of O
the O
filtration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reabsorption B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
barrier I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
undergo O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
ultrastructural I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
changes I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
that O
with O
time B_TIME[MEASURE]
elapsed O
( O
7 B_MEASURE
, O
14 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
) O
gradually O
pass O
away O
, O
and O
amount B_MEASURE/B_DISEASE
of O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
with O
hypertrophic B_DISEASE/B_MEASURE
processes I_DISEASE/I_MEASURE
increases I_DISEASE/I_MEASURE
. O

The O
purified O
RAG1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
overexpressed O
in O
E O
. O
coli O
exhibited O
the O
expected O
cleavage O
activity O
when O
combined O
with O
RAG2 B_GENE
purified O
from O
transfected O
293T O
cells O
. O

19 B_MEASURE
, O
4967 B_MEASURE
- O
4973 B_MEASURE
) O
. O

preventing O
the O
heterosexual B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HIV B_DISEASE
into O
this O
vulnerable B_LOCATION/B_PERSON
population I_LOCATION/I_PERSON
is O
a O
formidable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
public I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
health I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
challenge I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
we O
show O
that O
GATA B_GENE
- I_GENE
1 I_GENE
and O
Sp1 B_GENE
synergize O
from O
a O
distance O
in O
constructs O
designed O
to O
mimic O
the O
architecture O
of O
globin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
downstream O
globin B_GENE/B_LOCATION
promoters B_GENE/I_LOCATION
. O

Superovulation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
intrauterine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insemination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SO B_DISEASE/B_PROTEIN[GENE]
- O
IUI B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
has O
been O
suggested O
as O
an O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
gamete O
intrafallopian B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transfer I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Gift B_TIME[MEASURE]/B_PERSON
) O
, O
despite O
the O
absence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Mammalian O
chromosome O
ends O
contain O
long O
arrays O
of O
TTAGGG O
repeats O
that O
are O
complexed O
to O
a O
telomere O
specific O
protein O
, O
the O
TTAGGG B_GENE
repeat I_GENE
binding I_GENE
factor I_GENE
, O
TRF1 B_GENE/B_DISEASE
. O

Genotype B_MEASURE/B_PERSON
- O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
male B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
a O
partial B_DISEASE/B_LOCATION
nullisomy I_DISEASE/I_LOCATION
of O
the O
X B_GENE
chromosome I_GENE
have O
suggested O
that O
at O
least O
one B_GENE/B_PERSON
locus I_GENE/I_PERSON
involved O
in O
MRX B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
on O
Xp22 B_MEASURE/B_LOCATION
. O
3 B_MEASURE
. O

Mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
disposition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
constants I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
+ B_MEASURE/B_DISEASE
/ O
- O
SD B_DISEASE/B_PROTEIN[GENE]
) O
were O
obtained O
from O
individualized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fits I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
V1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O
0 B_MEASURE
. O
398 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
336 B_MEASURE
liter I_MEASURE
/ O
kg B_MEASURE
, O
Vdarea B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O
2 B_MEASURE
. O
53 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
72 B_TIME[MEASURE]
liter I_TIME[MEASURE]
/ O
kg B_MEASURE
, O
alpha B_PROTEIN[GENE]/B_MEASURE
: O
0 B_NUMBER[MEASURE]
. O
316 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
294 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
- O
1 B_NUMBER[MEASURE]
, O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
0 B_NUMBER[MEASURE]
. O
00204 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
00262 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
- O
1 B_NUMBER[MEASURE]
, O
k2 O
: O
0 B_NUMBER[MEASURE]
. O
0305 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
0101 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
- O
1 B_NUMBER[MEASURE]
) O
. O

The O
gene B_GENE/B_LOCATION
, O
from O
the O
initiator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
methionine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O
the O
polyadenylation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
is O
contained O
within O
13 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
244 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basepairs I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
contains O
19 B_GENE
exons I_GENE
. O

In O
the O
unit B_LOCATION
housing I_LOCATION
of O
a O
compact B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclotron I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
positron B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
emission I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
CT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
PET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
, O
positron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
emitting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gas I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
15O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
11C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
C15O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
C15O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
etc B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

is O
supplied O
from O
a O
cyclotron B_LOCATION
to O
a O
Pet B_LOCATION/B_PRODUCT[OBJECT]
room B_LOCATION/I_PRODUCT[OBJECT]
through O
a O
transportation B_LOCATION/B_PRODUCT[OBJECT]
pipe B_LOCATION/I_PRODUCT[OBJECT]
with O
an O
appropriate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shield I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
reduce O
positron B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
annihilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Adhesion O
was O
inhibited O
by O
mAbs O
against O
the O
COOH O
- O
terminus O
and O
central O
cell O
binding O
domains O
of O
fibronectin B_GENE
, O
as O
well O
as O
by O
the O
corresponding O
CS1 B_GENE/B_LOCATION
and O
RGD B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
not O
obtained O
using O
either O
preimmune B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
antiserum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
the O
luminal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
portion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
glycoprotein B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
precursor I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
. O

Cerebral B_DISEASE/B_PROTEIN[GENE]
blood B_DISEASE/I_PROTEIN[GENE]
flow B_DISEASE/I_PROTEIN[GENE]
was O
measured O
using O
the O
iv B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
133 B_MEASURE/B_PROTEIN[GENE]
- O
Xe B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CBF I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
AVDO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
measured O
using O
systemic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arterial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
jugular B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venous B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

activation O
of O
the O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
( O
MAPK B_GENE/B_LOCATION
) O
pathway O
enhances O
long O
- O
range O
transactivation O
by O
the O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
LCR O
) O
( O
W O
. O

In O
situ O
hybridization O
of O
whole O
- O
mount O
mouse O
embryos O
with O
Mex5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antisense I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
provide O
no O
evidence O
for O
the O
exclusion O
of O
Mex5 B_GENE
during O
embryonic O
development O
. O

In O
three B_PERSON/B_TIME[MEASURE]
other B_PERSON/I_TIME[MEASURE]
patients B_PERSON/I_TIME[MEASURE]
the O
electrophysiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
atrioventricular B_DISEASE/B_BIO
conduction I_DISEASE/I_BIO
prevented O
a O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
psychophysical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
receptive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
field I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
like B_LOCATION/B_PROTEIN[GENE]
properties B_LOCATION/I_PROTEIN[GENE]
- O
- O
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

3 B_NUMBER[MEASURE]
. O

New B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
prevent O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rethrombosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON/B_LOCATION
with O
minimal B_DISEASE
atherosclerosis I_DISEASE
after O
thrombolytic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
acute B_DISEASE/B_LOCATION
myocardial I_DISEASE/I_LOCATION
infarction I_DISEASE/I_LOCATION
. O

The O
Ick B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
involved O
in O
antibody O
- O
mediated O
CD4 B_GENE
( O
CDR3 B_GENE/B_DISEASE
- I_GENE/I_DISEASE
loop I_GENE/I_DISEASE
) O
signal O
transduction O
that O
inhibits O
HIV O
- O
1 O
transcription O
. O

programmed O
peritoneal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lavage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
suppurative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
complications I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
perforated B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ulcer I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
stomach B_BODY_PART_OR_ORGAN_COMPONENT
. O

Deletion O
analysis O
of O
the O
7 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
that O
a O
1 O
. O
1 O
- O
kb O
DNA O
sequence O
is O
critical O
for O
expression O
of O
GATA B_GENE
- I_GENE
2 I_GENE
in O
neurons O
. O

The O
model O
therefore O
predicts O
that O
1 O
) O
on O
- O
line O
calculation O
of O
airway O
dead O
space O
and O
end O
- O
expired O
lung O
volume O
can O
be O
made O
by O
the O
addition O
of O
an O
oxygen O
sine O
- O
wave O
perturbation O
component O
to O
the O
mean O
FIO2 O
; O
and O
( O
2 O
) O
QS O
/ O
QT O
can O
be O
measured O
from O
the O
resultant O
oxygen O
perturbation O
sine O
- O
wave O
amplitudes O
in O
the O
expired O
gas O
and O
in O
arterial O
and O
mixed O
- O
venous O
blood O
and O
is O
independent O
of O
the O
mean O
blood O
oxygen O
partial O
pressure O
and O
oxyhemoglobin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
saturation O
values O
. O

consistent O
with O
this O
, O
rh5 B_GENE/B_SPECIES[BIO]
expression O
in O
R8 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disappears O
when O
R7 O
cells O
are O
absent O
( O
in O
sevenless B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I_PERSON/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
fusion O
gene O
cassette O
was O
placed O
under O
the O
control O
of O
a O
vaccinia B_GENE/B_PERSON
virus I_GENE/I_PERSON
early I_GENE/I_PERSON
promoter I_GENE/I_PERSON
and O
cloned O
in O
a O
host O
- O
restricted O
fowlpox O
viral O
vector O
. O

psoriasis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
tumor B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Fulminant O
hepatic O
failure O
in O
these O
cases O
could O
be O
characterized O
by O
: O
( O
1 O
) O
rapid O
decrease O
in O
serum B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alanine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transaminase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ALT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
level O
after O
discontinuation O
of O
ecarazine O
, O
( O
2 O
) O
prolonged O
jaundice O
despite O
discontinuation O
of O
ecarazine O
, O
( O
3 O
) O
high O
incidence O
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
ANA B_DISEASE/B_GENE
) O
( O
57 O
% O
) O
, O
and O
( O
4 O
) O
histological O
findings O
of O
extensive O
hepatocellular O
necrosis O
ranging O
from O
bridging O
necrosis O
to O
massive O
necrosis O
. O

These O
data O
suggest O
that O
the O
secreted O
, O
truncated O
receptor O
encoded O
by O
the O
2 B_GENE
. I_GENE
6 I_GENE
- I_GENE
kb I_GENE
c I_GENE
- I_GENE
erbB I_GENE
transcript I_GENE
can O
bind O
to O
TGF B_GENE
alpha I_GENE
and O
may O
play O
an O
important O
growth O
- O
regulatory O
function O
in O
vitro O
. O

localization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
porcine B_PROTEIN[GENE]
enzyme I_PROTEIN[GENE]
in O
the O
endoplasmic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
immuno B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
electron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
microscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
pig B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hepatocytes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
close O
homologue O
of O
the O
APK2a B_GENE/B_BIO
gene I_GENE/I_BIO
, O
named O
APK2b B_PROTEIN[GENE]/B_BIO
, O
was O
also O
isolated O
from O
the O
Arabidopsis O
cDNA O
library O
. O

Thus O
, O
the O
rates O
of O
a B_GENE
- I_GENE
factor I_GENE
receptor I_GENE
endocytosis O
and O
consequent O
vacuolar O
turnover O
depend O
on O
the O
available O
level O
of O
ubiquitin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
in O
the O
cell O
. O

Using O
the O
same O
approach O
we O
have O
shown O
that O
hFIRE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binds O
the O
stimulatory O
proteins O
Sp1 B_GENE/B_LOCATION
and O
Sp3 B_GENE
in O
addition O
to O
CBF B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Non B_DISEASE
- O
specific B_DISEASE/B_PERSON
immunological I_DISEASE/I_PERSON
abnormalities I_DISEASE/I_PERSON
were O
detected O
in O
8 B_NUMBER[MEASURE]
of O
the O
13 B_PERSON/B_BIO
patients I_PERSON/I_BIO
in O
whom O
they O
were O
looked O
for O
. O

Using O
a O
combined B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pharmacokinetic I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
pharmacodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
impact B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
effective B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bioavailability I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
on O
its O
estimation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
the O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
- O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
ratio B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
required O
to O
produce O
the O
same B_LOCATION/B_MEASURE
area B_LOCATION/I_MEASURE
under O
the O
response B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curve B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
acute B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O
are O
explored O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
The O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
and O
best B_DISEASE_ADJECTIVE[DISEASE]
characterized O
RNA B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
motifs B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
cyclin B_GENE/B_BIO
- I_GENE/I_BIO
dependent I_GENE/I_BIO
kinase I_GENE/I_BIO
Cdk2 I_GENE/I_BIO
associates O
with O
cyclins B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
has O
been O
implicated O
in O
the O
control O
of O
the O
G1 O
to O
S O
phase O
transition O
in O
mammals O
. O

Mol B_PERSON/B_BIO
. O

The O
amino B_GENE/B_LOCATION
- I_GENE/I_LOCATION
terminal I_GENE/I_LOCATION
gag I_GENE/I_LOCATION
- I_GENE/I_LOCATION
encoded I_GENE/I_LOCATION
region I_GENE/I_LOCATION
of O
P140gag B_GENE/B_MEASURE
- O
fps B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O
a O
phosphotyrosine O
residue O
in O
addition O
to O
normal O
gag B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O
sites O
. O

Rad18 B_GENE/B_SPECIES[BIO]
is O
required O
for O
DNA O
repair O
and O
checkpoint O
responses O
in O
fission O
yeast O
. O

A O
less O
common B_DISEASE_ADJECTIVE[DISEASE]
and O
much O
more O
perplexing B_DISEASE_ADJECTIVE[DISEASE]
circumstance I_DISEASE_ADJECTIVE[DISEASE]
occurs O
when O
evaluating O
patients B_PERSON/B_BIO
with O
sarcoidosis B_DISEASE
established O
for O
several B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
years I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
progressive B_DISEASE_ADJECTIVE[DISEASE]
or O
chronic B_DISEASE_ADJECTIVE[DISEASE]
pulmonary I_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
and O
dyspnea B_DISEASE
. O

2 O
, O
4 B_NUMBER[MEASURE]
- O
and O
2 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
- O
toluenediamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
hydrolysed B_BODY_PART_OR_ORGAN_COMPONENT
plasma I_BODY_PART_OR_ORGAN_COMPONENT
and O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
test B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
chamber B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
humans B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
2 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
and O
2 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
- O
toluene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diisocyanate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
warranted O
to O
determine O
whether O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
idiosyncratic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
coincidental B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
or O
a O
more O
general B_DISEASE_ADJECTIVE[DISEASE]
phenomenon I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
none B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
labeled O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
detected O
. O

This O
substrate O
was O
cleaved O
efficiently O
in O
trans O
by O
protease B_ENZYME[GENE]
3C I_ENZYME[GENE]
derived O
from O
another O
recombinant O
vaccinia O
virus O
expressing O
a O
3C B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precursor I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
activity O
of O
gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
serum O
of O
problem O
drinkers O
. O

patients B_PERSON/B_BIO
with O
endocarditis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O
vascular B_DISEASE
infection I_DISEASE
were O
more O
frequently O
immunocompromised O
and O
older B_TIME[MEASURE]/B_DISEASE
than O
those O
with O
acute B_DISEASE
Q I_DISEASE
fever I_DISEASE
. O

The O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
oxalate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
products B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
the O
exposed O
dentine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
: O
an O
SEM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
used O
by O
this O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
involves O
a O
transient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
externally O
applied O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
resistance B_DISEASE/B_MEASURE
to O
breathing B_DISEASE/B_MEASURE
. O

We O
evaluated O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
ECD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
SPECT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
comparing O
with O
rCBF B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
obtained O
by O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
12 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
with O
spinocerebellar B_DISEASE
degeneration I_DISEASE
( O
SCD B_MEASURE/B_DISEASE
) O
. O

Monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
hapten B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenyloxazolone I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
raised O
7 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
immunization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
six B_NUMBER[MEASURE]/B_BIO
strains I_NUMBER[MEASURE]/I_BIO
( O
BALB B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O
c B_DISEASE/B_LOCATION
, O
C57BL B_BIO/B_PROTEIN[GENE]
- O
Igha B_MEASURE/B_DISEASE
, O
DBA2 B_LOCATION/B_PROTEIN[GENE]
, O
RF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
J B_OTHER/B_PROTEIN[GENE]
, O
and O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

In O
particular O
, O
lacZ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesised O
this O
way O
are O
highly O
unstable O
and O
yield O
little O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Six O
cDNAs O
represent O
human O
homologs O
of O
genes O
known O
in O
other O
species O
, O
namely O
, O
mouse B_GENE/B_SPECIES[BIO]
HSPE71 B_GENE/I_SPECIES[BIO]
, O
Rat B_GENE
RhoGAP I_GENE
protein I_GENE
, O
S B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
leucyl I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
S B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chromosome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ORF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YBLO44W I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
thalamic B_DISEASE/B_PROTEIN[GENE]
SD B_DISEASE/I_PROTEIN[GENE]
was O
regularly O
triggered O
by O
short B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
0 B_MEASURE/B_LOCATION
. O
02 B_MEASURE
- O
0 B_MEASURE
. O
05 B_MEASURE
s I_MEASURE
) O
high B_GENE/B_MEASURE
- O
frequency B_MEASURE
( O
200 B_MEASURE
- O
500 B_MEASURE
Hz I_MEASURE
) O
ES B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
parietal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cortical B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
surface B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

All O
three O
SSV O
- O
transformed O
cells O
secreted O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sis I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p44 B_PROTEIN[GENE]/B_LOCATION
) O
. O

p44 B_GENE
was O
secreted O
but O
remained O
tightly O
associated O
with O
the O
cell O
surface O
. O

It O
is O
suggested O
that O
the O
mechanism B_LOCATION/B_MEASURE
of O
intestinal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
25 B_MEASURE
- O
hydroxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
differ O
in O
man B_PERSON/B_MEASURE
, O
the O
absorption B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
25 B_MEASURE
- O
hydroxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O
being O
less O
dependent B_DISEASE_ADJECTIVE[DISEASE]
on O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

To O
determine O
the O
role O
of O
elevated O
FAK B_GENE
expression O
in O
facilitating O
epidermal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
EGF B_GENE
) O
- O
stimulated O
human O
adenocarcinoma O
( O
A549 O
) O
cell O
motility O
, O
antisense O
oligonucleotides O
were O
used O
to O
reduce O
FAK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
> O
75 O
% O
. O

It O
tends O
to O
be O
higher B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
frazioni B_PERSON/B_LOCATION
of O
the O
same B_LOCATION/B_PERSON
community I_LOCATION/I_PERSON
than O
between O
communities B_LOCATION/B_PERSON
. O

The O
BRSV B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
6573 O
nt O
in O
length O
and O
the O
derived O
polypeptide O
has O
2162 O
AA O
. O

To O
further O
study O
the O
role O
of O
tTG B_GENE
in O
liver O
disease O
, O
we O
initiated O
investigations O
into O
the O
effect O
of O
a O
proinflammatory O
mediator O
, O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TNF B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
tTG B_GENE
activity O
in O
cultured O
liver O
cells O
. O

availability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
less O
palatable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
chow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
following O
presentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
palatable B_DISEASE
diets I_DISEASE
will O
not O
result O
in O
diminished B_DISEASE/B_MEASURE
caloric I_DISEASE/I_MEASURE
intake I_DISEASE/I_MEASURE
, O
body B_DISEASE/B_GENE
weight I_DISEASE/I_GENE
, O
obesity B_DISEASE
and O
hyperinsulinemia B_DISEASE/B_MEASURE
. O

By O
contrast O
, O
CIS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
failed O
to O
affect O
the O
IL B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
9 I_DISEASE_ADJECTIVE[DISEASE]
response O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
With O
an O
array B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
112 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unipole I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epicardial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maps I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
electrically O
induced O
AF B_DISEASE/B_PROTEIN[GENE]
in O
6 B_MEASURE
dogs I_MEASURE
( O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
group I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O
, O
self B_DISEASE_ADJECTIVE[DISEASE]
- O
sustained O
AF B_DISEASE
in O
6 B_NUMBER[MEASURE]/B_BIO
dogs B_NUMBER[MEASURE]/I_BIO
( O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
sinus B_DISEASE
rhythm I_DISEASE
and O
atrial B_DISEASE
pacing I_DISEASE
in O
3 B_MEASURE
dogs I_MEASURE
( O
control B_DISEASE_ADJECTIVE[DISEASE]
group I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
analyzed O
before O
and O
after O
creating O
linear B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
radiofrequency I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ablation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
both O
atria B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
that O
eliminated O
the O
AF B_DISEASE/B_PROTEIN[GENE]
. O

In O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
phosphorus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
limitation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
fungus B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Neurospora I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
crassa I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
synthesizes O
a O
number B_MEASURE/B_LOCATION
of O
enzymes B_ENZYME[GENE]
that O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
bring O
more B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
inoculum B_MEASURE
size I_MEASURE
, O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
temperature B_MEASURE
, O
and O
duration B_MEASURE
of O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
on O
the O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
susceptibility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
testing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
Aspergillus B_BACTERIUM[BIO]
fumigatus I_BACTERIUM[BIO]
were O
investigated O
using O
broth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
micro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
and O
macro B_DISEASE
- O
dilution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
have O
analyzed O
the O
function O
of O
these O
putative O
SL O
structures O
in O
RNA O
translation O
by O
constructing O
chimeric B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloramphenicol B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
acetyltransferase B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CAT B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNAs B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
flanked O
either O
by O
both O
5 O
' O
- O
and O
3 O
' O
- O
terminal O
sequence O
domains O
from O
the O
RV O
genome O
or O
several O
deletion O
derivatives O
of O
the O
same O
sequences O
. O

Periarteritis B_DISEASE
nodosa O
with O
ruptures B_DISEASE
of O
the O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
vessels B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
hepatitis B_DISEASE/B_PROTEIN[GENE]
B B_DISEASE/I_PROTEIN[GENE]
and O
C B_DISEASE/B_PROTEIN[GENE]
viruses B_DISEASE/I_PROTEIN[GENE]
in O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
. O

Despite O
the O
fact O
that O
biochemical O
estimates O
of O
bone O
turnover O
indicate O
that O
( O
short O
- O
term O
) O
administration O
of O
rhGH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
IGF B_GENE
- I_GENE
I I_GENE
stimulates O
bone O
metabolism O
in O
non O
- O
osteoporotic O
older O
people O
, O
no O
significant O
changes O
have O
been O
observed O
in O
bone O
mineral O
density O
at O
the O
proximal O
femur O
. O

compression B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
right B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventricular B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
outflow B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tract B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
by O
aneurysm B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ascending O
aorta B_BODY_PART_OR_ORGAN_COMPONENT
. O

However O
, O
patients B_PERSON/B_DISEASE
with O
DPX B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
observed O
for O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
an O
associated B_DISEASE
condition I_DISEASE
. O

Blood O
pressure O
was O
controlled O
long O
term O
( O
with O
/ O
without O
diuretics O
/ O
beta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
adrenoreceptor I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
blocking O
drugs O
) O
in O
sixteen O
out O
of O
nineteen O
patients O
with O
mild O
- O
moderate O
hypertension O
. O

However O
, O
FosB B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
FosB B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
not O
differ O
in O
all O
trans O
- O
regulatory O
properties O
: O
Trans O
- O
activation O
of O
a O
5x O
TRE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O
construct O
in O
HeLa O
and O
NIH O
- O
3T3 O
cells O
was O
found O
with O
both O
FosB B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O
. O

mutations O
in O
glnB B_GENE/B_BACTERIUM[BIO]
, O
nifR1 B_GENE
( O
ntrC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
and O
NifR4 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ntrA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O
sigma B_GENE/B_LOCATION
54 I_GENE/I_LOCATION
) O
had O
no O
influence O
on O
put B_GENE
gene I_GENE
expression O
. O

disruption O
of O
INP53 B_GENE/B_BIO
, O
but O
not O
the O
related O
INP51 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
INP52 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulted O
in O
alpha B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
maturation O
defects O
and O
exacerbated O
alpha B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
maturation O
defects O
when O
combined O
with O
chc1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
521 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cytokine B_DISEASE
gene I_DISEASE
polymorphisms I_DISEASE
on O
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
coronary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
artery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
bypass B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
graft B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Regardless O
of O
muscle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
tensioning I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
or O
marination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
aging O
of O
the O
carcass B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
for O
24 B_MEASURE
h O
( O
T1 B_PROTEIN[GENE]
, O
T2 B_PROTEIN[GENE]
, O
and O
T3 B_PROTEIN[GENE]
) O
produced O
meats B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
lower B_MEASURE
shear I_MEASURE
values I_MEASURE
than O
those O
from O
hot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
boned B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
carcasses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
T4 B_PROTEIN[GENE]
and O
T5 B_PROTEIN[GENE]
) O
. O

Blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
whole B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mercury I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
determined O
in O
pups B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
PN B_MEASURE/B_PROTEIN[GENE]
0 I_MEASURE/I_PROTEIN[GENE]
( O
birth B_TIME[MEASURE]/B_PERSON
) O
and O
PN B_MEASURE
21 I_MEASURE
( O
weaning O
) O
. O

By O
subtractive O
and O
differential O
screening O
, O
we O
have O
cloned O
12 O
of O
these O
sequences O
, O
2 O
of O
which O
were O
c B_GENE
- I_GENE
fos I_GENE
and O
krox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
24 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

When O
stratifying O
FLM B_MEASURE/B_LOCATION
values B_MEASURE/I_LOCATION
< O
34 B_MEASURE
and O
> B_MEASURE/B_LOCATION
34 I_MEASURE/I_LOCATION
wks I_MEASURE/I_LOCATION
' I_MEASURE/I_LOCATION
gestation I_MEASURE/I_LOCATION
, O
again O
no O
difference B_MEASURE
was O
found O
in O
mean B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
L B_OTHER/B_PROTEIN[GENE]
/ O
S B_OTHER/B_PROTEIN[GENE]
and O
LB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
before O
and O
after O
34 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
wks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

Cotransfection O
of O
a O
junB B_GENE/B_BACTERIUM[BIO]
stimulated O
the O
basal O
activity O
of O
the O
alpha B_GENE
2 I_GENE
( I_GENE
I I_GENE
) I_GENE
collagen I_GENE
promoter I_GENE
93 O
- O
fold O
, O
respectively O
. O

Glutathione B_GENE/B_PERSON
reductase I_GENE/I_PERSON
( O
GR B_LOCATION/B_PROTEIN[GENE]
) O
was O
purified O
from O
the O
cyanobacterium O
Anabaena O
PCC O
7120 O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
simulations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
account O
for O
interactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
spatial B_MEASURE
frequency I_MEASURE
with O
stimulus B_MEASURE/B_LOCATION
duration B_MEASURE/I_LOCATION
, O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
adaptation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
properties B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
residual B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
traces I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
opposed O
to O
visual B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persistence I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Fractional B_MEASURE
Ca I_MEASURE
retention B_MEASURE/B_DISEASE
was O
measured O
from O
the O
72 B_MEASURE
- O
h B_MEASURE/B_PERSON
postdose I_MEASURE/I_PERSON
WBR I_MEASURE/I_PERSON
divided O
by O
WBR B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
time B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
included O
70 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
acute B_DISEASE
coronary I_DISEASE
syndromes I_DISEASE
( O
14 B_MEASURE
with O
recent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
56 B_NUMBER[MEASURE]
with O
unstable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
angina I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pectoris I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
105 B_MEASURE
patients I_MEASURE
with O
stable B_DISEASE/B_GENE
angina I_DISEASE/I_GENE
pectoris I_DISEASE/I_GENE
, O
and O
75 B_PERSON
control I_PERSON
subjects I_PERSON
. O

Furthermore O
, O
rubella B_DISEASE
IgM I_DISEASE
antibody I_DISEASE
was O
never O
detected O
after O
immunization O
in O
women O
who O
were O
Hai O
- O
negative O
and O
LA O
- O
positive O
during O
pregnancy O
. O

Disease B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
was O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
node B_DISEASE/B_GENE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Lx I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
both O
T1 B_PROTEIN[GENE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
007 B_MEASURE
) O
and O
T2 B_PROTEIN[GENE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
presentations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

5 O
' O
- O
Deletion O
of O
the O
Stat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O
all O
promoter O
- O
reporter O
activity O
in O
response O
to O
PRL B_GENE
. O

A O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
156 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
younger I_PERSON/I_TIME[MEASURE]
than O
40 B_NUMBER[MEASURE]
treated O
at O
our O
Department B_LOCATION/B_ORGANIZATION
between O
1960 B_MEASURE
and O
1991 B_MEASURE
with O
transitional B_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
of O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
that O
89 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
had O
superficial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Ta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
T1 B_PROTEIN[GENE]/B_LOCATION
) O
disease B_DISEASE
and O
the O
remaining O
10 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
presented O
with O
invasive B_DISEASE
disease I_DISEASE
. O

Plasma B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
beta B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
thromboglobulin B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
( O
beta B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
TG I_PROTEIN[GENE]/I_LOCATION
) O
, O
a O
platelet O
- O
specific O
protein O
, O
is O
a O
marker O
of O
intravascular O
platelet O
degranulation O
. O

John B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wort I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Design B_PERSON/B_MEASURE
, O
setting O
AND O
Subjects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
based O
on O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O
in O
the O
first B_MEASURE/B_LOCATION
two B_MEASURE/I_LOCATION
rounds B_MEASURE/I_LOCATION
of O
the O
nationally O
representative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ghana I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Living I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Standards I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
held O
in O
1987 B_MEASURE
/ O
88 B_MEASURE
( O
GLSS B_DISEASE/B_LOCATION
- O
I B_OTHER/B_PROTEIN[GENE]
) O
and O
1988 B_MEASURE
/ O
89 B_MEASURE
( O
GLSS B_DISEASE/B_LOCATION
- O
II B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
, O
with O
both O
surveys B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
covering O
approximately O
3000 B_MEASURE/B_LOCATION
households B_MEASURE/I_LOCATION
. O

The O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
binding O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
without O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
plasmids B_GENE/B_BACTERIUM[BIO]
lacking O
binding O
sites B_LOCATION/B_ENT
or O
when O
the O
binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
located O
further O
upstream O
. O

The O
Gastrointestinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Tumor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
GITSG B_DISEASE/B_ORGANIZATION
) O
protocol B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GI I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
7175 B_NUMBER[MEASURE]/B_LOCATION
randomized O
227 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
1975 B_MEASURE
and O
1980 B_MEASURE
following O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
stages B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B2 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
C B_PROTEIN[GENE]
rectal O
adenocarcinoma B_DISEASE
to O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
( O
1 B_SEQUENCE[MEASURE]/B_LOCATION
) O
no O
adjuvant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
( O
2 B_NUMBER[MEASURE]/B_PERSON
) O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O
, O
( O
3 B_NUMBER[MEASURE]/B_LOCATION
) O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O
, O
and O
( O
4 B_NUMBER[MEASURE]
) O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
combined O
modality B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

The O
RTI40 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
spans O
35 O
kilobase O
pairs O
; O
it O
contains O
6 O
exons O
and O
at O
least O
6 O
rat O
Identifier O
repetitive O
elements O
. O

The O
DNA O
element O
through O
which O
EBNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activates O
the O
LMP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
includes O
a O
Spi B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
/ O
Spi B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
site O
, O
previously O
characterized O
as O
an O
important O
EBNA B_MEASURE/B_LOCATION
- B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
response B_MEASURE/I_LOCATION
element B_MEASURE/I_LOCATION
. O

DP B_PROTEIN[GENE]
- I_PROTEIN[GENE]
1 I_PROTEIN[GENE]
and O
DP B_GENE
- I_GENE
2 I_GENE
encode O
maternally O
stored O
transcripts O
that O
are O
expressed O
during O
early O
development O
. O

Furthermore O
, O
deletion O
of O
two O
potential O
Ste11 B_GENE/B_LOCATION
recognition I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
in O
the O
fus1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O
abolished O
transcription O
, O
and O
expression O
could O
be O
restored O
when O
we O
inserted O
a O
different O
Ste11 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
the O
mat1 B_TIME[MEASURE]/B_PERSON
- I_TIME[MEASURE]/I_PERSON
P I_TIME[MEASURE]/I_PERSON
promoter I_TIME[MEASURE]/I_PERSON
. O

However O
, O
an O
analogous O
myristoylated O
peptide O
derived O
from O
c B_GENE
- I_GENE
Yes I_GENE
also O
has O
no O
inhibitory O
activity O
. O

The O
oral B_DISEASE_ADJECTIVE[DISEASE]
movements I_DISEASE_ADJECTIVE[DISEASE]
which O
did O
occur O
in O
the O
Hal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
slower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Finally O
, O
we O
demonstrate O
that O
animals O
carrying O
a O
snf B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutation O
that O
converts O
SNF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
bifunctional O
protein O
to O
a O
U1 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
snRNP I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
viable O
. O

These O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
reflected O
in O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
three B_DISEASE/B_BIO
cell B_DISEASE/I_BIO
lines B_DISEASE/I_BIO
. O

This O
pathway O
has O
been O
reported O
to O
mediate O
heterodimer O
interactions O
with O
the O
proapoptotic O
regulator O
, O
Bad B_GENE
. O

Mutating O
bases B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
142 B_MEASURE
to O
- O
151 B_MEASURE
abolishes I_MEASURE
formation I_MEASURE
of O
complex B_LOCATION/B_BIO
VII I_LOCATION/I_BIO
and O
partially O
inhibits O
complex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
IV B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
suggesting O
that O
the O
proteins B_LOCATION/B_GENE
forming O
these O
complexes B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bind O
neighboring B_LOCATION/B_BIO
segments I_LOCATION/I_BIO
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
DFA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
slide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
prepared O
from O
the O
ThinPrep B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Test I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DFA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O
from O
the O
endocervical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
swab I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
evaluated O
independently O
. O

Moclobemide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
well O
- O
tolerated O
alternative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antidepressant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
there O
is O
a O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
controlled O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
evaluate O
its O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

methods B_MEASURE
: O
Autocapture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
devices B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O
Pacesetter B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Microny I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
- O
and O
Regency B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SR I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
- O
; O
Pacesetter B_PERSON/B_TIME[MEASURE]
, O
Solna B_PERSON/B_LOCATION
, O
Sweden B_LOCATION
) O
and O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
eluting O
epicardial B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
pacing I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
leads I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Medtronic B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CapSure I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epi I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10366 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Medtronic B_PERSON/B_LOCATION
, O
Inc B_ORGANIZATION/B_MEASURE
, O
Minneapolis B_LOCATION/B_PERSON
, O
MN B_LOCATION
) O
were O
implanted O
in O
14 B_PERSON/B_ENT
children I_PERSON/I_ENT
. O

hormonal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
replacement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O
women B_PERSON
with O
a O
personal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
breast B_DISEASE
cancer I_DISEASE
. O

Recently O
, O
we O
reported O
that O
SMRT B_GENE
also O
directly O
associates O
with O
LAZ3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BCL B_GENE/B_DISEASE
- I_GENE/I_DISEASE
6 I_GENE/I_DISEASE
) O
, O
a O
POZ O
/ O
Zn O
finger O
transcriptional O
repressor O
involvedin O
the O
pathogenesis O
of O
non O
- O
Hodgkin O
lymphomas O
. O

Using O
reporter O
gene O
constructs O
driven O
by O
the O
CD4 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
we O
report O
that O
HHV O
- O
6 O
can O
efficiently O
transactivate O
such O
genetic O
elements O
. O

characterization O
of O
a O
cDNA B_GENE/B_LOCATION
encoding I_GENE/I_LOCATION
CNN I_GENE/I_LOCATION
predicts O
a O
novel O
structural O
protein O
with O
three O
leucine O
zipper O
motifs O
and O
several O
coiled O
- O
coil O
domains O
exhibiting O
limited O
homology O
to O
the O
rod O
portion O
of O
myosin B_GENE
. O

A O
preformed O
SREBP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1a B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
32P B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O
specifically O
to O
membrane O
- O
immobilized O
GST B_GENE/B_BIO
- O
CBP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fusion O
proteins O
that O
contained O
amino O
- O
terminal O
portions O
of O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pyridostigmine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pretreatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O
supplemented O
by O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
an O
antidotal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
TM B_PROTEIN[GENE]/B_DISEASE
, O
B B_OTHER/B_LOCATION
) O
consisting O
of O
0 B_MEASURE
. O
05 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
atropine I_MEASURE
, O
2 B_MEASURE
. O
24 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_LOCATION
TMB I_MEASURE/I_LOCATION
- O
4 B_NUMBER[MEASURE]
, O
and O
0 B_MEASURE
. O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benactyzine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
assured O
survival B_DISEASE_ADJECTIVE[DISEASE]
in O
five B_NUMBER[MEASURE]/B_BIO
of O
six B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
three B_NUMBER[MEASURE]/B_LOCATION
separate I_NUMBER[MEASURE]/I_LOCATION
exposures I_NUMBER[MEASURE]/I_LOCATION
to O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
LD50 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
soman I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Previous O
work O
established O
that O
the O
TAL1 B_GENE
proteins I_GENE
are O
phosphorylated O
exclusively O
on O
serine O
and O
identified O
Ser122 O
as O
a O
substrate O
for O
the O
mitogen B_ENZYME[GENE]
- I_ENZYME[GENE]
activated I_ENZYME[GENE]
protein I_ENZYME[GENE]
kinase I_ENZYME[GENE]
ERK I_ENZYME[GENE]
- I_ENZYME[GENE]
1 I_ENZYME[GENE]
. O

Rapid B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gas I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
8 B_MEASURE
- O
methoxypsoralen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
human B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
plasma I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

If O
the O
size B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cystic B_DISEASE/B_MEASURE
liver I_DISEASE/I_MEASURE
- O
lesions B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
excludes O
a O
curative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O
if O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
refuses O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
indication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
mebendazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
given O
. O

When O
cotransfected O
with O
the O
HIV B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
CV O
- O
1 O
cells O
, O
both O
the O
pCD41 B_GENE/B_MEASURE
and O
pGD41 B_GENE
clones O
trans O
- O
activated O
the O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
induction O
of O
the O
composite O
H B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
PK I_PROTEIN[GENE]/I_LOCATION
/ O
Tag B_GENE/B_MEASURE
and O
SV B_GENE/B_LOCATION
- I_GENE/I_LOCATION
PK I_GENE/I_LOCATION
/ O
Tag B_GENE/B_LOCATION
transgenes O
by O
a O
carbohydrate O
- O
rich O
diet O
in O
the O
liver O
was O
similar O
to O
that O
of O
the O
endogenous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
PK I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

patients B_PERSON/B_BIO
with O
advanced B_DISEASE/B_LOCATION
ovarian I_DISEASE/I_LOCATION
carcinoma I_DISEASE/I_LOCATION
, O
Stage B_PROTEIN[GENE]/B_TIME[MEASURE]
III I_PROTEIN[GENE]/I_TIME[MEASURE]
or O
IV B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
International B_ORGANIZATION/B_LOCATION
Federation I_ORGANIZATION/I_LOCATION
of O
Gynaecology B_PERSON/B_DISEASE
and O
Obstetrics B_DISEASE/B_LOCATION
) O
, O
were O
randomized O
to O
primary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
and O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
or O
minus B_MEASURE
hexamethylmelamine I_MEASURE
, O
and O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
chap B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Exit O
from O
mitosis O
in O
Drosophila O
syncytial O
embryos O
requires O
proteolysis O
and O
cyclin B_GENE
degradation O
, O
and O
is O
associated O
with O
localized O
dephosphorylation O
. O

cough B_DISEASE/B_PROTEIN[GENE]
- O
CPR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O
a O
deep B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rhythmic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
forceful I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cough I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
repeated O
30 B_MEASURE
- O
60 B_TIME[MEASURE]/B_ENT
times I_TIME[MEASURE]/I_ENT
per O
minute B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
can O
be O
an O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
resuscitative I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
technique I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
during O
emergencies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurring O
in O
the O
cardiac B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
catheterization I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
laboratory I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

To O
understand O
this O
dramatic O
effect O
, O
we O
examined O
the O
localization O
of O
SR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
found O
that O
SC35 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
shifted O
to O
the O
cytoplasm O
in O
sky1Delta B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
yeast O
, O
although O
this O
phenomenon O
was O
not O
obvious O
with O
ASF B_LOCATION/B_GENE
/ O
SF2 B_GENE/B_LOCATION
, O
indicating O
that O
nuclear O
import O
of O
SR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
differentially O
regulated O
by O
phosphorylation O
. O

Probiotics B_TIME[MEASURE]/B_LOCATION
, O
prebiotics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
vaccination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
acidification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
drinking B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
assessed O
as O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
reducing O
Salmonella B_DISEASE/B_BACTERIUM[BIO]
. O

On O
the O
contrary O
i O
. O
v O
. O
administration O
of O
calcitonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
intrapyloric O
pressure O
via O
vagal O
nerves O
in O
atropinized O
or O
gallaminized O
animals O
. O

We O
conclude O
that O
in O
the O
presence O
of O
fatty O
acids O
in O
the O
medium O
transcription O
of O
SPS19 B_GENE
is O
directly O
regulated O
by O
both O
Pip2p B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
Oaf1p B_MEASURE
and O
Adr1p B_GENE
. O

Gas B_PERSON/B_DISEASE
exchange I_PERSON/I_DISEASE
was O
measured O
breath B_BODY_PART_OR_ORGAN_COMPONENT
by O
breath B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
. O

We O
found O
that O
in O
premature O
infants O
plasminogen B_GENE
levels O
are O
low O
; O
thus O
, O
defense O
against O
intra O
- O
alveolar O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O
during O
birth O
trauma O
is O
reduced O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nt B_GENE
sequence I_GENE
was O
carried O
out O
on O
three B_NUMBER[MEASURE]
out O
of O
the O
more B_MEASURE
than O
15 B_NUMBER[MEASURE]
of O
these O
regions B_PERSON/B_GENE
present B_PERSON/I_GENE
in O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Studies O
on O
the O
reaction O
of O
cytochrome B_BIO/B_DISEASE
c I_BIO/I_DISEASE
with O
corticosteroids O
. O

However O
, O
both O
RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
RXR B_PROTEIN[GENE]/B_LOCATION
- O
specific O
ligands O
increase O
CaSki O
number O
by O
> O
or O
= O
20 O
% O
. O

Also O
, O
in O
patients B_PERSON/B_MEASURE
with O
MYD B_DISEASE
, O
there O
was O
a O
significant B_MEASURE
decrease I_MEASURE
in O
arterial B_DISEASE/B_GENE
PO2 I_DISEASE/I_GENE
from O
the O
seated B_LOCATION/B_TIME[MEASURE]
posture B_LOCATION/I_TIME[MEASURE]
to O
the O
supine B_DISEASE/B_LOCATION
posture I_DISEASE/I_LOCATION
, O
without O
a O
significant B_MEASURE/B_DISEASE
change B_MEASURE/I_DISEASE
in O
the O
arterial B_MEASURE/B_DISEASE
PCO2 B_MEASURE/I_DISEASE
. O

The O
primary O
structures O
of O
the O
human B_SPECIES[BIO]/B_PROTEIN[GENE]
KB I_SPECIES[BIO]/I_PROTEIN[GENE]
cell I_SPECIES[BIO]/I_PROTEIN[GENE]
( I_SPECIES[BIO]/I_PROTEIN[GENE]
FR I_SPECIES[BIO]/I_PROTEIN[GENE]
- I_SPECIES[BIO]/I_PROTEIN[GENE]
KB1 I_SPECIES[BIO]/I_PROTEIN[GENE]
) I_SPECIES[BIO]/I_PROTEIN[GENE]
folate I_SPECIES[BIO]/I_PROTEIN[GENE]
receptor I_SPECIES[BIO]/I_PROTEIN[GENE]
( O
FR B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
and O
of O
a O
human B_GENE/B_BIO
placental I_GENE/I_BIO
( I_GENE/I_BIO
FR I_GENE/I_BIO
- I_GENE/I_BIO
P2 I_GENE/I_BIO
) I_GENE/I_BIO
FR I_GENE/I_BIO
, O
proteins O
important O
in O
cellular O
accumulation O
of O
folates O
, O
have O
been O
deduced O
from O
cDNA O
sequences O
. O

The O
general O
concept O
of O
RARE B_DISEASE/B_GENE
- O
cleavage O
mapping O
as O
well O
as O
its O
applications O
and O
limitations O
are O
discussed O
. O

To O
further O
investigate O
the O
role O
of O
PKR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transcriptional O
signaling O
, O
we O
expressed O
the O
wild B_GENE
type I_GENE
human I_GENE
PKR I_GENE
and O
a O
catalytically O
inactive O
dominant O
negative O
PKR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
murine O
pre O
- O
B O
lymphoma O
70Z O
/ O
3 O
cells O
. O

selective O
upper O
abdominal O
sympathectomy O
increased O
basal O
acid O
output O
in O
rats O
but O
was O
without O
effect O
on O
stimulated O
acid O
output O
, O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gastrin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O
, O
and O
gastric B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
histidine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
. O

reasons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
presented O
to O
support O
the O
contention B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
this O
increase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
in O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
real B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

patients B_PERSON
received O
either O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cephalothin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravenously O
before O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
for O
up O
to O
8 B_TIME[MEASURE]
additional I_TIME[MEASURE]
doses I_TIME[MEASURE]
. O

In O
- O
111 O
- O
BLMC O
uptake O
was O
directly O
proportional O
to O
Ki B_GENE
- I_GENE
67 I_GENE
/ O
MIB B_MEASURE/B_GENE
- I_MEASURE/I_GENE
1 I_MEASURE/I_GENE
activity O
and O
number O
of O
mitoses O
in O
tumor O
tissue O
. O

heating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O
either O
force B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
slowing B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
relaxation B_DISEASE/B_ORGANISM_FUNCTION
during O
fatiguing O
contractions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

binding O
of O
transformed O
Ah B_GENE
receptor I_GENE
complex I_GENE
to O
a O
dioxin O
responsive O
transcriptional O
enhancer O
: O
evidence O
for O
two O
distinct O
heteromeric O
DNA O
- O
binding O
forms O
. O

Interestingly O
, O
VDR B_GENE
was O
able O
to O
bind O
to O
VDREs O
with O
high O
affinity O
and O
to O
fully O
activate O
transcription O
in O
intact O
yeast O
cells O
in O
the O
presence O
of O
the O
retinoid B_GENE
X I_GENE
receptor I_GENE
( O
RXR B_PROTEIN[GENE]/B_LOCATION
) O
. O

Thus O
, O
it O
appears O
that O
moxalactam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
reliable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
useful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibiotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
complicated B_DISEASE/B_LOCATION
urinary I_DISEASE/I_LOCATION
tract I_DISEASE/I_LOCATION
infections I_DISEASE/I_LOCATION
. O

A O
fine O
- O
structure O
radiation O
hybrid O
map O
for O
the O
region O
that O
extends O
from O
D8S520 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
distal O
) O
to O
D8S1759 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
proximal O
) O
was O
prepared O
, O
followed O
by O
construction O
of O
a O
single O
, O
integrated O
YAC O
/ O
BAC O
contig O
for O
the O
interval O
. O

The O
protein O
contains O
a O
SHAQKYF O
amino O
acid O
signature O
motif O
in O
the O
second O
myb B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
highly O
conserved O
in O
a O
number O
of O
recently O
identified O
plant B_GENE/B_BIO
myb I_GENE/I_BIO
- I_GENE/I_BIO
related I_GENE/I_BIO
genes I_GENE/I_BIO
, O
thus O
defining O
a O
new O
class O
of O
plant O
DNA O
- O
binding O
proteins O
. O

IV B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
been O
shown O
that O
renin B_GENE
secretion O
is O
stimulated O
by O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
recently O
discovered O
peptide O
with O
strong O
vasoconstrictive O
properties O
and O
stimulating O
effects O
on O
renin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O
. O

Here O
we O
describe O
the O
cloning O
and O
initial O
characterization O
of O
IPP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
novel O
human O
gene O
that O
predicts O
a O
kelch B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homologous O
to O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ipp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
previously O
described O
kelch B_PERSON/B_BIO
family B_PERSON/I_BIO
member B_PERSON/I_BIO
. O

The O
encoded O
260 B_MEASURE/B_PROTEIN[GENE]
- I_MEASURE/I_PROTEIN[GENE]
amino I_MEASURE/I_PROTEIN[GENE]
- I_MEASURE/I_PROTEIN[GENE]
acid I_MEASURE/I_PROTEIN[GENE]
( I_MEASURE/I_PROTEIN[GENE]
aa I_MEASURE/I_PROTEIN[GENE]
) I_MEASURE/I_PROTEIN[GENE]
( I_MEASURE/I_PROTEIN[GENE]
H1 I_MEASURE/I_PROTEIN[GENE]
- I_MEASURE/I_PROTEIN[GENE]
I I_MEASURE/I_PROTEIN[GENE]
) I_MEASURE/I_PROTEIN[GENE]
and O
240 B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
aa I_PROTEIN[GENE]/I_LOCATION
( I_PROTEIN[GENE]/I_LOCATION
H1 I_PROTEIN[GENE]/I_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
II I_PROTEIN[GENE]/I_LOCATION
) I_PROTEIN[GENE]/I_LOCATION
polypeptides I_PROTEIN[GENE]/I_LOCATION
possess O
the O
typical O
tripartite O
organization O
of O
animal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
histones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
variable O
N O
- O
and O
C O
- O
terminal O
domains O
flanking O
a O
conserved O
' O
globular O
' O
DNA O
- O
binding O
domain O
. O

Instead O
, O
the O
large O
difference O
in O
ssDNA O
- O
binding O
affinities O
reflects O
the O
loss O
of O
hexamerization O
ability O
by O
uvsY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
suggesting O
that O
a O
form O
of O
intrahexamer O
synergism O
or O
cooperativity O
between O
binding O
sites O
within O
the O
uvsY B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexamer I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O
to O
its O
high O
observed O
affinity O
for O
ssDNA O
. O

No O
significant O
difference O
was O
seen O
found O
between O
the O
two O
groups O
in O
the O
degree O
of O
postoperative O
deterioration O
in O
cardiopulmonary O
function O
or O
in O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
. O

The O
PK O
domain O
showed O
pairwise O
in O
vitro O
binding O
interactions O
with O
the O
pseudokinase O
, O
HisRS B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
C O
- O
term O
domains O
; O
additionally O
, O
the O
HisRS B_ENZYME[GENE]/B_LOCATION
domain I_ENZYME[GENE]/I_LOCATION
interacted O
with O
the O
C O
- O
term O
region O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
erythrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Red B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
rose O
Bengal B_LOCATION/B_COLOR
B I_LOCATION/I_COLOR
( O
Red B_MEASURE/B_PROTEIN[GENE]
105 I_MEASURE/I_PROTEIN[GENE]
) O
and O
thyroidectomy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
thyroid B_DISEASE
tumor I_DISEASE
were O
examined O
in O
male B_SPECIES[BIO]/B_GENE
Wistar I_SPECIES[BIO]/I_GENE
rats I_SPECIES[BIO]/I_GENE
treated O
with O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_OTHER
- O
bis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
2 B_MEASURE
- O
hydroxypropyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
nitrosamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DHPN B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
AmyI B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
specific O
3 O
' O
- O
UTR O
is O
characterized O
by O
the O
absence O
of O
IR O
sequences O
and O
the O
presence O
of O
a O
putative O
' O
AATAAA O
' O
polyadenylation O
signal O
. O

To O
initiate O
our O
analysis O
of O
factors O
required O
for O
eIF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
2 I_GENE/I_DISEASE
alpha I_GENE/I_DISEASE
expression O
, O
selected O
a O
Cap O
- O
proximal O
element O
shown O
by O
in O
vivo O
methylation O
protection O
analysis O
to O
bind O
a O
potential O
regulatory O
factor O
. O

Furthermore O
, O
addition O
of O
the O
recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
restores O
NF B_GENE
- I_GENE
Y I_GENE
binding O
. O

reversible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pressure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
amorphization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
solid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C70 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
Raman B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
photoluminescence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
activators B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
as O
an O
initiator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
element I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
late B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
help O
explain O
how O
polyomavirus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
regulated O
during O
lytic B_DISEASE/B_ORGANISM_FUNCTION
growth B_DISEASE/I_ORGANISM_FUNCTION
and O
provides O
a O
model B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
development B_DISEASE/B_ORGANISM_FUNCTION
. O

Our O
results O
suggest O
that O
Sp1 B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
can O
function O
as O
a O
distinct O
TGF B_GENE/B_PERSON
- I_GENE/I_PERSON
beta I_GENE/I_PERSON
responsive I_GENE/I_PERSON
element I_GENE/I_PERSON
for O
TGF B_GENE
- I_GENE
beta I_GENE
mediated O
promoter O
expression O
and O
Sp1 B_GENE/B_LOCATION
per O
se O
can O
mediate O
this O
response O
. O

Effect O
of O
bromocriptine O
and O
metoclopramide O
on O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
patients O
with O
amyotrophic O
lateral O
sclerosis O
. O

Phase B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
study O
of O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
leucovorin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
14 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
circadian B_TIME[MEASURE]/I_LOCATION
infusion B_TIME[MEASURE]/I_LOCATION
in O
metastatic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
adenocarcinoma I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
patients I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
release B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pulley I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
after O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
tendons B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
this O
area B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improved O
gliding O
excursions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
tendons B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistance B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
motion B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
repaired O
tendons B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
provide O
support B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
A2 B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pulley B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incision B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
tendons B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
the O
area B_LOCATION/B_MEASURE
of O
the O
pulley B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Heart B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxygen B_DISEASE/B_PROTEIN[GENE]
consumption B_DISEASE/I_PROTEIN[GENE]
increased O
75 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_TIME[MEASURE]
bpm I_TIME[MEASURE]
and O
26 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
4 B_MEASURE
ml I_MEASURE
O2 I_MEASURE
/ O
kg B_MEASURE
x O
min B_MEASURE/B_PERSON
( O
- O
1 B_MEASURE
) O
from O
supine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
resting I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
values I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

To O
evaluate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thromboxane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
platelet B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactivity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
refractory B_DISEASE
unstable I_DISEASE
angina I_DISEASE
, O
OKY B_PROTEIN[GENE]/B_LOCATION
- O
046 B_NUMBER[MEASURE]
( O
600 B_TIME[MEASURE]
mg I_TIME[MEASURE]
/ O
day B_TIME[MEASURE]
, O
p B_TIME[MEASURE]/B_DISEASE
. O
o O
. O
) O
was O
administered O
to O
another O
14 B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
with O
refractory B_DISEASE
unstable I_DISEASE
angina I_DISEASE
in O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Prolongation O
of O
prothrombin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O
was O
not O
due O
to O
depletion O
of O
vitamin O
K O
- O
dependent O
coagulation O
factors O
or O
manifest O
fibrinolysis O
, O
but O
due O
to O
the O
presence O
of O
circulating O
fibrinogen B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrinmonomer I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
FDP O
complexes O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
glycogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
producing O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
intestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
microflora I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
in O
white B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

mutation O
of O
K14 O
in O
H3 B_GENE
, O
which O
serves O
as O
the O
major O
target O
of O
recombinant B_GENE
Gcn5p I_GENE
acetylation O
in O
vitro O
, O
confers O
a O
strong O
, O
synthetic O
growth O
defect O
in O
gcn5 B_GENE/B_DISEASE
cells O
. O

On O
the O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
V3 B_MEASURE/B_PERSON
' B_MEASURE/I_PERSON
values B_MEASURE/I_PERSON
were O
not O
significantly O
correlated O
with O
the O
degree B_MEASURE/B_DISEASE
of O
tremor B_DISEASE
, O
seborrhea B_BIO/B_MEASURE
, O
and O
duration B_MEASURE/B_DISEASE
of O
the O
illness B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

All O
patients O
whose O
PSA B_GENE
levels O
reached O
0 O
. O
1 O
ng O
. O
/ O
ml O
. O

In O
addition O
, O
we O
found O
that O
the O
transactivation O
mediated O
by O
the O
p68c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
ets I_GENE/I_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
pr I_GENE/I_LOCATION
p55erg I_GENE/I_LOCATION
through O
the O
Polyomavirus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
specifically O
inhibited O
by O
the O
p46kDaPax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
QNR B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transient O
transfection O
assay O
. O

Treatment O
with O
ACE B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O
after O
acute O
myocardial O
infarction O
. O

Conversely O
, O
as O
a O
GAL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chimera I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
the O
isolated O
LAZ3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
BCL6 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
BTB I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
POZ O
domain O
appears O
nearly O
as O
efficient O
as O
the O
entire O
protein O
at O
inducing O
transcriptional O
repression O
. O

A O
new O
myocyte B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
recognizes O
a O
conserved O
element O
associated O
with O
multiple O
muscle O
- O
specific O
genes O
. O

Diclofenac O
sodium O
: O
blood O
concentration O
of O
the O
slow O
- O
release O
form O
and O
influence O
on O
the O
metabolism O
of O
kallikrein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

The O
LS B_GENE/B_BIO
gene I_GENE/I_BIO
promoter I_GENE/I_BIO
sequence I_GENE/I_BIO
has O
homology O
with O
Escherichia O
coli O
promoter O
sequences O
; O
its O
terminator O
sequence O
is O
capable O
of O
forming O
a O
stem O
- O
and O
- O
loop O
structure O
. O

We O
demonstrate O
that O
the O
recently O
proposed O
synthetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
imaging I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
[ O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Overexpression O
of O
either O
Sp1 B_GENE
or O
phosphorylated B_GENE
CREB I_GENE
transactivated O
the O
mCgA B_GENE
promoter I_GENE
dose O
dependently O
, O
while O
coexpression O
of O
both O
transcription O
factors O
resulted O
in O
an O
additive O
mCgA B_GENE
promoter I_GENE
response O
. O

mCgA B_MEASURE/B_GENE
- O
92 O
to O
- O
64 O
BP O
, O
comprising O
the O
Sp1 B_GENE/B_LOCATION
/ O
Egr B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
site O
and O
the O
CRE O
motif O
, O
conferred O
gastrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsiveness O
to O
a O
heterologous B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thymidine B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O
, O
and O
therefore O
functions O
as O
a O
' O
true O
' O
enhancer O
element O
. O

Together O
with O
the O
up O
- O
regulation O
of O
the O
cAMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
modulator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREM B_GENE/B_LOCATION
) O
mRNA O
and O
protein O
levels O
demonstrated O
previously O
in O
CREB B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mice O
, O
we O
suggest O
that O
the O
up O
- O
regulation O
of O
CREB B_GENE
beta I_GENE
may O
also O
contribute O
to O
compensation O
within O
the O
CREB B_GENE/B_LOCATION
/ O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O
of O
transcription O
factors O
, O
when O
CREB B_GENE
delta I_GENE
and O
CREB B_GENE
alpha I_GENE
are O
absent O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
obtained O
with O
cellular B_GENE/B_BIO
RNA I_GENE/I_BIO
from O
HepG2 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O
that O
transcription B_GENE
is O
initiated O
891 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
bases I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
upstream O
of O
the O
translation B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
start B_LOCATION/B_MEASURE
site I_LOCATION/I_MEASURE
and O
that O
the O
polyadenylation B_GENE/B_TIME[MEASURE]
site I_GENE/I_TIME[MEASURE]
is O
located O
550 B_MEASURE/B_LOCATION
bases B_MEASURE/I_LOCATION
downstream O
of O
the O
stop B_GENE
codon I_GENE
. O

Finally O
, O
there O
is O
now O
appropriate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recognition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
pivotal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
forestalling O
pressure B_DISEASE
- O
related O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
, O
even O
among O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
risk B_PERSON/B_ORGANIZATION
persons I_PERSON/I_ORGANIZATION
with O
diabetes B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mellitus I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
insufficiency I_DISEASE
. O

Individual O
and O
combined O
effects O
of O
fumonisin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
B1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
present O
in O
Fusarium O
moniliforme O
culture O
material O
and O
diacetoxyscirpenol O
or O
ochratoxin O
A O
in O
turkey O
poults O
. O

It O
is O
hypothesized O
this O
occurs O
through O
antagonism O
of O
PML B_GENE/B_DISEASE
/ O
RAR B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
actions O
in O
these O
leukemic O
cells O
. O

13 O
: O
961 O
- O
969 O
, O
1993 O
) O
suggested O
that O
T B_GENE
antigen I_GENE
could O
mediate O
transcriptional O
activation O
through O
interaction O
with O
the O
TATA B_GENE/B_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
protein I_GENE/I_BIO
, O
as O
well O
as O
upstream O
bound O
transcription O
factors O
. O

The O
Grb2 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SH3 B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
C B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
binding B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
Gab1 B_GENE
has O
significant O
homology O
to O
a O
region O
of O
the O
adapter B_BIO/B_GENE
protein I_BIO/I_GENE
SLP I_BIO/I_GENE
- I_BIO/I_GENE
76 I_BIO/I_GENE
. O

A O
phase O
II O
study O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 O
- O
fluorouracil O
in O
advanced O
renal O
carcinoma O
: O
clinical O
data O
and O
laboratory O
evidence O
of O
protease O
activation O
. O

activation O
of O
the O
cytotactin B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
by O
the O
homeobox B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Evx B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
/ O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
found O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
hip B_DISEASE/B_LOCATION
fracture I_DISEASE/I_LOCATION
in O
women B_PERSON
younger I_PERSON
than O
75 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
with O
Type B_MEASURE/B_ORGANIZATION
I O
diabetes B_DISEASE/B_PERSON
or O
with O
Type B_DISEASE
II I_DISEASE
diabetes I_DISEASE
of O
long B_PERSON
duration I_PERSON
. O

Maternal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
assessed O
using O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
techniques I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Rat B_GENE/B_DISEASE
p8 I_GENE/I_DISEASE
mRNA I_GENE/I_DISEASE
was O
discovered O
because O
of O
its O
strong O
activation O
in O
pancreas O
during O
the O
acute O
phase O
of O
pancreatitis O
. O

LV B_DISEASE/B_PROTEIN[GENE]
compliance B_DISEASE/I_PROTEIN[GENE]
was O
determined O
from O
the O
slope B_MEASURE
of O
the O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diastolic B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
( O
LVEDP B_LOCATION/B_DISEASE
) O
vs B_DISEASE/B_MEASURE
. O

The O
practice O
of O
measuring O
of O
AChE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
in O
acute O
poisoning O
is O
limited O
. O

vasodilation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
congestive B_DISEASE/B_PERSON
heart I_DISEASE/I_PERSON
failure I_DISEASE/I_PERSON
is O
an O
established O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
collicular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
labels B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
found O
after O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
within O
the O
MST B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
their O
distribution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
deep B_DISEASE/B_PROTEIN[GENE]
SC B_DISEASE/I_PROTEIN[GENE]
subdivision B_DISEASE/I_PROTEIN[GENE]
, O
whereas O
they O
spared O
all O
the O
superficial B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
layers B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O
the O
deep B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
SO B_LOCATION/B_PROTEIN[GENE]
. O

When O
furA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O
katG B_GENE
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B_BACTERIUM[BIO]/B_GENE
could O
regulate O
genes O
, O
other O
than O
katG B_GENE
, O
that O
are O
involved O
in O
pathogenesis O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cefazolin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
given O
into O
the O
III B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cerebral I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O
different B_TIME[MEASURE]/B_PERSON
doses I_TIME[MEASURE]/I_PERSON
were O
studied O
on O
GABA B_GENE
content I_GENE
, O
GAD B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
T B_GENE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
stem B_BODY_PART_OR_ORGAN_COMPONENT
of O
young B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
chickens I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Gallus B_BIO/B_PROTEIN[GENE]
domesticus B_BIO/I_PROTEIN[GENE]
) O
. O

Subclones O
of O
R15 O
which O
reverted O
to O
kappa B_GENE/B_DISEASE
light I_GENE/I_DISEASE
chain I_GENE/I_DISEASE
production O
contained O
genomic O
deletions O
of O
R15ns O
and O
/ O
or O
the O
surrounding O
intron O
. O

The O
disorders B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O
accompanied O
by O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
but O
similarly O
reversible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
electroencephalographic B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
delayed O
activation O
of O
the O
prostaglandin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter O
in O
bovine O
granulosa O
cells O
is O
associated O
with O
down O
- O
regulation O
of O
truncated O
upstream B_GENE
stimulatory I_GENE
factor I_GENE
- I_GENE
2 I_GENE
. O

The O
authors O
recommend O
in O
cases O
with O
an O
elevated O
transaminase O
serum O
activity O
more O
frequent O
check O
- O
up O
examinations O
to O
avoid O
missing O
of O
a O
relapse O
, O
and O
to O
examine O
repeatedly O
IgM B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
anti I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
HAV I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O
in O
protracted O
forms O
of O
hepatitis O
IgM B_DISEASE/B_PERSON
anti I_DISEASE/I_PERSON
- I_DISEASE/I_PERSON
HAV I_DISEASE/I_PERSON
may O
persist O
even O
when O
the O
transaminase O
activity O
is O
normal O
. O

Mean B_PERSON
latency I_PERSON
periods I_PERSON
were O
29 B_MEASURE
. O
6 B_MEASURE
among O
insulators B_PERSON
, O
35 B_MEASURE
. O
4 B_MEASURE
among O
dock B_PERSON/B_ORGANIZATION
workers I_PERSON/I_ORGANIZATION
, O
43 B_MEASURE
. O
7 B_SEQUENCE[MEASURE]
in O
a O
heterogeneous B_MEASURE/B_LOCATION
group B_MEASURE/I_LOCATION
defined O
as O
various B_NUMBER[MEASURE]/B_PERSON
, O
46 B_MEASURE
. O
4 B_MEASURE
in O
non B_DISEASE/B_LOCATION
- O
shipbuilding B_PERSON/B_ORGANIZATION
industry I_PERSON/I_ORGANIZATION
workers I_PERSON/I_ORGANIZATION
, O
49 B_MEASURE
. O
4 B_MEASURE
in O
shipyard B_PERSON/B_ORGANIZATION
workers I_PERSON/I_ORGANIZATION
, O
51 B_MEASURE
. O
7 B_MEASURE
among O
women B_PERSON
with O
a O
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
domestic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
asbestos B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
56 B_MEASURE
. O
2 B_MEASURE
in O
people B_PERSON
employed O
in O
maritime B_LOCATION/B_ORGANIZATION
trades I_LOCATION/I_ORGANIZATION
. O

The O
strategy O
uses O
RNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
add O
DNA O
oligonucleotide O
priming O
sites O
to O
the O
RNA O
for O
subsequent O
reverse O
transcription O
and O
PCR O
( O
RNA B_PROTEIN[GENE]/B_LOCATION
ligase I_PROTEIN[GENE]/I_LOCATION
, O
reverse O
transcription O
- O
PCR O
, O
or O
RL O
/ O
RT O
/ O
PCR O
) O
. O

We O
analyzed O
the O
effects O
of O
light O
on O
tubulin B_GENE
mRNA I_GENE
abundance O
in O
Arabidopsis O
seedlings O
using O
RNA O
gel O
blot O
hybridizations O
and O
gene O
- O
specific O
probes O
. O

More O
important O
, O
ligand O
- O
activated O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylate O
SHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro O
, O
indicating O
that O
SHC B_GENE/B_PERSON
proteins I_GENE/I_PERSON
could O
be O
direct O
substrates O
for O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
chimera O
transduced O
IL B_GENE
- I_GENE
4 I_GENE
- O
specific O
signals O
in O
response O
to O
IL B_GENE
- I_GENE
2 I_GENE
binding O
and O
dramatically O
enhanced O
type O
2 O
responses O
( O
IL B_GENE
- I_GENE
4 I_GENE
, O
IL B_GENE
- I_GENE
5 I_GENE
, O
and O
immunoglobulin B_GENE
E I_GENE
production O
) O
upon O
in O
vitro O
TCR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O
or O
in O
vivo O
antigen O
challenge O
. O

A O
distinct B_DISEASE/B_MEASURE
5 I_DISEASE/I_MEASURE
' I_DISEASE/I_MEASURE
- O
sequence B_LOCATION/B_GENE
in O
clone B_GENE/B_BIO
hMIWC2 I_GENE/I_BIO
suggested O
an O
alternative B_GENE
upstream I_GENE
transcription I_GENE
initiation I_GENE
site I_GENE
. O

Two O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetylglucosaminyltransferases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forming O
the O
core O
2 O
O O
- O
glycan O
branch O
, O
C2GnT O
and O
the O
I B_MEASURE/B_GENE
antigen I_MEASURE/I_GENE
, O
IGnT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
homologous O
to O
each O
other O
in O
three O
regions O
of O
the O
catalytic O
domain O
( O
A O
, O
B O
, O
C O
) O
and O
their O
genes O
reside O
at O
the O
same O
locus O
, O
chromosome O
9 O
, O
band O
q21 O
( O
Bierhuizen O
, O
M O
. O
F O
. O
A O
. O
, O
Mattei O
, O
M O
. O
- O
G O
. O
and O
Fukuda O
, O
M O
. O
, O
genes O
Dev O
. O
, O
7 O
, O
468 O
- O
478 O
, O
1993 O
) O
. O

significantly O
higher O
levels O
of O
vitamin O
C O
and O
catalase B_ENZYME[GENE]
activity O
were O
found O
in O
vegetarians O
( O
C O
- O
63 O
. O
6 O
and O
86 O
. O
5 O
mumol O
/ O
l O
; O
Cat O
- O
1497 O
and O
1313 O
U O
/ O
ml O
for O
males O
and O
females O
, O
respectively O
) O
when O
compared O
to O
nonvegetarians O
( O
C O
- O
41 O
. O
3 O
and O
54 O
. O
4 O
mumol O
/ O
l O
; O
Cat O
- O
1192 O
and O
1086 O
U O
/ O
ml O
) O
. O

cutting O
the O
intraorbital B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nerves I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
produced O
a O
temporary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
retrieval I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
impairment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O
was O
indistinguishable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O
that O
produced O
by O
intramystacial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
lidocaine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

developmental O
regulation O
of O
expression O
of O
the O
malate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
transgenic O
plants O
. O

In O
contrast O
, O
no O
change O
in O
the O
level O
of O
either O
p53 B_GENE
or O
activation O
of O
mdm2 B_GENE
protein I_GENE
by O
p53 B_GENE
was O
observed O
in O
hamster O
UV61 O
cells O
after O
UV O
exposure O
. O

On O
day B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
at O
3500 B_MEASURE/B_ORGANISM_FUNCTION
m B_MEASURE/I_ORGANISM_FUNCTION
, O
RI B_PROTEIN[GENE]/B_LOCATION
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
body B_MEASURE/B_LOCATION
weight I_MEASURE/I_LOCATION
( O
BW B_LOCATION/B_MEASURE
) O
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
SL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
but O
AI B_LOCATION/B_PROTEIN[GENE]
maintained O
it O
. O

Transcriptional O
activation O
of O
the O
proopiomelanocortin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
responsive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
element I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
NF1 B_PERSON/B_LOCATION
family B_PERSON/I_LOCATION
members O
and O
HNF4 B_GENE/B_PERSON
interacted O
with O
overlapping O
sequences O
of O
the O
L O
- O
II O
element O
, O
wherein O
the O
5 O
' O
half O
- O
site O
was O
more O
critical O
for O
NF1 B_GENE/B_DISEASE
binding O
, O
and O
the O
3 O
' O
site O
was O
more O
important O
for O
HNF4 B_GENE/B_LOCATION
binding O
. O

RAP B_GENE/B_DISEASE
has O
been O
shown O
to O
be O
a O
useful O
vaccine O
target O
site O
, O
and O
RIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
inhibitory O
AIPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
therapeutic O
molecules O
to O
prevent O
and O
suppress O
S O
. O
aureus O
infections O
. O

After O
institution O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
diabetic O
control O
was O
improved O
as O
demonstrated O
by O
decreasing O
levels O
of O
HbA1 B_DISEASE/B_GENE
. O

The O
mouse O
lactoferrin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O
promoter O
was O
active O
in O
human O
endometrium O
carcinoma O
RL O
95 O
- O
2 O
cells O
and O
in O
rat O
glioma O
C6 O
cells O
. O

The O
1 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
and O
2 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
survival I_TIME[MEASURE]
rates I_TIME[MEASURE]
for O
the O
patients B_PERSON/B_BIO
with O
N0 B_LOCATION/B_PROTEIN[GENE]
- O
3 B_NUMBER[MEASURE]/B_DISEASE
significantly O
exceeded O
those O
of O
N4 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
. O

Measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
spectral B_PROTEIN[GENE]/B_LOCATION
sensitivity I_PROTEIN[GENE]/I_LOCATION
and O
the O
ERG B_MEASURE
can O
thus O
help O
in O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
three B_DISEASE_ADJECTIVE[DISEASE]
hereditary I_DISEASE_ADJECTIVE[DISEASE]
diseases I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
a O
quantitative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cochlear B_MEASURE/B_DISEASE
function I_MEASURE/I_DISEASE
, O
2f1 B_PROTEIN[GENE]/B_MEASURE
- O
F2 B_MEASURE
distortion I_MEASURE
- O
product B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
otoacoustic I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
emissions I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
DPOAEs B_DISEASE/B_LOCATION
) O
were O
monitored O
systematically O
over O
time B_TIME[MEASURE]/B_LOCATION
in O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
rabbits B_BIO/B_PERSON
, O
with O
each O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiencing O
a O
unique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paradigm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
incorporated O
repeated O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
the O
low B_MEASURE/B_COLOR
- O
frequency B_MEASURE/B_LOCATION
tone I_MEASURE/I_LOCATION
. O

The O
subjects B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lungs I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
ventilated O
with O
N2O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
O2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
FIO2 B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
3 B_MEASURE
) O
to O
the O
end B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tidal B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CO2 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
and O
then O
CBF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
measured O
using O
intravenous B_NUMBER[MEASURE]
133Xe I_NUMBER[MEASURE]
and O
ten B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintillation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
five B_NUMBER[MEASURE]/B_LOCATION
over O
each O
cerebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hemisphere I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
indicates O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
postvaccination B_DISEASE_ADJECTIVE[DISEASE]
allergy I_DISEASE_ADJECTIVE[DISEASE]
to O
BCG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Analysis O
of O
1 O
MB O
of O
published O
sequence O
from O
the O
region O
of O
conserved O
synteny O
on O
human O
chromosome O
5q31 O
- O
q33 O
identified O
45 O
gene O
candidates O
, O
including O
35 O
expressed O
genes O
in O
the O
human B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
IL I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
4 I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cytokine I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gene I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cluster O
. O

There O
is O
no O
indication O
from O
these O
experiments O
that O
linker B_PERSON/B_GENE
histones I_PERSON/I_GENE
bind O
fundamentally O
differently O
to O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
bulk O
nucleosomes O
. O

km O
values O
of O
the O
uncoupled O
enzymes O
IIGlc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
glucose O
ranged O
from O
0 O
. O
5 O
to O
2 O
. O
5 O
mm O
, O
2 O
orders O
of O
magnitude O
higher O
than O
the O
value O
of O
normal O
IIGlc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Cytochrome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bd I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
biosynthesis O
in O
Escherichia O
coli O
: O
the O
sequences O
of O
the O
cydC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cydD B_LOCATION/B_GENE
genes I_LOCATION/I_GENE
suggest O
that O
they O
encode O
the O
components O
of O
an O
ABC B_ENZYME[GENE]/B_BIO
membrane I_ENZYME[GENE]/I_BIO
transporter I_ENZYME[GENE]/I_BIO
. O

In O
contrast O
, O
inhibition O
of O
MAPK B_GENE
activity O
by O
MAPK B_GENE
kinase I_GENE
inhibitor O
( O
PD O
98059 O
) O
or O
by O
overexpression O
of O
kinase O
- O
deficient O
MAPKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated O
basal O
and O
GnRH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
GnRHR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Luc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
. O

The O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gas B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
composition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
air B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
on O
pipping B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
liver B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
embryonic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
chicks I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Historically O
, O
Cyps B_BIO/B_PERSON
were O
first O
identified O
by O
their O
ability O
to O
bind O
the O
immunosuppressive O
agent O
cyclosporin O
A O
( O
CsA O
) O
with O
high O
affinity O
; O
they O
later O
were O
found O
to O
have O
peptidyl B_ENZYME[GENE]
- I_ENZYME[GENE]
prolyl I_ENZYME[GENE]
cis I_ENZYME[GENE]
- I_ENZYME[GENE]
trans I_ENZYME[GENE]
isomerase I_ENZYME[GENE]
( O
PPIase B_GENE/B_LOCATION
) O
activity O
, O
which O
catalyzes O
the O
folding O
of O
oligopeptides O
at O
proline O
- O
peptide O
bonds O
in O
vitro O
and O
may O
be O
important O
for O
protein O
folding O
in O
vivo O
. O

Thus O
, O
oxyR B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
locked O
on O
for O
Ag43 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
, O
whereas O
dam B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
locked O
off O
for O
Ag43 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
. O

A O
rare O
tRNA B_GENE/B_MEASURE
- I_GENE/I_MEASURE
Arg I_GENE/I_MEASURE
( I_GENE/I_MEASURE
CCU I_GENE/I_MEASURE
) I_GENE/I_MEASURE
that O
regulates O
Ty1 B_DISEASE_ADJECTIVE[DISEASE]
element I_DISEASE_ADJECTIVE[DISEASE]
ribosomal O
frameshifting O
is O
essential O
for O
Ty1 B_GENE
retrotransposition O
in O
Saccharomyces O
cerevisiae O
. O

Several O
35 O
- O
mm O
slides O
of O
dystrophin B_GENE
- O
, O
laminin B_GENE
- O
, O
and O
concanavalin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ConA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
- O
stained O
muscle O
sections O
were O
used O
to O
calculate O
myofiber O
cross O
- O
sectional O
areas O
and O
to O
compare O
different O
techniques O
and O
settings O
of O
an O
image O
capture O
system O
. O

In O
addition O
, O
both O
inhibitors O
blocked O
phosphatidylcholine O
hydrolysis O
and O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
translocation O
. O

New O
, O
selective O
catechol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O
as O
therapeutic O
agents O
in O
Parkinson O
' O
s O
disease O
. O

Furthermore O
, O
the O
social B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
learning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
depression B_TIME[MEASURE]/B_DISEASE
, O
developed O
by O
Lewinsohn B_PERSON
, O
is O
described O
. O

laser O
soldering O
with O
exogenous O
fibrinogen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
feasible O
without O
topical O
administration O
of O
additional O
clotting O
agents O
, O
significantly O
improves O
the O
bursting O
strength O
of O
primary O
laser O
welded O
anastomoses O
, O
and O
appears O
to O
result O
from O
urokinase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
resistant O
fibrinogen B_GENE
cross O
- O
linking O
. O

intensity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
the O
variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
removed O
, O
and O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
evaluated O
for O
correlation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
lateralized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Routine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
modalities I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
a O
total B_MEASURE/B_LOCATION
of O
79 B_NUMBER[MEASURE]/B_ORGANIZATION
metastases I_NUMBER[MEASURE]/I_ORGANIZATION
. O

We O
have O
previously O
reported O
that O
analgesic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accelerate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mortality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O
to O
hemorrhage B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Feuerstein B_PERSON/B_LOCATION
and O
Siren B_PERSON
: O
Circ B_MEASURE/B_ENT
Shock I_MEASURE/I_ENT
19 I_MEASURE/I_ENT
: O
293 B_MEASURE
- O
300 B_MEASURE
, O
1986 B_MEASURE
) O
. O

We O
describe O
a O
novel O
stat B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
related I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
p93 B_GENE
, O
that O
is O
found O
in O
EGF B_GENE
- O
treated O
A431 O
cell O
extracts O
but O
appears O
to O
be O
absent O
in O
bovine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
untreated O
cells O
. O

p93 B_GENE/B_PERSON
appears O
to O
be O
antigenically O
related O
to O
stat91 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
. O

p185c B_GENE
- O
neu B_GENE
+ O
, O
EGFr B_GENE
+ I_GENE
( O
M1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
p185c B_GENE
- O
neu B_GENE
- O
kinase O
inactive O
, O
EGFr B_GENE
+ I_GENE
( O
NEN757 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
addition O
, O
Fc B_GENE
epsilon I_GENE
R1 I_GENE
cross O
- O
linking O
activates O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC O
box O
, O
EBS B_DISEASE/B_GENE
, O
and O
GT O
box O
in O
PFP9a20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
at O
least O
3 O
- O
fold O
less O
CAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

Ribosome O
association O
of O
GCN2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
translational O
activator O
of O
the O
GCN4 B_GENE
gene I_GENE
of O
Saccharomyces O
cerevisiae O
. O

Treatment O
with O
H7 O
did O
not O
affect O
IL B_GENE
- I_GENE
4R I_GENE
- O
mediated O
immediate O
signaling O
events O
such O
as O
tyrosine O
phosphorylation O
of O
Jak1 B_GENE
, O
Jak3 B_GENE
, O
insulin B_GENE
receptor I_GENE
substrate I_GENE
( I_GENE
IRS I_GENE
) I_GENE
- I_GENE
1 I_GENE
and O
IRS B_GENE
- I_GENE
2 I_GENE
, O
or O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
Stat6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
STK1 B_NUMBER[MEASURE]/B_PERSON
is O
most O
likely O
the O
human B_PERSON/B_GENE
homologue I_PERSON/I_GENE
of I_PERSON/I_GENE
MO15 I_PERSON/I_GENE
. O

Background O
: O
Recent O
iterative O
methods O
for O
sequence O
alignment O
have O
indicated O
that O
the O
380 O
kDa O
motor O
unit O
of O
dynein B_BACTERIUM[BIO]/B_GENE
belongs O
to O
the O
AAA B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
chaperone B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
the O
VBP B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
was O
solely O
expressed O
, O
it O
located O
to O
the O
cytoplasm O
and O
did O
not O
localize O
to O
the O
nucleus O
. O

Consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
these O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
the O
most O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
significance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
relation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phosphorus B_ORGANISM_FUNCTION/B_DISEASE
balance I_ORGANISM_FUNCTION/I_DISEASE
in O
ruminants B_SPECIES[BIO]/B_PERSON
is O
discussed O
. O

Transfection O
assays O
using O
the O
first O
600 O
BP O
of O
the O
upstream O
nucleotide O
sequences O
indicated O
that O
a O
region O
from O
- O
75 O
to O
- O
120 O
was O
necessary O
for O
the O
ALDH2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expression O
, O
and O
especially O
NF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
Y I_GENE/I_LOCATION
/ O
CP1 B_GENE
binding O
site O
from O
- O
92 O
to O
- O
96 O
( O
CCAAT O
box O
) O
is O
important O
in O
the O
expression O
of O
the O
gene O
. O

This O
distinct O
biochemical O
difference O
between O
STAT5A B_GENE
and O
STAT5B B_GENE
was O
confirmed O
with O
purified O
activated O
STAT5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
in O
uninfected B_PERSON/B_PROTEIN[GENE]
NIH B_PERSON/I_PROTEIN[GENE]
- O
3T3 B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Avarol I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
i B_OTHER/B_DISEASE
) O
causes O
a O
50 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O
at O
the O
high B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
of O
29 B_MEASURE
. O
6 B_MEASURE
microM I_MEASURE
and O
( O
ii B_MEASURE/B_PROTEIN[GENE]
) O
is O
accumulated O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
close O
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

Blood B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coagulation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
X I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
activated O
form O
Factor B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Xa I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
play O
an O
essential O
role O
in O
the O
midphase O
of O
the O
clotting O
Cascade O
. O

The O
exon O
sequences O
determined O
from O
genomic O
DNA O
sequencing O
showed O
some O
differences O
when O
compared O
to O
the O
published O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GLUT2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Intramolecular O
interaction O
is O
believed O
to O
result O
in O
the O
formation O
of O
MxA B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
monomers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O
whereas O
intermolecular O
interaction O
may O
induce O
the O
formation O
of O
large B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MxA I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oligomers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
psbA B_GENE
gene I_GENE
encodes O
the O
D1 B_PROTEIN[GENE]/B_PERSON
protein I_PROTEIN[GENE]/I_PERSON
of O
photosystem B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
synthesized O
at O
very O
high O
rates O
in O
the O
light O
in O
order O
to O
replace O
photodamaged O
protein O
. O

The O
three O
more O
slower O
migrating O
Stat5B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands O
observed O
in O
response O
to O
GH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contain O
phosphorylated O
tyrosyl O
residues O
. O

The O
maximum B_MEASURE
levels I_MEASURE
of O
reporter B_GENE
proteins I_GENE
attained O
in O
transformed O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
after O
prolonged B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
represented O
from O
1 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
to O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
total B_MEASURE/B_PERSON
cellular B_MEASURE/I_PERSON
protein B_MEASURE/I_PERSON
. O

Specifically O
, O
we O
demonstrate O
that O
this O
25 O
- O
base O
pair O
region O
mediates O
the O
up O
- O
regulatory O
effect O
of O
TGF B_GENE
- I_GENE
beta I_GENE
on O
COL1A2 B_GENE
promoter I_GENE
activity O
and O
allows O
antagonistic O
activity O
of O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
TGF B_GENE
- I_GENE
beta I_GENE
effect O
. O

Sin4 B_GENE
and O
Srb10 B_GENE/B_DISEASE
, O
components O
of O
specific O
RNA B_GENE/B_BIO
polymerase I_GENE/I_BIO
II I_GENE/I_BIO
sub I_GENE/I_BIO
- I_GENE/I_BIO
complexes I_GENE/I_BIO
that O
are O
required O
for O
Ssn6 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Tup1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B_GENE/B_BIO
repression O
function O
. O

Translation O
of O
mok B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
tightly O
regulated O
by O
Sok B_GENE/B_BIO
RNA I_GENE/I_BIO
, O
and O
Sok B_GENE/B_BIO
RNA I_GENE/I_BIO
thus O
regulates O
hok B_SPECIES[BIO]/B_GENE
translation O
indirectly O
through O
mok B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Depending O
on O
the O
patient B_PERSON/B_BIO
' O
s B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
telemetrically O
measured O
CSF B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
pressures B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
varied O
between O
- O
20 B_MEASURE
cmH2O I_MEASURE
in O
erect B_DISEASE/B_LOCATION
and O
15 B_MEASURE
cmH2O I_MEASURE
in O
supine B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
position I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

One B_NUMBER[MEASURE]
- O
hour B_MEASURE
O3 I_MEASURE
, O
NO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
SO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
personal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exposures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
measured O
using O
samplers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
developed O
in O
our O
laboratory B_LOCATION/B_ORGANIZATION
, O
while O
short B_PERSON/B_MEASURE
- O
term B_MEASURE/B_LOCATION
PM2 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
, O
CO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
VOCs B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposures B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
using O
currently O
available B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
Tlr B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
unlike O
others O
reported O
to O
date O
, O
were O
identified O
within O
a O
genomic O
database O
. O

We O
hypothesized O
that O
subjects B_PERSON/B_BIO
would O
demonstrate O
PKAR B_DISEASE/B_GENE
during O
both O
hopping O
and O
stepping O
, O
adding O
support B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
PKAR B_GENE/B_LOCATION
is O
a O
centrally O
mediated O
adaptation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
general B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
locomotor B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
trajectory B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
that O
is O
not O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
form B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
locomotion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
used O
while O
on O
the O
rotating O
disk B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

In O
this O
study O
, O
transcriptional O
fusions O
were O
constructed O
between O
the O
xcpP B_GENE/B_BACTERIUM[BIO]
and O
xcpR B_GENE
genes I_GENE
and O
the O
lacZ B_GENE/B_PERSON
reporter I_GENE/I_PERSON
. O

To O
explore O
the O
mechanism O
of O
insulin B_GENE
receptor I_GENE
phosphorylation O
we O
have O
used O
NIH3T3 O
cells O
transfected O
with O
two O
receptor O
constructs O
: O
one O
encoding O
a O
chimeric O
receptor O
composed O
of O
the O
extracellular O
domain O
of O
the O
human B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
EGF B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
cytosolic O
domain O
of O
the O
human B_GENE
insulin I_GENE
receptor I_GENE
beta I_GENE
- I_GENE
subunit I_GENE
, O
and O
a O
second O
construct O
encoding O
a O
kinase O
- O
defiecient O
human B_PROTEIN[GENE]
insulin I_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
. O

It O
is O
pathogenetically O
proved O
to O
use O
antithrombin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
III I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
concentrate O
preparations O
with O
anti O
- O
and O
dysaggregatory O
properties O
, O
fibronectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
preparations O
, O
trasylol O
or O
its O
analogs O
during O
complex O
preoperative O
preparation O
of O
patients O
. O

Stimulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
endosteal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
mainly O
impaired O
in O
D B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
depleted O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulting O
in O
trabecular B_DISEASE/B_GENE
bone I_DISEASE/I_GENE
loss I_DISEASE/I_GENE
, O
which O
, O
in O
- O
D B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mother I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
associated O
with O
decreased O
bone B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ash B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
total B_MEASURE/B_DISEASE
bone B_MEASURE/I_DISEASE
calcium B_MEASURE/I_DISEASE
. O

Hematopoietic B_GENE
progenitor I_GENE
kinase I_GENE
1 I_GENE
( O
HPK1 B_GENE/B_LOCATION
) O
is O
a O
member O
of O
the O
mitogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAP4K B_GENE/B_LOCATION
) O
family O
and O
an O
upstream O
activator O
of O
the O
c B_GENE/B_DISEASE
- I_GENE/I_DISEASE
Jun I_GENE/I_DISEASE
N I_GENE/I_DISEASE
- I_GENE/I_DISEASE
terminal I_GENE/I_DISEASE
kinase I_GENE/I_DISEASE
( O
JNK B_GENE/B_ORGANIZATION
) O
signaling O
Cascade O
. O

We O
have O
used O
the O
chloramphenicol B_GENE
acetyltransferase I_GENE
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
reporter O
gene O
system O
to O
study O
the O
effect O
of O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
long O
terminal O
repeats O
( O
LTRs O
) O
of O
a O
large O
family O
of O
human O
endogenous O
retrovirus O
- O
like O
sequences O
, O
RTVL O
- O
H O
. O

To O
investigate O
this O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
conducted O
split B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
visual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
we O
manipulated O
stimulus B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sets I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
recognition B_MEASURE/B_LOCATION
task I_MEASURE/I_LOCATION
, O
and O
exposure B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duration B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ANH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
had O
no O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
endocrine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
stress I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O
orthopedic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
under O
epidural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Finally O
, O
the O
conservation O
of O
the O
two O
residues O
most O
sensitive O
to O
mutations O
( O
Y949 O
and O
Y953 O
) O
in O
TM11 O
, O
and O
in O
the O
homologous O
TM5 O
, O
of O
all O
mammalian B_BIO/B_GENE
P I_BIO/I_GENE
- I_BIO/I_GENE
gps I_BIO/I_GENE
and O
also O
in O
other O
ABC B_BIO/B_GENE
transporters I_BIO/I_GENE
, O
suggests O
that O
these O
residues O
and O
domains O
may O
play O
an O
important O
role O
in O
structural O
as O
well O
as O
mechanistic O
aspects O
common O
to O
this O
family O
of O
proteins O
. O

Based O
on O
the O
requirement O
for O
CREM B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
ICER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
Rad6B B_GENE
proteins I_GENE
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B_GENE
, O
Rad6B B_GENE/B_BACTERIUM[BIO]
, O
CREM B_LOCATION/B_DISEASE
/ O
ICER B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O
, O
and O
the O
Skp1 B_GENE
- O
Cullin B_PROTEIN[GENE]/B_DISEASE
- O
F O
- O
box O
ubiquitin B_GENE/B_BIO
protein O
ligase O
subunits O
Cul B_GENE
- I_GENE
1 I_GENE
and O
Cul B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
2 I_PROTEIN[GENE]/I_MEASURE
, O
which O
are O
associated O
with O
Cdc34 B_GENE
activity O
during O
murine O
testicular O
development O
. O

The O
enigma B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aging O
bone B_DISEASE/B_LOCATION
loss I_DISEASE/I_LOCATION
. O

Transcription B_GENE
factor I_GENE
IIIC I_GENE
( O
TFIIIC B_PROTEIN[GENE]/B_DISEASE
) O
is O
required O
for O
the O
assembly O
of O
a O
preinitiation O
complex O
on O
5S B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
tRNA O
, O
and O
adenovirus B_VIRUS[BIO]/B_PERSON
VA I_VIRUS[BIO]/I_PERSON
RNA O
genes O
and O
contains O
two O
separable O
components O
, O
TFIIIC1 B_PROTEIN[GENE]/B_DISEASE
and O
TFIIIC2 B_PROTEIN[GENE]
. O

Furthermore O
, O
we O
show O
that O
Nck B_GENE
- I_GENE
2 I_GENE
is O
capable O
of O
recognizing O
several O
key O
components O
of O
growth B_GENE
factor I_GENE
receptor I_GENE
kinase I_GENE
- O
signaling O
pathways O
including O
EGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
PDGF B_GENE
receptor I_GENE
- I_GENE
beta I_GENE
, O
and O
IRS B_GENE
- I_GENE
1 I_GENE
. O

These O
two O
enhancer O
elements O
also O
enhanced O
transcription O
when O
fused O
separately O
to O
the O
basal O
promoter O
region O
of O
the O
chicken B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
vimentin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
they O
were O
exposed O
to O
intermittent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
schedules B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
punishment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
fixed O
- O
interval B_MEASURE/B_LOCATION
[ O
fi B_LOCATION/B_MEASURE
] I_MEASURE
120 B_MEASURE
s I_MEASURE
or O
fi B_MEASURE
300 I_MEASURE
s I_MEASURE
) O
, O
SIB B_DISEASE/B_ORGANIZATION
for O
all O
but O
1 B_NUMBER[MEASURE]
of O
the O
participants B_PERSON
increased O
to O
levels B_MEASURE/B_LOCATION
similar I_MEASURE/I_LOCATION
to O
those O
observed O
during O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Deep B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bite I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
CL I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
II I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
div I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

patients B_PERSON
with O
binocular B_DISEASE
pregeniculate I_DISEASE
visual I_DISEASE
loss I_DISEASE
, O
patients B_PERSON
with O
balanced B_DISEASE/B_GENE
binocular I_DISEASE/I_GENE
pregeniculate I_DISEASE/I_GENE
loss I_DISEASE/I_GENE
without O
RAPD B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
patients B_PERSON/B_BIO
with O
monocular B_DISEASE
pregeniculate I_DISEASE
visual I_DISEASE
loss I_DISEASE
had O
significantly O
larger B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pupils B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
age B_TIME[MEASURE]/B_PERSON
- O
matched O
controls B_PERSON/B_BIO
. O

protein O
sequencing O
, O
electrophoretic O
mobility O
shift O
assay O
, O
and O
immunoblot O
analyses O
identify O
p54 B_GENE
and O
p47 B_GENE
/ I_GENE
48 I_GENE
as O
members O
of O
the O
hepatocyte B_GENE/B_DISEASE
nuclear I_GENE/I_DISEASE
factor I_GENE/I_DISEASE
3 I_GENE/I_DISEASE
( O
HNF3 B_GENE/B_LOCATION
[ O
forkhead B_PROTEIN[GENE]/B_BIO
] O
) O
family O
of O
transcription O
factors O
. O

p54 B_GENE/B_DISEASE
belongs O
to O
the O
subfamily O
of O
HNF3 B_GENE/B_BIO
beta I_GENE/I_BIO
proteins I_GENE/I_BIO
, O
while O
p47 B_GENE/B_TIME[MEASURE]
/ I_GENE/I_TIME[MEASURE]
48 I_GENE/I_TIME[MEASURE]
binding O
activity O
includes O
HNF3 B_GENE/B_PERSON
gamma I_GENE/I_PERSON
. O

In O
this O
cross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
over O
controlled O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
five B_PERSON
male I_PERSON
volunteers I_PERSON
donated O
one B_MEASURE/B_LOCATION
unit I_MEASURE/I_LOCATION
of O
red B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
MCS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
one B_NUMBER[MEASURE]/B_ORGANIZATION
unit I_NUMBER[MEASURE]/I_ORGANIZATION
of O
whole B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
conventional B_DISEASE/B_LOCATION
manual B_DISEASE/I_LOCATION
method B_DISEASE/I_LOCATION
, O
3 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
apart O
. O

promoter O
activity O
was O
assayed O
by O
transient O
transfection O
of O
luciferase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O
nested O
deletions O
of O
the O
upstream O
sequence O
in O
the O
human O
RPE O
cell O
lines O
ARPE19 O
and O
D407 O
, O
as O
well O
as O
in O
the O
SK O
- O
Mel O
- O
28 O
and O
HeLa O
cell O
lines O
. O

This O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
exploits O
the O
polyomavirus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
late I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
termination I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
polyadenylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
signals I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
sufficiently O
weak B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
allow O
the O
production B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
many B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
multigenome B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
length B_MEASURE/B_GENE
primary B_MEASURE/I_GENE
transcripts B_MEASURE/I_GENE
with O
repeating O
introns B_GENE/B_LOCATION
, O
exons B_GENE/B_LOCATION
, O
and O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
sites B_LOCATION/B_ENT
. O

Magnification B_TIME[MEASURE]/B_PERSON
- O
corrected O
planimetry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
parapapillary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
performed O
according O
to O
Littmann B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
method I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
312 B_PERSON/B_ENT
unselected I_PERSON/I_ENT
eyes I_PERSON/I_ENT
with O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
primary I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
open I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
angle B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
in O
125 B_PERSON/B_LOCATION
normal I_PERSON/I_LOCATION
eyes I_PERSON/I_LOCATION
of O
an O
age B_MEASURE/B_LOCATION
- O
and O
refraction B_DISEASE/B_MEASURE
- O
matched O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
using O
optic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disk I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
photographs I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Although O
the O
elevated O
signalling O
is O
eliminated O
by O
deletion O
of O
Ste20p B_GENE/B_BIO
( O
or O
components O
downstream O
of O
Ste20p B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
the O
growth O
and O
morphological O
abnormalities O
of O
cells O
lacking O
Akr1p B_GENE/B_SPECIES[BIO]
are O
not O
rescued O
by O
deletion O
of O
any O
of O
the O
known O
pheromone O
response O
pathway O
components O
. O

Southern O
hybridization O
of O
genomic O
DNA O
from O
WT O
and O
Lp B_PROTEIN[GENE]/B_LOCATION
/ O
Lp B_PROTEIN[GENE]/B_LOCATION
embryos O
failed O
to O
identify O
specific O
rearrangements O
at O
or O
near O
the O
Nhlh1 B_GENE/B_LOCATION
locus I_GENE/I_LOCATION
, O
and O
Northern O
RNA O
blotting O
and O
RT O
- O
PCR O
evaluation O
of O
Nhlh1 B_GENE
mRNA I_GENE
expression O
indicated O
that O
both O
the O
levels O
and O
types O
of O
Nhlh1 B_GENE
mRNAs I_GENE
produced O
in O
WT O
and O
Lp B_LOCATION/B_PROTEIN[GENE]
/ O
Lp B_PROTEIN[GENE]/B_LOCATION
embryos O
were O
indistinguishable O
. O

In O
addition O
, O
mrp17 B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
, O
in O
combination O
with O
some O
mutations O
affecting O
another O
mitochondrial O
ribosomal O
protein O
, O
caused O
a O
synthetic O
defective O
phenotype O
. O

expression O
, O
characterization O
, O
and O
genomic O
structure O
of O
carp B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
JAK1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

significantly O
, O
the O
murine B_GENE/B_BIO
P I_GENE/I_BIO
- I_GENE/I_BIO
selectin I_GENE/I_BIO
gene I_GENE/I_BIO
had O
several O
features O
not O
found O
in O
the O
human O
gene O
. O

fluorescent O
in O
situ O
hybridization O
( O
Fish O
) O
analysis O
showed O
that O
the O
novel O
regions O
involved O
in O
the O
NFKB2 B_GENE
rearrangement O
originated O
from O
chromosome O
7q34 O
, O
thus O
implying O
the O
occurrence O
of O
a O
t O
( O
7 O
; O
10 O
) O
( O
q34 O
; O
q24 O
) O
reciprocal O
chromosomal O
translocation O
. O

Transient O
- O
expression O
assay O
analysis O
of O
subclones O
of O
pPstI O
- O
G O
localized O
the O
trans O
- O
active O
factor O
to O
a O
3 B_GENE
. I_GENE
0 I_GENE
- I_GENE
kilobase I_GENE
XbaI I_GENE
fragment I_GENE
. O

MGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
novel O
member O
of O
the O
cytokine B_ORGANIZATION/B_LOCATION
- I_ORGANIZATION/I_LOCATION
regulated I_ORGANIZATION/I_LOCATION
transcription I_ORGANIZATION/I_LOCATION
factor I_ORGANIZATION/I_LOCATION
gene I_ORGANIZATION/I_LOCATION
family I_ORGANIZATION/I_LOCATION
. O

This O
is O
the O
first O
report O
that O
the O
PH B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
IRS B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
can O
function O
in O
a O
dominant O
negative O
manner O
to O
inhibit O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
. O

A O
29 B_MEASURE
. O
425 B_MEASURE
kb I_MEASURE
segment I_MEASURE
on O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
arm I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
yeast B_GENE/B_SPECIES[BIO]
chromosome B_GENE/I_SPECIES[BIO]
XV B_GENE/I_SPECIES[BIO]
contains O
more B_MEASURE
than O
twice O
as O
many B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unknown B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
known O
open B_GENE/B_BIO
reading I_GENE/I_BIO
frames I_GENE/I_BIO
. O

This O
result O
, O
together O
with O
the O
fact O
that O
unrearranged B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
transcriptionally O
silent O
, O
suggests O
that O
structural O
features O
of O
both O
the O
V B_PROTEIN[GENE]
kappa I_PROTEIN[GENE]
and O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O
to O
the O
overall O
transcriptional O
efficiency O
of O
a O
rearranged O
V B_MEASURE/B_DISEASE
kappa B_MEASURE/I_DISEASE
- O
C B_GENE
kappa I_GENE
gene O
. O

The O
first B_GENE/B_LOCATION
270 I_GENE/I_LOCATION
bp I_GENE/I_LOCATION
of O
the O
promoter B_GENE/B_LOCATION
region I_GENE/I_LOCATION
were O
sequenced O
and O
found O
to O
contain O
a O
CATAA B_GENE/B_DISEASE
box B_GENE/I_DISEASE
rather O
than O
a O
TATAA B_GENE/B_LOCATION
box I_GENE/I_LOCATION
and O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
found O
in O
activation B_GENE/B_SPECIES[BIO]
genes B_GENE/I_SPECIES[BIO]
. O

C O
. O
glabrata O
cells O
containing O
the O
CBF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
under O
the O
influence O
of O
a O
shutdown O
promoter O
( O
tetO O
- O
ScHOP O
) O
arrested O
their O
growth O
after O
5 O
h O
of O
cultivation O
in O
the O
presence O
of O
the O
reactive O
drug O
doxycycline O
. O

SF1 B_GENE/B_LOCATION
/ O
mBBP B_MEASURE/B_PROTEIN[GENE]
utilizes O
a O
' B_GENE/B_MEASURE
maxi I_GENE/I_MEASURE
- I_GENE/I_MEASURE
K I_GENE/I_MEASURE
homology I_GENE/I_MEASURE
' I_GENE/I_MEASURE
( O
maxi B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
KH I_PROTEIN[GENE]/I_LOCATION
) O
domain O
for O
recognition O
of O
the O
single O
- O
stranded O
BPS O
and O
requires O
a O
cooperative O
interaction O
with O
splicing O
factor O
U2AF65 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O
to O
an O
adjacent O
polypyrimidine O
tract O
( O
PPT O
) O
for O
high O
- O
affinity O
binding O
. O

An O
X O
- O
linked O
zinc B_GENE/B_DISEASE
finger B_GENE/I_DISEASE
gene B_GENE/I_DISEASE
mapping O
to O
Xq21 O
. O
1 O
- O
q21 O
. O
3 O
closely O
related O
to O
ZFX B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ZFY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
possible O
origins O
from O
a O
common O
ancestral O
gene O
. O

validity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
short B_NUMBER[MEASURE]
- O
form B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
QIF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
assessed O
by O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
motor B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
using O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
variance B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
motor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
motor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
score I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groupings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

juvenile B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
angiofibromas I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

comment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
' O
Critical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
binary B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mixture I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
salt B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' O
. O

The O
pineal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
melatonin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
MLT B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
able B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
exert O
an O
oncostatic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
addition O
, O
there O
was O
an O
increase O
in O
the O
amount O
of O
p120 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
Ras I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
specific O
GTPase B_GENE
- I_GENE
activating I_GENE
protein I_GENE
( O
GAP B_LOCATION/B_GENE
) O
and O
GAP B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
associated O
p190 O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
both O
ADN B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
eliminated O
the O
remaining O
sigmoidal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
correlation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
between O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
RSNA B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
further B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
resting O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
RSNA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pregnancy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
ensued O
in O
4 B_TIME[MEASURE]
cases I_TIME[MEASURE]
in O
group B_ORGANIZATION/B_MEASURE
I O
. O

The O
1 O
. O
3 O
- O
kb O
DNA O
, O
when O
placed O
upstream O
of O
the O
chloramphenicol B_GENE/B_BIO
acetyltransferase I_GENE/I_BIO
gene I_GENE/I_BIO
, O
was O
shown O
to O
be O
functionally O
active O
. O

controversy B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
exists O
regarding O
both O
the O
natural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
life I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cycle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
this O
parasite B_SPECIES[BIO]
as O
well O
as O
the O
species B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
opossum B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Sarcocystis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
mean B_MEASURE
was O
66 B_MEASURE
cells I_MEASURE
/ O
mm2 B_MEASURE
in O
the O
laser B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
63 B_MEASURE
. O
7 B_MEASURE
cells I_MEASURE
/ O
mm2 B_MEASURE
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

prazosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
high B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
. O

The O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
antagonist O
ondansetron O
reduced O
alcohol O
intake O
in O
both O
the O
medium O
and O
high O
alcohol O
preferring O
rats O
at O
doses O
between O
0 O
. O
01 O
and O
0 O
. O
16 O
mg O
/ O
kg O
. O

Oral B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
hypoglycemic I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
agents I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

1 B_NUMBER[MEASURE]
. O

In O
this O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
enhancers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
act O
primarily O
to O
increase O
the O
probability B_MEASURE
of O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transcription I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complex I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

The O
relationship O
between O
donor O
status O
for O
antibody O
to O
hepatitis B_DISEASE
B I_DISEASE
core I_DISEASE
antigen I_DISEASE
and O
the O
occurrence O
of O
non O
- O
A O
, O
non O
- O
B O
posttransfusion O
hepatitis O
in O
the O
recipient O
was O
prospectively O
studied O
in O
112 O
patients O
undergoing O
open O
- O
heart O
surgery O
who O
were O
followed O
for O
6 O
. O
5 O
months O
after O
surgery O
. O

By O
sequencing O
of O
exonuclease B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
III I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
deletion O
clones O
an O
open O
reading O
frame O
of O
405 O
nucleotides O
was O
found O
coding O
for O
a O
protein O
of O
135 O
amino O
acids O
with O
a O
molecular O
mass O
of O
15 O
kDa O
. O

The O
pepI B_GENE
gene I_GENE
was O
overexpressed O
in O
Escherichia O
coli O
. O

Treatment O
of O
steroid O
resistant O
rejection O
following O
renal O
transplantation O
: O
benefits O
and O
risks O
of O
OKT3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

The O
level B_MEASURE/B_LOCATION
of O
transcription B_TIME[MEASURE]/B_GENE
generated O
by O
all O
of O
these O
activators B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
greater B_MEASURE
than O
the O
sum B_MEASURE/B_LOCATION
of O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
generated O
by O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
a O
phenomenon B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
designated O
transcriptional B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergy B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conservation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
zinc B_LOCATION/B_GENE
finger B_LOCATION/I_GENE
motif B_LOCATION/I_GENE
from O
yeast B_SPECIES[BIO]
to O
mouse B_SPECIES[BIO]/B_DISEASE
and O
human B_SPECIES[BIO]/B_PERSON
implies O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
importance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O
organellar B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transfer B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
event B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
strikingly O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
experimentally O
accessible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nuclear B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
integration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
introduced O
heterologous B_GENE/B_BIO
DNA I_GENE/I_BIO
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
the O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
the O
single B_NUMBER[MEASURE]
- O
sample B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
model I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O
confirmed O
to O
give O
excellent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
AUC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
AUC B_MEASURE/B_LOCATION
( O
mg B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
ml B_MEASURE/B_PERSON
x O
min B_TIME[MEASURE]/B_PERSON
) O
= O
0 B_MEASURE
. O
93 B_MEASURE
x O
C3h B_MEASURE
+ O
0 B_MEASURE
. O
47 B_MEASURE
( O
MPE B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
= O
4 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
RMSE B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
= O
8 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

SH3A B_GENE
competes O
with O
the O
SH3 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Grb2 B_GENE
in O
binding O
to O
mSos1 B_GENE
, O
and O
the O
intersectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mSos1 B_GENE
complex O
can O
be O
separated O
from O
Grb2 B_GENE
by O
sucrose O
gradient O
centrifugation O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
the O
Ricketts B_PERSON/B_SPECIES[BIO]
and O
Bimler B_PERSON/B_ORGANIZATION
therapeutic I_PERSON/I_ORGANIZATION
technics I_PERSON/I_ORGANIZATION
in O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cases B_PERSON/B_DISEASE
of O
class B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
division B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I O
mmalocclusion O
. O

This O
resulted O
in O
a O
shift O
of O
C1 O
/ O
C2 O
, O
so O
that O
the O
effect O
of O
collagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
more O
pronounced O
( O
maximal O
increase O
of O
C1 O
/ O
C2 O
= O
134 O
% O
) O
than O
ADP O
( O
maximal O
increase O
of O
C1 O
/ O
C2 O
= O
79 O
% O
) O
. O

We O
conclude O
that O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ST B_MEASURE/B_LOCATION
- O
segment B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
elevation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
patients B_PERSON/B_BIO
without O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
left O
ventricular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aneurysm I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
is O
caused O
by O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spasm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
major B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
coronary I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vessel I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Xnr3 B_GENE
is O
transcriptionally O
activated O
by O
wnt B_GENE
signaling O
during O
gastrulation O
in O
the O
Xenopus O
embryo O
. O

For O
economical B_PERSON/B_TIME[MEASURE]
reasons I_PERSON/I_TIME[MEASURE]
, O
we O
could O
not O
send O
a O
questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
all O
the O
35 B_MEASURE
, O
779 B_MEASURE/B_PERSON
individuals I_MEASURE/I_PERSON
, O
but O
based O
the O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
a O
SRS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
4 B_MEASURE
, O
000 B_MEASURE/B_SPORT[ENT]
men I_MEASURE/I_SPORT[ENT]
, O
post B_LOCATION/B_DISEASE
- O
stratified O
in O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
a O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
risk B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
waveforms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
both O
the O
somatosensory B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N20 B_LOCATION/B_PROTEIN[GENE]
, O
P B_OTHER/B_PROTEIN[GENE]
/ O
N B_MEASURE/B_PROTEIN[GENE]
30 I_MEASURE/I_PROTEIN[GENE]
, O
and O
P200 B_PROTEIN[GENE]/B_MEASURE
) O
and O
the O
brainstem B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
auditory I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
evoked O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
I B_OTHER/B_PROTEIN[GENE]
, O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
, O
IV B_TIME[MEASURE]/B_PROTEIN[GENE]
, O
and O
V B_OTHER/B_PROTEIN[GENE]
) O
demonstrated O
shorter B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
latencies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
retarded O
fetuses B_PERSON
relative I_PERSON
to O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sized B_BIO/B_TIME[MEASURE]
fetuses B_BIO/I_TIME[MEASURE]
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
choline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnesium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trisalicylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
prostacyclin B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O
isolated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vascular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
rat B_SPECIES[BIO]/B_GENE
. O

The O
sequences O
of O
two O
previously O
known O
tail B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
S B_PROTEIN[GENE]/B_DISEASE
, O
of O
the O
temperate O
bacteriophage O
P2 O
and O
the O
sequence O
of O
an O
additional O
open O
reading O
frame O
( O
orf O
- O
30 O
) O
located O
between O
S B_OTHER/B_PROTEIN[GENE]
and O
V B_PROTEIN[GENE]/B_LOCATION
, O
were O
determined O
. O

The O
high B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
atrial B_DISEASE/B_LOCATION
septal I_DISEASE/I_LOCATION
defect I_DISEASE/I_LOCATION
in O
tetralogy B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
Fallot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O
cited O
as O
a O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
right B_DISEASE/B_MEASURE
ventricular I_DISEASE/I_MEASURE
pressure I_DISEASE/I_MEASURE
is O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
right B_MEASURE/B_DISEASE
ventricular B_MEASURE/I_DISEASE
compliance B_MEASURE/I_DISEASE
is O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
birth B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
stress B_DISEASE
/ O
BHV B_DISEASE/B_PROTEIN[GENE]
- O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
model I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
resulted O
in O
a O
mild B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
respiratory I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
all O
calves B_PERSON/B_LOCATION
with O
no O
difference B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
between O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

solution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Boltzmann B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
equation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
a O
random B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

GH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
signals O
by O
interacting O
with O
GH B_GENE
receptor I_GENE
( O
GHR B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

ultraviolet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crosslinking I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
element B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
the O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
two B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
approximately O
43 B_MEASURE
and O
80 B_MEASURE
kDa I_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
At O
short B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dwell B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
uncorrected B_MEASURE
( O
whole B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
plasma I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
D B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
P B_OTHER/B_PROTEIN[GENE]
and O
CP B_LOCATION/B_PROTEIN[GENE]
of O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
corrected O
( O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
water I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
5 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
5 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

The O
recovery B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
xanthomegnin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
added O
to O
corn B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
levels B_MEASURE/B_GENE
of O
0 B_MEASURE
. O
75 B_MEASURE
- O
- O
9 B_MEASURE
. O
6 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
averaged O
41 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
a O
coefficient B_MEASURE/B_LOCATION
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

The O
extraordinary O
high O
substrate O
specificity O
of O
rPulA B_PROTEIN[GENE]/B_SPECIES[BIO]
together O
with O
its O
thermal O
stability O
makes O
this O
enzyme O
a O
good O
candidate O
for O
biotechnological O
applications O
in O
the O
starch O
- O
processing O
industry O
. O

A O
relationship B_PERSON/B_MEASURE
between O
the O
immunological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
disease B_DISEASE
stage I_DISEASE
was O
discovered O
: O
the O
index B_MEASURE
of O
the O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
thymidine B_MEASURE/B_LOCATION
incorporation I_MEASURE/I_LOCATION
was O
found O
to O
be O
67 B_MEASURE
. O
9 B_MEASURE
at O
the O
stage B_ENT/B_MEASURE
of O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exacerbation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
208 B_MEASURE
. O
8 B_MEASURE
at O
the O
stage B_ENT/B_MEASURE
of O
remission B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
the O
complement B_MEASURE
titre I_MEASURE
reached O
, O
respectively O
, O
46 B_MEASURE
. O
64 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
28 B_MEASURE
and O
112 B_MEASURE
. O
0 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
. O
0 B_MEASURE
units I_MEASURE
per O
ml B_TIME[MEASURE]/B_PERSON
. O

Sodium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecylsulfate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SDS B_PERSON/B_PROTEIN[GENE]
- O
Page B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
showed O
two B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
about O
the O
same B_MEASURE/B_LOCATION
intensity I_MEASURE/I_LOCATION
with O
apparent B_MEASURE/B_LOCATION
molecular I_MEASURE/I_LOCATION
masses I_MEASURE/I_LOCATION
of O
24 B_MEASURE
. O
5 B_MEASURE
and O
22 B_MEASURE
. O
5 B_MEASURE
kDa I_MEASURE
. O

consistent O
with O
an O
effect O
on O
transcription O
, O
p21 B_GENE
was O
localized O
in O
nuclei O
of O
transfected O
cells O
. O

Analysis O
of O
pseudo B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
VH B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
segment B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
recombination B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
products B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reveals O
no O
bias O
in O
D B_MEASURE/B_GENE
gene I_MEASURE/I_GENE
segment I_MEASURE/I_GENE
reading O
frame O
utilization O
. O

Plasma B_GENE/B_MEASURE
prolactin B_GENE/I_MEASURE
concentrations O
during O
incubation O
, O
25 O
. O
8 O
+ O
/ O
- O
2 O
. O
3 O
ng O
/ O
ml O
, O
decreased O
to O
baseline O
levels O
, O
10 O
. O
8 O
+ O
/ O
- O
1 O
. O
9 O
ng O
/ O
ml O
, O
within O
24 O
hr O
after O
nestbox O
removal O
. O

After O
30 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
amifostine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
the O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
MDS B_DISEASE
switched O
to O
a O
chronic B_DISEASE_ADJECTIVE[DISEASE]
myelomonocytic I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_DISEASE_ADJECTIVE[DISEASE]
( O
CMML B_DISEASE/B_LOCATION
) O
- O
like B_DISEASE/B_MEASURE
appearance I_DISEASE/I_MEASURE
, O
with O
continuously O
increasing O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O
so O
that O
we O
discontinued O
amifostine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
1 B_TIME[MEASURE]
month I_TIME[MEASURE]
to O
exclude O
a O
possible B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
amifostine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Heart B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
new O
B O
- O
cell O
- O
specific O
enhancer O
element O
has O
been O
identified O
3 O
' O
of O
E4 B_GENE/B_MEASURE
and O
the O
octamerlike O
motifs O
in O
the O
human B_GENE/B_BIO
immunoglobulin I_GENE/I_BIO
heavy I_GENE/I_BIO
- I_GENE/I_BIO
chain I_GENE/I_BIO
gene I_GENE/I_BIO
enhancer I_GENE/I_BIO
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
This O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
experience I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicates O
that O
there O
is O
short B_PERSON/B_MEASURE
- O
to O
middle B_MEASURE/B_PERSON
- O
term B_MEASURE/B_DISEASE
efficiency I_MEASURE/I_DISEASE
and O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
when O
using O
GKS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
treat O
MTLE B_DISEASE/B_GENE
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Paraquat B_DISEASE
poisoning I_DISEASE
of O
anticonservative B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
origin I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O
described O
. O

genetic O
mutation O
or O
loss O
of O
activin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
transforming B_GENE/B_LOCATION
growth I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
- I_GENE/I_LOCATION
beta I_GENE/I_LOCATION
( I_GENE/I_LOCATION
TGFbeta I_GENE/I_LOCATION
) I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
function O
has O
been O
shown O
in O
human O
lymphoid O
, O
breast O
, O
and O
colorectal O
tumors O
as O
well O
as O
Hep2B O
and O
Mv1Lu O
cell O
lines O
. O

A O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ortho B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ester I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
designed O
for O
combined O
ocular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
delivery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O
subconjunctival B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
release B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

We O
now O
describe O
a O
HepG2 B_GENE/B_LOCATION
cell I_GENE/I_LOCATION
casein I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
II I_GENE/I_LOCATION
beta I_GENE/I_LOCATION
subunit I_GENE/I_LOCATION
cDNA I_GENE/I_LOCATION
of O
2 O
. O
57 O
kb O
containing O
96 O
bases O
of O
5 O
' O
untranslated O
sequence O
, O
645 O
bases O
of O
open O
reading O
frame O
, O
and O
1832 O
bases O
of O
3 O
' O
untranslated O
sequence O
with O
two O
polyadenylation O
consensus O
signal O
sequences O
and O
two O
poly O
( O
A O
) O
stretches O
. O

Brome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mosaic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
like O
protein B_GENE
2a I_GENE
is O
directed O
to O
the O
endoplasmic O
reticulum O
by O
helicase B_GENE
- O
like O
viral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
1a I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

diagnostic O
importance O
of O
determining O
leucine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
aminotransferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
in O
acute O
pancreatitis O
. O

Therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
iodine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
125 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
hyperthyroidism B_DISEASE
: O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
special B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiobiological I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effect I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
follicular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Maintenance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
metabolizable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
ME B_DISEASE/B_PROTEIN[GENE]
) O
requirement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
averaged O
31 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
kcal I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
body I_MEASURE
wt I_MEASURE
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
of O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
because O
it O
completes O
an O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
central B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
near I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
location B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- O
report B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bar I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
probe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
DNA B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
was O
identified O
which O
binds O
to O
two B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
novel I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
( O
i O
) O
at O
the O
5 B_NUMBER[MEASURE]
' O
flanking O
site B_LOCATION/B_MEASURE
of O
the O
breakpoint B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
junction B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
chromosome B_GENE/B_DISEASE
8 I_GENE/I_DISEASE
in O
a O
patient B_PERSON/B_LOCATION
with O
T B_PROTEIN[GENE]/B_DISEASE
- O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
( O
ALL B_DISEASE/B_NUMBER[MEASURE]
) O
carrying O
the O
t B_DISEASE/B_GENE
( O
8 B_NUMBER[MEASURE]
; O
14 B_MEASURE
) O
( O
q24 O
; O
q11 O
) O
rearrangement B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
and O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
on O
chromosome B_GENE/B_MEASURE
1 I_GENE/I_MEASURE
in O
three B_NUMBER[MEASURE]/B_PERSON
of O
five B_DISEASE/B_PROTEIN[GENE]
T B_DISEASE/I_PROTEIN[GENE]
- O
All B_LOCATION/B_DISEASE
patients I_LOCATION/I_DISEASE
with O
the O
t B_DISEASE/B_GENE
( O
1 B_NUMBER[MEASURE]
; O
14 B_MEASURE
) O
( O
p32 B_MEASURE/B_GENE
; O
q11 B_MEASURE
) O
rearrangement B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

Nedocromil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shifted O
the O
severity B_MEASURE
of O
the O
early B_DISEASE
allergic I_DISEASE
reaction I_DISEASE
( O
ear B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O
from O
mean B_MEASURE/B_LOCATION
- O
34 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
to O
- O
6 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
inhibited O
the O
later B_DISEASE_ADJECTIVE[DISEASE]
allergic I_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
( O
lar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
) O
from O
- O
30 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
to O
+ O
0 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
005 B_MEASURE
) O
. O

The O
Mer1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
the O
KH O
motif O
found O
in O
some O
RNA O
- O
binding O
proteins O
, O
and O
RNA O
gel O
mobility O
shift O
assays O
demonstrate O
that O
Mer1 B_GENE/B_BIO
binds O
specifically O
to O
MER2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
obtained O
from O
the O
tritium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
direct B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
chemical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
compared O
. O

We O
found O
that O
in O
anesthetized B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
paralyzed B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cats I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
visual B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O
potential B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
VEP B_DISEASE/B_PROTEIN[GENE]
) O
was O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
only O
on O
magnitude B_MEASURE
of O
delta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O
each O
pattern B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
was O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
starting B_TIME[MEASURE]/B_LOCATION
or O
ending O
contrast B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
. O

Experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O
Clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
measured O
over O
a O
12 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
after O
the O
zymosan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
had O
been O
given O
. O

Direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
saturation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

From O
this O
asymmetry O
, O
we O
suggested O
previously O
that O
GCN4 B_GENE
interacts O
with O
nonequivalent O
and O
possibly O
overlapping O
half O
- O
sites O
( O
ATGAC O
and O
ATGAG O
) O
that O
have O
different O
affinities O
. O

Furthermore O
the O
aldosterone O
stimulating O
effect O
of O
low O
sodium O
diet O
( O
17 O
children O
) O
, O
severe O
and O
prolonged O
vomiting O
( O
19 O
children O
) O
and O
synthetic O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
10 O
children O
) O
has O
been O
studied O
by O
our O
modified O
method O
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
1 B_MEASURE
: O
2 B_MEASURE
) O
of O
182 B_MEASURE/B_PERSON
pairs I_MEASURE/I_PERSON
of O
Hepatitis B_PERSON/B_DISEASE
A I_PERSON/I_DISEASE
was O
carried O
out O
in O
Weng B_PERSON/B_LOCATION
- O
Ling B_PERSON/B_LOCATION
Zhe I_PERSON/I_LOCATION
- O
Jiang B_PERSON/B_LOCATION
during O
April B_TIME[MEASURE]/B_PERSON
1988 I_TIME[MEASURE]/I_PERSON
. O

The O
mutant O
strain O
carries O
three O
tandem O
copies O
of O
the O
18 O
BP O
sequence O
that O
is O
duplicated O
in O
the O
amdI66 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O
. O

Although O
cDNA O
encoding O
a O
human B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
phagocyte I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
formyl I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptide I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
reported O
recently O
( O
Boulay O
, O
F O
. O
, O
Tardif O
, O
M O
. O
, O
Brouchon O
, O
L O
. O
, O
and O
Vignais O
, O
P O
. O

In O
NIH O
3T3 O
fibroblasts O
the O
high O
affinity O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2R B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bearing O
a O
deletion O
of O
a O
region O
rich O
in O
acidic O
amino O
acids O
( O
the O
' O
acidic O
' O
region O
) O
in O
the O
IL B_GENE
- I_GENE
2R I_GENE
beta I_GENE
- I_GENE
chain I_GENE
failed O
to O
induce O
the O
tyrosine O
phosphorylation O
of O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
the O
expression O
of O
the O
all O
three O
nuclear O
Proto O
- O
oncogenes O
. O

A O
small O
molecule O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
suppresses O
the O
phosphorylation O
of O
PKB B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
Ser O
- O
473 O
but O
not O
the O
Thr O
- O
308 O
site O
in O
the O
PTEN B_GENE/B_DISEASE
mutant O
cells O
. O

The O
avian O
carcinoma O
virus O
MH2 O
contains O
a O
hybrid O
gene O
delta B_PROTEIN[GENE]/B_VIRUS[BIO]
gag I_PROTEIN[GENE]/I_VIRUS[BIO]
- O
mht B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
contiguous O
open O
reading O
frame O
of O
2682 O
base O
pairs O
as O
well O
as O
v B_SPECIES[BIO]/B_GENE
- I_SPECIES[BIO]/I_GENE
myc I_SPECIES[BIO]/I_GENE
and O
avian O
helper O
virus O
- O
related O
sequences O
. O
delta B_GENE/B_VIRUS[BIO]
gag I_GENE/I_VIRUS[BIO]
is O
a O
partial O
retroviral B_GENE
core I_GENE
protein I_GENE
gene I_GENE
while O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mht I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
v B_GENE
- I_GENE
myc I_GENE
are O
cell O
- O
drived O
sequences O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
untreated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
demonstrate O
the O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bulk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
laparotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Of O
3841 O
serum O
samples O
from O
sows O
received O
from O
the O
Tennessee O
State O
diagnostic O
Laboratory O
in O
1991 O
- O
1992 O
, O
1130 O
were O
positive O
for O
Toxoplasma B_DISEASE
gondii I_DISEASE
antibody I_DISEASE
. O

These O
findings O
also O
demonstrate O
that O
unless O
excluded O
by O
other O
factors O
, O
the O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
likely O
to O
be O
located O
along O
the O
length O
of O
nascent O
transcripts O
. O

In O
this O
group O
of O
patients O
, O
the O
mean O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
9 O
. O
3 O
+ O
/ O
- O
5 O
. O
9 O
IU O
/ O
l O
) O
and O
sex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SHBG B_GENE/B_LOCATION
) O
( O
54 O
. O
5 O
+ O
/ O
- O
22 O
. O
9 O
nmol O
/ O
l O
) O
concentrations O
were O
significantly O
greater O
than O
those O
of O
five O
normal O
control O
subjects O
( O
4 O
. O
7 O
+ O
/ O
- O
1 O
. O
11 O
IU O
/ O
l O
and O
26 O
. O
0 O
+ O
/ O
- O
7 O
. O
0 O
nmol O
/ O
l O
respectively O
) O
. O

We O
have O
now O
completed O
the O
primary O
structure O
of O
fibrillin B_GENE
, O
elucidated O
the O
exon O
/ O
intron O
organization O
of O
the O
gene O
and O
derived O
a O
physical O
map O
of O
the O
genetic O
locus O
. O

The O
BCL B_GENE/B_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
6 B_GENE/I_SPECIES[BIO]
POZ O
domain O
and O
other O
POZ O
domains O
interact O
with O
the O
co O
- O
repressors O
N B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CoR I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SMRT B_GENE/B_LOCATION
. O

Cytokine O
inducibility O
of O
VCAM1 B_GENE/B_DISEASE
in O
endothelial O
cells O
utilizes O
the O
interaction O
of O
heterodimeric O
p50 B_GENE
/ O
p65 B_GENE/B_MEASURE
proteins O
with O
IRF B_GENE
- I_GENE
1 I_GENE
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
MF B_PERSON/B_BIO
males I_PERSON/I_BIO
receiving O
either O
a O
5 B_MEASURE
. O
0 B_MEASURE
- O
mg B_MEASURE/B_LOCATION
/ O
kg B_MEASURE
CDP I_MEASURE
dose I_MEASURE
or O
a O
3 B_MEASURE
. O
0 B_MEASURE
- O
mg B_MEASURE/B_LOCATION
/ O
kg B_MEASURE
RO I_MEASURE
dose I_MEASURE
explored O
the O
object B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O
often O
than O
mm B_PERSON
males I_PERSON
. O
( O
abstract B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED I_TIME[MEASURE]/I_ORGANIZATION
AT O
250 B_LOCATION/B_MEASURE
Words I_LOCATION/I_MEASURE
) O
. O

To O
gain O
additional O
insights O
into O
this O
novel O
apoptotic O
checkpoint O
, O
we O
have O
now O
characterized O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
survivin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Both O
proteins O
share O
sequence O
similarity O
with O
the O
myelin B_GENE
- I_GENE
associated I_GENE
glycoprotein I_GENE
, O
an O
adhesion O
molecule O
of O
oligodendrocytes O
and O
Schwann O
cells O
that O
has O
been O
implicated O
in O
the O
process O
of O
myelination O
, O
raising O
the O
important O
question O
of O
whether O
myelin B_GENE/B_BIO
- I_GENE/I_BIO
associated I_GENE/I_BIO
glycoprotein I_GENE/I_BIO
is O
also O
a O
sialic B_PROTEIN[GENE]/B_PERSON
acid I_PROTEIN[GENE]/I_PERSON
- I_PROTEIN[GENE]/I_PERSON
binding I_PROTEIN[GENE]/I_PERSON
protein I_PROTEIN[GENE]/I_PERSON
. O

localized O
Bicaudal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
a O
protein O
containing O
a O
KH O
domain O
, O
the O
RNA O
binding O
motif O
of O
FMR1 B_GENE
. O

To O
facilitate O
the O
characterization O
of O
NF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O
in O
human O
cells O
, O
we O
isolated O
cDNAs O
encoding O
two O
members O
of O
the O
small B_PERSON/B_BIO
Maf B_PERSON/I_BIO
family B_PERSON/I_BIO
, O
MafK B_LOCATION/B_GENE
and O
MafG B_PROTEIN[GENE]/B_BACTERIUM[BIO]
. O

Indigenous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microbial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
flora I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
large B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
intestine B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
tadpoles B_SPECIES[BIO]/B_LOCATION
. O

Copyright B_MEASURE/B_LOCATION
1998 I_MEASURE/I_LOCATION
The O
Association B_ORGANIZATION/B_LOCATION
for O
the O
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Animal B_EDU[ORGANIZATION]/B_PERSON
behaviour I_EDU[ORGANIZATION]/I_PERSON
. O

In O
contrast O
to O
the O
restricted O
tissue O
expression O
of O
gonadotropin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TSH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
gonads O
and O
thyroid O
, O
respectively O
, O
LGR4 B_GENE
is O
expressed O
in O
diverse O
tissues O
including O
ovary O
, O
testis O
, O
adrenal O
, O
placenta O
, O
thymus O
, O
spinal O
cord O
, O
and O
thyroid O
, O
whereas O
LGR5 B_GENE/B_MEASURE
is O
found O
in O
muscle O
, O
placenta O
, O
spinal O
cord O
, O
and O
brain O
. O

Not O
only O
will O
it O
substantially O
reduce O
incident B_DISEASE
cases I_DISEASE
of O
hepatitis B_DISEASE
B I_DISEASE
for O
the O
next B_PERSON/B_LOCATION
decade I_PERSON/I_LOCATION
, O
it O
will O
also O
provide O
a O
framework B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
successful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
future B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
adolescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vaccine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
initiatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Australia B_LOCATION
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phases B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O
within O
a O
polymer B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blend I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
described O
in O
this O
paper B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Radioactively O
labeled O
microspheres B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
to O
determine O
and O
compare O
the O
hemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SNP B_PROTEIN[GENE]/B_LOCATION
) O
, O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NTG B_PROTEIN[GENE]/B_LOCATION
) O
, O
and O
deep B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enflurane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
oral B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tissues B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
during O
controlled O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O
compared O
with O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Their O
central B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projections I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
indistinguishable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
from O
those O
of O
control B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
axons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
four B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trigeminal I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
subnuclei I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

The O
JNK B_GENE/B_DISEASE
/ O
SAPK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator O
mixed B_GENE/B_LOCATION
lineage I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
3 I_GENE/I_LOCATION
( O
MLK3 B_GENE
) O
transforms O
NIH O
3T3 O
cells O
in O
a O
MEK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
fashion O
. O

The O
decision B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
uses O
the O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
at O
its O
core B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
helps O
not O
only O
in O
reaching O
a O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
but O
also O
in O
finding O
the O
optimal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
way I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
reach O
that O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast O
to O
the O
effect O
on O
DNA O
replication O
, O
the O
L13V O
substitution O
in O
large B_GENE/B_BIO
T I_GENE/I_BIO
antigen I_GENE/I_BIO
did O
not O
prevent O
complex O
formation O
with O
Hsc70 B_GENE
and O
the O
Rb B_GENE/B_BIO
protein I_GENE/I_BIO
. O

To O
explore O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
persistent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cardiomegaly O
on O
cardiovascular B_DISEASE/B_ORGANISM_FUNCTION
function I_DISEASE/I_ORGANISM_FUNCTION
, O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
newborn B_PERSON/B_BIO
rats I_PERSON/I_BIO
inhaled O
up O
to O
500 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ppm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
CO I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
33 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
after O
which O
development B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
in O
ambient B_MEASURE/B_PERSON
air I_MEASURE/I_PERSON
. O

bandwidth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
auditory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
units B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
chick B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
forebrain I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O
field B_LOCATION
L I_LOCATION
/ O
Hv B_MEASURE/B_PROTEIN[GENE]
complex I_MEASURE/I_PROTEIN[GENE]
) O
was O
measured O
with O
isointensity B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tone I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stimuli I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Members O
of O
the O
steroid B_GENE/B_BIO
/ I_GENE/I_BIO
hormone I_GENE/I_BIO
nuclear I_GENE/I_BIO
receptor I_GENE/I_BIO
superfamily I_GENE/I_BIO
regulate O
target O
gene O
transcription O
via O
recognition O
and O
association O
with O
specific O
cis O
- O
acting O
sequences O
of O
DNA O
, O
called O
hormone O
response O
elements O
( O
HREs O
) O
. O

Indeed O
, O
Dex O
also O
enhanced O
the O
RA O
- O
dependent O
increase O
in O
RARbeta B_GENE
mRNA I_GENE
in O
a O
cycloheximide O
- O
sensitive O
manner O
. O

The O
highest B_MEASURE
concentration I_MEASURE
of O
respirable B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mineral B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibres B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
during O
the O
overhaul B_SEQUENCE[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
truck B_PRODUCT[OBJECT]/B_LOCATION
with O
asbestos B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
insulation I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
respirable B_MEASURE/B_LOCATION
fibre B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
reached O
the O
value B_MEASURE/B_LOCATION
of O
5 B_MEASURE
f O
/ O
cm3 B_MEASURE
, O
and O
total B_MEASURE/B_LOCATION
dust B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
- O
the O
value B_MEASURE/B_LOCATION
of O
about O
80 B_MEASURE
mg I_MEASURE
/ O
m3 B_MEASURE
. O

Avian B_GENE/B_BIO
EMILIN I_GENE/I_BIO
was O
extracted O
from O
19 O
- O
day O
- O
old O
embryonic O
chick O
aortas O
and O
associated O
blood O
vessels O
and O
purified O
by O
ion O
- O
exchange O
chromatography O
and O
gel O
filtration O
. O

CYP51P1 B_GENE
is O
96 O
. O
5 O
% O
identical O
to O
the O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
CYP51 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
coding O
sequence O
and O
is O
not O
interrupted O
with O
introns O
but O
has O
six O
in O
- O
frame O
stop O
codons O
resulting O
from O
point O
mutations O
. O

We O
report O
here O
that O
AChE B_GENE/B_BIO
activity O
tends O
to O
decrease O
in O
individuals O
sampled O
in O
tanks O
at O
a O
salinity O
of O
30 O
per O
thousand O
as O
temperature O
increases O
. O

Three O
RasV12 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
S35 B_PROTEIN[GENE]
, O
G37 B_PROTEIN[GENE]
, O
and O
C40 B_PROTEIN[GENE]/B_MEASURE
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
effectors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Raf B_GENE/B_DISEASE
, O
Ral B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GEFs I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
p110 B_GENE/B_PERSON
subunit I_GENE/I_PERSON
of I_GENE/I_PERSON
PI I_GENE/I_PERSON
3 I_GENE/I_PERSON
- I_GENE/I_PERSON
kinase I_GENE/I_PERSON
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
Nr O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

mating B_TIME[MEASURE]/B_PERSON
response I_TIME[MEASURE]/I_PERSON
, O
ovulation B_MEASURE/B_BIO
rate I_MEASURE/I_BIO
, O
follicle B_BODY_PART_OR_ORGAN_COMPONENT
and O
corpus B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
luteum I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
size I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
gestation B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
, O
pregnancy B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
, O
lambing B_MEASURE/B_PERSON
rate I_MEASURE/I_PERSON
, O
and O
Lamb B_MEASURE/B_ORGANISM_FUNCTION
birth I_MEASURE/I_ORGANISM_FUNCTION
weight I_MEASURE/I_ORGANISM_FUNCTION
were O
recorded O
. O

Membrane B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
interfaced O
with O
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
mass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
volatile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

A O
significant O
difference O
in O
the O
distribution O
of O
antibodies O
to O
thyroglobulin B_GENE
and O
thyroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peroxidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
subgroup O
2 O
. O

Here O
, O
we O
characterize O
TCR B_GENE
/ O
CD48 B_GENE
and O
TCR B_GENE
/ O
CD28 B_GENE/B_LOCATION
costimulation O
in O
T O
cells O
expressing O
Lck B_GENE
Src I_GENE
homology I_GENE
3 I_GENE
( O
SH3 B_GENE
) O
mutants O
. O

High O
expression O
of O
p51A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
TAp63gamma B_GENE/B_LOCATION
) O
in O
the O
skeletal O
muscle O
tissue O
drove O
us O
to O
investigate O
a O
differentiation O
- O
inducible O
myoblastic O
cell O
line O
which O
showed O
increased O
p51A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
after O
differentiation O
induction O
. O

The O
rate B_DISEASE
for O
Arm B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
III I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
caf B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O
was O
61 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
32 B_MEASURE
/ O
52 B_MEASURE
) O
, O
a O
little B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
higher B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
that O
for O
the O
other B_PERSON/B_LOCATION
two B_PERSON/I_LOCATION
. O

These O
results O
induce O
that O
the O
putative O
TATA O
box O
and O
initiator O
are O
not O
involved O
in O
the O
promoter O
activity O
, O
and O
that O
the O
vitronectin B_GENE
promoter I_GENE
lacks O
the O
TATA O
box O
, O
initiator O
and O
GC O
box O
. O

Using O
the O
interaction O
- O
trap O
assay O
to O
identify O
candidate O
proteins O
that O
bind O
the O
cytoplasmic O
region O
of O
the O
LAR B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transmembrane I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PT B_LOCATION/B_GENE
- I_LOCATION/I_GENE
Pase I_LOCATION/I_GENE
) O
, O
we O
isolated O
a O
cDNA O
encoding O
a O
2861 O
- O
amino O
acid O
protein O
termed O
Trio B_GENE/B_ENT
that O
contains O
three O
enzyme O
domains O
: O
two O
functional O
GEF B_LOCATION/B_PERSON
domains I_LOCATION/I_PERSON
and O
a O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PSK B_GENE/B_LOCATION
) O
domain O
. O

We O
have O
isolated O
two O
H19 B_GENE
cDNAs I_GENE
( O
AP B_LOCATION
and O
ES B_LOCATION/B_PROTEIN[GENE]
) O
that O
contain O
this O
ORF4 O
and O
correspond O
to O
incomplete O
copies O
of O
the O
unique O
2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H19 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
combined O
in O
vitro O
effects O
of O
ethanol O
wih O
methaqualone O
, O
phenobarbital O
, O
pyrazole O
or O
disulfiram O
were O
studied O
using O
rat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microsomal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATPase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
related O
adhesion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
focal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
tyrosine O
- O
phosphorylated O
after O
beta1 B_GENE
- I_GENE
integrin I_GENE
stimulation O
in O
B O
cells O
and O
binds O
to O
p130cas B_GENE
. O

Earlier O
reports O
have O
localized O
mutations O
which O
affect O
the O
processing O
and O
transport O
of O
herpes O
simplex O
virus O
1 O
glycoproteins O
to O
a O
region O
located O
between O
the O
genes O
specifying O
glycoprotein B_GENE/B_ORGANISM_FUNCTION
B I_GENE/I_ORGANISM_FUNCTION
and O
the O
major O
viral O
DNA O
- O
binding O
protein O
( O
beta B_GENE/B_DISEASE
8 I_GENE/I_DISEASE
) O
. O

These O
results O
indicate O
that O
the O
2127 O
- O
BP O
cDNA O
encodes O
a O
functional O
feline O
L B_ENZYME[GENE]/B_MEASURE
/ I_ENZYME[GENE]/I_MEASURE
B I_ENZYME[GENE]/I_MEASURE
/ I_ENZYME[GENE]/I_MEASURE
K I_ENZYME[GENE]/I_MEASURE
- I_ENZYME[GENE]/I_MEASURE
type I_ENZYME[GENE]/I_MEASURE
ALP I_ENZYME[GENE]/I_MEASURE
expressed O
on O
cell O
surfaces O
via O
phosphatidylinositol O
- O
glycan O
linkage O
. O

Our O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O
that O
T2 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
weighting I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
adequate B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
is O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
choice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
necrosis B_DISEASE
of O
the O
lunate B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Analysis O
of O
a O
Het B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mutation O
in O
Anabaena O
SP O
. O
strain O
PCC O
7120 O
implicates O
a O
secondary O
metabolite O
in O
the O
regulation O
of O
heterocyst O
spacing O
. O

Here O
we O
report O
that O
components O
of O
the O
Ras B_GENE/B_DISEASE
/ O
Raf B_GENE/B_DISEASE
/ O
MAPK B_GENE/B_LOCATION
pathway O
are O
constitutively O
activated O
in O
these O
lck B_VIRUS[BIO]/B_DISEASE
- O
transformed O
immature O
thymoblasts O
. O

p56 B_GENE/B_DISEASE
( O
lck B_GENE/B_BACTERIUM[BIO]
) O
utilizes O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Grb2 B_GENE/B_LOCATION
adaptors I_GENE/I_LOCATION
to O
mediate O
activation O
of O
p21 B_GENE/B_DISEASE
( O
ras B_GENE/B_DISEASE
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B_GENE/B_BIO
protein I_GENE/I_BIO
and O
constitutive O
interaction O
between O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Grb2 B_GENE
. O

The O
rec8 B_GENE/B_DISEASE
( I_GENE/I_DISEASE
+ I_GENE/I_DISEASE
) I_GENE/I_DISEASE
, O
rec10 B_MEASURE/B_GENE
( I_MEASURE/I_GENE
+ I_MEASURE/I_GENE
) I_MEASURE/I_GENE
, O
and O
rec11 B_GENE/B_BIO
( I_GENE/I_BIO
+ I_GENE/I_BIO
) I_GENE/I_BIO
genes I_GENE/I_BIO
of I_GENE/I_BIO
the I_GENE/I_BIO
fission I_GENE/I_BIO
yeast I_GENE/I_BIO
Schizosaccharomyces I_GENE/I_BIO
pombe I_GENE/I_BIO
exhibit O
similar O
specificities O
for O
meiotic O
recombination O
and O
rec8 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
+ I_GENE/I_LOCATION
) I_GENE/I_LOCATION
is O
required O
for O
sister O
chromatid O
cohesion O
and O
homolog O
pairing O
. O

Based O
on O
the O
results O
of O
this O
analysis O
, O
we O
also O
predict O
that O
the O
budding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
yeast I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
arsenate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Acr2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
ORF B_GENE/B_PERSON
Ygr203w I_GENE/I_PERSON
encode O
protein O
phosphatases O
with O
catalytic O
properties O
similar O
to O
that O
of O
the O
Cdc25 B_SPECIES[BIO]/B_GENE
family I_SPECIES[BIO]/I_GENE
. O

At O
onset B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
first B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
weaning O
estrus B_LOCATION/B_PERSON
, O
sows B_PERSON/B_SPECIES[BIO]
received O
either O
an O
intravulval B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
3 B_MEASURE
. O
75 B_MEASURE
mg I_MEASURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analogue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
or O
, O
served O
as O
a O
non B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
injected O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
CON B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

We O
concluded O
that O
HFV B_PERSON/B_DISEASE
can O
achieve O
values B_MEASURE
of O
CO2 B_DISEASE/B_PROTEIN[GENE]
elimination B_DISEASE/I_PROTEIN[GENE]
close O
to O
the O
estimated O
metabolic B_MEASURE/B_LOCATION
CO2 I_MEASURE/I_LOCATION
production I_MEASURE/I_LOCATION
in O
normal B_BIO/B_PERSON
unintubated I_BIO/I_PERSON
subjects I_BIO/I_PERSON
over O
short B_TIME[MEASURE]/B_LOCATION
periods I_TIME[MEASURE]/I_LOCATION
of O
time B_TIME[MEASURE]
. O

The O
PHO5 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
is O
activated O
by O
the O
Pho4p B_GENE
transcription I_GENE
factor I_GENE
, O
which O
itself O
is O
negatively O
regulated O
through O
phosphorylation O
by O
the O
products O
of O
PHO80 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PHO85 B_GENE
. O

Although O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
authoritative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
way I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
determine O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
diet B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
on O
urinary B_DISEASE/B_ORGANISM_FUNCTION
pH I_DISEASE/I_ORGANISM_FUNCTION
is O
a O
feeding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
there O
is O
no O
universally O
accepted O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
measuring O
urinary B_DISEASE/B_MEASURE
pH I_DISEASE/I_MEASURE
. O

Analysis O
of O
the O
DNA O
sequence O
upstream O
of O
the O
narQ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
encodes O
the O
second O
nitrate O
- O
responsive O
sensor O
- O
transmitter O
protein O
in O
Escherichia O
coli O
, O
revealed O
an O
open O
reading O
frame O
( O
ORF O
) O
whose O
product O
shows O
a O
high O
degree O
of O
similarity O
to O
a O
number O
of O
iron B_GENE/B_BIO
- I_GENE/I_BIO
sulfur I_GENE/I_BIO
proteins I_GENE/I_BIO
as O
well O
as O
to O
the O
beta O
subunit O
of O
glutamate B_ENZYME[GENE]
synthase I_ENZYME[GENE]
( O
gltD B_DISEASE/B_LOCATION
) O
of O
E O
. O
coli O
. O

Endothelial B_DISEASE_ADJECTIVE[DISEASE]
purine I_DISEASE_ADJECTIVE[DISEASE]
content I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
suggest O
that O
the O
responses O
to O
types B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
collagen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
caused O
by O
a O
cross O
- O
reaction O
with O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
III I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
collagen I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
peptides O
. O

possibilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
limints B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
immunofluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rabies B_DISEASE/B_LOCATION
. O

The O
5 O
' O
half O
of O
the O
EWS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
recently O
been O
described O
to O
be O
fused O
to O
the O
3 O
' O
regions O
of O
genes O
encoding O
the O
DNA O
- O
binding O
domain O
of O
several O
transcriptional O
regulators O
, O
including O
ATF1 B_GENE/B_LOCATION
, O
FLI B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
, O
and O
ERG B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
several O
human O
tumors O
. O

PDGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
CDK2 B_GENE
activity O
in O
mesangial O
cells O
and O
decreased O
the O
level O
of O
p27 B_GENE
( O
kip1 B_PROTEIN[GENE]/B_LOCATION
) O
cyclin O
kinase O
inhibitor O
protein O
. O

Recombinant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
apoA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recovered O
from O
the O
soluble O
fraction O
of O
the O
bacterial O
cell O
pellet O
was O
purified O
to O
greater O
than O
95 O
% O
homogeneity O
by O
reversed O
- O
phase O
high O
- O
performance O
liquid O
chromatography O
. O

The O
influence O
of O
different O
temperatures O
between O
13 O
degrees O
C O
and O
45 O
degrees O
C O
on O
coagulation O
factors O
in O
vitro O
was O
studied O
by O
measuring O
clotting O
time O
with O
the O
recalcification O
time O
, O
partial O
thromboplastin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O
( O
PTT O
) O
, O
and O
thromboplastin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O
test O
. O

On O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
, O
rCMRglc B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
23 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
below O
control B_MEASURE/B_LOCATION
values I_MEASURE/I_LOCATION
for O
all O
regions B_LOCATION/B_BIO
studied O
, O
with O
the O
greatest B_MEASURE
differences I_MEASURE
in O
posterior B_BODY_PART_OR_ORGAN_COMPONENT
brain I_BODY_PART_OR_ORGAN_COMPONENT
regions I_BODY_PART_OR_ORGAN_COMPONENT
( O
visual B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
association I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
primary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
visual I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
parietal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
thalamus B_BODY_PART_OR_ORGAN_COMPONENT
. O

Thus O
, O
transgene O
expression O
directed O
by O
both O
the O
human O
and O
mouse B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Rb I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
is O
restricted O
to O
a O
subset O
of O
tissues O
in O
which O
Rb B_GENE/B_DISEASE
is O
normally O
expressed O
during O
embryogenesis O
. O

Thus O
, O
Tax1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activates O
CArG O
- O
mediated O
transcription O
without O
mitogenic O
signals O
through O
interaction O
with O
a O
CArG B_GENE/B_PERSON
- I_GENE/I_PERSON
binding I_GENE/I_PERSON
factor I_GENE/I_PERSON
, O
p67SRF B_GENE
. O

In O
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
subjects B_PERSON
were O
required O
to O
discriminate O
male B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
from O
female B_PERSON/B_ENT
faces I_PERSON/I_ENT
and O
no O
hemispheric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asymmetries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
. O

Membrane B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
depolarization I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
critical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
element I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
neuronal B_DISEASE_ADJECTIVE[DISEASE]
signaling I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
transcription O
start O
site O
was O
localized O
224 O
BP O
upstream O
the O
ATG O
codon O
by O
RNase B_ENZYME[GENE]
protection O
and O
primer O
extension O
mapping O
. O

All O
the O
cognate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
clones I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
constructed O
, O
using O
either O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
amplified O
from O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
gap B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
repair B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Rising O
antibody O
titres O
to O
the O
astrovirus O
particles O
were O
demonstrated O
in O
one O
child O
, O
and O
IgM B_GENE/B_DISEASE
was O
also O
demonstrated O
in O
this O
patient O
' O
s O
serum O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isobarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
electrocardiographic B_DISEASE
indices I_DISEASE
in O
hypertensive B_DISEASE/B_SPECIES[BIO]
disease B_DISEASE/I_SPECIES[BIO]
. O

Although O
RAD17 B_GENE/B_DISEASE
, O
RAD24 B_GENE/B_DISEASE
and O
MEC3 B_GENE/B_MEASURE
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
Hu O
) O
, O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
Hu O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
Hu O
- O
induced O
DNA O
damage O
. O

Long B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
CoA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
esters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
important B_LOCATION/B_MEASURE
intermediates I_LOCATION/I_MEASURE
in O
degradation B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
and O
synthesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
having O
important B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
intermediary B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

PTP1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lacZ B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O
indicate O
that O
PTP1 B_GENE
is O
spatially O
localized O
to O
prestalk O
and O
anterior O
- O
like O
cell O
types O
. O

When O
translated O
in O
- O
frame O
with O
PKC B_GENE
zeta I_GENE
, O
a O
stop O
codon O
is O
located O
28 O
amino O
acids O
towards O
the O
N O
- O
terminus O
of O
the O
divergence O
point O
and O
the O
intervening O
sequence O
lacks O
an O
expected O
initiating O
methionine O
. O
psi B_GENE
PKC I_GENE
zeta I_GENE
is O
non O
- O
functional O
in O
terms O
of O
protein O
synthesis O
since O
Western O
blotting O
with O
an O
antibody O
directed O
against O
the O
C O
- O
terminus O
of O
PKC B_GENE
zeta I_GENE
failed O
to O
reveal O
a O
protein O
smaller O
than O
PKC B_GENE/B_MEASURE
zeta B_GENE/I_MEASURE
, O
and O
synthetic O
psi B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PKC I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zeta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
failed O
to O
support O
protein O
synthesis O
in O
a O
translation O
system O
in O
vitro O
. O

W B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Touster B_PERSON
, O
O B_OTHER/B_PERSON
. O

Electrically O
induced O
undulations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
competition B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
electrically O
induced O
convection B_DISEASE_ADJECTIVE[DISEASE]
in O
cholesteric B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
liquid B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
crystals B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O
upstream O
of O
the O
translation B_GENE
start I_GENE
site I_GENE
was O
G B_PROTEIN[GENE]/B_LOCATION
+ O
C B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
rich I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
greater B_MEASURE
than O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
and O
contained O
a O
consensus B_GENE
CCAAT I_GENE
sequence I_GENE
despite O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
TATA B_GENE
box I_GENE
. O

These O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
determine O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
level B_MEASURE/B_LOCATION
of O
indoor B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollutants I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
tobacco B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
smoke I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
gases B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
by O
cooling O
processes B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etc I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
) O
and O
of O
allergens B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
derived O
from O
mites B_BIO/B_DISEASE
, O
domestic B_BIO
animals I_BIO
and O
cockroaches B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

Nevertheless O
, O
lower B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
alone O
were O
lacking O
in O
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
100 B_MEASURE
- O
250 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
B1 I_MEASURE
and O
B6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
1 B_MEASURE
- O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_LOCATION
B12 I_MEASURE/I_LOCATION
p I_MEASURE/I_LOCATION
. O
o B_MEASURE
. O
) O
dose B_MEASURE
- O
dependently O
potentiated O
the O
antinociceptive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

For O
O3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
personal B_LOCATION/B_ORGANIZATION
exposures I_LOCATION/I_ORGANIZATION
and O
ambient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
weakest B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
in O
the O
winter B_TIME[MEASURE]/B_LOCATION
for O
residential B_PERSON/B_LOCATION
microenvironments I_PERSON/I_LOCATION
( O
rs B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
0 B_MEASURE
. O
05 B_MEASURE
, O
p B_MEASURE
> B_MEASURE/B_LOCATION
0 I_MEASURE
. O
05 B_MEASURE
) O
, O
and O
was O
strongest B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
summer B_TIME[MEASURE]
for O
outdoor B_LOCATION/B_ORGANIZATION
near O
- O
roadway B_LOCATION/B_ORGANIZATION
microenvironments I_LOCATION/I_ORGANIZATION
( O
rs B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
0 B_MEASURE
. O
91 B_MEASURE
, O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_NUMBER[MEASURE]
. O
05 B_MEASURE
) O
. O

Changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
electrolyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
edema B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
formation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
after O
acute B_DISEASE_ADJECTIVE[DISEASE]
, O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hypertension B_DISEASE
were O
studied O
in O
albino B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rabbits I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Like O
Rev B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Erb B_PROTEIN[GENE]/B_MEASURE
, O
BD73 B_GENE/B_LOCATION
binds O
as O
a O
monomer O
to O
a O
DNA O
sequence O
which O
consists O
of O
a O
specific O
A O
/ O
T O
- O
rich O
sequence O
upstream O
of O
the O
consensus O
hexameric O
half O
- O
site O
specified O
by O
the O
P O
box O
of O
the O
DNA O
- O
binding O
domain O
. O

In O
contrast O
, O
the O
holo B_GENE/B_MEASURE
- I_GENE/I_MEASURE
dTFIIA I_GENE/I_MEASURE
( O
L O
/ O
S O
) O
binds O
TBP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
high O
affinity O
. O

Overexpression O
of O
wild O
type O
and O
SeCys O
/ O
Cys O
mutant O
of O
human B_GENE/B_LOCATION
thioredoxin I_GENE/I_LOCATION
reductase I_GENE/I_LOCATION
in O
E O
. O
coli O
: O
the O
role O
of O
selenocysteine O
in O
the O
catalytic O
activity O
. O

Biopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lesion B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
granulomatous B_DISEASE_ADJECTIVE[DISEASE]
inflammation I_DISEASE_ADJECTIVE[DISEASE]
and O
numerous B_DISEASE
septate I_DISEASE
hyphae I_DISEASE
. O

Western O
and O
immunocytochemical O
analysis O
implied O
that O
PREB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accumulates O
specifically O
in O
GH3 O
cell O
nuclei O
. O

Two O
genes O
from O
the O
family O
encoding O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
S16 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
cloned O
, O
sequenced O
, O
and O
analyzed O
. O

A O
novel O
serine B_ENZYME[GENE]/B_LOCATION
kinase I_ENZYME[GENE]/I_LOCATION
activated O
by O
rac1 B_GENE/B_DISEASE
/ O
CDC42Hs B_GENE/B_BIO
- O
dependent O
autophosphorylation O
is O
related O
to O
PAK65 B_GENE
and O
STE20 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
deduced O
gene O
product O
was O
found O
to O
have O
significant O
sequence O
similarity O
to O
the O
yeast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
prokaryotic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O
with O
subunit O
assembly O
. O

Maximum O
overexpression O
of O
holoenzyme O
activity O
was O
achieved O
by O
the O
inclusion O
in O
such O
plasmids O
of O
Salmonella O
typhimurium O
cysG O
, O
which O
encodes O
a O
uroporphyrinogen B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
required O
for O
the O
synthesis O
of O
siroheme O
, O
a O
cofactor O
for O
the O
hemoprotein O
. O

Overexpression O
of O
SNURF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cultured O
mammalian O
cells O
enhanced O
not O
only O
androgen O
, O
glucocorticoid O
, O
and O
progesterone B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent O
transactivation O
but O
also O
basal O
transcription O
from O
steroid O
- O
regulated O
promoters O
. O

The O
human O
protein O
binds O
most O
strongly O
to O
the O
SH3 B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
from O
the O
abl B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proto B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
oncogene B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Suprapubic B_BODY_PART_OR_ORGAN_COMPONENT/B_EDU[ORGANIZATION]
and O
intravesical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENT
methods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENT
. O

These O
data O
show O
that O
tyrosine O
phosphorylation O
by O
FES B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
affects O
the O
interaction O
of O
BCR B_GENE
with O
multiple O
signaling O
partners O
and O
suggest O
a O
general O
role O
for O
BCR B_GENE/B_DISEASE
in O
non O
- O
receptor O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulation O
and O
signal O
transduction O
. O

We O
have O
shown O
that O
the O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
MRC I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
closely O
resembles O
the O
murine B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MRC I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
in O
both O
its O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
composition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
its O
fractionation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
chromatographic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
1977 B_MEASURE
to O
1985 B_MEASURE
, O
42 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
squamous B_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
of O
the O
anal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
canal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
treated O
with O
mitomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
) O
and O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
750 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
) O
on O
day B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
5 B_TIME[MEASURE]/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
750 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
/ O
d B_OTHER/B_TIME[MEASURE]
) O
alone O
on O
days B_NUMBER[MEASURE]/B_ENT
2 I_NUMBER[MEASURE]/I_ENT
to O
5 B_MEASURE
, O
and O
radiation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
3000 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cGy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
on O
days B_TIME[MEASURE]
7 I_TIME[MEASURE]
to O
28 B_SEQUENCE[MEASURE]
. O

For O
any O
given O
age B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
high O
- O
stressed O
plantaris B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tendons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
of O
a O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
fatigue B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
quality B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
low O
- O
stressed O
extensor B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tendons I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

In O
addition O
to O
TAK1 B_GENE
, O
TGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
stimulated O
JNK B_GENE
activity O
. O

Foamy O
viruses O
( O
FVs O
) O
express O
the O
Gag B_GENE
protein I_GENE
as O
a O
precursor O
with O
a O
molecular O
mass O
of O
74 O
kDa O
( O
pr74 B_PROTEIN[GENE]/B_MEASURE
) O
from O
which O
a O
70 O
- O
kDa O
protein O
( O
p70 B_PROTEIN[GENE]/B_DISEASE
) O
is O
cleaved O
by O
the O
viral O
protease O
. O

Our O
results O
suggest O
that O
at O
least O
some O
chloroplast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
wheat O
mtDNA O
are O
transcribed O
, O
with O
transcripts O
undergoing O
processing O
, O
post O
- O
transcriptional O
modification O
and O
3 O
' O
- O
CCA O
addition O
, O
to O
produce O
mature O
tRNAs O
that O
may O
participate O
in O
mitochondrial O
protein O
synthesis O
. O

If O
, O
however O
, O
myocardial B_DISEASE
stunning I_DISEASE
is O
severe B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
it O
involves O
large B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
parts I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
thus O
impairs O
global B_DISEASE_ADJECTIVE[DISEASE]
LV I_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
can O
be O
reversed O
with O
inotropic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
agents I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
procedures B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

268 B_MEASURE
, O
6858 B_MEASURE
- O
6861 B_MEASURE
) O
. O

The O
occurrence O
of O
the O
different O
types O
of O
TCRB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rearrangement O
patterns O
has O
implications O
for O
PCR O
- O
based O
clonality O
assessment O
and O
for O
PCR O
- O
based O
detection O
of O
minimal O
residual O
disease O
via O
TCRB B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O
. O

Under O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
7 B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_ENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O
not O
modify O
the O
hyperlocomotion B_DISEASE_ADJECTIVE[DISEASE]
produced O
by O
d B_PROTEIN[GENE]/B_DISEASE
- O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Six B_PERSON
patients I_PERSON
underwent O
an O
electrophysiologic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
study I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

rats B_BIO/B_PERSON
on O
the O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dosage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
given O
unlabelled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HMCF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
their O
drinking B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
13 B_TIME[MEASURE]
days I_TIME[MEASURE]
before O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
a O
bolus B_MEASURE
dose I_MEASURE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
14C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HMCF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
day B_TIME[MEASURE]/B_PERSON
14 B_TIME[MEASURE]/I_PERSON
. O

After O
multivariate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
analysis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
TWA B_DISEASE/B_LOCATION
correlated O
with O
age B_TIME[MEASURE]/B_LOCATION
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
02 B_MEASURE
) O
and O
LV B_DISEASE/B_MEASURE
function I_DISEASE/I_MEASURE
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
002 B_MEASURE
) O
and O
occurred O
more O
often O
in O
patients B_PERSON/B_BIO
after O
nonanterior B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MI B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
03 B_MEASURE
) O
. O

No O
patient O
demonstrated O
a O
decrease O
in O
bone O
marrow O
fibrosis O
as O
determined O
by O
serial O
procollagen B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
PC B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
serum O
level O
analysis O
. O

Asthma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnoses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
made O
according O
to O
recommended O
National B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Asthma I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expert I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Panel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Guidelines I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Charcot B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
joints I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Idealized B_PERSON
versus I_PERSON
realized O
overall B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Non B_DISEASE
- O
suppressed O
thyroidal B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radioactive B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iodine B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RAIU B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
thyrotoxic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
subacute B_DISEASE/B_PERSON
thyroiditis I_DISEASE/I_PERSON
with O
thyroid O
- O
stimulating O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TSAb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Ultra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
UHE B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
imaging B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
usually O
performed O
in O
simultaneous B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
18 B_MEASURE
FDG I_MEASURE
/ O
Tc B_PROTEIN[GENE]/B_LOCATION
- O
99m B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
MIBI I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
studies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Bilateral B_DISEASE/B_MEASURE
renal I_DISEASE/I_MEASURE
oncocytoma I_DISEASE/I_MEASURE
in O
a O
Greyhound B_SPECIES[BIO]/B_PERSON
dog I_SPECIES[BIO]/I_PERSON
. O

Uncoupling O
gene O
activity O
from O
chromatin O
structure O
: O
promoter O
mutations O
can O
inactivate O
transcription O
of O
the O
yeast B_GENE/B_BIO
HSP82 I_GENE/I_BIO
gene I_GENE/I_BIO
without O
eliminating O
nucleosome O
- O
free O
regions O
. O

Ectopic O
expression O
of O
cyclin B_GENE
D1 I_GENE
in O
progestin O
- O
inhibited O
cells O
led O
to O
the O
reappearance O
of O
the O
120 O
- O
kDa O
active O
form O
of O
cyclin B_GENE
E I_GENE
- O
Cdk2 B_PROTEIN[GENE]/B_MEASURE
preceding O
the O
resumption O
of O
cell O
cycle O
progression O
. O

Unlike O
these O
contaminant O
- O
responsive O
T O
cells O
, O
those O
that O
are O
truly O
specific O
for O
natural O
AChR B_DISEASE
epitopes I_DISEASE
appear O
less O
heterogeneous O
and O
therefore O
more O
suitable O
targets O
for O
selective O
immunotherapy O
. O

Because O
the O
wa B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
mapped O
previously O
to O
the O
vicinity O
of O
the O
EGF B_GENE/B_DISEASE
/ I_GENE/I_DISEASE
TGF I_GENE/I_DISEASE
- I_GENE/I_DISEASE
alpha I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
( O
EGFR B_GENE/B_LOCATION
) O
gene O
on O
mouse O
chromosome O
11 O
, O
we O
hypothesized O
that O
the O
wa B_DISEASE/B_GENE
- I_DISEASE/I_GENE
2 I_DISEASE/I_GENE
phenotype I_DISEASE/I_GENE
might O
result O
from O
a O
defect O
in O
either O
the O
expression O
or O
activity O
of O
EGFR B_GENE/B_BIO
, O
or O
both O
. O

Region B_LOCATION/B_PERSON
I O
includes O
the O
two B_MEASURE/B_PERSON
cysteine I_MEASURE/I_PERSON
- O
cysteine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
zinc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fingers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
comprise O
a O
DNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
binding O
domain B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
which O
typifies O
all O
members B_PERSON/B_LOCATION
of O
the O
superfamily O
. O

Southern O
zoo O
blot O
analysis O
indicated O
that O
ZNF236 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
conserved O
in O
the O
genomes O
of O
all O
mammalian O
species O
tested O
, O
but O
not O
in O
yeast O
. O

RNA O
determinants O
required O
for O
L4 B_GENE/B_DISEASE
- O
mediated O
attenuation O
control O
of O
the O
S10 B_GENE/B_BIO
r I_GENE/I_BIO
- I_GENE/I_BIO
protein I_GENE/I_BIO
operon I_GENE/I_BIO
of I_GENE/I_BIO
Escherichia I_GENE/I_BIO
coli I_GENE/I_BIO
. O

Spodoptera O
frugiperda O
( O
Sf9 O
) O
cells O
have O
proved O
a O
suitable O
cell O
system O
in O
which O
to O
study O
this O
association O
and O
to O
produce O
recombinant B_GENE
CR3 I_GENE
, O
and O
we O
show O
here O
that O
another O
lepidopteran O
cell O
line O
, O
Trichoplusia O
niTN O
- O
5B1 O
- O
4 O
( O
High O
- O
Five O
) O
cells O
, O
allows O
the O
recovery O
of O
large O
amounts O
of O
functional B_GENE
recombinant I_GENE
CR3 I_GENE
. O

interventions O
: O
Postoperative O
follow O
- O
up O
consisted O
of O
serial O
determination O
of O
different O
biochemical O
markers O
( O
CK B_GENE/B_LOCATION
, O
CK B_GENE/B_LOCATION
- I_GENE/I_LOCATION
MB I_GENE/I_LOCATION
, O
cTnI B_LOCATION/B_GENE
) O
, O
ECGs O
, O
and O
echocardiography O
. O

At O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
1 B_MEASURE
- O
43 B_MEASURE
MS I_MEASURE
for O
the O
VMN B_LOCATION/B_PROTEIN[GENE]
and O
1 B_MEASURE
- O
10 B_MEASURE
MS I_MEASURE
for O
the O
LN B_LOCATION/B_DISEASE
) O
the O
hypothalamic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
cortical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
completely O
inhibited O
the O
formation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
VC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
the O
light B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulus B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

6 B_MEASURE
, O
320 B_MEASURE
cells I_MEASURE
/ O
mm3 B_MEASURE
, O
respectively O
; O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
. O
005 B_MEASURE
) O
; O
twelve B_NUMBER[MEASURE]
( O
86 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
of O
the O
14 B_PERSON
inmates I_PERSON
who O
developed O
AIDS B_DISEASE/B_GENE
had O
counts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
5 B_MEASURE
, O
000 B_MEASURE
cells I_MEASURE
/ O
mm3 B_MEASURE
, O
compared O
with O
only O
six B_NUMBER[MEASURE]
( O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
of O
the O
42 B_PERSON
controls I_PERSON
( O
P B_MEASURE
less I_MEASURE
than O
. O
00001 B_MEASURE
) O
. O

There O
is O
, O
however O
, O
uncertainty B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
to O
how O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
obtained O
in O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
scale O
up O
to O
landscape B_LOCATION/B_PERSON
and O
regional B_LOCATION/B_BIO
levels I_LOCATION/I_BIO
and O
generalize O
across O
ecosystem B_LOCATION/B_ORGANIZATION
types I_LOCATION/I_ORGANIZATION
and O
processes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
facilitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
started O
preceding O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
electromyographic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
masseter B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 B_GENE/B_DISEASE
( O
neu B_GENE/B_DISEASE
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament O
interaction O
site O
provides O
a O
physical O
model O
for O
integrating O
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

Deletion O
of O
the O
region O
from O
amino O
acid O
residues O
2 O
- O
67 O
in O
E1A B_GENE/B_MEASURE
, O
which O
has O
been O
postulated O
to O
interact O
with O
p300 B_GENE/B_LOCATION
/ O
CBP B_MEASURE/B_GENE
, O
also O
abolished O
the O
inhibitory O
effect O
of O
E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
deletion O
of O
the O
region O
from O
residues O
120 O
to O
140 O
had O
no O
effect O
. O

quantitative B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tl I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
201 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
stress B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
also O
shown O
viable B_DISEASE_ADJECTIVE[DISEASE]
myocardium I_DISEASE_ADJECTIVE[DISEASE]
in O
most O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
moderate O
( O
51 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
to O
85 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
normal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
uptake B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
irreversible B_LOCATION/B_DISEASE
Tl I_LOCATION/I_DISEASE
- O
201 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
defects I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
point O
mutation O
Asp O
- O
316 O
- O
- O
> O
Asn O
in O
the O
C O
- O
terminus O
of O
p38 B_GENE
, O
analogous O
to O
the O
ERK2 B_GENE
( O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
sevenmaker B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O
, O
dramatically O
decreases O
its O
binding O
to O
MKP B_GENE
- I_GENE
1 I_GENE
and O
substantially O
compromises O
its O
stimulatory O
effect O
on O
the O
catalytic O
activity O
of O
this O
phosphatase O
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

causal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
modeling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
combines O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
because O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O
within O
the O
context B_LOCATION
of O
the O
proposed O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
offers O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
advancing O
the O
science B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
while O
maintaining O
the O
specificity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
practice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
one O
trial O
, O
116 O
subjects O
with O
transfusion O
- O
related O
chronic O
hepatitis O
C O
were O
treated O
with O
lymphoblastoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
5 O
Mu O
/ O
m2 O
three O
times O
a O
week O
for O
2 O
Mo O
, O
then O
3 O
Mu O
/ O
m2 O
three O
times O
a O
week O
for O
4 O
or O
10 O
Mo O
) O
. O

A O
derived B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
resistant B_LOCATION/B_GENE
line I_LOCATION/I_GENE
, O
NT2 B_PROTEIN[GENE]/B_LOCATION
/ O
D1 B_LOCATION/B_PROTEIN[GENE]
- O
R1 B_MEASURE/B_PERSON
, O
is O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
this O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
is O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

BCR B_PROTEIN[GENE]/B_LOCATION
- O
ABL B_MEASURE/B_GENE
elicits O
transformation O
of O
both O
fibroblast O
and O
hematopoietic O
cells O
and O
blocks O
apoptosis O
following O
cytokine O
deprivation O
in O
various O
factor O
- O
dependent O
cells O
. O

aggregation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
washed B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
platelets B_BIO/B_LOCATION
from O
rats B_BIO/B_PERSON
with O
diabetes B_DISEASE/B_LOCATION
was O
enhanced O
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
region B_GENE/B_LOCATION
showed O
it O
contained O
five B_MEASURE/B_LOCATION
potential B_MEASURE/I_LOCATION
copies B_MEASURE/I_LOCATION
of O
the O
sterol B_GENE
regulatory I_GENE
element I_GENE
( O
SRE B_PROTEIN[GENE]/B_DISEASE
- O
1 B_NUMBER[MEASURE]
) O
( O
Smith B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
R B_OTHER/B_LOCATION
. O
, O
Osborne B_PERSON/B_ORGANIZATION
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
F B_OTHER/B_LOCATION
. O
, O
Brown B_PERSON
, O
M B_LOCATION
. O
S B_OTHER/B_LOCATION
. O
, O
Goldstein B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Gil B_PERSON
, O
G B_OTHER/B_PERSON
. O

mutations O
in O
Saccharomyces O
cerevisiae O
that O
block O
meiotic O
prophase O
chromosome O
metabolism O
and O
confer O
cell O
cycle O
arrest O
at O
pachytene O
identify O
two O
new O
meiosis B_GENE/B_BIO
- I_GENE/I_BIO
specific I_GENE/I_BIO
genes I_GENE/I_BIO
SAE1 I_GENE/I_BIO
and O
SAE3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

isolation O
and O
characterization O
of O
human O
orthologs O
of O
yeast O
CCR4 B_GENE
- O
NOT B_GENE/B_LOCATION
complex O
subunits O
. O

Thus O
, O
the O
i B_GENE/B_MEASURE
- I_GENE/I_MEASURE
leader I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
is O
a O
viral O
gene O
product O
of O
unknown O
function O
and O
high O
stability O
that O
is O
made O
in O
large O
quantities O
at O
intermediate O
times O
of O
productive O
infection O
. O
( O
abstract O
TRUNCATED O
AT O
400 O
Words O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Latanoprost B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O
once O
daily O
was O
significantly O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
reducing O
IOP B_DISEASE/B_PROTEIN[GENE]
compared O
with O
unoprostone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administered O
twice O
daily O
in O
patients B_PERSON
with O
POAG B_LOCATION/B_DISEASE
and O
OH B_DISEASE
. O

The O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
simulations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
provide O
insight B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
conformational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
flexibility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
these O
analogs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
alfalfa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
insecticides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
caused O
significant B_DISEASE
mortality I_DISEASE
to O
most B_NUMBER[MEASURE]/B_PERSON
of O
the O
insects B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluated O
. O

Therefore O
, O
we O
have O
reevaluated O
the O
age O
- O
related O
changes O
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leptin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
and O
their O
relationship O
with O
adiposity O
and O
androgen O
levels O
in O
a O
large O
group O
of O
community O
dwelling O
men O
. O

injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PD B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
solutions B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O
13 B_MEASURE
. O
6 B_MEASURE
, O
22 B_MEASURE
. O
7 B_MEASURE
, O
and O
38 B_MEASURE
. O
6 B_MEASURE
g I_MEASURE
/ O
liter B_MEASURE
of O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reduced O
the O
ingestion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
sucrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O
12 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
23 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
36 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
, O
respectively O
, O
but O
did O
not O
affect O
the O
ingestion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

It O
is O
recommended O
that O
area B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
correction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
be O
attempted O
in O
bioequivalence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
where O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
intrasubject I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
variability I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
clearance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
known O
or O
suspected O
. O

expression O
of O
the O
E2 B_GENE
protein I_GENE
resulted O
in O
rapid O
repression O
of O
HPV B_GENE/B_VIRUS[BIO]
E6 I_GENE/I_VIRUS[BIO]
and O
E7 B_PROTEIN[GENE]
expression O
, O
followed O
approximately O
12 O
h O
later O
by O
profound O
inhibition O
of O
cellular O
DNA O
synthesis O
. O

Plasma B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renin I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
activity O
in O
end O
- O
stage O
kidney O
disease O
. O

Immunoblotting O
with O
antiphosphotyrosine O
antibody O
showed O
that O
many O
yeast O
proteins O
, O
including O
the O
p34CDC28 B_ENZYME[GENE]
kinase I_ENZYME[GENE]
, O
became O
phosphorylated O
at O
tyrosine O
in O
cells O
expressing O
v B_GENE
- I_GENE
src I_GENE
. O

Renal B_DISEASE/B_PERSON
cell I_DISEASE/I_PERSON
carcinoma I_DISEASE/I_PERSON
induced O
Coombs B_DISEASE
negative I_DISEASE
autoimmune I_DISEASE
hemolytic I_DISEASE
anemia I_DISEASE
and O
severe B_DISEASE_ADJECTIVE[DISEASE]
thrombocytopenia I_DISEASE_ADJECTIVE[DISEASE]
responsive I_DISEASE_ADJECTIVE[DISEASE]
to O
nephrectomy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
different B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
CCl4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
prolongation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TMO B_MEASURE/B_LOCATION
half B_MEASURE/I_LOCATION
- O
life B_TIME[MEASURE]/B_LOCATION
, O
and O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
area B_LOCATION/B_MEASURE
under O
the O
curve B_MEASURE
( O
AUC B_LOCATION/B_MEASURE
) O
, O
and O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
clearance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
but O
the O
apparent B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
of O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Vd B_LOCATION/B_DISEASE
) O
was O
not O
significantly O
decreased O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B_GENE
( O
MAPK B_GENE
) O
kinase O
( O
MKK3 B_GENE
) O
together O
with O
the O
p38 B_GENE
( O
MAPK B_GENE/B_DISEASE
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B_GENE
D1 I_GENE
expression O
was O
observed O
. O

In O
patients B_PERSON/B_BIO
autografted O
in O
CR1 B_MEASURE
, O
the O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
mortality B_DISEASE
( O
TRM B_LOCATION/B_DISEASE
) O
was O
15 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
the O
relapse B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incidence I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
RI B_LOCATION/B_PROTEIN[GENE]
) O
was O
58 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
% I_MEASURE
, O
the O
leukaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
LFS B_DISEASE
) O
was O
36 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
% I_MEASURE
and O
the O
overall B_DISEASE
survival I_DISEASE
was O
47 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
% I_MEASURE
at O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
FR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
34235 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reduced O
aortic B_DISEASE
blood I_DISEASE
pressure I_DISEASE
and O
increased O
cardiac B_DISEASE/B_GENE
output I_DISEASE/I_GENE
in O
anesthetized B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dogs I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
ameroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
coronary B_DISEASE
artery I_DISEASE
occlusion I_DISEASE
. O

The O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
acceptable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hospital I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
that O
exhaled O
- O
volume B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monitoring I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
be O
performed O
for O
all O
patients B_PERSON/B_LOCATION
and O
that O
O2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
be O
performed O
both O
when O
setting O
FIO2 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
continuously O
when O
FIO2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
critical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

The O
RHO1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
a O
homolog O
of O
the O
mammalian O
RhoA B_GENE/B_BIO
small I_GENE/I_BIO
GTP I_GENE/I_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
protein I_GENE/I_BIO
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

As O
regards O
the O
short O
stature O
, O
they O
have O
proved O
that O
the O
syndrome O
is O
related O
to O
low O
levels O
of O
somatomedin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
SmC B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

2 B_NUMBER[MEASURE]
. O

menstrual B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
lunar B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cycles I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

HBO O
had O
marked O
effects O
on O
these O
enzymes O
: O
lung B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SOD I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O
( O
Guinea O
pigs O
47 O
% O
, O
rats O
88 O
% O
) O
and O
CAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
GSHPx B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O
decreased O
( O
33 O
% O
) O
in O
brain O
and O
lung O
. O

Smectic B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
A B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ordering I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
a O
liquid B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
vapor B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interface I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

phylogenetic O
analysis O
of O
yeast O
, O
invertebrate O
, O
and O
multiple O
mammalian O
isoforms O
of O
SNF4 B_GENE
shows O
that O
the O
gene O
duplication O
likely O
occurred O
early O
in O
the O
metazoan O
lineage O
, O
as O
the O
protein O
products O
of O
the O
different O
loci O
are O
relatively O
divergent O
. O

Hard B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
methacrylic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
polymers I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Thus O
the O
Hi O
- O
Rare O
represents O
a O
new O
type O
of O
RA O
response O
element O
with O
a O
role O
in O
the O
modulation O
of O
the O
expression O
of O
MHC B_GENE
class I_GENE
1 I_GENE
family O
genes O
. O

We O
found O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
start I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
located O
within O
a O
15 B_NUMBER[MEASURE]
- O
base B_MEASURE/B_LOCATION
pair I_MEASURE/I_LOCATION
region I_MEASURE/I_LOCATION
, O
205 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
base B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pairs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
upstream O
of O
the O
translation B_GENE/B_PERSON
start I_GENE/I_PERSON
codon I_GENE/I_PERSON
. O

During O
the O
last B_TIME[MEASURE]/B_ENT
three I_TIME[MEASURE]/I_ENT
days I_TIME[MEASURE]/I_ENT
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mean B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
osmolality B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Uosm B_LOCATION/B_PROTEIN[GENE]
) O
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TCH2O B_PROTEIN[GENE]/B_LOCATION
) O
increased O
significantly O
: O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formula I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
see O
text B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
structural O
intestinal O
defects O
are O
presumed O
to O
be O
the O
result O
of O
defective O
collagen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O
in O
these O
hereditary O
connective O
tissue O
disorders O
. O

Rev B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
indomethacin O
is O
useful O
for O
examining O
the O
role O
of O
cyclooxygenase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
asthmatic O
responses O
, O
it O
should O
not O
be O
considered O
in O
the O
treatment O
of O
asthma O
. O

incidence O
of O
beta O
- O
thalassemia O
carriers O
and O
those O
deficient O
in O
erythrocyte B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
greater O
Buenos O
Aires O
area O
. O

Both O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
c B_GENE
- I_GENE
Myb I_GENE
bind O
specifically O
to O
delta B_GENE
E3 I_GENE
. O

anatomical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
considerations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
transsphenoidal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
hypophysectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
. O

The O
salt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
two B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pairs I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
involved O
in O
the O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Zn2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
NC B_DISEASE/B_PROTEIN[GENE]
- O
F1 B_PROTEIN[GENE]/B_MEASURE
) O
with O
polynucleotide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
one B_NUMBER[MEASURE]/B_PERSON
ion I_NUMBER[MEASURE]/I_PERSON
pair I_NUMBER[MEASURE]/I_PERSON
is O
found O
in O
the O
metal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
nucleic B_PROTEIN[GENE]
acid I_PROTEIN[GENE]
complex I_PROTEIN[GENE]
. O

Investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
the O
asymmetrical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
yields B_DISEASE
in O
90Sr B_LOCATION/B_PROTEIN[GENE]
- O
90Y B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
irradiated O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
and O
L B_PROTEIN[GENE]/B_LOCATION
- O
alanines B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

An O
hcr1 B_GENE
null O
mutant O
was O
viable O
, O
but O
showed O
slight O
reduction O
of O
growth O
when O
compared O
with O
the O
wild O
- O
type O
strain O
. O

serum O
levels O
of O
total O
and O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IgE B_PROTEIN[GENE]/B_LOCATION
) O
have O
been O
determined O
by O
radioimmunoassays O
in O
sixty O
- O
nine O
allergic O
subjects O
. O

IgE B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Psocoptera O
were O
determined O
by O
immunoblotting O
experiments O
. O

We O
also O
show O
that O
the O
products O
of O
both O
the O
GIY B_TIME[MEASURE]/B_GENE
- I_TIME[MEASURE]/I_GENE
YIG I_TIME[MEASURE]/I_GENE
ORF O
and O
the O
non O
- O
canonical O
LAGLI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
DADG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
GIY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
YIG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
ORF O
, O
which O
is O
generated O
by O
its O
integration O
, O
have O
endonuclease O
activities O
which O
recognize O
and O
cut O
the O
insertion O
site O
of O
the O
optional O
sequence O
. O

Further O
, O
we O
find O
that O
the O
BMI1 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
also O
interact O
with O
itself O
. O

Indeed O
, O
ectopic O
expression O
of O
MOX4 B_GENE
in O
aerobic O
cells O
resulted O
in O
partially O
constitutive O
expression O
of O
DAN1 B_GENE
. O

We O
measured O
electromyograms B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
EMG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
of O
the O
alae B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
nasi I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
to O
determine O
the O
relationship B_PERSON/B_MEASURE
between O
their O
activity B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
timing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
contraction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
rib B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
diaphragm B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
during O
obstructive B_DISEASE/B_ORGANISM_FUNCTION
apnea I_DISEASE/I_ORGANISM_FUNCTION
in O
nine B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

Hybridization O
was O
detected O
between O
polyadenylated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
isolated O
from O
the O
majority O
of O
the O
hybridomas O
, O
and O
the O
VH B_DISEASE/B_GENE
probe O
. O

identification O
of O
a O
putative O
infC B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rpmI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
rplT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon O
flanked O
by O
long O
inverted O
repeats O
in O
Mycoplasma O
fermentans O
( O
incognitus O
strain O
) O
. O

The O
standardized B_MEASURE
incidence I_MEASURE
in O
Europeans B_LOCATION/B_BIO
has O
risen O
significantly O
to O
4 B_MEASURE
. O
7 B_MEASURE
/ O
10 B_MEASURE
( O
5 B_MEASURE
) O
/ O
year B_TIME[MEASURE]/B_PERSON
from O
3 B_MEASURE
. O
4 B_MEASURE
/ O
10 B_MEASURE
( O
5 B_MEASURE
) O
/ O
year B_TIME[MEASURE]/B_PERSON
in O
the O
1970s B_TIME[MEASURE]/B_LOCATION
( O
Chi B_PERSON/B_PROTEIN[GENE]
2 I_PERSON/I_PROTEIN[GENE]
= O
8 B_MEASURE
. O
1 B_MEASURE
, O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
005 B_MEASURE
) O
. O

Neurological B_DISEASE
toxicity I_DISEASE
occurred O
in O
8 B_MEASURE
/ O
219 B_MEASURE
patients I_MEASURE
treated O
with O
fludarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FAMP B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
30 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
per O
day B_TIME[MEASURE]
and O
cytosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
C B_PROTEIN[GENE]/B_LOCATION
) O
, O
0 B_MEASURE
. O
5 B_MEASURE
g I_MEASURE
/ O
m2 O
per O
hour B_TIME[MEASURE]/B_ENT
for O
2 B_NUMBER[MEASURE]
- O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
for O
5 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
for O
new B_DISEASE_ADJECTIVE[DISEASE]
or O
relapsed B_DISEASE_ADJECTIVE[DISEASE]
acute I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_DISEASE_ADJECTIVE[DISEASE]
or O
myelodysplasia B_DISEASE
. O

Evaluation O
of O
gamma B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I_DISEASE_ADJECTIVE[DISEASE]
in O
myocardial O
infarction O
. O

Loss O
of O
pRb B_GENE
or O
p107 B_GENE
binding O
results O
in O
the O
loss O
of O
transforming O
activity O
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
suggests O
that O
seroprevalence B_DISEASE/B_MEASURE
of O
Lyme B_DISEASE/B_SPECIES[BIO]
borreliosis I_DISEASE/I_SPECIES[BIO]
in O
dogs B_BIO/B_PERSON
of O
the O
Kosice B_LOCATION/B_BIO
region I_LOCATION/I_BIO
is O
not O
negligible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Peak O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O
to O
glucose O
infusion O
declined O
from O
Groups O
1 O
to O
3 O
( O
51 O
+ O
/ O
- O
14 O
, O
42 O
. O
4 O
+ O
/ O
- O
31 O
, O
20 O
. O
4 O
+ O
/ O
- O
6 O
. O
8 O
microU O
/ O
ml O
, O
respectively O
) O
with O
Group O
3 O
exhibiting O
a O
significantly O
decreased O
mean O
peak O
level O
compared O
to O
the O
other O
groups O
. O

iris B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
binding I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
bioavailability B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
n I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PUFA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
measures B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DISEASE/B_GENE
peroxidation I_DISEASE/I_GENE
has O
been O
equivocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
proliferative O
potential O
of O
the O
pilocytic O
astrocytoma O
: O
the O
relation O
between O
MIB B_GENE
- I_GENE
1 I_GENE
labeling O
and O
clinical O
and O
neuro O
- O
radiological O
follow O
- O
up O
. O

Results O
: O
Here O
, O
we O
report O
the O
identification O
of O
two O
major O
and O
novel O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tyrosine O
phosphorylation O
sites O
, O
Y239 O
and O
Y240 O
. O

dominant O
- O
negative O
upf1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O
were O
isolated O
following O
in O
vitro O
mutagenesis O
of O
a O
plasmid O
containing O
the O
UPF1 B_GENE
gene I_GENE
. O

The O
tensile B_MEASURE
strengths I_MEASURE
of O
an O
adhesive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
luting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
resin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
' O
Panavia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
EX I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
' O
to O
the O
bovine B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dentin I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decreased O
significantly O
by O
the O
zinc B_TIME[MEASURE]
iontophoresis I_TIME[MEASURE]
. O

We O
previously O
identified O
a O
highly O
conserved O
L O
- O
X O
- O
X O
- O
L O
- O
F O
sequence O
near O
the O
C O
terminus O
of O
the O
p6 B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
of O
the O
Gag B_GENE
precursor I_GENE
as O
the O
major O
virion O
association O
motif O
for O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Vpr I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Papillomavirus O
type O
16 O
oncogenes O
downregulate O
expression O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive O
genes O
and O
upregulate O
proliferation O
- O
associated O
and O
NF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
kappaB I_GENE/I_DISEASE
- O
responsive O
genes O
in O
cervical O
keratinocytes O
. O

The O
A3B3 B_GENE
domain I_GENE
had O
a O
mass B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
34 B_MEASURE
, O
462 B_MEASURE
, O
with O
a O
glycosylation B_MEASURE/B_LOCATION
mass I_MEASURE/I_LOCATION
of O
14 B_MEASURE
, O
900 B_MEASURE
, O
in O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
agreement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
seven B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
linked O
glycosylation B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
sites B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
of O
average B_GENE
mass I_GENE
2100 I_GENE
. O

We O
found O
that O
the O
frequency B_MEASURE/B_ENT
spectrum I_MEASURE/I_ENT
of O
physiologic B_DISEASE/B_ENT
chest I_DISEASE/I_ENT
sounds I_DISEASE/I_ENT
is O
contained O
entirely O
within O
that O
of O
jet B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
rotocraft I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
noise I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA11 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O
to O
be O
located O
between O
the O
secretor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fucosyltransferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
FUT1 B_PROTEIN[GENE]
- O
FUT2 B_PROTEIN[GENE]/B_MEASURE
- O
FUT2P B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
D B_GENE
- I_GENE
site I_GENE
binding I_GENE
protein I_GENE
gene I_GENE
( O
DBP B_GENE/B_DISEASE
) O
on O
chromosome O
19q13 O
. O
3 O
. O

An O
anoerxiant O
, O
mazindol O
suppresses O
food O
intake O
by O
1 O
) O
stimulating O
beta B_DISEASE/B_ORGANISM_FUNCTION
- I_DISEASE/I_ORGANISM_FUNCTION
adrenergic I_DISEASE/I_ORGANISM_FUNCTION
receptors I_DISEASE/I_ORGANISM_FUNCTION
, O
2 O
) O
inhibiting O
the O
feeding O
center O
and O
, O
3 O
) O
stimulating O
the O
satiety O
center O
in O
the O
hypothalamus O
. O

These O
segments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
represent O
pseudogenes B_DISEASE/B_BACTERIUM[BIO]
. O

The O
fusion O
of O
AML1 B_GENE/B_DISEASE
to O
MDS1 B_GENE/B_DISEASE
is O
in O
frame O
, O
and O
adds O
127 O
codons O
to O
the O
interrupted O
AML1 B_GENE/B_LOCATION
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lasalocid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
rumen B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
anaerobic B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
fungus B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Neocallimastix B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
frontalis B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
RK B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
21 B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
was O
examined O
. O

WBC B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differential B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Seg B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Band B_ENT/B_GENE
, O
LYMPH B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
MONO B_LOCATION/B_DISEASE
, O
EOSINO B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BASO B_LOCATION/B_MEASURE
) O
usually O
showed O
log B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
normal B_MEASURE/B_LOCATION
distribution I_MEASURE/I_LOCATION
. O

A O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
oligomerization B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
folding B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

chromosome B_BIO/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
STSs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
for O
27 B_DISEASE
telomeres I_DISEASE
were O
identified O
from O
the O
196 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
TYACs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Second O
, O
overexpression O
of O
RIM11 B_GENE
can O
suppress O
an O
ime1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
missense O
mutation O
( O
ime1 B_PROTEIN[GENE]/B_DISEASE
- I_PROTEIN[GENE]/I_DISEASE
L321F I_PROTEIN[GENE]/I_DISEASE
) O
but O
not O
an O
ime1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deletion O
. O

calculation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
energy B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
, O
E1 O
transition B_MEASURE/B_ORGANIZATION
amplitudes I_MEASURE/I_ORGANIZATION
, O
and O
parity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
violation I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
francium B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
except O
the O
last B_SEQUENCE[MEASURE]
two I_SEQUENCE[MEASURE]
interventions I_SEQUENCE[MEASURE]
are O
physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
create O
a O
wound B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
tissue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
environment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
healing B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
50 O
- O
kDa O
protein O
contains O
two O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
an O
inter B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SH2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
p85alpha B_GENE
, O
but O
the O
SH3 B_GENE
and O
bcr B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
p85alpha B_GENE/B_PERSON
were O
replaced O
by O
a O
unique O
6 O
- O
amino O
acid O
sequence O
. O

Hydropathy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
deduced B_GENE
A4 I_GENE
amino I_GENE
acid I_GENE
sequence I_GENE
revealed O
four B_MEASURE/B_LOCATION
putative B_MEASURE/I_LOCATION
membrane B_MEASURE/I_LOCATION
- O
spanning O
alpha B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O
helices B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
double I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
topical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
miconazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
clotrimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
superficial B_DISEASE
fungal I_DISEASE
infections I_DISEASE
and O
erythrasma B_DISEASE
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
low B_MEASURE/B_COLOR
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contraceptives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
cervical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
circulating O
D B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
norgestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
17alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ethynyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Herewith B_LOCATION
C I_LOCATION
. O
psittaci B_BACTERIUM[BIO]/B_PERSON
could O
be O
diagnosed O
in O
all O
positive B_LOCATION/B_PERSON
samples I_LOCATION/I_PERSON
. O

The O
more O
sustained O
effect O
of O
cyclofenil O
on O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O
with O
a O
reduced O
frequency O
of O
relapse O
, O
and O
the O
lower O
oestradiol O
level O
, O
which O
might O
indicate O
a O
reduced O
risk O
of O
thromboembolism O
, O
suggest O
that O
this O
drug O
has O
some O
advantage O
over O
bromocriptine O
in O
the O
inhibition O
of O
postpartum O
lactation O
. O

Response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
surface I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methodology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
employed O
to O
describe O
the O
relationship B_PERSON/B_MEASURE
between O
soman B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
incapacitation B_DISEASE
and O
the O
ATR B_LOCATION/B_PROTEIN[GENE]
/ O
DZ B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
ATR B_LOCATION/B_PROTEIN[GENE]
/ O
SCP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dosages I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
brains B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
bisected O
and O
T1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
T2 B_PROTEIN[GENE]/B_LOCATION
relaxation I_PROTEIN[GENE]/I_LOCATION
times I_PROTEIN[GENE]/I_LOCATION
were O
determined O
for O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
left O
hemispheres B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
MR B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spectroscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
immediately O
after O
dissection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

simulations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
velocities B_MEASURE/B_DISEASE
, O
vorticity B_MEASURE/B_LOCATION
, O
pressure B_DISEASE/B_MEASURE
and O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stress B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
values B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
developed O
by O
a O
computer B_PRODUCT[OBJECT]/B_PERSON
and O
displayed O
for O
man B_PERSON
- O
machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
the O
present O
study O
, O
we O
report O
the O
entire O
genomic O
structure O
of O
KCNQ1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
consists O
of O
19 O
exons O
spanning O
400 O
kb O
on O
chromosome O
11p15 O
. O
5 O
. O

Northern O
( O
RNA O
) O
blot O
hybridization O
analysis O
with O
the O
p68c B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
ets I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
specific O
sequence O
and O
RNase B_ENZYME[GENE]
protection O
experiments O
showed O
that O
the O
corresponding O
mRNA O
was O
expressed O
in O
normal O
chicken O
spleen O
and O
not O
in O
normal O
chicken O
thymus O
or O
in O
various O
T O
lymphoid O
cell O
lines O
. O

To O
investigate O
this O
issue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
we O
used O
a O
recognition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
two B_ENT/B_MEASURE
strings I_ENT/I_MEASURE
of O
letters B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
presented O
sequentially O
. O

Kettin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
large O
modular O
protein O
associated O
with O
thin O
filaments O
in O
the O
Z O
- O
disc O
region O
of O
insect O
muscles O
. O

enzymatic B_GENE
and O
chemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
probing O
revealed O
mainly O
the O
conserved B_LOCATION/B_MEASURE
terminal I_LOCATION/I_MEASURE
part I_LOCATION/I_MEASURE
( O
termed O
3 B_NUMBER[MEASURE]
' O
C B_PROTEIN[GENE]/B_LOCATION
) O
of O
the O
DI9c B_MEASURE
3 I_MEASURE
' O
UTR B_GENE/B_LOCATION
containing O
distinctive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
RNA B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
i O
. O
e O
. O
, O
a O
stable B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
stem I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
loop B_LOCATION/B_ORGANIZATION
, O
SL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
near O
the O
RNA B_NUMBER[MEASURE]
3 I_NUMBER[MEASURE]
' O
terminus B_LOCATION/B_MEASURE
and O
a O
considerably O
less O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stem B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
loop B_LOCATION
, O
SL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
that O
forms O
the O
5 B_NUMBER[MEASURE]
' O
portion B_MEASURE/B_LOCATION
of O
3 B_NUMBER[MEASURE]
' O
C B_GENE/B_LOCATION
. O

This O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chronicles O
the O
characteristics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
deliberate B_DISEASE_ADJECTIVE[DISEASE]
and O
accidental B_DISEASE
mass I_DISEASE
poisonings I_DISEASE
that O
occurred O
in O
World B_TIME[MEASURE]/B_PROTEIN[GENE]
Wars I_TIME[MEASURE]/I_PROTEIN[GENE]
I I_TIME[MEASURE]/I_PROTEIN[GENE]
and O
II B_TIME[MEASURE]/B_PROTEIN[GENE]
, O
in O
Bhopal B_LOCATION/B_PERSON
, O
and O
in O
other B_LOCATION
historical I_LOCATION
cases I_LOCATION
up O
to O
and O
including O
modern B_LOCATION/B_ENT
wars I_LOCATION/I_ENT
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
7 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
per O
day B_TIME[MEASURE]/B_PERSON
) O
( O
CyA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
on O
the O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vascularized B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
osteochondral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
rat B_PERSON/B_LOCATION
strains I_PERSON/I_LOCATION
[ I_PERSON
Da I_PERSON
( O
donor B_PERSON
) O
and O
Lewis B_PROTEIN[GENE]/B_BIO
( O
recipient B_PERSON/B_BIO
) O
] B_OTHER/B_DISEASE
and O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
host B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
graft B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antigen I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
immunosuppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
examined O
. O

By O
incorporating O
a O
stent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
with O
posts B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
that O
pivot O
about O
their O
base B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
such B_TIME[MEASURE]/B_LOCATION
that O
a O
10 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
expansion I_TIME[MEASURE]/I_LOCATION
at O
the O
commissures B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
is O
realized O
, O
we O
were O
able B_TIME[MEASURE]/B_PERSON
to O
reduce O
the O
compressive B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
commissural B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
stressing O
from O
250 B_MEASURE
to O
150 B_MEASURE
kPa I_MEASURE
. O

In O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
mean O
z B_MEASURE
- O
score B_MEASURE/B_ENT
for O
GFR B_NUMBER[MEASURE]/B_PERSON
was O
- O
0 B_MEASURE
. O
27 B_MEASURE
( O
94 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
in O
group B_MEASURE/B_PERSON
2 I_MEASURE/I_PERSON
mean I_MEASURE/I_PERSON
z O
- O
score B_MEASURE/B_ENT
was O
- O
1 B_MEASURE
. O
51 B_MEASURE
( O
72 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
two B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
kidneys I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
) O
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
022 B_MEASURE
, O
Mann B_PERSON
- O
Whitney B_PERSON
U I_PERSON
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

The O
cooperation B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
health B_PERSON/B_LOCATION
and O
hospital B_ORGANIZATION/B_PERSON
services I_ORGANIZATION/I_PERSON
. O

The O
free B_MEASURE/B_DISEASE
fraction I_MEASURE/I_DISEASE
of O
amitriptyline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
AT O
) O
, O
measured O
by O
equilibrium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dialysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
29 B_MEASURE
AT O
- O
treated O
depressed B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
5 B_NUMBER[MEASURE]
. O
4 B_MEASURE
- O
9 B_NUMBER[MEASURE]
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
mean B_MEASURE
7 I_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
which O
was O
the O
same B_MEASURE/B_LOCATION
as O
the O
values B_MEASURE
in O
26 B_PERSON/B_MEASURE
healthy I_PERSON/I_MEASURE
controls I_PERSON/I_MEASURE
( O
4 B_NUMBER[MEASURE]
. O
9 B_MEASURE
- O
9 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
mean O
7 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reoxygenation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
electrical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
muscle I_BODY_PART_OR_ORGAN_COMPONENT
. O

Metastatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumours B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
in O
Nigerians B_BIO/B_PERSON
. O

However O
, O
microinjection O
of O
reconstituted O
mRNPs O
into O
Xenopus O
oocytes O
demonstrates O
that O
although O
translational O
repression O
occurs O
in O
the O
absence O
of O
consensus O
RNA O
binding O
sequences O
for O
FRGY2 B_GENE
, O
the O
presence O
of O
FRGY2 B_GENE
recognition I_GENE
elements I_GENE
within O
mRNA O
potentiates O
translational O
repression O
. O

Any O
respectative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
material I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
class B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
0 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
was O
not O
obtained O
from O
334 B_MEASURE
patients I_MEASURE
( O
4 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
, O
class B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
- O
II B_NUMBER[MEASURE]/B_PROTEIN[GENE]
findings I_NUMBER[MEASURE]/I_PROTEIN[GENE]
belonged O
to O
6m141 B_MEASURE
patients I_MEASURE
( O
76 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
950 B_MEASURE
patients I_MEASURE
( O
11 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
classified O
as O
class B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
HII I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IV B_MEASURE
, O
578 B_MEASURE
patients I_MEASURE
( O
7 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
as O
class B_LOCATION/B_PERSON
V B_LOCATION/I_PERSON
. O

However O
, O
whether O
this O
was O
associated O
with O
spleen B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
removal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O
adjustment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
determined O
. O

Virgin B_PERSON/B_COLOR
, O
P B_OTHER/B_MEASURE
. O

IL B_GENE/B_BACTERIUM[BIO]
- B_GENE/I_BACTERIUM[BIO]
6 B_GENE/I_BACTERIUM[BIO]
was O
detected O
in O
the O
urine O
of O
52 O
% O
of O
children O
with O
pyelonephritis O
compared O
with O
15 O
% O
of O
other O
children O
( O
P O
< O
0 O
. O
001 O
) O
. O

We O
have O
determined O
the O
complete O
cDNA O
sequence O
of O
rat B_GENE
plectin I_GENE
from O
a O
number O
of O
well O
- O
characterized O
overlapping O
lambda O
gt11 O
clones O
. O

setting O
- O
- O
Hospital B_LOCATION/B_PERSON
laboratories B_LOCATION/I_PERSON
in O
the O
United B_LOCATION
States I_LOCATION
submitting O
pneumococcal B_VIRUS[BIO]/B_DISEASE
isolates O
to O
the O
CDC B_ORGANIZATION/B_LOCATION
between O
October B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
1991 B_MEASURE
, O
and O
September B_TIME[MEASURE]
30 I_TIME[MEASURE]
, O
1992 B_MEASURE
. O

The O
terminal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
sequence B_LOCATION/B_GENE
of O
the O
herpes B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simplex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
the O
promoter B_GENE
of O
a O
gene B_GENE/B_LOCATION
located O
in O
the O
repeat B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
sequences I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
L B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast O
to O
p62 B_GENE
( O
dok B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
, O
DOKL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lacks O
YxxP O
motifs O
in O
the O
C O
terminus O
and O
does O
not O
bind O
to O
Ras B_GENE
GTPase I_GENE
- I_GENE
activating I_GENE
protein I_GENE
( O
RasGAP B_GENE/B_DISEASE
) O
upon O
phosphorylation O
. O

These O
observations O
demonstrate O
that O
KSR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
capable O
of O
uncoupling O
the O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O
from O
its O
target O
phosphorylation O
, O
and O
thus O
provide O
a O
novel O
mechanism O
for O
modulating O
the O
Ras B_GENE/B_DISEASE
- O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
pathway O
. O

G B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CSF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
10 O
microg O
/ O
kg O
) O
was O
started O
on O
day O
+ O
1 O
and O
all O
patients O
engrafted O
within O
a O
median O
day O
number O
of O
12 O
( O
range O
, O
10 O
- O
22 O
) O
until O
leukocytes O
> O
1 O
. O
0 O
x O
10 O
( O
9 O
) O
/ O
l O
and O
a O
median O
day O
number O
of O
56 O
( O
range O
, O
10 O
- O
180 O
) O
until O
platelets O
> O
20 O
. O
0 O
x O
10 O
( O
9 O
) O
/ O
l O
( O
ie O
platelet O
transfusion O
independence O
) O
. O

A O
higher O
percentage O
of O
children O
with O
cerebral O
malaria O
( O
40 O
per O
cent O
) O
than O
with O
non O
- O
cerebral O
malaria O
( O
29 O
per O
cent O
) O
or O
controls O
( O
20 O
per O
cent O
) O
also O
had O
either O
serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ferritin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
< O
100 O
micrograms O
/ O
l O
and O
inflammation O
or O
sTfR B_GENE
> O
7 O
. O
3 O
mg O
/ O
l O
or O
both O
. O

During O
the O
burst O
period O
( O
approximately O
5 O
- O
10 O
min O
) O
, O
local O
blood O
H2O2 O
concentrations O
and O
xanthine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activities O
were O
highly O
correlated O
( O
r O
= O
0 O
. O
999 O
) O
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
demonstrated O
that O
the O
21 B_MEASURE
- O
or O
the O
72 B_MEASURE
- O
BP B_LOCATION/B_MEASURE
repeat I_LOCATION
transcriptional B_LOCATION/B_PERSON
control I_LOCATION
elements I_LOCATION
enhance O
the O
efficiency B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
SV40 B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
replication I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
provided O
either O
of O
these O
repeats B_GENE/B_DISEASE
is O
located O
near O
the O
end B_LOCATION
of O
the O
core B_GENE/B_LOCATION
replication I_GENE/I_LOCATION
origin I_GENE/I_LOCATION
containing O
the O
17 B_MEASURE
- O
BP B_LOCATION/B_GENE
A I_LOCATION/I_GENE
+ I_LOCATION/I_GENE
T I_LOCATION/I_GENE
- O
containing O
sequence B_GENE/B_LOCATION
. O

UV O
cross O
- O
linking O
and O
Southwestern O
analysis O
suggested O
that O
KTP1 B_GENE
is O
a O
DNA O
- O
binding O
protein O
clearly O
distinct O
from O
AP2 B_GENE
, O
and O
this O
protein O
may O
be O
responsible O
for O
the O
basal O
keratinocyte O
- O
specific O
expression O
of O
the O
BPAG1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
model O
of O
the O
complex O
provides O
a O
rationale O
for O
conserved O
ITAM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
residues O
, O
substrate O
specificity O
, O
and O
suggests O
that O
substrate O
binds O
only O
the O
active O
conformation O
of O
the O
Src B_ENZYME[GENE]
family I_ENZYME[GENE]
tyrosine I_ENZYME[GENE]
kinase I_ENZYME[GENE]
, O
unlike O
the O
ATP O
cofactor O
, O
which O
can O
bind O
the O
inactive O
form O
. O

Here O
we O
demonstrate O
that O
a O
region O
of O
high O
homology O
between O
the O
members O
of O
this O
class O
of O
proteins O
contains O
a O
type O
A O
nucleotide O
binding O
site O
consensus O
sequence O
which O
has O
ATPase B_ENZYME[GENE]
activity O
and O
is O
sufficient O
to O
bind O
DNA O
containing O
specific O
mismatched O
residues O
. O

Copyright B_LOCATION/B_PERSON
1999 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

nickel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
tools B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
the O
Swedish B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
market I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

S O
- O
phase O
- O
promoting O
cyclin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Cdks B_GENE/B_LOCATION
) O
and O
the O
kinase O
Dbf4 B_GENE
- O
Cdc7 B_MEASURE
then O
act O
to O
initiate O
replication O
. O

NF B_GENE
- I_GENE
kappaB I_GENE
only O
partially O
mediates O
Epstein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Barr I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
latent I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
membrane I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O
of O
B O
cells O
. O

Purified O
fER B_GENE
exhibited O
a O
distribution O
constant O
( O
KD O
) O
for O
17 O
beta O
- O
estradiol O
of O
0 O
. O
45 O
nm O
. O

The O
long B_GENE/B_LOCATION
terminal I_GENE/I_LOCATION
repeat I_GENE/I_LOCATION
is O
590 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bp I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
length B_MEASURE/B_BIO
, O
with O
the O
U3 B_LOCATION/B_BIO
region I_LOCATION/I_BIO
containing O
consensus B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
likely I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
be O
involved O
in O
viral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

An O
incorrect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
enhanced O
the O
accuracy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
in O
the O
left B_TIME[MEASURE]/B_LOCATION
visual I_TIME[MEASURE]/I_LOCATION
field I_TIME[MEASURE]/I_LOCATION
( O
LVF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
peptides O
are O
generated O
in O
the O
cytosol O
, O
then O
translocated O
across O
the O
membrane O
of O
the O
endoplasmic O
reticulum O
by O
the O
transporter B_ENZYME[GENE]
associated I_ENZYME[GENE]
with I_ENZYME[GENE]
antigen I_ENZYME[GENE]
processing I_ENZYME[GENE]
( O
TAP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

It O
competes O
with O
the O
calcium O
ion O
which O
brings O
about O
inhibition O
of O
myosine B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
therefore O
a O
drop O
in O
phosphorylated O
myosine O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Sera B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O
in O
1973 B_TIME[MEASURE]/B_LOCATION
- O
1975 B_MEASURE
from O
3053 B_NUMBER[MEASURE]/B_LOCATION
residents I_NUMBER[MEASURE]/I_LOCATION
of O
12 B_NUMBER[MEASURE]
selected O
Alaskan B_LOCATION
Eskimo I_LOCATION
villages I_LOCATION
were O
tested O
for O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hepatitis B_DISEASE
B I_DISEASE
virus I_DISEASE
infection I_DISEASE
. O

injection O
of O
horseradish B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
HRP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
into O
the O
cerebellar O
flocculus O
of O
the O
rat O
was O
employed O
to O
identify O
neurons O
in O
the O
abducens O
nucleus O
that O
project O
to O
the O
flocculus O
. O

To O
assay O
for O
sequences O
that O
could O
potentially O
regulate O
Xenopus B_GENE
proenkephalin I_GENE
expression O
, O
we O
transfected O
constructs O
that O
contained O
upstream O
genomic O
sequences O
linked O
to O
the O
CAT B_GENE
reporter I_GENE
gene I_GENE
into O
various O
eukaryotic O
cell O
lines O
. O

This O
suggests O
that O
the O
ratio O
of O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
6 I_GENE/I_LOCATION
to O
IL B_GENE
- I_GENE
10 I_GENE
may O
be O
used O
to O
predict O
the O
injury O
severity O
after O
trauma O
. O

UVB O
- O
induced O
association O
of O
tumor B_GENE
necrosis I_GENE
factor I_GENE
( I_GENE
TNF I_GENE
) I_GENE
receptor I_GENE
1 I_GENE
/ O
TNF B_GENE/B_MEASURE
receptor I_GENE/I_MEASURE
- I_GENE/I_MEASURE
associated I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
- I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
mediates O
activation O
of O
Rel B_GENE
proteins I_GENE
. O

A O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feature B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
genomic B_GENE
sequence I_GENE
is O
the O
presence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
first B_GENE
intron I_GENE
( O
Il B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
215 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bp I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
long O
, O
located O
48 B_LOCATION
BP I_LOCATION
downstream I_LOCATION
of O
the O
translation B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
start O
ATG B_LOCATION/B_GENE
codon I_LOCATION/I_GENE
. O

Experimental O
studies O
and O
clinical O
application O
of O
plasma B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ACTH B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
radioimmunoassay O
kit O
without O
extraction O
process O
. O

In O
the O
cervical B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
enlargement B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
they O
were O
located O
in O
the O
middle B_LOCATION/B_BIO
part I_LOCATION/I_BIO
of O
lamina B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
VII B_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
and O
in O
lamina B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
VIII I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
accounting O
for O
about O
25 B_SEQUENCE[MEASURE]/B_LOCATION
% I_SEQUENCE[MEASURE]/I_LOCATION
of O
the O
total B_MEASURE
labeled O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

nature B_MEASURE/B_DISEASE
and O
incidence B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
conditioned B_DISEASE
responses I_DISEASE
in O
a O
methadone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
a O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
laboratory B_LOCATION/B_PERSON
, O
clinic B_LOCATION/B_EDU[ORGANIZATION]
, O
and O
naturalistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
settings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

While O
some O
still O
automatically O
refuse O
all O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
positive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediastinoscopy I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
most B_PERSON
authors I_PERSON
still O
remain O
very O
interventionistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
N2 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
selected O
on O
very O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
are O
analyzed O
above O
. O

Our O
previous O
studies O
demonstrated O
that O
the O
promyelocytic O
leukemia O
gene O
, O
PML B_GENE/B_DISEASE
which O
involved O
in O
the O
15 O
; O
17 O
translocation O
in O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
a O
growth O
and O
transformation O
suppressor O
. O

A O
sharp B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
transition B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
from O
a O
random B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
chaotic I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
state I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
a O
correlated O
turbulent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
state B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
finite B_MEASURE
coherence I_MEASURE
time I_MEASURE
is O
found O
when O
the O
Rayleigh B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
becomes O
larger B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
a O
critical B_MEASURE
value I_MEASURE
Ra O
( O
c B_OTHER/B_PROTEIN[GENE]
) O
approximately O
equal B_MEASURE
to O
5 B_NUMBER[MEASURE]
x O
10 B_MEASURE
( O
7 B_MEASURE/B_LOCATION
) O
. O

Our O
data O
define O
Ile O
( O
16 O
) O
, O
Val O
( O
18 O
) O
, O
Val O
( O
31 O
) O
, O
and O
Ile O
( O
33 O
) O
as O
crucial O
for O
protein B_GENE/B_BIO
S I_GENE/I_BIO
binding O
, O
with O
secondary O
effects O
from O
Leu O
( O
38 O
) O
and O
Val O
( O
39 O
) O
. O

In O
the O
yeast O
two O
- O
hybrid O
assays O
, O
PNRC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacted O
with O
the O
orphan O
receptors O
SF1 B_GENE/B_LOCATION
and O
ERRalpha1 B_GENE
in O
a O
ligand O
- O
independent O
manner O
. O

Nuclear O
export O
of O
proteins O
in O
plants O
: O
AtXPO1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
export O
receptor O
for O
leucine O
- O
rich O
nuclear O
export O
signals O
in O
Arabidopsis O
thaliana O
. O

Thus O
, O
CR2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O
an O
essential O
function O
besides O
pRb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
. O

From O
the O
autopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
in O
5 B_NUMBER[MEASURE]
out O
of O
the O
remaining O
23 B_MEASURE
expired O
patients B_PERSON
, O
Legionella B_DISEASE
pneumonia I_DISEASE
seemed O
to O
be O
successfully O
treated O
, O
but O
other B_DISEASE/B_BACTERIUM[BIO]
disease B_DISEASE/I_BACTERIUM[BIO]
or O
other B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bacterial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
put O
an O
end B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Nitroglycerin O
( O
glyceryl O
trinitrate O
) O
as O
a O
monoamine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
. O

This O
high B_MEASURE/B_PROTEIN[GENE]
dose B_MEASURE/I_PROTEIN[GENE]
5 B_MEASURE/I_PROTEIN[GENE]
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Act B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
drug B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
resistant I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cases I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
MEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

With O
stimulation B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beyond O
the O
theta B_PROTEIN[GENE]/B_MEASURE
- O
range B_MEASURE/B_LOCATION
three B_MEASURE/I_LOCATION
phenomena B_MEASURE/I_LOCATION
occurred O
: O
shift O
of O
the O
burst B_MEASURE
frequencies I_MEASURE
to O
higher B_MEASURE/B_LOCATION
or O
lower B_MEASURE
harmonics I_MEASURE
of O
stimulation B_MEASURE/B_ENT
frequencies I_MEASURE/I_ENT
; O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
basic B_MEASURE
background I_MEASURE
frequency I_MEASURE
with O
rhythm B_TIME[MEASURE]/B_ENT
of O
stimulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
' O
beating B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O
) O
; O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
background O
theta O
- O
burst B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
in O
spite B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
continuing O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
' O
escape B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Transpulmonary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stable I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
air I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microbubbles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bound O
to O
a O
galactose B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carrier B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O
a O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
contrast I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
agent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
insufficient B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
native I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transcranial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Doppler B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

K562 O
erythroleukemia O
cells O
stably O
transfected O
with O
constructs O
containing O
the O
human B_GENE/B_LOCATION
Agamma I_GENE/I_LOCATION
- I_GENE/I_LOCATION
globin I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
linked O
to O
an O
enhanced B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
green I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
EGFP B_GENE/B_DISEASE
) O
reporter O
, O
with O
or O
without O
HS2 O
, O
were O
analyzed O
for O
EGFP B_GENE
expression O
by O
flow O
cytometry O
. O

Gastrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulates O
transcription O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histidine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HDC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
gene O
through O
binding O
to O
the O
G B_GENE
- I_GENE
protein I_GENE
- O
coupled O
cholecystokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
gastrin B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
. O

Here O
, O
we O
report O
the O
isolation O
of O
a O
new O
spindle O
checkpoint O
gene O
, O
mph1 B_GENE/B_DISEASE
( O
Mps1p B_LOCATION/B_SPECIES[BIO]
- B_LOCATION/I_SPECIES[BIO]
like B_LOCATION/I_SPECIES[BIO]
pombe B_LOCATION/I_SPECIES[BIO]
homolog B_LOCATION/I_SPECIES[BIO]
) O
, O
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
, O
that O
is O
required O
for O
checkpoint O
activation O
in O
response O
to O
spindle O
defects O
. O

mph1 B_GENE/B_DISEASE
functions O
upstream O
of O
mad2 B_GENE/B_BIO
, O
a O
previously O
characterized O
component O
of O
the O
spindle O
checkpoint O
. O

Hepatocyte B_GENE/B_MEASURE
growth I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
( O
HGF B_GENE
) O
is O
an O
inducible O
cytokine O
that O
is O
essential O
for O
the O
normal O
growth O
and O
development O
of O
various O
tissues O
, O
such O
as O
the O
liver O
. O

However O
, O
all O
pathophysiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reported O
to O
date B_TIME[MEASURE]/B_PERSON
have O
been O
carried O
out O
during O
or O
immediately O
after O
IVOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
utilization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

reduced O
concentrations O
of O
antithrombin B_GENE
III I_GENE
, O
plasminogen B_GENE
, O
( O
free O
) O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
and O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
in O
some O
patients O
but O
were O
not O
associated O
with O
either O
thrombosis O
or O
lupus O
anticoagulant O
. O

The O
first B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
decision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
management B_PERSON/B_MEASURE
is O
to O
consider O
cardioversion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
which O
can O
be O
achieved O
in O
suitable B_PERSON/B_LOCATION
cases I_PERSON/I_LOCATION
electrically O
, O
or O
pharmacologically O
with O
a O
class B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiarrhythmic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
propafenone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Structure O
and O
chromosomal O
localization O
of O
the O
human O
gene O
of O
the O
phosphotyrosyl B_GENE/B_MEASURE
phosphatase I_GENE/I_MEASURE
activator I_GENE/I_MEASURE
( O
PTPA B_GENE/B_DISEASE
) O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
chest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wall I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
maximum B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
35 B_MEASURE
. O
6 B_MEASURE
cmH2O I_MEASURE
. O
L B_OTHER/B_MEASURE
- O
1 B_MEASURE/B_LOCATION
. O
SEC B_ORGANIZATION/B_MEASURE
- O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
2 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
SE I_MEASURE/I_LOCATION
) O
at O
0 B_MEASURE
. O
2 B_MEASURE
Hz I_MEASURE
- O
10 B_MEASURE/B_LOCATION
ml I_MEASURE/I_LOCATION
and O
decreased O
with O
increasing O
f O
and O
VT B_PROTEIN[GENE]/B_MEASURE
, O
although O
the O
VT B_MEASURE/B_DISEASE
effect I_MEASURE/I_DISEASE
diminished O
at O
the O
higher B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
f I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Since O
1988 B_MEASURE/B_ENT
Modulit I_MEASURE/I_ENT
- O
SZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
20 B_NUMBER[MEASURE]
has O
been O
tested O
for O
localization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nephroliths B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
ureteroliths B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

JCAHO B_PERSON/B_ORGANIZATION
moves O
to O
rewrite O
many B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
rules I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
to O
lessen O
hospitals B_DISEASE/B_MEASURE
' I_DISEASE/I_MEASURE
regulatory I_DISEASE/I_MEASURE
burden I_DISEASE/I_MEASURE
. O

These O
transcripts O
directed O
the O
synthesis O
of O
three O
proteins O
: O
the O
virus B_GENE
trans I_GENE
- I_GENE
activator I_GENE
protein I_GENE
( O
EIAV B_GENE/B_DISEASE
Tat I_GENE/I_DISEASE
) O
encoded O
by O
ORF O
S1 O
, O
a O
protein O
of O
unknown O
function O
encoded O
by O
ORF O
S2 O
, O
and O
the O
virus O
envelope B_GENE
glycoprotein I_GENE
. O

However O
, O
no O
significant B_MEASURE
difference I_MEASURE
in O
either O
the O
Valsalva B_MEASURE/B_PROTEIN[GENE]
ratio B_MEASURE/I_PROTEIN[GENE]
or O
delta B_MEASURE
SBP I_MEASURE
was O
found O
between O
diabetic B_PERSON/B_BIO
patients I_PERSON/I_BIO
and O
controls B_PERSON/B_BIO
. O

transmural B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
metabolic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
heterogeneity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O
high B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
therefore O
investigated O
whether O
the O
promoter O
activity O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TRH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
directly O
regulated O
by O
RA O
using O
a O
transient O
transfection O
assay O
into O
CV O
- O
1 O
cells O
. O

Spinal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injuries B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
a O
multiple B_DISEASE/B_PERSON
trauma I_DISEASE/I_PERSON
patient I_DISEASE/I_PERSON
. O

The O
unusual O
properties O
of O
TRAC B_ENZYME[GENE]/B_MEASURE
activity O
and O
its O
relationship O
, O
if O
any O
, O
with O
the O
enigmatic O
Ku B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
are O
discussed O
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
radioprotective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
mercaptoethylamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analogs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
their O
electron B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
functional B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
compensation B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
after O
its O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
destruction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
a O
neoplasm B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
RNA B_GENE/B_BIO
, O
whether O
antisense B_GENE
, O
ribozyme B_GENE/B_BIO
, O
or O
RNA B_GENE/B_BIO
aptamer I_GENE/I_BIO
, O
must O
be O
efficiently O
transcribed O
, O
stabilized O
against O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
degradation B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
, O
folded O
correctly O
, O
and O
directed O
to O
the O
part B_MEASURE/B_LOCATION
of O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
where O
it O
can O
be O
most O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
isolated O
and O
determined O
the O
complete O
nucleotide O
sequence O
of O
another O
operon O
, O
cpeCD B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
that O
encodes O
the O
linker O
proteins O
associated O
with O
phycoerythrin B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
hexamers B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
phycobilisome B_BIO
. O

A B_PERSON/B_LOCATION
. I_PERSON/I_LOCATION
thaliana I_PERSON/I_LOCATION
cystathionine I_PERSON/I_LOCATION
beta I_PERSON/I_LOCATION
- I_PERSON/I_LOCATION
lyase I_PERSON/I_LOCATION
exhibits O
22 O
% O
sequence O
identity O
with O
the O
E O
. O
coli O
corresponding O
enzyme O
and O
contains O
a O
70 O
amino O
acid O
N O
- O
terminal O
additional O
sequence O
compared O
with O
the O
bacterial O
protein O
. O

The O
enzyme B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ACC I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
catalyses O
the O
last O
step O
of O
ethylene O
biosynthesis O
in O
plants O
, O
converting O
1 O
- O
aminocyclopropane O
- O
1 O
- O
carboxylic O
acid O
( O
ACC O
) O
to O
ethylene O
. O

A O
99m B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tc I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
bone I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
focal B_DISEASE/B_MEASURE
area I_DISEASE/I_MEASURE
of O
an O
increased O
uptake B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
the O
site B_LOCATION/B_MEASURE
of O
the O
mass B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
below O
the O
calcaneus B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Renal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
evaluated O
in O
a O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
24 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
( O
21 B_TIME[MEASURE]/B_PERSON
men I_TIME[MEASURE]/I_PERSON
and O
3 B_PERSON/B_NUMBER[MEASURE]
women I_PERSON/I_NUMBER[MEASURE]
, O
mean O
age B_NUMBER[MEASURE]/B_PERSON
47 I_NUMBER[MEASURE]/I_PERSON
years I_NUMBER[MEASURE]/I_PERSON
) O
who O
had O
survived O
the O
malignant B_DISEASE_ADJECTIVE[DISEASE]
phase I_DISEASE_ADJECTIVE[DISEASE]
of O
hypertension B_DISEASE/B_LOCATION
during O
the O
period B_TIME[MEASURE]/B_DISEASE
of O
1969 B_MEASURE
- O
1979 B_MEASURE
. O

The O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guidelines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
clear B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
both O
clinical B_PERSON/B_EDU[ORGANIZATION]
and O
scientific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
grounds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

When O
expressed O
in O
thymidine B_GENE
kinase I_GENE
- O
deficient O
L O
cells O
or O
3T3 O
cells O
, O
C B_GENE
/ I_GENE
EBPalpha I_GENE
is O
detected O
in O
a O
protein O
complex O
which O
binds O
to O
the O
E2F B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O
in O
the O
promoters O
of O
the O
genes O
for O
E2F B_GENE
- I_GENE
1 I_GENE
and O
dihydrofolate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DHFR B_PROTEIN[GENE]/B_LOCATION
) O
. O

Members O
of O
the O
CRE B_GENE
- I_GENE
binding I_GENE
protein I_GENE
( O
CREB B_GENE/B_DISEASE
) O
/ O
activating B_GENE
transcription I_GENE
factor I_GENE
transcription O
family O
as O
well O
as O
members O
of O
the O
Jun B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Fos B_GENE/B_LOCATION
family O
have O
been O
shown O
to O
bind O
to O
this O
sequence O
. O

Csk B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
C B_GENE/B_LOCATION
- I_GENE/I_LOCATION
terminal I_GENE/I_LOCATION
Src I_GENE/I_LOCATION
kinase I_GENE/I_LOCATION
) O
is O
a O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
phosphorylates O
Src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tails I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
downregulation O
of O
Src B_GENE/B_NUMBER[MEASURE]
family O
members O
. O

Role O
of O
double B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stranded I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
mediating O
hypersensitivity O
of O
Fanconi O
anemia O
complementation O
group O
C O
cells O
to O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
double O
- O
stranded O
RNA O
. O

In O
clinical B_PERSON
stroke I_PERSON
cardiovascular I_PERSON
abnormalities I_PERSON
are O
frequently O
neglected O
although O
they O
occur O
more O
often O
than O
it O
is O
generally O
assumed O
. O

In O
the O
presence B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
100 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
1 B_NUMBER[MEASURE]
, O
thiopental B_MEASURE/B_LOCATION
50 B_MEASURE/I_LOCATION
microg B_MEASURE/I_LOCATION
mL B_MEASURE/I_LOCATION
- O
1 B_NUMBER[MEASURE]
) O
marked O
relaxation B_DISEASE
was O
observed O
( O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
up O
to O
- O
49 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
, O
05 B_MEASURE
; O
thiopental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
23 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
up O
to O
- O
67 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Our O
results O
suggest O
a O
dose O
- O
dependent O
activity O
of O
lysine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vasopressin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
the O
EEG O
, O
which O
might O
be O
similar O
to O
that O
observed O
in O
animal O
and O
man O
after O
administration O
of O
nicotine O
. O

mutations O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTEN I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Guanylyl B_GENE/B_LOCATION
cyclase I_GENE/I_LOCATION
C I_GENE/I_LOCATION
, O
the O
apparent O
guanylin B_GENE/B_PERSON
receptor I_GENE/I_PERSON
, O
was O
found O
in O
abundant O
amounts O
in O
the O
intestine O
by O
Northern O
analysis O
, O
and O
by O
the O
polymerase O
chain O
reaction O
or O
cDNA O
cloning O
it O
was O
also O
found O
in O
adrenal O
gland O
, O
airway O
epithelial O
cells O
, O
brain O
, O
and O
olfactory O
and O
tracheal O
mucosa O
. O

In O
the O
present O
study O
we O
have O
used O
Southern O
blot O
analysis O
to O
demonstrate O
that O
TSG6 B_GENE
is O
a O
single O
- O
copy O
gene O
in O
the O
human O
and O
murine O
species O
. O

reaction O
of O
aromatic O
/ O
heterocyclic O
sulfonamides O
possessing O
free O
amino O
, O
imino O
or O
hydrazino O
moieties O
with O
7 O
- O
chloro O
- O
4 O
- O
chloromethylcoumarin O
afforded O
a O
series O
of O
N O
- O
[ O
( O
7 O
- O
chloro O
- O
4 O
- O
coumarinyl O
) O
- O
methyl O
] O
- O
derivatives O
which O
showed O
effective O
inhibition O
of O
three O
carbonic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CA B_LOCATION/B_ORGANIZATION
) O
isozymes O
. O

As O
well O
, O
variation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
capillary B_MEASURE
size I_MEASURE
and O
density B_MEASURE/B_LOCATION
was O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
ventricles B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
fetal B_PERSON
and O
neonatal B_PERSON
periods I_PERSON
. O

The O
Polycomb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
group I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
involved O
in O
maintenance O
of O
the O
silenced O
state O
of O
several O
developmentally O
regulated O
genes O
. O

uncertainty O
exists O
about O
the O
function O
of O
these O
potential O
isoforms O
of O
the O
Cbfa1 B_GENE
gene I_GENE
. O

When O
using O
the O
high B_DISEASE/B_MEASURE
- O
impedance B_MEASURE/B_LOCATION
testing I_MEASURE/I_LOCATION
device I_MEASURE/I_LOCATION
, O
the O
post B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shock B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
initially O
displayed O
as O
' O
no O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' O
( O
Hewlett B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Packard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
XL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
or O
' O
asystole B_DISEASE_ADJECTIVE[DISEASE]
' O
( O
Physio B_TIME[MEASURE]/B_PERSON
- O
Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
LIFEPAK I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
9 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

Human B_GENE
CD38 I_GENE
, O
a O
leukocyte O
receptor O
and O
ectoenzyme O
, O
is O
a O
member O
of O
a O
novel O
eukaryotic O
gene O
family O
of O
nicotinamide B_GENE/B_NUMBER[MEASURE]
adenine I_GENE/I_NUMBER[MEASURE]
dinucleotide I_GENE/I_NUMBER[MEASURE]
+ I_GENE/I_NUMBER[MEASURE]
- I_GENE/I_NUMBER[MEASURE]
converting I_GENE/I_NUMBER[MEASURE]
enzymes I_GENE/I_NUMBER[MEASURE]
: O
extensive O
structural O
homology O
with O
the O
genes O
for O
murine B_SPECIES[BIO]/B_GENE
bone I_SPECIES[BIO]/I_GENE
marrow I_SPECIES[BIO]/I_GENE
stromal I_SPECIES[BIO]/I_GENE
cell I_SPECIES[BIO]/I_GENE
antigen I_SPECIES[BIO]/I_GENE
1 I_SPECIES[BIO]/I_GENE
and O
aplysian B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADP I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribosyl I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclase I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
noteworthy O
that O
under O
more O
physiological O
conditions O
mimicking O
the O
cellular O
GDP O
/ O
GTP O
ratio O
, O
Raf B_GENE/B_DISEASE
enhances O
the O
GEF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
stimulated O
GDP O
/ O
GTP O
exchange O
on O
Ha B_GENE
- I_GENE
Ras I_GENE
, O
in O
agreement O
with O
the O
sequestration O
of O
Ras B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
GTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
Raf B_GENE/B_DISEASE
. O

When O
O O
- O
2A O
/ O
c B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
myc I_PROTEIN[GENE]/I_MEASURE
cells O
underwent O
terminal O
differentiation O
APprog B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
lost O
and O
conventional O
AP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
DNA O
- O
binding O
activity O
became O
evident O
, O
particularly O
in O
astrocytes O
. O

From O
the O
deduced O
amino O
acid O
sequence O
, O
a O
molecular O
weight O
of O
38 O
, O
549 O
was O
calculated O
for O
the O
ADH B_GENE
subunit I_GENE
. O

The O
higher B_MEASURE
level I_MEASURE
of O
calories B_DISEASE
was O
attained O
by O
an O
increased O
intake B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
carbohydrates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

A O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fitting O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
moving O
192Ir B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
source I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
proposed O
. O

TAF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O
transcription O
constitutively O
and O
was O
mapped O
to O
the O
first O
32 O
amino O
acids O
of O
the O
A O
- O
region O
. O

For O
the O
first B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
short B_MEASURE
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
concurrent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
) O
tal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
different I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
- O
flavored B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
stimuli I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O
presented O
at O
the O
same B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
, O
one B_NUMBER[MEASURE]/B_PERSON
associated O
with O
simultaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
intragastric I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
an O
aversive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
product I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
hypertonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
great B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
vein I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
flow I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
became O
zero B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
due I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
cardiac B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrest I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
remained O
at O
zero B_MEASURE/B_LOCATION
for O
a O
moment B_TIME[MEASURE]
( O
dead B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
) O
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

internet B_ORGANIZATION/B_PERSON
is O
literally O
a O
world B_LOCATION/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
dialogue B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
discourse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
on O
any O
topic B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaginable I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
right O
at O
your O
fingertips B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

Attention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
devoted O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
action B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
thermoregulating O
nervous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
mechanisms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
mammalian B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
UPR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
is O
mediated O
by O
the O
cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
acting O
ER B_GENE/B_LOCATION
stress I_GENE/I_LOCATION
response I_GENE/I_LOCATION
element I_GENE/I_LOCATION
consisting O
of O
19 B_MEASURE/B_GENE
nt B_MEASURE/I_GENE
( O
CCAATN B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
9 B_NUMBER[MEASURE]/B_LOCATION
) O
CCACG B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
) O
, O
the O
CCACG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
which O
is O
considered O
to O
provide O
specificity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
formation B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
loop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
an O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
DNA B_NUMBER[MEASURE]/B_LOCATION
double I_NUMBER[MEASURE]/I_LOCATION
- O
strand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
break I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
repair I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
through O
recombination B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O

The O
cDNA O
is O
predicted O
to O
encode O
a O
polypeptide O
of O
298 O
amino O
acids O
that O
is O
homologous O
to O
the O
Y B_GENE
- I_GENE
box I_GENE
( I_GENE
inverted I_GENE
CCAAT I_GENE
) I_GENE
family I_GENE
of I_GENE
DNA I_GENE
- I_GENE
binding I_GENE
transcription I_GENE
factors I_GENE
. O

Toward O
this O
end O
, O
we O
used O
two O
cultured O
colon O
cancer O
cell O
lines O
; O
one O
( O
RKO O
) O
has O
a O
transcriptionally O
activated O
u B_GENE/B_LOCATION
- I_GENE/I_LOCATION
PAR I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
, O
and O
the O
other O
( O
GEO O
) O
overexpresses O
the O
receptor O
only O
after O
phorbol O
ester O
treatment O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
conserved O
cysteine O
residue O
( O
tom1C3235A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
in O
the O
hect B_GENE
- I_GENE
domain I_GENE
, O
supposed O
to O
be O
necessary O
for O
thioester O
- O
bond O
formation O
with O
ubiquitin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
, O
abolished O
the O
gene O
function O
. O

The O
two O
yeast B_PROTEIN[GENE]/B_BIO
pheromone I_PROTEIN[GENE]/I_BIO
receptors I_PROTEIN[GENE]/I_BIO
, O
the O
a B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alpha I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptors I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
share O
many O
functional O
similarities O
: O
both O
G B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
- I_GENE/I_LOCATION
coupled I_GENE/I_LOCATION
receptors I_GENE/I_LOCATION
couple O
to O
the O
same O
downstream O
signal O
transduction O
pathway O
, O
and O
both O
receptors O
undergo O
feedback O
regulation O
involving O
increased O
phosphorylation O
on O
their O
C O
- O
terminal O
domains O
in O
response O
to O
ligand O
challenge O
. O

Moreover O
, O
the O
formation O
of O
the O
complex O
between O
IclR B_GENE
and O
the O
operator O
/ O
promoter O
region O
has O
been O
found O
to O
be O
impaired O
by O
phosphoenol O
pyruvate O
but O
insensitive O
to O
acetate O
, O
acetyl O
- O
CoA O
, O
pyruvate O
, O
and O
oxaloacetate O
. O

After O
enzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrolysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
water B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
soluble I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fraction I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
is O
shown O
that O
28 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
again O
extractable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
DCM B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
which O
57 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
consists O
of O
unchanged B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
SC4453 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
is O
therefore O
the O
main B_PERSON/B_MEASURE
partner B_PERSON/I_MEASURE
of O
conjugated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
expression O
pattern O
of O
the O
reporter O
gene O
was O
compared O
to O
that O
of O
the O
endogenous B_GENE/B_PERSON
PDGFbeta I_GENE/I_PERSON
r I_GENE/I_PERSON
gene I_GENE/I_PERSON
. O

The O
two O
SH3 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
separated O
by O
a O
54 O
amino O
acid O
linker O
region O
, O
whose O
length O
is O
highly O
conserved O
in O
xenopus O
, O
chicken O
, O
and O
mamalian B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Crk I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
II I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
complex O
was O
eliminated O
by O
mutation O
of O
either O
half O
- O
site O
, O
and O
it O
was O
supershifted O
by O
antibodies O
against O
chicken B_GENE
ovalbumin I_GENE
upstream I_GENE
promoter I_GENE
- I_GENE
transcription I_GENE
factor I_GENE
( O
COUP B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
TF I_PROTEIN[GENE]/I_LOCATION
) O
. O

The O
fz B_GENE
- I_GENE
1 I_GENE
and O
fz B_GENE
- I_GENE
2 I_GENE
genes I_GENE
are O
widely O
expressed O
in O
rat O
tissues O
with O
the O
highest O
steady O
- O
state O
levels O
of O
mRNA O
in O
kidney O
, O
liver O
, O
heart O
, O
uterus O
, O
and O
ovary O
. O

fz B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
and I_GENE/I_PERSON
- I_GENE/I_PERSON
2 I_GENE/I_PERSON
mRNA I_GENE/I_PERSON
levels O
were O
greater O
in O
neonatal O
than O
in O
corresponding O
adult O
tissues O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
thyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
scan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
RAIU B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
attributable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
TSAb B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
were O
the O
AOAC B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
method I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
dilution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mercuric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
charcoal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
Carrez B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
2 B_TIME[MEASURE]/B_LOCATION
different I_TIME[MEASURE]/I_LOCATION
pH I_TIME[MEASURE]/I_LOCATION
values I_TIME[MEASURE]/I_LOCATION
; O
and O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sample B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
no O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Cytochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O
ultrastructural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
tegument B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
trematode B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
Megalodiscus I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
temperatus I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
this O
report O
, O
we O
establish O
that O
the O
heteromeric O
CCAAT B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
binding I_PROTEIN[GENE]/I_LOCATION
factor I_PROTEIN[GENE]/I_LOCATION
CBF I_PROTEIN[GENE]/I_LOCATION
is O
the O
major O
component O
of O
the O
C1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
C1F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
in O
human O
cells O
. O

A O
40 O
- O
fold O
stimulation O
of O
chloramphenicol B_GENE
acetyltransferase I_GENE
activity O
mediated O
by O
four O
tandem O
repeats O
of O
the O
SNE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
induced O
within O
2 O
h O
( O
and O
up O
to O
250 O
- O
fold O
within O
6 O
h O
) O
after O
addition O
of O
TPA O
in O
DNA O
- O
transfected O
U O
- O
937 O
cells O
, O
indicating O
that O
the O
stimulation O
appeared O
likely O
to O
be O
a O
true O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
mediated O
signal O
transduction O
event O
rather O
than O
a O
differentiation O
response O
. O

This O
increased O
frequency B_MEASURE
of O
infection B_DISEASE
has O
been O
accompanied O
by O
significant B_DISEASE
excess I_DISEASE
mortality I_DISEASE
. O

Deletion O
mutants O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CHOP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identify O
a O
region O
comprising O
nucleotides O
- O
75 O
to O
- O
104 O
required O
for O
both O
constitutive O
and O
ER O
- O
stress O
- O
inducible O
expression O
. O

The O
duration B_MEASURE/B_LOCATION
of O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elevations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
the O
peak B_MEASURE/B_PERSON
values I_MEASURE/I_PERSON
were O
influenced O
by O
day B_TIME[MEASURE]/B_LOCATION
of O
the O
cycle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
propose O
that O
the O
cDNA B_GENE
encodes O
an O
apical B_GENE
plasma I_GENE
membrane I_GENE
protein I_GENE
that O
plays O
a O
role B_MEASURE/B_PERSON
in O
the O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
amiloride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sensitive B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epithelial I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Electrophysiology B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pharmacology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
epicardial B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
endocardial B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
and O
M B_BODY_PART_OR_ORGAN_COMPONENT
cells I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
contrast O
, O
an O
N B_GENE/B_BIO
- I_GENE/I_BIO
terminal I_GENE/I_BIO
RNAP I_GENE/I_BIO
mutant I_GENE/I_BIO
that O
has O
a O
decreased O
capacity O
to O
bind O
single O
- O
stranded O
RNA O
forms O
halted O
complexes O
with O
much O
lower O
levels O
of O
stability O
than O
the O
WT O
enzyme O
, O
and O
these O
complexes O
are O
not O
stabilized O
by O
the O
presence O
of O
the O
NT O
strand O
. O

A O
cephalothoracophagus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
disymmetros I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
buffalo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
calf I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

A O
mouse O
brain O
cDNA O
library O
in O
lambdagt11 O
was O
screened O
for O
this O
association O
, O
and O
two O
positive O
clones O
encoding O
tyrosine B_GENE
phosphatase I_GENE
SH I_GENE
- I_GENE
PTP2 I_GENE
were O
isolated O
. O

Disorganization O
scores O
of O
the O
hypertrophy O
zone O
and O
trabecular O
bone O
were O
low O
, O
approaching O
normal O
( O
P O
< O
0 O
. O
05 O
) O
, O
for O
turkey O
poults O
fed O
on O
diets O
with O
phytase B_LOCATION/B_PROTEIN[GENE]
supplementation O
, O
and O
tibial O
abnormality O
scores O
were O
linearly O
decreased O
( O
P O
< O
0 O
. O
001 O
) O
as O
nP O
levels O
increased O
( O
zero O
score O
is O
considered O
normal O
) O
. O

repression O
was O
strictly O
dependent O
on O
the O
presence O
of O
upstream O
Oshox1 B_GENE/B_LOCATION
binding O
sites O
in O
the O
reporter O
gene O
constructs O
and O
a O
function O
of O
the O
N O
- O
terminal O
region O
of O
Oshox1 B_GENE
, O
preceding O
the O
homeodomain B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Ondansetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
thus O
an O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
first I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
line B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
antiemetic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
in O
children B_PERSON/B_BIO
undergoing O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

To O
elucidate O
the O
molecular O
mechanism O
by O
which O
the O
Ras B_GENE/B_DISEASE
signaling O
pathway O
activates O
a O
cell O
- O
type O
- O
specific O
gene O
, O
we O
have O
used O
the O
pituitary B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolactin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
rPRL B_PROTEIN[GENE]/B_DISEASE
) O
promoter O
as O
a O
target O
of O
oncogenic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ras I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Raf B_GENE/B_DISEASE
in O
GH4 O
rat O
pituitary O
cells O
. O

The O
human O
RFC B_GENE/B_BIO
- I_GENE/I_BIO
1 I_GENE/I_BIO
gene I_GENE/I_BIO
differs O
from O
the O
mouse O
and O
hamster O
genes O
both O
in O
terms O
of O
the O
total O
number O
of O
exons O
and O
in O
regard O
to O
alternatives O
of O
exon O
1 O
which O
encode O
5 O
' O
end O
heterogeneity O
. O

Type B_PERSON/B_BIO
C I_PERSON/I_BIO
units I_PERSON/I_BIO
summate O
the O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
two B_NUMBER[MEASURE]/B_COLOR
- O
tone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
and O
show O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
no O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

HGF B_MEASURE/B_GENE
treatment O
increased O
cyclin B_GENE
A I_GENE
, O
cyclin B_GENE
G1 I_GENE
and O
nuclear O
transcriptional O
factor O
( O
NFkappaB B_GENE/B_DISEASE
) O
protein O
expression O
. O

Since O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serotonin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
primarily O
produced O
peripherally O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
some O
aspect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
serotonin I_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DISEASE_ADJECTIVE[DISEASE]
is O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
major B_DISEASE/B_LOCATION
depression I_DISEASE/I_LOCATION
. O

Although O
several B_NUMBER[MEASURE]/B_PERSON
large B_NUMBER[MEASURE]/I_PERSON
waterborne B_NUMBER[MEASURE]/I_PERSON
outbreaks B_NUMBER[MEASURE]/I_PERSON
occurred O
during O
the O
past B_TIME[MEASURE]/B_ORGANIZATION
decade I_TIME[MEASURE]/I_ORGANIZATION
, O
most B_NUMBER[MEASURE]/B_PERSON
were O
in O
small B_LOCATION/B_SPORT[ENT]
communities I_LOCATION/I_SPORT[ENT]
. O

cytogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
mixte B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
karyotype I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
: O
mosaicim B_MEASURE/B_PERSON
46 I_MEASURE/I_PERSON
XX I_MEASURE/I_PERSON
/ O
46 B_MEASURE
XY I_MEASURE
with O
a O
ratio B_MEASURE/B_LOCATION
of O
a O
80 B_NUMBER[MEASURE]
/ O
20 B_MEASURE
. O

The O
1 O
. O
6 O
- O
kb O
cDNA O
( O
CBF B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
A I_PROTEIN[GENE]/I_MEASURE
) O
encoding O
285 O
amino O
acids O
( O
AA O
) O
was O
obtained O
, O
and O
a O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fusion I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
bacterially O
produced O
from O
the O
cDNA O
, O
bound O
to O
DNA O
fragments O
containing O
several O
CArG O
boxes O
. O

Mutant B_PERSON/B_GENE
M I_PERSON/I_GENE
proteins I_PERSON/I_GENE
were O
tested O
for O
their O
ability O
to O
complement O
growth O
of O
the O
temperature O
- O
sensitive O
M B_DISEASE/B_SPECIES[BIO]
protein B_DISEASE/I_SPECIES[BIO]
mutant B_DISEASE/I_SPECIES[BIO]
virus O
tsO23 O
at O
the O
nonpermissive O
temperature O
. O

In O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
we O
review O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
smoking B_DISEASE
and O
lung B_DISEASE
cancer I_DISEASE
among O
Latinos B_PERSON/B_ORGANIZATION
, O
including O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
unpublished I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
technical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
yjr041c B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
haploid O
cells O
gave O
rise O
to O
microcolonies O
comprising O
about O
20 O
to O
50 O
cells O
. O

Despite O
these O
high O
initial O
rates O
of O
transcription O
, O
of O
all O
the O
promoter O
constructs O
only O
LAT B_DISEASE/B_PROTEIN[GENE]
- O
LTR O
was O
able O
to O
remain O
transcriptionally O
active O
after O
the O
establishment O
of O
a O
latent O
state O
. O

Two O
mutants O
, O
mapping O
at O
the O
HindIII B_LOCATION/B_MEASURE
site I_LOCATION/I_MEASURE
( O
between O
the O
consensus O
sequences O
) O
of O
the O
pSC101 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tetA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
studied O
: O
MA2 O
corresponds O
to O
a O
4 O
BP O
deletion O
between O
positions O
- O
12 O
and O
- O
15 O
; O
B30 O
bears O
a O
44 O
BP O
insertion O
C O
( O
ta O
) O
21 O
G O
at O
the O
HindIII B_LOCATION
site I_LOCATION
. O

We O
concluded O
that O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O
the O
feasibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
usefulness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N B_OTHER/B_MEASURE
- O
of O
- O
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
rheumatology B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sci B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Effects O
of O
timepidium O
bromide O
( O
TB O
; O
anticholinergic O
agent O
) O
, O
acetylcholine O
( O
ACh O
) O
and O
neostigmine O
( O
Neost O
) O
on O
gastric O
and O
duodenal O
blood O
flow O
distribution O
were O
studied O
by O
the O
use O
of O
131I O
- O
labeled O
macroaggregated O
human O
serum O
albumin O
( O
MAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
in O
rabbits O
. O

These O
extrachromosomal B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
copies I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
isolated O
as O
covalently O
closed B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
lengths B_MEASURE/B_LOCATION
around O
3mu B_NUMBER[MEASURE]
. O

comparison O
of O
the O
footprint O
patterns O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
human I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPRT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O
that O
the O
in O
vivo O
binding O
of O
regulatory O
proteins O
between O
these O
species O
is O
generally O
conserved O
but O
not O
identical O
. O

Here O
, O
we O
describe O
the O
three B_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_LOCATION
structure B_MEASURE/I_LOCATION
of O
the O
enzyme B_ENZYME[GENE]/B_LOCATION
from O
Escherichia B_BACTERIUM[BIO]
colidetermined O
and O
refined O
to O
2 B_MEASURE
. O
0 B_MEASURE
A O
resolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

Our O
Northern O
and O
Southern O
blot O
analyses O
of O
meningiomas O
clearly O
suggest O
the O
CLH B_GENE
- I_GENE
22 I_GENE
gene I_GENE
may O
be O
involved O
in O
the O
tumor O
development O
and O
can O
be O
considered O
as O
a O
candidate O
for O
a O
tumor O
suppressor O
. O

Plasmodium B_DISEASE_ADJECTIVE[DISEASE]
vivax I_DISEASE_ADJECTIVE[DISEASE]
malaria I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
genetic B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
physical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O
a O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
yeast B_GENE/B_BIO
RNA I_GENE/I_BIO
- O
binding O
proteins B_LOCATION/B_GENE
in O
transcriptional B_GENE/B_BIO
regulation B_GENE/I_BIO
. O

Population B_PERSON/B_TIME[MEASURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
105 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
followed O
prospectively O
( O
male B_PERSON/B_MEASURE
: O
87 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
age B_TIME[MEASURE]/B_PERSON
: O
56 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_TIME[MEASURE]/B_PERSON
) O
; O
clinical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
evaluation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
performed O
in O
the O
1st B_SEQUENCE[MEASURE]
, O
3rd B_SEQUENCE[MEASURE]
and O
6th B_SEQUENCE[MEASURE]
month I_SEQUENCE[MEASURE]
, O
SEKG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
4th B_SEQUENCE[MEASURE]
month I_SEQUENCE[MEASURE]
and O
recatheterization B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
angiographic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
the O
6th B_TIME[MEASURE]
month I_TIME[MEASURE]
. O

All O
other B_DISEASE/B_PERSON
cysts I_DISEASE/I_PERSON
showed O
a O
unilocular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
purely O
cystic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
with O
homogeneous B_DISEASE/B_MEASURE
fluids I_DISEASE/I_MEASURE
, O
although O
the O
T2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relaxation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
times I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
four B_DISEASE/B_PERSON
lesions I_DISEASE/I_PERSON
overlapped O
those O
of O
odontogenic B_NUMBER[MEASURE]/B_PERSON
keratocysts I_NUMBER[MEASURE]/I_PERSON
. O

Genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
respiratory B_DISEASE/B_LOCATION
diseases I_DISEASE/I_LOCATION
. O

The O
c B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Jun I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
delta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibits O
neuroendocrine O
promoter O
activity O
in O
a O
DNA O
sequence O
- O
and O
pituitary O
- O
specific O
manner O
. O

Cross B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sectional B_LOCATION/B_ORGANIZATION
studies I_LOCATION/I_ORGANIZATION
continue O
to O
dominate O
. O

The O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
medical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
facilities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
prognosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
patient B_PERSON
with O
tetanus B_DISEASE
specially O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
considering O
at O
the O
same B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
the O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
disease B_DISEASE
and O
the O
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
deserve O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
order B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
contribute O
to O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
assistance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
patients B_PERSON
with O
tetanus B_DISEASE
. O

differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
not O
found O
in O
colons B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
SEM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

increasing O
the O
height B_MEASURE/B_DISEASE
of O
the O
agar B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
column I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
overlying O
the O
SN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fabric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
diminished O
the O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
on O
microbial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O

Neither O
raw B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
nor O
retrograded O
resistant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
starch I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
lowers O
fasting O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
healthy B_PERSON/B_BIO
normolipidemic B_PERSON/I_BIO
subjects B_PERSON/I_BIO
. O

( O
5 B_MEASURE
) O
. O

Hepatitis B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
B I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
markers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
Lancashire B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
police I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
officers I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
two I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
NAAR B_LOCATION/B_DISEASE
and O
PLA B_LOCATION/B_PROTEIN[GENE]
) O
, O
no O
variation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
serum B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
protease B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
observed O
. O

Maximum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
likelihood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
estimation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
covariance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
truncated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

A O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
cef B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
intravenously O
to O
11 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
autoimmune B_DISEASE/B_GENE
diseases I_DISEASE/I_GENE
and O
varying O
degrees B_MEASURE
of O
renal B_DISEASE
impairment I_DISEASE
( O
Group B_ORGANIZATION/B_MEASURE
I O
CLCR O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
50 B_MEASURE
ml I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
, O
Group B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
CLCR B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
50 B_MEASURE
ml I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
) O
. O

The O
liver O
- O
specific O
sequence O
contains O
unique O
consensus O
sites O
for O
phosphorylation O
by O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gentamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
kidney B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
functional B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
state B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
experimental B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pyelonephritis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

They O
represent O
a O
physiologically O
more O
meaningful B_MEASURE
pattern I_MEASURE
than O
the O
arithmetic B_MEASURE/B_PERSON
mean B_MEASURE/I_PERSON
with O
standard B_MEASURE/B_PERSON
deviation I_MEASURE/I_PERSON
. O

The O
Valpha B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Vbeta B_GENE
domains I_GENE
have O
the O
canonical O
features O
of O
known O
teleost B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mammalian I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TCR I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
V I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
conserved O
residues O
in O
the O
beginning O
of O
FR2 B_PROTEIN[GENE]/B_LOCATION
and O
at O
the O
end O
of O
FR3 B_GENE
. O

Whether O
this O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
preferential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repair I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
to O
be O
explained O
by O
a O
defect B_DISEASE_ADJECTIVE[DISEASE]
in O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
or O
in O
general B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
unclear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
examines O
LEIBNIZ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
idea I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
Veterinary B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medicine I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
biographical B_LOCATION/B_PERSON
context I_LOCATION/I_PERSON
. O

Dipetalonema B_BACTERIUM[BIO]/B_MEASURE
( O
Acanthocheilonema B_DISEASE/B_PROTEIN[GENE]
) O
didelphis B_BACTERIUM[BIO]/B_PERSON
SP I_PERSON
. O

n B_OTHER/B_MEASURE
. O

However O
, O
the O
MCMI B_LOCATION/B_DISEASE
- O
III B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
magnitude B_MEASURE
compared O
with O
the O
MCMI B_LOCATION/B_DISEASE
- O
II B_NUMBER[MEASURE]/B_PROTEIN[GENE]
. O

While O
there O
is O
growing O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
perception B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
imagery B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
share O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neural B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
F B_OTHER/B_LOCATION
. O
shows O
intact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imagery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
face B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
a O
massive B_DISEASE
perceptual I_DISEASE
deficit I_DISEASE
in O
form B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
vision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
challenges O
recent B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestions I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
these O
two B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
psychological B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
processes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
share O
common B_LOCATION
input I_LOCATION
pathways I_LOCATION
in O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
ethnic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
made O
of O
8947 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
central B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CNS B_DISEASE/B_LOCATION
) O
tumors B_DISEASE
seen O
at O
the O
Armed B_LOCATION/B_ORGANIZATION
Forces B_LOCATION/I_ORGANIZATION
Institute B_LOCATION/I_ORGANIZATION
of O
Pathology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
AFIP B_DISEASE/B_ORGANIZATION
) O
, O
Washington B_LOCATION/B_PERSON
, O
DC B_LOCATION
, O
from O
1971 B_MEASURE
to O
1985 B_MEASURE
. O

The O
exact O
function O
of O
IP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
yet O
known O
, O
but O
it O
may O
play O
a O
role O
in O
gamma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
immune O
reactions O
. O

The O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressed O
from O
these O
chimeric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
COS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
assessed O
by O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
by O
metabolic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labeling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
followed O
by O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SDS B_PROTEIN[GENE]/B_DISEASE
- O
PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
this O
report O
, O
we O
demonstrate O
that O
FRS2 B_GENE
forms O
a O
complex O
with O
the O
N B_GENE/B_MEASURE
- I_GENE/I_MEASURE
terminal I_GENE/I_MEASURE
SH2 I_GENE/I_MEASURE
domain I_GENE/I_MEASURE
of O
the O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Shp2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
response O
to O
FGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O
. O

It O
is O
concluded O
that O
the O
drinking B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
ampules I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
VP B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
16 B_MEASURE
- O
213 B_MEASURE
can O
be O
replaced O
with O
the O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
capsules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
a O
recommended O
initial B_MEASURE
dose I_MEASURE
of O
100 B_MEASURE
- O
130 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
m2 B_MEASURE
given O
in O
5 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
courses I_TIME[MEASURE]/I_LOCATION
every O
21 B_MEASURE
- O
28 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

The O
H5 B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
: O
DH5 B_PROTEIN[GENE]
( O
all O
amino O
acids O
in O
D O
configuration O
) O
and O
H5F B_PROTEIN[GENE]/B_BIO
( O
where O
all O
His O
are O
replaced O
by O
Phe O
at O
positions O
3 O
, O
7 O
, O
8 O
, O
15 O
, O
18 O
, O
19 O
, O
21 O
) O
. O

Although O
the O
number B_MEASURE/B_ORGANIZATION
of O
kits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
increased O
, O
the O
precision B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O
improved O
, O
showing O
that O
more B_NUMBER[MEASURE]/B_PERSON
robust I_NUMBER[MEASURE]/I_PERSON
methods I_NUMBER[MEASURE]/I_PERSON
are O
now O
employed O
. O

These O
results O
establish O
that O
the O
DNA O
fragment O
we O
have O
isolated O
contains O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gp130 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
interleukin B_GENE/B_DISEASE
- I_GENE/I_DISEASE
6 I_GENE/I_DISEASE
type I_GENE/I_DISEASE
cytokines I_GENE/I_DISEASE
may O
influence O
the O
activity O
of O
this O
promoter O
via O
activated O
STATs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
targeted O
to O
the O
GAL1 B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
by O
fusing O
with O
the O
Gal4p B_GENE
DNA I_GENE
- I_GENE
binding I_GENE
domain I_GENE
, O
Sko1p B_GENE
acts O
as O
an O
Ssn6 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Tup1p B_MEASURE/B_BIO
- O
dependent O
repressor O
regulated O
by O
osmotic O
stress O
. O

The O
unexpected O
prevalence O
of O
c B_GENE
- I_GENE
myc I_GENE
and O
alpha B_GENE
- I_GENE
tubulin I_GENE
in O
the O
S O
- O
phase O
library O
is O
supported O
by O
Northern O
analysis O
of O
RNA O
from O
phase O
- O
synchronous O
cells O
. O

Growth O
factors O
promote O
cell O
survival O
through O
phosphorylation O
of O
Bad B_GENE
, O
resulting O
in O
its O
dissociation O
from O
Bcl B_GENE
- I_GENE
2 I_GENE
and O
Bcl B_GENE
- I_GENE
x I_GENE
( I_GENE
L I_GENE
) I_GENE
and O
its O
association O
with O
14 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3tau I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
representative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
patients B_PERSON/B_BIO
undergoing O
open B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
radical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
nephrectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
for O
clinical B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
T1 B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
T2 B_DISEASE/B_LOCATION
lesions I_DISEASE/I_LOCATION
was O
also O
identified O
. O

By O
applying O
a O
sufficiently O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
crusher I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gradient I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
EPI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pulse I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
temporal B_MEASURE
variation I_MEASURE
induced O
by O
SSFP B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbance B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
suppressed O
due B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
diffusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
in O
each O
case O
in O
which O
either O
the O
DQ B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
- I_GENE/I_MEASURE
or I_GENE/I_MEASURE
DQ I_GENE/I_MEASURE
beta I_GENE/I_MEASURE
- I_GENE/I_MEASURE
chain I_GENE/I_MEASURE
was O
exchanged O
, O
major O
alterations O
or O
reversals O
of O
this O
pattern O
of O
interaction O
were O
observed O
. O

Only O
the O
native O
structure O
of O
phosphorylated O
ERK B_GENE
was O
recognized O
by O
VHR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
was O
inactivated O
with O
a O
second O
- O
order O
rate O
constant O
of O
40 O
, O
000 O
M O
- O
1 O
s O
- O
1 O
. O

From O
1998 B_MEASURE
to O
1999 B_MEASURE
, O
a O
large B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
community B_ORGANIZATION/B_LOCATION
- O
acquired O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tract I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
isolates I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
Streptococcus B_BACTERIUM[BIO]/B_DISEASE
pneumoniae I_BACTERIUM[BIO]/I_DISEASE
( O
n B_MEASURE
= O
566 B_MEASURE
) O
, O
Haemophilus B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
influenzae I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_MEASURE
= O
513 B_MEASURE
) O
and O
Moraxella B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
catarrhalis I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_MEASURE
= O
228 B_MEASURE
) O
were O
collected O
from O
15 B_LOCATION/B_MEASURE
centres I_LOCATION/I_MEASURE
in O
Australia B_LOCATION
, O
Hong B_LOCATION
Kong I_LOCATION
, O
Japan B_LOCATION
, O
China B_LOCATION
, O
the O
Philippines B_LOCATION
, O
Singapore B_LOCATION
, O
South B_LOCATION
Africa I_LOCATION
and O
Taiwan B_LOCATION
through O
the O
SENTRY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Antimicrobial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Surveillance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Diethyldithiocarbamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stereotype I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
used O
an O
immobilized O
template O
- O
based O
assay O
to O
examine O
transcription O
termination O
by O
VA1 B_PROTEIN[GENE]/B_DISEASE
, O
7SL B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
Alu B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
templates O
and O
the O
role O
of O
transcript O
release O
in O
the O
pol B_LOCATION/B_GENE
III B_LOCATION/I_GENE
terminator O
- O
dependent O
inhibition O
of O
processing O
of O
B1 B_PROTEIN[GENE]/B_DISEASE
- O
Alu B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcripts O
. O

A O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zinc I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
finger I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
containing O
RNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
protein B_GENE/B_BACTERIUM[BIO]
conserved O
from O
fruitflies B_SPECIES[BIO]
to O
humans B_SPECIES[BIO]
. O

Although O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
activate O
ERK B_GENE
- I_GENE
1 I_GENE
in O
HepG2 O
cells O
, O
STAT3 B_GENE
transactivation O
and O
Ser O
( O
727 O
) O
phosphorylation O
were O
not O
reduced O
by O
using O
the O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
ERK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
inhibitor O
PD98059 O
or O
by O
overexpression O
of O
dominant O
- O
negative O
Raf B_GENE/B_DISEASE
. O

6 B_MEASURE/B_LOCATION
h O
after O
ingestion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
day B_TIME[MEASURE]
14 I_TIME[MEASURE]
, O
both O
TX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
PGI2 B_LOCATION/B_PROTEIN[GENE]
levels I_LOCATION/I_PROTEIN[GENE]
also O
significantly O
decreased O
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

Tritiated B_MEASURE
1 I_MEASURE
, O
24 B_MEASURE
, O
25 B_MEASURE
- O
trihydroxyvitamin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
synthesized O
biologically O
and O
used O
as O
tracer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
monitor O
the O
recovery B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
isolation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Joint O
ultrasonography O
demonstrating O
thickening O
of O
synoviae O
and O
tendons O
has O
become O
a O
useful O
non O
- O
invasive O
diagnostic O
tool O
, O
although O
it O
is O
not O
specific O
for O
beta B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amyloidosis O
, O
and O
results O
depend O
on O
observer O
experience O
. O

Immunofluorescence O
tests O
for O
Borrelia B_DISEASE/B_VIRUS[BIO]
burgdorferi B_DISEASE/I_VIRUS[BIO]
serum B_DISEASE/I_VIRUS[BIO]
antibodies B_DISEASE/I_VIRUS[BIO]
had O
positive O
results O
, O
but O
G O
- O
penicillin O
treatment O
was O
ineffective O
. O

The O
size B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
the O
predicted O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_GENE/B_LOCATION
sequence B_GENE/I_LOCATION
of O
the O
mouse B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
confirmed O
experimentally O
. O

Nuclear O
runoff O
assays O
show O
that O
complementation O
by O
HPV16 B_DISEASE/B_GENE
E7 B_DISEASE/I_GENE
restores O
the O
ability O
of O
the O
E1A B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
stimulate O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
at O
the O
level O
of O
transcription O
. O

Yet O
IL B_GENE
- I_GENE
2 I_GENE
and O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
are O
independently O
regulated O
, O
as O
demonstrated O
by O
their O
differential O
expression O
in O
certain O
T O
cell O
subsets O
, O
suggesting O
that O
the O
regulatory O
elements O
in O
these O
two O
genes O
must O
differ O
. O

We O
conclude O
that O
a O
0 O
. O
25 O
mg O
dose O
of O
triazolam O
does O
not O
effectively O
counteract O
a O
posture O
- O
induced O
sleep O
disturbance O
, O
but O
induces O
changes O
in O
the O
EEG O
spectra O
which O
are O
typical O
for O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O
. O

anisotropy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Hc2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
breadth B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
resistive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
polycrystalline B_LOCATION/B_PROTEIN[GENE]
YBa2Cu B_LOCATION/I_PROTEIN[GENE]
. O

microscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
colonies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
high B_MEASURE/B_LOCATION
percentage I_MEASURE/I_LOCATION
of O
histiocytes B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
identical I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
those O
seen O
in O
the O
patient B_PERSON/B_BIO
' O
s B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

functional O
uncoupling O
of O
the O
Janus B_GENE
kinase I_GENE
3 I_GENE
- O
Stat5 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O
in O
malignant O
growth O
of O
human O
T O
cell O
leukemia O
virus O
type O
1 O
- O
transformed O
human O
T O
cells O
. O

The O
herpesvirus B_GENE
entry I_GENE
mediator I_GENE
C I_GENE
( O
HveC B_LOCATION/B_DISEASE
) O
, O
previously O
known O
as O
poliovirus B_GENE
receptor I_GENE
- I_GENE
related I_GENE
protein I_GENE
1 I_GENE
( O
PRR1 B_GENE/B_LOCATION
) O
, O
and O
the O
herpesvirus B_GENE
Ig I_GENE
- I_GENE
like I_GENE
receptor I_GENE
( O
HIgR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
are O
the O
bona O
fide O
receptors O
employed O
by O
herpes O
simplex O
virus O
- O
1 O
and O
- O
2 O
( O
HSV O
- O
1 O
and O
- O
2 O
) O
for O
entry O
into O
the O
human O
cell O
lines O
most O
frequently O
used O
in O
HSV O
studies O
. O

4 O
- O
Hydroxyproline O
assays O
were O
performed O
to O
determine O
collagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
content O
. O

The O
combination O
of O
ICP47 B_GENE
and O
US11 B_MEASURE/B_GENE
rendered O
fibroblasts O
negative O
for O
surface B_GENE
class I_GENE
I I_GENE
MHC I_GENE
and O
allowed O
a O
class B_GENE/B_DISEASE
I I_GENE/I_DISEASE
MHC I_GENE/I_DISEASE
- O
low O
population O
of O
T O
cells O
to O
be O
sorted O
by O
flow O
cytometry O
. O

Although O
IRS B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
, I_GENE/I_MEASURE
- I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
, I_GENE/I_MEASURE
and I_GENE/I_MEASURE
- I_GENE/I_MEASURE
4 I_GENE/I_MEASURE
are O
similar O
in O
overall O
structure O
, O
IRS B_GENE/B_MEASURE
- I_GENE/I_MEASURE
3 I_GENE/I_MEASURE
is O
approximately O
50 O
% O
shorter O
and O
differs O
with O
respect O
to O
sites O
of O
tyrosine O
phosphorylation O
. O

The O
interaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
different B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
systems I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
microtubules B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
is O
a O
critical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
function I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
of O
these O
organelles B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
, O
we O
mapped O
a O
putative O
hnRNP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
U5 B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
demonstrated O
that O
p40CRS B_GENE
( O
hnRNP B_PROTEIN[GENE]/B_MEASURE
A1 I_PROTEIN[GENE]/I_MEASURE
) O
binding O
to O
that O
site O
correlates O
with O
CRS B_DISEASE/B_GENE
function O
. O

Sailer B_PERSON
, O
K B_OTHER/B_PERSON
. O

Copyright B_LOCATION/B_PERSON
2000 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

This O
element O
was O
required O
for O
both O
basal O
and O
activated O
expression O
and O
almost O
certainly O
functions O
as O
a O
TATA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interaction O
site O
. O

In O
HepG2 O
cells O
, O
SREBP B_GENE
- I_GENE
1c I_GENE
mRNA I_GENE
and O
precursor O
protein O
levels O
were O
induced O
by O
treatment O
with O
22 O
( O
R O
) O
- O
hydroxycholesterol O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
confirming O
that O
endogenous O
LXR B_PROTEIN[GENE]/B_MEASURE
- O
RXR B_PROTEIN[GENE]/B_DISEASE
activation O
can O
induce O
endogenous B_GENE
SREBP I_GENE
- I_GENE
1c I_GENE
expression O
. O

Univariate B_TIME[MEASURE]/B_PERSON
and O
multivariate B_MEASURE
analysis I_MEASURE
was O
used O
to O
calculate O
the O
5 B_NUMBER[MEASURE]
- O
year B_MEASURE/B_LOCATION
survival I_MEASURE/I_LOCATION
probabilities I_MEASURE/I_LOCATION
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
age B_MEASURE/B_LOCATION
( O
< B_OTHER/B_LOCATION
or O
= O
65 B_MEASURE
, O
> O
65 B_MEASURE
) O
, O
sex B_PERSON/B_DISEASE
, O
depth B_MEASURE/B_LOCATION
of O
invasion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
mucosal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
submucosal B_BODY_PART_OR_ORGAN_COMPONENT
) O
tumor B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
location I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O
middle B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
lower B_LOCATION/B_MEASURE
third I_LOCATION/I_MEASURE
) O
, O
gross B_MEASURE/B_LOCATION
appearance I_MEASURE/I_LOCATION
( O
type B_MEASURE/B_LOCATION
I O
, O
type B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
II I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
and O
type B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
III I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
size B_MEASURE/B_LOCATION
( O
< B_MEASURE/B_OTHER
or O
= O
1 B_MEASURE
. O
5 B_MEASURE
cm I_MEASURE
, O
> O
1 B_MEASURE
. O
5 B_MEASURE
cm I_MEASURE
) O
, O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
absence B_MEASURE/B_DISEASE
of O
lymph B_DISEASE
node I_DISEASE
metastasis I_DISEASE
, O
histological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
type I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
intestinal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
diffuse B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
, O
extent B_DISEASE/B_MEASURE
of O
lymphadenectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
limited O
or O
extended O
) O
, O
and O
type B_MEASURE/B_LOCATION
of O
gastrectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
total B_MEASURE/B_LOCATION
or O
distal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
subtotal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

This O
integration O
results O
in O
the O
production O
of O
MMTV B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
/ B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mdr3 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transcripts B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
originate O
from O
the O
antisense O
5 B_GENE/B_LOCATION
' B_GENE/I_LOCATION
LTR B_GENE/I_LOCATION
of O
the O
provirus O
. O

In O
32 B_NUMBER[MEASURE]/B_PERSON
of O
them O
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
an O
exercise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
performance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
heart B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
submaximal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exercise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
VO2 B_MEASURE
, O
170 B_TIME[MEASURE]
[ I_TIME[MEASURE]
bpm I_TIME[MEASURE]
] I_TIME[MEASURE]
) O
was O
compared O
with O
another O
index B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
physical B_DISEASE_ADJECTIVE[DISEASE]
performance I_DISEASE_ADJECTIVE[DISEASE]
capacity I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
heart B_MEASURE
rate I_MEASURE
: O
the O
ventilatory B_MEASURE/B_ORGANIZATION
threshold B_MEASURE/I_ORGANIZATION
. O

sequence O
comparisons O
reveal O
that O
the O
P B_GENE/B_BIO
. I_GENE/I_BIO
woesei I_GENE/I_BIO
GTP I_GENE/I_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
protein I_GENE/I_BIO
is O
strikingly O
related O
in O
sequence O
to O
eubacterial B_SPECIES[BIO]/B_GENE
FtsZ I_SPECIES[BIO]/I_GENE
and O
is O
marginally O
more O
similar O
to O
eukaryotic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
tubulins I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
than O
are O
bacterial B_SPECIES[BIO]/B_GENE
FtsZ I_SPECIES[BIO]/I_GENE
proteins I_SPECIES[BIO]/I_GENE
. O

Four O
of O
15 O
patients O
with O
R2 B_DISEASE/B_GENE
had O
rheumatoid O
arthritis O
and O
in O
two O
of O
these O
four O
cases O
the O
antibody O
was O
of O
the O
IgA B_PROTEIN[GENE]/B_DISEASE
class O
. O

phosphate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
compounds B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
isolated B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
perfused O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
pH O
variation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
extracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PCO2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
bicarbonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
Dbl B_GENE
are O
members O
of O
a O
novel O
class O
of O
oncogene O
proteins O
that O
share O
significant O
sequence O
identity O
in O
a O
approximately O
250 O
- O
amino O
- O
acid O
domain O
, O
designated O
the O
Dbl B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domain I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

serum O
AFP B_GENE
is O
a O
useful O
tumor O
marker O
for O
monitoring O
the O
results O
of O
therapy O
. O

The O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
equivalency I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
a O
short B_MEASURE/B_PERSON
form B_MEASURE/I_PERSON
and O
the O
long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
Multiple B_TIME[MEASURE]/B_DISEASE
affect O
Adjective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Check I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
revised O
( O
MAACL B_LOCATION/B_DISEASE
- O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Zuckerman B_PERSON
& O
Lubin B_PERSON
, O
1985 B_MEASURE
) O
was O
studied O
by O
correlating O
both O
forms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
MAACL B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
R B_OTHER/B_PROTEIN[GENE]
with O
the O
State B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
trait I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Personality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Inventory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
Spielberger B_PERSON
, O
1995 B_MEASURE
) O
; O
the O
affect B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scale I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Bradburn B_PERSON
, O
1969 B_MEASURE
) O
; O
and O
the O
sensation B_DISEASE/B_GENE
seeking O
Scale B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Zuckerman B_PERSON
, O
1978 B_MEASURE
) O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
processing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
as O
a O
function B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intensity B_MEASURE/B_LOCATION
is O
modified O
not O
only O
at O
the O
retina B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
but O
also O
at O
later B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
processing I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sites I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
masked O
toxins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
the O
exotoxin B_BIO
complex I_BIO
of O
Staphylococcus B_LOCATION/B_BACTERIUM[BIO]
pyogenes I_LOCATION/I_BACTERIUM[BIO]
und I_LOCATION/I_BACTERIUM[BIO]
Cl I_LOCATION/I_BACTERIUM[BIO]
. O
perfringens B_BACTERIUM[BIO]/B_PERSON
; O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
their O
existence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
clarifying O
of O
the O
masking B_DISEASE/B_BIO
mechanism I_DISEASE/I_BIO
. O

Unlike O
LANA1 B_GENE
, O
LANA2 B_GENE/B_LOCATION
does O
not O
elicit O
a O
serologic O
response O
from O
patients O
with O
KS O
, O
PEL O
, O
or O
CD O
as O
measured O
by O
Western O
blot O
hybridization O
. O

However O
, O
this O
posttranslational O
modification O
of O
the O
gar2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
does O
not O
appear O
to O
be O
essential O
for O
normal O
production O
of O
18S B_GENE
rRNA I_GENE
. O

Here O
, O
we O
analyzed O
the O
interaction O
of O
CYT B_GENE
- I_GENE
18 I_GENE
with O
a O
small O
RNA O
( O
P4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
corresponding O
to O
the O
isolated O
P4 B_GENE/B_LOCATION
- B_GENE/I_LOCATION
P6 B_GENE/I_LOCATION
domain B_GENE/I_LOCATION
of O
the O
N B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crassa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mitochondrial I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
large I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
intron I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
deduced O
amino O
acid O
sequence O
of O
PutR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
154 O
amino O
acid O
residues O
) O
showed O
homology O
to O
the O
small O
regulatory O
proteins O
Lrp B_GENE
, O
BkdR B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
and O
AsnC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
yeast O
cells O
reach O
a O
critical O
size O
in O
late O
G1 O
they O
simultaneously O
start O
budding O
, O
initiate O
DNA O
synthesis O
, O
and O
activate O
transcription O
of O
a O
set O
of O
genes O
that O
includes O
G1 B_GENE/B_DISEASE
cyclins I_GENE/I_DISEASE
CLN1 I_GENE/I_DISEASE
, O
CLN2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
many O
DNA O
synthesis O
genes O
. O

Functional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PET I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
preoperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cerebral B_DISEASE
arteriovenous I_DISEASE
malformations I_DISEASE
. O

In O
addition B_MEASURE/B_LOCATION
, O
269 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
a O
( O
Mus B_DISEASE/B_PROTEIN[GENE]
spretus B_DISEASE/I_PROTEIN[GENE]
x O
C57BL B_BIO/B_PROTEIN[GENE]
/ O
6J B_MEASURE
) O
F1 B_PROTEIN[GENE]/B_SPECIES[BIO]
x O
C57BL B_BIO/B_PROTEIN[GENE]
/ O
6J B_MEASURE/B_PERSON
interspecific I_MEASURE/I_PERSON
backcross I_MEASURE/I_PERSON
were O
also O
used O
to O
order O
marker B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loci I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
calculate O
intergene B_MEASURE/B_GENE
distances I_MEASURE/I_GENE
for O
this O
region B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Accordingly O
, O
superpeptide O
antigenic O
material O
was O
readily O
detected O
by O
immunoblotting O
cell O
extracts O
and O
enriched O
in O
vacuolar O
preparations O
of O
PrA B_GENE
deficient O
mutant O
cells O
. O

blockade O
of O
T O
cell O
activation O
using O
a O
surface O
- O
linked O
single O
- O
chain O
antibody O
to O
CTLA B_GENE
- I_GENE
4 I_GENE
( O
CD152 B_GENE
) O
. O

Water B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pair I_NUMBER[MEASURE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
three B_NUMBER[MEASURE]/B_LOCATION
- O
body B_MEASURE/B_LOCATION
potential I_MEASURE/I_LOCATION
of O
spectroscopic B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
AB B_LOCATION/B_MEASURE
initio I_LOCATION/I_MEASURE
calculations I_LOCATION/I_MEASURE
. O

4 O
) O
mutation O
of O
the O
three O
extracellular O
cysteine O
residues O
of O
GFKAR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
the O
two O
conserved O
cysteine O
residues O
( O
C305 O
and O
C385 O
) O
, O
located O
between O
two O
transmembrane O
segments O
, O
form O
a O
solvent O
- O
accessible O
disulfide O
bond O
. O

In O
this O
work O
, O
we O
have O
used O
Xenopus O
oocyte O
maturation O
as O
a O
read O
- O
out O
for O
examining O
the O
ability O
of O
the O
neu B_GENE/B_BIO
tyrosine I_GENE/I_BIO
kinase I_GENE/I_BIO
( O
p185neu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
to O
participate O
with O
the O
epidermal B_GENE/B_BIO
growth I_GENE/I_BIO
factor I_GENE/I_BIO
( I_GENE/I_BIO
EGF I_GENE/I_BIO
) I_GENE/I_BIO
receptor I_GENE/I_BIO
in O
a O
common O
signal O
transduction O
pathway O
. O

The O
best O
- O
studied O
neurotrophin O
, O
nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NGF B_GENE/B_LOCATION
) O
, O
is O
a O
major O
survival O
factor O
in O
sympathetic O
and O
sensory O
neurons O
and O
promotes O
differentiation O
in O
a O
well O
- O
studied O
model O
system O
, O
PC12 O
cells O
. O

In O
contrast O
, O
MAPK B_GENE/B_LOCATION
activation O
stimulated O
by O
the O
Gq B_GENE
- O
coupled O
alpha O
1B O
AR O
or O
M1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscarinic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholinergic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
unaffected O
by O
expression O
of O
beta B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ARKct I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
RasN17 B_GENE
expression O
or O
by O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B_GENE
delta I_GENE
Raf I_GENE
or O
by O
PKC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depletion O
. O

Transcriptional O
analysis O
indicates O
that O
human B_GENE/B_SPECIES[BIO]
TBP I_GENE/I_SPECIES[BIO]
functions O
poorly O
at O
promoters O
recognized O
by O
RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
at O
RNA B_GENE/B_LOCATION
Pol I_GENE/I_LOCATION
II I_GENE/I_LOCATION
promoters I_GENE/I_LOCATION
lacking O
a O
conventional O
TATA O
element O
. O

The O
steady O
- O
state O
levels O
of O
Cdk2 B_GENE
, O
Cdk4 B_GENE
and O
Cyclin B_GENE
A I_GENE
proteins I_GENE
were O
unaffected O
by O
HPR O
, O
while O
those O
of O
Cyclin B_GENE
D1 I_GENE
were O
significantly O
reduced O
in O
all O
three O
cell O
lines O
. O

mapping O
the O
5 O
' O
and O
3 O
' O
termini O
of O
TED B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
that O
the O
LTRs O
have O
a O
retroviral O
U3 O
- O
R O
- O
U5 O
structural O
organization O
that O
is O
capable O
of O
directing O
the O
synthesis O
of O
transcripts O
that O
represent O
potential O
substrates O
for O
reverse O
transcription O
and O
intermediates O
in O
transposition O
. O

Human B_PERSON/B_PROTEIN[GENE]
forearm I_PERSON/I_PROTEIN[GENE]
was O
used O
as O
a O
dummy B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ear I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
the O
electrode B_LOCATION
HN I_LOCATION
- O
5 B_MEASURE
was O
fixed O
thereon B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
and O
a O
sound B_MEASURE
stimulus I_MEASURE
of O
90dBnHL B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
delivered O
by O
the O
earphone B_PRODUCT[OBJECT]/B_PERSON
( O
NC B_LOCATION/B_PROTEIN[GENE]
- O
3 B_MEASURE
) O
. O

These O
proteins O
were O
detected O
by O
an O
antibody O
which O
recognizes O
the O
N O
- O
terminus O
of O
SRK3 B_GENE
and O
, O
in O
an O
F2 O
progeny O
segregating O
for O
the O
S3 B_GENE/B_MEASURE
haplotype I_GENE/I_MEASURE
, O
were O
only O
expressed O
in O
plants O
possessing O
the O
S3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
haplotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
43 B_PERSON/B_BIO
subjects B_PERSON/I_BIO
were O
compared O
during O
rapid B_DISEASE_ADJECTIVE[DISEASE]
weight I_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
and O
at O
identical B_MEASURE/B_PERSON
weights I_MEASURE/I_PERSON
during O
post B_DISEASE/B_MEASURE
- O
fast B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
weight I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
gain I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

The O
animals O
were O
followed O
over O
a O
1 O
- O
to O
6 O
- O
h O
posttraumatic O
course O
, O
and O
processed O
for O
the O
LM O
and O
TEM O
visualization O
of O
HRP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Total B_MEASURE/B_LOCATION
body I_MEASURE/I_LOCATION
water I_MEASURE/I_LOCATION
and O
distribution B_MEASURE/B_LOCATION
space I_MEASURE/I_LOCATION
of O
Na24 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
women B_PERSON/B_MEASURE
with O
various B_DISEASE/B_LOCATION
body I_DISEASE/I_LOCATION
weight I_DISEASE/I_LOCATION
. O

Three O
experiments O
using O
20 O
microM O
2 O
- O
( O
hydroxyamino O
) O
- O
1 O
- O
methyl O
- O
6 O
- O
phenylimidazo O
[ O
4 O
, O
5 O
- O
b O
] O
pyridine O
( O
N O
- O
OH O
- O
PhIP O
) O
were O
performed O
to O
induce O
mutations O
in O
the O
dihydrofolate B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
reductase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
DHFR B_PROTEIN[GENE]/B_LOCATION
) O
gene O
of O
a O
hemizygous O
Chinese O
hamster O
ovary O
( O
Cho O
) O
cell O
line O
( O
UA21 O
) O
. O

This O
is O
mediated O
by O
vascular B_DISEASE/B_GENE
remodeling I_DISEASE/I_GENE
, O
an O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
results O
in O
a O
change B_TIME[MEASURE]
in O
the O
geometry B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessel I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
results O
separate O
these O
factors O
into O
four O
regulatory O
classes O
: O
( O
i O
) O
constitutive O
factors O
, O
such O
as O
Oct B_GENE
- I_GENE
1 I_GENE
and O
probably O
Sp1 B_GENE
, O
that O
are O
expressed O
in O
thymocytes O
at O
all O
stages O
; O
( O
ii O
) O
inducible O
factors O
, O
such O
as O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
and O
complexes O
binding O
to O
the O
region O
of O
a O
CD28 B_GENE
response I_GENE
element I_GENE
, O
that O
can O
be O
activated O
in O
all O
thymocytes O
, O
including O
those O
cells O
( O
CD4 B_GENE
+ I_GENE
CD8 I_GENE
+ I_GENE
TcRlow I_GENE
) O
that O
can O
undergo O
selection O
; O
( O
III O
) O
inducible O
factors O
, O
such O
as O
NF B_GENE
- I_GENE
AT I_GENE
and O
AP B_GENE
- I_GENE
1 I_GENE
, O
that O
can O
be O
activated O
in O
mature O
( O
CD4 B_GENE/B_PERSON
+ I_GENE/I_PERSON
CD8 I_GENE/I_PERSON
- I_GENE/I_PERSON
TcRhigh I_GENE/I_PERSON
) O
and O
immature O
( O
CD4 B_GENE/B_PERSON
- I_GENE/I_PERSON
CD8 I_GENE/I_PERSON
- I_GENE/I_PERSON
TcR I_GENE/I_PERSON
- I_GENE/I_PERSON
) O
thymocytes O
alike O
but O
not O
in O
the O
transitional O
stages O
when O
the O
cells O
( O
CD4 B_GENE/B_MEASURE
+ I_GENE/I_MEASURE
CD8 I_GENE/I_MEASURE
+ I_GENE/I_MEASURE
TcRlow I_GENE/I_MEASURE
) O
are O
subject O
to O
selection O
; O
and O
( O
IV O
) O
a O
factor O
containing O
CREB B_GENE/B_MEASURE
, O
which O
can O
be O
activated O
in O
thymocytes O
of O
all O
developmental O
stages O
by O
culture O
but O
does O
not O
require O
specific O
induction O
. O

Thus O
, O
22 B_PERSON
% I_PERSON
of O
MDS B_PERSON
responded O
to O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plac I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

posterior B_DISEASE
osteophytes I_DISEASE
around O
the O
posterior B_LOCATION/B_MEASURE
edges I_LOCATION/I_MEASURE
of O
vertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
resulted O
in O
intervertebral B_DISEASE
insufficiency I_DISEASE
, O
and O
corresponded O
to O
hypertrophic B_DISEASE
spur I_DISEASE
in O
osteochondrosis B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

They O
showed O
moderate B_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
antifungal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
against O
a O
wide B_MEASURE
variety I_MEASURE
of O
fungi B_SPECIES[BIO]
and O
yeasts B_SPECIES[BIO]
including O
clinically O
important B_SPECIES[BIO]
pathogens I_SPECIES[BIO]
, O
and O
were O
highly O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
Candida B_SPECIES[BIO]/B_DISEASE
albicans I_SPECIES[BIO]/I_DISEASE
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
iv B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
im B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Of O
these O
four O
PP2C B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
, O
the O
expression O
of O
the O
PP2Cbeta B_SEQUENCE[MEASURE]/B_PERSON
gene I_SEQUENCE[MEASURE]/I_PERSON
has O
been O
reported O
to O
be O
tissue O
- O
specific O
and O
development O
- O
dependent O
. O

We O
also O
show O
that O
in O
fusions O
with O
the O
DNA O
binding O
domain O
of O
GAL4 B_GENE/B_SPECIES[BIO]
, O
full O
activity O
requires O
the O
entire O
BHV B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
alpha B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TIF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
although O
both O
amino O
and O
carboxyl O
termini O
display O
some O
activity O
on O
their O
own O
. O

The O
induction O
by O
dexamethasone O
of O
rat B_GENE
liver I_GENE
CYP3A1 I_GENE
differs O
from O
classical O
glucocorticoid O
gene O
regulation O
in O
part O
because O
both O
glucocorticoids O
and O
antiglucocorticoids O
such O
as O
pregnenolone O
16 O
alpha O
- O
carbonitrile O
( O
PCN O
) O
induce O
CYP3A1 B_GENE
through O
transcriptional O
gene O
activation O
. O

Moreover O
, O
antibody O
binding O
to O
the O
same O
two O
determinants O
was O
also O
inhibited O
when O
ZAP B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
70 I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
SH2 B_PROTEIN[GENE]/B_BIO
domains I_PROTEIN[GENE]/I_BIO
bound O
to O
the O
zeta O
chain O
or O
to O
a O
2pY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ITAM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

This O
surface B_LOCATION/B_BIO
in O
specimens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
from O
unfertilized B_LOCATION
eggs I_LOCATION
is O
almost O
flat B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Fetal B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplants I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rescue O
axial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representations I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
M1 B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
of O
neonatally O
transected O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
develop O
weight B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
examined O
the O
contribution O
of O
the O
M B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MuLV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
transcriptional O
activity O
and O
pathogenesis O
of O
M O
- O
MuLV O
by O
constructing O
LTRs O
containing O
heterologous O
enhancer O
elements O
. O

There O
were O
no O
major B_DISEASE_ADJECTIVE[DISEASE]
postoperative I_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
and O
at O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_LOCATION/B_NUMBER[MEASURE]
of O
the O
13 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
10 B_MEASURE/B_LOCATION
to O
26 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
satisfactory B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
immunoreactive O
antithrombin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
III I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
increased O
significantly O
while O
the O
increase O
in O
antithrombin B_GENE
III I_GENE
activity O
was O
insignificant O
in O
20 O
male O
Caucasian O
Danes O
upon O
3 O
weeks O
supplementation O
of O
the O
diet O
with O
10 O
ml O
daily O
of O
a O
cod O
liver O
oil O
concentrate O
. O

Northern O
blot O
analysis O
confirmed O
that O
ADAMTS B_GENE
- I_GENE
1 I_GENE
was O
up O
- O
regulated O
in O
both O
metaphyseal O
( O
14 O
- O
to O
35 O
- O
fold O
) O
and O
diaphyseal O
( O
4 O
. O
2 O
- O
fold O
) O
bone O
1 O
h O
after O
PTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
38 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
injection O
and O
returned O
to O
control O
levels O
by O
24 O
h O
. O

The O
transcriptional B_GENE/B_DISEASE
transactivator I_GENE/I_DISEASE
( O
Tas B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
simian O
foamy O
virus O
type O
1 O
strongly O
augments O
gene O
expression O
directed O
by O
both O
the O
promoter O
in O
the O
viral O
long O
terminal O
repeat O
and O
the O
newly O
discovered O
internal O
promoter O
located O
within O
the O
env B_GENE
gene I_GENE
. O

In O
the O
other B_TIME[MEASURE]/B_LOCATION
two B_TIME[MEASURE]/I_LOCATION
cases B_TIME[MEASURE]/I_LOCATION
, O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjunct I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
benefits B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
no O
additional B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Deletion O
of O
this O
consensus O
element O
from O
the O
spo6 B_GENE/B_BIO
promoter I_GENE/I_BIO
abolished O
the O
transcription O
of O
spo6 B_GENE
+ I_GENE
and O
resulted O
in O
a O
sporulation O
deficiency O
. O

Chem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

mutations O
in O
the O
beta B_GENE
- I_GENE
galactosidase I_GENE
gene I_GENE
result O
in O
the O
lysosomal O
storage O
disorders O
GM1 O
- O
gangliosidosis O
and O
Morquio O
B O
syndrome O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicated O
that O
hobbies B_PERSON/B_LOCATION
/ O
leisure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
mobility B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
transport B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
social B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
working O
capacity B_TIME[MEASURE]/B_LOCATION
, O
energy B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
doing O
things B_PERSON/B_LOCATION
slower O
were O
aspects B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relevant I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
IPF B_DISEASE/B_ORGANIZATION
patients I_DISEASE/I_ORGANIZATION
' I_DISEASE/I_ORGANIZATION
QOL I_DISEASE/I_ORGANIZATION
. O

We O
have O
generated O
transgenic O
fly O
strains O
with O
mutations O
affecting O
specific O
TRA B_GENE/B_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
isoforms I_GENE/I_LOCATION
to O
investigate O
their O
individual O
roles O
in O
regulating O
the O
alternative O
processing O
of O
doublesex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
exuperantia B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
tra B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B_GENE/B_BIO
- I_GENE/I_BIO
early I_GENE/I_BIO
gene I_GENE/I_BIO
US1 I_GENE/I_BIO
( O
ICP22 B_PROTEIN[GENE]/B_LOCATION
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B_SPECIES[BIO]/B_MEASURE
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B_PROTEIN[GENE]/B_VIRUS[BIO]
) O
, O
pseudorabies O
virus O
( O
RSp40 B_PROTEIN[GENE]/B_DISEASE
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
define O
a O
class B_PERSON/B_LOCATION
of O
DNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
mode B_LOCATION/B_MEASURE
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
has O
not O
been O
heretofore O
described O
. O

We O
were O
able O
to O
demonstrate O
a O
significant O
statistical O
interaction O
effect O
between O
gender O
and O
globulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
concentration O
on O
Vu O
( O
p O
= O
0 O
. O
022 O
) O
. O

Chest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
X I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
P B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
an O
abnormal B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shadow I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
upper I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

From O
the O
frozen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
a O
large B_MEASURE
number I_MEASURE
of O
sections B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
good B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
morphologic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
produced O
. O

These O
include O
not O
only O
antioxidants O
, O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O
, O
inhibitors O
of O
glutamate O
release O
, O
calcium O
channel O
blockers O
, O
polyamine O
antagonists O
, O
and O
nitric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O
, O
but O
cannabinoids O
, O
aspirin O
, O
melatonin O
, O
and O
vitamin O
B O
- O
12 O
. O

A O
series O
of O
mutations O
were O
constructed O
within O
the O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
open O
reading O
frame O
which O
delete O
various O
regions O
of O
the O
conserved O
DNA O
binding O
and O
transactivation O
domains O
as O
well O
as O
the O
internal O
hinge O
region O
. O

CrkII B_GENE
and O
CrkL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constitutively O
formed O
complex O
with O
the O
guanine B_GENE
nucleotide I_GENE
exchange I_GENE
factor I_GENE
C3G I_GENE
, O
in O
unstimulated O
as O
well O
as O
PDGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
cells O
. O

In O
further O
support O
of O
the O
biological O
significance O
of O
these O
DNA O
- O
protein O
interactions O
, O
the O
IL2RA B_GENE/B_MEASURE
oligonucleotide O
from O
- O
291 O
to O
- O
245 O
proved O
to O
be O
sufficient O
in O
either O
orientation O
to O
confer O
PMA O
inducibility O
to O
the O
mitogen O
- O
insensitive O
thymidine B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
in O
Jurkat O
cells O
. O

The O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
steroid I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
CAPD B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
patients I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
after O
each O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
equal B_MEASURE
to O
or O
greater B_MEASURE
than O
the O
levels B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
BCPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
12 B_NUMBER[MEASURE]
achieved O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
11 B_MEASURE
evidenced O
a O
75 B_MEASURE
% I_MEASURE
response I_MEASURE
, O
and O
7 B_NUMBER[MEASURE]
displayed O
a O
50 B_DISEASE
% I_DISEASE
response I_DISEASE
. O

The O
RPC31 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
the O
C31 B_ENZYME[GENE]
subunit I_ENZYME[GENE]
of I_ENZYME[GENE]
Saccharomyces I_ENZYME[GENE]
cerevisiae I_ENZYME[GENE]
RNA I_ENZYME[GENE]
polymerase I_ENZYME[GENE]
C I_ENZYME[GENE]
( I_ENZYME[GENE]
III I_ENZYME[GENE]
) I_ENZYME[GENE]
has O
been O
isolated O
, O
starting O
from O
a O
C O
- O
terminal O
fragment O
cloned O
on O
a O
lambda O
gt11 O
library O
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrated O
that O
sequences O
within O
this O
region O
bind O
members O
of O
the O
Sp1 B_GENE/B_BIO
family I_GENE/I_BIO
of I_GENE/I_BIO
transcription I_GENE/I_BIO
factors I_GENE/I_BIO
. O

The O
phosphatase B_LOCATION
active I_LOCATION
site I_LOCATION
is O
located O
within O
residues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
367 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
374 B_MEASURE
. O

After O
at O
least O
one B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
argon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
laser I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
( O
p B_MEASURE
less I_MEASURE
of O
0 B_MEASURE
, O
01 B_MEASURE
; O
Kolmogorow B_PERSON
- O
Smirnov B_MEASURE/B_SPORT[ENT]
test I_MEASURE/I_SPORT[ENT]
) O
on O
the O
stabilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
or O
the O
amelioration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
visual B_DISEASE
acuity I_DISEASE
compared O
with O
the O
non B_TIME[MEASURE]/B_DISEASE
treated O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Further O
studies O
aim O
at O
characterizing O
the O
trans O
- O
acting O
factors O
that O
mediate O
the O
spatial O
and O
temporal O
expression O
of O
Hox B_GENE
genes I_GENE
in O
the O
developing O
embryo O
. O

contraindications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
noted O
in O
this O
article B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
to O
the O
side O
effects O
of O
SISO O
, O
cylindruria O
with O
aggravation O
of O
microscopic O
hematuria O
and O
elevations O
of O
GOT B_GENE/B_DISEASE
, O
GPT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A1 B_LOCATION/B_GENE
- I_LOCATION/I_GENE
P I_LOCATION/I_GENE
were O
observed O
each O
one O
of O
them O
, O
respectively O
. O

Serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
measured O
in O
1 O
, O
282 O
school O
children O
with O
abnormal O
urinary O
findings O
between O
1980 O
and O
1997 O
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sensory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
employed O
, O
S2 B_PROTEIN[GENE]/B_MEASURE
/ O
S1 B_MEASURE
x O
100 B_MEASURE
amplitude I_MEASURE
ratio I_MEASURE
and O
S1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
S2 B_MEASURE
amplitude I_MEASURE
difference I_MEASURE
. O

Computer O
analysis O
revealed O
that O
the O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O
to O
amino O
acid O
residues O
within O
the O
N O
- O
terminal O
RNA O
binding O
domain O
displays O
high O
homology O
( O
greater O
than O
54 O
% O
identity O
; O
61 O
to O
94 O
% O
similarity O
) O
with O
two O
animal O
virus O
proteins O
which O
possess O
RNA O
binding O
activity O
( O
vaccinia B_PROTEIN[GENE]/B_SPECIES[BIO]
virus I_PROTEIN[GENE]/I_SPECIES[BIO]
E3L I_PROTEIN[GENE]/I_SPECIES[BIO]
; O
rotavirus B_VIRUS[BIO]/B_PROTEIN[GENE]
VP2 B_VIRUS[BIO]/I_PROTEIN[GENE]
) O
and O
two O
proteins O
of O
unknown O
function O
( O
murine B_GENE
TIK I_GENE
; O
rotavirus B_VIRUS[BIO]/B_GENE
NS34 I_VIRUS[BIO]/I_GENE
) O
, O
but O
which O
are O
likely O
RNA O
binding O
proteins O
. O

Determinants O
of O
recurrent O
ischaemia O
and O
revascularisation O
procedures O
after O
thrombolysis O
with O
recombinant O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasminogen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
primary O
coronary O
occlusion O
. O

For O
large B_DISEASE/B_MEASURE
breasts I_DISEASE/I_MEASURE
( O
> O
70 B_MEASURE
mm I_MEASURE
) O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
X B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O
ray B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sets I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
such I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
as O
the O
IGE B_PRODUCT[OBJECT]/B_ENT
DMR I_PRODUCT[OBJECT]/I_ENT
, O
which O
automatically O
select O
the O
beam B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
quality B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O
each O
breast B_BIO/B_DISEASE
, O
resulted O
in O
lower B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
with O
sets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O
manual B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tube I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
selection I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
poults B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
with O
each O
of O
two B_NUMBER[MEASURE]/B_PERSON
strains B_NUMBER[MEASURE]/I_PERSON
representing O
the O
rarely O
reported O
capsular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
indicated O
that O
both O
were O
virulent B_DISEASE_ADJECTIVE[DISEASE]
. O

Computer B_ORGANIZATION/B_PERSON
system B_ORGANIZATION/I_PERSON
trains O
employees B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
meet O
JCAHO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
safety I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ED I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Finally O
, O
transfection O
of O
Grb10 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
specific O
mutations O
in O
their O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O
apoptosis O
in O
HTC O
- O
IR O
and O
COS O
- O
7 O
cells O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
volume I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
histograms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O
that O
the O
6 B_MEASURE
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plan I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
spared O
relatively O
more B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
heart I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
whereas O
the O
8 B_MEASURE
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plan I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
spared O
relatively O
more B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
lung B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

We O
have O
demonstrated O
that O
a O
putative O
HOX B_GENE/B_MEASURE
cofactor I_GENE/I_MEASURE
, O
PBX1A B_GENE
, O
participates O
in O
cooperative O
DNA O
binding O
with O
HOXA B_GENE
- I_GENE
1 I_GENE
and O
the O
Deformed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O
protein O
HOXD B_GENE/B_LOCATION
- I_GENE/I_LOCATION
4 I_GENE/I_LOCATION
. O

The O
CHL B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CTF B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
gene O
product O
of O
Saccharomyces O
cerevisiae O
is O
important O
for O
chromosome O
transmission O
and O
normal O
cell O
cycle O
progression O
in O
G2 O
/ O
M O
. O

Heterotrimeric O
guanine B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
G B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
function O
as O
signal O
transducers O
for O
a O
variety O
of O
hormone O
- O
coupled O
enzyme O
and O
ion O
transport O
systems O
in O
eukaryotic O
cells O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
polypropylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
glycol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
PG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
C B_MEASURE/B_OTHER
, O
and O
corn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O
removed O
68 B_MEASURE
- O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
MDI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
first B_SEQUENCE[MEASURE]
h O
, O
74 B_MEASURE
- O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
at O
4 B_NUMBER[MEASURE]
h O
, O
and O
72 B_MEASURE
- O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
at O
8 B_MEASURE
h O
. O

DDD B_DISEASE_ADJECTIVE[DISEASE]
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
pacing O
with O
automatic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mode I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
switch I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
patients B_PERSON
with O
paroxysmal B_DISEASE
atrial I_DISEASE
fibrillation I_DISEASE
following O
AV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
nodal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ablation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
was O
a O
highly O
significant O
decrease O
in O
serum B_DISEASE/B_GENE
eosinophil I_DISEASE/I_GENE
cationic I_DISEASE/I_GENE
protein I_DISEASE/I_GENE
in O
patients O
with O
elevated O
AGA B_GENE/B_DISEASE
. O

sequence O
analysis O
revealed O
that O
Hv B_GENE/B_BIO
- I_GENE/I_BIO
p68 I_GENE/I_BIO
belongs O
to O
the O
large O
family O
of O
FAD B_ENZYME[GENE]/B_BIO
- I_ENZYME[GENE]/I_BIO
dependent I_ENZYME[GENE]/I_BIO
glucose I_ENZYME[GENE]/I_BIO
methanol I_ENZYME[GENE]/I_BIO
choline I_ENZYME[GENE]/I_BIO
oxidoreductases I_ENZYME[GENE]/I_BIO
and O
that O
it O
shares O
significant O
sequence O
identity O
( O
> O
67 O
% O
) O
with O
the O
alcohol B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
methylotrophic O
yeasts O
. O

It O
is O
required O
for O
correct B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
both O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
LTR B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
this O
region O
has O
been O
demonstrated O
to O
have O
both O
positive O
and O
negative O
regulatory O
effects O
on O
HIV O
gene O
expression O
. O

A O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
attenuation B_MEASURE/B_DISEASE
- O
corrected O
and O
- O
uncorrected O
transmission B_DISEASE/B_MEASURE
- O
emission B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SPECT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O
with O
Tl B_LOCATION/B_PROTEIN[GENE]
- O
201 B_NUMBER[MEASURE]/B_BIO
in O
CAD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

accumulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
amines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
isolated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
perfused I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
rabbit I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lung I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Since O
it O
is O
often O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
resort O
to O
thoracotomy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
making O
such O
a O
diagnosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
have O
sought O
a O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
is O
simpler B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
while O
capable B_PERSON/B_LOCATION
of O
providing O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Mn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
quail B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accumulated O
5 B_NUMBER[MEASURE]/B_LOCATION
to O
10 B_TIME[MEASURE]
times I_TIME[MEASURE]
more I_TIME[MEASURE]
Mn I_TIME[MEASURE]
in O
their O
livers B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
similarly O
treated O
rodents B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Small B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
t I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
inhibited O
the O
dephosphorylation O
of O
cAMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PKA B_GENE/B_LOCATION
) O
- O
phosphorylated O
CREB B_GENE
in O
rat O
liver O
nuclear O
extracts O
. O

A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
accumulated O
over O
a O
21 B_NUMBER[MEASURE]
- O
month B_TIME[MEASURE]
period I_TIME[MEASURE]
, O
from O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
September B_TIME[MEASURE]
1991 I_TIME[MEASURE]
, O
regarding O
investigational B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
a O
308 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
nanometer I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Xenon I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
chloride I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Excimer I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Laser I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
Coronary I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
angioplasty I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ELCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
( O
Advanced B_ORGANIZATION/B_PERSON
Interventional B_ORGANIZATION/I_PERSON
Systems B_ORGANIZATION/I_PERSON
, O
Inc B_ORGANIZATION/B_LOCATION
. O
, O
Irvine B_LOCATION/B_PERSON
, O
CA B_LOCATION
) O
was O
performed O
. O

presently O
, O
we O
made O
chain O
pair O
switch O
, O
chimeric O
, O
and O
site O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
delta B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCRs B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
transfected O
them O
into O
TCR O
- O
mutant O
Jurkat O
T O
cells O
to O
examine O
the O
effects O
of O
changing O
the O
TCR B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gamma B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
junctional B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O
reactivity O
to O
prenyl B_GENE
pyrophosphate I_GENE
Ags I_GENE
. O

Fos B_GENE/B_LOCATION
/ O
Jun B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O
to O
an O
unacetylated O
nucleosome O
with O
only O
a O
4 O
- O
to O
5 O
- O
fold O
reduction O
in O
DNA O
binding O
affinity O
compared O
with O
naked O
DNA O
. O

Activated B_GENE
Ki I_GENE
- I_GENE
Ras I_GENE
suppresses O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
- O
induced O
activation O
of O
the O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
colon O
cancer O
cells O
. O

Electromobility O
shift O
analysis O
using O
oligonucleotides O
encompassing O
the O
proximal O
, O
distal O
, O
and O
Bed O
/ O
AP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
- O
binding O
regions O
failed O
to O
demonstrate O
selective O
transactivation O
after O
CD2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
of O
LPMC O
. O

The O
present O
report O
shows O
that O
a O
cis O
- O
acting O
element O
between O
- O
189 O
and O
- O
175 O
BP O
, O
which O
binds O
thyroid B_GENE
transcription I_GENE
factor I_GENE
- I_GENE
1 I_GENE
( O
TTF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
, O
is O
involved O
in O
both O
activities O
. O

increased O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O
and O
intimal O
thickening O
during O
healing O
of O
Dacron O
grafts O
in O
a O
canine O
model O
. O

Despite O
their O
high O
degree O
of O
sequence O
similarity O
, O
all O
five O
RFC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
essential O
for O
cell O
proliferation O
in O
S O
. O
cerevisiae O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E12 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL7Ralpha B_GENE
, O
lambda5 B_GENE
, O
and O
Rag B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
ability O
to O
induce O
kappa B_GENE/B_DISEASE
light I_GENE/I_DISEASE
chain I_GENE/I_DISEASE
in O
response O
to O
mitogen O
. O

Also O
, O
anti B_GENE
- I_GENE
HIV I_GENE
gp120 I_GENE
and O
anti B_GENE
- I_GENE
CD4 I_GENE
crosslinking O
induced O
a O
10 O
- O
15 O
- O
fold O
increase O
in O
levels O
of O
both O
PI B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
PI I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
in O
anti B_DISEASE/B_GENE
- I_DISEASE/I_GENE
CD4 I_DISEASE/I_GENE
precipitates O
. O

The O
differences B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
percentages B_DISEASE_ADJECTIVE[DISEASE]
for O
HIV B_DISEASE
- O
1 B_DISEASE/B_GENE
infection I_DISEASE/I_GENE
in O
intravenous B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
drug I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
users I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
IVDU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
were O
67 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
in O
non B_MEASURE/B_PERSON
IVDU B_MEASURE/I_PERSON
were O
3 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
with O
a O
significant B_MEASURE/B_DISEASE
statistical B_MEASURE/I_DISEASE
difference B_MEASURE/I_DISEASE
( O
chi B_PROTEIN[GENE]/B_PERSON
2 I_PROTEIN[GENE]/I_PERSON
= O
557 B_MEASURE
. O
5 B_MEASURE
; O
p O
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

One O
of O
the O
ORFs O
in O
the O
Methanococcus O
jannaschii O
genome O
possesses O
high O
similarity O
to O
the O
M B_SPECIES[BIO]/B_SEQUENCE[MEASURE]
. I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
aeolicus I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
ilvB I_SPECIES[BIO]/I_SEQUENCE[MEASURE]
, O
indicating O
that O
it O
is O
an O
authentic O
AHAS B_GENE/B_MEASURE
. O

More B_MEASURE
than O
80 B_MEASURE
% I_MEASURE
appropriate I_MEASURE
lever I_MEASURE
responding O
was O
established O
after O
27 B_MEASURE
, O
38 B_MEASURE
and O
44 B_TIME[MEASURE]
daily I_TIME[MEASURE]
training I_TIME[MEASURE]
sessions I_TIME[MEASURE]
with O
DN B_LOCATION/B_DISEASE
- O
2327 B_MEASURE
, O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
PTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
as O
the O
training B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
used O
nuclear B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
magnetic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resonance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
NMR B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
to O
obtain O
the O
structure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
an O
RNA B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
' O
kissing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O
hairpin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
formed O
between O
the O
HIV B_DISEASE/B_GENE
- O
2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tar I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hairpin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loop I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
hairpin B_GENE
with O
a O
complementary B_GENE/B_LOCATION
loop I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
men B_PERSON/B_MEASURE
, O
weight B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O
height2 B_MEASURE/B_LOCATION
met O
the O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
a O
satisfactory B_MEASURE/B_PERSON
index B_MEASURE/I_PERSON
in O
that O
there O
was O
a O
very O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
triceps B_MEASURE/B_BIO
skinfold I_MEASURE/I_BIO
, O
and O
a O
negligible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
height B_MEASURE/B_GENE
. O

PRP20 B_GENE/B_PERSON
is O
related O
, O
both O
in O
structure O
and O
function O
, O
to O
the O
RCC1 B_GENE/B_BIO
gene I_GENE/I_BIO
of O
mammals O
and O
the O
PIM1 B_GENE/B_BIO
gene I_GENE/I_BIO
of O
Schizosaccharomyces O
pombe O
, O
both O
of O
which O
appear O
to O
regulate O
entry O
into O
mitosis O
and O
chromosome O
condensation O
. O

No O
consensus B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O
be O
discerned O
in O
these O
fragments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
bound O
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
in O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equilibrium I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
unbound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
selective O
transcriptional O
induction O
system O
for O
mammalian O
cells O
based O
on O
Gal4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion O
proteins O
. O

kinase O
renaturation O
tests O
designed O
to O
detect O
reactivated O
protein O
kinases O
after O
electrophoresis O
in O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
revealed O
the O
presence O
of O
a O
60 O
- O
kDa O
kinase O
in O
the O
washed O
immunoprecipitate O
obtained O
from O
liver O
cytosol O
using O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IgG B_GENE/B_LOCATION
) O
and O
protein O
A O
/ O
G O
/ O
agarose O
beads O
but O
not O
when O
a O
nonspecific O
IgG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
used O
instead O
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Immunoblotting O
using O
a O
phosphospecific B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Src B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
416Y B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
ceramide O
- O
induced O
increase O
in O
pp60 B_GENE/B_DISEASE
( O
src B_GENE/B_MEASURE
) O
tyrosine O
phosphorylation O
. O

In O
contrast O
, O
dominant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
negative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Rac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
N17Rac1 B_PROTEIN[GENE]/B_LOCATION
) O
inhibited O
JNK B_GENE
activation O
by O
Galpha12 B_GENE
in O
HEK293 O
cells O
as O
well O
as O
three O
other O
cell O
lines O
. O

Metabolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
psychotropic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
man B_PERSON/B_BIO
. O

Reading O
disability B_DISEASE
in O
twins B_PERSON/B_LOCATION
. O

These O
results O
suggest O
that O
1a B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
also O
interacts O
independently O
with O
the O
ER O
and O
viral O
RNA O
, O
is O
a O
key O
organizer O
of O
RNA O
replication O
complex O
assembly O
. O

HrpE B_BACTERIUM[BIO]/B_LOCATION
is O
similar O
to O
YscL B_BIO/B_GENE
of O
Yersinia O
spp O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugar B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
some O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
regulatory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
indicators I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
young B_PERSON/B_BIO
men I_PERSON/I_BIO
. O

production B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
chicken B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
meat I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
broth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
suitable I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
for O
the O
mass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
Haemophilus B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gallinarum B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bacterin B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
indicate O
that O
expression O
of O
proU B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
E O
. O
coli O
is O
directed O
from O
two O
promoters O
, O
one O
( O
P2 O
) O
characterized O
earlier O
by O
other O
workers O
with O
the O
start O
site O
of O
transcription O
60 O
nucleotides O
upstream O
of O
the O
initiation O
codon O
of O
the O
first O
structural O
gene O
( O
proV B_LOCATION/B_PROTEIN[GENE]
) O
, O
and O
the O
other O
( O
P1 O
) O
situated O
250 O
nucleotides O
upstream O
of O
proV B_GENE
. O

The O
maximal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
rise B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenaline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
of O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
all O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
but O
a O
lower B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
required O
to O
stimulate O
this O
hormonal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
' B_PERSON/B_ORGANIZATION
unaware I_PERSON/I_ORGANIZATION
' O
patients B_PERSON/B_ORGANIZATION
, O
in O
whom O
the O
plasma B_MEASURE
adrenaline I_MEASURE
concentration I_MEASURE
was O
lower B_MEASURE
at O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
the O
reaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Through O
interactions O
with O
the O
pre O
- O
mRNA O
and O
the O
CTD O
domain O
of O
the O
Polymerase B_GENE/B_LOCATION
II I_GENE/I_LOCATION
, O
SR B_GENE/B_BIO
proteins I_GENE/I_BIO
have O
been O
shown O
to O
regulate O
alternative O
splicing O
. O

One B_PERSON
child I_PERSON
, O
recently O
fed O
, O
vomited O
a O
small B_MEASURE
amount I_MEASURE
of O
breast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
milk I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
a O
short B_TIME[MEASURE]
period I_TIME[MEASURE]
of O
crying B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
apparently O
had O
a O
laryngospasm B_DISEASE
, O
shown O
by O
a O
sudden B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
drop I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
PtcO2 B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
level B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
without O
any O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
discomfort B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
size B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
organisation B_ORGANIZATION/B_LOCATION
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
man B_PERSON
and O
his O
ancestors B_PERSON/B_ORGANIZATION
. O

Only O
Staphylococcus B_BACTERIUM[BIO]/B_NUMBER[MEASURE]
xylosus B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
SX63 B_BACTERIUM[BIO]/I_NUMBER[MEASURE]
was O
detected O
as O
a O
strain B_BIO
with O
high B_DISEASE
adherence I_DISEASE
activity I_DISEASE
. O

It O
also O
produces O
an O
NH2 O
terminus O
that O
corresponds O
to O
an O
equivalent O
NH2 O
terminus O
on O
the O
processed O
matrix O
form O
of O
the O
similar O
alpha1 B_PROTEIN[GENE]
( I_PROTEIN[GENE]
XI I_PROTEIN[GENE]
) I_PROTEIN[GENE]
chain I_PROTEIN[GENE]
, O
thus O
suggesting O
physiological O
significance O
. O

Transmission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
mutans B_BACTERIUM[BIO]/B_PERSON
streptococci O
to O
infants B_PERSON/B_BIO
following O
short B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
term I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
an O
iodine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
NAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
mothers B_PERSON/B_BIO
' I_PERSON/I_BIO
dentition I_PERSON/I_BIO
. O

expression O
of O
Msx B_GENE
- I_GENE
1 I_GENE
and O
Msx B_GENE
- I_GENE
2 I_GENE
has O
been O
studied O
during O
development O
of O
the O
osteoblast O
phenotype O
, O
but O
the O
role O
of O
Dlx B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
this O
context O
and O
in O
the O
regulation O
of O
bone O
- O
expressed O
genes O
is O
unknown O
. O

scalp B_MEASURE/B_PROTEIN[GENE]
blood B_MEASURE/I_PROTEIN[GENE]
flow B_MEASURE/I_PROTEIN[GENE]
was O
recorded O
by O
a O
laser B_PRODUCT[OBJECT]
Doppler I_PRODUCT[OBJECT]
flow I_PRODUCT[OBJECT]
sensor I_PRODUCT[OBJECT]
that O
was O
incorporated O
in O
the O
transcutaneous B_PRODUCT[OBJECT]/B_ENT
PO2 I_PRODUCT[OBJECT]/I_ENT
electrode I_PRODUCT[OBJECT]/I_ENT
. O

Design O
: O
Activating B_GENE
protein I_GENE
- I_GENE
1 I_GENE
( O
AP B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
and O
Tat B_GENE
- O
induced O
transcription O
were O
assessed O
using O
Jun B_PERSON/B_MEASURE
and O
hybrid O
Tat B_GENE
/ O
Jun B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
expression O
plasmids O
and O
reporter O
gene O
constructs O
which O
contained O
AP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
upstream O
of O
the O
rat B_GENE
prolactin I_GENE
TATAA I_GENE
element I_GENE
or O
an O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
AP B_GENE/B_MEASURE
- I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
sites I_GENE/I_MEASURE
replaced O
the O
TAR O
element O
. O

Mycobacterium O
tuberculosis O
inhibits O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O
responses O
without O
inhibiting O
activation O
of O
STAT1 B_GENE
. O

Rabbit B_SPECIES[BIO]/B_GENE
KCC1 I_SPECIES[BIO]/I_GENE
( O
rbKCC1 B_GENE
) O
and O
rat B_GENE
KCC1 I_GENE
( O
rtKCC1 B_GENE/B_SPECIES[BIO]
) O
were O
cloned O
by O
screening O
rabbit O
kidney O
and O
rat O
brain O
cDNA O
libraries O
using O
homologous O
cDNA O
probes O
. O

However O
, O
using O
wet B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
dry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
weight I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
methodology I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
we O
found O
that O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
U74006F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
reduced O
water B_DISEASE/B_MEASURE
content I_DISEASE/I_MEASURE
in O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hippocampus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
contralateral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
the O
site B_LOCATION/B_MEASURE
of O
injury B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
compared O
to O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

GH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O
the O
activity O
of O
promoter O
fragments O
with O
5 O
' O
- O
ends O
between O
nucleotide O
( O
nt O
) O
- O
2001 O
and O
nt O
- O
653 O
by O
1 O
. O
9 O
- O
to O
2 O
. O
7 O
- O
fold O
. O

We O
have O
recently O
shown O
that O
induced O
expression O
of O
a O
CDK B_GENE/B_DISEASE
target O
site O
- O
deficient O
mutant O
, O
Op18 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
S25A O
, O
S38A O
, O
blocks O
human O
cell O
lines O
during O
G2 O
/ O
M O
transition O
. O

A O
protein O
which O
promotes O
DNA O
strand O
transfer O
between O
linear O
double O
- O
stranded O
M13mp19 O
DNA O
and O
single O
- O
stranded O
viral O
M13mp19 O
DNA O
has O
been O
isolated O
from O
recA B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E O
. O
coli O
. O

The O
brains B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
processed O
according O
to O
the O
tetramethylbenzidine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
TMB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Mesulam B_LOCATION/B_DISEASE
( O
' O
78 B_MEASURE
) O
and O
studied O
with O
darkfield B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recurrence I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HR B_MEASURE/B_PROTEIN[GENE]
1 I_MEASURE/I_PROTEIN[GENE]
. O
30 B_MEASURE
; O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
CI I_LOCATION/I_MEASURE
= O
0 B_MEASURE
. O
84 B_MEASURE
, O
2 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
and O
antiepileptic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
HR B_MEASURE/B_DISEASE
0 I_MEASURE/I_DISEASE
. O
97 B_MEASURE
; O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
CI I_LOCATION/I_MEASURE
= O
0 B_MEASURE
. O
67 B_MEASURE
, O
1 B_MEASURE
. O
38 B_MEASURE
) O
did O
not O
influence O
mortality B_DISEASE
rate I_DISEASE
. O

One O
day O
postoperatively O
, O
the O
mononuclear O
leukocyte O
beta B_GENE/B_MEASURE
2 B_GENE/I_MEASURE
- B_GENE/I_MEASURE
receptor B_GENE/I_MEASURE
density O
decreased O
maximally O
by O
45 O
+ O
/ O
- O
11 O
% O
in O
the O
enflurane O
patients O
, O
and O
by O
53 O
+ O
/ O
- O
6 O
% O
in O
the O
neurolept O
patients O
. O

The O
serum O
levels O
of O
cortisol O
and O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O
nasal O
instillation O
of O
a O
suspension O
of O
vaginal O
exudate O
showed O
lower O
values O
than O
in O
control O
conditions O
( O
nasal O
instillation O
of O
saline O
) O
. O

IgE B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibody I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
twelve O
common O
food O
and O
inhalant O
allergens O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
in O
the O
sera O
of O
thirteen O
atopic O
patients O
with O
one O
or O
more O
allergic O
disorders O
( O
asthma O
occurring O
in O
eleven O
; O
rhinitis O
in O
ten O
; O
eczema O
in O
six O
; O
urticaria O
in O
four O
; O
mouth O
and O
gastro O
- O
intestinal O
symptoms O
in O
six O
) O
, O
of O
twelve O
non O
- O
atopic O
patients O
with O
various O
clinical O
symptoms O
( O
asthma O
in O
four O
; O
rhinitis O
in O
four O
; O
eczema O
in O
one O
; O
urticaria O
in O
two O
; O
mouth O
and O
gastro O
- O
intestinal O
symptoms O
in O
four O
) O
and O
sixteen O
cord O
blood O
sera O
. O

innervation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
reticular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
papillae I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
sheep B_SPECIES[BIO]
and O
goats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Biochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
status I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
examined O
using O
erythrocyte B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
enzyme I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vitamin I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sexual B_DISEASE
adventurism I_DISEASE
, O
high B_MEASURE/B_DISEASE
- O
risk B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
human B_DISEASE
immunodeficiency I_DISEASE
virus I_DISEASE
- O
1 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seroconversion I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
the O
chicago B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MACS I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CCS B_MEASURE/B_PERSON
cohort I_MEASURE/I_PERSON
, O
1984 B_MEASURE
to O
1992 B_MEASURE
. O

Pendulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
Drosophila O
protein O
with O
cell O
cycle O
- O
dependent O
nuclear O
localization O
, O
is O
required O
for O
normal O
cell O
proliferation O
. O

Paradoxically O
there O
is O
a O
decrease O
in O
the O
level O
of O
soluble B_GENE
A I_GENE
beta I_GENE
secreted O
from O
the O
cells O
. O

signaling O
through O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
and O
Rac B_GENE/B_PERSON
/ O
Rho B_GENE
does O
not O
duplicate O
the O
effects O
of O
activated O
Ras B_GENE/B_DISEASE
on O
skeletal O
myogenesis O
. O

Internalization O
of O
prolactin B_GENE
receptor I_GENE
and O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
transfected O
cells O
does O
not O
involve O
nuclear O
translocation O
. O

Using O
mammalian O
expression O
vectors O
( O
pRSV O
- O
neo O
and O
pSV2 O
- O
neo O
) O
, O
antisense O
constructs O
for O
perforin B_GENE/B_BACTERIUM[BIO]
and O
granzyme B_GENE
B I_GENE
were O
independently O
electroporated O
into O
YT O
- O
Indy O
, O
a O
human O
non O
- O
MHC B_GENE/B_DISEASE
- O
restricted O
, O
IL B_GENE
- I_GENE
2 I_GENE
- O
independent O
, O
cytotoxic O
lymphocyte O
. O

When O
expressed O
in O
Escherichia O
coli O
, O
SH B_GENE
- I_GENE
PTP2 I_GENE
displays O
tyrosine B_ENZYME[GENE]
- I_ENZYME[GENE]
specific I_ENZYME[GENE]
phosphatase I_ENZYME[GENE]
activity O
. O

The O
structure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elucidation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
iridoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
3 B_NUMBER[MEASURE]
are O
discussed O
in O
detail B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
investigate O
the O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
propolis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
containing O
mouthrinse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
de B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
novo B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
plaque B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
are O
presented O
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
shosaikoto B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
an O
oriental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
medicinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
on O
restraint B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
stressed O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
region O
surrounding O
the O
ZNF35 B_DISEASE/B_GENE
zinc I_DISEASE/I_GENE
finger I_DISEASE/I_GENE
protein I_DISEASE/I_GENE
gene I_DISEASE/I_GENE
on O
3p21 O
is O
of O
particular O
interest O
, O
as O
this O
region O
of O
chromosome O
3 O
is O
frequently O
involved O
in O
rearrangements O
and O
/ O
or O
deletions O
associated O
with O
various O
human O
tumors O
including O
lung O
and O
renal O
carcinoma O
. O

In O
the O
promoters O
of O
many O
immediate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
c B_GENE
- I_GENE
fos I_GENE
, O
CArG O
DNA O
regulatory O
elements O
mediate O
basal O
constituitive O
expression O
and O
rapid O
and O
transient O
serum O
induction O
. O

The O
biological O
activity O
of O
these O
mutants O
was O
tested O
by O
determining O
their O
capacity O
to O
( O
i O
) O
reconstitute O
RNA B_ENZYME[GENE]/B_BIO
polymerase I_ENZYME[GENE]/I_BIO
activity O
in O
vivo O
by O
cotransfection O
with O
proteins O
NP B_PROTEIN[GENE]/B_DISEASE
, O
PB1 B_PROTEIN[GENE]/B_LOCATION
, O
and O
PA B_PROTEIN[GENE]/B_DISEASE
and O
a O
virion O
- O
like O
RNA O
encoding O
the O
cat B_PROTEIN[GENE]/B_DISEASE
gene O
into O
vaccinia O
virus O
T7 O
- O
infected O
COS O
- O
1 O
cells O
and O
( O
ii O
) O
complete O
with O
the O
wild B_GENE
- I_GENE
type I_GENE
PB2 I_GENE
activity O
. O

Transient B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thyrotoxicosis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
phospholipid B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
. O

We O
were O
unable O
to O
construct O
chvI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
chvG B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
insertion B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
of O
R O
. O
meliloti O
, O
whereas O
mutants O
carrying O
insertions O
outside O
of O
these O
genes O
were O
readily O
obtained O
. O

Western O
blot O
analyses O
reveals O
that O
cJun B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
C B_GENE/B_PERSON
/ I_GENE/I_PERSON
EBP I_GENE/I_PERSON
family I_GENE/I_PERSON
member I_GENE/I_PERSON
C I_GENE/I_PERSON
/ I_GENE/I_PERSON
EBP I_GENE/I_PERSON
- I_GENE/I_PERSON
beta I_GENE/I_PERSON
are O
physiologically O
relevant O
transcription O
factors O
whose O
expression O
corresponds O
with O
mda B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
. O

In O
isolated O
olfactory O
cilia O
certain O
odorants O
elicit O
a O
rapid O
and O
transient O
Camp O
response O
, O
terminated O
by O
a O
concerted O
process O
which O
requires O
the O
action O
of O
two O
protein O
kinases O
, O
protein B_ENZYME[GENE]
kinase I_ENZYME[GENE]
A I_ENZYME[GENE]
( O
PKA B_GENE/B_LOCATION
) O
and O
a O
receptor B_GENE/B_PERSON
- I_GENE/I_PERSON
specific I_GENE/I_PERSON
kinase I_GENE/I_PERSON
( O
GRK3 B_GENE/B_LOCATION
) O
( O
Schleicher O
, O
S O
. O
, O
Boekhoff O
, O
I O
. O

Acetyl B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
carboxylase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
yeast O
is O
an O
essential O
enzyme O
and O
is O
regulated O
by O
factors O
that O
control O
phospholipid O
metabolism O
. O

To O
investigate O
the O
role O
of O
this O
domain O
in O
the O
incorporation O
of O
the O
SIV B_GENE
Env I_GENE
into O
virions O
, O
we O
generated O
a O
series O
of O
SIV B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Env B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O
small O
in O
- O
frame O
deletions O
within O
the O
cytoplasmic O
domain O
. O

Computer B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
distribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
1 B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
of O
freedom B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
significant B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
vertical B_DISEASE
root I_DISEASE
fracture I_DISEASE
and O
the O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
instrumentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
obturation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
canal B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
025 B_MEASURE
) O
, O
the O
length B_MEASURE/B_LOCATION
of O
the O
post B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
05 B_MEASURE
) O
, O
and O
the O
existence B_DISEASE/B_MEASURE
of O
the O
post B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_NUMBER[MEASURE]
. O
05 B_MEASURE
) O
. O

Minute B_GENE/B_DISEASE
virus I_GENE/I_DISEASE
of I_GENE/I_DISEASE
mice I_GENE/I_DISEASE
NS1 I_GENE/I_DISEASE
, O
an O
83 O
- O
kDa O
mainly O
nuclear O
phosphoprotein O
, O
is O
the O
only O
viral O
nonstructural O
protein O
required O
in O
all O
cell O
types O
and O
it O
is O
involved O
in O
multiple O
processes O
necessary O
for O
virus O
propagation O
. O

The O
TDx B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
its O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
blood B_MEASURE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples I_MEASURE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
compared O
with O
HPLC B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
RIA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
the O
sequence O
of O
mRAR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differs O
from O
that O
of O
mRAR B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
beta I_PROTEIN[GENE]/I_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
by O
an O
additional O
27 O
C O
- O
terminal O
amino O
acids O
encoded O
in O
an O
81 O
nucleotide O
- O
long O
putative O
exon O
which O
is O
spliced O
in O
between O
the O
exons O
encoding O
the O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRAR I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
propose O
that O
GCD7 B_GENE
and O
GCD2 B_GENE
play O
important O
roles O
in O
the O
regulatory O
interaction O
between O
eIF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
and O
eIF B_GENE
- I_GENE
2B I_GENE
and O
that O
the O
suppressor O
mutations O
we O
isolated O
in O
these O
genes O
decrease O
the O
susceptibility O
of O
eIF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
the O
inhibitory O
effects O
of O
phosphorylated O
eIF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
impairing O
the O
essential O
catalytic O
function O
of O
eIF B_GENE
- I_GENE
2B I_GENE
in O
translation O
initiation O
. O

The O
3 O
' O
region O
of O
the O
transcript O
contained O
a O
fully O
conserved O
, O
correctly O
spliced O
TCR B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
C I_GENE/I_LOCATION
region I_GENE/I_LOCATION
which O
was O
polyadenylated O
at O
the O
3 O
' O
end O
. O

These O
data O
demonstrate O
that O
CCTalpha B_GENE
can O
be O
regulated O
by O
lipids O
by O
two O
independent O
domains O
: O
( O
i O
) O
the O
three O
amphipathic O
alpha O
- O
helical O
repeats O
that O
interact O
with O
both O
neutral O
and O
anionic O
lipid O
mixtures O
and O
( O
ii O
) O
the O
last O
57 O
residues O
that O
interact O
with O
anionic O
lipids O
. O

sorting O
information O
to O
the O
chloroplastic O
inner O
envelope O
is O
contained O
in O
an O
NH2 O
- O
proximal O
part O
of O
mature B_GENE
IEP110 I_GENE
( O
110N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

Most B_NUMBER[MEASURE]/B_PERSON
of O
these O
elements B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
adjacent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
type B_GENE/B_BIO
X I_GENE/I_BIO
telomeric I_GENE/I_BIO
repeats I_GENE/I_BIO
, O
and O
regions B_LOCATION/B_DISEASE
flanking O
four B_NUMBER[MEASURE]/B_PERSON
of O
five B_NUMBER[MEASURE]/B_PERSON
characterized O
S B_DISEASE/B_PROTEIN[GENE]
. O
paradoxus B_SPECIES[BIO]/B_GENE
insertions I_SPECIES[BIO]/I_GENE
carry O
autonomously O
replicating O
sequences B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

From O
1981 B_MEASURE
to O
1989 B_MEASURE
, O
a O
total B_MEASURE
of O
26 B_PERSON
women I_PERSON
with O
locally O
or O
regionally O
advanced B_DISEASE
carcinoma I_DISEASE
of O
the O
uterine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cervix I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O
treated O
with O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
) O
and O
pelvic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regional I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hyperthermia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
HT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
in O
the O
Divisions B_LOCATION/B_ORGANIZATION
of O
Radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
Oncology I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
at O
the O
University B_LOCATION/B_ORGANIZATION
of O
Utah B_LOCATION
Medical I_LOCATION
Center I_LOCATION
( O
UU B_LOCATION/B_DISEASE
) O
and O
the O
Kenneth B_LOCATION/B_ORGANIZATION
Norris I_LOCATION/I_ORGANIZATION
Jr I_LOCATION/I_ORGANIZATION
Cancer I_LOCATION/I_ORGANIZATION
Hospital I_LOCATION/I_ORGANIZATION
of O
the O
University B_LOCATION/B_ORGANIZATION
of O
Southern B_LOCATION
California I_LOCATION
( O
USC B_LOCATION/B_ORGANIZATION
) O
. O

The O
Are O
is O
loosely O
defined O
as O
the O
five B_NUMBER[MEASURE]
- O
nucleotide B_GENE/B_LOCATION
sequence B_GENE/I_LOCATION
AUUUA B_GENE/I_LOCATION
embedded O
in O
a O
uracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

lack O
of O
changes O
in O
milk O
production O
and O
milk O
composition O
suggest O
that O
acute O
increases O
in O
somatotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
concomitant O
increases O
in O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
not O
sufficient O
to O
stimulate O
synthesis O
of O
milk O
and O
milk O
components O
by O
cows O
during O
established O
lactation O
. O

The O
material B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
then O
was O
cut O
with O
a O
diamond B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
saw B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
into O
sheets B_PRODUCT[OBJECT]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
8 B_MEASURE
x O
10 B_MEASURE
x O
3 B_MEASURE
mm I_MEASURE
, O
and O
the O
upper B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
surface I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
polished O
by O
colloidal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
SiO2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
/ O
or O
covered O
with O
a O
carbon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
titanium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
C B_LOCATION/B_GENE
: O
Ti B_PERSON/B_LOCATION
) O
layer B_LOCATION
( O
3 B_MEASURE
. O
3 B_MEASURE/B_PERSON
microm I_MEASURE/I_PERSON
) O
using O
the O
plasma B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
enhanced O
physical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vapor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
deposition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Iomazenil O
- O
SPECT O
revealed O
a O
highly O
significant O
increase O
in O
the O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uptake O
in O
all O
studied O
cortical O
regions O
except O
temporal O
cortices O
. O

Both O
in O
the O
Federal B_LOCATION/B_MEASURE
Republic I_LOCATION/I_MEASURE
of O
Germany B_LOCATION
and O
in O
some O
neighbouring B_LOCATION
countries I_LOCATION
the O
epizootic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
situation B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Aujeszky B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
has O
been O
unsatisfactory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
long B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
, O
especially O
in O
areas B_LOCATION/B_PERSON
with O
a O
high B_LOCATION/B_DISEASE
pig I_LOCATION/I_DISEASE
density I_LOCATION/I_DISEASE
. O

Since O
RIP140 B_PROTEIN[GENE]/B_LOCATION
generally O
down O
- O
regulates O
receptor O
activity O
in O
mammalian O
cells O
and O
specifically O
down O
- O
regulates O
coactivation O
mediated O
by O
SRC B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
, O
we O
propose O
a O
model O
in O
which O
RIP140 B_GENE
indirectly O
regulates O
nuclear B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
AF I_GENE/I_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
activity O
by O
competition O
for O
coactivators O
such O
as O
SRC B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
. O

DIC B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
low B_DISEASE
grade I_DISEASE
fibrinolysis I_DISEASE
may O
account O
for O
the O
coagulation B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
syndrome B_DISEASE/B_PERSON
. O

As O
in O
the O
case O
of O
the O
chicken O
homologue O
, O
there O
are O
two O
hPR B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
forms O
, O
A O
and O
B O
, O
which O
originate O
from O
translational O
initiation O
at O
AUG2 O
( O
codon O
165 O
) O
and O
AUG1 O
, O
respectively O
. O

fluctuations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
measured O
ECF B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
energy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
- O
related O
substances B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
corresponded O
to O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presumably O
involving O
hypoxia B_DISEASE
/ O
ischemia B_DISEASE
. O

Using O
lasers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
diabetic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wound I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healing I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Furthermore O
, O
the O
zincon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
loaded O
resin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
applied O
to O
the O
selective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trace B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
chalcophile B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
water I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
neutron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
cells O
stably O
transfected O
with O
G B_GENE
alpha I_GENE
i I_GENE
- I_GENE
2 I_GENE
or O
G B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
i I_GENE/I_LOCATION
- I_GENE/I_LOCATION
3 I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
5 O
' O
- O
flanking O
sequences O
fused O
to O
firefly O
luciferase B_GENE/B_BIO
cDNA O
reporter O
, O
temporal O
10 O
- O
15 O
- O
fold O
transcriptional O
activation O
of O
both O
genes O
occurred O
before O
cellular O
polarization O
. O

conclusions O
: O
These O
results O
suggest O
that O
histamine B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
mechanisms O
may O
not O
be O
involved O
in O
postoperative O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O
. O

In O
resume B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
usual B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
doxycycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plus O
streptomycin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
doxycycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rifampicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
being O
however O
time B_TIME[MEASURE]
elapsed O
until O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ceases O
of O
mean B_MEASURE
length I_MEASURE
in O
hospital B_PERSON/B_ORGANIZATION
stay I_PERSON/I_ORGANIZATION
shorter I_PERSON/I_ORGANIZATION
in O
the O
group B_ORGANIZATION/B_PERSON
receiving O
doxycycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
streptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

fibrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
adjacent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
myocardium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
seen O
in O
five B_TIME[MEASURE]/B_PERSON
cases B_TIME[MEASURE]/I_PERSON
. O

Purified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
four B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AGT B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
an O
approximately O
similar B_MEASURE
degree I_MEASURE
( O
74 B_MEASURE
- O
120 B_MEASURE
- O
fold B_MEASURE
) O
of O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
rate B_MEASURE/B_LOCATION
of O
reaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
O6 B_GENE/B_NUMBER[MEASURE]
- O
benzylguanine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Significant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
noted O
in O
vertical B_MEASURE/B_LOCATION
GRFs I_MEASURE/I_LOCATION
per O
Newton B_PERSON/B_MEASURE
of O
body B_MEASURE/B_DISEASE
weight I_MEASURE/I_DISEASE
exerted O
at O
10 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
0009 B_MEASURE
) O
and O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
0383 B_MEASURE
) O
of O
stance B_MEASURE/B_LOCATION
phase I_MEASURE/I_LOCATION
and O
in O
anteroposterior B_MEASURE/B_PERSON
GRFs I_MEASURE/I_PERSON
exerted O
at O
10 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
0009 B_MEASURE
) O
and O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
0033 B_MEASURE
) O
of O
stance B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
phase I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
when O
ambulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
was O
compared O
with O
and O
without O
the O
orthotic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
device B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PRODUCT[OBJECT]
. O

identification O
of O
a O
68 B_GENE
- I_GENE
kilodalton I_GENE
nuclear I_GENE
ATP I_GENE
- I_GENE
binding I_GENE
phosphoprotein I_GENE
encoded O
by O
bovine O
papillomavirus O
type O
1 O
. O

It O
is O
suggested O
that O
biliary B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
both O
TBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
FBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
their O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
contribute O
to O
this O
recycling B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

During O
chordotonal B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
organ B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
the O
3 B_GENE
' I_GENE
enhancer I_GENE
directs O
expression B_GENE
in O
proneural B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
clusters I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
; O
whereas O
successive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
modular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
enhancers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
located O
in O
the O
5 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
region I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
drive I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
tissue I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
chordotonal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
organ B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
precursors B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
embryo B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
larval B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
leg I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
wing B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
antennal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaginal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discs I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
self B_PERSON/B_LOCATION
- O
measured O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
determinations O
in O
assessing O
dynamics B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
compliance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
amlodipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
once O
a O
day B_TIME[MEASURE]
, O
morning B_MEASURE/B_LOCATION
versus I_MEASURE/I_LOCATION
evening I_MEASURE/I_LOCATION
. O

Nucleocapsid B_MEASURE/B_ORGANIZATION
structure I_MEASURE/I_ORGANIZATION
and O
thermostability B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
virion B_GENE
, O
nucleocapsid B_BIO/B_GENE
and O
polymerase B_GENE
complex I_GENE
. O

A O
vascular B_DISEASE_ADJECTIVE[DISEASE]
component I_DISEASE_ADJECTIVE[DISEASE]
to O
impotence B_DISEASE
was O
shown O
to O
be O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
those O
with O
neurological B_DISEASE
impairment I_DISEASE
, O
and O
may O
alter O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
- O
The O
maximal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
early I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
asthmatic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
after O
allergen B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
18 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
SE B_MEASURE
4 I_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
with O
Web B_MEASURE/B_ORGANIZATION
2086 I_MEASURE/I_ORGANIZATION
18 I_MEASURE/I_ORGANIZATION
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
4 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

column B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chromatographic I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
determination I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
polymyxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

usefulness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
computerized B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
hemodialysis B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
. O

The O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
whether O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
augment O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
diastolic I_BODY_PART_OR_ORGAN_COMPONENT
filling O
at O
rest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
during O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
patients B_PERSON/B_BIO
with O
ischemic B_DISEASE
cardiomyopathy I_DISEASE
and O
whether O
any O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O
between O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
diastolic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
filling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
exercise B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
pharmacology B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
9 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
10 B_MEASURE
- O
dihydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
10 B_MEASURE
- O
( O
1 B_MEASURE
- O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
4 B_MEASURE
- O
piperidylidene B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
) O
- O
9 B_MEASURE
- O
anthrol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
WA B_MEASURE/B_LOCATION
335 B_MEASURE/I_LOCATION
) O
, O
a O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

methodology B_MEASURE/B_EDU[ORGANIZATION]
: O
A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
survivors B_PERSON/B_BIO
with O
gestational B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
( O
GA B_LOCATION/B_DISEASE
) O
< O
28 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
or O
birthweight B_MEASURE/B_PERSON
( O
BW B_LOCATION/B_PROTEIN[GENE]
) O
< O
1000 B_MEASURE
g I_MEASURE
using O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collected O
prospectively O
in O
our O
Neonatal B_LOCATION
intensive I_LOCATION
Care I_LOCATION
Unit I_LOCATION
database I_LOCATION
. O

There O
are O
two O
regulatory O
regions O
between O
the O
US3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
US6 B_GENE
transcription I_GENE
units I_GENE
. O

Database O
searches O
revealed O
a O
50 O
- O
63 O
% O
similarity O
and O
34 O
- O
42 O
% O
identity O
with O
several O
families O
of O
serine B_BIO/B_GENE
proteases I_BIO/I_GENE
, O
in O
particular O
the O
trypsin B_BIO/B_ENZYME[GENE]
- I_BIO/I_ENZYME[GENE]
like I_BIO/I_ENZYME[GENE]
proteases I_BIO/I_ENZYME[GENE]
, O
members O
of O
the O
glandular B_PERSON/B_BIO
kallikrein I_PERSON/I_BIO
family I_PERSON/I_BIO
( O
including O
prostate B_GENE/B_DISEASE
- I_GENE/I_DISEASE
specific I_GENE/I_DISEASE
antigen I_GENE/I_DISEASE
, O
nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
epidermal B_GENE
growth I_GENE
factor I_GENE
- I_GENE
binding I_GENE
protein I_GENE
) O
and O
the O
activators O
for O
the O
kringle B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
including O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hepatocyte I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

manifestation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
superfluidity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
an O
evolving O
Bose B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O
einstein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
condensed I_PERSON
Gas B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
We O
study O
the O
generation B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
excitations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
due O
to O
an O
' O
impurity B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
( O
static B_PROTEIN[GENE]/B_LOCATION
perturbation I_PROTEIN[GENE]/I_LOCATION
) O
placed O
into O
an O
oscillating O
Bose B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Einstein B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condensed B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gas B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
time B_MEASURE/B_LOCATION
- O
dependent B_LOCATION/B_MEASURE
trapping I_LOCATION/I_MEASURE
field I_LOCATION/I_MEASURE
. O

4 O
. O
7 B_MEASURE
+ O
/ O
- O
0 B_MEASURE
. O
6 B_MEASURE
micromol I_MEASURE
. O

kg B_MEASURE
- O
1 B_MEASURE/B_LOCATION
. O

min O
- O
1 B_TIME[MEASURE]
) O
but O
was O
not O
changed O
by O
training B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

We O
established O
that O
, O
in O
unstimulated O
lymphocytes O
, O
the O
Src B_GENE
homology I_GENE
2 I_GENE
( O
SH2 B_GENE/B_DISEASE
) O
and O
SH3 B_GENE/B_PERSON
domain I_GENE/I_PERSON
- I_GENE/I_PERSON
containing I_GENE/I_PERSON
protein I_GENE/I_PERSON
Grb2 I_GENE/I_PERSON
and O
the O
p85 B_GENE
subunit O
of O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
associate O
constitutively O
with O
Cbl B_GENE
via O
their O
SH3 B_GENE/B_BIO
domains I_GENE/I_BIO
. O

Zta B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
the O
HAT B_ENZYME[GENE]/B_DISEASE
activity O
of O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
had O
been O
partially O
purified O
or O
immunoprecipitated O
from O
mammalian O
cells O
as O
well O
as O
from O
affinity O
- O
purified O
, O
baculovirus O
expressed O
CBP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

increased O
gliadin B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
were O
found O
more O
frequently O
in O
patients O
with O
subtotal O
villous O
atrophy O
( O
9 O
out O
of O
17 O
patients O
, O
or O
53 O
% O
; O
p O
less O
than O
0 O
. O
05 O
) O
than O
in O
patients O
with O
partial O
villous O
atrophy O
( O
2 O
out O
of O
13 O
patients O
, O
or O
15 O
% O
) O
or O
normal O
villous O
appearance O
( O
2 O
out O
of O
10 O
patients O
, O
or O
20 O
% O
) O
. O

However O
, O
the O
optimum B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compressive B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strength B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O
values B_MEASURE
up O
to O
40 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
CC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
free B_MEASURE
samples I_MEASURE
. O

expression O
of O
the O
Hox B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
egl I_GENE/I_DISEASE
- I_GENE/I_DISEASE
5 I_GENE/I_DISEASE
and O
mab B_MEASURE/B_GENE
- I_MEASURE/I_GENE
5 I_MEASURE/I_GENE
is O
reduced O
in O
lin B_GENE/B_LOCATION
- I_GENE/I_LOCATION
49 I_GENE/I_LOCATION
and O
lin B_MEASURE/B_PERSON
- I_MEASURE/I_PERSON
59 I_MEASURE/I_PERSON
mutants I_MEASURE/I_PERSON
, O
suggesting O
lin B_GENE/B_PERSON
- I_GENE/I_PERSON
49 I_GENE/I_PERSON
and O
lin B_MEASURE/B_GENE
- I_MEASURE/I_GENE
59 I_MEASURE/I_GENE
regulate O
HOM B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
C O
. O
elegans O
as O
the O
trx B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
G I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
genes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
do O
in O
Drosophila O
. O

lin B_GENE/B_DISEASE
- I_GENE/I_DISEASE
49 I_GENE/I_DISEASE
and O
lin B_MEASURE/B_GENE
- I_MEASURE/I_GENE
59 I_MEASURE/I_GENE
transgenes I_MEASURE/I_GENE
are O
expressed O
widely O
throughout O
C O
. O
elegans O
animals O
. O

Interleukin B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
1 I_PERSON/I_LOCATION
increased O
the O
noradrenaline O
release O
. O

Magnetic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
central B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
system B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
function B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

3 O
patients O
with O
acute O
leukaemia O
, O
HLA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O
and O
thrombocytopenia O
refractory O
to O
random O
donor O
platelet O
transfusions O
were O
treated O
with O
high O
- O
dose O
i O
. O
v O
. O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
genes O
( O
ptsI B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O
ptsA B_PROTEIN[GENE]/B_LOCATION
) O
that O
encode O
homologues O
of O
the O
energy O
coupling O
Enzyme B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
phosphoenolpyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sugar I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphotransferase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O
( O
PTS O
) O
have O
previously O
been O
identified O
on O
the O
Escherichia O
coli O
chromosome O
. O

Eight O
of O
these O
suppressors O
for O
into O
two O
complementation O
groups O
, O
designated O
KCS1 B_GENE/B_DISEASE
and O
KCS2 B_PROTEIN[GENE]/B_DISEASE
. O

These O
results O
point O
towards O
post O
- O
translational O
steric O
and O
/ O
or O
allosteric O
control O
of O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O
that O
may O
be O
important O
not O
just O
for O
its O
DNA O
binding O
ability O
, O
but O
also O
for O
its O
potential O
to O
interact O
with O
other O
proteins O
that O
fully O
establish O
the O
correct O
stereospecific O
array O
leading O
to O
efficient O
switching O
of O
beta B_GENE
- I_GENE
globin I_GENE
transcription O
during O
development O
. O

Oxalates B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
digestive B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

However O
, O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
FPFD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
101 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
marked O
improvement B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
their O
symptoms B_DISEASE
. O

Western O
blot O
experiments O
detected O
SMBP B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
a O
70 O
kDa O
protein O
that O
may O
be O
further O
cleaved O
into O
an O
active O
34 O
kDa O
N O
- O
terminal O
polypeptide O
. O

The O
aetiology B_DISEASE
and O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
diabetic B_DISEASE
impotence I_DISEASE
is O
well O
- O
documented O
; O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diabetes B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
female B_DISEASE_ADJECTIVE[DISEASE]
sexuality I_DISEASE_ADJECTIVE[DISEASE]
are O
not O
so O
clear B_DISEASE_ADJECTIVE[DISEASE]
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
diabetes B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
retinal B_DISEASE
complications I_DISEASE
. O

The O
activated O
glucocorticoid B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
forms O
a O
complex O
with O
Stat5 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
enhances O
Stat5 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
transcriptional O
induction O
. O

taken O
together O
, O
these O
findings O
demonstrate O
that O
ZNF76 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ZNF143 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
two O
members O
of O
a O
same O
family O
of O
transactivator O
proteins O
. O

For O
example O
, O
the O
presence O
of O
two O
related O
genes O
, O
b B_PROTEIN[GENE]/B_DISEASE
and O
b B_PROTEIN[GENE]/B_DISEASE
' I_PROTEIN[GENE]/I_DISEASE
, O
in O
the O
cyanobacterium O
suggests O
that O
its O
ATP B_GENE
synthase I_GENE
is O
a O
complex O
of O
nine O
polypeptides O
, O
and O
that O
it O
may O
have O
single O
copies O
of O
related O
b B_PROTEIN[GENE]/B_DISEASE
and O
b B_PROTEIN[GENE]
' I_PROTEIN[GENE]
proteins I_PROTEIN[GENE]
rather O
than O
two O
copies O
of O
identical O
b B_GENE/B_LOCATION
subunits I_GENE/I_LOCATION
as O
found O
in O
the O
E O
. O
coli O
enzyme O
. O
4 O
+ O
off O
. O

Antiserum O
raised O
against O
rat B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S6 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
immunoprecipitates O
the O
purified O
32P O
- O
labeled O
H4 O
hepatoma O
insulin O
- O
stimulated O
S6 B_ENZYME[GENE]/B_MEASURE
kinase I_ENZYME[GENE]/I_MEASURE
. O

CRKL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
an O
SH2 B_GENE/B_DISEASE
- O
SH3 B_LOCATION/B_GENE
- O
SH3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adapter O
protein O
, O
is O
one O
of O
the O
major O
tyrosine B_GENE/B_BIO
phosphoproteins I_GENE/I_BIO
detected O
in O
primary O
leukemic O
neutrophils O
from O
patients O
with O
CML O
. O

Ku B_PERSON/B_PROTEIN[GENE]
- O
1257 B_NUMBER[MEASURE]
also O
significantly O
accelerated O
the O
healing B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
acetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
duodenal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ulcers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
as O
well O
as O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
roxatidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

To O
further O
identify O
the O
residues O
responsible O
for O
the O
activity O
, O
we O
isolated O
the O
mutant O
viruses O
that O
were O
not O
neutralized O
with O
the O
soluble O
form O
of O
MHV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
since O
such O
mutants O
were O
expected O
to O
have O
mutations O
in O
amino O
acids O
responsible O
for O
receptor O
- O
binding O
activity O
. O

It O
is O
suggested O
that O
death B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
S B_DISEASE/B_LOCATION
. O
mansoni B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cercariae I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
during O
penetration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
mammalian B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
host I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skin I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
probably O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
exhaustion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
energy B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reserves B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Especially O
if O
the O
number B_MEASURE/B_LOCATION
of O
dimensions B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
it O
can O
be O
said O
that O
BPN B_DISEASE/B_MEASURE
is O
better B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
k B_MEASURE/B_PROTEIN[GENE]
- O
NN B_MEASURE/B_BIO
in O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
contrast O
, O
inactivation O
of O
the O
Sir4p B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
interacting I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rap1p I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O
partitioning O
by O
a O
LexA B_GENE/B_BACTERIUM[BIO]
- O
Sir4p B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fusion O
. O

Nine B_PERSON/B_ENT
individuals I_PERSON/I_ENT
who O
were O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
1 B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
randomized O
to O
a O
further B_TIME[MEASURE]/B_ORGANIZATION
month I_TIME[MEASURE]/I_ORGANIZATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dosage B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
during O
which O
one B_NUMBER[MEASURE]/B_PERSON
of O
four B_NUMBER[MEASURE]/B_PERSON
at O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dosage B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
had O
a O
partial B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
none B_PERSON/B_NUMBER[MEASURE]
of O
five B_NUMBER[MEASURE]/B_PERSON
at O
low B_MEASURE
dosage I_MEASURE
manifested I_MEASURE
response I_MEASURE
. O

Background O
: O
Murine B_GENE/B_PERSON
Nramp I_GENE/I_PERSON
is O
a O
candidate O
for O
the O
macrophage O
resistance O
gene O
Ity B_LOCATION/B_PERSON
/ O
Lsh B_LOCATION/B_PERSON
/ O
Bcg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
cases O
in O
which O
it O
was O
identified O
, O
insulitis O
affected O
23 O
% O
of O
islets O
containing O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
affected O
only O
1 O
% O
of O
islets O
which O
were O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficient O
, O
thus O
supporting O
the O
concept O
that O
insulitis O
represents O
an O
immunologically O
mediated O
destruction O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secreting O
B O
cells O
. O

( O
4 B_TIME[MEASURE]/B_LOCATION
) O
Expression B_GENE
in O
different B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
central B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
system I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
driven O
by O
separable B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
elements B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
widely O
dispersed O
throughout O
8 B_MEASURE
kb I_MEASURE
3 I_MEASURE
' O
of O
the O
gene B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

To O
investigate O
possible O
roles O
for O
HCP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
during O
late O
erythroid O
differentiation O
, O
effects O
of O
manipulating O
HCP B_PROTEIN[GENE]/B_BIO
expression O
or O
recruitment O
on O
EPO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hemoglobinization O
in O
erythroleukemic O
SKT6 O
cells O
have O
been O
investigated O
. O

The O
other O
end O
of O
this O
cluster O
contained O
the O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
type I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cytokeratin I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
K20 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
K12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci O
. O

An O
11 B_MEASURE
. O
5 B_MEASURE
- O
kb B_GENE/B_LOCATION
intron I_GENE/I_LOCATION
is O
found O
at O
the O
end B_LOCATION
of O
transmembrane B_GENE
6 I_GENE
, O
and O
the O
rest B_LOCATION/B_MEASURE
of O
the O
ORF B_GENE/B_LOCATION
is O
in O
exon B_GENE/B_LOCATION
3 I_GENE/I_LOCATION
. O

Are O
there O
any O
lessons B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
learnt B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

eighteen B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
advanced B_DISEASE
epidermoid I_DISEASE
carcinoma I_DISEASE
of O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT
and O
neck B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O
entered O
into O
a O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
N B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Methylformamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NMF B_DISEASE/B_MEASURE
) O
, O
800 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
M2 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IV I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
for O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
every O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
. O

We O
provided O
evidence O
that O
CaM B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O
a O
role O
in O
regulating O
neurite O
outgrowth O
and O
growth O
cone O
motility O
in O
these O
cells O
, O
and O
that O
the O
autophosphorylation O
is O
essential O
for O
the O
kinase O
to O
sufficiently O
exert O
its O
cellular O
function O
in O
vivo O
[ O
Y O
. O

However O
, O
in O
transient O
transfection O
assays O
, O
a O
truncation O
of O
as O
little O
as O
15 O
Nurr1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
COOH O
- O
terminal O
amino O
acids O
diminished O
transcriptional O
activation O
of O
B1A B_GENE/B_BIO
- O
thymidine B_GENE
kinase I_GENE
- O
chloramphenicol B_GENE
acetyltransferase I_GENE
reporter O
. O

All O
sows B_NUMBER[MEASURE]/B_PERSON
nursed O
nine B_TIME[MEASURE]/B_PERSON
pigs B_TIME[MEASURE]/I_PERSON
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
the O
untreated B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fellow I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
eye I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
microscopically O
intact B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
was O
shown O
( O
as O
the O
treated O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
) O
to O
alter O
the O
concentration B_MEASURE
of O
uronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
different B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
sclera B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
studied O
of O
extremely O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
frequency B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
electromagnetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
radiation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
EHF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
EMR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
on O
indices B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
endocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
48 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
presenting O
with O
hyperplastic B_DISEASE
processes I_DISEASE
in O
endometrium B_LOCATION/B_PERSON
. O

characterization O
of O
human B_GENE
activating I_GENE
transcription I_GENE
factor I_GENE
4 I_GENE
, O
a O
transcriptional O
activator O
that O
interacts O
with O
multiple O
domains O
of O
cAMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREB B_GENE/B_DISEASE
) O
- O
binding O
protein O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
constant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
carcinogenesis B_DISEASE
. O

In O
contrast O
to O
the O
reciprocal O
effects O
of O
Gab1 B_GENE
and O
Gab2 B_GENE
in O
mediating O
Elk B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
induction O
, O
these O
two O
molecules O
have O
a O
similar O
function O
in O
extracellular B_GENE
signal I_GENE
- I_GENE
regulated I_GENE
kinase I_GENE
activation O
induced O
by O
either O
oncogenic O
Ras B_GENE/B_DISEASE
or O
growth O
factor O
stimulation O
. O

This O
result O
is O
consistent O
with O
the O
previous O
observation O
that O
expression O
of O
the O
hsp70 B_GENE/B_BACTERIUM[BIO]
genes I_GENE/I_BACTERIUM[BIO]
in I_GENE/I_BACTERIUM[BIO]
T I_GENE/I_BACTERIUM[BIO]
. I_GENE/I_BACTERIUM[BIO]
brucei I_GENE/I_BACTERIUM[BIO]
is O
mainly O
controlled O
at O
the O
posttranscriptional O
level O
. O

A O
definition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
bias B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
founded O
on O
the O
concept B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
base I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Chromaffin O
cells O
transfected O
with O
a O
plasmid O
with O
the O
entire O
coding O
sequence O
of O
c B_GENE
- I_GENE
Rabphilin3a I_GENE
inserted O
in O
the O
antisense O
orientation O
inhibited O
secretion O
of O
co O
- O
expressed O
GH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
approximately O
30 O
% O
. O

Using O
a O
set O
of O
sera O
for O
which O
full O
chlamydial O
micro O
- O
immunofluorescence O
results O
suggested O
a O
clear O
diagnosis O
, O
we O
have O
evaluated O
the O
Chlamydia O
Spot O
- O
IF O
test O
( O
bioMerieux O
) O
, O
which O
allows O
a O
comparison O
of O
titres O
to O
Chlamydia B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trachomatis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psittaci B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
suboptimal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
food I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
storage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
cooking B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperatures B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
restaurant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
cross B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contamination B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
foods B_BIO
may O
have O
contributed O
to O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attributable B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O
for O
Chile B_DISEASE/B_LOCATION
rellenos I_DISEASE/I_LOCATION
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
areas I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O
- O
sensory B_DISEASE/B_LOCATION
deprivation I_DISEASE/I_LOCATION
, O
enriched O
environments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
nervous B_DISEASE/B_PERSON
system I_DISEASE/I_PERSON
plasticity I_DISEASE/I_PERSON
, O
and O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
periods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
neurodevelopment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
- O
suggests O
that O
sensory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
potentially O
beneficial B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
STR B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
. O

In O
each O
study B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
elevated O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
serum B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
were O
observed O
. O

With O
repetitive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
intermittent I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
exercise I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
gradual B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
increases B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
blood B_MEASURE/B_DISEASE
lactate I_MEASURE/I_DISEASE
concentration I_MEASURE/I_DISEASE
[ I_MEASURE/I_DISEASE
( O
LA B_LOCATION/B_PROTEIN[GENE]
] I_LOCATION/I_PROTEIN[GENE]
b I_LOCATION/I_PROTEIN[GENE]
) O
occurred O
, O
whereas O
its O
rate B_MEASURE
of O
accumulation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
delta B_LOCATION/B_MEASURE
[ I_LOCATION/I_MEASURE
LA I_LOCATION/I_MEASURE
] I_LOCATION/I_MEASURE
b I_LOCATION/I_MEASURE
) O
decreased O
. O

A O
physical O
and O
genetic O
map O
covering O
the O
entire O
RP12 B_LOCATION/B_GENE
candidate I_LOCATION/I_GENE
gene I_LOCATION/I_GENE
region I_LOCATION/I_GENE
was O
constructed O
. O

The O
single O
copy O
flotillin B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
is O
located O
at O
6p21 O
. O
3 O
in O
the O
MHC B_SPECIES[BIO]/B_MEASURE
class I_SPECIES[BIO]/I_MEASURE
I I_SPECIES[BIO]/I_MEASURE
region I_SPECIES[BIO]/I_MEASURE
and O
consists O
of O
13 O
exons O
over O
15 O
kb O
. O

An O
atypical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
juvenile B_DISEASE
myasthenia I_DISEASE
gravis I_DISEASE
associated O
with O
severe B_DISEASE
emaciation I_DISEASE
, O
muscle B_DISEASE
atrophy I_DISEASE
, O
ophthalmoplegia B_DISEASE
, O
bulbar B_DISEASE
signs I_DISEASE
and O
joint B_DISEASE
contracture I_DISEASE
. O

The O
in O
vivo O
response O
of O
the O
PacC B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
like I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
decamers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
external O
pH O
was O
dependent O
on O
the O
status O
of O
the O
pH O
- O
regulated O
activator O
YlRim101p B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
homologous O
to O
the O
A O
. O
nidulans O
PacC B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regulator O
. O

electron O
microscopic O
visualization O
of O
the O
general O
population O
of O
active O
genes O
in O
flies O
overexpressing O
hnRNP B_GENE
proteins I_GENE
also O
indicated O
that O
the O
great O
majority O
of O
genes O
seemed O
normal O
in O
terms O
of O
cotranscriptional O
RNA O
processing O
events O
, O
although O
there O
were O
a O
few O
abnormalities O
consistent O
with O
rare O
exon O
- O
skipping O
events O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
calmodulin B_GENE
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
calmodulin B_GENE
( O
GFP B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
Camlp I_PROTEIN[GENE]/I_LOCATION
) O
in O
fission O
yeast O
, O
where O
calmodulin B_GENE/B_BIO
had O
not O
been O
localized O
by O
any O
method O
. O

Sera O
from O
33 O
newborn O
infants O
with O
gestational O
ages O
ranging O
from O
27 O
to O
41 O
weeks O
were O
tested O
by O
radioimmunoassay O
for O
IgG B_GENE/B_MEASURE
antibodies O
to O
surface O
antigens O
of O
group O
B O
streptococci O
( O
GBS O
) O
types O
Ia O
, O
Ib O
, O
II O
and O
III O
. O

In O
frozen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O
spots B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
appear O
as O
blue B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
labelled O
neurones B_LOCATION/B_BIO
with O
a O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
as O
a O
brilliant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
red B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
neurones B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
surrounded O
by O
reddish B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_COLOR
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_COLOR
with O
a O
fluorescence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
microscope B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
percentage B_MEASURE
distribution I_MEASURE
of O
types B_DISEASE/B_MEASURE
of O
fixation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disparity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
curves B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
found O
to O
be O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
some O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
with O
a O
higher B_MEASURE/B_LOCATION
prevalence I_MEASURE/I_LOCATION
of O
Type B_MEASURE/B_ORGANIZATION
I O
curve B_MEASURE
( O
64 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
, O
followed O
by O
Type B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
( O
28 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
Type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
III B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
7 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
curves B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
BUR B_MEASURE/B_PROTEIN[GENE]
was O
set O
at O
20 B_MEASURE
/ O
min B_MEASURE/B_PERSON
and O
the O
IT O
at O
. O
5 B_MEASURE/B_ENT
seconds I_MEASURE/I_ENT
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
in O
the O
context B_LOCATION
of O
the O
pathogenesis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
EEC B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

seminal O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
significantly O
elevated O
in O
all O
infertile O
males O
. O

Northern O
blot O
analysis O
identified O
retina O
- O
specific O
transcripts O
of O
3 O
. O
0 O
kb O
for O
rod B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O
2 O
. O
6 O
kb O
for O
cone B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O

In O
the O
univariate O
models O
of O
either O
fixed O
or O
time O
dependent O
covariates O
, O
many O
variables O
were O
significantly O
associated O
with O
risk O
of O
progression O
to O
AIDS O
( O
T4 O
cell O
count O
, O
T4 O
/ O
T8 O
ratio O
, O
blastogenic O
responses O
to O
phytohemagglutinin B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
concanavalin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
pokeweed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
serum B_DISEASE
IgA I_DISEASE
, O
appearance O
of O
p24 B_DISEASE/B_GENE
antigen I_DISEASE/I_GENE
, O
and O
the O
development O
of O
oral O
hairy O
leukoplakia O
, O
thrush O
, O
or O
herpes O
zoster O
) O
. O

Adenovirus O
- O
mediated O
gene O
transfer O
of O
MMAC1 B_GENE
/ O
PTEN B_PROTEIN[GENE]/B_MEASURE
to O
glioblastoma O
cells O
inhibits O
S O
phase O
entry O
by O
the O
recruitment O
of O
p27Kip1 B_GENE
into O
cyclin B_GENE
E I_GENE
/ O
CDK2 B_GENE
complexes O
. O

cost B_LOCATION/B_ORGANIZATION
analysis I_LOCATION/I_ORGANIZATION
and O
the O
HSA B_LOCATION/B_ORGANIZATION
: O
a O
framework B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

These O
cells O
also O
showed O
an O
increase O
in O
cyclin B_GENE
A I_GENE
and O
cyclin B_GENE
A I_GENE
- I_GENE
and I_GENE
E I_GENE
- I_GENE
associated I_GENE
kinase I_GENE
activities O
characteristic O
of O
S O
phase O
induction O
. O

characterization O
of O
a O
tonB B_GENE/B_BACTERIUM[BIO]
- O
phoA B_BACTERIUM[BIO]/B_GENE
gene O
fusion O
suggests O
that O
the O
amino O
- O
terminal O
41 O
amino O
acids O
of O
TonB B_GENE/B_BACTERIUM[BIO]
are O
sufficient O
to O
promote O
export O
of O
the O
fusion O
protein O
and O
presumably O
TonB B_BACTERIUM[BIO]/B_GENE
as O
well O
. O

Calcium B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
bilirubinate I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
crystals I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
seen O
in O
gallbladder B_BODY_PART_OR_ORGAN_COMPONENT
bile I_BODY_PART_OR_ORGAN_COMPONENT
or O
wall B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scrapings I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
7 B_NUMBER[MEASURE]
of O
8 B_NUMBER[MEASURE]/B_PERSON
TPN I_NUMBER[MEASURE]/I_PERSON
animals I_NUMBER[MEASURE]/I_PERSON
but O
in O
none B_PERSON/B_NUMBER[MEASURE]
of O
the O
controls B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
. O

This O
domain O
encompasses O
the O
region O
of O
ARP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
/ O
COUP B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
TFII I_PROTEIN[GENE]/I_MEASURE
corresponding O
to O
helices O
3 O
to O
12 O
in O
the O
recently O
published O
crystal O
structure O
of O
other O
members O
of O
the O
nuclear B_GENE/B_BIO
receptor I_GENE/I_BIO
superfamily I_GENE/I_BIO
. O

Different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variants I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
empty B_DISEASE_ADJECTIVE[DISEASE]
sella I_DISEASE_ADJECTIVE[DISEASE]
turcica I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
are O
demonstrated O
, O
including O
variants B_LOCATION/B_DISEASE
resultant O
from O
substitution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
thyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypofunction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
from O
dopamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
agonist I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
hyperprolactinemic B_DISEASE
hypogonadism I_DISEASE
, O
from O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
hypophyseal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adenoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Both O
genes B_GENE
ARO3 I_GENE
and O
ARO4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
strongly O
regulated O
under O
the O
general O
control O
regulatory O
system O
. O

Polar O
effects O
of O
transposon O
insertions O
demonstrated O
that O
all O
of O
these O
mRNAs O
arose O
from O
a O
single O
promoter O
region O
, O
where O
transcription O
initiated O
80 O
BP O
5 O
' O
to O
nifH B_TIME[MEASURE]/B_LOCATION
. O

J B_OTHER/B_LOCATION
. O
, O
& O
Olefsky B_PERSON/B_LOCATION
, O
J B_OTHER/B_PERSON
. O

importantly O
, O
a O
single O
base O
change O
in O
the O
fifth O
position O
of O
the O
c B_GENE/B_LOCATION
- I_GENE/I_LOCATION
fos I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
( O
GGTCTnnnAGACC O
to O
GGTCA O
/ O
GnnnAGACC O
) O
produced O
an O
element O
that O
bound O
the O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
conferred O
estrogen O
- O
dependent O
transcriptional O
activation O
of O
a O
reporter O
gene O
. O

measuring O
the O
dim B_MEASURE/B_LOCATION
light I_MEASURE/I_LOCATION
melatonin I_MEASURE/I_LOCATION
onset I_MEASURE/I_LOCATION
( O
DLMO B_LOCATION/B_DISEASE
) O
is O
a O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
practical B_DISEASE_ADJECTIVE[DISEASE]
way I_DISEASE_ADJECTIVE[DISEASE]
to O
assess O
circadian B_DISEASE
phase I_DISEASE
position I_DISEASE
in O
humans B_PERSON/B_BIO
. O

Co O
- O
expression O
of O
a O
gag B_GENE
- O
TRalpha B_GENE
fusion O
protein O
in O
AEV O
- O
transformed O
cells O
and O
addition O
of O
ligand O
derepresses O
CAII B_GENE/B_VIRUS[BIO]
transcription O
. O

The O
IB2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HGMW O
- O
approved O
symbol O
MAPK8IP2 B_GENE/B_TIME[MEASURE]
) O
maps O
to O
human O
chromosome O
22q13 O
and O
contains O
10 O
coding O
exons O
. O

transcription O
start O
sites O
of O
sal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
salR B_GENE
genes I_GENE
were O
determined O
to O
lie O
30 O
- O
and O
24 O
- O
BP O
upstream O
of O
the O
respective O
initiation O
codons O
and O
separated O
from O
each O
other O
by O
78 O
nucleotides O
. O

1 O
. O
23 O
) O
as O
a O
PPARalpha B_MEASURE/B_GENE
- I_MEASURE/I_GENE
interacting I_MEASURE/I_GENE
protein I_MEASURE/I_GENE
. O

Here O
we O
demonstrate O
that O
the O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
70 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoreceptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
essential O
for O
the O
membrane O
recruitment O
of O
SOS B_GENE/B_DISEASE
and O
Vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
carried O
out O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
investigate O
this O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

When O
linked O
to O
the O
herpes O
simplex O
thymidine B_ENZYME[GENE]/B_VIRUS[BIO]
kinase B_ENZYME[GENE]/I_VIRUS[BIO]
minimal O
promoter O
, O
this O
fragment O
acts O
as O
an O
enhancing O
element O
in O
Rcho O
but O
not O
GC O
cells O
. O

A O
mammalian O
protein O
called O
RFX B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
NF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
X I_GENE/I_DISEASE
binds O
to O
the O
X O
box O
( O
or O
X1 O
box O
) O
in O
the O
promoters O
of O
a O
number O
of O
major B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Site B_LOCATION/B_BIO
- O
directed O
mutagenesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
was O
conducted O
to O
investigate O
the O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
element B_LOCATION
and O
the O
3 B_NUMBER[MEASURE]
' I_NUMBER[MEASURE]
minus I_NUMBER[MEASURE]
- O
strand B_GENE/B_LOCATION
terminal I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
' O
3 B_NUMBER[MEASURE]
' O
- O
OH B_LOCATION/B_PROTEIN[GENE]
- O
CCCUAU B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
' O
which O
contains O
the O
minus B_NUMBER[MEASURE]
- O
strand B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
3 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
' I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
end B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
' O
3 B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
- O
OH B_LOCATION/B_PROTEIN[GENE]
- O
CC B_LOCATION/B_DISEASE
( O
1 B_MEASURE/B_LOCATION
- O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
U B_OTHER/B_LOCATION
) O
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
U B_OTHER/B_LOCATION
) O
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
U B_OTHER/B_LOCATION
) O
' O
found O
in O
all O
carmovirus B_BIO/B_GENE
RNAs I_BIO/I_GENE
. O

The O
incidence O
of O
the O
variability O
of O
the O
free O
PSA B_PROTEIN[GENE]
/ O
total O
PSA B_GENE
ratio O
on O
the O
early O
diagnosis O
of O
prostate O
cancer O
. O

VBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
a1 B_GENE
/ I_GENE
EBP I_GENE
could O
mediate O
the O
high O
rates O
of O
ALV O
and O
RSV B_DISEASE/B_VIRUS[BIO]
LTR B_DISEASE/I_VIRUS[BIO]
- O
enhanced O
transcription O
in O
bursal O
lymphoma O
cells O
and O
many O
other O
cell O
types O
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
37 B_PERSON/B_BIO
students I_PERSON/I_BIO
were O
given O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
sulphamethoxazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
160 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
SMX B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
800 I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
38 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TMP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
and O
in O
35 B_NUMBER[MEASURE]
a O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
given O
b B_DISEASE/B_MEASURE
. O
i O
. O
d O
. O
for O
five B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

developmental O
slot O
blots O
demonstrate O
that O
mRNAs O
corresponding O
to O
the O
three O
LHM B_GENE/B_LOCATION
cDNAs I_GENE/I_LOCATION
are O
transcribed O
from O
prophase O
of O
meiosis O
I O
to O
the O
uninucleate O
microspore O
stage O
, O
while O
Northern O
analysis O
reveals O
these O
tapetally O
expressed O
cDNAs O
to O
correspond O
with O
transcripts O
of O
some O
500 O
BP O
. O

One B_PERSON/B_ENT
hundred I_PERSON/I_ENT
men I_PERSON/I_ENT
who O
received O
alpha B_PROTEIN[GENE]
- O
tocopherol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
matched O
on O
age B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
study B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
center I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
length B_MEASURE/B_LOCATION
of O
time B_TIME[MEASURE]/B_DISEASE
between O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_NUMBER[MEASURE]
draws O
to O
100 B_PERSON/B_SPORT[ENT]
men I_PERSON/I_SPORT[ENT]
who O
received O
a O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B_LOCATION/B_PERSON
binding I_LOCATION/I_PERSON
domain I_LOCATION/I_PERSON
of O
Raf B_GENE/B_DISEASE
( O
RafRBD B_PROTEIN[GENE]/B_LOCATION
) O
to O
Ras B_GENE/B_DISEASE
- O
Raf B_GENE/B_DISEASE
interaction O
and O
Ras B_GENE/B_DISEASE
- O
dependent O
Raf B_GENE/B_DISEASE
activation O
has O
remained O
unresolved O
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recommendations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
enhancing O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiplatelet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
variety B_ENT/B_MEASURE
of O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
situations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O
provided O
. O

Results B_MEASURE/B_LOCATION
- O
- O
261 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
were O
enrolled O
into O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
of O
these O
, O
138 B_MEASURE
( O
53 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON/B_LOCATION
attended O
for O
repeat B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colposcopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
one B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
omentum B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_BIO/B_MEASURE
strains I_BIO/I_MEASURE
after O
intraperitoneal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
sheep B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
erythrocytes B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study O
, O
we O
sought O
to O
determine O
the O
specific O
effect O
of O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protease I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O
on O
patient O
weight O
. O

However O
massive B_DISEASE/B_NUMBER[MEASURE]
necrosis I_DISEASE/I_NUMBER[MEASURE]
of O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tubules I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
had O
been O
found O
with O
more B_MEASURE
than O
15mg B_TIME[MEASURE]
of O
DSM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
apparatus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
measure O
DEOAEs B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
described O
together O
with O
typical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
emissions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

To O
obtain O
information O
on O
the O
functional O
role O
of O
the O
Rac1 B_GENE
/ O
p38 B_GENE
/ O
MAPKAPK B_GENE
- I_GENE
2 I_GENE
pathway O
in O
RA O
signaling O
, O
the O
effects O
of O
pharmacological O
inhibition O
of O
p38 B_GENE
on O
RA O
- O
induced O
gene O
transcription O
and O
cell O
differentiation O
were O
determined O
. O

The O
cost B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
effectiveness B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
nurse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
education I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
- O
1 B_NUMBER[MEASURE]
. O

The O
ATF B_LOCATION/B_GENE
/ O
CRE O
site O
is O
also O
essential O
for O
CD4 B_GENE/B_MEASURE
promoter I_GENE/I_MEASURE
activation O
by O
forskolin O
, O
an O
activator O
of O
adenylate B_GENE
cyclase I_GENE
. O

YLL031c B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
essential O
gene O
. O

restricted O
expression O
of O
a O
novel O
murine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
atonal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
undifferentiated O
neural O
precursors O
. O

Since O
the O
early B_TIME[MEASURE]
1900s I_TIME[MEASURE]
, O
a O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
suggested O
. O

We O
report O
the O
genomic O
organization O
of O
the O
mouse O
orphan B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Ryk B_GENE
) O
, O
a O
structurally O
unclassified O
member O
of O
the O
growth B_GENE
factor I_GENE
receptor I_GENE
family O
. O

In O
contrast O
, O
T229E B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p70s6k I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migrated O
more O
slowly O
in O
SDS O
- O
polyacrylamide O
gels O
, O
but O
demonstrated O
partial O
kinase O
activity O
( O
approximately O
20 O
% O
compared O
with O
the O
wild O
type O
) O
. O

The O
structure O
and O
expression O
of O
the O
murine B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
encoding I_GENE/I_LOCATION
granulocyte I_GENE/I_LOCATION
- I_GENE/I_LOCATION
macrophage I_GENE/I_LOCATION
colony I_GENE/I_LOCATION
stimulating I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
: O
evidence O
for O
utilisation O
of O
alternative O
promoters O
. O

Thus O
, O
the O
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
acquired O
susceptibility B_DISEASE/B_LOCATION
to O
nontuberculous B_DISEASE
mycobacteria I_DISEASE
is O
also O
a O
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
susceptibility B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
MTB B_DISEASE/B_PERSON
as O
well O
as O
an O
opportunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
recognize O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
can O
be O
exploited O
therapeutically O
. O

liver O
disease O
and O
HCV O
infection O
after O
transplantation O
of O
organs O
from O
hepatitis B_DISEASE/B_GENE
C I_DISEASE/I_GENE
antibody I_DISEASE/I_GENE
positive O
donors O
. O

After O
dialysis O
online O
, O
lactate O
was O
converted O
by O
means O
of O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immobilized O
to O
porous O
glass O
, O
and O
the O
depletion O
of O
oxygen O
was O
registered O
by O
means O
of O
a O
Clark O
electrode O
. O

The O
deduced O
amino O
- O
acid O
sequence O
of O
the O
mature O
enzyme O
showed O
very O
low O
homology O
( O
< O
20 O
. O
4 O
% O
identity O
) O
to O
those O
of O
known O
pectinolytic O
enzymes O
in O
the O
large O
pectate B_LOCATION/B_PERSON
lyase I_LOCATION/I_PERSON
superfamily I_LOCATION/I_PERSON
( O
the O
polysaccharide B_PERSON/B_LOCATION
lyase I_PERSON/I_LOCATION
family I_PERSON/I_LOCATION
1 I_PERSON/I_LOCATION
) O
. O

Incubation O
of O
HeLa O
cell O
cytoplasmic O
extracts O
with O
a O
purified O
recombinant O
glutathione B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
raf B_GENE/B_DISEASE
fusion O
protein O
in O
the O
presence O
of O
ATP O
released O
active O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
that O
could O
be O
detected O
by O
electrophoretic O
gel O
mobility O
shift O
assay O
. O

Despite O
this O
loss O
, O
YEpFAS1 B_PERSON
is O
still O
able O
to O
complement O
a O
fas1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O
at O
the O
enoyl B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
reductase B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
domain O
. O

Cross O
- O
species O
characterization O
of O
the O
promoter B_GENE/B_LOCATION
region I_GENE/I_LOCATION
of I_GENE/I_LOCATION
the I_GENE/I_LOCATION
cystic I_GENE/I_LOCATION
fibrosis I_GENE/I_LOCATION
transmembrane I_GENE/I_LOCATION
conductance I_GENE/I_LOCATION
regulator I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
reveals O
multiple O
levels O
of O
regulation O
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
not O
necessary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
improve O
survival B_DISEASE_ADJECTIVE[DISEASE]
: O
16 B_MEASURE
of O
17 B_MEASURE
( O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
infected O
and O
visibly O
ill B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
animals I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O
received O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ticarcillin B_MEASURE
6 I_MEASURE
h O
after O
thigh B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inoculation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
survived O
versus B_MEASURE
30 I_MEASURE
of O
44 B_MEASURE
( O
68 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
control B_SPECIES[BIO]/B_ORGANIZATION
animals I_SPECIES[BIO]/I_ORGANIZATION
treated O
with O
ticarcillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

The O
predicted O
vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O
several O
motifs O
reminiscent O
of O
transcriptional O
factors O
. O

The O
pharmacokinetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
best O
described O
by O
a O
two B_NUMBER[MEASURE]
- O
compartment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
giving O
distribution B_MEASURE/B_LOCATION
half I_MEASURE/I_LOCATION
- O
lives B_PERSON/B_TIME[MEASURE]
of O
0 B_MEASURE
. O
31 B_MEASURE
h O
and O
1 B_MEASURE
. O
53 B_MEASURE
h O
, O
and O
elimination B_MEASURE/B_PERSON
half I_MEASURE/I_PERSON
- O
lives B_PERSON/B_TIME[MEASURE]
of O
69 B_MEASURE
. O
7 B_MEASURE
h O
and O
60 B_MEASURE
. O
3 B_MEASURE
h O
for O
oxolinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxytetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

The O
predictive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
remotely O
sensed O
map B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
based O
on O
NDVI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
appears O
to O
be O
better B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
that O
from O
forecast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
based O
only O
on O
climatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

It O
has O
been O
confirmed O
in O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
the O
number B_MEASURE/B_LOCATION
of O
microspheres B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
myocardial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
approximately O
follows O
a O
Poisson B_MEASURE
distribution I_MEASURE
, O
under O
adequate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Hepatitis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulins I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
HIV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
gene O
is O
divided O
into O
six O
exons O
spanning O
about O
3kb O
, O
and O
encodes O
a O
175 O
amino O
acid O
protein O
with O
40 O
- O
52 O
% O
identity O
with O
the O
other O
five O
mouse B_GENE/B_PERSON
Reg I_GENE/I_PERSON
( O
regenerating B_PROTEIN[GENE]/B_LOCATION
gene I_PROTEIN[GENE]/I_LOCATION
product I_PROTEIN[GENE]/I_LOCATION
) O
proteins O
. O

The O
p63 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
features O
an O
acidic O
domain O
characteristic O
of O
transcriptional O
activation O
factors O
, O
as O
well O
as O
sequence O
blocks O
displaying O
limited O
similarity O
to O
positionally O
equivalent O
regions O
in O
sigma B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
eubacteria O
related O
to O
mitochondria O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
LDLR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
DAF17 B_GENE
, O
abbreviated O
HLD B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B_GENE
receptor I_GENE
( O
LDLR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
place O
of O
the O
DAF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
derived I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
serine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
threonine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
rich I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
does O
not O
become O
GPI O
anchored O
. O

Thus O
, O
the O
pathway O
to O
Fc B_GENE
epsilonRI I_GENE
- O
mediated O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
ERK B_GENE
and O
ERK B_GENE
activation O
can O
apparently O
bypass O
Ras B_GENE/B_DISEASE
and O
Raf B_GENE
- I_GENE
1 I_GENE
. O

To O
assess O
whether O
thallium B_LOCATION
- O
201 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thallous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Tl B_PROTEIN[GENE]/B_LOCATION
) O
can O
detect O
childhood B_DISEASE
tumors I_DISEASE
and O
whether O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectiveness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O
with O
combined O
blood B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
28 B_PERSON/B_ENT
children I_PERSON/I_ENT
( O
1 B_MEASURE
. O
0 B_MEASURE
- O
18 B_NUMBER[MEASURE]
. O
6 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
were O
studied O
using O
single B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
photon B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
emission B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
computed O
tomography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SPECT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
: O
Tl B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
. O
3 B_MEASURE
- O
1 B_MEASURE
. O
8 B_MEASURE
mCi I_MEASURE
intravenously O
) O
, O
followed O
in O
13 B_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_MEASURE
by O
technetium B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
99m B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hexamethylpropyleneamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
oxime I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
99mTc B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HMPAO B_MEASURE/B_DISEASE
; O
8 B_NUMBER[MEASURE]
- O
18 B_TIME[MEASURE]/B_LOCATION
mCi I_TIME[MEASURE]/I_LOCATION
intravenously O
) O
. O

Ftz B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
on O
the O
other O
hand O
, O
influences O
Ftz B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
F1 B_GENE
activity O
by O
interacting O
with O
its O
AF O
- O
2 O
domain O
in O
a O
manner O
that O
mimics O
a O
nuclear O
receptor O
coactivator O
. O

successive O
5 O
' O
deletions O
of O
the O
[ O
- O
326 O
; O
+ O
20 O
] O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sPLA2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
that O
the O
region O
upstream O
of O
position O
- O
195 O
inhibits O
the O
transcription O
activity O
sixfold O
in O
HepG2 O
cells O
but O
not O
in O
HeLa O
cells O
. O

Forty B_NUMBER[MEASURE]
- O
five B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
with O
recent B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
onset B_DISEASE/B_ORGANISM_FUNCTION
hyperthyroidism I_DISEASE/I_ORGANISM_FUNCTION
( O
< B_PROTEIN[GENE]/B_LOCATION
12 I_PROTEIN[GENE]/I_LOCATION
weeks I_PROTEIN[GENE]/I_LOCATION
) O
were O
sex B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
menopause B_PERSON/B_MEASURE
stratified O
and O
randomly O
allocated O
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Neotomizol B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
CT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
Calsynar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
100 B_MEASURE/B_LOCATION
IU I_MEASURE/I_LOCATION
/ O
day B_TIME[MEASURE]
, O
2 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
/ O
week B_TIME[MEASURE]
) O
, O
or O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
high B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Calsynar B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
100 B_MEASURE
IU I_MEASURE
/ O
day B_TIME[MEASURE]
, O
14 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
/ O
month B_TIME[MEASURE]
) O
. O

The O
cloning O
of O
CWH43 B_BIO/B_GENE
showed O
that O
it O
corresponds O
to O
YCR017c B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
encodes O
a O
protein O
with O
14 O
- O
16 O
transmembrane O
segments O
containing O
several O
putative O
phosphorylation O
and O
glycosylation O
sites O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
DdPIK2 B_GENE/B_DISEASE
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B_GENE/B_BIO
and O
DdPIK3 B_GENE
and O
DdPIK2 B_GENE
and O
DdPIK3 B_GENE/B_LOCATION
appear O
to O
be O
lethal O
. O

This O
mechanism O
seems O
to O
be O
involved O
in O
VIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
PRL B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gene B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regulation O
. O

Competition O
and O
methylation O
interference O
assays O
showed O
that O
the O
binding O
site O
for O
the O
novel O
factor O
was O
limited O
to O
nucleotides O
in O
the O
3 O
' O
half O
of O
the O
kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
site I_GENE/I_LOCATION
. O

These O
properties O
prompted O
us O
to O
investigate O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
32 O
human O
astroglial O
tumors O
of O
WHO O
grades O
I O
- O
IV O
and O
to O
correlate O
the O
data O
with O
the O
expression O
pattern O
of O
VEGF B_GENE
, O
Flt B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
, O
and O
KDR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mean O
concentration O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
maternal O
plasma O
across O
all O
sampling O
times O
was O
higher O
in O
ethanol O
treated O
animals O
. O

The O
strongly O
DNA O
binding O
p50 B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
only O
very O
weak O
, O
if O
any O
, O
induction O
of O
gene O
expression O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
demonstrate O
the O
applicability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
countercurrent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ultratrace B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
cHa B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transformed O
rat O
embryo O
fibroblast O
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA O
binding O
activities O
of O
AP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
significantly O
altered O
composition O
. O

Minor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
within O
the O
transmembrane B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TMS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
sometimes O
produced O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
effects I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
more O
drastic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
TMS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
ablated O
surface B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
entirely O
. O

Nuclear O
localization O
of O
this O
SNF2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
putative O
helicase B_ENZYME[GENE]/B_LOCATION
is O
dependent O
on O
a O
nuclear O
localization O
sequence O
located O
in O
the O
NH2 O
- O
terminal O
region O
. O

The O
feasibility O
of O
creating O
CR1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Ig B_GENE/B_LOCATION
chimeras O
makes O
possible O
a O
new O
strategy O
of O
targeting O
complement O
inhibition O
by O
the O
use O
of O
Ig B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partners B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
particular O
antigenic O
specificities O
. O

Morphological B_LOCATION/B_DISEASE
- O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
status I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
the O
edentulous B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mandible I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O
selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
most O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
functional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
impression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
taking B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

They O
are O
both O
insensitive O
to O
inhibitors O
of O
serine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteinases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
are O
sensitive O
to O
sulfhydryl O
reagents O
and O
0 O
. O
5 O
mm O
ZnCl2 O
. O

The O
tau B_PROTEIN[GENE]/B_MEASURE
v B_PROTEIN[GENE]/I_MEASURE
at O
rest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
4 B_MEASURE
. O
06 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_NUMBER[MEASURE]
. O
16 B_MEASURE
s I_MEASURE
and O
decreased O
to O
2 B_MEASURE
. O
44 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
07 B_TIME[MEASURE]
s I_TIME[MEASURE]
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
at O
1 B_TIME[MEASURE]/B_LOCATION
Hz I_TIME[MEASURE]/I_LOCATION
and O
to O
1 B_MEASURE
. O
81 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
4 B_MEASURE/B_LOCATION
s I_MEASURE/I_LOCATION
at O
5 B_MEASURE/B_LOCATION
Hz I_MEASURE/I_LOCATION
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigate O
in O
a O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
211 B_PERSON
children I_PERSON
aged O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
6 B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
incl O
. O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
33 B_NUMBER[MEASURE]
2 I_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
ones I_PERSON
, O
in O
1990 B_MEASURE
and O
checked O
in O
1991 B_MEASURE
at O
two B_LOCATION/B_ENT
sites I_LOCATION/I_ENT
in O
Bratislava B_LOCATION
- O
- O
a O
town B_LOCATION
with O
a O
varying O
concentration B_MEASURE/B_LOCATION
of O
nox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
SO2 B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
dustiness B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dust B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fallout I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
their O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
type B_DISEASE
and O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
relapsing O
respiratory B_DISEASE
disease I_DISEASE
. O

However O
, O
no O
statistical B_MEASURE
difference I_MEASURE
in O
the O
ca B_LOCATION
/ O
P B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
, O
carbon B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
and O
surface B_MEASURE
energy I_MEASURE
were O
observed O
with O
different B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heat I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Using O
in O
vivo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genomic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dimethyl I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
KMnO4 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
footprinting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
we O
showed O
that O
the O
promoter B_ENZYME[GENE]/B_LOCATION
region I_ENZYME[GENE]/I_LOCATION
is O
differentially O
protected O
, O
depending O
upon O
which O
holoenzyme B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O
bound O
. O

Here O
we O
show O
that O
inhibition O
occurs O
with O
a O
NS1 B_GENE/B_BIO
- O
Rev B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimera O
in O
which O
the O
78 O
amino O
- O
terminal O
amino O
acids O
of O
the O
NS1A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
comprising O
its O
entire O
RNA O
- O
binding O
domain O
is O
deleted O
, O
thereby O
establishing O
that O
this O
carboxyl O
portion O
of O
the O
NS1A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
function O
as O
an O
independent O
effector O
domain O
. O

Overall O
, O
it O
appears O
that O
prenatal B_PERSON/B_MEASURE
exposure I_PERSON/I_MEASURE
to O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
based O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O
a O
masculinizing B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
/ O
or O
defeminizing B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
human B_PERSON
behavioral I_PERSON
development I_PERSON
, O
whereas O
prenatal B_PERSON/B_MEASURE
exposure I_PERSON/I_MEASURE
to O
natural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progesterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
based O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
feminizing B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
/ O
or O
demasculinizing B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
particularly O
among O
female B_PERSON
subjects I_PERSON
. O

The O
testes O
of O
8 O
specimens O
of O
Triturus O
marmoratus O
were O
collected O
during O
each O
month O
of O
1987 O
and O
processed O
for O
electron O
microscopy O
and O
light O
microscopy O
demonstration O
of O
testosterone O
( O
T O
) O
following O
the O
ABC B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
avidin B_LOCATION
- I_LOCATION
biotin I_LOCATION
peroxidase I_LOCATION
complex I_LOCATION
) O
method O
. O

MTX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
decreased O
GA B_LOCATION/B_ORGANIZATION
- O
67 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
tumor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

In O
stage B_ENT/B_MEASURE
I O
, O
histochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
copper B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
11 B_NUMBER[MEASURE]
out O
of O
21 B_MEASURE
cases I_MEASURE
: O
6 B_MEASURE
cases I_MEASURE
were O
T B_PROTEIN[GENE]/B_DISEASE
+ I_PROTEIN[GENE]/I_DISEASE
; O
1 B_PERSON/B_PROTEIN[GENE]
case B_PERSON/I_PROTEIN[GENE]
R B_PERSON/I_PROTEIN[GENE]
+ B_PERSON/I_PROTEIN[GENE]
and O
2 B_DISEASE
cases I_DISEASE
O I_DISEASE
+ I_DISEASE
; O
2 B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
were O
T B_GENE
+ I_GENE
, O
R B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
O B_LOCATION/B_MEASURE
+ I_LOCATION/I_MEASURE
. O

encapsulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
dye B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Primer O
extension O
analysis O
and O
subcloning O
of O
the O
virJ B_SPECIES[BIO]/B_GENE
- O
phoA B_GENE/B_BACTERIUM[BIO]
fusion O
indicate O
that O
the O
acetosyringone O
- O
inducible O
promoter O
lies O
directly O
upstream O
of O
the O
virJ B_GENE/B_BIO
structural I_GENE/I_BIO
gene I_GENE/I_BIO
. O

To O
isolate O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contain O
zinc B_GENE/B_MEASURE
finger I_GENE/I_MEASURE
motifs I_GENE/I_MEASURE
, O
a O
human B_GENE
brain I_GENE
cDNA I_GENE
library I_GENE
was O
screened O
with O
an O
oligonucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complementary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
conserved O
' B_LOCATION/B_PERSON
linker I_LOCATION/I_PERSON
' I_LOCATION/I_PERSON
sequence I_LOCATION/I_PERSON
between O
adjacent B_LOCATION/B_GENE
zinc I_LOCATION/I_GENE
fingers I_LOCATION/I_GENE
. O

percentage B_MEASURE/B_LOCATION
incremental B_MEASURE/I_LOCATION
18 B_MEASURE/I_LOCATION
- O
OHB B_TIME[MEASURE]/B_LOCATION
responses I_TIME[MEASURE]/I_LOCATION
to O
metoclopramide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
greater B_MEASURE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
in O
the O
subjects B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
after O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
on O
a O
200 B_MEASURE
- O
meq B_MEASURE
sodium I_MEASURE
intake I_MEASURE
than O
after O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
on O
a O
10 B_MEASURE
- O
meq B_MEASURE
sodium I_MEASURE
intake I_MEASURE
. O

Using O
in O
vivo O
screening O
, O
we O
first O
identified O
a O
gene O
that O
appeared O
to O
interfere O
with O
the O
His O
- O
Asp O
phosphorelay O
between O
the O
HPt O
domain O
and O
the O
receiver O
domain O
of O
OmpR B_GENE/B_BACTERIUM[BIO]
, O
provided O
that O
the O
gene O
product O
was O
expressed O
through O
a O
multicopy O
plasmid O
. O

The O
non B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
major B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
histocompatibility B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
complex B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
MHC B_GENE/B_LOCATION
) O
- O
encoded O
CD1 B_GENE/B_LOCATION
family I_GENE/I_LOCATION
has O
recently O
emerged O
as O
a O
new O
antigen O
- O
presenting O
system O
that O
is O
distinct O
from O
either O
MHC B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
class I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
class I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
II I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
molecules I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
predicted O
amino O
acid O
sequence O
of O
Pst1p B_GENE/B_MEASURE
possessed O
high O
sequence O
homology O
with O
the O
Sin3 B_LOCATION/B_GENE
family I_LOCATION/I_GENE
of O
proteins O
, O
known O
for O
their O
interaction O
with O
histone B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
deacetylases B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Quinethazone B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
heterocyclic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compounds I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

removal O
of O
ink4a B_GENE
dramatically O
reduces O
the O
lymphoid O
and O
neurological O
defects O
seen O
in O
bmi B_GENE
- I_GENE
1 I_GENE
- O
deficient O
mice O
, O
indicating O
that O
ink4a B_GENE
is O
a O
critical O
in O
vivo O
target O
for O
Bmi B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
found O
that O
RXR B_GENE/B_LOCATION
and O
VDR B_GENE/B_LOCATION
transactivated O
selectively O
from O
VDRE O
- O
linked O
templates O
exclusively O
as O
a O
heterodimeric O
complex O
, O
since O
neither O
receptor O
alone O
enhanced O
transcription O
in O
vitro O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
performed O
nasal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mupirocin I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O
10 B_PERSON/B_BIO
infants I_PERSON/I_BIO
who O
were O
MRSA B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
in O
the O
nose B_BODY_PART_OR_ORGAN_COMPONENT
or O
the O
pharynx B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
evaluated O
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
mupirocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O
the O
eradication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
MRSA B_BACTERIUM[BIO]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Of O
10 B_MEASURE
, O
709 B_MEASURE
, O
701 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemistry I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
submitted O
to O
the O
participating O
laboratories B_LOCATION/B_ORGANIZATION
during O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
37 B_MEASURE
, O
208 B_MEASURE
( O
0 B_MEASURE
. O
35 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
rejected O
prior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Early O
complement O
components O
, O
C1q B_PROTEIN[GENE]
and O
C4 B_PROTEIN[GENE]
, O
and O
IgA B_NUMBER[MEASURE]/B_PERSON
secretory O
piece O
were O
absent O
. O

Administration O
of O
SnCl2 O
and O
ZnSO4 O
( O
group O
V O
) O
resulted O
in O
a O
decrease O
of O
ALA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
and O
in O
an O
increase O
in O
CP O
- O
U O
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B_GENE
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B_GENE/B_LOCATION
- O
Sp3 B_GENE/B_LOCATION
interactions O
define O
a O
pathway O
for O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
the O
supposition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
there O
exists O
a O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
connection B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
certain B_DISEASE
psychopathological I_DISEASE
symptoms I_DISEASE
, O
and O
/ O
or O
syndromes B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
e B_PROTEIN[GENE]/B_DISEASE
. O
g B_DISEASE/B_MEASURE
. O
, O
hallucinations B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
regional B_DISEASE
cerebral I_DISEASE
dysfunction I_DISEASE
, O
patients B_PERSON/B_BIO
suffering O
from O
auditory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
tactile B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hallucinations I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
were O
investigated O
, O
in O
a O
symptom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
oriented O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
using O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
technetium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
99m B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Hexamethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
propylenamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Oxime I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
99m B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Tc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
HMPAO B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
Single B_LOCATION/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
photon B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emission B_LOCATION/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Computed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SPECT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
and O
compared O
with O
normal B_PERSON/B_BIO
controls I_PERSON/I_BIO
. O

The O
lack B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
chronically O
depressed B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LCBF B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
after O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
) O
may O
be O
related O
to O
the O
quick B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
structural I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
endothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

In O
this O
study O
, O
to O
elucidate O
the O
possible O
mechanism O
of O
action O
of O
Em O
, O
we O
examined O
the O
effect O
of O
the O
drug O
on O
the O
expression O
of O
neutrophil O
adhesion O
molecules O
such O
as O
L B_GENE
- I_GENE
selectin I_GENE
and O
Mac B_GENE
- I_GENE
1 I_GENE
. O

Tissue B_DISEASE/B_PROTEIN[GENE]
expansion B_DISEASE/I_PROTEIN[GENE]
was O
used O
successfully O
to O
prepare O
adequate B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
soft I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
tissue I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
for O
closure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
following O
a O
difficult B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clubfoot B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
correction B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
transcription B_GENE
start I_GENE
site I_GENE
was O
identified O
by O
primer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
over O
800 B_MEASURE/B_LOCATION
BP I_MEASURE/I_LOCATION
of O
5 B_MEASURE/B_GENE
' I_MEASURE/I_GENE
flanking O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
sequenced O
. O

The O
reporter B_GENE
gene I_GENE
with O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
copies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
transcribed O
actively O
in O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
deprived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
was O
repressed O
by O
more B_MEASURE
than O
80 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
when O
sterols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
tension B_DISEASE/B_MEASURE
were O
monitored O
isometrically O
on O
spiral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
strips B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
freshly O
obtained O
bovine B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
basilar I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

A O
1 B_MEASURE
. O
5 B_MEASURE
- O
month B_TIME[MEASURE]
- O
old B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boy B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Sandifer B_DISEASE
' I_DISEASE
s I_DISEASE
syndrome I_DISEASE
is O
described O
. O

However O
, O
PC12 O
cell O
clones O
which O
expressed O
p33rsu B_GENE
- I_GENE
1 I_GENE
at O
an O
increased O
level O
in O
a O
regulatable O
fashion O
in O
response O
to O
dexamethasone O
were O
isolated O
. O

In O
this O
study O
, O
we O
verified O
that O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
associates O
with O
the O
CD4 B_GENE/B_DISEASE
: O
p56lck B_GENE/B_LOCATION
complex I_GENE/I_LOCATION
as O
judged O
by O
the O
presence O
of O
Pi O
3 O
- O
phosphate O
generated O
from O
anti B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CD4 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immunoprecipitates O
and O
detected O
by O
high O
- O
pressure O
liquid O
chromatographic O
analysis O
. O

The O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
picture B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appearance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
histochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
described O
in O
six B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
fibroma B_DISEASE
of O
tendon B_BODY_PART_OR_ORGAN_COMPONENT
sheath I_BODY_PART_OR_ORGAN_COMPONENT
. O

However O
, O
their O
stability B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
already O
reported O
for O
the O
ars B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
S B_OTHER/B_LOCATION
. O
occidentalis B_LOCATION/B_BACTERIUM[BIO]
. O

In O
this O
study O
, O
a O
site O
of O
PDGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
tyrosine O
phosphorylation O
was O
mapped O
to O
Tyr O
138 O
in O
the O
SH3 B_GENE
domain I_GENE
; O
Tyr O
138 O
is O
exposed O
on O
the O
SH3 B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
peptide B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
binding B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
surface B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
in O
patients B_PERSON/B_BIO
with O
syndrome B_DISEASE/B_GENE
X I_DISEASE/I_GENE
, O
myocardial B_DISEASE
ischemia I_DISEASE
frequently O
develops O
during O
daily B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
life I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O
silent B_DISEASE
ischemia I_DISEASE
is O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
syndrome B_DISEASE
; O
and O
increased O
oxygen B_DISEASE
demand I_DISEASE
in O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
impaired B_DISEASE
coronary I_DISEASE
vasodilatory I_DISEASE
capacity I_DISEASE
is O
not O
the O
only B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
myocardial B_DISEASE
ischemia I_DISEASE
. O

We O
also O
identified O
a O
DNA O
fragment O
, O
10 O
. O
7 O
kbp O
upstream O
from O
the O
first O
coding O
exon O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aFGF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
whose O
sequence O
is O
conserved O
in O
both O
the O
primate O
and O
rodent O
genomes O
. O

The O
false B_MEASURE/B_DISEASE
positive I_MEASURE/I_DISEASE
fraction I_MEASURE/I_DISEASE
( O
FPF B_PROTEIN[GENE]/B_LOCATION
) O
decreased O
significantly O
if O
the O
count B_MEASURE/B_DISEASE
density I_MEASURE/I_DISEASE
increased O
; O
no O
difference B_MEASURE
in O
FPF B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
found O
for O
a O
change B_MEASURE
in O
lesion B_MEASURE/B_PERSON
tracer I_MEASURE/I_PERSON
concentration I_MEASURE/I_PERSON
. O

These O
events O
were O
only O
weakly O
stimulated O
by O
the O
activated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PDGF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Human B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plastin I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Buserelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
offers O
an O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
carcinoma B_DISEASE
of O
the O
prostate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
, O
apart O
from O
impotence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
does O
not O
have O
the O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

C B_GENE
/ I_GENE
EBP I_GENE
delta I_GENE
( O
NFIL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
was O
not O
detected O
in O
complexes O
utilizing O
extracts O
from O
the O
IL B_TIME[MEASURE]/B_SPECIES[BIO]
- I_TIME[MEASURE]/I_SPECIES[BIO]
1 I_TIME[MEASURE]/I_SPECIES[BIO]
nonproducing O
T O
cell O
line O
. O

reduced O
risk O
of O
upper O
gastrointestinal O
ulcer O
complications O
with O
celecoxib O
, O
a O
novel O
COX B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
. O

Moreover O
, O
our O
recent O
findings O
on O
the O
Tc52 B_GENE
encoding I_GENE
gene I_GENE
underline O
the O
interest O
of O
genetic O
manipulation O
of O
T O
. O
cruzi O
, O
not O
only O
making O
it O
possible O
to O
use O
more O
closely O
an O
in O
vitro O
approach O
to O
find O
out O
how O
genes O
function O
, O
but O
also O
to O
obtain O
' O
attenuated O
' O
strains O
that O
could O
be O
used O
in O
the O
development O
of O
vaccinal O
strategies O
. O

Infra B_COLOR/B_DISEASE
- O
red B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
tissues B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
700 B_MEASURE
- O
400 B_MEASURE
cm I_MEASURE
- O
1 B_LOCATION/B_MEASURE
region B_LOCATION/I_MEASURE
. O

YDL003w B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
also O
termed O
MCD1 B_GENE/B_DISEASE
) O
is O
a O
homologue O
of O
Schizosaccharomyces B_GENE/B_BACTERIUM[BIO]
pombe I_GENE/I_BACTERIUM[BIO]
rad21 I_GENE/I_BACTERIUM[BIO]
, O
an O
essential O
gene O
implicated O
in O
DNA O
double O
- O
strand O
break O
repair O
and O
nuclear O
organization O
in O
fission O
yeast O
. O

The O
recent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
concept I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
a O
bioartificial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
an O
attempt B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
avoid O
such B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disadvantages I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
objectives B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
1 B_NUMBER[MEASURE]
) O
to O
quantify O
the O
comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
static B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
fatigue B_DISEASE_ADJECTIVE[DISEASE]
properties I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
pointe B_PRODUCT[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
shoe I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
toe I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
box I_PRODUCT[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
2 B_SEQUENCE[MEASURE]
) O
to O
evaluate O
the O
preferred B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shoe I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
determined O
by O
a O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
local B_PERSON/B_SPORT[ENT]
dancers I_PERSON/I_SPORT[ENT]
. O

In O
the O
postoperative B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patient I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
tetralogy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Fallot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O
symptomatic B_DISEASE
ventricular I_DISEASE
arrhythmias I_DISEASE
, O
it O
is O
concluded O
that O
electrophysiologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
reproducing O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episodes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
VT B_DISEASE
and O
in O
selecting O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
antiarrhythmic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
medication I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
; O
a O
small B_MEASURE
number I_MEASURE
of O
patients B_PERSON
with O
ventricular B_DISEASE
premature I_DISEASE
complexes I_DISEASE
alone O
will O
have O
inducible B_DISEASE_ADJECTIVE[DISEASE]
sustained O
VT B_DISEASE
during O
electrophysiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
prognosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
improved O
by O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
results O
in O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
VT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
and O
in O
patients B_PERSON/B_LOCATION
with O
right B_DISEASE
ventricular I_DISEASE
hypertension I_DISEASE
, O
VT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
refractory B_DISEASE_ADJECTIVE[DISEASE]
to O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Indications O
for O
therapy O
using O
MAO B_GENE
inhibitors O
. O

The O
absorbance B_MEASURE/B_LOCATION
of O
the O
eluent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
monitored O
at O
254 B_MEASURE/B_LOCATION
nm I_MEASURE/I_LOCATION
. O

Here O
, O
we O
describe O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O
at O
identifying O
the O
gene B_GENE
or O
genes B_PROTEIN[GENE]/B_LOCATION
responsible I_PROTEIN[GENE]/I_LOCATION
for O
the O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
- O
arrest B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
with O
human B_GENE/B_LOCATION
chromosome I_GENE/I_LOCATION
- O
9 B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Footprints O
on O
the O
HPV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
18 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
show O
five O
protected O
regions O
with O
homologies O
to O
NF1 B_GENE/B_DISEASE
, O
AP1 B_GENE/B_DISEASE
and O
EFII B_GENE/B_LOCATION
transcription I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
motifs I_GENE/I_LOCATION
. O

Insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
to O
the O
alpha O
- O
subunit O
of O
its O
receptor O
stimulates O
the O
receptor B_GENE
tyrosine I_GENE
kinase I_GENE
to O
phosphorylate O
the O
beta O
- O
subunit O
and O
several O
endogenous O
protein O
substrates O
, O
including O
pp120 B_GENE/B_LOCATION
/ O
HA4 B_MEASURE/B_GENE
, O
a O
liver O
- O
specific O
plasma O
membrane O
glycoprotein O
of O
M O
( O
r O
) O
20 O
, O
000 O
. O

Motilin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum O
levels O
were O
measured O
for O
one O
hour O
. O

The O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phosphorylation B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
desensitization I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
using O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O
in O
COS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
or O
Chinese B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
hamster I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lung I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fibroblasts I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

First B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aid I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Improvement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
some O
pharmaceutical B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
properties I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
clofibrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
cyclodextrin B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
detection B_MEASURE
limits I_MEASURE
obtained O
by O
using O
the O
mixed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eluent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
0 B_MEASURE/B_LOCATION
. O
05 B_MEASURE
- O
0 B_MEASURE
. O
13 B_MEASURE
mg I_MEASURE
/ O
L B_OTHER/B_MEASURE
, O
several B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
those O
obtained O
by O
using O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
KHPh I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
eluent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
early B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
surgical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
division I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
biliary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
pancreatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
duct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
recommended O
for O
children B_PERSON
with O
AAPBD B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B_GENE/B_BIO
proteins I_GENE/I_BIO
( O
ARIP3 B_GENE/B_DISEASE
/ O
PIASx B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Miz1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
PIASx B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
GBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
PIAS1 B_GENE/B_DISEASE
, O
and O
PIAS3 B_GENE
) O
play O
in O
the O
regulation O
of O
steroid B_GENE
receptor I_GENE
- O
or O
STAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
transcriptional O
activation O
. O

comparison O
of O
the O
predicted O
amino O
acid O
sequence O
with O
that O
of O
the O
Drosophila B_GENE/B_BIO
virilis I_GENE/I_BIO
gene I_GENE/I_BIO
shows O
that O
several O
blocks O
of O
amino O
acid O
sequence O
have O
been O
very O
highly O
conserved O
. O

Analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focused O
on O
two B_NUMBER[MEASURE]/B_PERSON
platyrrhine I_NUMBER[MEASURE]/I_PERSON
( O
New B_PROTEIN[GENE]/B_SPECIES[BIO]
World I_PROTEIN[GENE]/I_SPECIES[BIO]
monkey I_PROTEIN[GENE]/I_SPECIES[BIO]
) O
species B_BIO/B_LOCATION
: O
the O
common B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
marmoset I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Callithrix B_SPECIES[BIO]/B_LOCATION
jacchus I_SPECIES[BIO]/I_LOCATION
) O
and O
the O
brown B_SPECIES[BIO]
capuchin I_SPECIES[BIO]
monkey I_SPECIES[BIO]
( O
Cebus B_SPECIES[BIO]
apella I_SPECIES[BIO]
) O
, O
each O
of O
which O
has O
paired O
, O
non B_DISEASE/B_NUMBER[MEASURE]
- O
allelic B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gamma I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
loci I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
( O
5 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
gamma B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
gamma B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
' O
) O
. O

A O
phase O
II O
clinical O
trial O
on O
MDS O
was O
conducted O
in O
a O
cooperative O
study O
with O
orally O
administrable O
Ara O
- O
C O
analogue O
, O
PLAC O
, O
which O
is O
resistant O
to O
cytidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
had O
shown O
an O
anti O
- O
tumor O
activity O
on O
various O
experimental O
tumors O
by O
oral O
route O
. O

A O
decrease O
was O
also O
found O
of O
the O
levels O
of O
total O
cholesterol O
and O
LDL B_GENE
- I_GENE
cholesterol I_GENE
. O

Previously O
, O
we O
had O
shown O
that O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
is O
constitutively O
expressed O
in O
HTLV O
- O
I O
- O
infected O
cells O
and O
in O
cells O
transiently O
expressing O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Unlike O
JNK B_GENE/B_DISEASE
activation O
, O
ERK B_GENE/B_LOCATION
activation O
could O
not O
be O
mapped O
to O
specific O
reovirus O
gene O
segments O
, O
suggesting O
that O
ERK B_GENE/B_LOCATION
activation O
and O
JNK B_GENE/B_DISEASE
activation O
are O
triggered O
by O
different O
events O
during O
virus O
- O
host O
cell O
interaction O
. O

Despite O
the O
same B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
RSNA B_DISEASE/B_PROTEIN[GENE]
was O
attenuated O
after O
15 B_MEASURE
and O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
of O
propofol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

To O
address O
this O
question O
with O
respect O
to O
skeletal O
muscle O
, O
we O
have O
examined O
the O
effects O
of O
the O
Providence O
mutation O
in O
cultured O
muscle O
cells O
, O
after O
adoptive O
gene O
transfer O
to O
adult O
mice O
, O
and O
in O
two O
infants O
homozygous O
for O
spectrin B_DISEASE/B_PERSON
Providence I_DISEASE/I_PERSON
. O

It O
appears O
to O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
untreated B_PERSON
patients I_PERSON
with O
stage B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
I O
or O
II B_TIME[MEASURE]/B_DISEASE
NHL I_TIME[MEASURE]/I_DISEASE
but O
no O
definite B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiographic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
with O
abnormal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
radiographs I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
but O
no O
extrathoracic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
in O
treated O
patients B_PERSON/B_LOCATION
with O
questionable B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiographs I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

B B_PROTEIN[GENE]/B_DISEASE
and O
C1 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fusions I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
yeast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GAL4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
also O
found O
to O
interact O
when O
synthesized O
and O
assayed O
in O
yeast O
. O

Because O
of O
the O
data O
, O
we O
suggest O
that O
LAC9 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contacts O
positions O
6 O
, O
7 O
, O
and O
8 O
, O
both O
plus O
and O
minus O
, O
of O
the O
UAS O
, O
which O
are O
separated O
by O
more O
than O
one O
turn O
of O
the O
DNA O
helix O
, O
and O
twists O
part O
way O
around O
the O
DNA O
, O
thus O
protecting O
the O
broad O
region O
of O
the O
minor O
groove O
between O
the O
major O
- O
groove O
contacts O
. O

On O
the O
optic B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tentacle I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
- O
gonadal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
male B_PERSON/B_NUMBER[MEASURE]
- O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
ovotestis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
slug B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
( O
Ariolimax B_SPECIES[BIO]/B_LOCATION
californicus I_SPECIES[BIO]/I_LOCATION
) O
. O

substitution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cholinergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
Alzheimer B_DISEASE/B_GENE
type I_DISEASE/I_GENE
dementia I_DISEASE/I_GENE
( O
AD B_LOCATION/B_DISEASE
/ O
SDAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
has O
hitherto B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
not O
been O
very O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
show O
that O
the O
nucleotide O
in O
the O
middle O
of O
the O
anticodon O
( O
i O
. O
e O
. O
, O
psi O
35 O
) O
also O
contributes O
to O
the O
suppressor O
efficiency O
displayed O
by O
cytoplasmic B_GENE/B_DISEASE
tRNA I_GENE/I_DISEASE
( I_GENE/I_DISEASE
Tyr I_GENE/I_DISEASE
) I_GENE/I_DISEASE
. O

The O
root B_MEASURE
- O
mean B_MEASURE/B_LOCATION
- O
square B_MEASURE/B_LOCATION
deviation I_MEASURE/I_LOCATION
of O
bond B_MEASURE
lengths I_MEASURE
from O
the O
ideal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
0 B_MEASURE
. O
02 B_MEASURE
A I_MEASURE
. O

jet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lag I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

In O
addition O
, O
these O
results O
suggest O
that O
the O
interactions O
, O
and O
consequently O
the O
mechanisms O
, O
governing O
transcriptional O
activation O
by O
CTF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O
distinct O
from O
those O
mediating O
DNA O
replication O
. O

A O
TAAATA B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
is O
present B_DISEASE_ADJECTIVE[DISEASE]
26 I_DISEASE_ADJECTIVE[DISEASE]
nt I_DISEASE_ADJECTIVE[DISEASE]
upstream O
from O
the O
major B_GENE/B_LOCATION
CAP I_GENE/I_LOCATION
site I_GENE/I_LOCATION
, O
and O
within O
the O
5 B_LOCATION/B_GENE
' I_LOCATION/I_GENE
- O
flanking O
region B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
there O
are O
several B_DISEASE_ADJECTIVE[DISEASE]
putative I_DISEASE_ADJECTIVE[DISEASE]
transcription I_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
binding O
sites B_LOCATION/B_ENT
. O

It O
was O
found O
that O
both O
versions B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
brief B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SL I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O
amp B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
; O
shy B_PERSON/B_LOCATION
; O
Asia B_LOCATION/B_PERSON
had O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
target B_MEASURE
variables I_MEASURE
as O
the O
full B_LOCATION/B_PROTEIN[GENE]
scale I_LOCATION/I_PROTEIN[GENE]
SL I_LOCATION/I_PROTEIN[GENE]
& O
amp B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
shy B_PERSON/B_LOCATION
; O
Asia B_LOCATION/B_MEASURE
. O

The O
reconstituted O
enzyme O
binds O
DNA O
with O
an O
affinity O
that O
is O
approximately O
20 O
- O
fold O
lower O
than O
that O
of O
the O
intact O
topo70 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
KP B_MEASURE/B_PROTEIN[GENE]
- O
45 B_MEASURE
preparation I_MEASURE
usually O
resulted O
in O
partial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tumor B_DISEASE
growth I_DISEASE
, O
accompanied O
by O
improvement B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
these O
patients B_PERSON/B_DISEASE
, O
as O
well O
as O
reappearance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
normal B_DISEASE_ADJECTIVE[DISEASE]
values I_DISEASE_ADJECTIVE[DISEASE]
of O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
picture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
biochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Istanbul B_LOCATION
, O
Turkey B_LOCATION/B_PERSON
. O

We O
propose O
that O
optimal O
transcription O
of O
the O
gD B_GENE
gene I_GENE
depends O
on O
the O
interaction O
of O
ICP4 B_GENE
with O
multiple O
binding O
sites O
across O
the O
gene O
and O
cellular O
factors O
that O
recognize O
specific O
sequence O
elements O
in O
the O
promoter O
. O

Recently O
, O
we O
and O
other O
laboratories O
have O
identified O
a O
family O
of O
caveolin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
caveolin B_LOCATION/B_PERSON
has O
been O
re O
- O
termed O
caveolin B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
. O

Role O
of O
zinc B_GENE
- I_GENE
finger I_GENE
proteins I_GENE
Sp1 I_GENE
and O
zif268 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
egr B_MEASURE
- I_MEASURE
1 I_MEASURE
in O
transcriptional O
regulation O
of O
the O
human B_GENE
synaptobrevin I_GENE
II I_GENE
gene I_GENE
. O

The O
human B_GENE
Fc I_GENE
gamma I_GENE
receptor I_GENE
gene I_GENE
Fc I_GENE
gamma I_GENE
RIIA I_GENE
is O
expressed O
in O
platelets O
, O
neutrophils O
, O
monocytes O
and O
macrophages O
. O

This O
dip B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
also O
occurred O
during O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
but O
did O
not O
occur O
when O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
added O
to O
prednisone O
, O
although O
the O
baseline B_MEASURE
value I_MEASURE
was O
lower B_MEASURE
at O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
combined O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

E O
. O
granulosus O
infection O
has O
been O
confirmed O
in O
25 O
patients O
( O
20 O
. O
6 O
% O
) O
, O
in O
16 O
cases O
by O
finding O
parasite O
protoscoleces O
or O
hooks O
and O
in O
nine O
cases O
by O
detection O
of O
an O
antigen O
specific O
for O
E B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
granulosus I_SPECIES[BIO]/I_GENE
, I_SPECIES[BIO]/I_GENE
antigen I_SPECIES[BIO]/I_GENE
5 I_SPECIES[BIO]/I_GENE
( O
Ag5 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
entopeduncular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
nucleus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
EP B_ENT/B_PROTEIN[GENE]
) O
on O
the O
jaw B_BODY_PART_OR_ORGAN_COMPONENT
- O
opening O
reflex B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
JOR B_LOCATION/B_GENE
) O
was O
studied O
in O
the O
cat B_SPECIES[BIO]/B_DISEASE
anesthetized O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
Premenstrual B_DISEASE_ADJECTIVE[DISEASE]
Syndrome I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
late B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
luteal I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
phase I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
disorder I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
DSM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
IIIR B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
identified O
in O
6 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
women B_PERSON
. O

First O
, O
mutations O
in O
the O
IFNgamma B_GENE/B_BIO
- I_GENE/I_BIO
activated I_GENE/I_BIO
sequence I_GENE/I_BIO
( O
GAS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
, O
either O
multimerized O
or O
in O
the O
context O
of O
the O
1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IRF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
failed O
to O
mediate O
a O
PRL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O
, O
showing O
that O
the O
IRF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
GAS I_GENE/I_DISEASE
is O
a O
target O
of O
PRL B_GENE
signaling O
. O

025 B_MEASURE
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
revealed O
wide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
CBF B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
regions B_LOCATION/B_DISEASE
during O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
particularly O
in O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
while O
rCMRO2 B_MEASURE/B_PERSON
decreased O
globally O
in O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O
both O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

This O
selective O
squelching O
activity O
suggests O
that O
GRIM B_GENE/B_DISEASE
can O
interact O
with O
an O
essential O
component O
of O
the O
RNA B_SPECIES[BIO]/B_GENE
polymerase I_SPECIES[BIO]/I_GENE
II I_SPECIES[BIO]/I_GENE
transcription O
machinery O
. O

This O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
an O
integron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
located O
on O
a O
composite B_BACTERIUM[BIO]/B_GENE
transposon B_BACTERIUM[BIO]/I_GENE
. O

The O
nine B_PERSON/B_BIO
subjects I_PERSON/I_BIO
were O
treated O
in O
random B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
cimetidine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_MEASURE
- O
1 B_MEASURE
- O
0 B_MEASURE
g I_MEASURE
on O
one B_NUMBER[MEASURE]/B_LOCATION
day I_NUMBER[MEASURE]/I_LOCATION
and O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capsules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
. O

The O
protein B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O
overexpressed O
in O
Escherichia B_BIO
coli I_BIO
and O
purified O
to O
homogeneity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

identification O
and O
characterization O
of O
a O
yeast O
gene O
encoding O
the O
U2 B_ENZYME[GENE]
small I_ENZYME[GENE]
nuclear I_ENZYME[GENE]
ribonucleoprotein I_ENZYME[GENE]
particle I_ENZYME[GENE]
B I_ENZYME[GENE]
' I_ENZYME[GENE]
protein I_ENZYME[GENE]
. O

A O
360 O
- O
BP O
DNA O
fragment O
located O
over O
500 O
BP O
upstream O
from O
the O
cfl B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O
start O
site O
was O
used O
in O
DNase B_GENE
I I_GENE
protection O
assays O
to O
define O
the O
specific O
bases O
bound O
by O
CorR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
certain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O
defined O
conditions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
frequent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feedings I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
supplementary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
feeding I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
before O
4 B_NUMBER[MEASURE]
- O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
method B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
only O
to O
be O
used O
in O
the O
absence B_DISEASE/B_TIME[MEASURE]
of O
menstruation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
Lam B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
relied O
on O
for O
contraceptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
protection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
up O
to O
1 B_TIME[MEASURE]
year I_TIME[MEASURE]
post I_TIME[MEASURE]
partum I_TIME[MEASURE]
. O

Nramp2 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O
a O
classical O
iron O
responsive O
element O
in O
the O
3 O
' O
untranslated O
region O
that O
confers O
iron O
dependent O
mRNA O
stabilization O
. O

Likewise O
, O
epidural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
does O
not O
modify O
the O
intraoperative B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolic B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
responses B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

conclusions O
- O
- O
Postlumbar O
puncture O
headache O
may O
be O
mediated O
by O
the O
release O
of O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
triggered O
by O
lumbar O
puncture O
, O
in O
patients O
predisposed O
to O
headache O
by O
a O
hypersensitivity O
to O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Continuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
arterial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sampling I_TIME[MEASURE]
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
based O
on O
the O
microsphere B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
model I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
used O
as O
a O
quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rCBF I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

A O
mutated B_DISEASE/B_PROTEIN[GENE]
ABF1 B_DISEASE/I_PROTEIN[GENE]
site B_DISEASE/I_PROTEIN[GENE]
that O
displays O
a O
very O
low O
affinity O
for O
ABF1 B_GENE
does O
not O
functionally O
replace O
the O
ILV1 B_GENE/B_LOCATION
REB1 I_GENE/I_LOCATION
site I_GENE/I_LOCATION
. O

Given O
a O
rapid O
induction O
of O
Egr B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
on O
stimulation O
with O
growth O
factors O
or O
injury O
, O
these O
findings O
may O
represent O
at O
least O
one O
of O
the O
molecular O
mechanisms O
underlying O
phenotypic O
modulation O
of O
smooth O
muscles O
after O
vascular O
injury O
. O

A O
nationwide O
survey O
uncovered O
a O
tenfold O
variation O
between O
counties O
in O
the O
prescribing O
of O
IFNB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
first B_SEQUENCE[MEASURE]
- O
person B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
account I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
author B_PERSON/B_ENT
chronicles O
her O
experience B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
being O
mentally O
ill B_DISEASE_ADJECTIVE[DISEASE]
and O
homeless B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O
New B_LOCATION
York I_LOCATION
and O
New B_LOCATION
Jersey I_LOCATION
in O
the O
early B_TIME[MEASURE]/B_LOCATION
1980s I_TIME[MEASURE]/I_LOCATION
. O

Rectal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperatures B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
the O
walk B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
were O
greater B_MEASURE
( O
P B_MEASURE
< I_MEASURE
. O
001 B_MEASURE
) O
in O
native B_SPECIES[BIO]/B_LOCATION
Simmental I_SPECIES[BIO]/I_LOCATION
( O
39 B_MEASURE
. O
87 B_MEASURE
+ I_MEASURE
/ O
- O
. O
05 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
) O
than O
in O
Bos B_LOCATION
indicus I_LOCATION
( O
39 B_MEASURE
. O
46 B_MEASURE
+ I_MEASURE
/ O
- O
. O
05 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
) O
. O

dominant O
- O
negative O
mutations O
in O
the O
G B_GENE/B_LOCATION
- I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
- I_GENE/I_LOCATION
coupled I_GENE/I_LOCATION
alpha I_GENE/I_LOCATION
- I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
map O
to O
the O
extracellular O
ends O
of O
the O
transmembrane O
segments O
. O

Such B_PERSON
simple I_PERSON
injuries I_PERSON
may O
however O
be O
accompanied O
by O
far O
reaching O
consequences B_DISEASE
. O

This O
is O
the O
first O
report O
which O
clearly O
proved O
CEA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O
in O
the O
cells O
of O
HCC O
. O

By O
screening O
a O
human O
testis O
cDNA O
library O
with O
a O
probe O
containing O
the O
mouse B_GENE
PEA3 I_GENE
ETS I_GENE
domain O
, O
we O
isolated O
a O
2 O
. O
2 O
kb O
clone O
containing O
a O
510 O
AA O
open O
reading O
frame O
. O

AU O
- O
rich O
elements O
in O
the O
3 O
' O
- O
untranslated O
region O
of O
a O
new O
mucin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family O
of O
Trypanosoma O
cruzi O
confers O
mRNA O
instability O
and O
modulates O
translation O
efficiency O
. O

These O
findings O
suggest O
that O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
, O
Rho B_GENE
- O
dependent O
cytoskeletal O
reorganization O
may O
cluster O
signaling O
molecules O
in O
specific O
architectures O
that O
are O
necessary O
for O
persistent O
cell O
activation O
in O
chronic O
inflammatory O
disease O
. O

Changes O
in O
testicular O
testosterone O
and O
acid O
and O
alkaline B_ENZYME[GENE]
phosphatase I_ENZYME[GENE]
activity O
in O
testis O
and O
accessory O
sex O
organs O
after O
induction O
of O
varicocele O
in O
Noble O
rats O
. O

M B_PROTEIN[GENE]/B_LOCATION
. O
, O
apps B_PERSON/B_ORGANIZATION
, O
D B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
data O
suggest O
that O
weight O
gain O
or O
increased O
caloric O
intake O
, O
in O
contrast O
to O
its O
large O
effect O
on O
peripheral O
thyroid O
function O
, O
has O
relatively O
little O
effect O
on O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRH I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
. O

Alfalfa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phosphorus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
release I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
kinetics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bacterial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
phosphorus I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
contamination I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1 B_MEASURE
- O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
acetylmethadol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
its O
principal B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
specimens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
by O
gas B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
chemical B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionization B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
multiple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ion I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O
tentative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggestions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
( O
a O
) O
possible B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
additional I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cigarette B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
smoking I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
b B_PROTEIN[GENE]/B_DISEASE
) O
avoidance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
venography B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
c B_OTHER/B_PROTEIN[GENE]
) O
avoidance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
varicose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
vein I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prolonged O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
labour B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pains I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Th B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1165a B_BIO/B_PERSON
and O
Isoptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
the O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
circulation B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O
organ B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
metabolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
mother B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Skytthe B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
K B_OTHER/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
Saccharomyces B_BIO/B_GENE
cerevisiae I_BIO/I_GENE
actin I_BIO/I_GENE
intron I_BIO/I_GENE
a O
silent O
branch O
point O
- O
like O
sequence O
( O
UACUAAG O
) O
is O
located O
7 O
nt O
upstream O
of O
the O
canonical O
sequence O
. O

The O
requirement O
for O
an O
essential O
interaction O
between O
NPH B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
H4L B_PROTEIN[GENE]/B_LOCATION
provides O
an O
explanation O
for O
the O
observed O
restriction O
of O
transcription O
termination O
to O
early O
viral O
genes O
. O

After O
birth O
, O
there O
was O
a O
significantly O
higher O
increase O
of O
IgA B_GENE
and O
IgM B_GENE/B_LOCATION
anti I_GENE/I_LOCATION
- I_GENE/I_LOCATION
M I_GENE/I_LOCATION
. I_GENE/I_LOCATION
leprae I_GENE/I_LOCATION
antibody I_GENE/I_LOCATION
activity O
in O
sera O
taken O
3 O
- O
6 O
months O
after O
birth O
from O
babies O
of O
Group O
1 O
compared O
to O
Group O
2 O
, O
but O
the O
IgA B_GENE
and O
IgM B_GENE
activity O
in O
sera O
taken O
after O
6 O
months O
of O
age O
showed O
the O
same O
increase O
in O
the O
two O
groups O
. O

The O
relation O
between O
the O
changes O
of O
bone O
density O
and O
the O
level O
of O
blood O
calcium O
, O
blood O
phosphorus O
and O
alkaline B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AKP B_DISEASE/B_GENE
) O
as O
well O
as O
the O
metabolism O
of O
vitamin O
D O
was O
studied O
. O

These O
results O
demonstrate O
the O
extensive O
homology O
in O
sequence O
among O
light O
chains O
of O
IgM B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoantibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
indicate O
that O
a O
particular O
V B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
germ I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
line I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
kappa B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
IIIb I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
expressed O
as O
a O
phylogenetic O
response O
to O
certain O
self O
antigens O
or O
as O
part O
of O
a O
selection O
process O
by O
which O
these O
autoimmune O
responses O
are O
regulated O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirmed O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
showed O
that O
monkeys B_BIO/B_PERSON
with O
total B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bilateral I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
striatectomies I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
require O
the O
ability B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
execute O
accurate B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
visually O
guided O
reaches B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

comparison O
of O
the O
sequences O
of O
the O
alpha B_GENE/B_BIO
- I_GENE/I_BIO
like I_GENE/I_BIO
DNA I_GENE/I_BIO
polymerases I_GENE/I_BIO
including O
E B_GENE/B_PERSON
. I_GENE/I_PERSON
coli I_GENE/I_PERSON
DNA I_GENE/I_PERSON
polymerase I_GENE/I_PERSON
II I_GENE/I_PERSON
showed O
that O
there O
were O
nine O
highly O
conserved O
regions O
, O
and O
we O
constructed O
an O
unrooted O
phylogenetic O
tree O
of O
the O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
the O
differences O
in O
these O
conserved O
regions O
. O

Before O
and O
6 O
and O
12 O
months O
after O
H O
. O
pylori O
eradication O
the O
patients O
were O
evaluated O
for O
fasting O
gastrinemia O
and O
pepsinogen B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
basal O
and O
peak O
acid O
output O
, O
and O
detailed O
histological O
assessment O
including O
the O
ECL O
cell O
proliferative O
patterns O
. O

Four B_PERSON
experiments I_PERSON
examined O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cholinergic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
projections I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
septum B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
vertical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nucleus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
diagonal B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
band I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
Broca B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
( O
VDB B_MEASURE/B_PROTEIN[GENE]
) O
in O
acquisition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
performance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
a O
conditional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
discrimination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

trans O
- O
activation O
of O
the O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
HIV B_GENE
- I_GENE
1 I_GENE
Tat I_GENE
and O
HTLV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
mediated O
by O
different O
cis O
- O
acting O
sequences O
. O

Defective O
concanavalin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
suppression O
in O
bancroftian O
filariasis O
. O

For O
more O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
constructed O
mouse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A9 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cells I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O
STFs B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
derived O
from O
human B_GENE/B_BIO
chromosome I_GENE/I_BIO
2 I_GENE/I_BIO
tagged O
with O
pSTneo B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
different B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
regions I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
in O
2q31 B_MEASURE/B_BIO
- O
qter B_MEASURE/B_PERSON
. O

Left O
ventricular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
insufficiency I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
requires O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
SP I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O
patient B_PERSON/B_TIME[MEASURE]
, O
with O
good B_DISEASE_ADJECTIVE[DISEASE]
results I_DISEASE_ADJECTIVE[DISEASE]
in O
approximately O
81 B_MEASURE
p I_MEASURE
. O
cent B_MEASURE/B_LOCATION
. O

However O
, O
there O
are O
some O
cows B_BIO/B_PERSON
that O
fail O
to O
produce O
adequate B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
, O
25 B_NUMBER[MEASURE]
- O
dihydroxyvitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
at O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O
lactation B_ORGANISM_FUNCTION/B_DISEASE
. O

acidic O
carboxyl O
- O
terminal O
domain O
of O
gene B_GENE
2 I_GENE
. I_GENE
5 I_GENE
protein I_GENE
of I_GENE
bacteriophage I_GENE
T7 I_GENE
is O
essential O
for O
protein O
- O
protein O
interactions O
. O

This O
result O
, O
together O
with O
the O
fact O
that O
unrearranged B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
V I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
kappa I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
genes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
transcriptionally O
silent O
, O
suggests O
that O
structural O
features O
of O
both O
the O
V B_PROTEIN[GENE]
kappa I_PROTEIN[GENE]
and O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contribute O
to O
the O
overall O
transcriptional O
efficiency O
of O
a O
rearranged B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
V I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
total B_MEASURE
of O
10 B_MEASURE
, O
763 B_MEASURE/B_PERSON
men I_MEASURE/I_PERSON
and O
3 B_NUMBER[MEASURE]
, O
118 B_MEASURE/B_PERSON
women I_MEASURE/I_PERSON
has O
been O
studied O
, O
of O
whom O
97 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
89 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
, O
have O
been O
traced O
and O
36 B_TIME[MEASURE]/B_PERSON
% I_TIME[MEASURE]/I_PERSON
and O
16 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
have O
died O
. O

NSD1 B_GENE/B_SPECIES[BIO]
contains O
a O
SET B_MEASURE/B_LOCATION
domain B_MEASURE/I_LOCATION
and O
multiple O
PhD O
fingers O
. O

EMG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
based O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
fatigue B_DISEASE
during O
a O
repetitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
squat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
exercise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

We O
have O
introduced O
the O
same O
change O
in O
a O
yeast B_GENE
tRNA I_GENE
( I_GENE
Trp I_GENE
) I_GENE
gene I_GENE
and O
demonstrated O
that O
the O
tRNA O
acts O
as O
an O
efficient O
amber O
suppressor O
in O
vivo O
. O

This O
evaluation O
examines O
several O
analytical O
and O
cost O
parameters O
for O
five O
representative O
assays O
: O
IgG B_GENE/B_DISEASE
, O
IgA B_GENE
, O
IgM B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phenytoin O
, O
and O
phenobarbital O
. O

These O
results O
suggest O
that O
UvrA B_GENE/B_BACTERIUM[BIO]
is O
involved O
in O
triplet O
repeat O
instability O
in O
cells O
. O

Among O
women O
, O
plasma B_LOCATION/B_DISEASE
factor I_LOCATION/I_DISEASE
VII I_LOCATION/I_DISEASE
: O
AG O
was O
inversely O
associated O
with O
income O
. O

A O
novel O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PKC B_GENE
) O
- O
interacting O
protein O
was O
identified O
by O
the O
yeast O
two O
- O
hybrid O
screening O
using O
the O
regulatory O
domain O
of O
PKC B_GENE
beta I_GENE
I I_GENE
as O
a O
bait O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
number B_MEASURE/B_PERSON
of O
Spanish B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
articles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
published O
in O
Anesthesiology B_ORGANIZATION/B_PERSON
, O
BJA B_DISEASE/B_EDU[ORGANIZATION]
, O
and O
Anesth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
Analg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
although O
the O
comparison B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
our O
productivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
that O
of O
other B_PERSON/B_LOCATION
EU I_PERSON/I_LOCATION
countries I_PERSON/I_LOCATION
in O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
GNPpc B_LOCATION/B_MEASURE
places O
us O
in O
an O
intermediate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
position I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

One O
of O
the O
repeating O
domains O
( O
Yheb1 B_PROTEIN[GENE]/B_LOCATION
) O
, O
consisting O
of O
67 O
amino O
acids O
, O
was O
cloned O
from O
the O
E O
. O
coli O
chromosome O
and O
purified O
by O
metal O
chelating O
chromatography O
. O

Phosphorylation O
at O
Ser O
( O
670 O
) O
impairs O
the O
ability O
of O
GRK2 B_GENE
to O
phosphorylate O
both O
soluble O
and O
membrane O
- O
incorporated O
receptor O
substrates O
and O
dramatically O
attenuates O
Gbetagamma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
activation O
of O
this O
enzyme O
. O

methods O
: O
CD4 B_GENE/B_MEASURE
cell O
counts O
and O
interview O
data O
were O
recorded O
in O
a O
survey O
of O
136 O
adult O
patients O
attending O
a O
community O
hospital O
- O
based O
HIV O
outpatient O
clinic O
. O

Biol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Inhibition O
of O
endogenous B_GENE
Cdk2 I_GENE
by O
dominant B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cdk2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O
phosphorylation O
of O
Thr447 O
, O
Thr490 O
and O
Thr497 O
, O
but O
had O
no O
effect O
upon O
Ser581 O
modification O
. O

A O
rabbit O
antiserum O
raised O
against O
a O
unique O
( O
V3 O
domain O
) O
bacterially O
expressed O
PKC B_GENE
theta I_GENE
fragment I_GENE
immunoprecipitated O
specifically O
an O
82 O
- O
kDa O
protein O
from O
Jurkat O
cell O
lysates O
. O

Histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
variable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
motor B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
limited O
to O
the O
injection B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
the O
most O
northern B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
, O
at O
the O
same B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
largest I_MEASURE/I_LOCATION
, O
Q B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
fever I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
epidemic I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
recorded O
in O
Germany B_LOCATION
over O
the O
last B_TIME[MEASURE]/B_ENT
28 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
. O

symptoms O
, O
skin O
- O
prick O
tests O
( O
SPT O
) O
with O
environmental O
allergens O
and O
PT O
salt O
, O
total O
serum B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgE B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lung O
function O
, O
and O
bronchial O
hyperresponsiveness O
were O
assessed O
by O
standard O
procedures O
. O

Binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites B_LOCATION/B_ENT
were O
mapped O
for O
each O
factor B_PROTEIN[GENE]
. O

complementary O
DNA O
libraries O
from O
liver O
and O
ovary O
of O
an O
immature O
female O
channel O
catfish O
were O
screened O
with O
a O
homologous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ERalpha B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O
. O

The O
binding O
of O
PTB B_GENE/B_DISEASE
was O
antagonistic O
to O
the O
binding O
of O
U2AF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
enhancer O
- O
located O
pyrimidine O
tract O
. O

VLA B_GENE
- I_GENE
4 I_GENE
integrin I_GENE
cross O
- O
linking O
on O
human O
monocytic O
THP O
- O
1 O
cells O
induces O
tissue O
factor O
expression O
by O
a O
mechanism O
involving O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
. O

However O
, O
studies O
using O
the O
A20 B_GENE
promoter I_GENE
demonstrated O
that O
LMP1 B_GENE
transcriptionally O
activates O
the O
A20 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
through O
cis O
- O
acting O
kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
. O

Southern O
blot O
analysis O
revealed O
that O
CCaMK B_GENE/B_PERSON
is O
encoded O
by O
a O
single O
gene O
. O

Surgical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
rhinophyma B_DISEASE
. O

Phenazopyridine O
- O
induced O
hemolytic O
anemia O
in O
a O
patient O
with O
G6PD B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O
. O

Finally O
, O
we O
demonstrated O
that O
although O
the O
DNA O
- O
binding O
domain O
of O
c B_GENE
- I_GENE
myb I_GENE
is O
required O
for O
both O
the O
differentiation O
block O
and O
the O
shift O
in O
cell O
cycle O
after O
PMA O
treatment O
, O
phosphorylation O
by O
casein B_GENE
kinase I_GENE
II I_GENE
and O
mitogen B_GENE
- I_GENE
activated I_GENE
protein I_GENE
kinase I_GENE
at O
positions O
11 O
and O
12 O
or O
532 O
of O
c B_GENE
- I_GENE
myb I_GENE
, O
respectively O
, O
are O
not O
. O

The O
activation O
of O
NF B_GENE
- I_GENE
kappaB I_GENE
- O
dependent O
reporter O
gene O
transcription O
by O
E1A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
potently O
suppressed O
upon O
coexpression O
of O
the O
E1B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
19 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
19K I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enantiomeric I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
separation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
mephenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
obtained O
by O
using O
a O
chiral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
capillary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
column I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
the O
retention B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
for O
S B_PROTEIN[GENE]/B_DISEASE
- O
and O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
mephenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
25 B_MEASURE
. O
5 B_MEASURE
and O
26 B_MEASURE
. O
2 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
respectively O
, O
with O
a O
detection B_MEASURE
limit I_MEASURE
less I_MEASURE
than O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
of O
mephenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
myeloid B_GENE
zinc I_GENE
finger I_GENE
gene I_GENE
1 I_GENE
( O
MZF1 B_GENE/B_DISEASE
) O
encodes O
a O
C B_GENE/B_MEASURE
( I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
) I_GENE/I_MEASURE
H I_GENE/I_MEASURE
( I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
) I_GENE/I_MEASURE
zinc I_GENE/I_MEASURE
finger I_GENE/I_MEASURE
transcription I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
that O
regulates O
granulopoiesis O
and O
may O
have O
a O
regulatory O
role O
in O
cellular O
proliferation O
and O
oncogenesis O
. O

snails B_BIO/B_PERSON
infected O
with O
three B_NUMBER[MEASURE]
or O
five B_NUMBER[MEASURE]
miracidia I_NUMBER[MEASURE]
produced O
more O
metacercariae B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
those O
infected O
with O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
miracidium B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

We O
conclude O
that O
GRF1 B_GENE/B_DISEASE
and O
GRF2 B_GENE/B_DISEASE
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B_GENE
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediates O
at O
least O
two O
pathways O
for O
Raf B_GENE/B_DISEASE
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B_GENE/B_DISEASE
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B_GENE
- I_GENE
Ras I_GENE
. O

For O
the O
target B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P3 B_MEASURE/B_DISEASE
amplitude I_MEASURE/I_DISEASE
and O
latency B_MEASURE
were O
negatively O
correlated O
and O
most O
tightly O
coupled O
over O
the O
frontal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
medial I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
/ O
lateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
recording I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
sites I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Mitoxantrone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
C B_OTHER/B_PROTEIN[GENE]
is O
an O
active B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
combination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
great B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
promise I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
the O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
previously O
untreated B_DISEASE/B_PERSON
patients I_DISEASE/I_PERSON
with O
AML B_DISEASE
. O

In O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
spleen O
, O
distal B_BODY_PART_OR_ORGAN_COMPONENT
colon I_BODY_PART_OR_ORGAN_COMPONENT
, O
ileum B_BODY_PART_OR_ORGAN_COMPONENT
, O
gallbladder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
stomach B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
body I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
regional B_DISEASE
O2 I_DISEASE
delivery I_DISEASE
was O
significantly O
decreased O
with O
hemodilution B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
20 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

( O
A O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
account I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Karl B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Touton I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
life I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
also O
included O
. O
) O
After O
reviewing O
the O
historical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
concept B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
giant B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interpretations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
their O
nature B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
unitarian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
view I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
polykaryons B_LOCATION/B_BIO
now O
favored O
by O
workers B_PERSON
in O
the O
field B_LOCATION
is O
extended O
to O
include O
also O
the O
' B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
xanthelasmatic I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
giant I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
' O
of O
Touton B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whose O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appearance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
determined O
merely O
by O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
demonstrable B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
lipid I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
in O
the O
cytoplasm B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
active B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatitis B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
pregnancy B_DISEASE
. O

Influenza O
virus O
- O
induced O
NF B_GENE
- I_GENE
kappaB I_GENE
- I_GENE
dependent I_GENE
gene I_GENE
expression O
is O
mediated O
by O
overexpression O
of O
viral O
proteins O
and O
involves O
oxidative O
radicals O
and O
activation O
of O
IkappaB B_GENE
kinase I_GENE
. O

These O
observed O
changes O
were O
not O
found O
when O
assessing O
NPY B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O
in O
plasma O
fluid O
. O

reversible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
topology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
a O
bifunctional B_GENE
transmembrane I_GENE
protein I_GENE
depends O
upon O
the O
charge B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
balance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
around O
its O
transmembrane B_LOCATION/B_BIO
domain I_LOCATION/I_BIO
. O

Protein B_LOCATION/B_GENE
kinase I_LOCATION/I_GENE
C I_LOCATION/I_GENE
( O
PKC B_GENE
) O
activation O
after O
treatment O
of O
human O
neuroblastoma O
SK O
- O
N O
- O
Be O
( O
2 O
) O
C O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
was O
found O
to O
enhance O
transcription O
of O
the O
human O
dopamine B_ENZYME[GENE]
beta I_ENZYME[GENE]
- I_ENZYME[GENE]
hydroxylase I_ENZYME[GENE]
( O
DBH B_GENE/B_LOCATION
) O
in O
those O
cells O
. O

The O
second B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
represented O
by O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosed O
as O
HSIL B_DISEASE
by O
cytology B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
illuminator B_LOCATION/B_PERSON
uses O
a O
grain B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
of O
- O
wheat B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light B_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bulb B_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
adjustable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
bulb I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
holder I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
fashioned O
from O
bent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clips B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Bedbug O
( O
Cimex O
lectularius O
) O
samples O
adult O
and O
nymphs O
either O
engorged O
or O
starved O
from O
Central O
Security O
Forces O
sleeping O
wards O
, O
laboratory O
animal O
house O
and O
control O
samples O
from O
laboratory O
reared O
colonies O
were O
ground O
and O
subjected O
to O
ELISA O
test O
of O
hepatitis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surface B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O
with O
276 O
serum O
samples O
from O
the O
recruits O
slept O
in O
those O
wards O
. O

The O
genomic O
organization O
in O
this O
region O
is O
similar O
to O
the O
neural O
- O
restricted O
family O
members O
, O
Hel B_PROTEIN[GENE]/B_DISEASE
- I_PROTEIN[GENE]/I_DISEASE
N1 I_PROTEIN[GENE]/I_DISEASE
( O
ELAVL2 B_GENE
) O
and O
mHuD B_PROTEIN[GENE]/B_DISEASE
( O
Elavl4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Synergistic O
induction O
of O
apoptosis O
in O
human O
leukemia O
cells O
( O
U937 O
) O
exposed O
to O
bryostatin O
1 O
and O
the O
proteasome O
inhibitor O
lactacystin O
involves O
dysregulation O
of O
the O
PKC B_GENE
/ O
MAPK B_GENE
Cascade O
. O

With O
the O
help B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
partially O
overlapping O
parenchymatous B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
sutures B_DISEASE_ADJECTIVE[DISEASE]/I_MEDICAL_DEVICE[OBJECT]
, O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
renal I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
segments I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
devitalized O
. O

promoter O
elements O
and O
transcriptional O
control O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetylcholinesterase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
average B_MEASURE/B_LOCATION
cumulative I_MEASURE/I_LOCATION
UVA I_MEASURE/I_LOCATION
dose I_MEASURE/I_LOCATION
was O
65 B_MEASURE
J I_MEASURE
/ O
cm2 B_MEASURE
; O
40 B_PERSON
patients I_PERSON
had O
received O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
200 B_MEASURE/B_PERSON
J I_MEASURE/I_PERSON
/ O
cm2 B_MEASURE/B_LOCATION
. O

malformations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
regenerating O
optic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tectum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
larvae B_SPECIES[BIO]/B_DISEASE
of O
the O
Egyptian B_SPECIES[BIO]
toad I_SPECIES[BIO]
, O
Bufo B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regularis I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Reuss I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
morphological O
changes O
are O
associated O
with O
a O
marked O
induction O
of O
P450arom B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
. O

The O
immunoprofile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
60 B_PERSON/B_TIME[MEASURE]
adult I_PERSON/I_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
of O
pulmonary B_DISEASE/B_LOCATION
tuberculosis I_DISEASE/I_LOCATION
was O
studied O
and O
compared O
with O
22 B_PERSON/B_DISEASE
normal I_PERSON/I_DISEASE
controls I_PERSON/I_DISEASE
. O

Central B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
venous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
catheter B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
related O
infection B_DISEASE
is O
readily O
diagnosed O
by O
comparing O
simultaneous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quantitative I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cultures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
via O
the O
catheter B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
a O
peripheral B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
vein I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
role O
of O
haptoglobin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
asphyxia O
mechanism O
( O
II O
) O
- O
- O
acute O
drowning O
and O
hanging O
. O

processing O
Mes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requires O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bit I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
manipulations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
heavy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
memory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
storage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
requirements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Thus O
, O
BCR B_GENE
ligation O
initiates O
a O
PI B_GENE
3 I_GENE
- I_GENE
kinase I_GENE
/ O
Akt B_GENE
/ O
GSK B_GENE/B_LOCATION
- I_GENE/I_LOCATION
3 I_GENE/I_LOCATION
signaling O
pathway O
. O

cDNA O
cloning O
and O
transcriptional O
properties O
of O
a O
novel O
GC B_GENE/B_PERSON
box I_GENE/I_PERSON
- I_GENE/I_PERSON
binding I_GENE/I_PERSON
protein I_GENE/I_PERSON
, O
BTEB2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
activity O
creates O
a O
4 O
- O
BP O
staggered O
cut O
with O
3 O
' O
OH O
overhangs O
within O
a O
specific O
sequence O
of O
the O
21S B_GENE/B_LOCATION
rRNA I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
of O
Omega O
- O
strains O
. O

The O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ORFs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
had O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
the O
putative B_GENE/B_BIO
replication I_GENE/I_BIO
protein I_GENE/I_BIO
from O
plasmid B_BIO/B_GENE
pTiK12 I_BIO/I_GENE
of O
Thiobacillus B_BACTERIUM[BIO]
intermedius I_BACTERIUM[BIO]
and O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
CoIE2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
- O
related O
plasmids B_BIO/B_GENE
. O

In O
contrast O
SF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
GM B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
3 I_GENE/I_LOCATION
, O
induced O
tyrosine O
phosphorylation O
of O
phospholipase B_GENE
C I_GENE
- I_GENE
gamma I_GENE
( O
PLC B_GENE/B_LOCATION
- I_GENE/I_LOCATION
gamma I_GENE/I_LOCATION
) O
. O

Phase B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mitomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

replacement O
of O
Val20 O
- O
Leu21 O
with O
Ala O
- O
Ala O
produced O
a O
dimeric B_PROTEIN[GENE]
RII I_PROTEIN[GENE]
beta I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
that O
binds O
AKAP75 B_LOCATION/B_GENE
approximately O
4 O
% O
as O
avidly O
as O
wild B_GENE
- I_GENE
type I_GENE
RII I_GENE
beta I_GENE
. O

The O
temporal O
expression O
of O
CRAlBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
similar O
to O
IRBP B_LOCATION/B_GENE
while O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
expressed O
until O
after O
photoreceptor O
differentiation O
is O
complete O
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
T O
cells O
these O
two O
signal O
pathways O
are O
critical O
for O
interleukin B_GENE
- I_GENE
2 I_GENE
production O
. O

replacement O
of O
a O
valine O
( O
V68 O
) O
in O
the O
ETS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O
of O
SAP1a B_GENE
by O
aspartic O
acid O
( O
as O
found O
in O
c B_GENE/B_DISEASE
- I_GENE/I_DISEASE
Ets I_GENE/I_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
, O
Elk B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
, O
and O
Net B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
enhanced O
ternary O
complex O
formation O
by O
more O
than O
60 O
- O
fold O
. O

In O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
investigate O
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
direct I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
action I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O
endometriosis B_DISEASE/B_ORGANISM_FUNCTION
, O
intravaginal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
intrauterine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
application B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
were O
tried O
. O

The O
NF B_GENE
- I_GENE
kappaB I_GENE
/ O
Rel B_GENE/B_LOCATION
transcription O
factors O
participate O
in O
the O
activation O
of O
immune O
system O
regulatory O
genes O
and O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O
the O
human B_DISEASE/B_GENE
immunodeficiency B_DISEASE/I_GENE
virus B_DISEASE/I_GENE
type B_DISEASE/I_GENE
1 B_DISEASE/I_GENE
long B_DISEASE/I_GENE
terminal B_DISEASE/I_GENE
repeat B_DISEASE/I_GENE
. O

A O
total B_MEASURE
of O
4 B_MEASURE
, O
916 B_MEASURE/B_LOCATION
children I_MEASURE/I_LOCATION
were O
examined O
and O
the O
questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfactorily O
completed O
by O
a O
relative B_PERSON
or O
guardian B_PERSON
( O
usually O
the O
mother B_PERSON
) O
of O
4 B_MEASURE
, O
651 B_MEASURE
. O

cDNA O
cloning O
reveals O
two O
mouse B_GENE
beta5 I_GENE
integrin I_GENE
transcripts I_GENE
distinct O
in O
cytoplasmic O
domains O
as O
a O
result O
of O
alternative O
splicing O
. O

Earlier B_PERSON/B_LOCATION
nonoptical I_PERSON/I_LOCATION
methods I_PERSON/I_LOCATION
probably O
did O
not O
include O
the O
portion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
film B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contained O
mucus B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
summarise O
quantitatively O
the O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
moderate B_DISEASE
alcohol I_DISEASE
intake I_DISEASE
and O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
risk B_DISEASE_ADJECTIVE[DISEASE]
of O
coronary B_DISEASE
heart I_DISEASE
disease I_DISEASE
and O
to O
predict O
how O
these O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
lower O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]
. O

Like O
other O
known O
GCD B_GENE/B_BIO
genes I_GENE/I_BIO
, O
GCD14 B_MEASURE/B_GENE
and O
GCD15 B_MEASURE/B_GENE
are O
therefore O
probably O
required O
for O
general O
translation O
initiation O
in O
addition O
to O
their O
roles O
in O
GCN4 B_GENE
- O
specific O
translational O
control O
. O

The O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
highly O
correlated B_MEASURE
frequencies I_MEASURE
provided O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
medium B_MEASURE/B_LOCATION
- O
frequency B_MEASURE/B_LOCATION
pattern I_MEASURE/I_LOCATION
generator I_MEASURE/I_LOCATION
which O
may O
remain O
operative B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beyond O
the O
neonatal B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
period I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
gene O
is O
named O
PKNOX1 B_GENE/B_LOCATION
by O
the O
Human O
Nomenclature O
Committee O
. O

differentiation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
porcine B_DISEASE/B_BIO
Mycoplasma I_DISEASE/I_BIO
strains I_DISEASE/I_BIO
by O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
simple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paper I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

HIV B_DISEASE/B_GENE
- O
2 B_TIME[MEASURE]/B_DISEASE
in O
Spain B_LOCATION
. O

No O
effect O
of O
4 O
beta O
- O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
was O
observed O
on O
the O
expression O
of O
hnRNP B_GENE
H I_GENE
. O

patients B_PERSON/B_LOCATION
commonly O
considered O
the O
external B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frame I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cumbersome I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
atf1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Schizosaccharomyces I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pombe I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
a O
bZIP B_ENZYME[GENE]/B_MEASURE
transcription I_ENZYME[GENE]/I_MEASURE
factor I_ENZYME[GENE]/I_MEASURE
with O
strong O
homology O
to O
the O
mammalian B_GENE/B_BIO
factor I_GENE/I_BIO
ATF I_GENE/I_BIO
- I_GENE/I_BIO
2 I_GENE/I_BIO
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sources B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
commercial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O
the O
humoral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
broilers B_PERSON/B_SPECIES[BIO]
to O
Newcastle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
disease B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
vaccination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

Multiple O
attempts O
aimed O
at O
disruption O
of O
the O
chromosomal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fabG I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gene I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
unsuccessful O
. O

Primary B_PERSON
TJRs I_PERSON
were O
clinically O
evaluated O
for O
degree B_DISEASE_ADJECTIVE[DISEASE]
of O
osteoarthrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Radiation B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
sensitivity B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
rats B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiated O
in O
a O
condition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
hypoxia B_DISEASE
. O

The O
activity O
of O
plasminogen B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
measured O
in O
tissue O
sections O
with O
the O
aid O
of O
a O
modified O
Todd O
technique O
. O

The O
complexity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
some O
of O
the O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
VACURG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O
led O
some O
to O
believe O
that O
this O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
opposed O
to O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
but O
that O
is O
not O
true B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Thus O
, O
the O
mutants O
are O
deficient O
in O
production O
of O
the O
O B_ENZYME[GENE]/B_SPECIES[BIO]
- I_ENZYME[GENE]/I_SPECIES[BIO]
antigen I_ENZYME[GENE]/I_SPECIES[BIO]
polymerase I_ENZYME[GENE]/I_SPECIES[BIO]
and O
were O
termed O
rfc B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Up O
to O
1988 B_MEASURE
, O
145 B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
had O
been O
reported O
in O
literature B_LOCATION/B_PERSON
and O
32 B_MEASURE/B_ENT
cases B_MEASURE/I_ENT
in O
our O
country B_LOCATION
. O

focal B_DISEASE
glomerulosclerosis I_DISEASE
- O
like B_DISEASE/B_MEASURE
disease I_DISEASE/I_MEASURE
with O
nephrotic B_DISEASE
syndrome I_DISEASE
in O
a O
horse B_BIO/B_PERSON
. O

The O
antihypertensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
corresponds O
to O
those O
of O
established O
diuretics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Interconversions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reduced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
haloperidol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
schizophrenic B_SPECIES[BIO]/B_LOCATION
patients I_SPECIES[BIO]/I_LOCATION
and O
Guinea B_PERSON/B_BIO
pigs I_PERSON/I_BIO
: O
a O
steady B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
frequency B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
eating O
dark B_COLOR/B_BODY_PART_OR_ORGAN_COMPONENT
- O
meat B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fish I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
positively O
associated O
with O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
eicosapentaenoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
docosahexaenoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
omega3 B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DISEASE_ADJECTIVE[DISEASE]
acids I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
inversely O
associated O
with O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stearic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
linoleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
hemodynamics B_DISEASE/B_ORGANISM_FUNCTION
. O

The O
D443N B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
substitution I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
is O
an O
activating O
mutation O
that O
increases O
the O
activity O
of O
SCAP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
renders O
it O
resistant O
to O
inhibition O
by O
25 O
- O
hydroxycholesterol O
. O

Central O
( O
heart O
rate O
, O
ve O
, O
VO2 O
) O
or O
local O
( O
muscle O
and O
blood O
lactate O
, O
adenosine O
triphosphate O
, O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
glycogen O
) O
cues O
highlighted O
in O
these O
studies O
demonstrate O
both O
the O
complexity O
of O
effort O
perception O
, O
and O
the O
need O
for O
better O
understanding O
of O
the O
physiological O
components O
upon O
which O
it O
is O
based O
. O

The O
gene B_GENE/B_MEASURE
is O
predicted O
to O
encode O
an O
880 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
acid B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
which O
contains O
two B_GENE
C2H2 I_GENE
zinc I_GENE
fingers I_GENE
, O
a O
nuclear B_GENE
localization I_GENE
sequence I_GENE
and O
two B_GENE
transcriptional I_GENE
activation I_GENE
domains I_GENE
. O

This O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allowed O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
baseline B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
well O
as O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
change B_MEASURE
in O
mileage B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
musculoskeletal B_DISEASE
problem I_DISEASE
, O
or O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
another O
health B_DISEASE_ADJECTIVE[DISEASE]
problem I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
rate B_MEASURE
of O
dropout B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

microalbuminuria B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
marker B_MEASURE/B_DISEASE
of O
systemic B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

Regulation O
of O
activating B_GENE
transcription I_GENE
factor I_GENE
- I_GENE
1 I_GENE
and O
the O
cAMP B_GENE/B_TIME[MEASURE]
response I_GENE/I_TIME[MEASURE]
element I_GENE/I_TIME[MEASURE]
- I_GENE/I_TIME[MEASURE]
binding I_GENE/I_TIME[MEASURE]
protein I_GENE/I_TIME[MEASURE]
by O
Ca2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Coronary B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
arteries B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
found O
in O
the O
biopsy B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
30 B_MEASURE
( O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
of O
the O
39 B_PERSON
patients I_PERSON
who O
formed O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Serum B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amyloid B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
A B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
SAA B_LOCATION/B_PROTEIN[GENE]
) O
is O
a O
plasma O
protein O
which O
has O
been O
associated O
with O
several O
diseases O
, O
including O
amyloidosis O
, O
arthritis O
, O
and O
atherosclerosis O
, O
and O
its O
abnormal O
expression O
, O
particularly O
in O
nonhepatic O
cells O
, O
is O
implicated O
in O
the O
pathogenesis O
of O
these O
diseases O
. O

Phenacetin B_DISEASE_ADJECTIVE[DISEASE]
nephritis I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
been O
developing O
a O
digital B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoroscopic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
replace O
the O
portal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
currently O
used O
to O
verify O
patient B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positioning B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p18 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spans O
at O
least O
7 O
. O
5 O
kb O
and O
is O
composed O
of O
three O
exons O
, O
two O
of O
which O
encode O
the O
p18 B_GENE
protein I_GENE
. O

serum O
creatinine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O
was O
7 O
, O
800 O
- O
17 O
, O
500 O
U O
/ O
l O
, O
making O
acute O
muscle O
damage O
likely O
, O
probably O
rhabdomyolysis O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
a O
highly O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
event I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
and O
not O
merely O
a O
consequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
decreased O
stability B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
EC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Like O
Mdm2 B_GENE/B_DISEASE
, O
MdmX B_GENE/B_BACTERIUM[BIO]
is O
able O
to O
bind O
p53 B_GENE/B_DISEASE
and O
inhibit O
p53 B_GENE/B_LOCATION
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B_GENE/B_BIO
to O
degrade O
p53 B_GENE
has O
yet O
to O
be O
examined O
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Second B_DISEASE
malignant I_DISEASE
neoplasms I_DISEASE
( O
SMNs B_DISEASE/B_PROTEIN[GENE]
) O
are O
a O
rare B_DISEASE
occurrence I_DISEASE
after O
the O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
childhood B_DISEASE
cancer I_DISEASE
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
geological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
focusing O
on O
the O
Davie B_LOCATION/B_ORGANIZATION
fracture I_LOCATION/I_ORGANIZATION
Zone I_LOCATION/I_ORGANIZATION
of O
the O
Mozambique B_LOCATION
Channel I_LOCATION
offer O
a O
resolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
this O
situation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
by O
suggesting O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
land B_LOCATION
- O
bridge B_LOCATION
from O
the O
mid B_TIME[MEASURE]/B_DISEASE
- O
Eocene B_TIME[MEASURE]/B_LOCATION
to O
the O
early B_TIME[MEASURE]/B_LOCATION
Miocene I_TIME[MEASURE]/I_LOCATION
, O
an O
interval B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
matches O
the O
ages B_TIME[MEASURE]/B_BIO
of O
Madagascar B_BIO/B_LOCATION
' I_BIO/I_LOCATION
s I_BIO/I_LOCATION
mammalian I_BIO/I_LOCATION
groups I_BIO/I_LOCATION
. O

The O
nucleotide O
sequence O
of O
a O
PCR O
- O
amplified O
SMT3A B_SPECIES[BIO]/B_GENE
genomic O
DNA O
fragment O
was O
found O
to O
be O
identical O
to O
that O
of O
SMT3A B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
indicating O
the O
absence O
of O
intron O
( O
s O
) O
in O
its O
protein O
coding O
region O
. O

mutant O
p53 B_GENE/B_DISEASE
DNA B_GENE/I_DISEASE
clones O
from O
human O
colon O
carcinomas O
cooperate O
with O
ras B_GENE/B_DISEASE
in O
transforming O
primary O
rat O
cells O
: O
a O
comparison O
of O
the O
' O
hot O
spot O
' O
mutant O
phenotypes O
. O

Gas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
headspace B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alkalinized B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
vaginal B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
discharges B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
indicated O
the O
presence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trimethylamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
all O
11 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
samples I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
with O
the O
fishy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
odor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
not O
in O
the O
other B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Standing B_TIME[MEASURE]/B_ENT
values I_TIME[MEASURE]/I_ENT
: O
placebo B_MEASURE/B_PERSON
114 I_MEASURE/I_PERSON
/ O
79 B_MEASURE
; O
BHT B_MEASURE/B_PROTEIN[GENE]
- O
933 B_MEASURE/B_PERSON
92 I_MEASURE/I_PERSON
/ O
67 B_MEASURE
. O

The O
Ixodes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fauna I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
the O
Michourin B_LOCATION
region I_LOCATION
, O
where O
the O
pastures B_LOCATION/B_SPECIES[BIO]
in O
1971 B_TIME[MEASURE]/B_LOCATION
were O
grazed O
only O
by O
sheep B_SPECIES[BIO]
, O
shows O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trends I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
H B_PROTEIN[GENE]/B_LOCATION
. O
punctata B_SPECIES[BIO]/B_DISEASE
and O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
turanicus B_SPECIES[BIO]/B_DISEASE
ticks I_SPECIES[BIO]/I_DISEASE
, O
which O
are O
preferably O
parasitising O
in O
sheep B_SPECIES[BIO]/B_LOCATION
, O
increase O
their O
relative B_MEASURE/B_LOCATION
share I_MEASURE/I_LOCATION
. O

The O
SEC27 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
cloned O
, O
and O
the O
sequence O
predicts O
a O
99 O
. O
4 O
- O
kDa O
protein O
with O
45 O
% O
sequence O
identity O
to O
mammalian O
beta B_GENE/B_PERSON
' I_GENE/I_PERSON
- I_GENE/I_PERSON
COP I_GENE/I_PERSON
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fetal B_MEASURE/B_EDU[ORGANIZATION]
maturity B_MEASURE/I_EDU[ORGANIZATION]
. O

Fetal B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
arterial I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O
sagittal B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
sinus B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pH B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
base B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
excess I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
po2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saturation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
decreased O
, O
and O
hydrogen B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pco2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O
during O
asphyxia B_DISEASE
alone O
and O
asphyxia B_DISEASE
plus O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Therefore O
, O
it O
appears O
that O
GCN2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O
is O
stimulated O
posttranslationally O
in O
amino O
acid O
- O
starved O
cells O
. O

Although O
paclitaxel O
alone O
failed O
to O
induce O
p38 B_GENE
MAPK O
activation O
, O
subsequent O
( O
but O
not O
prior O
) O
exposure O
to O
PD98059 O
induced O
a O
dramatic O
increase O
in O
p38 B_GENE
MAPK O
phosphorylation O
. O

In O
3 B_NUMBER[MEASURE]
of O
the O
5 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
AVNRT B_DISEASE/B_LOCATION
and O
AJR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
junctional B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beats B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
served O
as O
a O
trigger B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
reentry B_DISEASE
. O

The O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
respective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
C5 B_PROTEIN[GENE]
, O
C10 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
C15 B_PROTEIN[GENE]/B_MEASURE
) O
were O
injected O
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
an O
open B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
frame I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predicting O
a O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
of O
299 B_MEASURE
amino I_MEASURE
acids I_MEASURE
( O
approximately O
32 B_MEASURE
kDa I_MEASURE
) O
, O
half O
the O
size B_MEASURE/B_LOCATION
of O
the O
bovine B_GENE
gamma I_GENE
subunit I_GENE
. O

A O
positive O
FTA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ABS B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19S B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgM B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O
indicates O
the O
necessity O
of O
treatment O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
some O
defects B_DISEASE
observed O
in O
BS B_LOCATION/B_DISEASE
, O
WS B_DISEASE/B_PROTEIN[GENE]
or O
RTS B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
the O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
unrestrained B_DISEASE
recombination I_DISEASE
. O

The O
promoter O
for O
HMG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
two O
binding O
sites O
for O
the O
sterol B_GENE/B_BIO
regulatory I_GENE/I_BIO
element I_GENE/I_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
proteins I_GENE/I_BIO
( O
SREBPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
chromatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
areas B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
V1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
V2 B_PROTEIN[GENE]/B_LOCATION
is O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
V4 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
, O
together O
with O
the O
behavioural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
that O
these O
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
some O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
colour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perception I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
curse B_PERSON/B_TIME[MEASURE]
of O
the O
Pharaohs B_PERSON/B_LOCATION
. O

covariates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
extremity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
range I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
motion B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sensory B_MEASURE/B_DISEASE
status I_MEASURE/I_DISEASE
. O

characterization O
and O
targeted O
disruption O
of O
murine B_GENE
Nup50 I_GENE
, O
a O
p27 B_GENE
( O
Kip1 B_PROTEIN[GENE]/B_LOCATION
) O
- O
interacting O
component O
of O
the O
nuclear O
pore O
complex O
. O

p27 B_GENE
( O
Kip1 B_GENE/B_LOCATION
) O
is O
a O
member O
of O
the O
Cip B_DISEASE/B_GENE
- O
Kip B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O
of O
cyclin B_GENE
- I_GENE
dependent I_GENE
kinase I_GENE
( O
Cdk B_GENE/B_LOCATION
) O
inhibitors O
that O
binds O
to O
cyclin B_GENE
- O
Cdk B_GENE
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B_GENE
( O
Kip1 B_GENE/B_DISEASE
) O
is O
regulated O
by O
several O
posttranscriptional O
mechanisms O
, O
including O
subcellular O
localization O
. O

Therefore O
, O
the O
Ogg1 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
eukaryotic O
DNA B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
glycosylase I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
AP B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lyase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_PERSON/B_NUMBER[MEASURE]
patient I_PERSON/I_NUMBER[MEASURE]
had O
chronic B_DISEASE
dysphoria I_DISEASE
and O
one B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encephalopatia I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxica I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alveoli B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
capillary B_LOCATION
diffusion I_LOCATION
. O

mutations O
of O
SIN4 B_GENE
, O
ROX3 B_GENE
, O
SRB8 B_GENE
, O
SRB9 B_GENE
, O
SRB10 B_GENE
, O
SRB11 B_GENE
, O
and O
two O
novel O
genes O
, O
NUT1 B_GENE/B_DISEASE
and O
NUT2 B_GENE/B_DISEASE
, O
relieve O
the O
requirement O
of O
Swi4p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
for O
expression O
of O
this O
reporter O
. O

The O
software B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
in O
Basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adapted O
for O
the O
Hewlett B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
Packard B_PERSON/B_PROTEIN[GENE]
calculators I_PERSON/I_PROTEIN[GENE]
HP I_PERSON/I_PROTEIN[GENE]
- O
9845B B_MEASURE
and O
HP B_ORGANIZATION/B_PROTEIN[GENE]
- O
85A B_MEASURE/B_PERSON
. O

For O
Thermus O
strain O
ZO5 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydroorotase I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DHOase B_PROTEIN[GENE]
; O
encoded O
by O
pyrC B_GENE/B_BACTERIUM[BIO]
) O
, O
the O
highest O
similarity O
scores O
( O
about O
40 O
% O
identity O
) O
were O
obtained O
with O
DHOases B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
B O
. O
caldolyticus O
and O
Bacillus O
subtilis O
. O

precision B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sodium B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinetics I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
hemodialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

These O
data O
suggest O
that O
the O
fibrinogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gly190 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Val202 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O
as O
a O
minimal O
recognition O
sequence O
for O
the O
leukocyte O
integrin O
CD11b B_GENE
/ O
CD18 B_GENE/B_MEASURE
. O

Attenuated O
serum O
cortisol O
responses O
were O
found O
in O
six O
of O
the O
patients O
despite O
a O
normal O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
test O
. O

We O
recently O
described O
the O
isolation O
and O
characterization O
of O
nontoxic O
PAP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
NT123 O
- O
2 O
, O
which O
has O
a O
point O
mutation O
( O
E176V O
) O
in O
the O
active O
site O
that O
abolishes O
enzymatic O
activity O
, O
and O
NT124 O
- O
3 O
, O
which O
has O
a O
nonsense O
mutation O
that O
results O
in O
deletion O
of O
the O
C O
- O
terminal O
25 O
AA O
( O
W237Stop O
) O
. O

toxicity O
of O
benzoyl O
chloride O
( O
2 O
, O
4 O
, O
6 O
- O
trichlorophenyl O
) O
hydrazone O
( O
Banamite O
) O
and O
potential O
metabolites O
to O
twospotted O
spider O
mites O
and O
potency O
as O
inhibitors O
of O
rat B_GENE
liver I_GENE
monoamine I_GENE
oxidase I_GENE
. O

The O
screen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
identifies O
mutants B_DISEASE/B_BIO
whose O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depends O
on O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
expression B_GENE
of O
that O
gene B_ENZYME[GENE]/B_MEASURE
. O

The O
genes O
expressed O
during O
the O
embryonic O
( O
zeta B_PROTEIN[GENE]
) O
or O
fetal O
and O
adult O
stage O
( O
alpha B_PROTEIN[GENE]
2 I_PROTEIN[GENE]
and O
alpha B_PROTEIN[GENE]
1 I_PROTEIN[GENE]
) O
can O
be O
modified O
by O
point O
mutations O
which O
affect O
either O
the O
processing O
- O
translation O
of O
mRNA O
or O
make O
the O
polypeptide O
chains O
extremely O
unstable O
. O

In O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
Singapore B_LOCATION/B_MEASURE
, O
Chinese B_LOCATION/B_PERSON
, O
Malay B_PERSON/B_LOCATION
and O
Indian B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
with O
pulmonary B_DISEASE
tuberculosis I_DISEASE
received O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
of O
daily B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
streptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
pyrazinamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
daily B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoniazid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
either O
with O
pyrazinamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
SHRZ B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HRZ B_LOCATION/B_PROTEIN[GENE]
) O
or O
without O
it O
( O
SHRZ B_LOCATION/B_PROTEIN[GENE]
/ O
HR B_LOCATION/B_PROTEIN[GENE]
) O
, O
allocated O
at O
random B_PERSON/B_MEASURE
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
/ O
human O
herpesvirus O
- O
8 O
ORF50 B_GENE
gene O
product O
contains O
a O
potent O
C O
- O
terminal O
activation O
domain O
which O
activates O
gene O
expression O
via O
a O
specific O
target O
sequence O
. O

NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
microcirculation B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
stomach B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
efficiency O
of O
transfections O
was O
normalized O
relative O
to O
the O
net O
amount O
of O
CAT B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasmid O
actually O
transfected O
into O
recipient O
cells O
, O
determined O
by O
a O
modified O
Southern O
hybridization O
procedure O
. O

Genomic O
Southern O
blot O
analysis O
suggests O
that O
the O
human O
haploid O
genome O
contains O
a O
single O
Gs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chelation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
time B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
following O
strontium B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
mice B_BIO/B_DISEASE
. O

In O
the O
present O
study O
we O
found O
that O
CD34 B_GENE
downregulation O
during O
hematopoiesis O
occured O
at O
the O
level O
of O
transcriptional O
initiation O
. O

allergen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
stimulated O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
PGD2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
1274 B_MEASURE
+ I_MEASURE
/ O
- O
565 B_MEASURE
versus I_MEASURE
1468 I_MEASURE
+ I_MEASURE
/ O
- O
679 B_MEASURE
after O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
likewise O
, O
allergen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
stimulated O
5 B_MEASURE
- O
HETE B_PROTEIN[GENE]
levels I_PROTEIN[GENE]
were O
95 B_MEASURE
+ I_MEASURE
/ O
- O
21 B_MEASURE
versus I_MEASURE
82 I_MEASURE
+ I_MEASURE
/ O
- O
21 B_MEASURE
; O
those O
of O
LTE4 B_GENE/B_MEASURE
were O
54 B_MEASURE
+ I_MEASURE
/ O
- O
20 B_MEASURE
versus I_MEASURE
91 I_MEASURE
+ I_MEASURE
/ O
- O
51 B_MEASURE
; O
and O
those O
of O
15 B_NUMBER[MEASURE]
- O
HETE B_MEASURE/B_PROTEIN[GENE]
were O
63 B_MEASURE
+ I_MEASURE
/ O
- O
19 B_MEASURE
versus I_MEASURE
60 I_MEASURE
+ I_MEASURE
/ O
- O
25 B_MEASURE
. O

foreign B_GENE/B_BIO
DNA I_GENE/I_BIO
inserts I_GENE/I_BIO
contained O
within O
the O
fowlpox B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
transferred O
to O
the O
viral B_BIO/B_GENE
genome I_BIO/I_GENE
by O
homologous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombination I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
occurring O
in O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
infected O
with O
a O
fowlpox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
virus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
temperature I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
transfected O
with O
both O
wild B_PERSON/B_BIO
- O
type B_MEASURE/B_PERSON
viral B_MEASURE/I_PERSON
DNA B_MEASURE/I_PERSON
and O
plasmid B_GENE/B_BIO
DNA I_GENE/I_BIO
. O

Although O
there O
is O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
cone B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
determine O
colour B_MEASURE/B_PERSON
appearance I_MEASURE/I_PERSON
under O
many B_LOCATION
conditions I_LOCATION
, O
the O
site B_LOCATION/B_TIME[MEASURE]
or O
sites B_LOCATION/B_MEASURE
of O
their O
computation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

Furthermore O
, O
we O
demonstrate O
that O
in O
myeloid O
and O
B O
cell O
extracts O
, O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O
a O
novel O
, O
specific O
, O
more O
slowly O
migrating O
complex O
( O
PU B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SF I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
when O
binding O
the O
GM B_GENE/B_DISEASE
- B_GENE/I_DISEASE
CSF B_GENE/I_DISEASE
receptor B_GENE/I_DISEASE
alpha B_GENE/I_DISEASE
promoter O
PU B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O
. O

Several B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
components I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
cytokine B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
signaling I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
remain O
unidentified B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

This O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
the O
level B_MEASURE/B_LOCATION
of O
the O
energy B_LOCATION/B_PERSON
coupling I_LOCATION/I_PERSON
proteins I_LOCATION/I_PERSON
of O
the O
pts B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
stem B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
- O
loop B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
structures I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
3 B_NUMBER[MEASURE]
, O
and O
4 B_NUMBER[MEASURE]
of O
the O
3 B_NUMBER[MEASURE]/B_PERSON
' O
domain B_LOCATION/B_GENE
showed O
great B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
size B_MEASURE/B_LOCATION
, O
sequence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
structure B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

A O
spectrophotometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
microdetermination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
periodate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

RESULT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
as O
followed O
: O
1 B_NUMBER[MEASURE]
) O
Early O
cancer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
like B_DISEASE/B_ENT
advanced I_DISEASE/I_ENT
cancers I_DISEASE/I_ENT
were O
consisted O
of O
133 B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lesions I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
of O
which O
128 B_MEASURE
lesions I_MEASURE
( O
96 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
had O
peptic B_DISEASE
ulcer I_DISEASE
in O
cancerous B_DISEASE/B_MEASURE
lesion B_DISEASE/I_MEASURE
( O
73 B_MEASURE
lesions I_MEASURE
were O
active B_DISEASE_ADJECTIVE[DISEASE]
stage I_DISEASE_ADJECTIVE[DISEASE]
and O
55 B_MEASURE
lesions I_MEASURE
were O
scarring O
stage B_DISEASE/B_MEASURE
) O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hyperaemia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
thallium B_LOCATION/B_DISEASE
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
redistribution I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
normal B_DISEASE/B_BIO
canine I_DISEASE/I_BIO
myocardium I_DISEASE/I_BIO
. O

Immunoblotting O
showed O
that O
both O
the O
( O
1 O
- O
404 O
) O
- O
peptide O
and O
( O
1 O
- O
506 O
) O
- O
peptide O
are O
recognized O
by O
95J10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
monoclonal O
antibody O
that O
was O
previously O
raised O
against O
perlecan B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
404 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed O
in O
Escherichia O
coli O
. O

The O
anesthesiologist B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
cardiac B_PERSON
surgeon I_PERSON
. O

To O
gain O
further O
insights O
into O
these O
events O
, O
the O
porcine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
i I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
minimal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
characterized O
and O
found O
67 O
base O
pairs O
upstream O
from O
the O
major O
transcription O
start O
site O
. O

FDP B_LOCATION/B_GENE
- O
1 B_NUMBER[MEASURE]
( O
200 B_MEASURE
micrograms I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_MEASURE/B_LOCATION
) O
of O
intracoronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O
collateral B_DISEASE
flow I_DISEASE
, O
reduced O
systemic B_DISEASE/B_GENE
artery I_DISEASE/I_GENE
resistance I_DISEASE/I_GENE
, O
and O
coronary B_DISEASE/B_MEASURE
systolic I_DISEASE/I_MEASURE
pressure I_DISEASE/I_MEASURE
in O
infarcted B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
region B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
and O
the O
area B_LOCATION/B_MEASURE
of O
infarction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreased O
from O
28 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
to O
15 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
, O
n B_OTHER/B_PROTEIN[GENE]
= O
6 B_MEASURE
) O
. O

pathophysiologic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
underlying O
spatial B_DISEASE
disorientation I_DISEASE
in O
patients B_PERSON/B_BIO
with O
Alzheimer B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Many O
human O
malignant O
cells O
lack O
methylthioadenosine B_GENE/B_DISEASE
phosphorylase I_GENE/I_DISEASE
( O
MTAP B_LOCATION/B_GENE
) O
enzyme O
activity O
. O

Following O
40 B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
min I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
' O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
, O
preparations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
treated O
with O
PC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recovered O
from O
transmural B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conduction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
more O
rapidly O
( O
PC1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
4 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
, O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
05 B_MEASURE
; O
PC2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
23 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
, O
ns B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
compared O
to O
control O
. O
( O
abstract B_MEASURE/B_LOCATION
TRUNCATED I_MEASURE/I_LOCATION
AT O
250 B_MEASURE/B_LOCATION
WORDS I_MEASURE/I_LOCATION
) O
. O

The O
novel B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spans O
16 B_MEASURE
. O
7 B_MEASURE
kb I_MEASURE
of O
genomic B_GENE/B_MEASURE
sequence I_GENE/I_MEASURE
and O
it O
is O
formed O
of O
11 B_NUMBER[MEASURE]
exons I_NUMBER[MEASURE]
and O
10 B_NUMBER[MEASURE]
intervening O
introns B_GENE/B_LOCATION
. O

G B_GENE/B_PERSON
- I_GENE/I_PERSON
box I_GENE/I_PERSON
binding I_GENE/I_PERSON
factors I_GENE/I_PERSON
( O
GBFs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
constitute O
a O
family O
of O
plant O
DNA O
- O
binding O
proteins O
that O
bind O
to O
the O
G O
- O
box O
motif O
, O
a O
regulatory O
cis O
element O
present O
in O
many O
plant O
genes O
with O
a O
palindromic O
DNA O
motif O
of O
CACGTG O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
an O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
canine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
progressive B_DISEASE
LCX I_DISEASE
coronary I_DISEASE
stenosis I_DISEASE
, O
CFR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
impaired O
in O
both O
ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
remote B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonischemic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
moderate B_DISEASE_ADJECTIVE[DISEASE]
ischemic I_DISEASE_ADJECTIVE[DISEASE]
- O
induced B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regional I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
third B_SEQUENCE[MEASURE]
- O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polynominal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
fit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
a O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
parameter B_MEASURE/B_PROTEIN[GENE]
Q B_MEASURE/I_PROTEIN[GENE]
* O
and O
MTT B_PROTEIN[GENE]/B_MEASURE
, O
whereas O
T B_GENE/B_MEASURE
and O
SImax B_LOCATION/B_MEASURE
were O
found O
to O
have O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Late B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
urotuberculosis B_DISEASE/B_BACTERIUM[BIO]
. O

Changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
frequency B_MEASURE/B_LOCATION
of O
X B_DISEASE
- O
chromatin B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
women B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
under O
Prednisone B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Other B_DISEASE_ADJECTIVE[DISEASE]
toxicities I_DISEASE_ADJECTIVE[DISEASE]
attributed O
to O
CPT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
11 B_NUMBER[MEASURE]
included O
dehydration B_DISEASE
, O
nausea B_DISEASE
, O
vomiting B_DISEASE
, O
and O
asthenia B_DISEASE
. O

Proceedings B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
mortality B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
murine B_DISEASE
hepatitis I_DISEASE
virus I_DISEASE
( O
MHV3 B_MEASURE/B_GENE
) O
. O

These O
results O
extend O
our O
knowledge O
of O
this O
SNF2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
suggest O
a O
role O
for O
PASG B_GENE/B_PERSON
in O
leukemogenesis O
. O

The O
difference O
between O
the O
results O
in O
the O
high O
dose O
AHLG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
in O
the O
control O
group O
was O
significant O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
when O
amniotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
stored O
frozen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_TIME[MEASURE]
and O
strict B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
maintained O
in O
analytic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
only O
minimal B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
occur O
in O
phospholipid B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O
12 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

Retinoic O
acid O
, O
which O
inhibits O
the O
progression O
of O
certain O
cancers O
, O
repressed O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
src B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
MMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O
. O

The O
pattern O
of O
net B_GENE/B_BACTERIUM[BIO]
RNA I_GENE/I_BACTERIUM[BIO]
expression O
in O
adult O
mouse O
tissues O
is O
different O
. O

Immunoprecipitation O
of O
spinophilin B_GENE/B_BACTERIUM[BIO]
or O
neurabin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
crude O
brain O
extracts O
selectively O
coprecipitated O
PP1gamma B_GENE
( I_GENE
1 I_GENE
) I_GENE
over O
PP1beta B_GENE/B_BIO
. O

The O
authors B_PERSON/B_ORGANIZATION
discussed O
their O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
investigating O
20 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
with O
maxillary B_DISEASE/B_LOCATION
malignant I_DISEASE/I_LOCATION
tumors I_DISEASE/I_LOCATION
using O
routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
x O
- O
ray B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
MR B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tomography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
13 B_TIME[MEASURE]/B_LOCATION
patients I_TIME[MEASURE]/I_LOCATION
, O
investigated O
in O
the O
same B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
way I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
plus O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

reduction O
of O
p53 B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
was O
detected O
after O
1 O
day O
of O
OM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
and O
reached O
maximal O
suppression O
of O
10 O
- O
20 O
% O
of O
control O
after O
3 O
days O
in O
H3922 O
and O
40 O
% O
of O
control O
after O
4 O
days O
in O
MCF O
- O
7 O
cells O
. O

Association O
of O
Syk B_GENE
protein I_GENE
tyrosine I_GENE
kinase I_GENE
( O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
with O
LMP2A B_GENE/B_DISEASE
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B_GENE
immunoreceptor I_GENE
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
tyrosine O
112 O
( O
Y112 O
) O
. O

The O
treatment O
with O
glucocorticoids O
and O
immunosuppressants O
resulted O
in O
a O
more O
noticeable O
decrease O
in O
the O
levels O
of O
T3 O
and O
E B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RCF I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four O
of O
these O
fibroblast O
clones O
were O
infected O
with O
a O
retrovirus O
containing O
the O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myoD I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
puromycin O
selection O
marker O
. O

serum O
estriol O
levels O
during O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O
infusion O
in O
the O
third O
trimester O
of O
pregnancy O
. O

In O
this O
study O
, O
we O
investigated O
the O
mechanism O
by O
which O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O
gene O
expression O
in O
conjunction O
with O
members O
of O
the O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
CREB B_GENE/B_LOCATION
family O
. O

Four B_NUMBER[MEASURE]/B_LOCATION
of O
12 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
( O
33 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
were O
initially O
diagnosed O
as O
having O
a O
benign B_DISEASE
disease I_DISEASE
( O
false B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
negatives B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

However O
, O
it O
was O
observed O
that O
storage B_MEASURE/B_DISEASE
time B_MEASURE/I_DISEASE
affected O
significantly O
the O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurring O
in O
the O
constituents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
carrots B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O
to O
gamma B_PROTEIN[GENE]
- O
irradiation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

suppression O
of O
the O
cka1 B_DISEASE_ADJECTIVE[DISEASE]
delta I_DISEASE_ADJECTIVE[DISEASE]
cka2 I_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
8 I_DISEASE_ADJECTIVE[DISEASE]
mutant I_DISEASE_ADJECTIVE[DISEASE]
phenotype O
occurs O
by O
interaction O
of O
CKB1 B_GENE
with O
the O
defective O
, O
cka2 B_GENE
- I_GENE
8 I_GENE
- O
encoded O
, O
catalytic O
subunit O
. O

The O
median B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cumulative B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
to O
be O
341 B_MEASURE
per O
million B_MEASURE
for O
males B_PERSON
and O
296 B_MEASURE
per O
million B_MEASURE
for O
females B_PERSON/B_BIO
. O

Thomas B_PERSON
, O
S B_PROTEIN[GENE]/B_DISEASE
. O
S B_OTHER/B_DISEASE
. O

Similarly O
, O
antisense B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TGF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
oligodeoxynucleotides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
resulted O
in O
a O
58 O
% O
increase O
in O
branching O
, O
compared O
to O
scrambled O
and O
mismatched O
sequence O
controls O
, O
while O
TGF B_GENE
- I_GENE
beta I_GENE
, I_GENE
type I_GENE
II I_GENE
receptor I_GENE
mRNA I_GENE
and O
its O
protein O
expression O
levels O
were O
suppressed O
by O
95 O
and O
84 O
% O
, O
respectively O
. O

secretion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cuticle B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
over O
and O
between O
the O
domed O
apical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surfaces I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
leads O
to O
a O
honeycomb B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
gives O
the O
superficial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wart I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
like B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
phenotype B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
mitotic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
clones I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
on O
the O
adult B_PERSON/B_BIO
. O

taken O
together O
, O
these O
results O
indicate O
that O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
critical O
elements O
for O
IL B_GENE/B_LOCATION
- I_GENE/I_LOCATION
18 I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
expression O
. O

Based O
on O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
has O
been O
concluded O
that O
an O
IPFSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
promote O
the O
healing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
process B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
in O
the O
avascular B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
zone I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
torn B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
meniscus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vascularity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
synovium B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
or O
the O
meniscus B_BODY_PART_OR_ORGAN_COMPONENT
is O
not O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
healing O
to O
occur O
. O

NASA B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CR I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1223 B_NUMBER[MEASURE]
. O

The O
magnitude B_MEASURE
of O
all O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
increased O
in O
an O
exponential B_TIME[MEASURE]/B_ORGANIZATION
fashion I_TIME[MEASURE]/I_ORGANIZATION
with O
increasing O
sperm B_MEASURE
number I_MEASURE
up O
to O
400 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
6 B_MEASURE
) O
per O
ejaculate B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
studied O
about O
the O
histological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
kidneys B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
including O
of O
the O
infiltrated O
macrophages B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
in O
one B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
kidney I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
biopsies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
one B_MEASURE/B_ENT
hour I_MEASURE/I_ENT
biopsies I_MEASURE/I_ENT
) O
and O
re B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
biopsies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
11 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

An O
additional O
stimulation O
of O
D1 B_PROTEIN[GENE]/B_BIO
receptors B_PROTEIN[GENE]/I_BIO
by O
giving O
SKF38393 O
30 O
min O
later O
produced O
an O
almost O
continuous O
pattern O
of O
jaw O
openings O
but O
less O
closure O
movements O
from O
the O
rest O
position O
, O
and O
the O
openings O
were O
accompanied O
by O
frequent O
tongue O
protrusions O
. O

( O
control B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hearts I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
( O
0 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
diffraction B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
synthesized B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HAP I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crystals I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
Col B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fiber I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
an O
around O
60 B_MEASURE
arching I_MEASURE
angle I_MEASURE
, O
while O
that O
on O
a O
ChS B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fiber I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
showed O
just O
around O
10 B_MEASURE
degrees I_MEASURE
. O

During O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
% B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
O2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
ventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pulmonary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vascular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resistance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PVR B_LOCATION/B_DISEASE
) O
and O
the O
dilator B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
both O
ACh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
2D B_PERSON/B_MEASURE
lungs I_PERSON/I_MEASURE
. O

To O
determine O
the O
role O
of O
the O
transmembrane O
region O
of O
HN B_PROTEIN[GENE]/B_DISEASE
on O
fusion O
- O
promoting O
activity O
, O
mutant B_GENE/B_BIO
HN I_GENE/I_BIO
proteins I_GENE/I_BIO
were O
expressed O
and O
their O
biological O
activities O
examined O
. O

To O
be O
a O
nurse B_PERSON
. O

Transient O
transfection O
assays O
indicated O
that O
the O
( O
- O
4551 O
) O
UCP1 B_GENE/B_LOCATION
- O
CAT B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
construct O
, O
containing O
the O
5 O
' O
- O
regulatory O
region O
of O
the O
rat B_GENE
ucp I_GENE
- I_GENE
1 I_GENE
gene I_GENE
, O
was O
activated O
by O
PPARalpha B_GENE
co O
- O
transfection O
in O
a O
dose O
- O
dependent O
manner O
and O
this O
activation O
was O
potentiated O
by O
Wy O
14 O
, O
643 O
and O
retinoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
2 B_MEASURE
- O
( O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
thiazolyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
alkanebenzimidazoles B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
- O
potential B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
anthelmintics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

Human B_GENE
CR2 I_GENE
has O
a O
restricted O
cellular O
distribution O
, O
being O
expressed O
on O
B O
lymphocytes O
, O
dendritic O
cells O
of O
the O
spleen O
, O
pharyngeal O
epithelial O
cells O
, O
and O
at O
low O
levels O
on O
some O
T O
lymphocytes O
. O

ADR1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
extracts O
made O
from O
glucose O
- O
repressed O
and O
- O
derepressed O
cells O
bound O
UAS1 O
DNA O
with O
similar O
affinities O
despite O
having O
greatly O
different O
abilities O
to O
activate O
ADH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
vivo O
. O

Furthermore O
, O
agonist O
action O
at O
a O
5 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
HT1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
antagonist O
action O
at O
5 B_GENE/B_PERSON
- I_GENE/I_PERSON
HT2 I_GENE/I_PERSON
receptors I_GENE/I_PERSON
both O
appear O
to O
contribute O
to O
antidepressant O
- O
like O
activity O
on O
the O
DRL O
72 O
- O
s O
schedule O
. O

MsEPV O
genes O
with O
putative O
functions O
in O
prevention O
and O
repair O
of O
DNA O
damage O
include O
a O
complete O
base O
excision O
repair O
pathway O
( O
uracil B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
AP B_ENZYME[GENE]
endonuclease I_ENZYME[GENE]
, O
DNA B_GENE
polymerase I_GENE
beta I_GENE
, O
and O
an O
NAD B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
photoreactivation O
repair O
pathway O
( O
cyclobutane B_GENE/B_DISEASE
pyrimidine I_GENE/I_DISEASE
dimer I_GENE/I_DISEASE
photolyase I_GENE/I_DISEASE
) O
, O
a O
LINE B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
type I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reverse I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
mutT B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homologue I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
further O
examined O
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
modulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
discharge B_MEASURE/B_BIO
rate I_MEASURE/I_BIO
i O
) O
during O
motor B_DISEASE/B_PROTEIN[GENE]
activity B_DISEASE/I_PROTEIN[GENE]
in O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
ii B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
at O
the O
transitional B_TIME[MEASURE]/B_LOCATION
phase I_TIME[MEASURE]/I_LOCATION
from O
SS B_DISEASE/B_PROTEIN[GENE]
to O
paradoxical B_DISEASE
sleep I_DISEASE
( O
PS B_LOCATION/B_PROTEIN[GENE]
) O
, O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
during O
rapid B_DISEASE_ADJECTIVE[DISEASE]
eye I_DISEASE_ADJECTIVE[DISEASE]
movements I_DISEASE_ADJECTIVE[DISEASE]
( O
REMs B_DISEASE/B_LOCATION
) O
in O
PS B_LOCATION/B_PROTEIN[GENE]
, O
and O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
following O
electrical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
midbrain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reticular I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
formation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
MRF B_LOCATION/B_PROTEIN[GENE]
) O
. O

Likewise O
, O
the O
consensus O
signal O
believed O
to O
be O
involved O
in O
terminating O
VV B_GENE
early I_GENE
gene I_GENE
transcription O
, O
TTTTTNT O
, O
was O
evident O
at O
the O
3 O
' O
- O
boundary O
of O
both O
the O
N2 O
and O
M1 O
ORFs O
suggesting O
that O
these O
genes O
may O
be O
VV B_DISEASE_ADJECTIVE[DISEASE]
early I_DISEASE_ADJECTIVE[DISEASE]
genes I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
radiolabeled O
, O
900 B_MEASURE
- O
bp B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
amplicon I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
as O
a O
hybridization B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
screen O
a O
cDNA B_GENE
library I_GENE
constructed O
from O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
RNA B_GENE/B_BIO
isolated O
from O
induced B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Taxus I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
from O
which O
a O
full B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
length B_GENE/B_MEASURE
transacetylase I_GENE/I_MEASURE
sequence I_GENE/I_MEASURE
was O
obtained O
. O

Low B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
8 B_PROTEIN[GENE]/B_LOCATION
degrees I_PROTEIN[GENE]/I_LOCATION
C I_PROTEIN[GENE]/I_LOCATION
) O
impairs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretory I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
again O
independently O
of O
the O
photoperiod B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
selected O
. O

Left O
ventricle B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
coronary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sinus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
fistula I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
report O
we O
describe O
the O
structure O
and O
DNA O
sequence O
of O
transcriptional O
control O
regions O
from O
both O
human B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Wistar I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
single I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copy I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EGF I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
functional O
analysis O
in O
epithelial O
cell O
cultures O
. O

The O
magnesium B_MEASURE
content I_MEASURE
in O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
could O
not O
be O
estimated O
because O
of O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
ion B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
Percoll B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
media B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
three B_NUMBER[MEASURE]/B_ENT
of O
them O
revealed O
pure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CAG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stretches B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
element B_GENE
II I_GENE
result O
in O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
RNA B_LOCATION/B_BIO
structure I_LOCATION/I_BIO
near O
element B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
III I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
a O
long B_MEASURE/B_LOCATION
- O
range B_PERSON/B_GENE
interaction B_PERSON/I_GENE
that O
may O
promote O
translation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
the O
QT B_MEASURE
duration I_MEASURE
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
0001 B_MEASURE
) O
at O
night B_MEASURE/B_LOCATION
, O
the O
beat B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
- O
beat B_MEASURE/B_LOCATION
variability I_MEASURE/I_LOCATION
of O
this O
interval B_MEASURE
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
: O
in O
the O
time B_MEASURE/B_LOCATION
domain I_MEASURE/I_LOCATION
( O
decreased O
standard B_MEASURE
deviation I_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
0005 B_MEASURE
) O
, O
in O
the O
frequency B_MEASURE/B_LOCATION
domain I_MEASURE/I_LOCATION
( O
decreased O
low B_MEASURE/B_DISEASE
- O
frequency B_MEASURE
power I_MEASURE
of O
the O
spectra B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p O
= O
0 B_MEASURE
. O
004 B_MEASURE
) O
, O
and O
the O
chaotic B_MEASURE/B_LOCATION
domain I_MEASURE/I_LOCATION
( O
tighter B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clustering I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
points B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
Poincare B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plots I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
biological O
functions O
of O
rat O
surfactant B_GENE
protein I_GENE
A I_GENE
( O
SP B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
A I_DISEASE/I_LOCATION
) O
, O
an O
oligomer O
composed O
of O
18 O
polypeptide O
subunits O
derived O
from O
a O
single O
gene O
, O
are O
dependent O
on O
intact O
disulfide O
bonds O
. O

A O
V1 B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
generated O
in O
vivo O
with O
11 O
of O
the O
14 O
N O
- O
terminal O
amino O
acids O
altered O
, O
was O
viable O
and O
produced O
symptoms O
typical O
of O
a O
wild O
- O
type O
infection O
. O

This O
seems O
to O
take O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
same B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
compartment I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O
normal B_GENE/B_BIO
cis I_GENE/I_BIO
splicing I_GENE/I_BIO
and O
proceeds B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
through O
Y O
- O
branched O
intermediates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analogous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
the O
lariats B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formed O
in O
cis B_GENE/B_SPECIES[BIO]
splicing B_GENE/I_SPECIES[BIO]
. O

We O
have O
demonstrated O
that O
the O
specific O
determination O
and O
identification O
of O
plasma O
FbDP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O
is O
not O
sufficient O
to O
follow O
the O
effectiveness O
of O
thrombolytic O
therapy O
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
recurrent B_DISEASE_ADJECTIVE[DISEASE]
multifocal I_DISEASE_ADJECTIVE[DISEASE]
osteomyelitis I_DISEASE_ADJECTIVE[DISEASE]
. O

Maximum B_MEASURE/B_PERSON
baroreceptor I_MEASURE/I_PERSON
activity I_MEASURE/I_PERSON
measured O
at O
140 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
Hg I_MEASURE/I_LOCATION
and O
the O
slope B_MEASURE/B_LOCATION
of O
the O
pressure B_MEASURE/B_DISEASE
- O
activity B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
were O
reduced O
in O
atherosclerotic B_DISEASE/B_GENE
( O
n B_MEASURE/B_LOCATION
= I_MEASURE/I_LOCATION
15 I_MEASURE/I_LOCATION
) O
compared O
with O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
13 B_MEASURE
) O
rabbits B_BIO/B_PERSON
( O
425 B_MEASURE
+ I_MEASURE
/ O
- O
34 B_MEASURE
versus I_MEASURE
721 I_MEASURE
+ I_MEASURE
/ O
- O
30 B_MEASURE/B_LOCATION
spikes I_MEASURE/I_LOCATION
per O
second B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
6 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
6 B_MEASURE
versus I_MEASURE
10 I_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
8 B_MEASURE
spikes I_MEASURE
per O
second B_SEQUENCE[MEASURE]
per O
mm B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Hg I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
respectively O
, O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
05 B_MEASURE
) O
. O

A O
pathogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
the O
Eisenmenger B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
' I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
s I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
is O
discussed O
. O

Coronary O
vasoconstriction O
caused O
by O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
enhanced O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Located O
between O
the O
3 O
' O
trans O
- O
spliced O
leader O
acceptor O
site O
and O
the O
translational O
initiation O
codon O
of O
the O
GP63 B_GENE
gene I_GENE
is O
an O
area O
of O
conserved O
hexanucleotide O
direct O
repeats O
( O
CTCGCC O
) O
which O
vary O
in O
number O
according O
to O
species O
. O

An O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
between O
zafirlukast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentrations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
PC8SRaw B_MEASURE
10 I_MEASURE
h O
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
p B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
secreting O
islet O
- O
cell O
tumours O
of O
the O
pancreas O
. O

disruption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
reconstruction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
: O
narrative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
insights I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O
the O
experience B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
family B_PERSON/B_LOCATION
members I_PERSON/I_LOCATION
caring O
for O
a O
relative B_PERSON
diagnosed O
with O
serious B_DISEASE/B_LOCATION
mental I_DISEASE/I_LOCATION
illness I_DISEASE/I_LOCATION
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
is O
more O
compliant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
than O
the O
anterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
that O
is O
, O
for O
a O
given O
difference B_MEASURE
in O
transmural B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
, O
the O
local B_MEASURE
segment I_MEASURE
length I_MEASURE
change I_MEASURE
of O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O
greater B_MEASURE
) O
. O

We O
have O
previously O
demonstrated O
that O
pyrene O
in O
diesel O
- O
exhaust O
particles O
( O
DEP O
) O
has O
an O
adjuvant O
activity O
on O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IgE B_PROTEIN[GENE]/B_LOCATION
) O
antibody O
production O
in O
mice O
immunized O
with O
Japanese O
Cedar O
pollen O
allergen O
( O
JCPA O
) O
or O
ovalbumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
OA B_LOCATION/B_DISEASE
) O
intraperitoneally O
. O

partial O
characterization O
of O
the O
CCAAT O
box O
in O
the O
promoter O
of O
the O
hLGFBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
interaction O
with O
negatively O
acting O
transcription O
factors O
in O
decidualized O
human O
endometrial O
stromal O
cells O
. O

We O
conclude O
that O
transcription O
of O
both O
SCD1 B_GENE/B_LOCATION
and O
SCD2 B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
is O
responsive O
to O
cellular O
sterol O
levels O
and O
to O
the O
levels O
of O
nuclear O
SREBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
ADD1 B_PROTEIN[GENE]/B_LOCATION
and O
that O
transcriptional O
induction O
requires O
three O
spatially O
conserved O
cis O
elements O
, O
that O
bind O
SREBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
NF B_GENE
- I_GENE
Y I_GENE
. O

Three O
transcriptional O
control O
elements O
within O
300 O
base O
pairs O
of O
the O
5 O
' O
- O
flanking O
region O
of O
the O
rat B_GENE/B_LOCATION
glucagon I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
interact O
with O
regulatory O
cellular O
proteins O
and O
direct O
transcription O
only O
in O
glucagon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
producing O
islet O
cells O
. O

A O
role O
for O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
regulation O
of O
beta B_GENE
1 I_GENE
integrin I_GENE
activity O
by O
the O
CD2 B_GENE/B_PERSON
antigen O
. O

relationship B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
age B_DISEASE
- O
associated O
endocrine B_DISEASE
deficiencies I_DISEASE
and O
muscle B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
elderly B_PERSON/B_DISEASE
women I_PERSON/I_DISEASE
: O
a O
cross B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sectional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
contrast O
, O
the O
sequences O
essential O
for O
the O
transcription O
of O
EFT1 B_GENE
were O
localized O
to O
the O
region O
between O
the O
start O
ATG O
and O
the O
stop O
codon O
of O
the O
VPS17 B_GENE
gene I_GENE
that O
terminates O
267 O
nt O
upstream O
on O
the O
same O
strand O
. O

exposure O
of O
raft O
cultures O
to O
activators O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
such O
as O
phorbol O
esters O
, O
results O
in O
the O
further O
induction O
of O
late B_GENE
gene I_GENE
expression O
as O
well O
as O
virion O
assembly O
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
2 B_DISEASE
cancers I_DISEASE
of O
the O
colon B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
' O
Gregg B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenomenon B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
implies O
that O
myocardial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
MVO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
increase B_DISEASE_ADJECTIVE[DISEASE]
when O
coronary B_DISEASE
perfusion I_DISEASE
is O
enhanced O
within O
or O
above O
the O
autoregulatory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
range B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
have O
mapped O
the O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domains B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O
each O
of O
the O
proteins B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsible I_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
this O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
each O
of O
the O
studied O
HPV O
types O
, O
the O
two O
CDP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
Cut B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
sites O
of O
PSM B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
overlap O
with O
the O
known O
or O
presumed O
binding O
sites O
of O
the O
replication B_PROTEIN[GENE]/B_BIO
initiator I_PROTEIN[GENE]/I_BIO
protein I_PROTEIN[GENE]/I_BIO
E1 I_PROTEIN[GENE]/I_BIO
. O

reduced O
cell B_MEASURE/B_LOCATION
numbers I_MEASURE/I_LOCATION
72 I_MEASURE/I_LOCATION
h O
after O
insonation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O
recorded O
when O
the O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O
insonated O
at O
an O
antinode B_LOCATION
but O
not O
when O
they O
were O
at O
a O
node B_LOCATION/B_DISEASE
. O

Hydroxyl O
radical O
footprinting O
of O
DNA O
complexes O
of O
the O
ets B_GENE/B_LOCATION
domain B_GENE/I_LOCATION
of O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
comparison O
to O
the O
crystal O
structure O
. O

ATF O
is O
formulated O
from O
the O
prothrombin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O
( O
PT O
) O
, O
fibrinogen B_MEASURE/B_PROTEIN[GENE]
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
FBG B_PROTEIN[GENE]/B_LOCATION
) O
content O
of O
blood O
plasma O
. O

( O
LH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
P O
< O
0 O
. O
05 O
, O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
FSH B_GENE
P O
< O
0 O
. O
01 O
) O
. O

Inhibition O
of O
Raf B_GENE
- I_GENE
1 I_GENE
signaling O
by O
a O
monoclonal O
antibody O
, O
which O
interferes O
with O
Raf B_GENE
- I_GENE
1 I_GENE
activation O
and O
with O
Mek B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substrate O
binding O
. O

Phenotypic O
and O
molecular O
analyses O
of O
patients O
with O
partial O
chromosome O
21 O
monosomy O
enabled O
us O
to O
define O
a O
region O
, O
spanning O
2 O
. O
4 O
MB O
between O
D21S190 B_GENE
and O
D21S226 B_GENE/B_TIME[MEASURE]
, O
associated O
with O
arthrogryposis O
, O
mental O
retardation O
, O
hypertonia O
, O
and O
several O
facial O
anomalies O
. O

The O
classic O
sterol O
regulatory O
cis O
element O
( O
sre O
- O
1 O
) O
in O
the O
LDL B_GENE
receptor I_GENE
promoter O
mediates O
sterol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SREBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
- O
binding O
and O
the O
effects O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PDGF B_GENE
) O
. O

The O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
concentration B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O
after O
intragastrically O
fenarimol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
doses O
1 B_MEASURE
/ O
40 B_MEASURE
, O
1 B_NUMBER[MEASURE]
/ O
20 B_MEASURE
and O
1 B_NUMBER[MEASURE]
/ O
10 B_MEASURE
LD50 I_MEASURE
) O
during O
5 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
days B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
investigated O
. O

In O
Cos O
7 O
cells O
transfected O
with O
oCRF1var B_GENE
, O
Camp O
accumulation O
was O
only O
observed O
at O
the O
highest O
concentration O
of O
oCRF B_PROTEIN[GENE]/B_DISEASE
utilized O
( O
100 O
nm O
) O
. O

Pyknotic B_DISEASE/B_GENE
osteocytes B_DISEASE/I_GENE
increased O
at O
12 B_MEASURE
h O
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
and O
2 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
of O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
right B_BODY_PART_OR_ORGAN_COMPONENT
cornea I_BODY_PART_OR_ORGAN_COMPONENT
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
cauterized O
by O
drops B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
1 B_MEASURE
. O
5 B_MEASURE/B_PERSON
N I_MEASURE/I_PERSON
HC1 I_MEASURE/I_PERSON
over O
30 B_TIME[MEASURE]/B_BIO
s B_TIME[MEASURE]/I_BIO
; O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
one I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
served O
as O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
isoproterenol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O
adjusted O
so O
that O
heart B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
( O
HR B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
was O
at O
least O
30 B_MEASURE
beats I_MEASURE
/ O
min B_TIME[MEASURE]/B_LOCATION
greater I_TIME[MEASURE]/I_LOCATION
than O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

This O
is O
probably O
because O
, O
in O
vivo O
, O
some O
bacteria O
( O
perhaps O
dormant O
forms O
) O
are O
not O
entirely O
dependent O
upon O
urease B_BACTERIUM[BIO]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
survival O
. O

The O
system O
consists O
of O
a O
microcomputer O
and O
six O
laboratory O
analyzers O
: O
a O
blood O
gas O
analyzer O
, O
a O
flame O
photometer O
, O
a O
plasma O
osmotic O
pressure O
meter O
, O
a O
chloride O
ion O
titrator O
, O
a O
blood O
sugar O
analyzer O
, O
and O
a O
hemoglobin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O
and O
saturation O
meter O
. O

comparing O
the O
outcome B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
group B_ORGANIZATION/B_PERSON
having O
histologically O
normal B_DISEASE_ADJECTIVE[DISEASE]
biopsies I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
group B_ORGANIZATION/B_PERSON
having O
nonspecifically O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ones I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O
is O
concluded O
that O
frontal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biopsy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
not O
of O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
high I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prognostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
value I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
has O
been O
claimed O
in O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

He O
presented O
with O
left O
lower B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
abdominal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
pain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
hematoma B_DISEASE
after O
a O
fall B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Fusion O
of O
mouse B_GENE
CD8 I_GENE
+ I_GENE
class I_GENE
I I_GENE
MHC I_GENE
- O
restricted O
T O
cells O
with O
the O
BW5147 O
thymoma O
invariably O
yields O
CD8 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
hybridomas O
in O
which O
RNA O
transcribed O
from O
the O
CD8 B_GENE
alpha I_GENE
( O
Lyt B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
2 I_PROTEIN[GENE]/I_MEASURE
) O
gene O
is O
undetectable O
. O

Peak O
plasma O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responses O
were O
not O
significantly O
different O
between O
control O
and O
patient O
groups O
. O

For O
the O
P B_GENE/B_LOCATION
transcript I_GENE/I_LOCATION
from O
phage O
with O
the O
G O
( O
- O
) O
orientation O
, O
full O
termination O
activity O
required O
both O
the O
region O
containing O
the O
stem O
- O
loop O
structure O
and O
upstream O
sequences O
. O

Development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
neural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
control I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
alimentary B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
motor B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
function B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
vertebrates B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nb2 O
- O
11C O
cells O
expressed O
three O
PNR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
2 O
. O
5 O
, O
3 O
. O
0 O
and O
> O
10 O
kb O
. O

These O
results O
suggest O
that O
the O
Reg1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Glc7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphatase O
is O
a O
cytoplasmic O
component O
of O
the O
machinery O
responsible O
for O
returning O
Snf1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
to O
its O
basal O
level O
and O
reestablishing O
glucose O
repression O
. O

However O
, O
the O
blend B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
Metanil B_COLOR/B_BIO
yellow I_COLOR/I_BIO
and O
orange B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
1 B_MEASURE
: O
1 B_MEASURE
) O
resulted O
in O
the O
D1 B_MEASURE/B_PERSON
50 I_MEASURE/I_PERSON
. O
value B_MEASURE
of O
288 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
majority O
of O
these O
cells O
were O
also O
OKT4 B_GENE
positive O
( O
helper O
/ O
inducer O
T O
lymphocytes O
) O
, O
while O
the O
minority O
were O
OKT8 B_GENE
positive O
( O
suppressor O
/ O
cytotoxic O
T O
lymphocytes O
) O
. O

aims O
: O
We O
postulated O
that O
perhexiline O
, O
a O
novel O
anti O
- O
ischaemic O
agent O
with O
an O
oxygen O
- O
sparing O
metabolic O
effect O
in O
the O
myocardium O
( O
via O
inhibition O
of O
carnitine B_GENE
palmitoyltransferase I_GENE
- I_GENE
1 I_GENE
) O
and O
no O
adverse O
haemodynamic O
effects O
, O
may O
improve O
symptomatic O
status O
in O
elderly O
patients O
with O
severe O
aortic O
stenosis O
. O

The O
IFNAR B_GENE
chain I_GENE
interacts O
with O
both O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IFN B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
demonstrated O
by O
cross O
- O
linking O
. O

To O
clone O
cDNAs O
for O
the O
beta O
subunit O
of O
rabbit B_GENE
eIF I_GENE
- I_GENE
2B I_GENE
, O
amino O
acid O
sequence O
data O
was O
first O
obtained O
and O
used O
to O
design O
redundant O
oligonucleotide O
primers O
for O
use O
in O
PCR O
. O

We O
report O
the O
cloning O
of O
the O
ade1 B_GENE
gene I_GENE
on O
a O
4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sau3A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
insert I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
yeast O
shuttle O
vector O
pWH5 O
. O

Nimodipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
5 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
) O
followed O
by O
infusion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
0 B_MEASURE
. O
75 B_MEASURE
microgram I_MEASURE
/ O
kg B_MEASURE/B_PERSON
/ O
min B_PERSON/B_TIME[MEASURE]
lowered O
the O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
by O
10 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
in O
both O
normotensive B_DISEASE_ADJECTIVE[DISEASE]
and O
hypertensive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
same B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
schedule I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
lower B_DISEASE_ADJECTIVE[DISEASE]
MAP I_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
may O
be O
relevant B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
pathogenesis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alveolitis B_DISEASE_ADJECTIVE[DISEASE]
in O
organic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dust I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
lung B_DISEASE/B_LOCATION
diseases I_DISEASE/I_LOCATION
. O

The O
odds B_MEASURE
of O
atopy B_DISEASE
( O
defined O
as O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
at O
least O
one B_NUMBER[MEASURE]
of O
the O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
were O
5 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
times I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
higher I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
odds B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
= O
7 B_MEASURE
. O
0 B_MEASURE
; O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
confidence I_MEASURE/I_LOCATION
interval I_MEASURE/I_LOCATION
= O
1 B_MEASURE
. O
6 B_MEASURE
- O
31 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
; O
p O
= O
0 B_MEASURE
. O
01 B_MEASURE
) O
in O
the O
uninfected B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
potential B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influence I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
gender B_PERSON/B_MEASURE
and O
age B_MEASURE/B_DISEASE
. O

A O
selectable O
marker O
for O
transformation O
was O
constructed O
by O
transcriptional O
fusion O
of O
a O
Ustilago B_GENE
maydis I_GENE
heat I_GENE
shock I_GENE
gene I_GENE
promoter I_GENE
with O
the O
hygromycin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
structure O
of O
the O
mAR B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
ORF O
was O
confirmed O
by O
sequence O
analysis O
of O
mAR B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cDNA O
fragments O
, O
which O
were O
obtained O
by O
PCR O
amplification O
of O
mouse O
testis O
cDNA O
, O
using O
mAR B_NUMBER[MEASURE]/B_BIO
specific O
primers O
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
visual I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O
chromatic O
stimuli B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
using O
magnetoencephalography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
MEG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

The O
role O
of O
NUT1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
regulation O
of O
nitrogen O
metabolism O
in O
the O
disease O
process O
was O
evaluated O
by O
pathogenicity O
assays O
. O

These O
three O
phases O
of O
cyclin B_GENE
E I_GENE
association O
with O
chromatin O
may O
facilitate O
the O
diverse O
activities O
of O
cyclin B_GENE/B_DISEASE
E I_GENE/I_DISEASE
- O
- O
Cdk2 B_GENE/B_MEASURE
in O
initiating O
replication O
, O
blocking O
rereplication O
, O
and O
allowing O
resetting O
of O
origins O
after O
mitosis O
. O

No O
IORT B_DISEASE
related I_DISEASE
mortality I_DISEASE
has O
been O
observed O
. O

Dermatophagoides O
farinae O
- O
sensitized O
lymphocytes O
in O
asthmatic O
children O
as O
evaluated O
by O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL B_GENE/B_MEASURE
- I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
) O
production O
and O
acquisition O
of O
IL B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responsiveness O
. O

Enterotoxin B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
staphylococci B_BACTERIUM[BIO]/B_DISEASE
isolated O
from O
foods B_LOCATION/B_PERSON
in O
France B_LOCATION/B_BIO
. O

Measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
a O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
partially O
inhibited O
the O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
Q B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
IBAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O
that O
the O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
ENAIBAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
attributable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
primarily O
to O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
Q B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
rather O
than O
to O
increasing O
saturation B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
uptake B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Plasma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
progesterone O
levels O
after O
single O
or O
multiple O
injections O
of O
synthetic O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
RH B_PROTEIN[GENE]/B_DISEASE
in O
anoestrous O
ewes O
and O
comparison O
with O
levels O
during O
the O
oestrous O
cycle O
. O

Material B_LOCATION/B_TIME[MEASURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O

But O
, O
when O
mated O
males B_PERSON/B_BIO
built O
nests B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
absence B_DISEASE/B_LOCATION
of O
young B_PERSON/B_BIO
, O
T B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
all O
other B_PERSON/B_LOCATION
conditions I_PERSON/I_LOCATION
, O
though O
only O
for O
early B_PERSON/B_BIO
broods I_PERSON/I_BIO
. O

Primers O
were O
developed O
for O
specific O
amplification O
of O
9804 B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
fragments I_GENE/I_DISEASE
. O

The O
promyelocytic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
leukemia B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interacts O
with O
Sp1 B_GENE
and O
inhibits O
its O
transactivation O
of O
the O
epidermal B_GENE
growth I_GENE
factor I_GENE
receptor I_GENE
promoter O
. O

The O
mutants B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
retained O
the O
parental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
participate O
in O
intergeneric B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coaggregation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
human B_BIO/B_GENE
oral B_BIO/I_GENE
actinomyces B_BIO/I_GENE
, O
indicating O
the O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
altering O
intrageneric B_DISEASE_ADJECTIVE[DISEASE]
coaggregations I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
Saccharomyces O
cerevisiae O
targets O
of O
rapamycin O
, O
TOR1 B_GENE
and O
TOR2 B_GENE
, O
signal O
activation O
of O
cell O
growth O
in O
response O
to O
nutrient O
availability O
. O

Biology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Anopheles B_SPECIES[BIO]/B_DISEASE
quadrimaculatus B_SPECIES[BIO]/I_DISEASE
under O
field B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
central B_LOCATION
Florida I_LOCATION
. O

immunogenicity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tested O
in O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
guinea B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pigs I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
reduced O
and O
corresponded O
to O
that O
of O
the O
reference B_DISEASE/B_PROTEIN[GENE]
STI B_DISEASE/I_PROTEIN[GENE]
- O
1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vaccine I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Thrombolysis O
in O
Myocardial O
Infarction O
( O
TIMI O
) O
Phase O
II O
Trial O
randomized O
3 O
, O
339 O
patients O
to O
either O
an O
invasive O
( O
INV O
, O
n O
= O
1 O
, O
681 O
) O
or O
a O
conservative O
( O
Con O
, O
n O
= O
1 O
, O
658 O
) O
strategy O
after O
intravenous O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
type I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
rt B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PA I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
acute O
myocardial O
infarction O
. O

In O
addition O
, O
mutations O
within O
the O
Ubx B_GENE/B_BIO
unit I_GENE/I_BIO
exons I_GENE/I_BIO
are O
known O
and O
most O
of O
these O
behave O
as O
null O
alleles O
. O

taken O
together O
, O
these O
data O
suggest O
that O
the O
Smad3 B_GENE
/ O
Smad4 B_GENE/B_MEASURE
complex O
has O
at O
least O
two O
separable O
nuclear O
functions O
: O
it O
forms O
a O
rapid O
, O
yet O
transient O
sequence O
- O
specific O
DNA O
binding O
complex O
, O
and O
it O
potentiates O
AP1 B_GENE
- O
dependent O
transcriptional O
activation O
. O

When O
phentermine O
was O
mixed O
with O
other O
unlabeled O
reversible O
MAO B_ENZYME[GENE]
inhibitors O
( O
e O
. O
g O
. O
pseudoephedrine O
, O
ephedrine O
, O
norephedrine O
; O
estradiol O
benzoate O
) O
, O
the O
degree O
of O
MAO B_GENE
inhibition O
was O
additive O
. O

Here O
we O
report O
that O
point O
mutations O
of O
the O
Abd B_GENE
- I_GENE
B I_GENE
gene I_GENE
in O
trans O
suppress O
the O
Fab B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
phenotype B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
a O
pairing O
- O
dependent O
manner O
and O
thus O
represent O
a O
type O
of O
transvection O
. O

4 O
382 O
new O
mothers O
were O
examined O
retrospectively O
with O
the O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
for O
IgG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O
to O
cytomegalovirus O
( O
CMV O
) O
during O
pregnancy O
. O

Also O
, O
residues O
273 O
to O
287 O
, O
which O
are O
identical O
in O
sequence O
to O
a O
15 O
- O
amino O
- O
acid O
segment O
near O
the O
carboxy O
terminus O
of O
the O
simian B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
foamy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Taf I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
can O
independently O
enhance O
the O
activity O
of O
the O
minimal O
activator O
region O
. O

An O
analogue B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
strontium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Sr I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
89 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
rapidly O
cleared O
from O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
after O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pneumoperitoneum B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dissemination B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
scar B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
implantation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
abdominal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tumor I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
two B_NUMBER[MEASURE]
of O
these O
nine B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
dyskinesia B_DISEASE
score I_DISEASE
was O
observed O
without O
a O
concomitant B_DISEASE_ADJECTIVE[DISEASE]
worsening I_DISEASE_ADJECTIVE[DISEASE]
of O
parkinsonian B_DISEASE
symptoms I_DISEASE
, O
whereas O
in O
the O
remaining O
seven B_NUMBER[MEASURE]/B_PERSON
, O
full B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
parkinsonian B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
akinesia B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O
THDL B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

alterations O
in O
TCR B_GENE
- O
MHC B_GENE/B_DISEASE
contacts O
subsequent O
to O
cross O
- O
recognition O
of O
class B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
singly O
substituted O
peptide O
variants O
. O

Two B_PERSON
patients I_PERSON
with O
Ewing B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s O
sarcoma B_DISEASE
relapsed O
( O
1 B_PERSON/B_TIME[MEASURE]
patient B_PERSON/I_TIME[MEASURE]
with O
both O
local B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
distant B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
failure B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
at O
26 B_MEASURE
and O
58 B_TIME[MEASURE]
months I_TIME[MEASURE]
and O
were O
again O
rendered O
disease B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
total B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
body I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irradiation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
further B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
cloning O
of O
human B_GENE/B_SPECIES[BIO]
apo B_GENE/I_SPECIES[BIO]
B B_GENE/I_SPECIES[BIO]
- B_GENE/I_SPECIES[BIO]
100 B_GENE/I_SPECIES[BIO]
has O
provided O
new O
insights O
into O
the O
structure O
and O
physicochemical O
properties O
of O
apo B_GENE
B I_GENE
- I_GENE
100 I_GENE
and O
will O
facilitate O
studies O
on O
the O
factors O
modulating O
apo B_GENE
B I_GENE
- I_GENE
100 I_GENE
biosynthesis O
and O
the O
expression O
of O
the O
apo B_GENE/B_DISEASE
B I_GENE/I_DISEASE
- I_GENE/I_DISEASE
100 I_GENE/I_DISEASE
gene I_GENE/I_DISEASE
in O
patients O
with O
dyslipoproteinemias O
. O

Angiographic B_PERSON
follow I_PERSON
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
obtained O
in O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
with O
a O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
angioplasty B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

acceptability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
home B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monitoring I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
an O
aid B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
conception B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

repeated O
interferon B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IFN B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
silencer O
B O
motifs O
and O
a O
lysozyme B_GENE/B_MEASURE
silencer I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
motif I_GENE/I_MEASURE
have O
been O
found O
in O
the O
CD95 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
at O
approximately O
- O
1 O
, O
600 O
and O
- O
1 O
, O
100 O
, O
respectively O
. O

Action O
against O
Vibrio O
cholerae O
O1 O
Tox B_GENE/B_DISEASE
+ B_GENE/I_DISEASE
of O
chemical O
products O
used O
in O
the O
lemon O
production O
. O

patients O
with O
the O
chronic O
photosensitivity O
dermatitis O
with O
actinic O
reticuloid O
syndrome O
have O
high O
total O
serum O
IgE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O
. O

The O
sequence B_LOCATION/B_MEASURE
of O
the O
25 B_MEASURE
- O
kDa B_PROTEIN[GENE]/B_MEASURE
chain I_PROTEIN[GENE]/I_MEASURE
of O
the O
alpha B_GENE
subunit I_GENE
was O
found O
in O
a O
cDNA B_GENE
clone I_GENE
, O
and O
the O
amino B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
deduced O
from O
the O
cDNA B_GENE
establishes O
the O
complete B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
25 B_MEASURE
- O
kDa B_PROTEIN[GENE]/B_MEASURE
chain I_PROTEIN[GENE]/I_MEASURE
. O

characterization O
of O
the O
chromosome O
19 O
breakpoint O
region O
revealed O
that O
the O
transcription B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
factor I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
encoding I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
USF2 I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
affected O
. O

Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
active O
Tax B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
able O
to O
abrogate O
the O
G1 O
arrest O
and O
apoptosis O
induced O
by O
p53 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
this O
effect O
does O
not O
correlate O
with O
an O
altered O
localization O
of O
nuclear B_GENE
p53 I_GENE
or O
with O
the O
disruption O
of O
p53 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
patients B_PERSON/B_BIO
were O
admitted O
within O
one B_TIME[MEASURE]
week I_TIME[MEASURE]
of O
the O
onset B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dark B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
45 B_PERSON/B_NUMBER[MEASURE]
% I_PERSON/I_NUMBER[MEASURE]
were O
found O
to O
be O
shedding O
HAV B_VIRUS[BIO]/B_DISEASE
, O
whereas O
only O
11 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
specimens B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
obtained O
from O
patients B_PERSON/B_LOCATION
admitted O
during O
the O
second B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O
virus B_DISEASE/B_BIO
. O

Biochemical O
studies O
have O
identified O
a O
cellular O
non B_PROTEIN[GENE]/B_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
P I_PROTEIN[GENE]/I_MEASURE
element I_PROTEIN[GENE]/I_MEASURE
- I_PROTEIN[GENE]/I_MEASURE
encoded I_PROTEIN[GENE]/I_MEASURE
DNA I_PROTEIN[GENE]/I_MEASURE
binding I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
, O
termed O
the O
inverted B_GENE/B_MEASURE
repeat I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
( O
IRBP B_DISEASE/B_GENE
) O
, O
that O
specifically O
interacts O
with O
the O
outer O
half O
of O
the O
31 O
- O
BP O
terminal O
inverted O
repeats O
. O

threefold B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
observed O
for O
men B_PERSON/B_LOCATION
with O
the O
highest B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
of O
intensity B_MEASURE/B_DISEASE
and O
for O
those O
with O
the O
highest B_MEASURE
probability I_MEASURE
of O
EMF B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
women B_PERSON
with O
heavy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
EMF I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O
not O
experience O
increased O
risk B_DISEASE
. O

In O
the O
spontaneous O
abortion O
group O
, O
the O
levels O
of O
PAPP B_GENE
- I_GENE
A I_GENE
were O
significantly O
lower O
than O
in O
normal O
pregnancy O
but O
higher O
than O
in O
non O
- O
pregnant O
controls O
. O

We O
report O
the O
sequence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
7941 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
left B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
arm I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
chromosome B_GENE
VII I_GENE
of O
Saccharomyces B_SPECIES[BIO]
cerevisiae I_SPECIES[BIO]
which O
contains O
four B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
open I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reading I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
frames I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ORFs B_GENE/B_BIO
) O
of O
greater B_LOCATION/B_MEASURE
than O
100 B_NUMBER[MEASURE]
amino I_NUMBER[MEASURE]
acid I_NUMBER[MEASURE]
residues I_NUMBER[MEASURE]
. O

A O
4 O
. O
0 O
- O
kb O
Nlk B_GENE/B_LOCATION
message I_GENE/I_LOCATION
is O
also O
present O
during O
embryogenesis O
, O
detectable O
at O
day O
E10 O
. O

promoting O
fat B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
utilisation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O
reducing O
the O
carbohydrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
fat B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
of O
the O
TPN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reduces O
free B_DISEASE/B_MEASURE
radical I_DISEASE/I_MEASURE
activity I_DISEASE/I_MEASURE
to O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
extent B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
fat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exclusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
E1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
E2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
DDX3 B_PROTEIN[GENE]/B_LOCATION
and O
core B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

Mutating O
this O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminated O
complex B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
formation I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
markedly O
reduced O
basal B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoter I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
transfected B_GENE
reporter I_GENE
genes I_GENE
. O

The O
lowest B_MEASURE
PaCO2 I_MEASURE
values I_MEASURE
were O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
MCE B_PROTEIN[GENE]/B_MEASURE
than O
in O
the O
F B_PROTEIN[GENE]/B_DISEASE
, O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
F B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
W I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
translational O
product O
of O
UL26 B_GENE/B_TIME[MEASURE]
. I_GENE/I_TIME[MEASURE]
5 I_GENE/I_TIME[MEASURE]
is O
infected B_GENE
- I_GENE
cell I_GENE
protein I_GENE
35c I_GENE
, I_GENE
d I_GENE
( O
ICP35c B_NUMBER[MEASURE]/B_LOCATION
, I_NUMBER[MEASURE]/I_LOCATION
d I_NUMBER[MEASURE]/I_LOCATION
) O
( O
F O
. O

The O
mouse B_GENE/B_LOCATION
tapasin I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
was O
mapped O
about O
70 O
kilobases O
from O
H2 B_LOCATION/B_PERSON
- I_LOCATION/I_PERSON
K I_LOCATION/I_PERSON
at O
the O
centromeric O
end O
of O
the O
mouse B_GENE/B_LOCATION
MHC I_GENE/I_LOCATION
. O

Due O
to O
significant O
homology O
to O
the O
C O
- O
terminus O
of O
the O
Mutator B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transposase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
this O
alternative O
gene O
product O
was O
named O
Trap B_GENE/B_DISEASE
( O
transposon B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
associated I_PROTEIN[GENE]/I_LOCATION
protein I_PROTEIN[GENE]/I_LOCATION
) O
. O

Nonetheless O
, O
the O
majority B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O
located O
within O
three B_LOCATION/B_BIO
short I_LOCATION/I_BIO
sequences I_LOCATION/I_BIO
at O
the O
N B_LOCATION
terminus I_LOCATION
, O
middle B_DISEASE/B_LOCATION
, O
and O
C B_LOCATION
terminus I_LOCATION
that O
are O
phylogenetically O
conserved O
among O
all O
known O
eubacterial B_SPECIES[BIO]
and O
chloroplast B_GENE/B_BIO
versions I_GENE/I_BIO
of O
this O
protein B_GENE/B_BACTERIUM[BIO]
. O

The O
c B_GENE/B_BIO
- I_GENE/I_BIO
raf I_GENE/I_BIO
- I_GENE/I_BIO
1 I_GENE/I_BIO
proto I_GENE/I_BIO
- I_GENE/I_BIO
oncogene I_GENE/I_BIO
is O
the O
cellular B_GENE/B_PERSON
homologue I_GENE/I_PERSON
of I_GENE/I_PERSON
v I_GENE/I_PERSON
- I_GENE/I_PERSON
raf I_GENE/I_PERSON
, O
the O
oncogene O
of O
the O
acutely O
transforming O
retrovirus O
3611 O
- O
MSV O
. O

Using O
gel O
retardation O
analysis O
, O
four O
binding O
sites O
for O
Rap1p B_GENE
have O
been O
identified O
within O
the O
promoter O
of O
the O
RAP1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
general B_PERSON/B_BIO
, O
the O
scallop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extract I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
potentiated O
phototactic B_DISEASE
suppression I_DISEASE
. O

Alcohol B_DISEASE_ADJECTIVE[DISEASE]
abuse I_DISEASE_ADJECTIVE[DISEASE]
and O
treatment B_DISEASE
resistance I_DISEASE
in O
skin B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
mean B_MEASURE
serum I_MEASURE
CDT I_MEASURE
increased O
from O
8 B_MEASURE
. O
5 B_MEASURE
( O
SD B_MEASURE
2 I_MEASURE
. O
2 B_MEASURE
) O
U B_MEASURE/B_OTHER
/ O
l B_MEASURE/B_DISEASE
to O
16 B_MEASURE
. O
6 B_MEASURE
( O
SD B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
. O
2 B_MEASURE
) O
U B_MEASURE/B_OTHER
/ O
l B_MEASURE/B_DISEASE
( O
P B_OTHER/B_MEASURE
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Subsequent O
analysis O
revealed O
that O
MyD88 B_GENE
possesses O
a O
unique O
modular O
structure O
, O
which O
consists O
of O
an O
N O
- O
terminal O
' O
death O
domain O
, O
' O
similar O
to O
the O
intracellular O
segments O
of O
TNF B_GENE
receptor I_GENE
1 I_GENE
and O
Fas B_GENE/B_MEASURE
, O
and O
a O
C O
- O
terminal O
region O
related O
to O
the O
cytoplasmic O
domains O
of O
the O
Drosophila B_SPECIES[BIO]
morphogen I_SPECIES[BIO]
Toll I_SPECIES[BIO]
and O
vertebrate O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

RT O
- O
PCR O
analysis O
of O
FGFR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
the O
presence O
of O
a O
splice O
variant O
in O
which O
exons O
7 O
and O
8 O
are O
deleted O
. O

In O
human O
myxoid O
liposarcoma O
, O
a O
chromosomal O
rearrangement O
leads O
to O
fusion O
of O
the O
growth O
- O
arresting O
and O
DNA O
- O
damage O
- O
inducible O
transcription O
factor O
CHOP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
( O
GADD153 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
to O
a O
peptide O
fragment O
encoded O
by O
the O
TLS B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
. O

They O
also O
show O
that O
M B_OTHER/B_LOCATION
. O
malmoense B_DISEASE/B_BACTERIUM[BIO]
can O
be O
isolated O
from O
the O
environment B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
which O
may O
be O
the O
source B_LOCATION
of O
the O
infection B_BIO/B_DISEASE
. O

The O
monkeys B_BIO/B_PERSON
had O
been O
administered O
a O
common B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lead I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
isotope I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
mix B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O
at O
the O
rate B_MEASURE/B_LOCATION
of O
about O
1300 B_MEASURE
micrograms I_MEASURE
Pb I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
wt I_MEASURE
/ O
day B_MEASURE
from O
age B_TIME[MEASURE]/B_ORGANISM_FUNCTION
10 I_TIME[MEASURE]/I_ORGANISM_FUNCTION
months I_TIME[MEASURE]/I_ORGANISM_FUNCTION
until O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
previously O
described O
the O
upregulation O
of O
the O
MT2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
urodele O
limb O
regeneration O
and O
characterized O
the O
MT2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
antigen I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
310 O
- O
to O
325 O
- O
kDa O
chondroitin O
- O
sulfated O
glycoprotein O
with O
a O
core O
protein O
of O
285 O
- O
300 O
kDa O
. O

Analysis O
of O
the O
MCV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RPO1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
high O
amino O
acid O
homologies O
to O
the O
corresponding O
polypeptides O
of O
vaccinia O
and O
variola O
virus O
. O

The O
effects O
of O
dopamine O
and O
of O
dopamine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O
haloperidol O
on O
the O
activity O
of O
carotid O
chemoreceptors O
were O
studied O
in O
24 O
anesthetized O
, O
paralyzed O
and O
artificially O
ventilated O
newborn O
kittens O
aged O
0 O
- O
17 O
days O
. O

Fifty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]
per O
cent B_SEQUENCE[MEASURE]
of O
the O
primary B_PERSON
patients I_PERSON
reporting O
mild B_DISEASE
symptoms I_DISEASE
had O
abnormal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
leucocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
their O
CSF B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

When O
proper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
used O
, O
the O
psychophysical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O
remarkably O
comparable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients B_PERSON/B_BIO
were O
treated O
with O
either O
4 B_MEASURE
. O
8 B_MEASURE
million I_MEASURE
units I_MEASURE
of O
procaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
penicillin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probenecid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_NUMBER[MEASURE]
. O
5 B_MEASURE
or O
4 B_MEASURE
. O
5 B_MEASURE
g I_MEASURE
of O
ampicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probenecid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
9 B_MEASURE
. O
5 B_MEASURE
g I_MEASURE
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
over O
4 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
Improved B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
crest B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
Complete I_BODY_PART_OR_ORGAN_COMPONENT
with O
longer O
rippled B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
outer B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
bristles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
provided O
significantly O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
interproximal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
penetration B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overall O
and O
at O
the O
gumline B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
the O
Colgate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Total I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
Oral B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
- O
B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantage I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brushes I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cardiac B_DISEASE/B_PROTEIN[GENE]
NE B_DISEASE/I_PROTEIN[GENE]
spillover B_DISEASE/I_PROTEIN[GENE]
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
05 B_MEASURE
) O
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O
the O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
in O
healthy B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
whole B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NE I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spillovers I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
study B_PERSON/B_ORGANIZATION
groups I_PERSON/I_ORGANIZATION
. O

The O
activity O
of O
platelet B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma O
of O
healthy O
and O
high O
risk O
newborns O
. O

Plasma B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
renin B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O
in O
essential O
arterial O
hypertension O
. O

A O
trend B_MEASURE
was O
observed O
toward O
increased O
graft B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
half I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
life B_TIME[MEASURE]
in O
era B_PERSON/B_BIO
2 I_PERSON/I_BIO
( O
p B_OTHER/B_MEASURE
= O
NS B_MEASURE
) O
. O

The O
proteins O
encoded O
by O
these O
genes O
, O
called O
GF14 B_GENE/B_BIO
proteins I_GENE/I_BIO
, O
participate O
in O
protein O
/ O
DNA O
complexes O
and O
show O
more O
than O
60 O
% O
identity O
with O
a O
highly O
conserved O
, O
widely O
distributed O
protein O
family O
, O
collectively O
referred O
to O
as O
14 B_GENE/B_MEASURE
- I_GENE/I_MEASURE
3 I_GENE/I_MEASURE
- I_GENE/I_MEASURE
3 I_GENE/I_MEASURE
proteins O
. O

The O
p58 B_GENE
( O
PITSLRE B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
protein O
kinase O
( O
PK O
) O
is O
a O
member O
of O
a O
large O
supergene O
family O
related O
to O
the O
master B_GENE
mitotic I_GENE
protein I_GENE
kinase I_GENE
, O
p34cdc2 B_GENE
. O

Maximal B_TIME[MEASURE]/B_LOCATION
exercise I_TIME[MEASURE]/I_LOCATION
duration I_TIME[MEASURE]/I_LOCATION
and O
peak B_MEASURE/B_LOCATION
oxygen I_MEASURE/I_LOCATION
consumption I_MEASURE/I_LOCATION
were O
not O
changed O
. O

In O
contrast O
, O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
activation O
was O
observed O
in O
these O
cells O
after O
PMA O
stimulation O
. O

PtdIns B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
P2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O
, O
on O
the O
other O
hand O
, O
is O
only O
moderately O
affected O
even O
in O
fab1Delta B_PERSON/B_DISEASE
mutants I_PERSON/I_DISEASE
. O

A O
simple O
procedure O
for O
accurate O
quantitation O
of O
factor B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O
. O

We O
found O
that O
48 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
patients B_PERSON/B_BIO
had O
their O
thoracolumbar B_DISEASE_ADJECTIVE[DISEASE]
blood I_DISEASE_ADJECTIVE[DISEASE]
supply I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
two B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anterior B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiculospinal B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arteries B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
lowest B_SEQUENCE[MEASURE]/B_LOCATION
of O
which O
was O
located O
at O
, O
or O
lower B_TIME[MEASURE]
than O
, O
T12 B_PROTEIN[GENE]
, O
and O
the O
second B_SEQUENCE[MEASURE]/B_LOCATION
and O
higher B_SEQUENCE[MEASURE]
one I_SEQUENCE[MEASURE]
between O
T6 B_PROTEIN[GENE]
and O
T10 B_MEASURE/B_PROTEIN[GENE]
. O

Low O
serum B_DISEASE/B_GENE
C3 B_DISEASE/I_GENE
values O
were O
observed O
in O
all O
11 O
children O
at O
some O
stage O
of O
their O
illness O
. O

The O
plants O
were O
then O
brought O
to O
our O
Houston O
laboratory O
where O
they O
were O
measured O
and O
analyzed O
for O
lignin O
and O
protein O
content O
and O
for O
phenylalanine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ammonia I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lyase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PAL B_DISEASE/B_LOCATION
) O
and O
peroxidase B_ENZYME[GENE]/B_DISEASE
activities O
. O

Pax B_GENE/B_TIME[MEASURE]
- I_GENE/I_TIME[MEASURE]
6 I_GENE/I_TIME[MEASURE]
constructs O
lacking O
the O
C O
- O
terminal O
activation O
domain O
repressed O
betaB1 B_GENE/B_DISEASE
- I_GENE/I_DISEASE
crystallin I_GENE/I_DISEASE
promoter I_GENE/I_DISEASE
activity O
as O
effectively O
as O
the O
full O
- O
length O
protein O
, O
but O
the O
PD B_DISEASE/B_GENE
alone O
or O
Pax B_GENE/B_MEASURE
- B_GENE/I_MEASURE
6 B_GENE/I_MEASURE
( B_GENE/I_MEASURE
5a B_GENE/I_MEASURE
) B_GENE/I_MEASURE
, O
a O
splice O
variant O
with O
an O
altered O
PD B_DISEASE/B_LOCATION
affecting O
its O
DNA O
binding O
specificity O
, O
did O
not O
. O

A O
regression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
showed O
that O
86 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
variance B_MEASURE
in O
weight B_DISEASE_ADJECTIVE[DISEASE]
gain I_DISEASE_ADJECTIVE[DISEASE]
was O
predicted O
by O
two B_NUMBER[MEASURE]
leading O
indicators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
the O
middle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Respiratory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
related B_MEASURE
electromyographic I_MEASURE
( O
EMG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
superior B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pharyngeal I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
constrictor I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
SPC B_DISEASE/B_PROTEIN[GENE]
) O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
was O
analyzed O
during O
the O
early B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
forced B_DISEASE/B_ORGANISM_FUNCTION
breathing B_DISEASE/I_ORGANISM_FUNCTION
. O

The O
predicted O
amino O
acid O
sequence O
contained O
all O
consensus O
regions O
for O
S B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adenosyl I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methionine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
presented O
26 O
% O
identity O
with O
Saccharomyces B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
cerevisiae I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
DHHB I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
38 O
% O
identity O
with O
the O
rat O
protein O
, O
as O
well O
as O
with O
a O
bacterial O
( O
Escherichia O
coli O
and O
Salmonella O
typhimurium O
) O
methyltransferase B_ENZYME[GENE]/B_BIO
encoded O
by O
the O
UBIG B_GENE
gene I_GENE
. O

letter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
Ballistocardiography B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
introduction O
of O
FWD1 B_GENE
into O
cells O
significantly O
promotes O
ubiquitination O
and O
degradation O
of O
IkappaBalpha B_GENE
in O
concert O
with O
IkappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
nuclear O
translocation O
of O
NF B_GENE
- I_GENE
kappaB I_GENE
. O

Fosinopril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
decreased O
blood B_DISEASE/B_GENE
pressure I_DISEASE/I_GENE
from O
174 B_MEASURE
/ O
101 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
to O
149 B_MEASURE
/ O
88 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
in O
patients B_PERSON
with O
diastolic B_DISEASE
hypertension I_DISEASE
and O
from O
182 B_MEASURE
/ O
86 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
to O
151 B_MEASURE
/ O
80 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
in O
patients B_PERSON
with O
ISH B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
CB B_LOCATION
- O
4 B_MEASURE/B_BIO
isolates I_MEASURE/I_BIO
were O
less O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
chlorine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
CB B_LOCATION
- O
5 B_MEASURE
isolates I_MEASURE
, O
after O
1 B_MEASURE
, O
000 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
of O
contact B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
0 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O
01 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
input B_BIO
virus I_BIO
was O
still O
infectious B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Sudeck B_PERSON/B_LOCATION
' O
s O
atrophy B_DISEASE
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
sympathetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
assess O
the O
effect O
on O
thrombus O
growth O
, O
we O
determined O
the O
accretion O
of O
125I O
- O
labeled O
fibrinogen B_GENE
onto O
autologous O
non O
- O
radioactive O
thrombi O
preformed O
in O
the O
jugular O
veins O
of O
rabbits O
. O

Thallium B_LOCATION/B_DISEASE
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O
dipyridamole B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercise I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
kinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
99mTc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DMSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
. O

crude B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O
aquatic B_LOCATION/B_PERSON
plants I_LOCATION/I_PERSON
. O

Yet O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
predominant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Type B_BIO/B_PERSON
II I_BIO/I_PERSON
male I_BIO/I_PERSON
morph I_BIO/I_PERSON
which O
neither O
courts B_PERSON/B_BIO
females I_PERSON/I_BIO
nor O
nests B_LOCATION/B_PERSON
, O
but O
instead O
parasitizes O
Type B_MEASURE/B_ORGANIZATION
I O
males O
with O
sneak B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
satellite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
spawning B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
tactics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
therapeutic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effectiveness I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
membrane B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
centrifugation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
plasmapheresis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

amino O
- O
terminal O
polymorphisms O
of O
the O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenergic I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
impart O
distinct O
agonist O
- O
promoted O
regulatory O
properties O
. O

Hence O
, O
it O
is O
perhaps O
not O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
perform O
spinal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
puncture I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
if O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purpose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
to O
determine O
the O
CSF B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O
serum B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
ratio I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B_GENE/B_SPECIES[BIO]
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B_PROTEIN[GENE]/B_DISEASE
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B_GENE/B_LOCATION
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
reporter O
plasmid O
containing O
GAL4 B_NUMBER[MEASURE]/B_PERSON
DNA O
- O
binding O
sites O
. O

Biochemical O
experiments O
and O
genome O
sequencing O
have O
shown O
that O
, O
despite O
the O
prokaryotic O
cell O
and O
genome O
organization O
, O
basal O
transcriptional O
elements O
of O
members O
of O
the O
domain O
Archaea O
( O
i O
. O
e O
. O
, O
TATA O
box O
- O
like O
sequences O
, O
RNA B_GENE
polymerase I_GENE
, O
and O
transcription O
factors O
TBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
TFIIB B_GENE/B_DISEASE
, O
and O
TFIIS B_GENE/B_DISEASE
) O
are O
of O
the O
eukaryotic O
type O
. O

Humoral O
immunity O
is O
altered O
with O
the O
drop O
in O
IgG B_GENE
levels O
. O

For O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
it O
was O
12 B_MEASURE
. O
5 B_MEASURE
wk I_MEASURE
for O
RIR B_PROTEIN[GENE]/B_PERSON
and O
10 B_NUMBER[MEASURE]
for O
WL B_PERSON/B_PROTEIN[GENE]
males I_PERSON/I_PROTEIN[GENE]
, O
whereas O
it O
was O
5 B_MEASURE
wk I_MEASURE
for O
RIR B_LOCATION/B_PROTEIN[GENE]
and O
6 B_MEASURE
for O
WL B_PERSON
females I_PERSON
. O

modified O
Grocott B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
methenamine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
silver I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
quick B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Pneumocystis B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
carinii B_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Additionally O
, O
VAHS B_DISEASE
is O
often O
associated O
with O
fatal B_DISEASE
infectious I_DISEASE
mononucleosis I_DISEASE
( O
IM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
In O
patients B_PERSON/B_SPECIES[BIO]
with O
necrotising O
fasciitis B_DISEASE
the O
arterial B_MEASURE/B_PROTEIN[GENE]
PO2 B_MEASURE/I_PROTEIN[GENE]
rose O
about O
7 B_NUMBER[MEASURE]
- O
fold B_SEQUENCE[MEASURE]
whereas O
the O
arterial B_MEASURE/B_LOCATION
PCO2 I_MEASURE/I_LOCATION
increased O
only O
slightly O
during O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
2 B_MEASURE
. O
5 B_MEASURE
absolute I_MEASURE
atmospheres I_MEASURE
( O
ATA B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
report O
on O
a O
case O
of O
a O
43 O
- O
old O
- O
male O
with O
a O
bronchogenic O
cyst O
in O
the O
distal O
esophagus O
, O
which O
was O
misdiagnosed O
as O
a O
malignant O
esophageal O
tumor O
based O
on O
preoperative O
imaging O
and O
high O
levels O
of O
the O
tumor O
markers O
CA B_GENE/B_DISEASE
19 I_GENE/I_DISEASE
- I_GENE/I_DISEASE
9 I_GENE/I_DISEASE
and O
CA B_MEASURE/B_GENE
125 I_MEASURE/I_GENE
. O

100 B_MEASURE
and O
51 B_MEASURE/B_LOCATION
p I_MEASURE/I_LOCATION
. O

A O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
rich B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
infiltrate B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
connective B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cores I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
papillae B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

During O
normoxic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
at O
a O
mean B_MEASURE
O2 I_MEASURE
uptake I_MEASURE
( O
VO2 B_PROTEIN[GENE]/B_LOCATION
) O
of O
4 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
l I_MEASURE/I_LOCATION
/ O
min B_TIME[MEASURE]/B_PERSON
, O
almitrine B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
arterial B_PROTEIN[GENE]/B_LOCATION
PO2 I_PROTEIN[GENE]/I_LOCATION
( O
PaO2 B_MEASURE/B_PROTEIN[GENE]
) O
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
, O
SaO2 B_MEASURE/B_PROTEIN[GENE]
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
and O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
and O
decreased O
arterial B_PROTEIN[GENE]/B_DISEASE
PCO2 I_PROTEIN[GENE]/I_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
without O
affecting O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hemodynamics B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
ventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
perfusion B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distributions B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Gene B_GENE/B_DISEASE
GPR B_GENE/I_DISEASE
51 B_GENE/I_DISEASE
was O
localized O
by O
radiation O
hybrid O
mapping O
to O
chromosome O
9 O
, O
4 O
. O
81 O
CR O
from O
the O
WI O
- O
8684 O
marker O
, O
and O
proximal O
to O
the O
hereditary B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sensory B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
neuropathy B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
locus B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

We O
conclude O
that O
the O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
uterine B_DISEASE/B_GENE
MMMT I_DISEASE/I_GENE
is O
mainly O
influenced O
by O
the O
initial B_MEASURE/B_LOCATION
stage I_MEASURE/I_LOCATION
and O
the O
type B_MEASURE/B_LOCATION
of O
epithelial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
component I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
expression O
of O
the O
leukocyte B_GENE
EL I_GENE
- I_GENE
246 I_GENE
antigen I_GENE
was O
regulated O
in O
the O
same O
manner O
as O
L B_GENE
- I_GENE
selectin I_GENE
and O
EL B_TIME[MEASURE]/B_PERSON
- I_TIME[MEASURE]/I_PERSON
246 I_TIME[MEASURE]/I_PERSON
recognized O
anti B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
L I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
selectin I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mAb I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
affinity O
- O
purified O
antigen O
in O
SDS O
/ O
Page O
Western O
blot O
analysis O
. O

Other B_MEASURE/B_PERSON
Fischer I_MEASURE/I_PERSON
- O
344 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
exposed O
for O
1 B_TIME[MEASURE]
hr I_TIME[MEASURE]
to O
0 B_MEASURE
. O
0 B_MEASURE
or O
to O
0 B_MEASURE
. O
6 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
O3 I_TIME[MEASURE]
. O

A O
computerized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
veterans B_PERSON
discharged O
from O
the O
military B_ORGANIZATION/B_LOCATION
after O
1967 B_MEASURE/B_ORGANIZATION
was O
selected O
as O
the O
source B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
because O
it O
contains O
about O
50 B_SEQUENCE[MEASURE]/B_PERSON
% I_SEQUENCE[MEASURE]/I_PERSON
of O
the O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Vietnam I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
era I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
veteran I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
reasonably O
unbiased B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O
and O
provides O
a O
feasible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
identifying O
twins B_PERSON
. O

To O
examine O
the O
functional O
relationship O
between O
distinct O
cis O
- O
active O
elements O
within O
the O
distal O
enhancer O
region O
of O
the O
rat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
have O
used O
deletional O
and O
mutational O
analysis O
of O
that O
region O
in O
transient O
transfection O
studies O
in O
GH3 O
pituitary O
tumor O
cells O
. O

The O
entire O
coding O
region O
of O
an O
ovine B_GENE
endometrial I_GENE
oxytocin I_GENE
receptor I_GENE
( O
OTR B_LOCATION/B_GENE
) O
cDNA O
was O
generated O
by O
PCR O
, O
subcloned O
into O
the O
SV40 B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
major I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
late I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
expression O
vector O
pSVLJ O
and O
transiently O
expressed O
in O
Cos O
- O
7 O
cells O
. O

Alcohol B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
stomach B_DISEASE
diseases I_DISEASE
. O

These O
operons O
encode O
subunits O
of O
photosystems B_PROTEIN[GENE]/B_BACTERIUM[BIO]
I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
( O
psa B_DISEASE/B_LOCATION
) O
and O
II O
( O
psb B_DISEASE/B_LOCATION
) O
, O
the O
cytochrome B_ENZYME[GENE]
bGf I_ENZYME[GENE]
complex I_ENZYME[GENE]
( O
pet B_LOCATION/B_PROTEIN[GENE]
) O
, O
the O
plastid O
NAD B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
H I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ndh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B_GENE/B_MEASURE
. O

The O
phosphatidylglycerol B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatidylinositol I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transfer I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PG B_GENE/B_LOCATION
/ I_GENE/I_LOCATION
PI I_GENE/I_LOCATION
- I_GENE/I_LOCATION
TP I_GENE/I_LOCATION
) O
is O
a O
new O
and O
original O
phospholipid B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PLTP B_GENE/B_DISEASE
) O
isolated O
from O
the O
Deuteromycete O
, O
Aspergillus O
oryzae O
. O

Transcriptional O
modulation O
of O
the O
anti B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptotic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BCL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
XL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
paired B_GENE
box I_GENE
transcription I_GENE
factors I_GENE
PAX3 I_GENE
and O
PAX3 B_GENE/B_LOCATION
/ O
FKHR B_MEASURE
. O

The O
level O
of O
expression O
of O
the O
PDE B_GENE
protein I_GENE
was O
monitored O
by O
immunoblot O
analysis O
using O
two O
specific O
cAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
by O
measuring O
the O
PDE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
activity O
. O

Blotting O
analysis O
of O
intestinal O
RNA O
and O
hybridization O
of O
the O
blots O
with O
carboxy O
apoB B_GENE/B_MEASURE
cDNA O
probes O
produced O
a O
single O
15 O
- O
kb O
hybridization O
band O
whereas O
hybridization O
with O
amino O
terminal O
probes O
produced O
two O
hybridization O
bands O
of O
15 O
and O
8 O
kb O
. O

Since O
UmuD B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
proteolytically O
processed O
to O
an O
active O
form O
( O
UmuD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
* I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
a O
RecA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
* O
- O
dependent O
fashion O
, O
and O
MucA B_TIME[MEASURE]/B_BACTERIUM[BIO]
shares O
extensive O
amino O
acid O
homology O
with O
UmuD B_GENE/B_BIO
, O
we O
examined O
whether O
MucA B_BACTERIUM[BIO]/B_PERSON
is O
similarly O
processed O
in O
the O
cell O
, O
using O
antiserum O
against O
a O
LacZ B_MEASURE/B_GENE
' I_MEASURE/I_GENE
- O
' B_GENE/B_BACTERIUM[BIO]
MucA I_GENE/I_BACTERIUM[BIO]
fusion O
protein O
. O

influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
zimelidine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
on O
LSD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
behavioural B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
determined O
the O
molecular O
organization O
and O
transcription O
start O
points O
( O
tsp O
) O
for O
the O
murine O
gene O
( O
TK B_GENE/B_DISEASE
) O
encoding O
thymidine B_GENE
kinase I_GENE
. O

Together O
with O
a O
number B_MEASURE/B_PERSON
of O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
I O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utilizing O
escalating O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
growth B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
or O
growth B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
stem I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
- O
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
support B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O
shown O
that O
substantial B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dose B_MEASURE/B_DISEASE
intensity B_MEASURE/I_DISEASE
can O
be O
achieved O
. O

It O
is O
an O
untested O
argument O
that O
conventional O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O
possess O
unwanted O
metabolic O
effects O
that O
may O
counter O
some O
of O
their O
potential O
cardiac O
benefits O
. O

genetic O
polymorphisms O
in O
the O
5 O
' O
- O
flanking O
region O
change O
transcriptional O
regulation O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytochrome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P450IIE1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
the O
occurrence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
ventricular B_DISEASE
ectopic I_DISEASE
activity I_DISEASE
, O
as O
detected O
by O
either O
or O
both O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
the O
incidence B_MEASURE/B_DISEASE
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
in O
patients B_PERSON
with O
coronary B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
( O
86 B_MEASURE/B_PERSON
percent I_MEASURE/I_PERSON
; O
77 B_MEASURE
/ O
90 B_MEASURE
) O
, O
as O
compared O
to O
that O
in O
normal B_PERSON/B_DISEASE
subjects I_PERSON/I_DISEASE
( O
40 B_MEASURE
percent I_MEASURE
; O
12 B_MEASURE
/ O
30 B_MEASURE
) O
. O

increased O
trabecular B_MEASURE/B_DISEASE
spacing I_MEASURE/I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
it O
occurs O
in O
osteoporosis B_DISEASE
, O
reduces O
the O
spatial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
field B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inhomogeneity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
thus O
prolongs O
T2 B_MEASURE/B_PROTEIN[GENE]
* O
, O
which O
has O
been O
shown O
both O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

healthy B_PERSON
preterm I_PERSON
infants I_PERSON
of O
gestational B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
26 I_MEASURE/I_PERSON
- O
29 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
showed O
a O
' O
mature B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
' O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
permeability B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
at O
birth B_PERSON/B_TIME[MEASURE]
, O
followed O
by O
a O
temporary B_MEASURE/B_LOCATION
period I_MEASURE/I_LOCATION
of O
enhanced O
permeability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
after O
3 B_SEQUENCE[MEASURE]/B_LOCATION
- O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
life B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

These O
studies O
reveal O
that O
CREM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
tissue O
- O
specific O
factor O
, O
is O
expressed O
and O
regulated O
by O
gonadotropins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
ovary O
, O
that O
the O
predominant O
CREM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts O
encode O
the O
repressor B_GENE/B_MEASURE
protein I_GENE/I_MEASURE
ICER I_GENE/I_MEASURE
, O
and O
that O
ICER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
capable O
of O
inhibiting O
Camp O
- O
induced O
expression O
of O
the O
inhibin B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
- I_GENE/I_MEASURE
subunit I_GENE/I_MEASURE
gene I_GENE/I_MEASURE
. O

The O
Brassica B_GENE/B_BIO
BTH1 I_GENE/I_BIO
gene I_GENE/I_BIO
may O
correspond O
to O
the O
Arabidopsis B_BIO/B_GENE
TH I_BIO/I_GENE
- I_BIO/I_GENE
1 I_BIO/I_GENE
gene I_BIO/I_GENE
. O

The O
same B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
firing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
seen O
with O
saccades B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
light B_COLOR/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
darkness I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
. O

While O
these O
could O
be O
unusual B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE/B_GENE
non I_DISEASE/I_GENE
- O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
non B_DISEASE/B_LOCATION
- O
B B_DISEASE
hepatitis I_DISEASE
, O
this O
can O
be O
only O
speculation B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
until O
a O
serologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
non B_DISEASE/B_GENE
- O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
non B_DISEASE/B_LOCATION
- O
B B_DISEASE/B_PROTEIN[GENE]
hepatitis B_DISEASE/I_PROTEIN[GENE]
becomes O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Acanthamoeba B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myosin I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heavy I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MIHCK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
phosphorylates O
the O
heavy O
chains O
of O
amoeba B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myosins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
increasing O
their O
actin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
activated O
ATPase B_ENZYME[GENE]
activities O
. O

mutation O
of O
the O
HNF3 B_GENE/B_MEASURE
element I_GENE/I_MEASURE
significantly O
reduced O
promoter O
activity O
in O
HepG2 O
cells O
, O
whereas O
this O
element O
in O
isolation O
conferred O
HNF3beta B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
responsiveness O
to O
a O
heterologous O
promoter O
. O

The O
mitochondrial B_ENZYME[GENE]
tyrosyl I_ENZYME[GENE]
- I_ENZYME[GENE]
tRNA I_ENZYME[GENE]
synthetase I_ENZYME[GENE]
of O
Podospora O
anserina O
is O
a O
bifunctional O
enzyme O
active O
in O
protein O
synthesis O
and O
RNA O
splicing O
. O

The O
findings O
in O
the O
human O
multiple O
myeloma O
cell O
lines O
represent O
the O
first O
examples O
of O
B O
cells O
with O
downregulated O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
and O
apparently O
contradict O
observations O
in O
the O
murine O
system O
in O
which O
PU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
expressed O
and O
active O
in O
plasmacytoma O
cell O
lines O
. O

The O
traW B_GENE
gene I_GENE
of I_GENE
the I_GENE
Escherichia I_GENE
coli I_GENE
K I_GENE
- I_GENE
12 I_GENE
sex I_GENE
factor I_GENE
, O
F O
, O
encodes O
one O
of O
the O
numerous O
proteins O
required O
for O
conjugative O
transfer O
of O
this O
plasmid O
. O

Mibefradil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ro B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5967 B_MEASURE
) O
is O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
nondihydropyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
technical O
advances O
have O
shown O
the O
limitations O
of O
these O
tests O
as O
tests O
for O
IgM B_GENE/B_DISEASE
can O
be O
positive O
because O
of O
residual O
specific O
IgM B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
even O
in O
subjects O
free O
of O
acute O
infection O
due O
to O
the O
existence O
of O
natural O
interfering O
IgM B_GENE/B_BIO
. O

carcinogenic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
action I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
groundnut B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
meal I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
containing O
aflatoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1991 B_MEASURE
) O
EMBO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
utilized O
transient O
transfections O
, O
mutation O
analysis O
, O
electromobility O
gel O
- O
shifts O
, O
and O
immunoblot O
analysis O
to O
test O
the O
hypothesis O
that O
expression O
of O
the O
CTalpha B_GENE
gene I_GENE
is O
controlled O
in O
part O
by O
the O
binding O
of O
three O
trans O
- O
acting O
nuclear O
factors O
, O
Sp1 B_GENE/B_LOCATION
, O
Sp2 B_GENE
, O
and O
Sp3 B_GENE/B_DISEASE
. O

AMPK B_GENE
is O
a O
heterotrimer O
composed O
of O
a O
catalytic O
subunit O
( O
alpha O
) O
and O
two O
regulatory O
subunits O
( O
beta O
and O
gamma O
) O
. O

The O
evolutionary O
significance O
of O
the O
similarities O
of O
intron O
secondary O
structures O
and O
open O
reading O
frames O
of O
the O
ND3 B_GENE/B_BIO
, I_GENE/I_BIO
4 I_GENE/I_BIO
and I_GENE/I_BIO
ATPase I_GENE/I_BIO
6 I_GENE/I_BIO
genes I_GENE/I_BIO
is O
discussed O
, O
including O
the O
possible O
separate O
evolution O
of O
structural O
and O
coding O
sequences O
. O

Antinuclear O
antibodies O
, O
rheumatoid B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
and O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reactive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
serum O
of O
normal O
women O
using O
oral O
contraceptives O
. O

The O
destruction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
mesometrium B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
lengthen O
the O
oestrous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
platelet B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
nitrite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
determined O
using O
simple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
sensitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
nitrite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorometric I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Power B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
deposition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
by O
inverse B_MEASURE
- O
bremsstrahlung B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
modeled O
with O
a O
scheme B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
based O
on O
Gaussian B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quadrature I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
accommodate O
a O
deposition B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
whose O
spatial B_MEASURE/B_LOCATION
variation I_MEASURE/I_LOCATION
is O
highly O
nonuniform B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

The O
sulfur B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
separated O
within O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
4 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
by O
CZE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
a O
pyromellitic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrolyte I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
pH B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
to O
5 B_MEASURE
. O
0 B_MEASURE
. O

We O
propose O
that O
unc B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
37 I_PERSON/I_LOCATION
may O
be O
regulated O
by O
unc B_GENE
- I_GENE
4 I_GENE
. O

Adenovirus O
infection O
of O
hepatoma O
cells O
inhibited O
transcription O
of O
the O
phosphoenolpyruvate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carboxykinase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GTP O
) O
( O
EC B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
4 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
32 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
( O
PEPCK B_GENE/B_SPECIES[BIO]
) O
gene O
and O
virtually O
eliminated O
transcription O
of O
a O
chimeric O
gene O
which O
contained O
the O
PEPCK B_GENE
promoter I_GENE
linked O
to O
the O
structural O
gene O
for O
chloramphenicol B_GENE
acetyltransferase I_GENE
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

After O
discharge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
he O
was O
finally O
given O
a O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
PCH B_DISEASE
because O
a O
Donath B_PERSON/B_DISEASE
- O
Landsteiner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
second B_GENE/B_SEQUENCE[MEASURE]
intron B_GENE/I_SEQUENCE[MEASURE]
is O
the O
smallest B_SEQUENCE[MEASURE]/B_LOCATION
of O
all O
the O
introns B_GENE/B_LOCATION
( O
116 B_TIME[MEASURE]/B_GENE
BP I_TIME[MEASURE]/I_GENE
) O
. O

expression O
of O
the O
gene O
encoding O
transcription B_GENE
factor I_GENE
cyclic I_GENE
adenosine I_GENE
3 I_GENE
' I_GENE
, I_GENE
5 I_GENE
' I_GENE
- I_GENE
monophosphate I_GENE
( I_GENE
cAMP I_GENE
) I_GENE
response I_GENE
element I_GENE
- I_GENE
binding I_GENE
protein I_GENE
( O
CREB B_GENE/B_DISEASE
) O
: O
regulation O
by O
follicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
induced O
Camp O
signaling O
in O
primary O
rat O
Sertoli O
cells O
. O

Efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
evaluated O
in O
24 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
of O
whom O
eight B_NUMBER[MEASURE]
received O
RD B_DISEASE/B_PROTEIN[GENE]
and O
16 B_MEASURE/B_LOCATION
SD B_MEASURE/I_LOCATION
. O

A O
silica B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
, O
fluoride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
placebo I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O
NaTPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
a O
NAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
silica B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
USP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reference I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
standard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toothpaste I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
as O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
toothpastes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

The O
overall B_MEASURE/B_PERSON
response I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
including O
CR B_LOCATION/B_DISEASE
and O
PR B_LOCATION/B_DISEASE
was O
23 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
4 B_MEASURE
/ O
17 B_MEASURE
) O
. O

High O
and O
pathological O
PAI B_GENE
- I_GENE
1 I_GENE
levels O
before O
and O
after O
the O
VO O
test O
were O
consistent O
with O
a O
defective O
fibrinolytic O
potential O
due O
to O
the O
inhibitory O
effect O
of O
PAI B_PROTEIN[GENE]/B_DISEASE
- I_PROTEIN[GENE]/I_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
on O
plasminogen B_GENE
activation O
. O

During O
hexamethylene O
bisactamide O
( O
HMBA O
) O
- O
induced O
differentiation O
of O
murine O
erythroleukemia O
( O
Mel O
) O
cells O
erythroid O
genes O
are O
transcriptionally O
activated O
while O
c B_GENE
- I_GENE
myb I_GENE
and O
several O
other O
nuclear O
Proto O
- O
oncogenes O
are O
down O
- O
regulated O
. O

The O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
adults B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
schistosomes B_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
extracorporeal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
filtration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

torsion B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
contralateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
testis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
5 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
years I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
after O
orchiopexy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

frequency B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
recurrence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fibroids B_DISEASE
after O
myomectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
has O
been O
evaluated O
in O
145 B_PERSON
women I_PERSON
( O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
38 I_MEASURE/I_PERSON
years I_MEASURE/I_PERSON
, O
range B_MEASURE/B_LOCATION
21 I_MEASURE/I_LOCATION
- O
52 B_MEASURE
) O
who O
underwent O
myomectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Choline B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acetyltransferase I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
immunohistochemistry O
combined O
with O
the O
retrograde O
transport O
of O
horseradish B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
showed O
that O
the O
reticular O
and O
mediodorsal O
thalamic O
nuclei O
of O
the O
cat O
receive O
an O
important O
input O
from O
cholinergic O
and O
non O
- O
cholinergic O
neurons O
of O
substantia O
innominata O
and O
adjacent O
structures O
in O
the O
basal O
forebrain O
. O

( O
i O
) O
The O
chimeric O
gene O
consisting O
of O
the O
coding O
and O
5 O
' O
nontranslated O
leader O
regions O
of O
the O
TK B_GENE
gene I_GENE
fused O
to O
portions O
of O
the O
domain O
of O
alpha B_GENE
gene I_GENE
0 I_GENE
extending O
largely O
upstream O
from O
the O
site O
of O
initiation O
of O
transcription O
of O
alpha B_GENE
gene I_GENE
0 I_GENE
was O
regulated O
in O
the O
same O
fashion O
as O
the O
alpha B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
4 I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
27 I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
TK I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chimeras O
. O

ethanol B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
strains B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selectively O
bred O
for O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

For O
the O
albino B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O
both O
the O
ST1 B_PROTEIN[GENE]/B_LOCATION
and O
ST2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
spatial I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
responses I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peak O
at O
around O
0 B_MEASURE
. O
3 B_MEASURE/B_LOCATION
cycles I_MEASURE/I_LOCATION
deg I_MEASURE/I_LOCATION
- O
1 B_MEASURE
, O
and O
both O
curves B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
displaced O
considerably O
to O
the O
low B_LOCATION/B_MEASURE
spatial I_LOCATION/I_MEASURE
frequency I_LOCATION/I_MEASURE
side I_LOCATION/I_MEASURE
of O
the O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
ST2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
spatial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Nuclear O
proteins O
bound O
the O
cad B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
75 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
cell O
cycle O
- O
dependent O
manner O
in O
electromobility O
shift O
assays O
; O
antibodies O
specific O
to O
USF B_PERSON/B_GENE
and O
Max B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
blocked O
the O
DNA O
- O
binding O
activity O
of O
different O
growth O
- O
regulated O
protein O
- O
DNA O
complexes O
. O

Thus O
, O
an O
unmodified O
threonine O
at O
position O
169 O
in O
Cdc28 B_GENE
is O
important O
for O
interaction O
with O
G1 B_GENE
cyclins I_GENE
. O

Additional O
genetic O
analyses O
described O
herein O
suggest O
that O
Skb1 B_GENE
is O
a O
component O
of O
the O
morphology O
control O
branch O
of O
the O
Ras B_GENE/B_DISEASE
signaling O
Cascade O
in O
S O
. O
pombe O
and O
that O
it O
positively O
modulates O
Shk1 B_GENE
function O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
concentrated O
on O
the O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
coffee B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
which O
vary O
from O
country B_LOCATION
to O
country B_LOCATION/B_ORGANIZATION
. O

From O
a O
chromosomal O
cosmid O
library O
of O
Streptomyces O
argillaceus O
, O
a O
Mtm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
producer O
, O
a O
clone O
( O
cosAR7 O
) O
was O
isolated O
by O
homology O
to O
the O
actI B_GENE
/ I_GENE
III I_GENE
region I_GENE
of O
S O
. O
coelicolor O
and O
the O
strDEM B_GENE/B_BIO
genes I_GENE/I_BIO
of O
S O
. O
griseus O
. O

In O
this O
report O
, O
we O
investigated O
whether O
the O
cleavage O
of O
the O
RRKR O
motif O
of O
MT B_GENE
- I_GENE
MMP1 I_GENE
by O
Golgi B_GENE
- I_GENE
associated I_GENE
furin I_GENE
is O
analogous O
to O
a O
similar O
enzyme O
activation O
mechanism O
observed O
with O
stromelysin B_GENE
- I_GENE
3 I_GENE
. O

Coexpression O
of O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
altered O
the O
cell O
specificity O
. O

A O
preterm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
formula I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O
a O
traditional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corn I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
MCT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
blend I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
containing O
38 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
MCTs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MCT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
compared O
to O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
fat I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
blend I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
designed O
to O
resemble O
human B_BIO/B_DISEASE
milk I_BIO/I_DISEASE
more I_BIO/I_DISEASE
, O
containing O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
MCTs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
LCT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Thirty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
small I_NUMBER[MEASURE]
glottic I_NUMBER[MEASURE]
carcinomas I_NUMBER[MEASURE]
( O
T1 B_PROTEIN[GENE]
and O
small B_PROTEIN[GENE]/B_DISEASE
T2 I_PROTEIN[GENE]/I_DISEASE
; O
UICC B_PERSON
, O
1978 B_MEASURE
) O
were O
examined O
by O
malignancy B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grading O
using O
the O
8 B_NUMBER[MEASURE]
- O
factor B_MEASURE/B_LOCATION
system I_MEASURE/I_LOCATION
proposed O
by O
Jakobsson B_PERSON/B_ORGANIZATION
et I_PERSON/I_ORGANIZATION
al I_PERSON/I_ORGANIZATION
. O

phenylalanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
and O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
those O
who O
received O
Vamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
55 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
infants B_PERSON/B_LOCATION
given O
Vamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Infant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
below O
the O
lower B_MEASURE/B_LOCATION
limit B_MEASURE/I_LOCATION
of O
the O
target B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
range B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
sought O
to O
test O
whether O
a O
prolonged O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
magnesium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MgSO B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE/B_LOCATION
) O
; O
40 B_MEASURE/B_LOCATION
mmol I_MEASURE/I_LOCATION
/ O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
) O
would O
normalize O
QT B_DISEASE/B_GENE
interval I_DISEASE/I_GENE
variability I_DISEASE/I_GENE
in O
patients B_PERSON
with O
compensated B_DISEASE/B_GENE
heart I_DISEASE/I_GENE
failure I_DISEASE/I_GENE
. O

Escherichia O
coli O
strains O
carrying O
recA730 B_GENE/B_LOCATION
( O
or O
other O
recA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
* B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O
exhibit O
dramatic O
increases O
in O
SOS O
- O
dependent O
spontaneous O
mutator O
activity O
. O

Outlook B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
oral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
cutaneous B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
Kaposi B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
' B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
s B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sarcoma B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
report O
the O
complete O
nucleotide O
sequence O
of O
the O
camC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O
with O
155 O
base O
pairs O
of O
5 O
' O
and O
175 O
base O
pairs O
of O
3 O
' O
flanking O
sequence O
. O

However O
, O
it O
is O
only O
loosely O
associated O
, O
or O
not O
associated O
, O
with O
viral B_DISEASE
particles I_DISEASE
. O

gp170 B_PROTEIN[GENE]/B_DISEASE
is O
generated O
by O
an O
alternatively O
spliced O
Env B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
a O
splice O
donor O
and O
splice O
acceptor O
pair O
localized O
within O
the O
env B_GENE
open I_GENE
reading I_GENE
frame I_GENE
( I_GENE
ORF I_GENE
) I_GENE
, O
which O
is O
normally O
used O
to O
generate O
Bell B_GENE/B_LOCATION
and O
Bet B_GENE/B_BIO
transcripts I_GENE/I_BIO
derived O
from O
the O
internal O
promoter O
within O
the O
env B_GENE/B_VIRUS[BIO]
ORF I_GENE/I_VIRUS[BIO]
. O

gp170 B_GENE/B_DISEASE
is O
expressed O
at O
a O
level O
30 O
to O
50 O
% O
of O
the O
Env B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
precursor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gp130 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
marked O
contrast O
to O
the O
previously O
published O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD6 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
mouse O
sequence O
predicts O
a O
long O
cytoplasmic O
tail O
that O
is O
not O
closely O
related O
to O
other O
proteins O
and O
possesses O
two O
proline O
- O
rich O
motifs O
containing O
the O
SH3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
three O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
nine O
casein B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
phosphorylation I_GENE/I_LOCATION
site I_GENE/I_LOCATION
motifs I_GENE/I_LOCATION
, O
and O
a O
serine O
- O
threonine O
- O
rich O
motif O
repeated O
three O
times O
. O

ET B_PERSON/B_DISEASE
- I_PERSON/I_DISEASE
1 I_PERSON/I_DISEASE
limited O
the O
electrocardiographic O
evidence O
of O
subendocardial O
ischemia O
and O
attenuated O
contractile O
dysfunction O
compared O
with O
mechanical O
stenosis O
at O
the O
same O
coronary O
flows O
, O
even O
though O
lactate O
flux O
was O
similar O
. O

Our O
results O
are O
consistent O
with O
TCOF1 B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O
to O
the O
Treacher O
Collins O
syndrome O
phenotype O
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
syndrome B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogous B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
hydramnios B_DISEASE/B_BACTERIUM[BIO]
in O
the O
rat B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fetus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Total B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cross I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
electron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scattering O
by O
CO2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
energy B_TIME[MEASURE]/B_LOCATION
range I_TIME[MEASURE]/I_LOCATION
400 I_TIME[MEASURE]/I_LOCATION
- O
5000 B_MEASURE
eV I_MEASURE
. O

Thus O
, O
the O
cognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
elderly B_PERSON/B_BIO
subjects I_PERSON/I_BIO
could O
be O
trained O
to O
a O
large B_MEASURE
extent I_MEASURE
. O

Partial B_DISEASE
albinism I_DISEASE
and O
immunodeficiency B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
haemophagocytosis B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
bone B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
erythroblasts B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
one B_PERSON/B_BIO
case I_PERSON/I_BIO
. O

residues O
that O
affect O
PLCbeta B_GENE
and O
adenylyl B_GENE
cyclase I_GENE
II I_GENE
activity O
are O
found O
on O
opposite O
sides O
of O
the O
central O
tunnel O
, O
suggesting O
that O
PLC B_GENE/B_DISEASE
and O
adenylyl B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
like O
the O
alpha O
subunit O
, O
make O
many O
contacts O
on O
the O
top O
surface O
. O

The O
dynamics B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
protozoa B_BIO/B_ORGANISM_FUNCTION
were O
studied O
in O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
rumen B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
fistulated O
cattle B_SPECIES[BIO]
fed O
on O
a O
basal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
molasses B_BIO/B_PROTEIN[GENE]
ad B_BIO/I_PROTEIN[GENE]
lib B_BIO/I_PROTEIN[GENE]
. O
, O
with O
oaten B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chaff I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
given O
at O
6 B_MEASURE
or O
18 B_MEASURE
g I_MEASURE
/ O
kg B_MEASURE
live I_MEASURE
weight I_MEASURE
. O

The O
CBS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
mapped O
to O
human O
chromosome O
10p12 O
between O
markers O
WI B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8535 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
WI B_MEASURE/B_GENE
- I_MEASURE/I_GENE
4724 I_MEASURE/I_GENE
, O
and O
is O
tightly O
linked O
to O
the O
two O
STRP O
markers O
of O
D10S1789 B_GENE/B_LOCATION
and O
D10S550 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Blood B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ammonia I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
males B_PERSON/B_BIO
at O
70 B_MEASURE
, O
80 B_MEASURE
and O
90 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
VO2 B_PERSON/B_MEASURE
peak I_PERSON/I_MEASURE
. O

value B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bone B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
Tc99MDP B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mobilization B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
total B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hip I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
prosthesis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Youssoufian B_PERSON/B_COLOR
, O
A O
. O

The O
dipper B_MEASURE/B_PERSON
( O
RONF B_MEASURE/B_LOCATION
of O
BP B_LOCATION/B_PROTEIN[GENE]
( O
or O
HR B_LOCATION/B_PROTEIN[GENE]
) O
> B_MEASURE/B_OTHER
or O
= O
10 B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
we O
have O
investigated O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SDZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ENA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
713 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
spatial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
learning I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
deficits I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
aged B_SPECIES[BIO]/B_DISEASE
rats I_SPECIES[BIO]/I_DISEASE
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
seven B_NUMBER[MEASURE]
- O
wavelength B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
- O
domain B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
photon I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
migration I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
probe I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
to O
perform O
noninvasive B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NIR I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measurements I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
breasts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
28 B_PERSON
healthy I_PERSON
women I_PERSON
, O
both O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
postmenopausal B_PERSON
, O
aged O
18 B_MEASURE
- O
64 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
. O

YACs B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BACs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
cosmids B_DISEASE/B_BACTERIUM[BIO]
, O
and O
STSs B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
are O
defined O
to O
aid O
in O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
gene B_PERSON/B_BIO
. O

HCVR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
L B_PROTEIN[GENE]/B_LOCATION
significantly O
increased O
dVAS B_DISEASE/B_PROTEIN[GENE]
/ O
dPCO2 B_MEASURE/B_PROTEIN[GENE]
to O
4 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
7 B_MEASURE
mm I_MEASURE
/ O
Torr B_MEASURE/B_PERSON
compared O
to O
HCVR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
S B_PROTEIN[GENE]/B_DISEASE
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

The O
MEF B_GENE/B_BIO
- I_GENE/I_BIO
2 I_GENE/I_BIO
proteins I_GENE/I_BIO
are O
a O
family O
of O
transcriptional O
activators O
that O
have O
been O
detected O
in O
a O
wide O
variety O
of O
cell O
types O
. O

The O
ferric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
uptake B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
fur B_BIO/B_PROTEIN[GENE]
) O
gene O
product O
participates O
in O
regulating O
expression O
of O
the O
manganese O
- O
and O
iron O
- O
containing O
superoxide B_PROTEIN[GENE]/B_BACTERIUM[BIO]
dismutase I_PROTEIN[GENE]/I_BACTERIUM[BIO]
genes I_PROTEIN[GENE]/I_BACTERIUM[BIO]
of I_PROTEIN[GENE]/I_BACTERIUM[BIO]
Escherichia I_PROTEIN[GENE]/I_BACTERIUM[BIO]
coli I_PROTEIN[GENE]/I_BACTERIUM[BIO]
. O

To O
date O
, O
6 O
mammalian O
GRKs B_GENE/B_BIO
have O
been O
identified O
by O
molecular O
cloning O
. O

[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
OP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
2Cu B_LOCATION
] O
+ B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
detected O
protections B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
C B_PROTEIN[GENE]/B_NUMBER[MEASURE]
alpha B_PROTEIN[GENE]/I_NUMBER[MEASURE]
- O
helix B_LOCATION
, O
the O
interdomain B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
hinge I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
strands B_PROTEIN[GENE]/B_LOCATION
2 I_PROTEIN[GENE]/I_LOCATION
- O
7 B_MEASURE
. O

The O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
the O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
long B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
term I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
naftidrofuryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Dusodril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
Lipha B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Arzn I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
twice O
daily O
in O
a O
dose B_MEASURE/B_LOCATION
of O
200 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
4 B_NUMBER[MEASURE]
- O
hour B_TIME[MEASURE]
infusion I_TIME[MEASURE]
in O
500 B_MEASURE
ml I_MEASURE
0 I_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
NaCl I_MEASURE/I_PERSON
to O
the O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
suffering O
from O
a O
peripheral B_DISEASE
arterial I_DISEASE
occlusive I_DISEASE
disease I_DISEASE
( O
PAOD B_DISEASE/B_LOCATION
) O
in O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
condition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
paid O
to O
transcutaneous O
partial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oxygen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
tcPO2 B_DISEASE/B_LOCATION
) O
and O
rheographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Vertebrate O
U6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
small I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
snRNA O
) O
loci O
exemplify O
a O
novel O
class O
of O
polymerase B_DISEASE/B_LOCATION
III I_DISEASE/I_LOCATION
- O
transcribed O
genes O
that O
lack O
an O
intragenic O
control O
region O
( O
ICR O
) O
. O

Elements O
of O
the O
hAT B_GENE/B_LOCATION
transposon I_GENE/I_LOCATION
family I_GENE/I_LOCATION
, O
such O
as O
the O
maize B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ac B_DISEASE/B_LOCATION
) O
, O
have O
been O
discovered O
in O
a O
large O
number O
of O
eukaryotic O
species O
. O

Judge B_PERSON/B_LOCATION
Christian I_PERSON/I_LOCATION
Byk I_PERSON/I_LOCATION
renders O
service B_ORGANIZATION/B_PERSON
to O
the O
steering B_ORGANIZATION/B_PERSON
Committee I_ORGANIZATION/I_PERSON
on O
Bioethics B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Council B_ORGANIZATION/B_LOCATION
of O
Europe B_LOCATION/B_PERSON
( O
CDBI B_DISEASE/B_ORGANIZATION
) O
by O
proposing O
a O
draft B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
destined O
to O
fill O
in O
a O
gap B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
international B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
law I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
status B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
the O
human B_ORGANIZATION/B_PERSON
embryo I_ORGANIZATION/I_PERSON
. O

correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
SF B_MEASURE/B_LOCATION
thickness B_MEASURE/I_LOCATION
and O
NIR B_MEASURE
optical I_MEASURE
density I_MEASURE
readings I_MEASURE
at O
940 B_MEASURE
nm I_MEASURE
( O
OD1 B_PROTEIN[GENE]/B_MEASURE
) O
and O
950 B_MEASURE
nm I_MEASURE
( O
OD2 B_PROTEIN[GENE]/B_MEASURE
) O
wavelengths B_LOCATION/B_DISEASE
ranged O
from O
r B_PROTEIN[GENE]/B_MEASURE
= O
- O
0 B_NUMBER[MEASURE]
. O
30 B_MEASURE
( O
subscapula B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O
to O
r B_PROTEIN[GENE]/B_MEASURE
= O
- O
0 B_NUMBER[MEASURE]
. O
67 B_MEASURE
( O
biceps B_BODY_PART_OR_ORGAN_COMPONENT
) O
for O
OD1 B_PROTEIN[GENE]/B_DISEASE
and O
r B_MEASURE/B_LOCATION
= I_MEASURE/I_LOCATION
- O
0 B_NUMBER[MEASURE]
. O
39 B_MEASURE
( O
axilla B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O
to O
r B_PROTEIN[GENE]/B_MEASURE
= O
- O
0 B_NUMBER[MEASURE]
. O
68 B_MEASURE
( O
biceps B_BODY_PART_OR_ORGAN_COMPONENT
) O
for O
OD2 B_PROTEIN[GENE]/B_DISEASE
. O

We O
found O
both O
the O
v B_PROTEIN[GENE]/B_LOCATION
- B_PROTEIN[GENE]/I_LOCATION
Ras B_PROTEIN[GENE]/I_LOCATION
- O
and O
PC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PLC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
transformed O
cells O
to O
be O
insensitive O
to O
stimulation O
with O
platelet B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PDGF B_GENE
) O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
domain B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
deletion I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
demonstrated O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergy I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
RRM B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
a O
central B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degenerate I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
binding O
to O
RNA B_GENE/B_BIO
. O

sequence O
analysis O
of O
the O
catfish O
JH B_PROTEIN[GENE]/B_LOCATION
- O
CH B_LOCATION/B_DISEASE
intron O
suggests O
that O
several O
sequences O
are O
present O
which O
appear O
similar O
to O
important O
transcriptional O
regulatory O
elements O
found O
within O
JH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CH B_LOCATION/B_DISEASE
introns O
of O
higher O
vertebrates O
. O

The O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
consisted O
of O
31 B_MEASURE
with O
dilated B_DISEASE
cardiomyopathy I_DISEASE
, O
22 B_MEASURE
with O
hypertrophic B_DISEASE
cardiomyopathy I_DISEASE
, O
38 B_MEASURE
with O
myocardial B_DISEASE
infarction I_DISEASE
, O
15 B_MEASURE
with O
angina B_DISEASE
pectoris I_DISEASE
and O
26 B_NUMBER[MEASURE]
with O
rheumatic B_DISEASE/B_PERSON
valvular I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
. O

100 B_NUMBER[MEASURE]
. O

However O
, O
the O
pre3 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
strengthened O
phenotypes O
induced O
by O
other O
20 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteasomal B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
the O
peptidylglutamyl O
peptide O
- O
hydrolyzing O
activity O
has O
to O
fulfill O
some O
rescue O
functions O
. O

Whereas O
Sprague B_PERSON
- O
Dawleys B_MEASURE/B_PERSON
displayed O
lights B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
off B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lights B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
on O
peaks B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ingestive B_DISEASE/B_ORGANISM_FUNCTION
activity B_DISEASE/I_ORGANISM_FUNCTION
, O
only O
a O
minority B_PERSON/B_MEASURE
of O
Fisher B_PERSON/B_LOCATION
- O
344s B_PERSON
displayed O
a O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lights I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
on O
peak B_MEASURE
of O
ingestive B_DISEASE/B_ORGANISM_FUNCTION
activity B_DISEASE/I_ORGANISM_FUNCTION
. O

Results B_MEASURE
: O
In O
76 B_MEASURE/B_SPORT[ENT]
trials I_MEASURE/I_SPORT[ENT]
, O
5 B_MEASURE
, O
351 B_MEASURE
patients I_MEASURE
received O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
different I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
tro B_GENE/B_LOCATION
operon I_GENE/I_LOCATION
is O
flanked O
by O
a O
Holliday B_GENE
structure I_GENE
DNA I_GENE
helicase I_GENE
homolog O
( O
upstream O
) O
and O
two O
ORFs O
representing O
a O
purine B_ENZYME[GENE]/B_SPECIES[BIO]
nucleoside B_ENZYME[GENE]/I_SPECIES[BIO]
phosphorylase B_ENZYME[GENE]/I_SPECIES[BIO]
homolog O
and O
tpp15 B_GENE/B_LOCATION
, O
a O
previously O
characterized O
gene O
encoding O
a O
membrane O
lipoprotein O
( O
downstream O
) O
. O

We O
report O
nine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consecutive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
ACB B_DISEASE/B_GENE
, O
which O
occurred O
in O
five B_PERSON
males I_PERSON
and O
four B_PERSON
females I_PERSON
and O
were O
detected O
in O
11 B_MEASURE
, O
159 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
routine I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spiral I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examinations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
chest B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
performed O
between O
1994 B_MEASURE
and O
1998 B_MEASURE
. O

In O
order O
to O
search O
for O
mutations O
in O
the O
multicopy B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RBM I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
might O
be O
associated O
with O
male O
infertility O
, O
we O
have O
used O
sequence O
data O
from O
the O
reported O
cDNA O
clone O
to O
determine O
the O
intron O
exon O
boundaries O
of O
the O
YRRM B_GENE
1 I_GENE
gene I_GENE
. O

98 B_MEASURE
, O
93 B_MEASURE
- O
98 B_MEASURE
) O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
excretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
selenium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
feces B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O
distribution B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
organs B_BODY_PART_OR_ORGAN_COMPONENT
of O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
radioactivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pharmacokinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
t1 B_LOCATION/B_PROTEIN[GENE]
/ O
2 B_NUMBER[MEASURE]
and O
Cltp B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
as O
indices B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
elimination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
ability I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O
discussed O
. O

Gastric B_DISEASE
secretory I_DISEASE
inhibition I_DISEASE
induced O
by O
three B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
methyl I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
analogs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
administered O
intragastrically O
to O
man B_PERSON/B_SPECIES[BIO]
. O

By O
RT O
- O
PCR O
, O
different O
levels O
of O
E75 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
can O
be O
detected O
in O
the O
epidermis O
, O
nerve O
cord O
and O
the O
eyestalk O
of O
early O
pre O
- O
molt O
shrimp O
. O

The O
vicinity B_LOCATION
of O
large B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
industrial I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
emissions I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
lead B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
where O
mean B_MEASURE/B_PROTEIN[GENE]
Pb B_MEASURE/I_PROTEIN[GENE]
- O
B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
usually O
twice O
as O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
as O
in O
rural B_LOCATION/B_MEASURE
areas I_LOCATION/I_MEASURE
of O
the O
Katowice B_LOCATION
voivodship I_LOCATION
. O

Forty B_NUMBER[MEASURE]
- O
five B_NUMBER[MEASURE]
per O
cent B_MEASURE
of O
the O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
excreted O
as O
methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
as O
opposed O
to O
18 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
normally O
seen O
after O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
methyldopa I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dosages I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

No O
cleavage O
of O
gp B_GENE
130 I_GENE
was O
observed O
in O
analogous O
pulse O
- O
chase O
radiolabelling O
of O
Ad O
- O
gB B_LOCATION/B_DISEASE
- O
infected O
human O
fibroblasts O
, O
even O
though O
these O
cells O
are O
permissive O
for O
HCMV O
replication O
and O
can O
process O
the O
native B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
phylogenetic O
comparison O
of O
32 O
species O
showed O
minor O
differences O
in O
the O
apoB B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
apoB B_GENE
mRNA I_GENE
from O
31 O
species O
was O
robustly O
edited O
in O
vitro O
. O

The O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
five B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
within O
the O
SRO B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
may O
provide O
an O
entrance B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
cloning B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
candidate B_GENE
genes I_GENE
for O
neuroblastoma B_DISEASE
. O

Sugar O
analysis O
was O
performed O
on O
alpha B_BIO/B_GENE
- I_BIO/I_GENE
TM I_BIO/I_GENE
to O
investigate O
a O
possible O
biosynthetic O
mechanism O
for O
part O
- O
time O
PGs O
. O

Pediatric B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
- O
- O
handle B_PERSON
with O
care B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
include O
the O
genes O
, O
undefined B_PROTEIN[GENE]
1 I_PROTEIN[GENE]
( O
UD1 B_GENE/B_DISEASE
) O
, O
UD2 B_GENE/B_DISEASE
, O
and O
UD3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B_PERSON/B_GENE
gene I_PERSON/I_GENE
encoding O
a O
new O
Kruppel B_ENZYME[GENE]
- I_ENZYME[GENE]
like I_ENZYME[GENE]
putative I_ENZYME[GENE]
transcription I_ENZYME[GENE]
factor I_ENZYME[GENE]
, O
the O
fly O
homologues O
of O
the O
mammalian B_ENZYME[GENE]/B_BIO
mitochondrial I_ENZYME[GENE]/I_BIO
trifunctional I_ENZYME[GENE]/I_BIO
enzyme I_ENZYME[GENE]/I_BIO
( O
thiolase B_LOCATION/B_GENE
) O
, O
and O
the O
TAR B_BIO/B_GENE
DNA I_BIO/I_GENE
- I_BIO/I_GENE
binding I_BIO/I_GENE
protein I_BIO/I_GENE
- I_BIO/I_GENE
43 I_BIO/I_GENE
( O
TBPH B_DISEASE/B_GENE
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B_GENE
4 I_GENE
superfamily I_GENE
( O
TM4SF B_GENE/B_MEASURE
) O
gene O
, O
a O
new O
homeodomain B_GENE/B_BIO
gene I_GENE/I_BIO
, O
and O
a O
gene O
coding O
for O
a O
putative O
nuclear O
binding O
protein O
( O
PNBP O
) O
that O
is O
homologous O
to O
maleless B_PERSON/B_BIO
, O
and O
a O
Copia B_GENE/B_BIO
- I_GENE/I_BIO
like I_GENE/I_BIO
element I_GENE/I_BIO
. O

TRAF2 B_GENE/B_DISEASE
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B_PROTEIN[GENE]/B_MEASURE
factor I_PROTEIN[GENE]/I_MEASURE
kappaB I_PROTEIN[GENE]/I_MEASURE
( O
NFkappaB B_GENE/B_LOCATION
) O
and O
the O
c B_GENE
- I_GENE
Jun I_GENE
N I_GENE
- I_GENE
terminal I_GENE
kinase I_GENE
/ O
stress B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
JNK B_GENE/B_LOCATION
/ O
SAPK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B_GENE
factor I_GENE
activating I_GENE
protein I_GENE
1 I_GENE
( O
AP1 B_GENE/B_DISEASE
) O
mainly O
via O
phosphorylation O
of O
the O
c B_GENE
- I_GENE
Jun I_GENE
component O
. O

A O
procaryotic O
regulatory O
factor O
with O
a O
histone B_GENE
H1 I_GENE
- I_GENE
like I_GENE
carboxy I_GENE
- I_GENE
terminal I_GENE
domain I_GENE
: O
clonal O
variation O
of O
repeats O
within O
algP B_GENE
, O
a O
gene O
involved O
in O
regulation O
of O
mucoidy O
in O
Pseudomonas O
aeruginosa O
. O

The O
host O
range O
( O
HR O
) O
of O
poliovirus O
is O
thought O
to O
be O
primarily O
determined O
by O
a O
cell O
surface O
molecule O
that O
functions O
as O
poliovirus B_GENE/B_BIO
receptor I_GENE/I_BIO
( O
PVR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
since O
it O
has O
been O
shown O
that O
transgenic O
mice O
are O
made O
poliovirus O
sensitive O
by O
introducing O
the O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PVR I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
into O
the O
genome O
. O

Human B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohol I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ADH B_DISEASE/B_GENE
) O
exists O
as O
a O
heterogeneous O
group O
of O
isozymes O
capable O
of O
oxidizing O
a O
wide O
variety O
of O
aliphatic O
and O
aromatic O
alcohols O
. O

The O
control O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aromatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
is O
complex O
in O
that O
several O
promoters O
drive O
aromatase B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
in O
a O
tissue O
- O
specific O
manner O
. O

In O
addition B_MEASURE/B_LOCATION
, O
renal B_DISEASE/B_GENE
sympathetic B_DISEASE/I_GENE
activity B_DISEASE/I_GENE
was O
measured O
in O
a O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
rats B_BIO/B_PERSON
. O

This O
incompatibility O
phenotype O
requires O
the O
global O
transcriptional O
repressor O
, O
KorB B_GENE/B_BACTERIUM[BIO]
, O
and O
the O
target O
for O
incC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
mediated O
incompatibility O
is O
a O
KorB B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
site I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

bodily O
referents B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
the O
experience B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
affect B_DISEASE/B_PERSON
. O

The O
effect O
of O
the O
negative O
regulatory O
element O
is O
negated O
by O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IE2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
L O
. O

RXRalpha B_GENE/B_LOCATION
/ O
RARalpha B_GENE
heterodimers O
and O
HNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O
to O
DR O
- O
1 O
motifs O
on O
elements O
B O
and O
I4 O
, O
respectively O
. O

Evidence O
for O
involvement O
of O
proteins O
HU B_GENE/B_DISEASE
and O
RpoS B_PROTEIN[GENE]/B_LOCATION
in O
transcription O
of O
the O
osmoresponsive O
proU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Escherichia O
coli O
. O

However O
, O
a O
lesser B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
noticed O
in O
nonpregnant B_PERSON/B_BIO
than O
seen O
in O
pregnant B_PERSON/B_DISEASE
rats I_PERSON/I_DISEASE
. O

Morphine B_PERSON/B_LOCATION
administration I_PERSON/I_LOCATION
acutely O
reduced O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
clearance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
sulfobromophthalein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BSP B_LOCATION/B_DISEASE
) O
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
increased O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retention B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
dye B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Buchstein B_PERSON
, O
L B_OTHER/B_PROTEIN[GENE]
. O
- O
L B_OTHER/B_PERSON
. O

Intraspinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
mediastinal B_DISEASE/B_LOCATION
foregut I_DISEASE/I_LOCATION
cyst I_DISEASE/I_LOCATION
compressing O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
nutraceuticals B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
minerals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
phytoestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
essential B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
supplementations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O
a O
vital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
component B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

characterization O
of O
a O
unique O
protein O
component O
of O
yeast B_SPECIES[BIO]/B_ENZYME[GENE]
RNase I_SPECIES[BIO]/I_ENZYME[GENE]
MRP I_SPECIES[BIO]/I_ENZYME[GENE]
: O
an O
RNA O
- O
binding O
protein O
with O
a O
zinc O
- O
cluster O
domain O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O
that O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
weak B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
advanced B_DISEASE/B_GENE
pancreatic I_DISEASE/I_GENE
cancer I_DISEASE/I_GENE
which O
seems O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
gemcitabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Like O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
envelope I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
intranuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
double I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lamellae I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
enclosed O
a O
defined O
cisterna B_LOCATION/B_MEASURE
that O
was O
interrupted O
by O
pores B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
but O
, O
unlike O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
envelope I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
pores I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O
they O
lacked O
NPCs B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

The O
22 B_NUMBER[MEASURE]
- O
d B_TIME[MEASURE]/B_LOCATION
orbital I_TIME[MEASURE]/I_LOCATION
flight I_TIME[MEASURE]/I_LOCATION
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
onboard O
the O
Cosmos B_LOCATION/B_PROTEIN[GENE]
- O
605 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biosatellite I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
followed O
by O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
erythroblastosis B_DISEASE_ADJECTIVE[DISEASE]
, O
alteration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
morphology B_MEASURE/B_ORGANIZATION
of O
megakaryocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
myelopoiesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

An O
OD B_MEASURE/B_LOCATION
650 I_MEASURE/I_LOCATION
greater I_MEASURE/I_LOCATION
than O
0 B_MEASURE
. O
15 B_MEASURE
appears O
to O
be O
a O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicator B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
fetal B_DISEASE
lung I_DISEASE
maturity I_DISEASE
. O

The O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Port B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
N2 B_DISEASE/B_LOCATION
tumours I_DISEASE/I_LOCATION
is O
not O
clear B_DISEASE_ADJECTIVE[DISEASE]
and O
may O
justify O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
concluded O
that O
RXR B_GENE
- I_GENE
gamma I_GENE
induced O
terminal O
differentiation O
in O
SCC O
lines O
, O
suggesting O
a O
potential O
tumor O
suppressor O
function O
for O
this O
transcription O
factor O
. O

Phosphorylated B_PERSON
tyrosine I_PERSON
residues I_PERSON
were O
subsequently O
identified O
by O
sequencing O
the O
separated O
phosphopeptides B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
matrix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assisted O
laser B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
desorption I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
ionization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
MALDI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
MS B_LOCATION/B_DISEASE
) O
and O
Edman B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
degradation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
. O

The O
infection O
of O
cells O
with O
Moloney O
murine O
leukemia O
virus O
( O
M O
- O
MuLV O
) O
causes O
an O
increase O
in O
specific O
cellular O
gene O
products O
, O
including O
the O
major B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
demonstrate O
that O
oleosin B_GENE
gene I_GENE
transcription O
is O
regulated O
in O
a O
tissue O
- O
specific O
and O
temporally O
regulated O
manner O
and O
clearly O
indicate O
that O
oleosin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
is O
co O
- O
ordinated O
primarily O
at O
the O
transcriptional O
level O
. O

Myocardial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technetium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
99m B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
teboroxime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
uptake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
during O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hyperemia B_DISEASE
in O
dogs B_BIO/B_PERSON
with O
either O
a O
critical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
coronary I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
stenosis I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
: O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
thallium B_LOCATION/B_DISEASE
- O
201 B_MEASURE/B_PERSON
and O
regional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blood I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flow I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

UICC B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
VM B_DISEASE/B_LOCATION
and O
35 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
for O
ve B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
not O
significant B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Although O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
CRP B_GENE
concentration O
increased O
, O
anemia O
obviously O
improved O
with O
hemoglobin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O
increasing O
from O
4 O
. O
8 O
g O
/ O
DL O
to O
8 O
. O
5 O
g O
/ O
DL O
without O
any O
side O
effects O
. O

Diff B_DISEASE/B_MEASURE
- O
Quik B_LOCATION/B_PERSON
stain I_LOCATION/I_PERSON
for O
Tzanck B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
smears B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Experience B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
using O
the O
Romashka B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
laser B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
unit B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
in O
treating O
suppurative B_DISEASE/B_GENE
wounds I_DISEASE/I_GENE
. O

At O
D28 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
149 B_MEASURE
of O
386 B_PERSON
patients I_PERSON
( O
49 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
had O
had O
episodes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
automatic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mode I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
switch I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prompted O
by O
atrial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrhythmias B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Together O
, O
these O
results O
implicate O
Fal1p B_GENE
in O
the O
18S B_GENE
rRNA I_GENE
maturation O
pathway O
rather O
than O
in O
translation O
initiation O
. O

Most B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
these O
two B_BIO/B_GENE
Leporipoxviruses B_BIO/I_GENE
are O
located O
in O
the O
telomeres B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

We O
challenge O
each O
of O
55 B_NUMBER[MEASURE]/B_PERSON
consecutive B_NUMBER[MEASURE]/I_PERSON
ragweed O
( O
RW B_LOCATION/B_PROTEIN[GENE]
) O
- O
allergic B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
with O
hay B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fever B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
with O
graded B_TIME[MEASURE]
increasing O
doses B_MEASURE
of O
ragweed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extract I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
investigate O
the O
frequency B_MEASURE/B_PERSON
and O
relationship B_PERSON/B_MEASURE
between O
the O
early B_DISEASE_ADJECTIVE[DISEASE]
( O
ER B_LOCATION/B_PROTEIN[GENE]
) O
, O
late O
( O
LPR B_LOCATION
) O
, O
and O
rechallenge B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
RCRs B_LOCATION/B_DISEASE
) O
to O
nasal O
challenge B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
expression O
of O
CAPL B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
second O
protein O
involved O
in O
calcium O
metabolism O
, O
was O
only O
moderately O
elevated O
in O
the O
doxorubicin O
- O
resistant O
cells O
. O

The O
central B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
the O
sarcomere B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
coincident B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O
the O
M B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
line I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
selectively O
labeled O
with O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
short B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
terminal B_LOCATION/B_MEASURE
form I_LOCATION/I_MEASURE
. O

Despite O
this O
dependency O
, O
however O
, O
a O
B B_DISEASE_ADJECTIVE[DISEASE]
. I_DISEASE_ADJECTIVE[DISEASE]
japonicum I_DISEASE_ADJECTIVE[DISEASE]
fixK I_DISEASE_ADJECTIVE[DISEASE]
mutant I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
have O
the O
phenotypic O
characteristics O
of O
B B_LOCATION/B_BIO
. I_LOCATION/I_BIO
japonicum I_LOCATION/I_BIO
fixL I_LOCATION/I_BIO
and O
fixJ B_DISEASE/B_LOCATION
mutants I_DISEASE/I_LOCATION
: O
the O
fixK B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O
neither O
fix O
- O
in O
symbiosis O
with O
soybean O
plants O
nor O
defective O
in O
anaerobic O
respiration O
with O
nitrate O
as O
the O
terminal O
electron O
acceptor O
. O

ANL B_MEASURE/B_PROTEIN[GENE]
- O
7535 B_MEASURE/B_LOCATION
. O

The O
QCS B_DISEASE
appears O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
MMSE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
is O
quicker B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
administer O
. O

We O
used O
high B_MEASURE/B_LOCATION
- O
resolution B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ultrasound B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
characterize O
postprandial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antral I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excursion I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
15 B_PERSON/B_BIO
healthy B_PERSON/I_BIO
volunteers B_PERSON/I_BIO
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Human B_GENE
PDNP3 I_GENE
is O
expressed O
in O
glioma O
cells O
, O
prostate O
, O
and O
uterus O
, O
but O
not O
in O
the O
alimentary O
tract O
. O

Epithelial B_PERSON
cells I_PERSON
had O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
accelerated B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exfoliation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
resulted O
in O
multifocal B_DISEASE
epithelial I_DISEASE
defects I_DISEASE
. O

tight O
- O
binding O
band B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
calculations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
beta B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
MNX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
M B_LOCATION
= O
Zr B_LOCATION/B_PERSON
, O
X B_OTHER/B_LOCATION
= O
Cl B_LOCATION
, O
BR B_LOCATION/B_PERSON
; O
M B_LOCATION
= O
Hf B_LOCATION
, O
X B_LOCATION
= I_LOCATION
Cl I_LOCATION
) O
, O
ZrCl B_LOCATION
, O
and O
Y B_OTHER/B_LOCATION
( O
2 B_NUMBER[MEASURE]
) O
C B_LOCATION/B_GENE
( O
2 B_NUMBER[MEASURE]
) O
BR B_LOCATION/B_ORGANIZATION
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
are O
reported O
. O

screening O
of O
a O
human O
foetal O
brain O
genomic O
DNA O
library O
allowed O
us O
to O
isolate O
an O
EcoRI B_GENE/B_DISEASE
- O
EcoRI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fragment O
containing O
6 O
kb O
of O
the O
5 O
' O
- O
flanking O
region O
, O
the O
open O
reading O
frame O
and O
4 O
kb O
of O
the O
3 O
' O
- O
flanking O
region O
of O
the O
alpha2C4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
psychosomatic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
approach I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
temporomandibular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arthrosis B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
rate O
of O
decrease O
of O
PRA O
after O
REM O
onset O
closely O
approximates O
the O
most O
recent O
estimations O
of O
PRA O
half O
- O
life O
, O
which O
suggests O
that O
REM O
onset O
is O
associated O
with O
a O
virtual O
cessation O
in O
renin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
. O

Similarly O
, O
interfering O
with O
MEKK B_GENE
, O
which O
lies O
upstream O
of O
JNK1 B_GENE
, O
using O
a O
dominant O
negative O
expression O
vector O
reduced O
MMP B_GENE
- I_GENE
9 I_GENE
promoter I_GENE
activity O
over O
the O
same O
concentration O
range O
which O
repressed O
the O
AP B_GENE
- I_GENE
1 I_GENE
- O
thymidine B_GENE
kinase I_GENE
CAT I_GENE
reporter O
construct O
. O

There O
was O
no O
difference O
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
transferrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
levels O
, O
but O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prealbumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O
in O
the O
group O
fed O
early O
were O
more O
desirable O
than O
those O
of O
the O
control O
group O
( O
from O
15 O
. O
8 O
+ O
/ O
- O
2 O
. O
5 O
mg O
/ O
DL O
to O
28 O
. O
9 O
+ O
/ O
- O
3 O
. O
8 O
mg O
/ O
DL O
vs O
from O
18 O
. O
0 O
+ O
/ O
- O
2 O
. O
0 O
mg O
/ O
DL O
to O
25 O
. O
9 O
+ O
/ O
- O
3 O
. O
9 O
mg O
/ O
DL O
) O
. O

The O
repeats B_GENE/B_DISEASE
are O
highly O
conserved O
both O
within O
a O
given O
element B_MEASURE/B_GENE
as O
well O
as O
between O
different B_PERSON/B_LOCATION
members I_PERSON/I_LOCATION
of O
the O
family B_PERSON/B_BIO
( O
less B_MEASURE
than O
10 B_MEASURE
% I_MEASURE
divergence I_MEASURE
) O
. O

utility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
thallium B_LOCATION/B_DISEASE
- O
201 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
detecting O
right B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
pulmonary B_DISEASE/B_PERSON
embolism I_DISEASE/I_PERSON
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
can O
be O
used O
as O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
detect O
air B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
trapping B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O
TGI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
carboxyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
terminal B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
75 B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
amino B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
acids B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
two B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contain O
the O
bHLH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differ O
from O
each O
other B_NUMBER[MEASURE]/B_PERSON
by O
only O
three B_NUMBER[MEASURE]/B_LOCATION
conservative I_NUMBER[MEASURE]/I_LOCATION
amino I_NUMBER[MEASURE]/I_LOCATION
acid I_NUMBER[MEASURE]/I_LOCATION
changes I_NUMBER[MEASURE]/I_LOCATION
, O
while O
the O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portions I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
are O
markedly O
divergent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
each O
other B_NUMBER[MEASURE]/B_PERSON
. O

In O
a O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
SAH B_DISEASE
, O
we O
assessed O
BBB B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
by O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O
14C B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
alpha B_PROTEIN[GENE]
- O
aminoisobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
technique B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Pollinosis B_BIO/B_TIME[MEASURE]
in O
the O
U B_OTHER/B_LOCATION
. O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O
R B_OTHER/B_LOCATION
. O

Northern O
blot O
analysis O
of O
enoyl B_GENE/B_BIO
- I_GENE/I_BIO
ACP I_GENE/I_BIO
reductase I_GENE/I_BIO
mRNA I_GENE/I_BIO
steady O
- O
state O
levels O
during O
seed O
development O
suggests O
that O
the O
increase O
in O
enzyme O
activity O
during O
the O
phase O
of O
storage O
lipid O
accumulation O
is O
regulated O
at O
the O
level O
of O
gene O
expression O
. O

Time B_TIME[MEASURE]/B_PERSON
between O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
usually O
less B_MEASURE
than O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
) O
did O
not O
affect O
the O
correlations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
but O
MMPI B_MEASURE/B_LOCATION
response I_MEASURE/I_LOCATION
- O
set B_MEASURE/B_LOCATION
variables I_MEASURE/I_LOCATION
( O
L B_OTHER/B_PROTEIN[GENE]
, O
F B_LOCATION/B_DISEASE
, O
K B_OTHER/B_LOCATION
, O
F B_PROTEIN[GENE]/B_DISEASE
- O
K B_OTHER/B_PROTEIN[GENE]
) O
did O
. O

The O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
binding O
( O
Kdapp B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
incorporation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
extension B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
kinetics B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
8 B_NUMBER[MEASURE]
- O
oxo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
dGTP B_PROTEIN[GENE]/B_LOCATION
compared O
to O
normal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dNTP I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
incorporation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
at O
template B_MEASURE
8 I_MEASURE
- O
oxo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
G B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adducts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O
that O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fidelity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
depend O
solely O
upon O
the O
overall B_LOCATION/B_MEASURE
geometry I_LOCATION/I_MEASURE
of O
Watson B_PERSON/B_LOCATION
- O
Crick B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
base I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
pairs I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O
reflects O
the O
asymmetry B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
the O
enzyme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
active I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
constant O
expression O
profile O
, O
coupled O
with O
the O
observation O
that O
over O
- O
expression O
of O
mSin3A B_GENE
does O
not O
augment O
the O
anti B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myc I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
of O
Mxi1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
SR O
in O
the O
rat O
embryo O
fibroblast O
( O
REF O
) O
transformation O
assay O
, O
suggests O
that O
mSin3A B_GENE
is O
not O
a O
limiting O
factor O
in O
the O
regulation O
of O
Myc B_GENE/B_BIO
superfamily I_GENE/I_BIO
function O
. O

The O
sequences O
at O
- O
10 O
and O
- O
35 O
relative O
to O
the O
transcriptional O
starting O
site O
showed O
55 O
% O
homology O
with O
the O
consensus O
sequences O
of O
the O
Escherichia B_GENE/B_BIO
coli I_GENE/I_BIO
sigma I_GENE/I_BIO
70 I_GENE/I_BIO
- I_GENE/I_BIO
type I_GENE/I_BIO
promoter I_GENE/I_BIO
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
subjected O
to O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
23 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
autopsies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
carried O
out O
in O
children B_PERSON/B_BIO
dying O
of O
intoxication B_DISEASE/B_PERSON
with O
Amanita B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
phalloides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

methods O
: O
The O
Die O
Deutsche O
diabetes O
Dialyse O
Studie O
is O
a O
prospective O
randomized O
placebo O
- O
controlled O
trial O
that O
tests O
the O
hypothesis O
that O
atorvastatin O
, O
a O
hydroxymethyl B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutaryl I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reductase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
, O
decreases O
the O
rate O
of O
cardiovascular O
mortality O
and O
of O
nonfatal O
myocardial O
infarction O
in O
patients O
with O
type O
2 O
diabetes O
who O
have O
been O
on O
hemodialysis O
treatment O
for O
no O
more O
than O
two O
years O
. O

There O
was O
no O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amiodarone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
desethylamiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
dosage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
monaural B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
middle B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ear B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
destruction B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
postnatal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
mouse B_DISEASE/B_PERSON
inferior I_DISEASE/I_PERSON
colliculus I_DISEASE/I_PERSON
. O

This O
unusual O
behaviour O
may O
be O
explained O
by O
the O
18 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CDR B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H3 B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
could O
be O
of O
value O
in O
the O
design O
of O
' O
single O
domain O
' O
antibodies O
. O

A O
definitive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
answer I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O
the O
question B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
must O
come O
from O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_LOCATION
in O
whom O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
/ O
benefit B_DISEASE_ADJECTIVE[DISEASE]
ratio I_DISEASE_ADJECTIVE[DISEASE]
of O
thrombolysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
unacceptably O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
in O
whom O
electrocardiographic B_DISEASE/B_LOCATION
criteria B_DISEASE/I_LOCATION
of O
infarction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
unequivocal B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
in O
whom O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
be O
initiated O
early O
after O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
symptoms B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
regimens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
will O
induce O
not O
only O
early B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recanalization I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
also O
sustained O
patency B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
infarct B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
related O
arteries B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sperm B_MEASURE/B_LOCATION
quality I_MEASURE/I_LOCATION
were O
evaluated O
before O
and O
after O
freezing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
/ O
thawing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

It O
has O
also O
been O
previously O
demonstrated O
that O
LPS O
treatment O
of O
splenic O
B O
cells O
from O
athymic O
mice O
results O
in O
a O
decrease O
in O
steady O
state O
mRNA O
encoding O
the O
A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Amongst B_MEASURE/B_LOCATION
53 I_MEASURE/I_LOCATION
' O
inoperable B_DISEASE_ADJECTIVE[DISEASE]
' O
( O
T4 B_PROTEIN[GENE]/B_DISEASE
, O
N0 B_PROTEIN[GENE]
, O
N1 B_PROTEIN[GENE]
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
, O
N2 B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
N3 B_PROTEIN[GENE]/B_DISEASE
) O
cases B_PERSON/B_DISEASE
, O
5 B_MEASURE
( O
10 B_MEASURE
% I_MEASURE
) O
had O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_NUMBER[MEASURE]
a O
doubtful B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Chemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
antibiotic B_MEASURE/B_PROTEIN[GENE]
SF I_MEASURE/I_PROTEIN[GENE]
- O
837 B_NUMBER[MEASURE]
. O

aspirin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
rheumatic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
diseases I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Is O
conventional B_TIME[MEASURE]/B_LOCATION
sperm I_TIME[MEASURE]/I_LOCATION
analysis I_TIME[MEASURE]/I_LOCATION
of O
any O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
computerised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
867 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
couples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
used O
to O
investigate O
the O
prognostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
semen B_MEASURE/B_PERSON
volume I_MEASURE/I_PERSON
, O
motility B_MEASURE/B_COLOR
, O
density B_MEASURE/B_PERSON
and O
morphology B_MEASURE/B_DISEASE
. O

It O
was O
observed O
that O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
IPC B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
24 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
% I_MEASURE
) O
and O
preischemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
LMK I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
21 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
% I_MEASURE
) O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
were O
smaller B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
than O
that O
in O
the O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
42 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
% I_MEASURE
) O
. O

High O
- O
affinity O
binding O
was O
also O
observed O
with O
recombinant B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH2 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
v B_GENE
- I_GENE
src I_GENE
and O
v B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fps I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
raising O
the O
possibility O
of O
protein O
- O
protein O
interactions O
between O
various O
members O
of O
the O
cytoplasmic B_GENE/B_BIO
PTK I_GENE/I_BIO
family I_GENE/I_BIO
. O

Mutational O
analysis O
of O
the O
putative O
effector O
domain O
of O
the O
GTP B_GENE/B_BIO
- I_GENE/I_BIO
binding I_GENE/I_BIO
Ypt1 I_GENE/I_BIO
protein I_GENE/I_BIO
in O
yeast O
suggests O
specific O
regulation O
by O
a O
novel O
GAP B_LOCATION/B_GENE
activity O
. O

The O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
with O
DBM B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
further O
qualified O
by O
a O
three B_NUMBER[MEASURE]
- O
way B_MEASURE
interaction I_MEASURE
that O
limited O
this O
pattern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
participants B_PERSON
scoring O
higher O
on O
self B_PERSON/B_DISEASE
- O
deception B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
broad O
range O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
genistein O
and O
the O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O
wortmannin O
and O
LY O
294002 O
( O
2 O
- O
( O
4 O
- O
morpholinyl O
) O
- O
8 O
- O
phenyl O
- O
4H O
- O
1 O
- O
benzopyran O
- O
4 O
- O
one O
) O
also O
blocked O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O
of O
p42 B_GENE
/ O
p44 B_MEASURE/B_GENE
MAPK O
. O

surprisingly O
, O
although O
Mist1 B_GENE/B_LOCATION
binds O
to O
E O
- O
boxes O
in O
vivo O
, O
the O
Mist1 B_GENE/B_BIO
protein I_GENE/I_BIO
lacks O
a O
functional O
transcription O
activation O
domain O
. O

As O
exogenously O
expressed O
PKR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
form O
heterodimers O
with O
endogenous B_GENE
PKR I_GENE
, O
the O
results O
obtained O
on O
the O
functional O
characterization O
of O
mutant O
forms O
of O
PKR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
taken O
with O
caution O
. O

Orlistat O
is O
a O
specific O
lipase B_GENE
inhibitor O
that O
impairs O
fat O
absorption O
, O
thereby O
reducing O
fat O
uptake O
. O

The O
metalloproteinase B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediating O
Met B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cleavage O
was O
specifically O
inhibited O
by O
the O
tissue B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
by O
TIMP B_GENE
- I_GENE
1 I_GENE
or O
TIMP B_GENE
- I_GENE
2 I_GENE
. O

This O
demonstrates O
a O
relative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
given O
synchronizer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
rhythmicity B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
at O
a O
tissue B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
from O
any O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
higher B_LOCATION/B_PERSON
regulatory B_LOCATION/I_PERSON
center B_LOCATION/I_PERSON
. O

It O
is O
also O
conceivable O
that O
elevated O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
may O
cause O
hypertriglyceridaemia O
and O
possibly O
other O
abnormalities O
of O
lipid O
metabolism O
. O

flicker B_ENT/B_LOCATION
thresholds B_ENT/I_LOCATION
were O
measured O
from O
1 B_NUMBER[MEASURE]
to O
40 B_MEASURE
Hz I_MEASURE
with O
a O
vertical B_LOCATION/B_NUMBER[MEASURE]
- O
line B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
for O
the O
asynchrony B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thresholds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
clr1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O
the O
expression O
of O
the O
cryptic B_GENE
mating I_GENE
- I_GENE
type I_GENE
loci I_GENE
of I_GENE
fission I_GENE
yeast I_GENE
. O

Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ELISAs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
canine B_DISEASE
atopy I_DISEASE
. O

A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Instead O
, O
HBx B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
shown O
to O
activate O
the O
cyclin B_GENE/B_LOCATION
A I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
, O
induce O
cyclin B_GENE
A I_GENE
- O
cyclin B_GENE/B_DISEASE
- I_GENE/I_DISEASE
dependent I_GENE/I_DISEASE
kinase I_GENE/I_DISEASE
2 I_GENE/I_DISEASE
complexes O
, O
and O
promote O
cycling O
of O
growth O
- O
arrested O
cells O
into O
G1 O
through O
a O
pathway O
involving O
activation O
of O
Src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Growth B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O
its O
effects O
on O
the O
ovarian O
follicular O
cycle O
directly O
or O
by O
local O
production O
of O
insulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IGF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
) O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
the O
ESRD O
treatment O
modality O
on O
the O
quality O
of O
life O
in O
patients O
with O
Type O
I O
( O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent O
) O
diabetes O
mellitus O
. O

The O
subjects B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
started O
on O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
25 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
thrice O
daily O
. O

A O
Buddhist B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
view I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
abortion B_PERSON/B_LOCATION
. O

The O
arterial B_DISEASE/B_PROTEIN[GENE]
blood B_DISEASE/I_PROTEIN[GENE]
pressure B_DISEASE/I_PROTEIN[GENE]
was O
measured O
by O
using O
bloody B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
anesthizied B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

After O
15 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hemorrhage B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
cardiovascular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
the O
same B_MEASURE/B_LOCATION
in O
fed B_PERSON/B_DISEASE
and O
starved O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
at O
45 B_MEASURE
min I_MEASURE
striking I_MEASURE
differences I_MEASURE
were O
observed O
. O

Decidual B_TIME[MEASURE]/B_GENE
/ I_TIME[MEASURE]/I_GENE
trophoblast I_TIME[MEASURE]/I_GENE
prolactin I_TIME[MEASURE]/I_GENE
- I_TIME[MEASURE]/I_GENE
related I_TIME[MEASURE]/I_GENE
protein I_TIME[MEASURE]/I_GENE
: O
characterization O
of O
gene O
structure O
and O
cell O
- O
specific O
expression O
. O

Fluorescence O
in O
situ O
hybridization O
was O
used O
to O
investigate O
the O
physical O
distribution O
and O
revealed O
that O
both O
retrotransposon O
families O
are O
present O
on O
all O
sugar O
beet O
chromosomes O
and O
largely O
excluded O
from O
chromosomal O
regions O
harbouring O
the O
18S B_GENE/B_DISEASE
- O
5 B_MEASURE/B_LOCATION
. I_MEASURE/I_LOCATION
8S I_MEASURE/I_LOCATION
- O
25S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rRNA O
genes O
. O

plasma B_LOCATION/B_PROTEIN[GENE]
NE I_LOCATION/I_PROTEIN[GENE]
and O
E B_OTHER/B_PROTEIN[GENE]
increased O
to O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
values B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
after O
15 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
the O
young B_PERSON/B_TIME[MEASURE]
subjects I_PERSON/I_TIME[MEASURE]
: O
1 B_MEASURE
. O
68 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
18 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O

An O
insertion O
sequence O
element O
( O
IS1170 O
) O
was O
identified O
upstream O
of O
the O
nimC B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
organelles O
synthesize O
their O
own O
set O
of O
Fe B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
they O
initiate O
the O
generation O
of O
extramitochondrial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Fe I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Most O
significantly O
, O
the O
cyclin B_GENE
E I_GENE
- O
Cdk2 B_GENE
complex O
is O
maximally O
active O
at O
the O
G1 O
/ O
S O
transition O
, O
and O
overexpression O
of O
cyclin B_GENE
E I_GENE
decreases O
the O
time O
it O
takes O
the O
cell O
to O
complete O
G1 O
and O
enter O
S O
phase O
. O

A O
genomic O
clone O
of O
the O
chicken B_GENE
osteopontin I_GENE
- I_GENE
encoding I_GENE
gene I_GENE
( O
opn B_GENE
) O
was O
isolated O
and O
found O
to O
be O
organized O
as O
follows O
: O
an O
untranslated O
5 O
' O
exon O
; O
a O
signal O
peptide O
; O
a O
recognition O
sequence O
for O
phosphorylation O
by O
casein B_GENE
kinase I_GENE
II I_GENE
; O
a O
domain O
containing O
a O
possible O
O O
- O
linkage O
site O
for O
glycosylation O
; O
a O
second O
casein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
an O
exon O
containing O
three O
functional O
regions O
, O
the O
poly O
- O
Asp O
sequence O
of O
seven O
consecutive O
Asp O
residues O
, O
the O
RGD B_LOCATION/B_TIME[MEASURE]
integrin B_LOCATION/I_TIME[MEASURE]
recognition B_LOCATION/I_TIME[MEASURE]
site B_LOCATION/I_TIME[MEASURE]
and O
a O
potential O
N O
- O
linkage O
site O
for O
glycosylation O
; O
and O
a O
large O
C O
- O
terminal O
exon O
which O
also O
contains O
a O
potential O
N O
- O
linkage O
site O
for O
glycosylation O
. O

However O
, O
neither O
SF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
NGF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IB I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
binding O
as O
monomers O
, O
increases O
transcription O
. O

satisfactory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
also O
obtained O
between O
the O
in O
vivo B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
in O
vitro B_TIME[MEASURE]/B_ORGANIZATION
results I_TIME[MEASURE]/I_ORGANIZATION
. O

structural O
organization O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Elk1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
processed O
pseudogene B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Elk2 B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
cumulative B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
occlusions B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O
15 B_MEASURE
, O
30 B_MEASURE
, O
45 B_MEASURE
, O
and O
90 B_TIME[MEASURE]
min I_TIME[MEASURE]
, O
transmural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
needle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
biopsies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
taken O
from O
the O
ischemic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
area I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O
be O
analyzed O
for O
adenine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nucleotides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
nucleosides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
creatine B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
ultrastructural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
prevalence B_MEASURE
of O
ocular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O
adnexal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SCC B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
significantly O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
all O
hair B_MEASURE/B_PERSON
colors I_MEASURE/I_PERSON
when O
compared O
with O
bay B_LOCATION/B_COLOR
, O
brown B_PERSON/B_COLOR
, O
or O
black B_COLOR/B_BIO
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Seven B_PERSON
patients I_PERSON
were O
without O
a O
syndromic B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
treatments B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
R1 I_PROTEIN[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
R2 B_PROTEIN[GENE]
, O
feed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
was O
restricted O
by O
withholding O
concentrates B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_NUMBER[MEASURE]
and O
4 B_MEASURE
. O
5 B_MEASURE/B_PERSON
Mo I_MEASURE/I_PERSON
, O
respectively O
. O

In O
addition O
, O
while O
GCN1 B_GENE
is O
required O
in O
vivo O
for O
phosphorylation O
of O
eIF B_GENE
- I_GENE
2 I_GENE
alpha I_GENE
by O
GCN2 B_GENE
, O
cell O
extracts O
from O
gcn1 B_GENE/B_NUMBER[MEASURE]
delta I_GENE/I_NUMBER[MEASURE]
strains O
contained O
wild O
- O
type O
levels O
of O
GCN2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
eIF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
kinase O
activity O
. O

SCOF B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
localized O
to O
the O
nucleus O
but O
did O
not O
bind O
directly O
to O
either O
C O
- O
repeat O
/ O
dehydration O
( O
CRT O
/ O
DRE O
) O
or O
ABA O
responsive O
element O
( O
ABRE O
) O
, O
cis O
- O
acting O
DNA O
regulatory O
elements O
present O
in O
COR B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
suggest O
that O
the O
acceptor B_PROTEIN[GENE]
peptide I_PROTEIN[GENE]
binds O
the O
transferase B_ENZYME[GENE]
in O
a O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
like B_LOCATION
conformation I_LOCATION
and O
that O
penultimate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
side I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
steric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interactions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O
play O
a O
role B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
determining O
extent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
that O
a O
given O
Ser B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Thr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
is O
glycosylated O
. O

The O
concentration B_MEASURE
of O
vitamin B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B1 I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B2 B_PROTEIN[GENE]
and O
B6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
found O
to O
be O
9 B_MEASURE
. O
96 B_MEASURE
, O
9 B_MEASURE
. O
92 B_MEASURE
and O
3 B_MEASURE
. O
01 B_MEASURE
mg I_MEASURE
, O
respectively O
in O
240 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
capsule B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
powder I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
a O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
company I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
name B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
not O
been O
disclosed O
due O
to O
secrecy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
. O

Polymorphisms O
in O
the O
CCR5 B_GENE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
genes B_GENE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O
African O
green O
monkeys O
and O
mice O
implicate O
specific O
amino O
acids O
in O
infections O
by O
simian O
and O
human O
immunodeficiency O
viruses O
. O

Furthermore O
, O
we O
detect O
hCoch B_GENE/B_DISEASE
- I_GENE/I_DISEASE
5B2 I_GENE/I_DISEASE
on O
three O
overlapping O
YACs O
, O
two O
of O
which O
also O
contain O
one O
of O
the O
markers O
linked O
to O
DFNA9 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mCoch B_GENE/B_DISEASE
- I_GENE/I_DISEASE
5B2 I_GENE/I_DISEASE
was O
genetically O
mapped O
in O
the O
mouse O
to O
chromosome O
12 O
, O
in O
a O
region O
of O
homologous O
synteny O
with O
human O
14q11 O
. O
2 O
- O
q13 O
, O
which O
contains O
the O
asp1 B_PROTEIN[GENE]/B_DISEASE
( O
audiogenic B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
seizure B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
prone B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
) O
locus O
in O
the O
mouse O
. O

Absence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
nitroso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
( O
14C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
methomyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
under O
simulated O
stomach B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
conditions B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Although O
no O
detectable O
phenotypes O
are O
associated O
with O
a O
disruption O
allele O
of O
ABP1 B_GENE
, O
mutations O
that O
create O
a O
requirement O
for O
this O
protein O
have O
now O
been O
isolated O
in O
the O
previously O
identified O
gene B_GENE/B_BIO
SAC6 I_GENE/I_BIO
and O
in O
two O
new O
genes O
, O
SLA1 B_PROTEIN[GENE]/B_LOCATION
and O
SLA2 B_GENE/B_DISEASE
. O

The O
local B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
median B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ranges B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
the O
above B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
as O
follows B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
AMT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
: O
9 B_MEASURE
( O
6 B_SEQUENCE[MEASURE]
- O
10 B_MEASURE
) O
; O
CMMS B_LOCATION/B_DISEASE
: O
25 B_MEASURE
( O
16 B_MEASURE
- O
28 B_MEASURE
) O
; O
SBT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
2 B_MEASURE
( O
0 B_MEASURE
- O
10 B_MEASURE
) O
; O
WL B_DISEASE/B_PROTEIN[GENE]
- O
i B_DISEASE/B_PROTEIN[GENE]
: O
17 B_MEASURE
( O
8 B_MEASURE
- O
27 B_MEASURE
) O
; O
WL B_DISEASE/B_PROTEIN[GENE]
- O
d B_PROTEIN[GENE]/B_DISEASE
: O
5 B_MEASURE
( I_MEASURE
0 I_MEASURE
- O
10 B_MEASURE
) O
; O
WL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
r B_PROTEIN[GENE]/B_LOCATION
: O
9 B_MEASURE
( O
1 B_MEASURE
- O
10 B_MEASURE
) O
; O
ST B_LOCATION/B_DISEASE
: O
13 B_MEASURE
( O
6 B_MEASURE
- O
25 B_MEASURE
) O
; O
BNT B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
14 B_MEASURE
( O
10 B_MEASURE
- O
15 B_MEASURE
) O
; O
CPT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1 B_MEASURE
( O
0 B_MEASURE
- O
3 B_MEASURE
) O
; O
BDT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
19 B_MEASURE
( O
0 B_MEASURE
- O
42 B_MEASURE
) O
; O
OAT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
20 B_MEASURE
( O
3 B_MEASURE
- O
33 B_MEASURE
) O
. O

Antigen B_TIME[MEASURE]/B_LOCATION
dose I_TIME[MEASURE]/I_LOCATION
- O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
drawn O
, O
and O
the O
cumulative B_MEASURE/B_LOCATION
dose I_MEASURE/I_LOCATION
required O
for O
a O
35 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
reduction B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
specific B_DISEASE
airway I_DISEASE
conductance I_DISEASE
was O
calculated O
and O
designated O
Provocation B_MEASURE/B_LOCATION
dose B_MEASURE/I_LOCATION
( O
PD35 B_PROTEIN[GENE]/B_LOCATION
) O
. O

Cross O
- O
talk O
between O
transcription O
factors O
NF B_GENE
- I_GENE
kappa I_GENE
B I_GENE
and O
C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
transcriptional O
regulation O
of O
genes O
. O

elective B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
aortic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
root I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
Marfan B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
detergent O
- O
solubilized O
complex O
oxidizes O
caldariella O
quinol O
at O
high O
rates O
and O
is O
completely O
inhibited O
by O
cyanide O
and O
by O
quinolone O
analogs O
, O
potent O
inhibitors O
of O
quinol B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
characterized O
a O
new O
cDNA O
, O
33k O
- O
6 O
, O
potentially O
encoding O
a O
tobacco B_ENZYME[GENE]
33 I_ENZYME[GENE]
kDa I_ENZYME[GENE]
chloroplast I_ENZYME[GENE]
RNP I_ENZYME[GENE]
( I_ENZYME[GENE]
cp33 I_ENZYME[GENE]
) I_ENZYME[GENE]
homologue I_ENZYME[GENE]
. O

The O
regions B_GENE/B_DISEASE
encoding O
the O
mature B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
cloned O
into O
an O
expression B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
vector I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
recombinant B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
produced O
in O
Escherichia B_SPECIES[BIO]
coli I_SPECIES[BIO]
. O

Furthermore O
, O
CL100 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O
the O
[ O
val12 O
] O
ras B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
activation O
of O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
cell O
- O
free O
system O
from O
Xenopus O
oocytes O
. O

The O
Xenopus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeobox I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
twin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O
Wnt B_GENE
induction O
of O
goosecoid B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
establishment O
of O
Spemann O
' O
s O
organizer O
. O

Between O
1988 B_MEASURE
and O
1994 B_MEASURE
, O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
3 B_LOCATION
large I_LOCATION
sites I_LOCATION
revealed O
a O
3 B_NUMBER[MEASURE]
- O
5 B_MEASURE/B_LOCATION
fold I_MEASURE/I_LOCATION
increase I_MEASURE/I_LOCATION
in O
the O
prevalence B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
antidepressant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
ATD B_DISEASE/B_PROTEIN[GENE]
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
youths B_PERSON
aged O
2 B_NUMBER[MEASURE]
- O
19 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
. O

The O
vaccinia O
virus O
D6R B_GENE
open O
reading O
frame O
encodes O
the O
small O
subunit O
of O
the O
heterodimeric O
vaccinia B_ENZYME[GENE]/B_LOCATION
virus I_ENZYME[GENE]/I_LOCATION
early I_ENZYME[GENE]/I_LOCATION
transcription I_ENZYME[GENE]/I_LOCATION
factor I_ENZYME[GENE]/I_LOCATION
( O
VETF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
activates O
transcription O
of O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro O
. O

The O
Sensititre B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MIC I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
panels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
meropenem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
offer O
a O
convenient B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
valid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
NCCLS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
susceptibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
potential B_BACTERIUM[BIO]
pathogens I_BACTERIUM[BIO]
likely I_BACTERIUM[BIO]
to O
be O
recovered O
from O
mixed B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
infections I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Recognition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
single B_PERSON/B_NUMBER[MEASURE]
- O
chain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
derivatives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
phage B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
434 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
affinity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
depends O
on O
both O
the O
contacted O
and O
non O
- O
contacted O
base B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pairs B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
calls O
for O
standardized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
question I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
formats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
a O
centralized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
body I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
monitor O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
these O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
sexual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behaviour I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
show O
that O
GCNF B_GENE
binds O
to O
one O
of O
the O
two O
DRO O
sequences O
in O
the O
Prm1 B_GENE/B_BIO
promoter I_GENE/I_BIO
, O
and O
to O
the O
DRO O
sequence O
in O
the O
Prm2 B_GENE/B_MEASURE
promoter I_GENE/I_MEASURE
in O
a O
specific O
manner O
. O

139La B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NQR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relaxation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
microSR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Zn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
doping O
effects B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
La2CuO4 B_LOCATION/B_BIO
. O

The O
data O
also O
suggest O
that O
gamma B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CACCC I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
box I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
binding I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
factors I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mediate O
LCR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
interactions O
which O
normally O
enhance O
gamma B_GENE
- I_GENE
globin I_GENE
and O
suppress O
beta B_GENE
- I_GENE
globin I_GENE
gene I_GENE
expression O
in O
fetal O
erythroid O
cells O
. O

However O
, O
the O
in O
vivo B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attachment I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strength I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
CSTi B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
coating I_MEASURE
was O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O
to O
CSTi B_LOCATION/B_GENE
- O
1 B_NUMBER[MEASURE]
and O
to O
an O
HA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
coated O
control B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
after O
8 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Octamer O
recognition O
is O
mediated O
by O
the O
POU B_GENE/B_DISEASE
domain O
, O
a O
conserved O
structural O
motif O
which O
- O
- O
like O
the O
zinc O
finger O
and O
leucine O
zipper O
- O
- O
defines O
a O
family O
of O
related O
transcription O
factors O
. O

All O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
raised O
plasma B_MEASURE/B_GENE
testosterone I_MEASURE/I_GENE
concentrations I_MEASURE/I_GENE
above O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
pretreatment B_MEASURE
levels I_MEASURE
( O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
synovex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
; O
all O
P B_MEASURE
< I_MEASURE
0 I_MEASURE
. O
05 B_MEASURE
) O
. O

lifestyle B_PERSON
characteristics I_PERSON
were O
ascertained O
by O
a O
self B_PERSON/B_LOCATION
- O
administered O
questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
major O
promoter O
element O
of O
the O
Xenopus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
laevis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5S I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
located O
within O
the O
transcribed O
region O
of O
the O
gene O
and O
forms O
the O
binding O
site O
for O
the O
transcription O
initiation O
factor O
TFIIIA B_GENE/B_LOCATION
. O

During O
each O
step O
of O
the O
pulse O
infusion O
the O
osteocalcin B_GENE
responses O
to O
changes O
in O
CaI O
in O
general O
were O
parallel O
to O
the O
changes O
in O
PTH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
r O
= O
0 O
. O
462 O
; O
P O
= O
0 O
. O
02 O
) O
and O
were O
inversely O
correlated O
to O
CaI O
( O
r O
= O
- O
0 O
. O
562 O
; O
P O
= O
0 O
. O
003 O
) O
. O

The O
gamma B_GENE
- I_GENE
GCS I_GENE
gene I_GENE
is O
expressed O
ubiquitously O
and O
induced O
coordinately O
with O
NAD B_GENE
( I_GENE
P I_GENE
) I_GENE
H I_GENE
: I_GENE
quinone I_GENE
oxidoreductase I_GENE
( I_GENE
1 I_GENE
) I_GENE
( O
NQO1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
glutathione B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ya I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GST B_GENE
Ya I_GENE
) O
in O
response O
to O
xenobiotics O
and O
antioxidants O
. O

Interestingly O
, O
the O
expression O
of O
Id4 B_GENE
in O
Sertoli O
cells O
is O
only O
detectable O
after O
stimulation O
with O
FSH B_GENE
or O
Camp O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
YeeK B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
YxeE B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CotF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
YrbA B_LOCATION/B_GENE
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
betamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
duodenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1 B_MEASURE
, O
25 B_MEASURE
- O
dihydroxy B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
vitamin I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
D3 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
production I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
chick B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Furthermore O
, O
it O
is O
also O
established O
that O
serine O
phosphorylation O
of O
STAT5a B_GENE/B_PERSON
transactivation O
domain O
, O
via O
the O
MAPK B_GENE
pathway O
, O
is O
a O
means O
of O
modifying O
GH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
transcriptional O
activation O
. O

es O
cells O
in O
which O
the O
gene O
for O
the O
erythroid O
transcription O
factor O
GATA B_GENE
- I_GENE
1 I_GENE
has O
been O
disrupted O
fail O
to O
produce O
mature O
erythroid O
cells O
either O
in O
vivo O
or O
in O
vitro O
. O

Two B_MEASURE/B_LOCATION
conserved I_MEASURE/I_LOCATION
motifs I_MEASURE/I_LOCATION
, O
W89RKRRY94 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
P156KKIKP161 B_GENE/B_DISEASE
, O
seemed O
to O
act O
as O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
addressing O
signals B_PRODUCT[OBJECT]/B_LOCATION
. O

It O
is O
concluded O
that O
the O
predominant O
action O
of O
LSD O
on O
the O
female O
copulatory O
response O
is O
not O
mediated O
by O
increased O
dopamine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
but O
that O
the O
LSD O
effect O
might O
be O
modulated O
by O
decreased O
dopaminergic O
activity O
. O

Therefore O
, O
in O
VDR B_GENE
- O
mediated O
transcriptional O
activation O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
VDR B_GENE/B_LOCATION
alters O
the O
conformation O
of O
the O
ligand O
binding O
domain O
such O
that O
it O
: O
( O
i O
) O
engages O
in O
strong O
heterodimerization O
with O
RXR B_GENE/B_LOCATION
to O
facilitate O
VDRE O
binding O
, O
( O
ii O
) O
influences O
the O
RXR B_GENE/B_LOCATION
ligand I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
such O
that O
it O
is O
resistant O
to O
the O
binding O
of O
9 O
- O
cis O
RA O
but O
active O
in O
recruiting O
coactivator O
to O
its O
AF O
- O
2 O
and O
( O
III O
) O
presents O
the O
AF O
- O
2 O
region O
in O
VDR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for O
coactivator O
association O
. O

In O
patients O
, O
750 O
mL O
of O
saline O
lowered O
DL O
( O
CO O
) O
( O
- O
8 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
D O
( O
M O
) O
( O
- O
10 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
aldosterone O
( O
- O
29 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
renin B_GENE
( O
- O
52 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
and O
hematocrit O
( O
- O
6 O
% O
, O
P O
< O
0 O
. O
05 O
versus O
baseline O
) O
and O
increased O
V O
( O
C O
) O
( O
20 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
without O
changing O
rap O
and O
wpp O
. O

We O
have O
previously O
identified O
LIT1 B_GENE/B_LOCATION
, O
a O
paternally O
expressed O
antisense O
RNA O
within O
the O
KvLQT1 B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
locus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
through O
a O
positional O
screening O
approach O
using O
human O
monochromosomal O
hybrids O
. O

A O
series B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
deletion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
expressed O
transiently O
in O
two B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
hepatocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
HepG2 B_PERSON/B_PROTEIN[GENE]
and O
PLC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
FlaB2 B_GENE
polypeptide I_GENE
was O
92 O
% O
identical O
to O
that O
of O
T B_SPECIES[BIO]/B_GENE
. B_SPECIES[BIO]/I_GENE
pallidum B_SPECIES[BIO]/I_GENE
FlaB2 B_SPECIES[BIO]/I_GENE
, O
with O
a O
76 O
% O
identity O
at O
the O
nucleotide O
level O
. O

Comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O
that O
the O
5 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
peripheral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O
a O
75 B_MEASURE/B_LOCATION
- O
bp B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
near O
sequences B_LOCATION
associated O
with O
the O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
the O
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
strand B_GENE/B_LOCATION
replication I_GENE/I_LOCATION
. O

The O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
with O
a O
short B_DISEASE
bowel I_DISEASE
, O
even O
if O
they O
need O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
parenteral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
nutrition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
good B_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
resistance B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
fluoroquinolones B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
shown O
for O
both O
enterococci B_BACTERIUM[BIO]/B_LOCATION
and O
MRSA B_BACTERIUM[BIO]
. O

The O
5 O
' O
ends O
of O
the O
P B_OTHER/B_PROTEIN[GENE]
and O
O B_PROTEIN[GENE]/B_LOCATION
gene I_PROTEIN[GENE]/I_LOCATION
mRNAs I_PROTEIN[GENE]/I_LOCATION
are O
separated O
by O
109 O
nucleotide O
pairs O
in O
the O
DNA O
template O
. O

Using O
community B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
approaches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Biol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
cloned O
the O
cDNA O
for O
the O
SLBP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
humans O
, O
mice O
, O
and O
frogs O
, O
using O
the O
recently O
developed O
yeast O
three O
- O
hybrid O
system O
. O

Along O
with O
these O
species B_BIO
, O
F B_LOCATION/B_DISEASE
. O
graminearum B_BACTERIUM[BIO]/B_DISEASE
group I_BACTERIUM[BIO]/I_DISEASE
2 I_BACTERIUM[BIO]/I_DISEASE
( O
ZON B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Don B_PERSON/B_MEASURE
and O
/ O
or O
3AcDON B_MEASURE
or O
15AcDON B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
F B_LOCATION/B_DISEASE
. O
chlamydosporum B_BACTERIUM[BIO]/B_DISEASE
; O
F B_LOCATION/B_DISEASE
. O
acuminatum B_DISEASE/B_BACTERIUM[BIO]
( O
type B_DISEASE/B_MEASURE
- O
A B_BIO/B_PROTEIN[GENE]
trichothecene B_BIO/I_PROTEIN[GENE]
derivatives B_BIO/I_PROTEIN[GENE]
) O
; O
and O
F B_LOCATION/B_DISEASE
. O
semitectum B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
were O
often O
found O
to O
be O
associated O
. O

TGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
phosphorylation O
of O
Smad2 B_GENE
and O
Smad3 B_GENE
in O
Mv1Lu O
mink O
lung O
epithelial O
cells O
. O

There O
is O
little O
supportive O
evidence O
that O
ACE B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O
( O
captopril O
or O
enalapril O
) O
are O
teratogenic O
. O

Thus O
, O
the O
potential O
induction O
of O
this O
gene O
rearrangement O
by O
E1A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
is O
unlikely O
to O
be O
clinically O
significant O
in O
the O
treatment O
of O
advanced O
malignant O
disease O
. O

Although O
the O
cDNAs O
of O
HMG B_GENE
- I_GENE
14 I_GENE
and O
HMG B_MEASURE/B_GENE
- I_MEASURE/I_GENE
17 I_MEASURE/I_GENE
do O
not O
cross O
- O
hybridize O
, O
they O
have O
several O
similar O
structural O
features O
: O
the O
open O
reading O
frame O
comprises O
only O
23 O
% O
of O
the O
transcripts O
, O
the O
5 O
' O
- O
untranslated O
region O
is O
extremely O
GC O
rich O
whereas O
the O
3 O
' O
- O
untranslated O
region O
is O
unusually O
long O
and O
AT O
rich O
. O

Previously O
, O
we O
reported O
the O
identification O
of O
a O
23 O
- O
kD O
protein O
that O
interacts O
with O
zyxin B_GENE/B_BACTERIUM[BIO]
in O
vitro O
( O
Sadler O
et O
al O
. O
, O
1992 O
) O
. O

If O
vascular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
between O
a O
vascular B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
carrier I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
and O
the O
selected B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
jejunal I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
segment I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
is O
done O
as O
a O
kind B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
flap B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prefabrication I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
jejunal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interposition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flap I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
be O
used O
without O
the O
need B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O
complex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
microsurgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
gel O
mobility O
shift O
assays O
, O
high O
binding O
activities O
of O
ATPC B_GENE
- I_GENE
2 I_GENE
and O
low O
binding O
activities O
of O
CBF B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
levels O
, O
and O
the O
opposite O
was O
observed O
with O
extracts O
from O
tissues O
with O
high O
AtpC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
levels O
. O

activation O
of O
tyrosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
heterotrimeric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhanced O
the O
activities O
of O
both O
MEK B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
293 O
and O
PC12 O
cells O
. O

The O
Fugu O
rubripes O
( O
Fugu O
) O
gene O
fragment O
was O
used O
to O
isolate O
the O
GH B_GENE/B_BIO
gene B_GENE/I_BIO
from O
a O
Fugu O
genomic O
library O
. O

An O
in O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
glass I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stomach I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' O
( O
containing O
various B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
volumes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
hydrochloric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
HCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
and O
ammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NH4Cl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
was O
used O
to O
evaluate O
the O
means B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
increasing O
' O
gastric B_DISEASE/B_MEASURE
' O
pH B_MEASURE
to O
that O
of O
the O
NH4 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
> B_MEASURE
NH3 I_MEASURE
transition I_MEASURE
that O
occurs O
significantly O
at O
pH B_MEASURE
9 I_MEASURE
. O
24 B_MEASURE
. O

Acyclovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
used O
topically O
one B_NUMBER[MEASURE]/B_LOCATION
to O
five B_NUMBER[MEASURE]/B_ENT
times I_NUMBER[MEASURE]/I_ENT
a O
day B_TIME[MEASURE]
on O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ocular B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HSV B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infection B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
measured O
by O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
corneal B_DISEASE
involvement I_DISEASE
, O
conjunctivitis B_DISEASE
, O
iritis B_DISEASE
, O
and O
corneal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clouding I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
documented O
previously O
that O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
modulate O
the O
posttranslational B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cell B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
surface I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mouse I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
mammary I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
tumor I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MMTV B_VIRUS[BIO]/B_DISEASE
) O
glycoproteins B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
viral B_DISEASE/B_VIRUS[BIO]
- O
infected B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
M1 B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O
54 B_TIME[MEASURE]/B_DISEASE
rat I_TIME[MEASURE]/I_DISEASE
HTC I_TIME[MEASURE]/I_DISEASE
hepatoma I_TIME[MEASURE]/I_DISEASE
cell I_TIME[MEASURE]/I_DISEASE
line I_TIME[MEASURE]/I_DISEASE
. O

partial O
proteolysis O
of O
cell O
surface O
- O
iodinated O
B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
G I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O
extremely O
similar O
patterns O
of O
spots O
, O
both O
within O
and O
between O
haplotypes O
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
University B_LOCATION
research I_LOCATION
laboratory I_LOCATION
. O

There O
was O
a O
57 O
% O
reduction O
in O
IGF B_GENE
IR I_GENE
mRNA I_GENE
levels O
in O
clone O
CA9 O
after O
confluence O
compared O
with O
clone O
ME10 O
. O

Oligomers O
corresponding O
to O
the O
region O
of O
the O
mlc B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
/ I_GENE/I_LOCATION
3 I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
, O
which O
encompasses O
this O
conserved O
sequence O
, O
bound O
MEF B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
competed O
for O
its O
binding O
to O
the O
mck B_SPECIES[BIO]/B_GENE
enhancer O
. O

Similar O
tissue O
- O
specific O
patterns O
are O
observed O
with O
a O
fusion O
between O
the O
caufliflower B_GENE/B_BIO
mosaic I_GENE/I_BIO
virus I_GENE/I_BIO
35S I_GENE/I_BIO
RNA I_GENE/I_BIO
promotor I_GENE/I_BIO
and O
the O
GUS B_GENE
gene I_GENE
. O

This O
difference O
between O
SP B_GENE
- I_GENE
1 I_GENE
and O
SP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
due O
to O
their O
differential O
uptake O
by O
cell O
, O
since O
approximately O
100 O
times O
more O
SP B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
2 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
peptide I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
could O
be O
found O
in O
cytoplasmic O
extracts O
than O
SP B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
experiments O
using O
radiolabeled O
peptides O
. O

One O
function O
of O
p53 B_GENE
is O
in O
regulating O
cell O
cycle O
check O
- O
point O
control O
after O
DNA O
damage O
. O

We O
used O
event B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
functional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnetic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
fMRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
during O
a O
cued B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
spatial I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
attention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
dissociate O
brain B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
related O
to O
attentional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
from O
that O
related O
to O
selective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
target B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimuli I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
: O
The O
extract B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
medicinal B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
plants I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
containing O
curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
traditionally O
believed O
to O
have O
a O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contraction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
gall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
. O

Apoptosis O
triggered O
through O
Fas B_GENE
and O
F B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
inhibited O
by O
coexpression O
of O
CrmA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
p35 B_GENE
, O
but O
not O
Bcl B_GENE
- I_GENE
xL I_GENE
. O

The O
product O
of O
one O
gene O
, O
Bv80 B_GENE/B_LOCATION
, O
has O
a O
single O
divergent O
copy O
of O
a O
sequence O
of O
149 O
amino O
acids O
( O
approx O
. O

The O
1031 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
wild I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIT1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
contained O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
164 O
amino O
acids O
and O
the O
AGG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
arginine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complemented O
all O
hit1 B_DISEASE/B_GENE
- I_DISEASE/I_GENE
1 I_DISEASE/I_GENE
mutant I_DISEASE/I_GENE
phenotypes I_DISEASE/I_GENE
, O
indicating O
that O
the O
mutant O
phenotypes O
were O
caused O
by O
the O
deletion O
of O
these O
genes O
. O

We O
found O
a O
prevalence O
of O
eating O
disorders O
of O
5 O
. O
9 O
% O
( O
lifetime O
prevalence O
of O
10 O
% O
) O
, O
irrespective O
of O
gender O
and O
type O
of O
diabetes O
; O
4 O
. O
1 O
% O
of O
the O
whole O
sample O
reported O
intentional O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
undertreatment O
or O
omission O
. O

Tilisolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
carboxymethylcellulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CMC B_DISEASE
) O
were O
used O
as O
the O
model B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ophthalmic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
viscous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
polymer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
respectively O
. O

These O
results O
are O
discussed O
in O
the O
context O
of O
a O
model O
of O
the O
myogenic O
lineage O
that O
is O
based O
on O
the O
expression O
of O
desmin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
identified O
two O
potential O
phosphorylation O
sites O
at O
serine49 O
and O
serine133 O
, O
both O
of O
which O
seem O
to O
be O
necessary O
for O
Myf B_GENE/B_MEASURE
- I_GENE/I_MEASURE
5 I_GENE/I_MEASURE
activity O
. O

We O
constructed O
a O
series O
of O
chimeric O
genes O
containing O
part O
of O
the O
first O
exon O
and O
increasingly O
longer O
5 O
' O
flanking O
sequences O
of O
the O
ODC B_GENE
gene I_GENE
fused O
to O
either O
bacterial B_ENZYME[GENE]
chloramphenicol I_ENZYME[GENE]
acetyltransferase I_ENZYME[GENE]
( O
CAT B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
luciferase B_GENE
reporter I_GENE
genes I_GENE
. O

CVO2 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
saturation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
a O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
detecting O
blood B_DISEASE/B_GENE
loss I_DISEASE/I_GENE
. O

The O
gene O
encoding O
the O
Neisseria B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lactamica I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
III I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
M B_SPECIES[BIO]/B_GENE
. B_SPECIES[BIO]/I_GENE
NlaIII B_SPECIES[BIO]/I_GENE
) O
which O
recognizes O
the O
sequence O
CATG O
has O
been O
cloned O
and O
expressed O
in O
Escherichia O
coli O
. O

This O
latter O
complex O
reacts O
with O
an O
antibody O
to O
serum B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SRF B_GENE/B_LOCATION
) O
and O
exhibits O
the O
same O
binding O
characteristics O
as O
purified O
SRF B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
second B_PERSON/B_DISEASE
patient B_PERSON/I_DISEASE
was O
successfully O
treated O
with O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prostaglandin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

alignment O
of O
the O
rat B_GENE
and I_GENE
human I_GENE
WIN I_GENE
cDNAs I_GENE
and O
their O
comparison O
with O
mouse O
genomic O
sequence O
revealed O
that O
the O
WIN B_GENE/B_MEASURE
DNA I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
domain I_GENE/I_MEASURE
is O
encoded O
by O
four O
exons O
, O
two O
of O
which O
( O
exons O
4 O
and O
6 O
) O
are O
alternatively O
spliced O
to O
generate O
at O
least O
three O
classes O
of O
mRNA O
transcripts O
. O

In O
a O
pilot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
two B_PERSON/B_BIO
dogs I_PERSON/I_BIO
were O
given O
parenteral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rifampin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
and O
after O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
grafts B_PERSON
were O
preclotted O
with O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
that O
contained O
rifampin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
was O
suggested O
that O
there O
was O
a O
slight B_DISEASE/B_MEASURE
increase B_DISEASE/I_MEASURE
in O
inhibition B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
24 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
93 B_TIME[MEASURE]/B_PERSON
% I_TIME[MEASURE]/I_PERSON
) O
. O

A O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
blood B_MEASURE/B_LOCATION
flow I_MEASURE/I_LOCATION
of O
the O
mitral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
valve I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
devised O
. O

Here O
, O
we O
analyzed O
the O
interaction O
of O
the O
Lactococcus B_PROTEIN[GENE]
lactis I_PROTEIN[GENE]
Ll I_PROTEIN[GENE]
. I_PROTEIN[GENE]
LtrB I_PROTEIN[GENE]
group I_PROTEIN[GENE]
II I_PROTEIN[GENE]
intron I_PROTEIN[GENE]
endonuclease I_PROTEIN[GENE]
with O
its O
DNA O
target O
site O
by O
DNA O
footprinting O
and O
modification O
- O
interference O
approaches O
. O

Clinical B_PERSON/B_ORGANIZATION
trials I_PERSON/I_ORGANIZATION
bring O
informations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
pharmacology B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
epidemiology B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O

In O
several O
steps O
we O
converted O
the O
retinoid O
specific O
response O
element O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O
the O
vitamin O
D O
/ O
retinoic O
acid O
response O
element O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteocalcin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
immediate O
5 O
' O
- O
flanking O
region O
was O
GC O
- O
rich O
with O
3 O
SP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
- I_GENE/I_LOCATION
like I_GENE/I_LOCATION
and O
2 O
AP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
2 I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
identified O
in O
close O
proximity O
to O
the O
transcription O
start O
site O
. O

Akt B_GENE
- O
dependent O
antiapoptotic O
action O
of O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
sensitive O
to O
farnesyltransferase O
inhibitor O
. O

For O
all O
samples B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
sensitivity B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
blast B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
flag I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
CD3500 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
85 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
with O
a O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
91 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
STKS B_LOCATION/B_DISEASE
: O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
; O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
85 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
; O
the O
sensitivity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
CD3500 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IG B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flag B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
72 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
with O
a O
specificity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
STKS B_LOCATION/B_DISEASE
: O
sensitivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
75 B_LOCATION/B_PERSON
% I_LOCATION/I_PERSON
: O
specificity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
73 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
; O
and O
the O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
NRBC B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flag B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
43 B_MEASURE
% I_MEASURE
with O
a O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
STKS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sensitivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
37 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
88 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ovulation B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
in O
mares B_SPECIES[BIO]/B_LOCATION
in O
the O
early B_TIME[MEASURE]/B_LOCATION
breeding B_TIME[MEASURE]/I_LOCATION
season B_TIME[MEASURE]/I_LOCATION
with O
ovarian B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

reasons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
given O
for O
suggesting O
that O
tiapamil B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
warrants I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
which O
it O
may O
join O
the O
more O
established B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
valuable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapeutic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
central B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
venous I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
fat B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
embolism B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Two O
of O
the O
proteins O
UPRF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
1 I_GENE/I_DISEASE
and O
UPRF B_GENE
- I_GENE
2 I_GENE
( O
which O
is O
apparently O
a O
proteolytic O
degradation O
product O
of O
UPRF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
) O
bind O
inefficiently O
to O
mutant O
versions O
of O
the O
UPR O
that O
are O
unable O
to O
confer O
responsiveness O
to O
unfolded O
proteins O
to O
the O
( O
CYC1 B_GENE/B_SPECIES[BIO]
) O
promoter O
. O

identification O
of O
domains O
mediating O
transcription O
activation O
, O
repression O
, O
and O
inhibition O
in O
the O
paired B_GENE/B_BIO
- I_GENE/I_BIO
related I_GENE/I_BIO
homeobox I_GENE/I_BIO
protein I_GENE/I_BIO
, O
Prx2 B_GENE
( O
S8 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
spatial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
counting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
the O
location B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
and O
every O
PN B_LOCATION/B_PROTEIN[GENE]
and O
NP B_LOCATION/B_PROTEIN[GENE]
in O
the O
stratum B_LOCATION/B_MEASURE
pyramidale I_LOCATION/I_MEASURE
of O
sectors B_PROTEIN[GENE]/B_LOCATION
CA1 I_PROTEIN[GENE]/I_LOCATION
- O
4 B_MEASURE
was O
applied O
to O
11 B_MEASURE
normal I_MEASURE
control I_MEASURE
( O
CONs B_LOCATION/B_PROTEIN[GENE]
) O
and O
10 B_MEASURE/B_PERSON
SZs I_MEASURE/I_PERSON
matched O
for O
age B_TIME[MEASURE]/B_DISEASE
and O
postmortem B_MEASURE/B_DISEASE
interval I_MEASURE/I_DISEASE
, O
as O
well O
as O
4 B_DISEASE
manic I_DISEASE
depressive I_DISEASE
( O
MD B_DISEASE/B_PROTEIN[GENE]
) O
subjects B_PERSON/B_LOCATION
matched O
for O
age B_TIME[MEASURE]/B_PERSON
. O

analytical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoelectrofocusing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Upstream B_GENE
stimulatory I_GENE
factor I_GENE
USF I_GENE
is O
a O
human O
transcriptional O
activation O
factor O
, O
which O
uses O
a O
basic O
/ O
helix O
- O
loop O
- O
helix O
/ O
leucin O
zipper O
( O
b O
/ O
HLH O
/ O
Z O
) O
motif O
to O
homodimerize O
and O
recognize O
specific O
sequences O
in O
the O
promoter O
region O
of O
both O
nuclear O
and O
viral O
genes O
transcribed O
by O
RNA B_GENE/B_VIRUS[BIO]
polymerase B_GENE/I_VIRUS[BIO]
II B_GENE/I_VIRUS[BIO]
. O

43 O
% O
, O
6 O
/ O
14 O
; O
P O
= O
0 O
. O
013 O
) O
, O
whereas O
, O
in O
RCC O
samples O
with O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation O
or O
mutation O
, O
the O
frequency O
of O
3p14 O
- O
p21 O
LOH O
did O
not O
differ O
from O
that O
of O
sp25 O
- O
p26 O
( O
72 O
% O
, O
18 O
/ O
25 O
vs O
. O

sequences O
homologous O
to O
the O
consensus O
TUF B_GENE/B_LOCATION
- I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
UAS I_GENE/I_LOCATION
boxes I_GENE/I_LOCATION
are O
present O
in O
the O
5 O
' O
flanking O
regions O
of O
both O
genes O
. O

The O
analysis O
predicted O
that O
progressive O
increases O
in O
serum O
creatinine O
or O
aspartate B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transaminase I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
activity O
will O
result O
in O
only O
a O
50 O
% O
reduction O
of O
clearance O
. O

Results O
: O
Although O
low O
levels O
of O
vIRF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
detected O
in O
the O
HHV O
- O
8 O
- O
positive O
BCBL O
- O
1 O
tumor O
cell O
line O
, O
12 O
- O
0 O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
treatment O
does O
not O
stimulate O
expression O
of O
vIRF B_GENE/B_DISEASE
- I_GENE/I_DISEASE
2 I_GENE/I_DISEASE
gene I_GENE/I_DISEASE
together O
with O
primary O
lytic O
cycle O
genes O
. O

Central B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projections B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gastric B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
afferent B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
vagal B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
inputs B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

DNA O
sequence O
of O
the O
UL6 B_PROTEIN[GENE]/B_DISEASE
to O
UL20 B_MEASURE/B_GENE
genes I_MEASURE/I_GENE
of O
infectious O
laryngotracheitis O
virus O
and O
characterization O
of O
the O
UL10 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
product I_GENE/I_LOCATION
as O
a O
nonglycosylated O
and O
nonessential O
virion O
protein O
. O

Coimmunoprecipitation O
analysis O
suggests O
that O
these O
residues O
likely O
contribute O
to O
the O
multimerization O
function O
required O
for O
homomeric O
complex O
formation O
or O
heteromeric O
complex O
formation O
with O
p50 B_GENE
in O
that O
no O
association O
of O
p65 B_GENE
delta I_GENE
with O
itself O
or O
with O
p50 B_GENE
was O
evident O
. O

Cytostatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
some O
essential B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oils I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O
Hep B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_PROTEIN[GENE]/B_MEASURE
cells I_PROTEIN[GENE]/I_MEASURE
. O

A O
yeast O
mitochondrial O
translation O
initiation O
codon O
mutation O
affecting O
the O
gene O
for O
cytochrome B_GENE
oxidase I_GENE
subunit I_GENE
III I_GENE
( O
COX3 B_PROTEIN[GENE]/B_LOCATION
) O
was O
partially O
suppressed O
by O
a O
spontaneous O
nuclear O
mutation O
. O

Only O
the O
27 O
- O
kDa O
protein O
was O
detected O
after O
N B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycosidase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
indicating O
that O
PLP B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
glycoprotein O
. O

Moreover O
, O
we O
studied O
the O
relationship B_PERSON/B_MEASURE
between O
initial B_MEASURE/B_DISEASE
percentage B_MEASURE/I_DISEASE
of O
bone B_DISEASE
marrow I_DISEASE
plasma I_DISEASE
cells I_DISEASE
and O
prognosis B_DISEASE
. O

These O
results O
demonstrate O
that O
GGTase B_GENE
- I_GENE
I I_GENE
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B_GENE
in O
a O
p53 B_GENE/B_MEASURE
- O
independent O
manner O
and O
that O
FTase B_GENE/B_PERSON
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B_GENE
nor O
p27KIP B_GENE
. O

We O
report O
here O
on O
an O
eight B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
boy I_PERSON
who O
first O
developed O
acute B_DISEASE
intravascular I_DISEASE
hemolysis I_DISEASE
following O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Amb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
and O
subsequently O
a O
delayed B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hemolytic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transfusion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reaction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
alloantibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

The O
temporal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
organ B_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
was O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
clotting B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
potential O
biological O
significance O
of O
the O
identified O
structural O
motif O
shared O
by O
the O
human B_GENE
CCR5 I_GENE
, O
CCR3 B_GENE
, O
CCR2B B_GENE
and O
other O
GPCRs B_GENE/B_BIO
is O
discussed O
. O

Analysis O
of O
rat O
brain O
, O
heart O
, O
lung O
, O
liver O
, O
kidney O
and O
skeletal O
muscle O
revealed O
psi B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PKC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
zeta B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
in O
brain O
. O

The O
papers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
a O
broad B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
MPAs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
include O
social B_EDU[ORGANIZATION]/B_LOCATION
, O
economic B_EDU[ORGANIZATION]/B_LOCATION
, O
cultural B_EDU[ORGANIZATION]/B_PERSON
, O
biological B_EDU[ORGANIZATION]/B_PERSON
and O
statistical B_EDU[ORGANIZATION]/B_LOCATION
components I_EDU[ORGANIZATION]/I_LOCATION
. O

Management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
patients B_PERSON/B_DISEASE
with O
Ewing B_DISEASE
' I_DISEASE
s I_DISEASE
sarcoma I_DISEASE
has O
been O
discussed O
with O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
achieve O
an O
excellent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
local I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
radiation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
now O
that O
patients B_PERSON
are O
experiencing O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_MEASURE
survival I_MEASURE
. O

Furthermore O
, O
the O
rapid O
light O
- O
mediated O
increase O
of O
CPRF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
insensitive O
to O
transcriptional O
inhibitors O
, O
suggesting O
that O
a O
post O
- O
transcriptional O
mechanism O
controls O
CPRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
accumulation O
. O

In O
those O
patients O
who O
before O
transplantation O
were O
serological O
negative O
for O
CMV O
but O
had O
received O
organs O
from O
CMV B_DISEASE
- I_DISEASE
IgG I_DISEASE
positive O
donors O
, O
the O
incidence O
of O
the O
disease O
was O
highest O
. O

Since O
1985 O
the O
combination O
of O
chlorambucil O
( O
10 O
mg O
daily O
, O
initially O
for O
six O
weeks O
, O
then O
alternating O
fortnights O
for O
12 O
weeks O
) O
and O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2b I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Schering O
- O
Plough O
; O
2 O
x O
10 O
( O
6 O
) O
U O
/ O
m2 O
three O
times O
weekly O
by O
subcutaneous O
injection O
for O
18 O
weeks O
) O
has O
been O
compared O
in O
a O
randomised O
trial O
with O
chlorambucil O
alone O
in O
previously O
untreated O
patients O
with O
stage O
III O
or O
IV O
follicular O
lymphoma O
. O

The O
BDU B_LOCATION/B_PROTEIN[GENE]
neurons I_LOCATION/I_PROTEIN[GENE]
and O
the O
ALM B_LOCATION/B_DISEASE
touch I_LOCATION/I_DISEASE
neurons I_LOCATION/I_DISEASE
are O
lineal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sister I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cells I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
AB B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
a O
lineage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
the O
VA B_LOCATION/B_PROTEIN[GENE]
and O
VB B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
motor I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
are O
lineal B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sister I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
AB B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
p B_GENE/B_LOCATION
lineage I_GENE/I_LOCATION
. O

We O
compared O
retrospectively O
the O
efficacy O
of O
granulocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
G B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
alone O
with O
chemotherapy O
plus O
G B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CSF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mobilizing O
CD34 B_GENE
- O
positive O
cells O
in O
patients O
with O
malignant O
lymphoma O
. O

Serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
patients B_PERSON/B_BIO
classified O
as O
C B_OTHER/B_DISEASE
were O
characteristically O
and O
inclined B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
hypergonadotropic B_DISEASE_ADJECTIVE[DISEASE]
and O
hypoestrogenic B_DISEASE_ADJECTIVE[DISEASE]
. O

Cervical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
CT I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
revealed O
an O
irregular B_DISEASE/B_LOCATION
low I_DISEASE/I_LOCATION
density I_DISEASE/I_LOCATION
at O
the O
periphery B_LOCATION/B_MEASURE
of O
the O
cervical B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vertebra I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
from O
the O
C2 B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
C4 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
level I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

incorporation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
brought O
about O
a O
revised O
five B_NUMBER[MEASURE]
- O
year B_SEQUENCE[MEASURE]/B_LOCATION
survival I_SEQUENCE[MEASURE]/I_LOCATION
estimate I_SEQUENCE[MEASURE]/I_LOCATION
of O
55 B_DISEASE/B_GENE
percent I_DISEASE/I_GENE
. O

These O
motifs B_LOCATION/B_GENE
, O
and O
their O
cognate B_PERSON/B_GENE
transcription I_PERSON/I_GENE
factors I_PERSON/I_GENE
, O
appear O
to O
act O
in O
concert B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
partial B_MEASURE/B_GENE
redundancy I_MEASURE/I_GENE
, O
so O
that O
discrete B_PERSON/B_BIO
mutations I_PERSON/I_BIO
were O
only O
partially O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
reducing O
transcriptional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
now O
show O
that O
purified O
recombinant O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
PDGF B_GENE
can O
induce O
this O
binding O
activity O
which O
we O
have O
termed O
SIF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
for O
sis B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Statistical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
conservation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
laws I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
turbulent B_LOCATION/B_ORGANIZATION
transport I_LOCATION/I_ORGANIZATION
. O

expression O
of O
the O
bacteriophage B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T4 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminase I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yields O
multiple O
proteins O
. O

Erdheim B_LOCATION/B_DISEASE
- O
Chester B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
: O
a O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
lipoidosis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O
part B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
spectrum B_DISEASE/B_MEASURE
of O
histiocytosis B_DISEASE
. O

Erdheim B_LOCATION/B_PERSON
- O
Chester B_DISEASE/B_PERSON
disease I_DISEASE/I_PERSON
has O
always O
been O
considered O
a O
distinct B_DISEASE
lipoidosis I_DISEASE
based O
on O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
radiographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Self B_PERSON/B_LOCATION
- O
consistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
calculation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
surface B_MEASURE/B_LOCATION
electronic I_MEASURE/I_LOCATION
structure I_MEASURE/I_LOCATION
of O
the O
( O
1 B_MEASURE
x O
2 B_MEASURE
) O
reconstructed O
Au B_LOCATION
( O
110 B_TIME[MEASURE]/B_LOCATION
) O
surface B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
plasmid B_GENE
was O
found O
to O
confer O
drug B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
specifically O
to O
LMB B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_PERSON/B_ORGANIZATION
pharmacokinetic I_PERSON/I_ORGANIZATION
models I_PERSON/I_ORGANIZATION
were O
compared O
. O

A O
higher B_MEASURE/B_LOCATION
median I_MEASURE/I_LOCATION
proportion I_MEASURE/I_LOCATION
of O
spirochaetes B_DISEASE
was O
observed O
in O
sites B_LOCATION/B_PERSON
after O
diagnosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
attachment B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ocular B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injuries B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
general B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anesthesia I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Of O
81 B_NUMBER[MEASURE]/B_LOCATION
girls I_NUMBER[MEASURE]/I_LOCATION
cured O
from O
the O
bacteriuria B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
24 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BACTERIUM[BIO]
recurred O
, O
5 B_NUMBER[MEASURE]
with O
a O
symptomatic B_DISEASE
pyelonephritis I_DISEASE
and O
3 B_NUMBER[MEASURE]
with O
cystitis B_DISEASE
. O

The O
performances O
of O
two O
tests O
, O
the O
ProstAsure O
index O
and O
the O
percent O
free O
PSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
test O
, O
were O
evaluated O
in O
detecting O
cancer O
. O

The O
protein O
encoded O
by O
the O
NF2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
a O
similarity O
to O
ezrin B_GENE/B_BACTERIUM[BIO]
, O
radixin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
moesin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ERM B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
proteins O
that O
link O
membrane O
proteins O
to O
the O
cytoskeleton O
. O

patients B_PERSON/B_MEASURE
- O
- O
125 B_TIME[MEASURE]/B_LOCATION
women B_TIME[MEASURE]/I_LOCATION
consulting O
the O
general B_PERSON/B_LOCATION
practitioner B_PERSON/I_LOCATION
for O
symptomatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bacterial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vaginosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
the O
healing O
tendons O
, O
the O
rate O
of O
collagen B_GENE/B_DISEASE
synthesis O
decreased O
and O
the O
rate O
of O
noncollagen O
protein O
synthesis O
remained O
unchanged O
. O

From O
our O
own B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
phantoms B_ENT
, O
the O
smallest B_MEASURE/B_ENT
signal B_MEASURE/I_ENT
- O
to O
- O
noise B_MEASURE/B_ENT
ratio B_MEASURE/I_ENT
( O
delta B_MEASURE/B_PROTEIN[GENE]
S B_MEASURE/I_PROTEIN[GENE]
min B_MEASURE/I_PROTEIN[GENE]
/ O
delta B_MEASURE
R I_MEASURE
) O
was O
obtained O
which O
determines O
the O
minimal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
contrast I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
given O
the O
film B_MEASURE/B_ORGANIZATION
properties I_MEASURE/I_ORGANIZATION
( O
film B_MEASURE
response I_MEASURE
S I_MEASURE
, O
film B_MEASURE
gradient I_MEASURE
gamma I_MEASURE
) O
and O
the O
amount B_MEASURE/B_LOCATION
of O
scatter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

However O
, O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
binds O
preferentially O
to O
G B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_LOCATION/B_GENE
promoters B_LOCATION/I_GENE
, O
and O
another O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
appears O
to O
bind O
preferentially O
to O
only O
two B_NUMBER[MEASURE]/B_PERSON
of O
the O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tested O
. O

Cardiovascular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
man B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prizidilol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SK B_LOCATION/B_PROTEIN[GENE]
& O
F B_LOCATION/B_PERSON
92657 I_LOCATION/I_PERSON
) O
; O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antihypertensive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

From O
the O
Centers B_LOCATION/B_ORGANIZATION
for O
Disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
Prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

expression O
of O
a O
cDNA O
clone O
in O
yeast O
containing O
a O
large O
portion O
of O
the O
open O
reading O
frame O
produced O
cAMP B_GENE
PDEase I_GENE
activity O
identical O
in O
properties O
to O
the O
Drosophila O
enzyme O
affected O
by O
the O
dnc B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

FdsR B_GENE
purified O
to O
homogeneity O
after O
overexpression O
of O
fdsR B_GENE
in O
E O
. O
coli O
is O
a O
130 O
kDa O
homotetramer O
binding O
to O
the O
fds B_GENE/B_BIO
control O
region O
located O
between O
the O
fdsR B_GENE
and O
fdsG B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
. O

ZNS B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
mmolar B_BODY_PART_OR_ORGAN_COMPONENT
range I_BODY_PART_OR_ORGAN_COMPONENT
, O
scavenged O
hydroxyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
radicals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
dose B_MEASURE
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
orthologs O
of O
the O
Y B_GENE/B_MEASURE
( I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
) I_GENE/I_MEASURE
and O
Y B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
subtypes I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
display O
high O
amino O
acid O
sequence O
identities O
between O
pig O
, O
human O
, O
and O
mouse O
( O
92 O
% O
- O
94 O
% O
) O
, O
whereas O
the O
Y B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
Y B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
5 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
y B_MEASURE/B_BIO
( I_MEASURE/I_BIO
6 I_MEASURE/I_BIO
) I_MEASURE/I_BIO
subtypes I_MEASURE/I_BIO
display O
lower O
identities O
( O
76 O
% O
- O
87 O
% O
) O
. O

binding O
of O
ZAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
70 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
phospho O
- O
TAMs O
is O
notable O
for O
the O
high O
level O
of O
cooperativity O
between O
the O
two O
SH2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
individually O
demonstrate O
low O
affinity O
interaction O
with O
the O
ligand O
. O

The O
benzo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
pyrone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Venalot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
considerable B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
reducing O
the O
protein B_MEASURE/B_DISEASE
concentration B_MEASURE/I_DISEASE
in O
the O
air B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spaces I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
interstitial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
and O
of O
the O
oedema B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
latter B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
delivered O
in O
a O
single B_MEASURE
4 I_MEASURE
- O
mJ B_TIME[MEASURE]/B_LOCATION
pulse I_TIME[MEASURE]/I_LOCATION
of O
200 B_MEASURE/B_LOCATION
microseconds I_MEASURE/I_LOCATION
duration I_MEASURE/I_LOCATION
by O
means B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
articulated B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
zirconium I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fluoride I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
optical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fibre I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
320 B_NUMBER[MEASURE]
- O
microns B_MEASURE/B_LOCATION
quartz I_MEASURE/I_LOCATION
- O
fibre B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tip I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

perception B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sweetness B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cannot I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
be O
used O
to O
accurately O
meter O
the O
metabolizable B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
energy B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
nutritive B_MEASURE/B_BIO
value I_MEASURE/I_BIO
of O
a O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

The O
leader O
peptide O
was O
hypothesized O
to O
inhibit O
ribosome O
release O
at O
the O
tnaC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
stop I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
codon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
thereby O
blocking O
Rho B_GENE
' O
s O
access O
to O
the O
transcript O
. O

Response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
properties I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
single B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
units I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
accessory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
optic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
of O
the O
dark O
- O
reared O
cat B_SPECIES[BIO]/B_DISEASE
. O

excretion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
radiopharmaceuticals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
milk I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

influence O
of O
huanglian O
used O
in O
combination O
with O
huangqin O
and O
gancao O
on O
the O
erythrocytic O
osmotic O
fragilitas O
of O
experimental O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deficiency O
in O
rats O
] O
objective O
: O
To O
study O
the O
influence O
of O
common O
combination O
of O
Huanglian O
( O
Coptis O
chinensis O
) O
on O
the O
erythrocytic O
osmotic O
fragilitas O
of O
glucose B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
G6PD B_GENE/B_LOCATION
) O
deficiency O
in O
rats O
. O

The O
leukotriene B_GENE
receptor I_GENE
antagonist O
zafirlukast O
inhibits O
sulfur O
dioxide O
- O
induced O
bronchoconstriction O
in O
patients O
with O
asthma O
. O

This O
sequence O
was O
sufficient O
to O
confer O
p53 B_GENE
- O
dependent O
activation O
to O
a O
heterologous O
promoter O
and O
p53 B_GENE/B_LOCATION
was O
capable O
of O
binding O
to O
this O
sequence O
as O
assessed O
by O
gel O
shift O
analysis O
. O

The O
embryology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
vertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
column I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
is O
reviewed O
briefly O
, O
and O
the O
origin B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
anomaly O
of O
the O
C2 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
vertebra I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
is O
traced O
to O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
two B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
development B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
follows O
: O
1 B_SEQUENCE[MEASURE]
) O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
mesenchymal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
vertebra I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
or O
2 B_NUMBER[MEASURE]
) O
its O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O
cartilage B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Two B_NUMBER[MEASURE]/B_PERSON
of O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
were O
submitted O
to O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypoxia B_DISEASE
( O
FiO2 B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
05 B_MEASURE
, O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
F5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
FiO2 B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
1 B_MEASURE
, O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
F10 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
and O
the O
third B_SEQUENCE[MEASURE]/B_PERSON
to O
normoxia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
FiO2 B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE/B_LOCATION
. O
21 B_MEASURE
, O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F21 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
a O
thermoneutral B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
controlled B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
environment B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Parathyroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responses O
of O
cyclic O
AMP O
- O
, O
serum O
- O
and O
phorbol O
ester O
- O
responsive O
reporter O
genes O
in O
osteoblast O
- O
like O
UMR O
- O
106 O
cells O
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O
suggest O
that O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
origin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
a O
distant B_GENE
replication I_GENE
enhancer I_GENE
element I_GENE
requires O
a O
small B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
target I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
essential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
initiator B_GENE
protein I_GENE
- O
mediated O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
looping B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

HNF4alpha7 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
also O
found O
in O
totipotent O
embryonic O
stem O
cells O
. O

Penicillamine O
- O
induced O
myasthenia O
gravis O
associated O
with O
antibodies O
to O
acetylcholine B_GENE
receptor I_GENE
. O

Magnetic B_DISEASE/B_MEASURE
force I_DISEASE/I_MEASURE
and O
torque B_MEASURE/B_DISEASE
at O
1 B_MEASURE
. O
5 B_MEASURE/B_LOCATION
T I_MEASURE/I_LOCATION
did O
not O
dislodge O
the O
GF B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
result O
in O
perforation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
canine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
IVC I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
GF B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

LCCH1 B_GENE/B_PERSON
was O
identical O
to O
the O
Rdl B_GENE
gene I_GENE
, O
a O
known O
GABA B_GENE/B_PERSON
receptor I_GENE/I_PERSON
subunit I_GENE/I_PERSON
gene I_GENE/I_PERSON
from O
D O
. O
melanogaster O
, O
whereas O
LCCH2 B_GENE/B_PERSON
and O
LCCH3 B_PROTEIN[GENE]/B_MEASURE
were O
novel O
D O
. O
melanogaster O
sequences O
that O
exhibited O
structural O
similarity O
to O
other O
members O
of O
the O
ligand B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gated I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
chloride I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
channel I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
gene I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
family I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
gastric B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucosal B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeability B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
six B_PERSON/B_SPECIES[BIO]
normal I_PERSON/I_SPECIES[BIO]
human I_PERSON/I_SPECIES[BIO]
subjects I_PERSON/I_SPECIES[BIO]
after O
instillation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 B_MEASURE
percent I_MEASURE
v O
/ O
v B_OTHER/B_MEASURE
) O
. O

Using O
a O
simulated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cough I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
analyzed O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adding O
tensio B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
liquids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
sol B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulant I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
clearance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mucus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
cough B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

First O
, O
the O
amino O
- O
terminal O
regulatory O
arm O
of O
the O
GDI B_ENZYME[GENE]/B_BIO
binds O
to O
the O
switch O
I O
and O
II O
domains O
of O
Cdc42 B_GENE
leading O
to O
the O
inhibition O
of O
both O
GDP O
dissociation O
and O
GTP O
hydrolysis O
. O

By O
a O
combination O
of O
alternative O
promoter O
usage O
and O
exon O
splicing O
, O
each O
ROR B_GENE
gene I_GENE
generates O
several O
isoforms O
that O
differ O
only O
in O
their O
amino O
terminus O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
showed O
a O
rapid O
induction O
of O
nuclear O
proteins O
that O
bound O
to O
the O
consensus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Analysis O
of O
larger O
cDNA O
clones O
demonstrates O
that O
there O
are O
at O
least O
two O
isoforms O
of O
RIP14 B_GENE
that O
differ O
in O
the O
N O
- O
terminal O
( O
A O
and O
B O
) O
and O
hinge O
( O
D O
) O
domains O
. O

Multiple B_MEASURE/B_LOCATION
copies I_MEASURE/I_LOCATION
of O
this O
binding B_GENE/B_LOCATION
site I_GENE/I_LOCATION
are O
found O
in O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

During O
subsequent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
alone O
trials B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
( O
+ B_MEASURE/B_DISEASE
) O
Mk B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
801 B_NUMBER[MEASURE]
- O
injected O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
extinguished O
as O
easily O
as O
those O
of O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
injected O
mice B_BIO/B_PERSON
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
tail B_BODY_PART_OR_ORGAN_COMPONENT
deviated O
ipsilaterally O
in O
cats B_BIO/B_PERSON
with O
a O
hemisection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
the O
tail B_BODY_PART_OR_ORGAN_COMPONENT
was O
ventroflexed O
in O
cats B_BIO/B_PERSON
with O
a O
transection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
major O
open O
reading O
frame O
of O
the O
cDNA O
predicts O
a O
protein O
of O
59 O
kD O
, O
with O
a O
leucine O
zipper O
situated O
adjacent O
to O
an O
myc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
has O
been O
proposed O
to O
assume O
a O
helix O
- O
loop O
- O
helix O
structure O
. O

This O
residue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
although O
located O
55 B_MEASURE
rather O
than O
35 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
residues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
NH2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
terminal B_LOCATION/B_MEASURE
of O
the O
essential B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
is O
undoubtedly O
the O
analog B_MEASURE/B_LOCATION
of O
the O
second B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
35 B_MEASURE/B_LOCATION
- O
Glu B_LOCATION/B_MEASURE
motif I_LOCATION/I_MEASURE
found O
in O
other B_SPECIES[BIO]
family I_SPECIES[BIO]
members I_SPECIES[BIO]
. O

In O
addition O
to O
loss O
of O
digit O
identity O
and O
varying O
degrees O
of O
polydactyly O
, O
proximal O
skeletal O
elements O
are O
severely O
shortened O
in O
Xt B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
ld B_DISEASE/B_MEASURE
double O
homozygous O
limbs O
. O

The O
PEP4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
isolated O
from O
a O
genomic O
DNA O
library O
by O
complementation O
of O
the O
pep4 B_GENE/B_TIME[MEASURE]
- I_GENE/I_TIME[MEASURE]
3 I_GENE/I_TIME[MEASURE]
mutation O
. O

A O
gene O
with O
a O
high O
degree O
of O
sequence O
identity O
with O
mammalian B_GENE/B_BIO
ADP I_GENE/I_BIO
- I_GENE/I_BIO
ribosylation I_GENE/I_BIO
factors I_GENE/I_BIO
( O
ARFs B_DISEASE/B_GENE
) O
, O
believed O
to O
be O
important O
in O
vesicular O
transport O
, O
was O
identified O
. O

Off O
- O
shell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
Rydberg B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
atom B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
alkali B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
atom B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
scattering I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Short B_PERSON/B_MEASURE
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
rhythms B_DISEASE
, O
chaos B_PERSON/B_DISEASE
, O
or O
noise B_ENT/B_DISEASE
. O

Association B_ORGANIZATION/B_TIME[MEASURE]
between O
diaphragm B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
asymptomatic B_DISEASE
bacteriuria I_DISEASE
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
iron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
toxigenicity B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
of O
Vibrio B_BACTERIUM[BIO]/B_DISEASE
cholerae I_BACTERIUM[BIO]/I_DISEASE
. O

The O
Tat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coded O
by O
human O
immunodeficiency O
virus O
( O
HIV O
) O
is O
a O
strong O
activator O
of O
viral O
gene O
expression O
from O
the O
long O
terminal O
repeat O
( O
LTR O
) O
. O

Is O
it O
time B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
a O
wine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

The O
average B_MEASURE
coefficient I_MEASURE
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
assays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
5 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
for O
radioimmunoassay B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
12 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
while O
the O
average B_MEASURE
coefficient I_MEASURE
of O
variation B_MEASURE
within O
assays B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
4 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
for O
radioimmunoassay B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

macrophages B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O
modulators B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
immunity B_DISEASE
. O

The O
NH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
for O
susceptibility B_DISEASE
to O
modification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
Nalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
( O
3 B_MEASURE
- O
maleimidylpropionyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
biocytin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
attaches O
a O
biotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
cysteine O
sulfhydryls B_MEASURE/B_BIO
. O

Production O
of O
VT O
was O
also O
examined O
retrospectively O
in O
32 O
E O
. O
coli O
strains O
of O
serotype O
O26 O
: O
H11 O
isolated O
from O
children O
with O
diarrhoea O
; O
eight O
( O
25 O
% O
) O
of O
them O
produced O
moderate O
to O
high O
levels O
of O
verotoxin B_DISEASE/B_PROTEIN[GENE]
1 B_DISEASE/I_PROTEIN[GENE]
despite O
several O
years O
storage O
in O
vitro O
. O

Serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pituitary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
adult B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
male B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
: O
one B_NUMBER[MEASURE]
value I_NUMBER[MEASURE]
is O
as O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
the O
mean B_MEASURE
of O
three B_NUMBER[MEASURE]/B_PERSON
. O

The O
sections O
were O
stained O
with O
anti O
- O
polymorphonuclear O
leukocyte O
antibody O
, O
the O
endothelial O
marker O
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
VIII B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
related B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
with O
hematoxylin O
and O
eosin O
. O

mapping O
of O
the O
region O
in O
KAP B_GENE/B_LOCATION
- I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
required O
for O
HP1 B_GENE/B_MEASURE
interaction O
showed O
that O
amino O
acid O
substitutions O
which O
abolish O
HP1 B_GENE/B_BIO
binding O
in O
vitro O
reduce O
KAP B_GENE/B_PERSON
- I_GENE/I_PERSON
1 I_GENE/I_PERSON
mediated O
repression O
in O
vivo O
. O

The O
flanking B_GENE/B_LOCATION
open I_GENE/I_LOCATION
reading I_GENE/I_LOCATION
frames I_GENE/I_LOCATION
in O
pARGC2 B_BIO/B_MEASURE
showed O
no O
homologies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
arginine O
biosynthetic B_ENZYME[GENE]
genes I_ENZYME[GENE]
. O

promoter O
activity O
of O
the O
proliferating B_GENE/B_LOCATION
- I_GENE/I_LOCATION
cell I_GENE/I_LOCATION
nuclear I_GENE/I_LOCATION
antigen I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
is O
associated O
with O
inducible O
CRE B_GENE
- I_GENE
binding I_GENE
proteins I_GENE
in O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
T O
lymphocytes O
. O

methods O
: O
levels O
of O
sIL B_GENE
- I_GENE
2R I_GENE
were O
measured O
simultaneously O
in O
plasma O
and O
pleural O
fluid O
in O
111 O
patients O
with O
pleural O
effusions O
of O
unknown O
causes O
. O

The O
GIS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ArcView B_LOCATION/B_ORGANIZATION
, O
was O
used O
for O
spatial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
distance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

chi2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
used O
to O
compare O
the O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
characteristics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
intersection B_LOCATION/B_MEASURE
and O
midblock B_LOCATION/B_MEASURE
collisions I_LOCATION/I_MEASURE
. O

A O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
initiated O
to O
evaluate O
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
pure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
isomer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
LV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
5 B_TIME[MEASURE]/B_LOCATION
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
along O
with O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
patients B_PERSON/B_BIO
with O
advanced B_DISEASE/B_LOCATION
pancreatic I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
After O
3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENT
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENT
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
patient B_PERSON/B_BIO
had O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
platelet B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
count I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
a O
baseline B_MEASURE/B_LOCATION
of O
5 B_MEASURE
, O
000 B_MEASURE
to O
8 B_MEASURE
, O
000 B_MEASURE
/ O
microliter B_MEASURE
to O
a O
maximal B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
of O
33 B_MEASURE
, O
000 B_MEASURE
/ O
microliter B_MEASURE
. O

The O
specificity O
of O
the O
transcriptional O
activation O
by O
ISGF3 B_GENE
is O
mediated O
by O
specific O
elements O
termed O
IFN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ISRE B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
located O
in O
the O
promoter O
region O
of O
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
inducible O
genes O
. O

It O
appears O
that O
the O
K B_OTHER/B_PROTEIN[GENE]
- O
ABC B_PROTEIN[GENE]/B_DISEASE
is O
a O
relatively O
nonbiased B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suitable I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
gifted B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
nongifted B_PERSON/B_ORGANIZATION
children I_PERSON/I_ORGANIZATION
regardless O
of O
race B_SPORT[ENT]/B_PERSON
or O
gender B_PERSON/B_LOCATION
. O

In O
another O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IRPF B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recurred O
in O
the O
ureter B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O
a O
living O
related B_PERSON/B_BIO
renal B_PERSON/I_BIO
graft B_PERSON/I_BIO
6 B_PERSON/I_BIO
months B_PERSON/I_BIO
after O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
mutants B_DISEASE/B_GENE
, O
assayed O
by O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O
Xenopus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
delimit O
the O
promoter B_GENE/B_LOCATION
to O
36 B_LOCATION/B_MEASURE
BP I_LOCATION/I_MEASURE
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upstream I_LOCATION
of O
the O
cap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
site I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
73 B_LOCATION
BP I_LOCATION
of O
the O
untranslated B_GENE/B_BIO
mRNA I_GENE/I_BIO
leader I_GENE/I_BIO
. O

upstream O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
novel O
and O
essential O
regulatory O
DNA O
motif O
in O
the O
human B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
TIMP B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
directly O
interacts O
with O
a O
30 O
- O
kDa O
nuclear O
protein O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
charcoal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
imbiber B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beads I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
the O
anion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchanges I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Dowex B_LOCATION/B_PROTEIN[GENE]
XFS I_LOCATION/I_PROTEIN[GENE]
- O
4022 B_NUMBER[MEASURE]
and O
Dowex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
SBR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
C1 B_MEASURE
, O
would O
not O
be O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
increasing O
the O
amount B_MEASURE/B_LOCATION
of O
dieldrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
eliminated O
via O
feces B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
( O
droppings B_LOCATION/B_PROTEIN[GENE]
) O
of O
chickens B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
receptor O
for O
CSF B_GENE
- I_GENE
1 I_GENE
, O
c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
expressed O
in O
osteoclasts O
, O
possesses O
intrinsic O
tyrosine B_ENZYME[GENE]
- I_ENZYME[GENE]
kinase I_ENZYME[GENE]
activity O
, O
and O
signals O
via O
rapid O
phosphorylation O
of O
selected O
proteins O
. O

adaptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
repeated O
immersion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
on O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
body I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

To O
this O
end O
we O
generated O
a O
detailed O
physical O
map O
of O
the O
genomic O
region O
spanning O
between O
sequence O
- O
tagged O
site O
markers O
D16S518 B_GENE
and O
D16S516 B_GENE
. O

Spinophilin B_MEASURE/B_LOCATION
, O
a O
novel O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localized O
to O
dendritic O
spines O
. O

We O
have O
found O
that O
pro B_GENE
- I_GENE
IGF I_GENE
- I_GENE
2 I_GENE
can O
initially O
form O
two O
disulfide O
isomers O
that O
undergo O
rearrangement O
to O
a O
single O
conformation O
in O
vivo O
. O

While O
working O
on O
the O
toxicity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
war B_LOCATION/B_MEASURE
gases I_LOCATION/I_MEASURE
. O

he O
formulated O
' O
Haber B_PERSON/B_COLOR
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rule B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
, O
also O
known O
as O
C B_PROTEIN[GENE]/B_MEASURE
x O
T B_PROTEIN[GENE]/B_OTHER
= O
constant B_MEASURE/B_DISEASE
in O
order B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
characterize O
the O
toxicity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
an O
inhalant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
existence O
of O
a O
TFIIIB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
assembly O
pathway O
leading O
to O
the O
faithful O
transcription O
of O
natural O
eukaryotic O
tRNA O
genes O
in O
the O
absence O
of O
TFIIIC B_GENE
provides O
novel O
insights O
into O
the O
functional O
flexibility O
of O
the O
eukaryotic O
tRNA O
gene O
transcription O
machinery O
and O
on O
its O
evolution O
from O
an O
ancestral O
RNA B_GENE
polymerase I_GENE
III I_GENE
system O
relying O
on O
upstream O
, O
TATA O
- O
centered O
control O
elements O
. O

Ectopic O
Xbra B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
induce O
Xegr B_GENE
- I_GENE
1 I_GENE
transcription O
by O
an O
indirect O
mechanism O
that O
appears O
to O
operate O
via O
primary O
activation O
of O
fibroblast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secretion O
. O

A O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mixing O
device B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
quasielastic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
light I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
scattering I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
reacting O
systems B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
major B_GENE/B_LOCATION
transcription I_GENE/I_LOCATION
start I_GENE/I_LOCATION
site I_GENE/I_LOCATION
, O
designated O
as O
+ B_PROTEIN[GENE]
1 I_PROTEIN[GENE]
, O
was O
determined O
by O
race B_DISEASE/B_GENE
( O
rapid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cDNA B_GENE
ends I_GENE
) O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_GENE
liver I_GENE
cDNA I_GENE
and O
was O
found O
to O
be O
located O
50 B_MEASURE/B_LOCATION
BP B_MEASURE/I_LOCATION
upstream O
from O
the O
translation B_LOCATION/B_ORGANIZATION
start I_LOCATION/I_ORGANIZATION
site I_LOCATION/I_ORGANIZATION
. O

These O
AA O
residues O
correspond O
to O
codons O
59 O
and O
108 O
in O
the O
P B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
falciparum B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DHFR B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
active B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
which O
similar O
AA O
substitutions O
( O
Cys O
Arg O
- O
59 O
and O
Ser O
Asn O
- O
108 O
) O
are O
associated O
with O
pyrimethamine O
resistance O
. O

Of O
all O
YASR B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndromes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
the O
highest B_MEASURE
stability I_MEASURE
was O
for O
the O
anxious B_DISEASE
/ O
depressed B_DISEASE_ADJECTIVE[DISEASE]
scale I_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
investigate O
the O
mechanism O
of O
TPA O
induction O
of O
FGF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O
expression O
in O
the O
human O
ME O
- O
180 O
SCC O
cell O
line O
. O

Between O
the O
RNA O
initiation O
site O
and O
the O
coding O
region O
is O
a O
GC O
- O
rich O
hairpin O
structure O
followed O
by O
8 O
T O
residues O
that O
looks O
like O
a O
rho B_GENE/B_LOCATION
- I_GENE/I_LOCATION
independent I_GENE/I_LOCATION
transcription I_GENE/I_LOCATION
terminator I_GENE/I_LOCATION
. O

Conversely O
the O
rate B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bioavailability B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
because O
from O
the O
Reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patch I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
the O
release B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
fast O
in O
the O
first B_MEASURE/B_LOCATION
24 B_MEASURE/I_LOCATION
h B_MEASURE/I_LOCATION
, O
leading O
to O
an O
E2 B_MEASURE/B_DISEASE
peak I_MEASURE/I_DISEASE
at O
8 B_MEASURE
h O
and O
to O
a O
Cmax B_MEASURE/B_LOCATION
in O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
at O
23 B_MEASURE
h O
. O

3 O
) O
The O
progress O
of O
fibrinolysis O
was O
observed O
by O
serial O
collection O
of O
middle O
ear O
fluid O
in O
the O
same O
side O
ear O
of O
5 O
cases O
out O
of O
17 O
cases O
having O
much O
activity O
for O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
degradation O
, O
and O
lowering O
of O
fibrinolytic O
activity O
was O
revealed O
in O
4 O
out O
of O
these O
5 O
cases O
as O
the O
result O
. O

Thus O
G17 B_GENE
targets O
the O
c B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fos I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
promoter I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
CArG I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sequence I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
via O
Rho B_GENE
A I_GENE
- O
dependent O
pathways O
, O
and O
Rho B_GENE/B_TIME[MEASURE]
A I_GENE/I_TIME[MEASURE]
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
the O
trophic O
action O
of O
G17 B_GENE
. O

The O
MIC90 O
of O
ABK O
against O
coagulase B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
type B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
IV B_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
strains O
was O
rather O
high O
, O
12 O
. O
5 O
micrograms O
/ O
ml O
. O

In O
each O
patient B_PERSON/B_LOCATION
, O
MBF B_DISEASE
was O
quantified O
in O
the O
three B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
major I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
vascular I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
territories I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
anterior I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
descending O
and O
left O
circumflex B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
territories B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
coronary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
control B_DISEASE/B_LOCATION
region I_DISEASE/I_LOCATION
) O
territory B_LOCATION
. O

These O
results O
demonstrate O
that O
m2 B_GENE
receptors I_GENE
couple O
to O
both O
G B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
G B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i3 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
and O
that O
this O
interaction O
is O
integral O
to O
both O
positive O
and O
negative O
regulatory O
pathways O
leading O
to O
activation O
of O
PLC B_GENE/B_DISEASE
and O
desensitization O
of O
receptor O
signaling O
. O

Platelet B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
count B_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O
plasma B_MEASURE/B_ORGANISM_FUNCTION
volume I_MEASURE/I_ORGANISM_FUNCTION
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
group B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
throughout O
pregnancy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
fru B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
has O
seven O
exons O
spanning O
15 O
- O
kb O
encoding O
two O
transcripts O
with O
ORFs O
of O
841 O
and O
695 O
amino O
acids O
. O

HC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
toxin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
exerts O
a O
potent O
cytostatic O
effect O
on O
plant O
and O
animal O
cells O
by O
inhibiting O
histone B_GENE
deacetylase I_GENE
. O

The O
human O
RIL B_GENE
gene I_GENE
: O
mapping O
to O
human O
chromosome O
5q31 O
. O
1 O
, O
genomic O
organization O
and O
alternative O
transcripts O
. O

The O
delta B_PROTEIN[GENE]/B_MEASURE
mean O
VAF B_DISEASE/B_PROTEIN[GENE]
and O
delta B_PROTEIN[GENE]/B_MEASURE
mean O
SABP B_DISEASE
indicated O
varied B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
VAF B_DISEASE/B_PROTEIN[GENE]
and O
SABP B_DISEASE/B_PROTEIN[GENE]
, O
respectively O
. O

Azoospermia B_DISEASE/B_SPECIES[BIO]
was O
graded O
in O
the O
following O
way B_LOCATION
: O
adequate B_DISEASE_ADJECTIVE[DISEASE]
spermatozoa I_DISEASE_ADJECTIVE[DISEASE]
( O
A1 B_PROTEIN[GENE]/B_LOCATION
) O
, O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
scanty B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spermatozoa I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A2 B_PROTEIN[GENE]
) O
, O
spermatid B_DISEASE/B_ORGANISM_FUNCTION
arrest I_DISEASE/I_ORGANISM_FUNCTION
( O
B1 B_PROTEIN[GENE]
) O
, O
spermatocyte B_DISEASE/B_ORGANISM_FUNCTION
arrest I_DISEASE/I_ORGANISM_FUNCTION
( O
B2 B_PROTEIN[GENE]
) O
, O
Sertoli B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
only B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
C B_PROTEIN[GENE]
) O
and O
sclerosis B_DISEASE
( O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

